{"3e1de3754d10df6a8849631e0616f7936010c2f6": [["IntroductionCorona Virus-19 Disease (COVID-19) is a disease with a speedy transmission time.IntroductionAs of March 21, 2020, COVID-19 has been spreading to 176 countries in the world, with a total of 234,073 confirmed cases and 9,840 deaths (Practice, 2020) .", [["deaths", "DISEASE", 235, 241], ["IntroductionCorona Virus-19", "ORGANISM", 0, 27], ["IntroductionCorona Virus-19 Disease (COVID-19", "SPECIES", 0, 45], ["IntroductionCorona Virus-19 Disease", "PROBLEM", 0, 35], ["a disease", "PROBLEM", 50, 59], ["COVID", "TEST", 126, 131], ["disease", "OBSERVATION", 52, 59]]], ["In Indonesia, the number of Covid-19 cases also continued to increase every day.", [["Covid", "TEST", 28, 33]]], ["Based on data as of March 21, 2020, there were 450 confirmed cases, and 38 people died (WHO, 2020) .", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81]]], ["The impact of the spread of COVID-19 can affect both physically, psychologically, and socially.", [["COVID-19", "CHEMICAL", 28, 36], ["COVID-19", "CHEMICAL", 28, 36], ["spread", "OBSERVATION_MODIFIER", 18, 24]]], ["This virus attacks the immune system, so health status becomes quickly declined, and worsening conditions will occur if the patient has a comorbid disease (Deng & Peng, 2020) .", [["immune system", "ANATOMY", 23, 36], ["patient", "ORGANISM", 124, 131], ["patient", "SPECIES", 124, 131], ["This virus attacks the immune system", "PROBLEM", 0, 36], ["worsening conditions", "PROBLEM", 85, 105], ["a comorbid disease", "PROBLEM", 136, 154]]], ["The progressive spread of the disease and the development of the disease and accompanying clinical symptoms can cause psychological problems (Duan & Zhu, 2020) .", [["the disease", "PROBLEM", 26, 37], ["the disease", "PROBLEM", 61, 72], ["accompanying clinical symptoms", "PROBLEM", 77, 107], ["psychological problems", "PROBLEM", 118, 140], ["progressive", "OBSERVATION_MODIFIER", 4, 15], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["disease", "OBSERVATION", 30, 37], ["disease", "OBSERVATION", 65, 72]]], ["This psychological problem can be experienced by the general public, health workers, and health service providers .IntroductionThe Centers for Disease Control and Prevention (2020) mentioned the psychological impacts often encountered as a result of COVID-19 are fear and worry about the health of oneself and loved ones, changes in sleep and eating patterns, lack of concentration, worsening of chronic health problems, and increased use of alcohol, tobacco/cigarettes, and other drugs. mentioned that like other outbreaks of infectious diseases, psychological transmission can also occur, which results in widespread fear, anxiety, and causes stigmatization of patients by their closest people, officers, and residents with the most pandemics.", [["alcohol", "CHEMICAL", 442, 449], ["infectious diseases", "DISEASE", 527, 546], ["anxiety", "DISEASE", 625, 632], ["alcohol", "CHEMICAL", 442, 449], ["alcohol", "SIMPLE_CHEMICAL", 442, 449], ["tobacco", "ORGANISM", 451, 458], ["patients", "ORGANISM", 663, 671], ["people", "ORGANISM", 689, 695], ["patients", "SPECIES", 663, 671], ["people", "SPECIES", 689, 695], ["Disease Control", "TREATMENT", 143, 158], ["chronic health problems", "PROBLEM", 396, 419], ["infectious diseases", "PROBLEM", 527, 546], ["anxiety", "PROBLEM", 625, 632], ["chronic", "OBSERVATION_MODIFIER", 396, 403], ["infectious", "OBSERVATION", 527, 537]]], ["These conditions cause uncomfortable conditions, anxiety, fear, and grief caused by a lack of information.", [["anxiety", "DISEASE", 49, 56], ["grief", "DISEASE", 68, 73], ["uncomfortable conditions", "PROBLEM", 23, 47], ["anxiety", "PROBLEM", 49, 56]]], ["Research by and showed that COVID-19 caused psychological problems namely depression (50.7%), anxiety (44.7%), insomnia (36.1%), stress symptoms (73.4%), and Post Traumatic Stress Symptoms (PTSS) by 7% of 285 respondents.IntroductionThe East Java Province Mental Health Technical Team conducted a preliminary study of the rapid response and early treatment of psychosocial aspects to the public (310 respondents) and health workers (87 respondents) online on March 18, 2020.", [["depression", "DISEASE", 74, 84], ["anxiety", "DISEASE", 94, 101], ["insomnia", "DISEASE", 111, 119], ["stress symptoms", "DISEASE", 129, 144], ["Traumatic Stress Symptoms", "DISEASE", 163, 188], ["PTSS", "DISEASE", 190, 194], ["COVID", "TEST", 28, 33], ["psychological problems", "PROBLEM", 44, 66], ["depression", "PROBLEM", 74, 84], ["anxiety", "PROBLEM", 94, 101], ["insomnia", "PROBLEM", 111, 119], ["stress symptoms", "PROBLEM", 129, 144], ["Post Traumatic Stress Symptoms", "PROBLEM", 158, 188], ["a preliminary study", "TEST", 295, 314]]], ["The results of the preliminary study showed that 32.6% of respondents exhibited symptoms of psychological disorders, 23.2% showed signs of mild depression, and 21.9% showed symptoms of mild anxiety.IntroductionDuring this pandemic, several activities related to mental health care have been carried out in Indonesia.", [["psychological disorders", "DISEASE", 92, 115], ["depression", "DISEASE", 144, 154], ["anxiety", "DISEASE", 190, 197], ["the preliminary study", "TEST", 15, 36], ["symptoms", "PROBLEM", 80, 88], ["psychological disorders", "PROBLEM", 92, 115], ["mild depression", "PROBLEM", 139, 154], ["symptoms", "PROBLEM", 173, 181], ["mild anxiety", "PROBLEM", 185, 197], ["mental health care", "TREATMENT", 262, 280], ["mild", "OBSERVATION_MODIFIER", 139, 143], ["depression", "OBSERVATION", 144, 154], ["mild", "OBSERVATION_MODIFIER", 185, 189], ["anxiety", "OBSERVATION", 190, 197]]], ["Mental Health and Psychosocial Support training has been conducted in Indonesia, targeting nurses and health workers whose aim is to provide provisions for health workers in overcoming psychosocial problems that arise due to COVID-19.IntroductionDuring the COVID-19 outbreak in Indonesia, several parties such as counselors, psychiatrists, psychologists, therapists, and social workers, have developed their own initiatives to assist with psychological first aid and to improve the psychological state of the general public including high-level disorders, levels of stress, crisis, depression, OCD, and other psychological conditions.", [["high-level disorders", "DISEASE", 534, 554], ["depression", "DISEASE", 582, 592], ["OCD", "DISEASE", 594, 597], ["Psychosocial Support training", "TREATMENT", 18, 47], ["overcoming psychosocial problems", "PROBLEM", 174, 206], ["COVID", "TEST", 225, 230], ["high-level disorders", "PROBLEM", 534, 554], ["stress", "PROBLEM", 566, 572], ["crisis", "PROBLEM", 574, 580], ["depression", "PROBLEM", 582, 592], ["OCD", "PROBLEM", 594, 597], ["other psychological conditions", "PROBLEM", 603, 633]]], ["The intervention was carried out through online counseling, distribution of disease prevention brochures, websites, YouTube tutorial videos, short films, online discussions through WhatsApp groups, and many more.", [["The intervention", "TREATMENT", 0, 16], ["online counseling", "TREATMENT", 41, 58], ["disease prevention", "TREATMENT", 76, 94], ["short films", "TEST", 141, 152]]], ["This form of treatment is still being administered separately based on recommendations (Ifdil, et al, 2020) .IntroductionEfforts to deal with psychosocial health problems include those launched by Practice (2020) by targeting various age groups, including among general population groups, health workers, team leaders or managers in health facilities, elderly groups, and isolated groups (WHO, 2020) .", [["treatment", "TREATMENT", 13, 22]]], ["In other countries such as China, the handling of psychosocial problems provided is psychological counseling services for patients and families affected by the COVID-19 outbreak and crisis interventions to deal with public health emergencies.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["crisis interventions", "TREATMENT", 182, 202]]], ["This intervention has been implemented in China and effective in reducing psychosocial problems caused by the extraordinary events of COVID-19 (Duan & Zhu, 2020) .", [["COVID-19", "CHEMICAL", 134, 142], ["COVID-19", "CHEMICAL", 134, 142], ["This intervention", "TREATMENT", 0, 17], ["reducing psychosocial problems", "PROBLEM", 65, 95], ["COVID", "TEST", 134, 139]]], ["One of the efforts implemented in overcoming psychosocial issues due to COVID-19 in Indonesia is to provide practical guidance for psychosocial management for the community and health workers through online access.IntroductionThe effects of COVID-19 are very similar to all countries by considering the consequences of mental health.", [["COVID-19", "CHEMICAL", 241, 249], ["psychosocial management", "TREATMENT", 131, 154], ["COVID", "TREATMENT", 241, 246]]], ["The challenges and protocols made are very effective in dealing with the psychological impacts on society.", [["protocols", "TREATMENT", 19, 28]]], ["Given this pandemic and the resources we need, it is crucial to train primary care doctors, specialists in other medical services, psychologists, and paramedical teams about the essence of psychological interventions (De Sousa, Mohandas, & Javed, 2020).Materials and methodsThe development method employed was based on events that are currently still ongoing situation.", [["psychological interventions", "TREATMENT", 189, 216]]], ["The method of developing this practical guide for psychosocial management for the community and health workers in Indonesia used the adaptation process approach.", [["psychosocial management", "TREATMENT", 50, 73]]], ["We used ADAPTE steps for the adaptation process.", [["ADAPTE steps", "TREATMENT", 8, 20], ["the adaptation process", "TREATMENT", 25, 47]]], ["We chose ADAPTE because it is a well-structured tool and represents the most widely used method for guideline adaptation.", [["ADAPTE", "TREATMENT", 9, 15], ["guideline adaptation", "TREATMENT", 100, 120]]], ["The adaptation process consisted of 3 stages: the set-up phase, the adaptation phase, and the finalization phase.", [["the adaptation phase", "TEST", 64, 84], ["the finalization phase", "TEST", 90, 112]]], ["In order to retrieve all the relevant scientific literature on the provided practical guidance for psychosocial management for the community and health workers in Indonesia, we searched articles and literature on the electronic databases.Study inclusion and exclusion criteriaSearching for the articles was limited according to the eligibility criteria, which were as follows: articles published online from December 2019 to March 2020.", [["psychosocial management", "TREATMENT", 99, 122], ["Study inclusion", "TEST", 238, 253], ["exclusion criteriaSearching", "TEST", 258, 285]]], ["Items were not limited to research articles, but all forms of articles include correspondence, comment, research letter, perspective, and analysis.", [["analysis", "TEST", 138, 146]]], ["We included studies that discussed meeting the needs of first-time beginners in mental and psychosocial health and published in English.Search strategy and selection processArticles that discussed mental health and psychosocial problems and recommendations should be developed using a defined and systematic process.", [["studies", "TEST", 12, 19], ["psychosocial problems", "PROBLEM", 215, 236], ["a defined and systematic process", "PROBLEM", 283, 315]]], ["If there were a debate about whether the article qualifies, the decision would be assisted by a third reviewer.ResultsWe screened 69 potentially relevant records and identified 27 publications for a fulltext screening to assess eligibility.", [["a fulltext screening", "TEST", 197, 217]]], ["Amongst these, we extracted data from 14 studies that were eligible for review.", [["14 studies", "TEST", 38, 48]]], ["Fig 1 describes the details of the search process and its results.ResultsTable1-2 summarizes the included study.", [["study", "TEST", 106, 111]]], ["As many as 78.6% of the articles were research articles obtained from search results on the specified database, while the rest were gray literature.ResultsMost of the research articles came from China (57%), where COVID-19 was first discovered, and the rest came from the UK, USA, and India.", [["COVID", "TEST", 214, 219]]], ["Meanwhile, 28.6 were research articles and one review article.ResultsThe following was the result of the adaptation process that we carried out consisting of 3 stages, namely the set-up phase, the adaptation phase, and the finalization phase.", [["the adaptation process", "PROBLEM", 101, 123], ["the finalization phase", "TEST", 219, 241]]], ["The team outlines the tasks that need to be completed before starting the adaptation process by identifying the skills and resources needed to determine whether adaptation is feasible or not.ResultsThe adaptation phase began by selecting the topic of psychosocial guidance needed by the people in Indonesia with its various characteristics.", [["people", "ORGANISM", 287, 293], ["people", "SPECIES", 287, 293], ["psychosocial guidance", "TREATMENT", 251, 272]]], ["We found and refer to existing psychosocial disaster management guidelines.", [["psychosocial disaster management", "TREATMENT", 31, 63]]], ["Based on the search results, we identified 14 articles that were potentially suitable for adaptation and were developed in the form of practical guidelines (Table 1) .ResultsThis guideline was then reviewed and evaluated by considering the needs and abilities of people in Indonesia.", [["people", "ORGANISM", 263, 269], ["people", "SPECIES", 263, 269]]], ["After reaching consensus, the next step was to draft a guideline based on various existing recommendations.ResultsThe final phase is carried out by guiding users through the process of obtaining document feedback from stakeholders, namely the Health Service consisting of 38 District Health Offices, Cities and communities that will be affected by the use of this psychosocial guideline.", [["this psychosocial guideline", "TREATMENT", 359, 386]]], ["In the final phase, consultations were also conducted with the East Java Provincial Health Office of Indonesia as a stakeholder, to review and update the instructions, so that a final document called a practical guide -response and early treatment of psychosocial aspects of COVID-19 in East Java Province, Indonesia.Recommendation 1Knowledge about the stages of the COVID-19 outbreak is a significant aspect that currently needs to be socialized to the public in order to anticipate psychosocial problems that might occur.", [["psychosocial problems", "PROBLEM", 484, 505]]], ["Psychosocial problems will significantly depend on the stage of the outbreak that occurs in an area.", [["Psychosocial problems", "PROBLEM", 0, 21], ["the outbreak", "PROBLEM", 64, 76]]], ["Knowledge, attitudes, and practices adopted by the community play an essential role in determining the readiness of the community to make behavior change.Recommendation 1Excellent knowledge, positive attitudes, and preventive actions taken by the community are significantly related to the ability of a country to conquer and handle the crisis during the COVID-19 outbreak (Azlan et al., 2020) .", [["the crisis", "PROBLEM", 333, 343], ["the COVID", "TEST", 351, 360]]], ["Understanding the stages of the outbreak must be given to the community (strong recommendation level).Recommendation 2Providing information on psychosocial responses that occur in the COVID-19 outbreak is necessary to understand the mental well-being conditions experienced by health workers and by the community, both those with good mental health conditions and those with mental disorders (strong recommendation level).", [["mental disorders", "PROBLEM", 375, 391]]], ["The monitoring of psychosocial responses starts before, beginning, and during critical conditions until after the outbreak of COVID-19.Recommendation 2Multidisciplinary collaboration in various health organizations needs to be carried out to gather comprehensive information about the psychosocial needs of the community during the COVID-19 outbreak (Hyun et al., 2020) .Mental and Psychosocial Health Support Interventions at Every Stage of the COVID-19OutbreakRecommendation 3Mental health interventions and psychosocial support during the COVID-19 outbreak must be provided for the community and health workers to overcome the psychosocial problems experienced.", [["COVID", "TEST", 126, 131], ["the COVID", "TREATMENT", 442, 451], ["3Mental health interventions", "TREATMENT", 477, 505], ["psychosocial support", "TREATMENT", 510, 530], ["the psychosocial problems", "PROBLEM", 626, 651]]], ["Interventions in the form of mental health and psychosocial support are carried out during the initial phase, the acute phase, or the recovery phase (strong recommendation level).", [["Interventions", "TREATMENT", 0, 13], ["psychosocial support", "TREATMENT", 47, 67]]], ["In disaster management, psychosocial support is no less important than infection control during an outbreak.", [["infection", "DISEASE", 71, 80], ["disaster management", "TREATMENT", 3, 22], ["psychosocial support", "TREATMENT", 24, 44], ["infection control", "TREATMENT", 71, 88]]], ["Guidelines for psychosocial care during the COVID-19 pandemic must be issued immediately to facilitate the implementation of interventions.", [["psychosocial care", "TREATMENT", 15, 32], ["interventions", "TREATMENT", 125, 138]]], ["Also, these guidelines have essential implications for disaster preparedness in general during this time of the outbreak (Hyun et al., 2020) .Recommendation 4The need for an emergency psychological crisis intervention is needed in the face of the outbreak in reducing the psychological impact of COVID-19.", [["COVID-19", "CHEMICAL", 296, 304], ["an emergency psychological crisis intervention", "TREATMENT", 171, 217], ["COVID", "TEST", 296, 301]]], ["However, the mechanism of psychosocial intervention in a pandemic condition must also adjust needs without breaking the rules of social distancing and physical distancing.", [["psychosocial intervention", "TREATMENT", 26, 51], ["a pandemic condition", "PROBLEM", 55, 75]]], ["The use of online facilities or hotline services will increase the reach of meeting psychological needs both for the community and health workers (strong recommendation level).", [["hotline services", "TREATMENT", 32, 48]]], ["Telemental Health is the use of information and communication technology to provide mental health care remotely, including consultation, evaluation, medication management, and psychotherapy.", [["communication technology", "TREATMENT", 48, 72], ["evaluation", "TEST", 137, 147], ["medication management", "TREATMENT", 149, 170], ["psychotherapy", "TREATMENT", 176, 189]]], ["However, in the future, it cannot be denied that telemental health is a method of providing mental health services that is safe, effective, comfortable, and measurable (Whaibeh, Mahmoud, & Naal, 2020) .Development of Practical GuidelinesThere are some promising new developments related to mental health and psychosocial support amid the COVID-19 outbreak.", [["Practical Guidelines", "TREATMENT", 217, 237], ["psychosocial support", "TREATMENT", 308, 328], ["the COVID", "TREATMENT", 334, 343], ["promising", "OBSERVATION_MODIFIER", 252, 261], ["new", "OBSERVATION_MODIFIER", 262, 265]]], ["Existing research literature relevant to this is not sufficient to justify the current recommendations, but further evaluative studies must be encouraged.", [["further evaluative studies", "TEST", 108, 134]]], ["An additional crucial area is the development and evaluation of interventions in the form of mental health and psychosocial support.Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest concerning the research, authorship, and publication of this article.FundingThe author(s) received no financial support for the research, authorship, and/or publication of this article.Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest concerning the research, authorship, and publication of this article.", [["evaluation", "TEST", 50, 60], ["interventions", "TREATMENT", 64, 77], ["psychosocial support", "TREATMENT", 111, 131], ["financial support", "TREATMENT", 328, 345], ["crucial", "OBSERVATION_MODIFIER", 14, 21], ["area", "OBSERVATION_MODIFIER", 22, 26]]]], "84f8bc2f354a67c4ad72f96aa6f7458a00da7e51": [["THE era of communicable diseases is hardly over.", [["communicable diseases", "DISEASE", 11, 32], ["communicable diseases", "PROBLEM", 11, 32], ["communicable diseases", "OBSERVATION", 11, 32]]], ["As well as AIDS , Legionnaire's disease and Lyme disease, other recent emerging infections include Escherichia coli 0157:H7 , cryptosporidiosis, multiple drug-resistant pneumococcus, Helicobacter pylori and vancomycin-resistant enterococcus.", [["AIDS", "DISEASE", 11, 15], ["Legionnaire's disease", "DISEASE", 18, 39], ["Lyme disease", "DISEASE", 44, 56], ["infections", "DISEASE", 80, 90], ["Escherichia coli 0157:H7", "CHEMICAL", 99, 123], ["cryptosporidiosis", "DISEASE", 126, 143], ["pneumococcus", "DISEASE", 169, 181], ["Helicobacter pylori", "DISEASE", 183, 202], ["vancomycin", "CHEMICAL", 207, 217], ["vancomycin", "CHEMICAL", 207, 217], ["Escherichia coli 0157:H7", "ORGANISM", 99, 123], ["pneumococcus", "ORGANISM", 169, 181], ["Helicobacter pylori", "ORGANISM", 183, 202], ["vancomycin-resistant enterococcus", "SIMPLE_CHEMICAL", 207, 240], ["Escherichia coli", "SPECIES", 99, 115], ["Helicobacter pylori", "SPECIES", 183, 202], ["Escherichia coli 0157:H7", "SPECIES", 99, 123], ["Helicobacter pylori", "SPECIES", 183, 202], ["AIDS", "PROBLEM", 11, 15], ["Legionnaire's disease", "PROBLEM", 18, 39], ["Lyme disease", "PROBLEM", 44, 56], ["other recent emerging infections", "PROBLEM", 58, 90], ["Escherichia coli", "PROBLEM", 99, 115], ["H7", "PROBLEM", 121, 123], ["cryptosporidiosis", "PROBLEM", 126, 143], ["multiple drug-resistant pneumococcus", "PROBLEM", 145, 181], ["Helicobacter pylori", "PROBLEM", 183, 202], ["vancomycin", "TREATMENT", 207, 217], ["resistant enterococcus", "PROBLEM", 218, 240], ["Lyme disease", "OBSERVATION", 44, 56], ["infections", "OBSERVATION", 80, 90], ["Escherichia coli", "OBSERVATION", 99, 115], ["multiple", "OBSERVATION_MODIFIER", 145, 153], ["drug", "OBSERVATION_MODIFIER", 154, 158], ["resistant", "OBSERVATION_MODIFIER", 159, 168], ["pneumococcus", "OBSERVATION", 169, 181], ["Helicobacter pylori", "OBSERVATION", 183, 202], ["resistant", "OBSERVATION_MODIFIER", 218, 227], ["enterococcus", "OBSERVATION", 228, 240]]], ["As human contact with vectors of potentially lethal pathogens increases 1 , a US Institute of Medicine report 2 has emphasized the need for improved surveillance, basic research and laboratory diagnosis for such diseases .", [["human", "ORGANISM", 3, 8], ["human", "SPECIES", 3, 8], ["human", "SPECIES", 3, 8], ["potentially lethal pathogens", "PROBLEM", 33, 61], ["laboratory diagnosis", "TEST", 182, 202], ["such diseases", "PROBLEM", 207, 220]]]], "PMC7340018": [["A variety of clinical infections including the current pandemic and a variety of physical events such as bee stings and trauma have been documented as triggers of acute cardiovascular illness such as venous thromboembolism, myocardial infarction, and stroke.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 A number of factors have been proposed to explain this association between infection and acute cardiovascular disease including activation of various inflammatory molecules and platelets, endothelial dysfunction, and/or augmented sympathetic nervous activity with release of high levels of catecholamines into the circulation.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 Indeed, it is possible that all of these elements may be occurring simultaneously leading to atherosclerotic plaque instability and a concomitant hypercoagulable state.", [["cardiovascular", "ANATOMY", 169, 183], ["venous", "ANATOMY", 200, 206], ["myocardial", "ANATOMY", 224, 234], ["cardiovascular", "ANATOMY", 391, 405], ["platelets", "ANATOMY", 473, 482], ["endothelial", "ANATOMY", 484, 495], ["sympathetic nervous", "ANATOMY", 526, 545], ["atherosclerotic plaque", "ANATOMY", 753, 775], ["infections", "DISEASE", 22, 32], ["bee stings", "DISEASE", 105, 115], ["trauma", "DISEASE", 120, 126], ["acute cardiovascular illness", "DISEASE", 163, 191], ["venous thromboembolism", "DISEASE", 200, 222], ["myocardial infarction", "DISEASE", 224, 245], ["stroke", "DISEASE", 251, 257], ["infection", "DISEASE", 371, 380], ["acute cardiovascular disease", "DISEASE", 385, 413], ["catecholamines", "CHEMICAL", 586, 600], ["atherosclerotic plaque instability", "DISEASE", 753, 787], ["catecholamines", "CHEMICAL", 586, 600], ["bee", "ORGANISM", 105, 108], ["venous", "MULTI-TISSUE_STRUCTURE", 200, 206], ["myocardial", "MULTI-TISSUE_STRUCTURE", 224, 234], ["platelets", "CELL", 473, 482], ["endothelial", "TISSUE", 484, 495], ["sympathetic nervous", "ANATOMICAL_SYSTEM", 526, 545], ["catecholamines", "SIMPLE_CHEMICAL", 586, 600], ["atherosclerotic plaque", "PATHOLOGICAL_FORMATION", 753, 775], ["inflammatory molecules", "PROTEIN", 446, 468], ["platelets", "CELL_TYPE", 473, 482], ["clinical infections", "PROBLEM", 13, 32], ["bee stings", "PROBLEM", 105, 115], ["trauma", "PROBLEM", 120, 126], ["acute cardiovascular illness", "PROBLEM", 163, 191], ["venous thromboembolism", "PROBLEM", 200, 222], ["myocardial infarction", "PROBLEM", 224, 245], ["stroke", "PROBLEM", 251, 257], ["infection", "PROBLEM", 371, 380], ["acute cardiovascular disease", "PROBLEM", 385, 413], ["various inflammatory molecules", "PROBLEM", 438, 468], ["platelets", "PROBLEM", 473, 482], ["endothelial dysfunction", "PROBLEM", 484, 507], ["augmented sympathetic nervous activity", "PROBLEM", 516, 554], ["atherosclerotic plaque instability", "PROBLEM", 753, 787], ["a concomitant hypercoagulable state", "PROBLEM", 792, 827], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["infections", "OBSERVATION", 22, 32], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["cardiovascular illness", "OBSERVATION", 169, 191], ["venous", "ANATOMY", 200, 206], ["thromboembolism", "OBSERVATION", 207, 222], ["myocardial", "ANATOMY", 224, 234], ["infarction", "OBSERVATION", 235, 245], ["stroke", "OBSERVATION", 251, 257], ["infection", "OBSERVATION", 371, 380], ["acute", "OBSERVATION_MODIFIER", 385, 390], ["cardiovascular disease", "OBSERVATION", 391, 413], ["various", "OBSERVATION_MODIFIER", 438, 445], ["inflammatory molecules", "OBSERVATION", 446, 468], ["endothelial dysfunction", "OBSERVATION", 484, 507], ["sympathetic nervous activity", "OBSERVATION", 526, 554], ["circulation", "ANATOMY", 610, 621], ["may be", "UNCERTAINTY", 710, 716], ["atherosclerotic", "OBSERVATION_MODIFIER", 753, 768], ["plaque", "OBSERVATION", 769, 775], ["concomitant", "OBSERVATION_MODIFIER", 794, 805], ["hypercoagulable state", "OBSERVATION", 806, 827]]]], "52a2eded63fd2d4c776d161018d3005ba7b0f582": [["Business process evaluation is a key support in narrowing down this gap.", [["Business process evaluation", "TEST", 0, 27], ["narrowing", "OBSERVATION", 48, 57]]], ["There are two evaluation techniques to analyze business processes, a.k.a., model-based analysis, and data-based analysis [1] .", [["two evaluation techniques", "TEST", 10, 35], ["model-based analysis", "TEST", 75, 95]]], ["While model-based analysis deals with the analysis of business process models, the data-based analysis mostly focuses on analyzing business processes based on their execution event logs.IntroductionProcess Mining is a discipline in the BPM area that enables data-based analysis for business processes in organizations [2] .", [["the data", "TEST", 79, 87], ["based analysis", "TEST", 88, 102]]], ["It allows analysts not only to evaluate the business processes but also to perform process discovery, compliance checking, and process enhancement based on the execution result, a.k.a., event logs.", [["compliance checking", "TEST", 102, 121]]], ["As the volume of logs increases, new opportunities and challenges also appear.", [["volume", "OBSERVATION_MODIFIER", 7, 13], ["logs", "OBSERVATION_MODIFIER", 17, 21], ["increases", "OBSERVATION_MODIFIER", 22, 31]]], ["The large volume of logs enables the discovery of more information about business processes; while also raises some challenges, such as feasibility, performance, and data management.IntroductionMost process mining techniques require data to be loaded first into memory, which is a feasibility technical challenge when applying them on a large volume of data in a single computer.", [["large", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16]]], ["It also defines an algorithm to compute Directly Follows Graph (DFG) inside the graph database, which shifts the heavy computation parts of process mining into the graph database.", [["the graph database", "TEST", 76, 94], ["heavy", "OBSERVATION_MODIFIER", 113, 118]]], ["As a result, it enables i) removing the requirement to move data into analysts' computer, ii) applying graph databases' fine-grained access control on event logs and preserving privacy while applying process mining, and iii) scaling the DFG computation vertically and horizontally.IntroductionThe approach is implemented in Neo4j, and its performance is evaluated in comparison with current techniques based on a real log file.", [["preserving privacy", "TREATMENT", 166, 184], ["process mining", "TREATMENT", 200, 214]]], ["The result shows that the approach can discover process models when the data is much bigger than the computational memory.", [["the data", "TEST", 68, 76]]], ["It also shows better performance when dicing data into small chunks.IntroductionThe remainder of this paper is organized as follows.", [["small chunks", "PROBLEM", 55, 67], ["small chunks", "OBSERVATION", 55, 67]]], ["Section 2 gives a short background on process mining and graph database.", [["graph database", "TEST", 57, 71]]], ["Section 5 reports the evaluation results.", [["the evaluation", "TEST", 18, 32]]], ["Section 6 discuss alternative approaches and related works, and finally, Section 7 concludes the paper and introduces future research.Process MiningProcess Mining is a research area that supports business process data-based analysis.", [["based analysis", "TEST", 218, 232]]], ["It is usual to have more information like the execution time and resource who has done the activity on the log as well.DFG CalculationThe next step is calculating the Directly Follows Graph (DFG).", [["DFG Calculation", "TEST", 119, 134]]], ["This graph shows the frequency of direct relations between activities that are captured in the log file.", [["This graph", "TEST", 0, 10]]], ["The result can be considered as a matrix with the activity names at rows and columns.", [["matrix", "CELLULAR_COMPONENT", 34, 40]]], ["Let's consider the cell that has the row for activity 1 and columns for activity 2 in Fig. 1.", [["cell", "ANATOMY", 19, 23], ["cell", "CELL", 19, 23]]], ["The number in the cell shows the number of times that the activity 2 happened after activity 1.", [["cell", "ANATOMY", 18, 22], ["cell", "CELL", 18, 22]]], ["Although the calculation of DFG comes back to alpha miner, which introduced around 20 years ago, it is still the backbone for many process mining algorithms and tools [26] .", [["DFG", "PROTEIN", 28, 31]]], ["There are different variations of DFG that store more information, but the basic idea is the same.DFG CalculationCalculating DFG can be very time consuming and costly if the log file is huge.", [["DFG", "PROTEIN", 34, 37], ["DFG CalculationCalculating DFG", "TREATMENT", 98, 128], ["different", "OBSERVATION_MODIFIER", 10, 19], ["variations", "OBSERVATION_MODIFIER", 20, 30], ["huge", "OBSERVATION", 186, 190]]], ["Also, many algorithms which are implemented in different tools like ProM and PM4PY requires to load logs to the memory first, which is problematic when calculating the big log files.", [["ProM", "GENE_OR_GENE_PRODUCT", 68, 72], ["PM4PY", "GENE_OR_GENE_PRODUCT", 77, 82], ["ProM", "PROTEIN", 68, 72], ["PM4PY", "PROTEIN", 77, 82]]], ["This step usually does not take much time since the computation is performed on top of DFG.Graph DatabaseGraph databases are Database Management Systems (DBMS) that support creating, storing, retrieving, and managing graph database models.", [["DFG", "PROTEIN", 87, 90], ["the computation", "TEST", 48, 63]]], ["Graph database models are defined as the data structure where the schema and instances are modeled as graphs, and the operation on graphs are graph-oriented [3] .", [["Graph database models", "TEST", 0, 21]]], ["The idea is not new, and it comes back to the late eighties when the object-oriented models were also introduced [3] .", [["not", "UNCERTAINTY", 12, 15], ["new", "OBSERVATION_MODIFIER", 16, 19]]], ["It enables leveraging parallel computing capabilities to analyze massive graphs.", [["massive graphs", "TEST", 65, 79]]], ["As a result, a new discipline is emerged in research, called Parallel Graph Analytics [19] .Graph DatabaseThere are different sorts of graph databases with different features.", [["Graph Database", "TEST", 92, 106], ["graph databases", "TEST", 135, 150], ["different features", "PROBLEM", 156, 174], ["different", "OBSERVATION_MODIFIER", 116, 125]]], ["For example, Neo4j is a graph DBMS that supports both vertical and horizontal scaling, meaning that not only the hardware of the system that runs the DBMS can be scaled out but the number of physical nodes that run the DBMS as a network can be increased.", [["physical nodes", "MULTI-TISSUE_STRUCTURE", 191, 205], ["Neo4j", "DNA", 13, 18], ["DBMS", "DNA", 150, 154], ["a graph DBMS", "PROBLEM", 22, 34], ["both vertical and horizontal scaling", "PROBLEM", 49, 85], ["both", "OBSERVATION_MODIFIER", 49, 53], ["vertical", "OBSERVATION_MODIFIER", 54, 62], ["horizontal", "OBSERVATION_MODIFIER", 67, 77], ["scaling", "OBSERVATION_MODIFIER", 78, 85], ["hardware", "OBSERVATION", 113, 121], ["nodes", "OBSERVATION", 200, 205], ["increased", "OBSERVATION_MODIFIER", 244, 253]]], ["Also, it allows different sorts of access controls, such as Fine-grained access control, Sub-graph access control, and role-based access control.", [["access controls", "TREATMENT", 35, 50], ["Fine-grained access control", "TREATMENT", 60, 87], ["Sub-graph access control", "TREATMENT", 89, 113], ["role-based access control", "TREATMENT", 119, 144]]], ["In this way, different data management strategy can be applied.Graph DatabaseThe left-side of Fig.2 shows a fictitious short example schema for a simple graph in a graph database.", [["Fig.2", "PROTEIN", 94, 99], ["different data management strategy", "TREATMENT", 13, 47], ["Graph Database", "TEST", 63, 77], ["a fictitious short example schema", "PROBLEM", 106, 139], ["a simple graph", "TEST", 144, 158], ["a graph database", "TEST", 162, 178], ["left", "ANATOMY_MODIFIER", 81, 85]]], ["It has four nodes, i.e., patient, disease, symptoms, and address.", [["nodes", "ANATOMY", 12, 17], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["disease", "PROBLEM", 34, 41], ["symptoms", "PROBLEM", 43, 51], ["four", "OBSERVATION_MODIFIER", 7, 11], ["nodes", "OBSERVATION", 12, 17]]], ["It also has relations among the nodes that specify their connection.", [["the nodes", "PROBLEM", 28, 37], ["nodes", "OBSERVATION", 32, 37]]], ["For example, a patient can live in an address, and a patient can be diagnosed with a disease.", [["patient", "ORGANISM", 15, 22], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 15, 22], ["patient", "SPECIES", 53, 60], ["a disease", "PROBLEM", 83, 92], ["disease", "OBSERVATION", 85, 92]]], ["Each node can have properties, e.g., the patient has a social security number (ssn).Graph DatabaseIn a graph database, it is possible to grant access to analysts to analyze the spread of diseases, e.g., COVID19, based on patients who live in the same address but not reveal the patient's information nor individual address.", [["node", "ANATOMY", 5, 9], ["node", "MULTI-TISSUE_STRUCTURE", 5, 9], ["patient", "ORGANISM", 41, 48], ["patients", "ORGANISM", 221, 229], ["patient", "ORGANISM", 278, 285], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 221, 229], ["patient", "SPECIES", 278, 285], ["Graph Database", "TEST", 84, 98], ["a graph database", "TEST", 101, 117], ["diseases", "PROBLEM", 187, 195], ["COVID19", "TREATMENT", 203, 210], ["node", "OBSERVATION", 5, 9], ["diseases", "OBSERVATION", 187, 195]]], ["To do so, we can set the access in a way that analysts can traverse relations from/to patients but cannotA sample GraphThe graph from researcher view Fig. 2 .", [["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94]]], ["An example of a graph schema in a graph database see patient's information.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60]]], ["Also, we can hide individual addresses and symptoms.", [["symptoms", "PROBLEM", 43, 51]]], ["Thus, the schema will be like the right-side of Fig.2 for analysts.", [["right", "ANATOMY_MODIFIER", 34, 39]]], ["In this way, the researcher can analyze how people who lived in the same address got the same disease.", [["people", "ORGANISM", 44, 50], ["people", "SPECIES", 44, 50], ["the same disease", "PROBLEM", 85, 101]]], ["The build-in access control mechanism enables us to design an approach that preserves the privacy of resources while performing process mining.A sample GraphTo traverse or query the graph, graph databases define their query language.", [["A sample GraphTo", "TEST", 143, 159], ["query the graph", "TEST", 172, 187], ["graph databases", "TEST", 189, 204]]], ["Cypher [13] is a declarative query language that allows the application of graph operations on graph databases, which is implemented in several graph databases, including Neo4j.ApproachThis section formalizes the approach and explains it through an example.", [["Neo4j", "GENE_OR_GENE_PRODUCT", 171, 176], ["Neo4j", "PROTEIN", 171, 176], ["Cypher", "TREATMENT", 0, 6], ["graph operations", "TREATMENT", 75, 91], ["graph databases", "TEST", 95, 110], ["ApproachThis section", "TREATMENT", 177, 197]]], ["This requires defining logs, traces, events, and event attributes as different nodes so that the access control can be limited for each node.DefinitionsDefinition 1 (Event Repository).", [["node", "ANATOMY", 136, 140], ["node", "MULTI-TISSUE_STRUCTURE", 136, 140], ["different nodes", "PROBLEM", 69, 84], ["the access control", "TREATMENT", 93, 111], ["each node", "PROBLEM", 131, 140], ["nodes", "OBSERVATION", 79, 84], ["node", "OBSERVATION", 136, 140]]], ["An event repository is a tupleDefinitions-N is the set of nodes with the following subsets:Definitions-L represents the set of logs, -T represents the set of traces, -E represents the set of events, -A represents the set of attributes, representing activities, where:Definitions-logs to traces, i.e., L \u00d7 T -traces to events, i.e., T \u00d7 E, -events to events, i.e., E \u00d7 E, -events to attributes, i.e., E \u00d7 A, where:DefinitionsLet's also define two operators on the graph's nodes as:Definitions-\u2022n represents the operator that retrieves the set of nodes from which there are relations to node n, i.e., \u2022n = {\u2200e \u2208 N |(e, n) \u2208 R}. n\u2022 represents the operator that retrieves the set of nodes to which there are relations from node n, i.e., n\u2022 = {\u2200e \u2208 N |(n, e) \u2208 R}.Definitionswhere N, L, T, E, A, R, representing the set of Nodes, Logs, Traces, Events, Attributes, Relations respectively, is sound iff:Definitions-\u2200t \u2208 T, | \u2022 t| = 1, meaning that a trace must belongs to 1 and only 1 log.Definitions-\u2200e \u2208 E, | \u2022 e \u2229 T | = 1, meaning that an event must belongs to 1 and only 1 trace. -\u2200e \u2208 E, | \u2022 e \u2229 E| <= 1, meaning that an event can only have at most 1 input flow from another event. -\u2200e \u2208 E, |e \u2022 \u2229E| <= 1, meaning that an event can only have at most 1 output flow to another event. -\u2200e \u2208 E, |e \u2022 \u2229A| = 1, meaning that an event must be related to 1 and only 1 attribute.DefinitionsNote that this formalization can be extended to enable several types of sequences among event logs.", [["R}.", "CHEMICAL", 756, 759], ["n\u2022", "PROTEIN", 626, 628], ["Definitionswhere", "TEST", 759, 775], ["Definitions", "TEST", 896, 907], ["Definitions", "TEST", 982, 993], ["an event", "TEST", 1032, 1040], ["nodes", "OBSERVATION", 58, 63], ["nodes", "OBSERVATION", 471, 476], ["nodes", "OBSERVATION", 545, 550], ["nodes", "OBSERVATION", 679, 684], ["node", "OBSERVATION", 719, 723], ["L", "ANATOMY_MODIFIER", 779, 780], ["Nodes", "OBSERVATION", 818, 823]]], ["Algorithm 1 defines how the DFG for a given sound event repository can be calculated.DefinitionsAlgorithm 1: Algorithm for calculating dfgExampleThis section elaborates on the definitions through an example.", [["DFG", "DNA", 28, 31], ["This section", "TEST", 145, 157]]], ["Fig.3 shows an example of a sound event repository graph.", [["Fig.3", "PROTEIN", 0, 5]]], ["The set of nodes for Log, Trace, Event, and Attribute are collored as green, red, white, and yellow respectively.", [["nodes", "MULTI-TISSUE_STRUCTURE", 11, 16], ["nodes", "OBSERVATION", 11, 16]]], ["This repository includes one log file, called l1, which has two traces, i.e., t1 and t2. t1 has three events that are happened with this order e1 \u2192 e2 \u2192 e3. t2 also has three events that are happened with this order e4 \u2192 e5 \u2192 e6.ExampleAs it can be seen, each event is related to one activity, e.g., e1 is the execution of activity a1.", [["l1", "DNA", 46, 48], ["t1", "DNA", 89, 91], ["e1", "DNA", 143, 145], ["e3", "DNA", 153, 155], ["t2", "DNA", 157, 159], ["l1", "ANATOMY", 46, 48]]], ["For some activities, there might be more than one events, e.g., \u2022a2 returns {e2, e4}.", [["\u2022a2", "CHEMICAL", 64, 67]]], ["The DFG calculation is described as bellow:Examplefor each pair of activities, the algorithm will calculate the frequency.", [["The DFG calculation", "TEST", 0, 19], ["the algorithm", "TEST", 79, 92]]], ["We show the calculation for one pair example, i.e., a2, a3:ImplementationThe approach presented in this paper is implemented in Neo4j, which was chosen because it supports i) storing graphs and doing graph operations, ii) both vertical and horizontal scaling, iii) querying the graph using Cypher, iii) finegrained access control, sub-graph access control, and role-based access control.", [["graph operations", "TREATMENT", 200, 216], ["vertical and horizontal scaling", "TREATMENT", 227, 258], ["Cypher, iii) finegrained access control", "TREATMENT", 290, 329], ["sub-graph access control", "TREATMENT", 331, 355], ["role-based access control", "TREATMENT", 361, 386]]], ["The supported access controls enable analysts to analyze event logs without the need to have access to individual details.ImplementationWe implemented a data-aware version of the approach.", [["the approach", "TREATMENT", 175, 187]]], ["The main differences with the formalization are:Implementation-Attributes have key and val, where key is set to predefined values, which are common in process mining applications, i.e., 'log concept name', 'case concept name', and 'concept name' representing the attribute that holds information for log, case, and activity name respectively.Implementation-This feature means that the activities are stored as one subset of activity set, and they shall be filtered based on the attributes' data.Implementationevents have timestamps to enable dicing information based on time.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["differences", "OBSERVATION_MODIFIER", 9, 20]]], ["Note that the timestamp cannot be defined as an attribute with its own key since we will end up with many extra nodes due to many timestamps that exist for each event.", [["extra nodes", "MULTI-TISSUE_STRUCTURE", 106, 117], ["many extra nodes", "PROBLEM", 101, 117], ["many timestamps", "PROBLEM", 125, 140], ["nodes", "OBSERVATION", 112, 117]]], ["Thus, they are kept as an attribute of Event class, following the same practice to deal with times in data warehousing [18] .ImplementationThe calculation of DFG is implemented using a Cypher query as bellow: The match clause in the query identifies all patterns in sub-graphs that match the expression.", [["match clause", "OBSERVATION", 213, 225], ["all", "OBSERVATION_MODIFIER", 250, 253], ["patterns", "OBSERVATION_MODIFIER", 254, 262]]], ["The expression select two attributes a1 and a2 with the type of concept name, which indicates that they are activities' names.", [["a2", "DNA", 44, 46]]], ["The return clause retrieves all combinations of attributes in addition to the number of total direct relations between their events, which is the calculation that we formalized in Algorithm 1.ImplementationTo limit the number of events base on their timestamp, we can easily add a where clause to the cypher query to limit the timestamp.", [["return clause", "OBSERVATION", 4, 17]]], ["For other attributes, the associated attribute node can be filtered.EvaluationThis section reports the evaluation result, which is done by calculating DFG using our approach and process mining for python (pm4py) library [5] based on a real public log file [8] .", [["node", "ANATOMY", 47, 51], ["node", "MULTI-TISSUE_STRUCTURE", 47, 51], ["the associated attribute node", "PROBLEM", 22, 51], ["Evaluation", "TEST", 68, 78], ["the evaluation", "TEST", 99, 113], ["node", "OBSERVATION", 47, 51]]], ["Docker is a Platform as a Service (PaaS) product that enables creating, running, and managing containers.", [["a Service (PaaS) product", "TREATMENT", 24, 48]]], ["It also enables the control of the resources that are available for each container, such as RAM and CPU.EvaluationAmong different process mining tools, we chose process mining for python (pm4py) library [5] , because i) it is open-source; ii) the DFG calculation step and discovery step can be separated easily, and iii) it can easily be encapsulated in a container.", [["Evaluation", "TEST", 104, 114]]], ["The separation of DFG calculation and discovery step in this library also enables reusing all discovery algorithms along using our approach, which makes our approach very reusable.EvaluationWe designed two experiment to evaluate our approach, which are listed in Table5 1 .", [["DFG calculation", "TEST", 18, 33], ["our approach", "TREATMENT", 127, 139]]], ["We also changed the CPU starting from half of a CPU (0.5), adding by the same amount in each round until we reached 4.0.", [["the CPU", "TREATMENT", 16, 23]]], ["Fig.4 shows the execution result for both containers, where the x, y and z axes refer to the available memory (RAM) (in megabytes), DFG calculation time (in seconds), and available CPU quotes, respectively.", [["Fig.4", "PROTEIN", 0, 5]]], ["The experiment related to neo4j and pm4py containers is plotted by red and blue, respectively.", [["neo4j", "GENE_OR_GENE_PRODUCT", 26, 31], ["neo4j and pm4py containers", "DNA", 26, 52], ["neo4j and pm4py containers", "TREATMENT", 26, 52]]], ["As can be Fig. 4 .", [["Fig", "OBSERVATION", 10, 13]]], ["Evaluating DFG calculation time by scaling resources seen, pm4py could not compute DFG when the memory was less than the size of the log, i.e., around 1.5 gigabytes, while neo4j could calculate DFG in that setting.", [["pm4py", "PROTEIN", 59, 64], ["neo4j", "PROTEIN", 172, 177], ["DFG", "OBSERVATION", 194, 197]]], ["This shows that the graph database can compute DFG when computational memory is less than the log size, which is an enabler when applying process mining on a very large volume of data.Experiment 1As it can be seen in the figure, the increasing amount of memory reduced the time that neo4j computed the DFG, while it has very little effect on pm4py.", [["pm4py", "GENE_OR_GENE_PRODUCT", 342, 347], ["neo4j", "PROTEIN", 283, 288], ["DFG", "PROTEIN", 302, 305], ["pm4py", "PROTEIN", 342, 347], ["the graph database", "TEST", 16, 34], ["log size", "OBSERVATION_MODIFIER", 94, 102], ["increasing", "OBSERVATION_MODIFIER", 233, 243], ["amount", "OBSERVATION_MODIFIER", 244, 250], ["memory reduced", "OBSERVATION", 254, 268]]], ["This is no surprise for in-memory calculation since if the log fits the memory, then the performance will not be increased much by adding more memory.", [["no surprise for", "UNCERTAINTY", 8, 23]]], ["It is also visible that assigning more CPU does not affect the performance of either of these approaches.Experiment 1It should also be mentioned that despite increasing memory can reduce the DFG calculation time for neo4j significantly; it cannot be faster than pm4py when calculating the DFG on the complete log file.", [["pm4py", "PROTEIN", 262, 267]]], ["Thus, for small log files that can fit the computer's memory, the in-memory approach can be better if the security and access control are not necessary.Experiment 2Event logs usually contain different variations that exist in the enactment of business processes [6] .", [["access control", "TREATMENT", 119, 133], ["different variations", "PROBLEM", 191, 211], ["different", "OBSERVATION_MODIFIER", 191, 200], ["variations", "OBSERVATION_MODIFIER", 201, 211]]], ["These variations make process mining challenging because discovering the process based on the whole even logs usually produces so-called spaghetti models, which usually cannot be comprehended by humans, so they have very little value.", [["humans", "ORGANISM", 195, 201], ["humans", "SPECIES", 195, 201], ["humans", "SPECIES", 195, 201]]], ["We diced the data in both settings by filtering events that happened during the first day; then, we added one more day to the filter condition to increase the events in an accumulative way.", [["the filter condition", "TREATMENT", 122, 142], ["the events", "PROBLEM", 155, 165]]], ["In this way, we could compare the performance by considering how the size of the filtered events affects the performance of calculating DFG.", [["the filtered events", "PROBLEM", 77, 96], ["calculating DFG", "PROBLEM", 124, 139], ["size", "OBSERVATION_MODIFIER", 69, 73]]], ["Fig.5 shows the evaluation result, where the x and y axes refer to the number of events (in millions) and DFG calculation time (in seconds).", [["Fig.5", "PROTEIN", 0, 5], ["the evaluation", "TEST", 12, 26], ["DFG calculation time", "TEST", 106, 126]]], ["However, pm4py performed better when the number of events exceeded 2 million.", [["pm4py", "GENE_OR_GENE_PRODUCT", 9, 14], ["pm4py", "PROTEIN", 9, 14]]], ["This is no surprise since pm4py loaded logs into memory first, so increasing the size will have less effect on its performance.Related Work and DiscussionThis section discusses the relationship between our approach to other research work.", [["pm4py", "CHEMICAL", 26, 31], ["pm4py", "SIMPLE_CHEMICAL", 26, 31], ["pm4py", "PROTEIN", 26, 31], ["This section", "TREATMENT", 154, 166], ["no", "UNCERTAINTY", 8, 10], ["size", "OBSERVATION_MODIFIER", 81, 85], ["less effect", "OBSERVATION_MODIFIER", 96, 107]]], ["The related work can be divided into three categories reflecting those that are about scalability, preserving privacy, and using graph databases in process mining.ScalabilityThe scalability issue in process mining is a big concern for applying the techniques on a large volume of data.", [["the techniques", "TEST", 244, 258], ["scalability", "OBSERVATION_MODIFIER", 178, 189]]], ["The evaluation of their approach shows a similar trend for a performance like what we presented in Fig.5 .", [["Fig.5", "PROTEIN", 99, 104], ["The evaluation", "TEST", 0, 14]]], ["The advantage of our approach can be considered as the capability to preserve privacy while computing DFG.ScalabilityMapReduce has used by other researchers for the aim of process mining, e.g., [10, 25] .", [["our approach", "TREATMENT", 17, 29], ["ScalabilityMapReduce", "TREATMENT", 106, 126]]], ["As discussed by [14] , MapReduce has used to support only event correlation discovery in [25] , and it is used to discover process models using Alpha Miner and the Flexible Heuristics Miner in [10] .Preserving privacyThis paper does not directly contribute to preserving privacy issues in process mining; however, it enables new sort of support by enabling the use of fine-grain access controls, which are supported by Graph Databases, in particular Neo4j.Preserving privacyPreserving privacy in process mining is an important issue that recently got a lot of attention due to its importance.", [["Neo4j", "PROTEIN", 450, 455], ["Alpha Miner", "TREATMENT", 144, 155], ["fine-grain access controls", "TREATMENT", 368, 394]]], ["As technological privacy challenges, authors mentioned the aggregation challenge that deals with enabling an analysis on aggregated event information without exposing the information at the individual level.", [["an analysis", "TEST", 106, 117]]], ["The approach in this paper can well address this issue due to access control capabilities that exist in Neo4j.", [["Neo4j", "PROTEIN", 104, 109], ["access control capabilities", "TREATMENT", 62, 89]]], ["There are potentials to address other challenges using our approach, but the discussion is out of the scope of this paper.Preserving privacyPika A. et al., proposed a framework for privacy-preserving when applying process mining in healthcare domain [23] .", [["our approach", "TREATMENT", 55, 67], ["privacy", "TREATMENT", 181, 188]]], ["They extend the work in [24] , where they discussed the result of applying some techniques in other domains.", [["some techniques", "TREATMENT", 75, 90]]], ["As mentioned by authors, there might be needs for techniques like access control even after the data anonymization for output results.", [["techniques like access control", "TREATMENT", 50, 80], ["the data anonymization", "TEST", 92, 114]]], ["Our approach enables access control in one step before, i.e., DFG computation, and it does not address other issues in other steps.Preserving privacyThere is also recent work to support the privacy issue in process mining like [4, 11, 12, 20, 22] , but as the best of our knowledge, no approach applied access control and security when computing DFG.Graph databaseThere are different attempts to use graph databases with process mining.", [["access control", "TREATMENT", 21, 35], ["approach applied access control", "TREATMENT", 286, 317], ["Graph database", "TEST", 350, 364], ["graph databases", "TEST", 400, 415], ["process mining", "TREATMENT", 421, 435]]], ["Still, as our best of knowledge, none of the approaches supports shifting the calculation of DFG to a graph database.", [["DFG", "PROTEIN", 93, 96], ["a graph database", "TEST", 100, 116]]], ["Thus, none of them can perform better than a traditional approach like pm4py.", [["pm4py", "GENE_OR_GENE_PRODUCT", 71, 76], ["pm4py", "PROTEIN", 71, 76]]], ["They have used Neo4j as the graph database and used Cypher to query the logs.", [["Neo4j", "PROTEIN", 15, 20], ["Neo4j", "TREATMENT", 15, 20], ["the graph database", "TEST", 24, 42], ["Cypher", "TREATMENT", 52, 58]]], ["The approach uses a graph database as a log repository to sore data without any predefined structure, which is quite different from the topic of this paper.", [["sore data", "PROBLEM", 58, 67]]], ["The main difference is that [9] demonstrates that the graph database has more capability to add more features to data, which is a very important topic in any machine learning related approach in general.Graph databaseJoishi J. and Sureka A. also used a graph database for storing non-structured event logs [16, 17] .", [["the graph database", "TEST", 50, 68], ["main", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19]]], ["They also demonstrated that Actor-activity matrix could be calculated using Cypher.", [["Actor-activity matrix", "TREATMENT", 28, 49], ["Cypher", "TREATMENT", 76, 82], ["Cypher", "OBSERVATION", 76, 82]]], ["However, the approach is context-dependent since the logs are not standardized like our approach.", [["dependent", "OBSERVATION_MODIFIER", 33, 42]]], ["Also, the approach cannot be used with other process discovery algorithm since it does not shift and separate the computation of DFG to a graph database.ConclusionThis paper introduced and formalized a new approach to support process mining using graph databases.", [["DFG", "PROTEIN", 129, 132], ["a graph database", "TEST", 136, 152], ["a new approach", "TREATMENT", 200, 214], ["graph databases", "TEST", 247, 262]]], ["The approach defines how log files shall be stored in a graph database, and it also defined how Directly Follows Graph (DFG) can be calculated in the graph database.", [["a graph database", "TEST", 54, 70], ["the graph database", "TEST", 146, 164]]], ["The approach is evaluated in comparison with pm4py by applying on a real log file.", [["pm4py", "PROTEIN", 45, 50]]], ["The evaluation result shows that the approach supports mining processes when the event log is bigger than computational memory.", [["The evaluation", "TEST", 0, 14], ["bigger", "OBSERVATION_MODIFIER", 94, 100]]], ["It also shows that it is scalable, and the performance is better when dicing the event log in a small chunk.", [["a small chunk", "PROBLEM", 94, 107], ["scalable", "OBSERVATION_MODIFIER", 25, 33], ["small", "OBSERVATION_MODIFIER", 96, 101]]], ["Also, we intend to do some case studies to show how this approach supports privacy Preserving in practice.", [["some case studies", "TEST", 22, 39]]]], "PMC6511300": [["IntroductionHuman rhinovirus (HRV) is the most commonly detected respiratory virus after hematopoietic cell transplantation (HCT) in both the upper and lower respiratory tract 1, 2.", [["hematopoietic cell", "ANATOMY", 89, 107], ["HCT", "ANATOMY", 125, 128], ["lower respiratory tract", "ANATOMY", 152, 175], ["IntroductionHuman rhinovirus", "ORGANISM", 0, 28], ["hematopoietic cell", "CELL", 89, 107], ["HCT", "CANCER", 125, 128], ["upper", "ORGANISM_SUBDIVISION", 142, 147], ["IntroductionHuman rhinovirus", "SPECIES", 0, 28], ["HRV", "SPECIES", 30, 33], ["IntroductionHuman rhinovirus", "PROBLEM", 0, 28], ["respiratory virus", "PROBLEM", 65, 82], ["hematopoietic cell transplantation", "TREATMENT", 89, 123], ["HCT", "TEST", 125, 128], ["respiratory virus", "OBSERVATION", 65, 82], ["hematopoietic cell transplantation", "OBSERVATION", 89, 123], ["both", "ANATOMY_MODIFIER", 133, 137], ["upper", "ANATOMY_MODIFIER", 142, 147], ["lower", "ANATOMY_MODIFIER", 152, 157], ["respiratory tract", "ANATOMY", 158, 175]]], ["Although rare, once virologically confirmed lower respiratory tract infection (LRTI) has developed, mortality rates due to HRV appear to be high (21% to 41%) and even similar to those seen with other respiratory viruses including influenza, respiratory syncytial virus (RSV), and parainfluenza viruses (PIVs) 3, 4, 5.", [["lower respiratory tract", "ANATOMY", 44, 67], ["lower respiratory tract infection", "DISEASE", 44, 77], ["LRTI", "DISEASE", 79, 83], ["respiratory viruses", "DISEASE", 200, 219], ["influenza", "DISEASE", 230, 239], ["respiratory syncytial virus (RSV), and parainfluenza viruses", "DISEASE", 241, 301], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 44, 67], ["influenza", "ORGANISM", 230, 239], ["respiratory syncytial virus", "ORGANISM", 241, 268], ["RSV", "ORGANISM", 270, 273], ["parainfluenza viruses", "ORGANISM", 280, 301], ["respiratory syncytial virus", "SPECIES", 241, 268], ["parainfluenza", "SPECIES", 280, 293], ["respiratory syncytial virus", "SPECIES", 241, 268], ["RSV", "SPECIES", 270, 273], ["lower respiratory tract infection", "PROBLEM", 44, 77], ["mortality rates", "TEST", 100, 115], ["HRV", "PROBLEM", 123, 126], ["other respiratory viruses", "PROBLEM", 194, 219], ["influenza", "PROBLEM", 230, 239], ["respiratory syncytial virus (RSV)", "PROBLEM", 241, 274], ["parainfluenza viruses (PIVs)", "TREATMENT", 280, 308], ["lower", "ANATOMY_MODIFIER", 44, 49], ["respiratory tract", "ANATOMY", 50, 67], ["infection", "OBSERVATION", 68, 77], ["respiratory", "ANATOMY", 200, 211], ["viruses", "OBSERVATION", 212, 219], ["respiratory syncytial", "ANATOMY", 241, 262], ["parainfluenza viruses", "OBSERVATION", 280, 301]]], ["Risk factors associated with LRTI in this population have been defined for RSV, PIVs, influenza, and human metapneumovirus (hMPV) 6, 7, 8, 9, 10, which include lymphopenia, use of high\u2013dose steroids, and conditioning regimen; this has not been done systematically in HCT recipients presenting with HRV upper respiratory tract infection (URTI).", [["upper respiratory tract", "ANATOMY", 302, 325], ["LRTI", "DISEASE", 29, 33], ["PIVs", "DISEASE", 80, 84], ["influenza", "DISEASE", 86, 95], ["human metapneumovirus", "DISEASE", 101, 122], ["hMPV", "DISEASE", 124, 128], ["lymphopenia", "DISEASE", 160, 171], ["steroids", "CHEMICAL", 190, 198], ["HRV upper respiratory tract infection", "DISEASE", 298, 335], ["URTI", "DISEASE", 337, 341], ["steroids", "CHEMICAL", 190, 198], ["RSV", "ORGANISM", 75, 78], ["human metapneumovirus", "ORGANISM", 101, 122], ["hMPV", "ORGANISM", 124, 128], ["HCT", "CANCER", 267, 270], ["upper respiratory", "ORGANISM_SUBDIVISION", 302, 319], ["tract", "ORGANISM_SUBDIVISION", 320, 325], ["human", "SPECIES", 101, 106], ["metapneumovirus", "SPECIES", 107, 122], ["RSV", "SPECIES", 75, 78], ["human metapneumovirus", "SPECIES", 101, 122], ["hMPV", "SPECIES", 124, 128], ["Risk factors", "PROBLEM", 0, 12], ["LRTI", "PROBLEM", 29, 33], ["RSV", "PROBLEM", 75, 78], ["PIVs", "TREATMENT", 80, 84], ["influenza", "PROBLEM", 86, 95], ["human metapneumovirus (hMPV)", "PROBLEM", 101, 129], ["lymphopenia", "PROBLEM", 160, 171], ["high\u2013dose steroids", "TREATMENT", 180, 198], ["conditioning regimen", "TREATMENT", 204, 224], ["HCT recipients", "TREATMENT", 267, 281], ["HRV upper respiratory tract infection", "PROBLEM", 298, 335], ["metapneumovirus", "OBSERVATION", 107, 122], ["lymphopenia", "OBSERVATION", 160, 171], ["upper", "ANATOMY_MODIFIER", 302, 307], ["respiratory tract", "ANATOMY", 308, 325], ["infection", "OBSERVATION", 326, 335]]], ["In a study of HRV infection that included both HCT recipients and patients with hematologic malignancies, factors more likely to be present in patients with LRTI included inpatient status, lymphopenia, and hypoalbuminemia [11].", [["HCT", "ANATOMY", 47, 50], ["hematologic malignancies", "ANATOMY", 80, 104], ["HRV infection", "DISEASE", 14, 27], ["hematologic malignancies", "DISEASE", 80, 104], ["LRTI", "DISEASE", 157, 161], ["lymphopenia", "DISEASE", 189, 200], ["hypoalbuminemia", "DISEASE", 206, 221], ["HCT", "CANCER", 47, 50], ["patients", "ORGANISM", 66, 74], ["hematologic malignancies", "CANCER", 80, 104], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 143, 151], ["HRV", "SPECIES", 14, 17], ["a study", "TEST", 3, 10], ["HRV infection", "PROBLEM", 14, 27], ["both HCT recipients", "TREATMENT", 42, 61], ["hematologic malignancies", "PROBLEM", 80, 104], ["LRTI", "PROBLEM", 157, 161], ["lymphopenia", "PROBLEM", 189, 200], ["hypoalbuminemia", "PROBLEM", 206, 221], ["infection", "OBSERVATION", 18, 27], ["lymphopenia", "OBSERVATION", 189, 200], ["hypoalbuminemia", "OBSERVATION", 206, 221]]], ["Of note, not all cases of LRTI were virologically confirmed in this study, and the analysis was not conducted in a time\u2013dependent manner.", [["LRTI", "DISEASE", 26, 30], ["LRTI", "PROBLEM", 26, 30], ["this study", "TEST", 63, 73], ["the analysis", "TEST", 79, 91]]], ["Furthermore, several key factors including viral load were not evaluated in this study.IntroductionIn the present study we aimed to identify specific risk factors for progression to LRTI in a cohort of patients presenting with URTI.", [["LRTI", "DISEASE", 182, 186], ["URTI", "DISEASE", 227, 231], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["viral load", "TEST", 43, 53], ["this study", "TEST", 76, 86], ["the present study", "TEST", 102, 119], ["LRTI", "PROBLEM", 182, 186], ["URTI", "PROBLEM", 227, 231], ["viral load", "OBSERVATION", 43, 53]]], ["We then developed a risk score for disease progression to help clinicians risk stratify patients who may benefit from more intensive monitoring and follow-up.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["disease progression", "PROBLEM", 35, 54], ["intensive monitoring", "TEST", 123, 143]]], ["Ultimately, identification of high\u2013risk patients will be important for clinical trial design that will require defining an enriched cohort at high risk for LRTI that may benefit from potential interventions.Patients and Data Collection ::: MethodsWe retrospectively identified all HCT patients who underwent transplant between January 1, 2009 and April 1, 2016, at Fred Hutchinson Cancer Research Center.", [["HCT", "ANATOMY", 281, 284], ["LRTI", "DISEASE", 156, 160], ["Cancer", "DISEASE", 381, 387], ["patients", "ORGANISM", 40, 48], ["Patients", "ORGANISM", 207, 215], ["HCT", "CANCER", 281, 284], ["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 40, 48], ["Patients", "SPECIES", 207, 215], ["patients", "SPECIES", 285, 293], ["clinical trial design", "TREATMENT", 71, 92], ["LRTI", "PROBLEM", 156, 160], ["potential interventions", "TREATMENT", 183, 206], ["transplant", "TREATMENT", 308, 318], ["Cancer", "OBSERVATION", 381, 387]]], ["Subjects were eligible for inclusion in the study if positive for HRV from the upper respiratory tract post-transplant.", [["upper respiratory tract", "ANATOMY", 79, 102], ["Subjects", "ORGANISM", 0, 8], ["upper respiratory", "ORGANISM_SUBDIVISION", 79, 96], ["tract", "ORGANISM_SUBDIVISION", 97, 102], ["the study", "TEST", 40, 49], ["HRV", "PROBLEM", 66, 69], ["the upper respiratory tract", "PROBLEM", 75, 102], ["upper", "ANATOMY_MODIFIER", 79, 84], ["respiratory tract", "ANATOMY", 85, 102]]], ["Patients with HRV infection before transplant were excluded.Patients and Data Collection ::: MethodsClinical data were collected from databases and supplemental review of the medical record.", [["HRV infection", "DISEASE", 14, 27], ["Patients", "ORGANISM", 0, 8], ["Patients", "ORGANISM", 60, 68], ["Patients", "SPECIES", 0, 8], ["Patients", "SPECIES", 60, 68], ["HRV infection", "PROBLEM", 14, 27], ["transplant", "TREATMENT", 35, 45], ["MethodsClinical data", "TEST", 93, 113], ["infection", "OBSERVATION", 18, 27]]], ["This study was approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center.", [["Cancer", "DISEASE", 81, 87], ["This study", "TEST", 0, 10], ["Cancer", "OBSERVATION", 81, 87]]], ["Subjects signed informed consent permitting the use of data for research.HRV Case Identification ::: MethodsRespiratory tract samples collected as part of routine clinical care from adult and pediatric patients with respiratory symptoms were tested for 12 respiratory viruses by real-time reverse-transcriptase PCR (RT-qPCR) assays, including RSV, hMPV, influenza viruses A and B, PIVs 1 to 4, adenovirus, human coronaviruses, HRV, and human bocavirus.", [["MethodsRespiratory tract samples", "ANATOMY", 101, 133], ["respiratory", "ANATOMY", 216, 227], ["patients", "ORGANISM", 202, 210], ["RSV", "ORGANISM", 343, 346], ["hMPV", "ORGANISM", 348, 352], ["influenza viruses A", "ORGANISM", 354, 373], ["B", "GENE_OR_GENE_PRODUCT", 378, 379], ["PIVs 1", "ORGANISM", 381, 387], ["adenovirus", "ORGANISM", 394, 404], ["human", "ORGANISM", 406, 411], ["coronaviruses", "ORGANISM", 412, 425], ["HRV", "ORGANISM", 427, 430], ["human", "ORGANISM", 436, 441], ["bocavirus", "ORGANISM", 442, 451], ["patients", "SPECIES", 202, 210], ["human", "SPECIES", 406, 411], ["human", "SPECIES", 436, 441], ["RSV", "SPECIES", 343, 346], ["hMPV", "SPECIES", 348, 352], ["adenovirus", "SPECIES", 394, 404], ["human coronaviruses", "SPECIES", 406, 425], ["HRV", "SPECIES", 427, 430], ["human", "SPECIES", 436, 441], ["MethodsRespiratory tract samples", "TEST", 101, 133], ["routine clinical care", "TREATMENT", 155, 176], ["respiratory symptoms", "PROBLEM", 216, 236], ["12 respiratory viruses", "PROBLEM", 253, 275], ["transcriptase PCR", "TEST", 297, 314], ["RT-qPCR", "TEST", 316, 323], ["assays", "TEST", 325, 331], ["RSV", "PROBLEM", 343, 346], ["hMPV", "PROBLEM", 348, 352], ["influenza viruses", "PROBLEM", 354, 371], ["PIVs", "TREATMENT", 381, 385], ["adenovirus", "TREATMENT", 394, 404], ["human bocavirus", "PROBLEM", 436, 451], ["influenza viruses", "OBSERVATION", 354, 371]]], ["RT-qPCR with this multiplex panel was performed on all respiratory samples during the time period of this study.", [["respiratory samples", "ANATOMY", 55, 74], ["RT-qPCR", "TEST", 0, 7], ["this multiplex panel", "TEST", 13, 33], ["all respiratory samples", "TEST", 51, 74], ["this study", "TEST", 101, 111]]], ["The RT-qPCR cycle threshold (CT) was used as a proxy for viral load, with lower CT indicating a higher viral load.", [["The RT-qPCR cycle threshold", "TEST", 0, 27], ["CT", "TEST", 29, 31], ["viral load", "PROBLEM", 57, 67], ["lower CT", "TEST", 74, 82], ["a higher viral load", "PROBLEM", 94, 113], ["viral load", "OBSERVATION", 103, 113]]], ["CT values were analyzed in quartiles as well as above and below the median.Definitions ::: MethodsURTI was defined as a positive HRV PCR result from an upper tract sample (nasopharyngeal swab or wash) only from a symptomatic patient, without any radiographic abnormalities.", [["upper tract sample", "ANATOMY", 152, 170], ["nasopharyngeal swab", "ANATOMY", 172, 191], ["upper tract", "ORGANISM_SUBDIVISION", 152, 163], ["nasopharyngeal swab", "ORGAN", 172, 191], ["patient", "ORGANISM", 225, 232], ["patient", "SPECIES", 225, 232], ["CT values", "TEST", 0, 9], ["a positive HRV PCR", "PROBLEM", 118, 136], ["an upper tract sample", "TEST", 149, 170], ["nasopharyngeal swab", "TEST", 172, 191], ["any radiographic abnormalities", "PROBLEM", 242, 272], ["upper tract", "ANATOMY", 152, 163]]], ["LRTI was defined as a positive lower tract sample (bronchoalveolar lavage [BAL], lung biopsy, or autopsy specimen) with or without radiographic abnormality (proven or probable LRTI, respectively) or a positive upper tract sample with radiographic abnormality (possible LRTI).", [["lower tract sample", "ANATOMY", 31, 49], ["bronchoalveolar lavage", "ANATOMY", 51, 73], ["BAL", "ANATOMY", 75, 78], ["lung", "ANATOMY", 81, 85], ["specimen", "ANATOMY", 105, 113], ["upper tract sample", "ANATOMY", 210, 228], ["LRTI", "DISEASE", 0, 4], ["LRTI", "DISEASE", 176, 180], ["LRTI", "DISEASE", 269, 273], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 51, 73], ["BAL", "MULTI-TISSUE_STRUCTURE", 75, 78], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 81, 92], ["upper tract", "ORGANISM_SUBDIVISION", 210, 221], ["LRTI", "PROBLEM", 0, 4], ["a positive lower tract sample", "PROBLEM", 20, 49], ["bronchoalveolar lavage", "TEST", 51, 73], ["lung biopsy", "TEST", 81, 92], ["autopsy specimen", "TEST", 97, 113], ["radiographic abnormality", "PROBLEM", 131, 155], ["LRTI", "PROBLEM", 176, 180], ["a positive upper tract sample", "PROBLEM", 199, 228], ["radiographic abnormality", "PROBLEM", 234, 258], ["LRTI", "PROBLEM", 269, 273], ["bronchoalveolar lavage", "OBSERVATION", 51, 73], ["lung", "ANATOMY", 81, 85], ["upper tract", "ANATOMY", 210, 221]]], ["Both chest x-rays and chest computed tomography results were included if completed within 2 weeks of last positive HRV date.", [["chest", "ANATOMY", 5, 10], ["Both chest x-rays", "TEST", 0, 17], ["chest computed tomography", "TEST", 22, 47], ["chest", "ANATOMY", 5, 10], ["chest", "ANATOMY", 22, 27]]], ["Lower tract sample results were included up to 3 months from URTI date.", [["Lower tract sample", "ANATOMY", 0, 18], ["URTI", "DISEASE", 61, 65], ["tract", "ORGANISM_SUBDIVISION", 6, 11], ["Lower tract sample", "TEST", 0, 18]]], ["The day of LRTI diagnosis was defined as the date when HRV was detected in the lower tract specimen (in proven/probable LRTI) or the date the radiographic abnormality was detected (in possible LRTI).", [["lower tract specimen", "ANATOMY", 79, 99], ["LRTI", "DISEASE", 11, 15], ["LRTI", "DISEASE", 120, 124], ["LRTI", "DISEASE", 193, 197], ["lower tract", "ORGANISM_SUBDIVISION", 79, 90], ["LRTI diagnosis", "TEST", 11, 25], ["HRV", "PROBLEM", 55, 58], ["LRTI", "PROBLEM", 120, 124], ["the radiographic abnormality", "PROBLEM", 138, 166], ["lower tract", "ANATOMY", 79, 90]]], ["Patients who met criteria for LRTI within 2 days of URTI were considered to have LRTI at presentation and were not included in the progression analyses.", [["LRTI", "DISEASE", 30, 34], ["URTI", "DISEASE", 52, 56], ["LRTI", "DISEASE", 81, 85], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["LRTI", "PROBLEM", 30, 34], ["URTI", "PROBLEM", 52, 56], ["LRTI", "PROBLEM", 81, 85]]], ["An HRV illness event was considered to be a new event if \u226512 weeks elapsed between 2 positive samples or if there were \u22652 negative HRV samples between 2 HRV positive samples.Statistical Analysis ::: MethodsThe probability of progression from upper to lower HRV infection was estimated using cumulative incidence, treating death as a competing risk event.", [["samples", "ANATOMY", 94, 101], ["samples", "ANATOMY", 135, 142], ["samples", "ANATOMY", 166, 173], ["HRV illness", "DISEASE", 3, 14], ["HRV infection", "DISEASE", 257, 270], ["death", "DISEASE", 322, 327], ["upper", "ORGANISM_SUBDIVISION", 242, 247], ["An HRV illness event", "PROBLEM", 0, 20], ["Methods", "TREATMENT", 199, 206], ["upper to lower HRV infection", "PROBLEM", 242, 270], ["death", "PROBLEM", 322, 327], ["progression", "OBSERVATION_MODIFIER", 225, 236], ["upper", "ANATOMY_MODIFIER", 242, 247], ["lower HRV", "ANATOMY", 251, 260], ["infection", "OBSERVATION", 261, 270]]], ["Factors associated with progression to LRTI were evaluated using Cox regression models.Statistical Analysis ::: MethodsThe following variables were considered potential predictors of progression: patient age; sex; donor type; cell source; year transplant performed; conditioning regimen; most recent WBC count; neutrophil, lymphocyte, monocyte, and platelet counts before HRV infection (within 2 weeks); lowest albumin level in the 2 weeks before HRV infection; highest daily steroid dose in the 2 weeks before HRV infection; pretransplant lung function; HCT-specific comorbidity index (HCT-CI) [12]; time from transplant to HRV infection; HRV CT values, acute and chronic graft-versus-host-disease; and recipient and donor cytomegalovirus (CMV) serostatus.", [["cell", "ANATOMY", 226, 230], ["WBC", "ANATOMY", 300, 303], ["neutrophil", "ANATOMY", 311, 321], ["lymphocyte", "ANATOMY", 323, 333], ["monocyte", "ANATOMY", 335, 343], ["platelet", "ANATOMY", 349, 357], ["lung", "ANATOMY", 540, 544], ["graft", "ANATOMY", 673, 678], ["LRTI", "DISEASE", 39, 43], ["HRV infection", "DISEASE", 372, 385], ["HRV infection", "DISEASE", 447, 460], ["steroid", "CHEMICAL", 476, 483], ["HRV infection", "DISEASE", 511, 524], ["HRV infection", "DISEASE", 625, 638], ["steroid", "CHEMICAL", 476, 483], ["patient", "ORGANISM", 196, 203], ["cell", "CELL", 226, 230], ["WBC", "CELL", 300, 303], ["neutrophil", "CELL", 311, 321], ["lymphocyte", "CELL", 323, 333], ["monocyte", "CELL", 335, 343], ["platelet", "CELL", 349, 357], ["albumin", "GENE_OR_GENE_PRODUCT", 411, 418], ["steroid", "SIMPLE_CHEMICAL", 476, 483], ["lung", "ORGAN", 540, 544], ["cytomegalovirus", "ORGANISM", 724, 739], ["CMV", "ORGANISM", 741, 744], ["neutrophil", "CELL_TYPE", 311, 321], ["lymphocyte", "CELL_TYPE", 323, 333], ["platelet", "CELL_TYPE", 349, 357], ["albumin", "PROTEIN", 411, 418], ["patient", "SPECIES", 196, 203], ["CMV", "SPECIES", 741, 744], ["progression to LRTI", "PROBLEM", 24, 43], ["Cox regression models", "TEST", 65, 86], ["donor type; cell source", "PROBLEM", 214, 237], ["year transplant", "TREATMENT", 239, 254], ["conditioning regimen", "TREATMENT", 266, 286], ["WBC count", "TEST", 300, 309], ["neutrophil", "TEST", 311, 321], ["lymphocyte", "TEST", 323, 333], ["monocyte", "TEST", 335, 343], ["platelet counts", "TEST", 349, 364], ["HRV infection", "PROBLEM", 372, 385], ["lowest albumin level", "TEST", 404, 424], ["HRV infection", "PROBLEM", 447, 460], ["highest daily steroid dose", "TREATMENT", 462, 488], ["HRV infection", "PROBLEM", 511, 524], ["pretransplant lung function", "TEST", 526, 553], ["HCT", "TEST", 555, 558], ["comorbidity index", "TEST", 568, 585], ["HCT", "TEST", 587, 590], ["transplant", "TREATMENT", 611, 621], ["HRV infection", "PROBLEM", 625, 638], ["HRV CT values", "TEST", 640, 653], ["acute and chronic graft", "PROBLEM", 655, 678], ["host-disease", "PROBLEM", 686, 698], ["donor cytomegalovirus", "PROBLEM", 718, 739], ["LRTI", "OBSERVATION", 39, 43], ["infection", "OBSERVATION", 451, 460], ["infection", "OBSERVATION", 515, 524], ["lung", "ANATOMY", 540, 544], ["infection", "OBSERVATION", 629, 638], ["acute", "OBSERVATION_MODIFIER", 655, 660], ["chronic", "OBSERVATION_MODIFIER", 665, 672], ["graft", "OBSERVATION", 673, 678], ["disease", "OBSERVATION", 691, 698], ["cytomegalovirus", "OBSERVATION", 724, 739]]], ["Recipient and donor statin use was defined as previously reported [13].Statistical Analysis ::: MethodsAll covariates with P \u2264 .2 in the univariable analyses were candidates for inclusion in the multivariable Cox regression models.", [["statin", "CHEMICAL", 20, 26], ["statin", "CHEMICAL", 20, 26], ["donor statin", "TREATMENT", 14, 26], ["Methods", "TREATMENT", 96, 103], ["the univariable analyses", "TEST", 133, 157]]], ["The multivariable model was further reduced for constructing the risk score by evaluating the change in the bootstrapped optimism corrected concordance statistic (c-statistic) when each factor was removed from the full model [14].", [["the change", "PROBLEM", 90, 100]]], ["The bootstrapped c-statistic was based on 100 replications.", [["The bootstrapped c-statistic", "TREATMENT", 0, 28]]], ["Score point contributions were developed using the hazard ratios from the final multivariable model.", [["the hazard ratios", "TEST", 47, 64]]], ["Hazard ratios were rounded to the nearest integer and scaled such that the maximum achievable score was 100.", [["Hazard ratios", "TEST", 0, 13], ["rounded", "OBSERVATION_MODIFIER", 19, 26]]], ["The risk score for each subject was calculated based on their covariate values and the associated points given.", [["The risk score", "TEST", 0, 14]]], ["Curves were constructed to examine impact of shifting cut points of the risk score on sensitivity and specificity rates.", [["sensitivity", "TEST", 86, 97], ["specificity rates", "TEST", 102, 119]]], ["Cumulative incidence curves for progression to LRTI for score values above (positive predictive value) and below (negative predictive value) a series of binary cut-off values as well as within categorized ranges of scores were evaluated and compared using log-rank tests and Gray's test.", [["LRTI", "DISEASE", 47, 51], ["Cumulative incidence curves", "TEST", 0, 27], ["LRTI", "TEST", 47, 51], ["score values", "TEST", 56, 68], ["log-rank tests", "TEST", 256, 270], ["Gray's test", "TEST", 275, 286]]], ["Subjects with missing values for albumin, CMV serostatus, and recipient statin status were excluded from univariable and multivariable analyses.Statistical Analysis ::: MethodsStatistical significance was defined as 2-sided P < .05.", [["statin", "CHEMICAL", 72, 78], ["Subjects", "ORGANISM", 0, 8], ["albumin", "GENE_OR_GENE_PRODUCT", 33, 40], ["CMV", "ORGANISM", 42, 45], ["albumin", "PROTEIN", 33, 40], ["CMV", "SPECIES", 42, 45], ["missing values", "PROBLEM", 14, 28], ["albumin", "TEST", 33, 40], ["CMV serostatus", "PROBLEM", 42, 56], ["recipient statin status", "PROBLEM", 62, 85], ["multivariable analyses", "TEST", 121, 143]]], ["SAS version 9.4 TS1M3 (SAS Institute, Inc., Cary, NC) and R version 3.3.0 [15] were used for statistical analyses.Cohort Description ::: ResultsAmong 3445 patients undergoing HCT during the study time period, 732 (21%) were positive for HRV from at least 1 respiratory site (Figure 1), resulting in 782 HRV illness events.", [["HRV illness", "DISEASE", 303, 314], ["patients", "ORGANISM", 155, 163], ["HCT", "CANCER", 175, 178], ["patients", "SPECIES", 155, 163], ["SAS version", "TEST", 0, 11], ["TS1M3", "TEST", 16, 21], ["NC", "TREATMENT", 50, 52], ["R version", "TEST", 58, 67], ["statistical analyses", "TEST", 93, 113], ["HCT", "TEST", 175, 178], ["the study", "TEST", 186, 195], ["HRV", "PROBLEM", 237, 240], ["HRV illness events", "PROBLEM", 303, 321]]], ["Of these, 665 events (85%) represented URTI at presentation, whereas 15% of events involved presentation with LRTI.", [["URTI", "DISEASE", 39, 43], ["LRTI", "DISEASE", 110, 114], ["URTI", "PROBLEM", 39, 43], ["LRTI", "PROBLEM", 110, 114], ["LRTI", "OBSERVATION", 110, 114]]], ["Of 665 URTI events, 588 events had complete data for all covariates and were included in the progression analyses.", [["URTI", "DISEASE", 7, 11], ["URTI events", "PROBLEM", 7, 18], ["complete data", "TEST", 35, 48], ["all covariates", "TEST", 53, 67]]], ["Among subjects with multiple HRV URTI events, the median time between events was 302 days (interquartile range [IQR], 140 to 515).", [["HRV URTI", "DISEASE", 29, 37], ["multiple HRV URTI events", "PROBLEM", 20, 44]]], ["In subjects with URTI at presentation, median age was 42.8 years (IQR, 22.2 to 57.7), and there was a slight male predominance (59%) (Table 1).", [["URTI", "DISEASE", 17, 21], ["IQR", "TEST", 66, 69], ["a slight male predominance", "PROBLEM", 100, 126], ["slight", "OBSERVATION_MODIFIER", 102, 108]]], ["Seventeen percent of URTI events (100/588) progressed to LRTI with 28 (28%) proven LRTI events and 72 (72%) possible LRTI events.", [["URTI", "DISEASE", 21, 25], ["LRTI", "DISEASE", 57, 61], ["LRTI", "DISEASE", 83, 87], ["LRTI", "DISEASE", 117, 121], ["URTI events", "PROBLEM", 21, 32], ["LRTI", "TEST", 57, 61], ["LRTI events", "PROBLEM", 83, 94], ["LRTI events", "PROBLEM", 117, 128], ["possible", "UNCERTAINTY", 108, 116], ["LRTI", "OBSERVATION", 117, 121]]], ["No probable LRTI events occurred.", [["LRTI", "DISEASE", 12, 16], ["LRTI events", "PROBLEM", 12, 23], ["probable", "UNCERTAINTY", 3, 11], ["LRTI", "OBSERVATION", 12, 16]]], ["Most HRV URTI events occurred in recipients of allogeneic HCT (438/588; 74%); 19% (84/438) of events progressed to LRTI in this group with 25 (30%) proven LRTI events and 59 (70%) possible LRTI events.", [["HRV URTI", "DISEASE", 5, 13], ["LRTI", "DISEASE", 115, 119], ["LRTI", "DISEASE", 155, 159], ["LRTI", "DISEASE", 189, 193], ["Most HRV URTI events", "PROBLEM", 0, 20], ["allogeneic HCT", "TEST", 47, 61], ["LRTI", "PROBLEM", 115, 119], ["LRTI events", "PROBLEM", 155, 166], ["LRTI events", "PROBLEM", 189, 200], ["possible", "UNCERTAINTY", 180, 188], ["LRTI", "OBSERVATION", 189, 193]]], ["Median time to progression from URTI to LRTI was 12 days for all events (IQR, 7 to 22) and 12 days for allogeneic subjects only (IQR, 8 to 24) (Figure 2A,B).", [["URTI", "DISEASE", 32, 36], ["LRTI", "DISEASE", 40, 44], ["all events", "PROBLEM", 61, 71], ["allogeneic subjects", "PROBLEM", 103, 122]]], ["Of subjects with possible LRTI events, none had a BAL performed.Risk Factors for Progression to LRTI ::: ResultsIn univariable analysis of all events, donor type, conditioning regimen, prior HRV events, steroid use, albumin level, recipient statin use, recipient CMV serostatus, and most recent WBC count, and neutrophil, lymphocyte, and monocyte counts were sufficiently associated with progression to LRTI to be considered for inclusion in a multivariable model (Table 2).", [["WBC", "ANATOMY", 295, 298], ["neutrophil", "ANATOMY", 310, 320], ["lymphocyte", "ANATOMY", 322, 332], ["monocyte", "ANATOMY", 338, 346], ["LRTI", "DISEASE", 26, 30], ["LRTI", "DISEASE", 96, 100], ["steroid", "CHEMICAL", 203, 210], ["statin", "CHEMICAL", 241, 247], ["LRTI", "DISEASE", 403, 407], ["steroid", "CHEMICAL", 203, 210], ["steroid", "SIMPLE_CHEMICAL", 203, 210], ["albumin", "GENE_OR_GENE_PRODUCT", 216, 223], ["CMV", "ORGANISM", 263, 266], ["WBC", "CELL", 295, 298], ["neutrophil", "CELL", 310, 320], ["lymphocyte", "CELL", 322, 332], ["monocyte", "CELL", 338, 346], ["albumin", "PROTEIN", 216, 223], ["neutrophil", "CELL_TYPE", 310, 320], ["lymphocyte", "CELL_TYPE", 322, 332], ["CMV", "SPECIES", 263, 266], ["LRTI events", "PROBLEM", 26, 37], ["a BAL", "TEST", 48, 53], ["univariable analysis", "TEST", 115, 135], ["all events", "PROBLEM", 139, 149], ["donor type, conditioning regimen", "TREATMENT", 151, 183], ["prior HRV events", "PROBLEM", 185, 201], ["steroid use", "TREATMENT", 203, 214], ["albumin level", "TEST", 216, 229], ["recipient statin", "TREATMENT", 231, 247], ["recipient CMV serostatus", "TEST", 253, 277], ["most recent WBC count", "TEST", 283, 304], ["neutrophil", "TEST", 310, 320], ["lymphocyte", "TEST", 322, 332], ["monocyte counts", "TEST", 338, 353], ["LRTI", "PROBLEM", 403, 407], ["neutrophil", "ANATOMY", 310, 320], ["lymphocyte", "ANATOMY", 322, 332]]], ["Notably, the presence of viral co-pathogens, pulmonary function, or intravenous immunoglobulin, and HRV CT values in the upper tract sample were not associated with progression to LRTI.", [["pulmonary", "ANATOMY", 45, 54], ["intravenous", "ANATOMY", 68, 79], ["upper tract sample", "ANATOMY", 121, 139], ["LRTI", "DISEASE", 180, 184], ["pulmonary", "ORGAN", 45, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 79], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 80, 94], ["upper tract", "ORGANISM_SUBDIVISION", 121, 132], ["intravenous immunoglobulin", "PROTEIN", 68, 94], ["viral co-pathogens", "PROBLEM", 25, 43], ["pulmonary function", "TEST", 45, 63], ["intravenous immunoglobulin", "TREATMENT", 68, 94], ["HRV CT values", "TEST", 100, 113], ["LRTI", "PROBLEM", 180, 184], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["co-pathogens", "OBSERVATION", 31, 43], ["pulmonary", "ANATOMY", 45, 54], ["upper tract", "ANATOMY", 121, 132], ["not associated with", "UNCERTAINTY", 145, 164], ["LRTI", "OBSERVATION", 180, 184]]], ["Univariate and multiple multivariate models for risk factors for progression to proven LRTI only are shown in Supplementary Tables 1 and 2.Risk Factors for Progression to LRTI ::: ResultsCandidate variables from univariable analysis were evaluated in a multivariate model.", [["LRTI", "DISEASE", 87, 91], ["LRTI", "DISEASE", 171, 175], ["Univariate", "TREATMENT", 0, 10], ["multiple multivariate models", "TREATMENT", 15, 43], ["risk factors", "PROBLEM", 48, 60], ["univariable analysis", "TEST", 212, 232]]], ["Covariates were added sequentially and c-statistic calculated for each model until the optimal model with the highest c-statistic was achieved (Table 3).", [["Covariates", "TREATMENT", 0, 10], ["c-statistic", "TEST", 39, 50]]], ["In the final model the c-statistic was .676, whereas the optimism corrected c-statistic was .656.Score Development and Performance ::: ResultsA risk score was developed as described and weighted contributions of each factor are shown in Table 3.", [["c-statistic", "TEST", 76, 87], ["ResultsA risk score", "TEST", 135, 154]]], ["Specificity and sensitivity of score cut\u2013offs for development of LRTI in the entire cohort and the allogeneic cohort are shown in Figure 3A and B, respectively.", [["LRTI", "DISEASE", 65, 69], ["Specificity", "TEST", 0, 11], ["score cut\u2013offs", "TEST", 31, 45], ["LRTI", "PROBLEM", 65, 69], ["the allogeneic cohort", "TREATMENT", 95, 116], ["LRTI", "OBSERVATION", 65, 69]]], ["Among all subjects the score cut-off with the highest sensitivity (57%) and specificity (71%) was 27, corresponding to a positive predictive value of 28% and a negative predictive value of 89% in this population.", [["specificity", "TEST", 76, 87]]], ["Cumulative incidence curves for progression to LRTI in all subjects, stratified by above and below a range of binary score cut\u2013offs are shown in Figure 4A and B, representing positive and negative predictive values for a given cut\u2013off, respectively.", [["LRTI", "DISEASE", 47, 51], ["Cumulative incidence curves", "PROBLEM", 0, 27], ["LRTI", "PROBLEM", 47, 51], ["LRTI", "OBSERVATION", 47, 51]]], ["Cumulative incidence of progression to LRTI for the \u226527 group was 28% versus 11% in the <27 group (log-rank and Gray's test both P < .001).", [["LRTI", "DISEASE", 39, 43], ["LRTI", "TEST", 39, 43], ["Gray's test", "TEST", 112, 123], ["progression", "OBSERVATION_MODIFIER", 24, 35]]], ["Cumulative incidence of progression to LRTI was as follows: scores < 16 (9%), 16 to <27 (13%), 27 to <46 (24%), and \u226546 (43%) (log-rank test and Gray's test both P < .001).", [["LRTI", "DISEASE", 39, 43], ["LRTI", "TEST", 39, 43], ["scores", "TEST", 60, 66], ["\u2265", "TEST", 116, 117], ["log-rank test", "TEST", 127, 140], ["Gray's test", "TEST", 145, 156], ["P", "TEST", 162, 163], ["progression", "OBSERVATION_MODIFIER", 24, 35], ["LRTI", "OBSERVATION", 39, 43]]], ["The weighted risk score was applied to the allogeneic subgroup only and cumulative incidence curves above and below the 27 cut\u2013off are shown Figure 5A.", [["The weighted risk score", "TEST", 0, 23], ["the allogeneic subgroup", "TREATMENT", 39, 62], ["cumulative incidence curves", "TEST", 72, 99]]], ["For scores \u2265 27 the cumulative incidence was 29% versus 13% for scores < 27 (log-rank test and Gray's test P < .001).", [["scores", "TEST", 4, 10], ["scores", "TEST", 64, 70], ["log-rank test", "TEST", 77, 90], ["Gray's test P", "TEST", 95, 108]]], ["The score was also applied to the whole cohort and evaluated with proven LRTI only as the outcome.", [["LRTI", "DISEASE", 73, 77]]], ["Figure 5B shows the cumulative incidence curves above and below 27 for progression to proven LRTI only.", [["LRTI", "DISEASE", 93, 97], ["Figure 5B", "TEST", 0, 9], ["the cumulative incidence curves", "TEST", 16, 47], ["LRTI", "OBSERVATION", 93, 97]]], ["For scores \u2265 27 the cumulative incidence was 9% versus 3% for scores < 27 (log-rank test and Gray's test P = .001).DiscussionIn this large retrospective study of HCT recipients infected with HRV in the upper respiratory tract, we established risk factors and developed a risk score for progression to LRTI.", [["upper respiratory tract", "ANATOMY", 202, 225], ["LRTI", "DISEASE", 301, 305], ["HCT", "CANCER", 162, 165], ["recipients", "ORGANISM", 166, 176], ["upper respiratory", "ORGANISM_SUBDIVISION", 202, 219], ["tract", "ORGANISM_SUBDIVISION", 220, 225], ["scores", "TEST", 4, 10], ["scores", "TEST", 62, 68], ["log-rank test", "TEST", 75, 88], ["Gray's test P", "TEST", 93, 106], ["HCT recipients", "TREATMENT", 162, 176], ["HRV in the upper respiratory tract", "PROBLEM", 191, 225], ["LRTI", "PROBLEM", 301, 305], ["upper", "ANATOMY_MODIFIER", 202, 207], ["respiratory tract", "ANATOMY", 208, 225], ["LRTI", "OBSERVATION", 301, 305]]], ["To our knowledge this is the largest and statistically most rigorous study to systematically examine patients specifically presenting with URTI to determine the risk of subsequent LRTI.", [["URTI", "DISEASE", 139, 143], ["LRTI", "DISEASE", 180, 184], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["rigorous study", "TEST", 60, 74], ["URTI", "PROBLEM", 139, 143], ["subsequent LRTI", "PROBLEM", 169, 184], ["largest", "OBSERVATION_MODIFIER", 29, 36], ["LRTI", "OBSERVATION", 180, 184]]], ["In multivariable models for any LRTI event in all subjects, significant risk factors identified include allogeneic transplant, prior HRV URTI events, lymphocyte count < 100 \u00d7 106 cells/L, recipient statin use, recipient CMV serostatus, and steroid use \u2265 2 mg/kg/day.", [["lymphocyte", "ANATOMY", 150, 160], ["cells", "ANATOMY", 179, 184], ["LRTI", "DISEASE", 32, 36], ["statin", "CHEMICAL", 198, 204], ["steroid", "CHEMICAL", 240, 247], ["steroid", "CHEMICAL", 240, 247], ["lymphocyte", "CELL", 150, 160], ["CMV", "ORGANISM", 220, 223], ["steroid", "SIMPLE_CHEMICAL", 240, 247], ["CMV", "SPECIES", 220, 223], ["any LRTI event", "PROBLEM", 28, 42], ["significant risk factors", "PROBLEM", 60, 84], ["allogeneic transplant", "TREATMENT", 104, 125], ["prior HRV URTI events", "PROBLEM", 127, 148], ["lymphocyte count", "TEST", 150, 166], ["cells", "TEST", 179, 184], ["recipient statin", "TREATMENT", 188, 204], ["recipient CMV serostatus", "TREATMENT", 210, 234], ["steroid use", "TREATMENT", 240, 251], ["CMV serostatus", "OBSERVATION", 220, 234]]], ["We further characterized risk factors for progression by calculating the change in the bootstrapped optimism corrected c-statistic for each risk factor and developed an optimized model for risk prediction.", [["each risk factor", "PROBLEM", 135, 151]]], ["The risk score presented in this article is a novel tool with potential to help risk stratify patients for clinical care and future clinical trials.DiscussionHRVs have recently been recognized as significant pathogens that can cause severe disease and poor outcomes in certain high risk groups, including infants, pregnant women, asthmatics, hospitalized adults, and immunocompromised children and adults 1, 3, 4, 11, 16, 17.", [["asthmatics", "DISEASE", 330, 340], ["patients", "ORGANISM", 94, 102], ["infants", "ORGANISM", 305, 312], ["women", "ORGANISM", 323, 328], ["children", "ORGANISM", 385, 393], ["patients", "SPECIES", 94, 102], ["infants", "SPECIES", 305, 312], ["women", "SPECIES", 323, 328], ["children", "SPECIES", 385, 393], ["The risk score", "PROBLEM", 0, 14], ["clinical care", "TREATMENT", 107, 120], ["significant pathogens", "PROBLEM", 196, 217], ["severe disease", "PROBLEM", 233, 247], ["poor outcomes", "PROBLEM", 252, 265], ["asthmatics", "PROBLEM", 330, 340], ["severe", "OBSERVATION_MODIFIER", 233, 239], ["disease", "OBSERVATION", 240, 247]]], ["Once HRV LRTI has developed in HCT recipients, mortality rates are comparable with those associated with RSV, influenza, and PIV [3].", [["LRTI", "DISEASE", 9, 13], ["influenza", "DISEASE", 110, 119], ["HCT", "CANCER", 31, 34], ["RSV", "ORGANISM", 105, 108], ["RSV", "SPECIES", 105, 108], ["HRV LRTI", "PROBLEM", 5, 13], ["HCT recipients", "TREATMENT", 31, 45], ["mortality rates", "TEST", 47, 62], ["RSV", "PROBLEM", 105, 108], ["influenza", "PROBLEM", 110, 119], ["PIV", "TREATMENT", 125, 128]]], ["In a study of HRV infection that included both HCT recipients and patients with hematologic malignancies, factors more likely to be present in patients with LRTI included inpatient status, lymphopenia, and hypoalbuminemia [11].", [["HCT", "ANATOMY", 47, 50], ["hematologic malignancies", "ANATOMY", 80, 104], ["HRV infection", "DISEASE", 14, 27], ["hematologic malignancies", "DISEASE", 80, 104], ["LRTI", "DISEASE", 157, 161], ["lymphopenia", "DISEASE", 189, 200], ["hypoalbuminemia", "DISEASE", 206, 221], ["HCT", "CANCER", 47, 50], ["patients", "ORGANISM", 66, 74], ["hematologic malignancies", "CANCER", 80, 104], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 143, 151], ["HRV", "SPECIES", 14, 17], ["a study", "TEST", 3, 10], ["HRV infection", "PROBLEM", 14, 27], ["both HCT recipients", "TREATMENT", 42, 61], ["hematologic malignancies", "PROBLEM", 80, 104], ["LRTI", "PROBLEM", 157, 161], ["lymphopenia", "PROBLEM", 189, 200], ["hypoalbuminemia", "PROBLEM", 206, 221], ["infection", "OBSERVATION", 18, 27], ["lymphopenia", "OBSERVATION", 189, 200], ["hypoalbuminemia", "OBSERVATION", 206, 221]]], ["In HCT recipients alone from the same center, hypoalbuminemia, and isolation of respiratory co-pathogen were associated with LRTI in multivariable models [4].", [["HCT", "ANATOMY", 3, 6], ["respiratory", "ANATOMY", 80, 91], ["hypoalbuminemia", "DISEASE", 46, 61], ["respiratory co-pathogen", "DISEASE", 80, 103], ["LRTI", "DISEASE", 125, 129], ["HCT", "CANCER", 3, 6], ["HCT recipients", "TREATMENT", 3, 17], ["hypoalbuminemia", "PROBLEM", 46, 61], ["respiratory co-pathogen", "PROBLEM", 80, 103], ["LRTI in multivariable models", "PROBLEM", 125, 153], ["hypoalbuminemia", "OBSERVATION", 46, 61], ["respiratory co-pathogen", "OBSERVATION", 80, 103]]], ["These analyses, although not done in a time-dependent manner, are similar to findings in the present study, in which lymphopenia and hypoalbuminemia were associated with progression to LRTI.", [["lymphopenia", "DISEASE", 117, 128], ["hypoalbuminemia", "DISEASE", 133, 148], ["LRTI", "DISEASE", 185, 189], ["These analyses", "TEST", 0, 14], ["the present study", "TEST", 89, 106], ["lymphopenia", "PROBLEM", 117, 128], ["hypoalbuminemia", "PROBLEM", 133, 148], ["LRTI", "PROBLEM", 185, 189], ["lymphopenia", "OBSERVATION", 117, 128], ["hypoalbuminemia", "OBSERVATION", 133, 148], ["LRTI", "OBSERVATION", 185, 189]]], ["We evaluated co-pathogens in the upper respiratory tract as a risk factor and did not find an association with LRTI.DiscussionLymphopenia has been associated with progression to LRTI for other respiratory viruses including PIVs, RSV, hMPV, and influenza 6, 7, 9, 10, 18, 19, and was also more common in HRV LRTI subjects in a prior study [4].", [["upper respiratory tract", "ANATOMY", 33, 56], ["LRTI", "DISEASE", 111, 115], ["DiscussionLymphopenia", "DISEASE", 116, 137], ["LRTI", "DISEASE", 178, 182], ["respiratory viruses", "DISEASE", 193, 212], ["hMPV", "DISEASE", 234, 238], ["influenza", "DISEASE", 244, 253], ["LRTI", "DISEASE", 307, 311], ["upper respiratory", "ORGANISM_SUBDIVISION", 33, 50], ["tract", "ORGANISM_SUBDIVISION", 51, 56], ["PIVs", "GENE_OR_GENE_PRODUCT", 223, 227], ["RSV", "ORGANISM", 229, 232], ["hMPV", "ORGANISM", 234, 238], ["RSV", "SPECIES", 229, 232], ["hMPV", "SPECIES", 234, 238], ["co-pathogens in the upper respiratory tract", "PROBLEM", 13, 56], ["LRTI", "PROBLEM", 111, 115], ["LRTI", "PROBLEM", 178, 182], ["other respiratory viruses", "PROBLEM", 187, 212], ["PIVs", "TREATMENT", 223, 227], ["RSV", "PROBLEM", 229, 232], ["hMPV", "PROBLEM", 234, 238], ["influenza", "PROBLEM", 244, 253], ["a prior study", "TEST", 324, 337], ["upper", "ANATOMY_MODIFIER", 33, 38], ["respiratory tract", "ANATOMY", 39, 56], ["LRTI", "OBSERVATION", 111, 115], ["respiratory", "ANATOMY", 193, 204], ["viruses", "OBSERVATION", 205, 212], ["PIVs", "OBSERVATION", 223, 227], ["RSV", "OBSERVATION", 229, 232], ["hMPV", "OBSERVATION", 234, 238], ["more common", "OBSERVATION_MODIFIER", 288, 299]]], ["Monocytopenia has not been evaluated systematically in prior respiratory virus progression studies, although there was a trend toward significance for hMPV [8], and monocytopenia was associated with mortality in HCT recipients with HRV and RSV LRTI 3, 20.", [["HCT", "ANATOMY", 212, 215], ["Monocytopenia", "DISEASE", 0, 13], ["hMPV", "DISEASE", 151, 155], ["monocytopenia", "DISEASE", 165, 178], ["LRTI", "DISEASE", 244, 248], ["hMPV", "ORGANISM", 151, 155], ["HCT", "CANCER", 212, 215], ["hMPV", "SPECIES", 151, 155], ["RSV", "SPECIES", 240, 243], ["Monocytopenia", "PROBLEM", 0, 13], ["prior respiratory virus progression studies", "PROBLEM", 55, 98], ["hMPV", "PROBLEM", 151, 155], ["monocytopenia", "PROBLEM", 165, 178], ["HCT recipients", "TREATMENT", 212, 226], ["HRV", "TEST", 232, 235], ["RSV LRTI", "TEST", 240, 248], ["RSV", "ANATOMY", 240, 243], ["LRTI", "OBSERVATION", 244, 248]]], ["The relative role of monocytes over lymphocytes in progression of disease is not understood, and most studies have not evaluated both cell types concurrently.", [["monocytes", "ANATOMY", 21, 30], ["lymphocytes", "ANATOMY", 36, 47], ["cell", "ANATOMY", 134, 138], ["monocytes", "CELL", 21, 30], ["lymphocytes", "CELL", 36, 47], ["cell", "CELL", 134, 138], ["monocytes", "CELL_TYPE", 21, 30], ["lymphocytes", "CELL_TYPE", 36, 47], ["monocytes over lymphocytes", "PROBLEM", 21, 47], ["disease", "PROBLEM", 66, 73], ["monocytes", "OBSERVATION", 21, 30], ["progression", "OBSERVATION_MODIFIER", 51, 62], ["disease", "OBSERVATION", 66, 73]]], ["A potential mechanism of inflammatory and immune modulation via HRV induced monocytic cell directed CXL10 and IFN-\u03b3 release is plausible [21].DiscussionSteroid use is a well described risk factor for progression to LRTI for many respiratory viruses 6, 8, 9, 18, and higher doses of \u22652 mg/kg/day were associated with HRV LRTI in the present study.", [["monocytic cell", "ANATOMY", 76, 90], ["LRTI", "DISEASE", 215, 219], ["respiratory viruses", "DISEASE", 229, 248], ["LRTI", "DISEASE", 320, 324], ["monocytic cell", "CELL", 76, 90], ["CXL10", "GENE_OR_GENE_PRODUCT", 100, 105], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 110, 115], ["CXL10", "PROTEIN", 100, 105], ["IFN", "PROTEIN", 110, 113], ["\u03b3", "PROTEIN", 114, 115], ["inflammatory and immune modulation", "PROBLEM", 25, 59], ["HRV", "TEST", 64, 67], ["CXL10", "TEST", 100, 105], ["IFN", "TEST", 110, 113], ["LRTI", "TREATMENT", 215, 219], ["many respiratory viruses", "PROBLEM", 224, 248], ["HRV LRTI", "PROBLEM", 316, 324], ["the present study", "TEST", 328, 345], ["potential mechanism of", "UNCERTAINTY", 2, 24], ["inflammatory", "OBSERVATION_MODIFIER", 25, 37], ["monocytic cell", "OBSERVATION", 76, 90], ["respiratory viruses", "OBSERVATION", 229, 248], ["LRTI", "OBSERVATION", 320, 324]]], ["Of note, high\u2013dose steroids are no longer frequently used for graft\u2013versus\u2013host disease treatment at our institution, as is reflected in the low frequency of use (3%) in this cohort.", [["steroids", "CHEMICAL", 19, 27], ["steroids", "CHEMICAL", 19, 27], ["high\u2013dose steroids", "SIMPLE_CHEMICAL", 9, 27], ["high\u2013dose steroids", "TREATMENT", 9, 27], ["graft\u2013versus\u2013host disease treatment", "TREATMENT", 62, 97], ["low frequency", "OBSERVATION_MODIFIER", 141, 154]]], ["However, even lower dose steroids (\u22651 to 2 mg/kg/day) showed a trend toward significance in the multivariable models, and this was included in the weighted score.", [["steroids", "CHEMICAL", 25, 33], ["steroids", "CHEMICAL", 25, 33], ["steroids", "SIMPLE_CHEMICAL", 25, 33], ["lower dose steroids", "TREATMENT", 14, 33]]], ["Other centers may have higher rates of high\u2013dose steroid use and should still be able to apply the score to their patient population.DiscussionPrior post-transplant HRV URTI infection was associated with increased risk of LRTI, an interesting and somewhat unexpected finding suggesting an effect of the cumulative burden of HRV infections, perhaps by mediating inflammatory responses that increase the likelihood of LRTI development.", [["steroid", "CHEMICAL", 49, 56], ["URTI infection", "DISEASE", 169, 183], ["LRTI", "DISEASE", 222, 226], ["HRV infections", "DISEASE", 324, 338], ["LRTI", "DISEASE", 416, 420], ["steroid", "CHEMICAL", 49, 56], ["steroid", "SIMPLE_CHEMICAL", 49, 56], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["high\u2013dose steroid use", "TREATMENT", 39, 60], ["DiscussionPrior post-transplant HRV URTI infection", "PROBLEM", 133, 183], ["LRTI", "PROBLEM", 222, 226], ["HRV infections", "PROBLEM", 324, 338], ["mediating inflammatory responses", "PROBLEM", 351, 383], ["LRTI development", "PROBLEM", 416, 432], ["LRTI", "OBSERVATION", 222, 226], ["infections", "OBSERVATION", 328, 338], ["inflammatory", "OBSERVATION", 361, 373], ["LRTI", "OBSERVATION", 416, 420]]], ["For parainfluenza viruses, URTI without LRTI is associated with late airflow decline, and a similar pathway may be at play for HRV infections [22].", [["parainfluenza viruses", "DISEASE", 4, 25], ["URTI", "DISEASE", 27, 31], ["LRTI", "DISEASE", 40, 44], ["HRV infections", "DISEASE", 127, 141], ["parainfluenza viruses", "ORGANISM", 4, 25], ["parainfluenza", "SPECIES", 4, 17], ["parainfluenza viruses", "PROBLEM", 4, 25], ["URTI", "PROBLEM", 27, 31], ["LRTI", "PROBLEM", 40, 44], ["late airflow decline", "PROBLEM", 64, 84], ["HRV infections", "PROBLEM", 127, 141], ["parainfluenza viruses", "OBSERVATION", 4, 25], ["airflow", "OBSERVATION", 69, 76]]], ["Although it is possible we overestimated new events, our definition of >12 weeks between events was chosen given our recent surveillance data showing the median duration of HRV shedding in HCT recipients is 9.5 days (range, 2 to 89) [23].", [["our recent surveillance data", "TEST", 113, 141], ["HRV shedding", "PROBLEM", 173, 185], ["HCT recipients", "TREATMENT", 189, 203], ["new", "OBSERVATION_MODIFIER", 41, 44]]], ["Given the long duration between events in the present study (median, 302 days; IQR, 140 to 515), we do not believe we are capturing prolonged viral shedding but rather truly new viral events.DiscussionRecipient CMV serostatus was associated with increased risk of LRTI, a novel finding for respiratory virus disease severity.", [["LRTI", "DISEASE", 264, 268], ["respiratory virus disease", "DISEASE", 290, 315], ["CMV", "ORGANISM", 211, 214], ["prolonged viral shedding", "PROBLEM", 132, 156], ["new viral events", "PROBLEM", 174, 190], ["CMV serostatus", "PROBLEM", 211, 225], ["LRTI", "PROBLEM", 264, 268], ["respiratory virus disease severity", "PROBLEM", 290, 324], ["LRTI", "OBSERVATION", 264, 268], ["respiratory virus", "OBSERVATION", 290, 307]]], ["CMV has a profound impact on the immune system in both immunocompetent and immunosuppressed individuals and known to have immunosuppressive effects 24, 25, 26.", [["immune system", "ANATOMY", 33, 46], ["CMV", "ORGANISM", 0, 3], ["immune system", "ANATOMICAL_SYSTEM", 33, 46], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["the immune system", "TREATMENT", 29, 46], ["immunosuppressed individuals", "PROBLEM", 75, 103], ["immunosuppressive effects", "TREATMENT", 122, 147], ["profound", "OBSERVATION_MODIFIER", 10, 18], ["impact", "OBSERVATION_MODIFIER", 19, 25], ["both", "ANATOMY_MODIFIER", 50, 54], ["immunocompetent", "OBSERVATION", 55, 70]]], ["It is well known to affect nonrelapse mortality in HCT patients [27].", [["HCT", "DISEASE", 51, 54], ["HCT", "CANCER", 51, 54], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["HCT patients", "TEST", 51, 63]]], ["CMV has also been shown to increase the risk of other viruses after HCT; however, the mechanisms are poorly understood.", [["CMV", "ORGANISM", 0, 3], ["HCT", "CANCER", 68, 71], ["CMV", "SPECIES", 0, 3], ["CMV", "TREATMENT", 0, 3], ["other viruses", "PROBLEM", 48, 61], ["HCT", "TEST", 68, 71], ["viruses", "OBSERVATION", 54, 61]]], ["That CMV was associated with progression in this study is plausible but the results should be validated in a different cohort, and further studies are needed to elucidate the mechanism.DiscussionRecipient statin use as a risk factor for HRV LRTI is also an intriguing finding and corroborates prior results from a separate cohort at our center that demonstrated a trend toward association between recipient statin use and all respiratory viral infections and LRTIs [13].", [["statin", "CHEMICAL", 205, 211], ["LRTI", "DISEASE", 241, 245], ["statin", "CHEMICAL", 407, 413], ["respiratory viral infections", "DISEASE", 426, 454], ["LRTIs", "DISEASE", 459, 464], ["statin", "CHEMICAL", 205, 211], ["statin", "CHEMICAL", 407, 413], ["CMV", "ORGANISM", 5, 8], ["CMV", "SPECIES", 5, 8], ["CMV", "PROBLEM", 5, 8], ["this study", "TEST", 44, 54], ["further studies", "TEST", 131, 146], ["statin", "TREATMENT", 205, 211], ["a risk factor", "PROBLEM", 219, 232], ["HRV LRTI", "PROBLEM", 237, 245], ["recipient statin", "TREATMENT", 397, 413], ["all respiratory viral infections", "PROBLEM", 422, 454], ["LRTIs", "PROBLEM", 459, 464], ["CMV", "OBSERVATION", 5, 8], ["progression", "OBSERVATION_MODIFIER", 29, 40], ["respiratory", "ANATOMY", 426, 437], ["viral infections", "OBSERVATION", 438, 454]]], ["Statins may act as immunosuppressants via direct inhibition of induction of MHC-II expression by IFN-\u03b3 and thus leading to reduced T cell activation [28] and may also have an effect of type I IFN receptor signaling in monocytes in the setting of HRV challenge, leading to reduced inflammatory response [29].", [["T cell", "ANATOMY", 131, 137], ["monocytes", "ANATOMY", 218, 227], ["Statins", "CHEMICAL", 0, 7], ["Statins", "CHEMICAL", 0, 7], ["MHC-II", "GENE_OR_GENE_PRODUCT", 76, 82], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 97, 102], ["T cell", "CELL", 131, 137], ["type I IFN receptor", "GENE_OR_GENE_PRODUCT", 185, 204], ["monocytes", "CELL", 218, 227], ["MHC-II", "PROTEIN", 76, 82], ["IFN-\u03b3", "PROTEIN", 97, 102], ["type I IFN receptor", "PROTEIN", 185, 204], ["monocytes", "CELL_TYPE", 218, 227], ["Statins", "TREATMENT", 0, 7], ["immunosuppressants", "TREATMENT", 19, 37], ["IFN", "TEST", 97, 100], ["reduced T cell activation", "PROBLEM", 123, 148], ["type I IFN receptor signaling in monocytes", "PROBLEM", 185, 227], ["HRV challenge", "TREATMENT", 246, 259], ["reduced inflammatory response", "PROBLEM", 272, 301], ["reduced", "OBSERVATION_MODIFIER", 272, 279], ["inflammatory", "OBSERVATION_MODIFIER", 280, 292]]], ["The role of statins on HRV progression should be validated in other cohorts and evaluated for other respiratory virus infections independently.DiscussionWe evaluated the impact of HRV viral load and found no association with progression to LRTI.", [["statins", "CHEMICAL", 12, 19], ["respiratory virus infections", "DISEASE", 100, 128], ["LRTI", "DISEASE", 240, 244], ["statins", "CHEMICAL", 12, 19], ["statins", "SIMPLE_CHEMICAL", 12, 19], ["statins", "TREATMENT", 12, 19], ["HRV progression", "PROBLEM", 23, 38], ["other respiratory virus infections", "PROBLEM", 94, 128], ["HRV viral load", "TEST", 180, 194], ["LRTI", "PROBLEM", 240, 244], ["respiratory", "ANATOMY", 100, 111], ["virus", "OBSERVATION", 112, 117], ["no association with", "UNCERTAINTY", 205, 224], ["LRTI", "OBSERVATION", 240, 244]]], ["CT value as a surrogate for viral load has limitations given the diversity of HRV genotypes and the resulting differences in amplification efficiency using RT-qPCR assays with a consensus HRV primer and probe set.", [["consensus HRV primer", "DNA", 178, 198], ["CT value", "TEST", 0, 8], ["a surrogate", "TEST", 12, 23], ["viral load", "PROBLEM", 28, 38], ["HRV genotypes", "PROBLEM", 78, 91], ["amplification efficiency", "PROBLEM", 125, 149], ["RT-qPCR assays", "TEST", 156, 170], ["a consensus HRV primer", "TREATMENT", 176, 198]]], ["RT digital PCR has been recently shown to provide more precise quantification [30].", [["RT digital PCR", "TEST", 0, 14]]], ["However, even when evaluating the extreme highest viral load group (CT values in the lowest 10th percentile), no effect was seen.", [["the extreme highest viral load group", "PROBLEM", 30, 66], ["CT values", "TEST", 68, 77], ["no", "UNCERTAINTY", 110, 112]]], ["In lung transplant recipients, higher HRV viral load was associated with increased symptoms associated with LRTI [31].", [["lung transplant", "ANATOMY", 3, 18], ["LRTI", "DISEASE", 108, 112], ["lung", "ORGAN", 3, 7], ["lung transplant recipients", "TREATMENT", 3, 29], ["higher HRV viral load", "PROBLEM", 31, 52], ["increased symptoms", "PROBLEM", 73, 91], ["LRTI", "PROBLEM", 108, 112], ["lung", "ANATOMY", 3, 7], ["transplant", "OBSERVATION", 8, 18]]], ["In immunocompetent pediatric patients, viral load was associated with disease severity in older but not younger children [32] and was also associated with higher rates of viremia and oxygen use [33].", [["viremia", "DISEASE", 171, 178], ["oxygen", "CHEMICAL", 183, 189], ["oxygen", "CHEMICAL", 183, 189], ["patients", "ORGANISM", 29, 37], ["children", "ORGANISM", 112, 120], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["patients", "SPECIES", 29, 37], ["children", "SPECIES", 112, 120], ["viral load", "PROBLEM", 39, 49], ["disease severity", "PROBLEM", 70, 86], ["viremia", "PROBLEM", 171, 178], ["viral load", "OBSERVATION", 39, 49], ["viremia", "OBSERVATION", 171, 178]]], ["The variable role of viral load in studies to date suggest both limitations in capturing accurate viral loads from clinical samples such as was done in our study and that other host factors including immune responses may be an important player in progression to LRTI and other clinical outcomes.", [["samples", "ANATOMY", 124, 131], ["LRTI", "DISEASE", 262, 266], ["viral load in studies", "TEST", 21, 42], ["clinical samples", "TEST", 115, 131], ["our study", "TEST", 152, 161], ["LRTI", "PROBLEM", 262, 266], ["viral load", "OBSERVATION", 21, 31]]], ["Additionally, HRV species were not evaluated in the present study, and data have suggested HRV-C may be associated with worse outcomes, especially in children 34, 35.", [["HRV-C", "GENE_OR_GENE_PRODUCT", 91, 96], ["children", "ORGANISM", 150, 158], ["children", "SPECIES", 150, 158], ["HRV species", "TEST", 14, 25], ["the present study", "TEST", 48, 65], ["HRV", "TEST", 91, 94]]], ["The presence of viral co\u2013pathogens in the upper respiratory tract was not associated with progression to HRV LRTI.DiscussionTo provide clinical applicability for our findings, we developed weighted risk scores for progression to LRTI using methodology that allows for multiple sampling within the dataset to develop an optimized model [14].", [["upper respiratory tract", "ANATOMY", 42, 65], ["LRTI", "DISEASE", 109, 113], ["LRTI", "DISEASE", 229, 233], ["upper respiratory", "ORGANISM_SUBDIVISION", 42, 59], ["tract", "ORGANISM_SUBDIVISION", 60, 65], ["viral co\u2013pathogens in the upper respiratory tract", "PROBLEM", 16, 65], ["HRV LRTI", "PROBLEM", 105, 113], ["methodology", "TREATMENT", 240, 251], ["viral co\u2013pathogens", "OBSERVATION", 16, 34], ["upper", "ANATOMY_MODIFIER", 42, 47], ["respiratory tract", "ANATOMY", 48, 65], ["not associated with", "UNCERTAINTY", 70, 89], ["LRTI", "OBSERVATION", 109, 113]]], ["Using this model we developed a weighted score and show specificity and sensitivity calculations for a range of score cut\u2013offs, as well as cumulative incidence curves stratified by score cut\u2013offs and within mutually exclusive score ranges.", [["a weighted score", "TEST", 30, 46], ["sensitivity calculations", "TEST", 72, 96], ["cumulative incidence curves", "PROBLEM", 139, 166], ["score cut\u2013offs", "TEST", 181, 195]]], ["Maximum sensitivity and specificity was demonstrated at a score cut\u2013off of 27; however, optimal score cut\u2013off depends on the ultimate application of the score.", [["Maximum sensitivity", "TEST", 0, 19], ["specificity", "TEST", 24, 35], ["a score cut\u2013off", "TEST", 56, 71]]], ["For example, if the risk score is used for patient risk stratification for interventional clinical trials, a score cut\u2013off with higher sensitivity and negative predictive value may be desirable.DiscussionSample size limited our ability to extensively evaluate proven LRTI, which for other respiratory viruses (RSV and PIV) has been associated with worse clinical outcomes 36, 37.", [["LRTI", "DISEASE", 267, 271], ["respiratory viruses", "DISEASE", 289, 308], ["patient", "ORGANISM", 43, 50], ["RSV", "ORGANISM", 310, 313], ["patient", "SPECIES", 43, 50], ["RSV", "SPECIES", 310, 313], ["PIV", "SPECIES", 318, 321], ["the risk score", "PROBLEM", 16, 30], ["interventional clinical trials", "TREATMENT", 75, 105], ["a score cut\u2013off", "TEST", 107, 122], ["LRTI", "PROBLEM", 267, 271], ["other respiratory viruses", "PROBLEM", 283, 308], ["RSV and PIV", "TREATMENT", 310, 321], ["respiratory", "ANATOMY", 289, 300], ["viruses", "OBSERVATION", 301, 308]]], ["In several separate multivariate models, however, risk factors for progression to proven LRTI were similar (low albumin, low monocyte count, and high\u2013dose steroids).", [["monocyte", "ANATOMY", 125, 133], ["LRTI", "DISEASE", 89, 93], ["steroids", "CHEMICAL", 155, 163], ["steroids", "CHEMICAL", 155, 163], ["albumin", "GENE_OR_GENE_PRODUCT", 112, 119], ["monocyte", "CELL", 125, 133], ["high\u2013dose steroids", "SIMPLE_CHEMICAL", 145, 163], ["risk factors", "PROBLEM", 50, 62], ["progression", "PROBLEM", 67, 78], ["LRTI", "PROBLEM", 89, 93], ["low albumin", "PROBLEM", 108, 119], ["low monocyte count", "PROBLEM", 121, 139], ["high\u2013dose steroids", "TREATMENT", 145, 163], ["low monocyte", "OBSERVATION_MODIFIER", 121, 133]]], ["We applied our risk score to the proven LRTI outcome only, and subjects with a risk score higher than 27 were associated with proven LRTI.", [["LRTI", "DISEASE", 40, 44], ["LRTI", "DISEASE", 133, 137], ["a risk score", "TEST", 77, 89], ["LRTI", "OBSERVATION", 133, 137]]], ["With a larger sample size a separate risk score for proven LRTI could be developed, although it is likely that risk factors would remain similar.", [["LRTI", "DISEASE", 59, 63], ["LRTI", "PROBLEM", 59, 63], ["risk factors", "PROBLEM", 111, 123], ["larger", "OBSERVATION_MODIFIER", 7, 13], ["size", "OBSERVATION_MODIFIER", 21, 25]]], ["Probable LRTI could represent contamination from the upper respiratory tract during the BAL procedure; however, there were no cases of probable LRTI in our cohort.DiscussionAlthough our analyses used an accepted resampling methodology (bootstrapping), ultimately a multicenter study is needed for validation of the score, especially given differences in clinical practices including the use of high\u2013dose steroids.", [["upper respiratory tract", "ANATOMY", 53, 76], ["BAL", "ANATOMY", 88, 91], ["LRTI", "DISEASE", 9, 13], ["LRTI", "DISEASE", 144, 148], ["steroids", "CHEMICAL", 404, 412], ["steroids", "CHEMICAL", 404, 412], ["upper respiratory", "ORGANISM_SUBDIVISION", 53, 70], ["tract", "ORGANISM_SUBDIVISION", 71, 76], ["high\u2013dose steroids", "SIMPLE_CHEMICAL", 394, 412], ["LRTI", "PROBLEM", 9, 13], ["contamination", "PROBLEM", 30, 43], ["the upper respiratory tract", "PROBLEM", 49, 76], ["the BAL procedure", "TREATMENT", 84, 101], ["LRTI", "PROBLEM", 144, 148], ["a multicenter study", "TEST", 263, 282], ["high\u2013dose steroids", "TREATMENT", 394, 412], ["LRTI", "OBSERVATION", 9, 13], ["could represent", "UNCERTAINTY", 14, 29], ["contamination", "OBSERVATION", 30, 43], ["upper", "ANATOMY_MODIFIER", 53, 58], ["respiratory tract", "ANATOMY", 59, 76]]], ["An immunodeficiency scoring index was developed for allogeneic HCT recipients with RSV infection to predict LRTI and RSV associated mortality [10]; the score was also applied to influenza [19].", [["HCT", "ANATOMY", 63, 66], ["RSV infection", "DISEASE", 83, 96], ["LRTI", "DISEASE", 108, 112], ["RSV", "DISEASE", 117, 120], ["influenza", "DISEASE", 178, 187], ["HCT", "ORGANISM", 63, 66], ["recipients", "ORGANISM", 67, 77], ["RSV", "ORGANISM", 83, 86], ["RSV", "ORGANISM", 117, 120], ["RSV", "SPECIES", 83, 86], ["RSV", "SPECIES", 117, 120], ["An immunodeficiency scoring index", "PROBLEM", 0, 33], ["allogeneic HCT recipients", "TREATMENT", 52, 77], ["RSV infection", "PROBLEM", 83, 96], ["LRTI", "PROBLEM", 108, 112], ["RSV associated mortality", "PROBLEM", 117, 141], ["the score", "TEST", 148, 157], ["influenza", "PROBLEM", 178, 187], ["immunodeficiency", "OBSERVATION", 3, 19], ["RSV infection", "OBSERVATION", 83, 96]]], ["Similar variables were evaluated in the present study and were not associated with the outcome with the exception of steroid use, suggesting rhinovirus progression may be determined by a unique set of risk factors compared with other respiratory viruses and a separate risk score is needed.DiscussionThis study has strengths and limitations.", [["steroid", "CHEMICAL", 117, 124], ["respiratory viruses", "DISEASE", 234, 253], ["steroid", "CHEMICAL", 117, 124], ["steroid", "SIMPLE_CHEMICAL", 117, 124], ["rhinovirus", "ORGANISM", 141, 151], ["the present study", "TEST", 36, 53], ["steroid use", "TREATMENT", 117, 128], ["rhinovirus progression", "PROBLEM", 141, 163], ["risk factors", "PROBLEM", 201, 213], ["other respiratory viruses", "PROBLEM", 228, 253], ["This study", "TEST", 300, 310], ["suggesting", "UNCERTAINTY", 130, 140], ["rhinovirus", "OBSERVATION", 141, 151]]], ["First, this is a retrospective study in which data collection, including viral load determination, was dependent on clinical databases.", [["a retrospective study", "TEST", 15, 36], ["data collection", "TEST", 46, 61], ["viral load determination", "TEST", 73, 97], ["viral load", "OBSERVATION", 73, 83]]], ["However, at our institution data from transplant recipients is prospectively recorded in a central database, and we also conducted detailed chart review on every patient to obtain additional clinical data.", [["recipients", "ORGANISM", 49, 59], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["transplant recipients", "TREATMENT", 38, 59], ["additional clinical data", "TEST", 180, 204]]], ["Second, we captured both proven LRTI (HRV detected in the lower respiratory tract with abnormal imaging) and possible LRTI (HRV detected in the upper respiratory tract with abnormal imaging but no lower tract sampling).", [["lower respiratory tract", "ANATOMY", 58, 81], ["upper respiratory tract", "ANATOMY", 144, 167], ["lower tract", "ANATOMY", 197, 208], ["LRTI", "DISEASE", 32, 36], ["LRTI", "DISEASE", 118, 122], ["lower", "ORGANISM_SUBDIVISION", 58, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["upper", "ORGANISM_SUBDIVISION", 144, 149], ["respiratory tract", "ORGANISM_SUBDIVISION", 150, 167], ["tract", "ORGANISM_SUBDIVISION", 203, 208], ["LRTI", "PROBLEM", 32, 36], ["HRV", "TEST", 38, 41], ["abnormal imaging", "TEST", 87, 103], ["LRTI", "PROBLEM", 118, 122], ["HRV", "PROBLEM", 124, 127], ["abnormal imaging", "PROBLEM", 173, 189], ["lower tract sampling", "PROBLEM", 197, 217], ["LRTI", "OBSERVATION", 32, 36], ["lower", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["possible", "UNCERTAINTY", 109, 117], ["LRTI", "OBSERVATION", 118, 122], ["upper", "ANATOMY_MODIFIER", 144, 149], ["respiratory tract", "ANATOMY", 150, 167]]], ["At our institution the use of BAL is based on standardized protocols outlining that BAL should be performed in HCT recipients with a respiratory virus detected in the upper respiratory tract and abnormal chest imaging.", [["upper respiratory tract", "ANATOMY", 167, 190], ["chest", "ANATOMY", 204, 209], ["BAL", "ORGANISM_SUBSTANCE", 84, 87], ["HCT", "CANCER", 111, 114], ["upper respiratory", "ORGANISM_SUBDIVISION", 167, 184], ["tract", "ORGANISM_SUBDIVISION", 185, 190], ["chest", "ORGANISM_SUBDIVISION", 204, 209], ["BAL", "TREATMENT", 30, 33], ["standardized protocols", "TREATMENT", 46, 68], ["BAL", "TEST", 84, 87], ["HCT recipients", "TREATMENT", 111, 125], ["a respiratory virus", "PROBLEM", 131, 150], ["abnormal chest imaging", "TEST", 195, 217], ["respiratory virus", "OBSERVATION", 133, 150], ["upper", "ANATOMY_MODIFIER", 167, 172], ["respiratory tract", "ANATOMY", 173, 190], ["chest", "ANATOMY", 204, 209]]], ["However, ultimately the need for BAL is determined by the attending physician, and thus some proven or probable cases (HRV detected in the lower respiratory tract without abnormal imaging) may have been missed.", [["lower respiratory tract", "ANATOMY", 139, 162], ["lower", "ORGANISM_SUBDIVISION", 139, 144], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["BAL", "TEST", 33, 36], ["HRV", "PROBLEM", 119, 122], ["abnormal imaging", "PROBLEM", 171, 187], ["lower", "ANATOMY_MODIFIER", 139, 144], ["respiratory tract", "ANATOMY", 145, 162]]], ["By including both proven and possible LRTI events (no probable events occurred), this effect is mitigated; however, proven LRTI may be the more relevant outcome given the mortality rates seen with proven HRV LRTI and the differences in outcomes observed in proven LRTI for PIV and RSV 3, 36, 37.", [["LRTI", "DISEASE", 38, 42], ["LRTI", "DISEASE", 123, 127], ["LRTI", "DISEASE", 208, 212], ["LRTI", "DISEASE", 264, 268], ["RSV", "SPECIES", 281, 284], ["LRTI events", "PROBLEM", 38, 49], ["LRTI", "PROBLEM", 123, 127], ["HRV LRTI", "PROBLEM", 204, 212], ["PIV", "TREATMENT", 273, 276], ["RSV", "TEST", 281, 284], ["no probable", "UNCERTAINTY", 51, 62], ["LRTI", "OBSERVATION", 208, 212]]], ["Regardless, many institutions do not routinely use BAL for virologic confirmation, and thus our results for any LRTI events can be broadly applicable.", [["LRTI", "DISEASE", 112, 116], ["BAL", "TEST", 51, 54], ["virologic confirmation", "TEST", 59, 81], ["any LRTI events", "PROBLEM", 108, 123]]], ["Finally, our data include both allogeneic and autologous HCT recipients, and there may be a bias toward increased testing in the allogeneic group and therefore more LRTI events captured.", [["HCT", "ANATOMY", 57, 60], ["LRTI", "DISEASE", 165, 169], ["HCT", "CANCER", 57, 60], ["both allogeneic and autologous HCT recipients", "TREATMENT", 26, 71], ["increased testing", "TEST", 104, 121], ["the allogeneic group", "TREATMENT", 125, 145], ["more LRTI events", "PROBLEM", 160, 176]]], ["However, the risk score performed reasonably well in the allogeneic subgroup.DiscussionWe were not able to evaluate risk factors for HRV LRTI cases without any co\u2013pathogens in the lower respiratory tract separately.", [["lower respiratory tract", "ANATOMY", 180, 203], ["LRTI", "DISEASE", 137, 141], ["lower", "ORGANISM_SUBDIVISION", 180, 185], ["respiratory tract", "ORGANISM_SUBDIVISION", 186, 203], ["the risk score", "TEST", 9, 23], ["HRV LRTI cases", "TEST", 133, 147], ["any co\u2013pathogens in the lower respiratory tract", "PROBLEM", 156, 203], ["lower", "ANATOMY_MODIFIER", 180, 185], ["respiratory tract", "ANATOMY", 186, 203]]], ["In a prior study the presence of co\u2013pathogens was not associated with mortality in HCT recipients with proven HRV LRTI, suggesting that HRV detection in the lower tract is pathogenic regardless of co\u2013pathogens and therefore making any proven HRV LRTI an important endpoint [3].", [["lower tract", "ANATOMY", 157, 168], ["LRTI", "DISEASE", 114, 118], ["LRTI", "DISEASE", 246, 250], ["lower tract", "ORGANISM_SUBDIVISION", 157, 168], ["HRV", "SPECIES", 110, 113], ["a prior study", "TEST", 3, 16], ["co\u2013pathogens", "PROBLEM", 33, 45], ["HCT recipients", "TREATMENT", 83, 97], ["HRV LRTI", "PROBLEM", 110, 118], ["HRV detection in the lower tract", "PROBLEM", 136, 168], ["co\u2013pathogens", "PROBLEM", 197, 209], ["LRTI", "OBSERVATION", 114, 118], ["lower tract", "ANATOMY", 157, 168]]], ["Because BAL was not done in possible LRTI cases, it is plausible that other pathogens are contributing to the radiographic changes, and thus these are not true LRTI events.", [["BAL", "ANATOMY", 8, 11], ["LRTI", "DISEASE", 37, 41], ["LRTI", "DISEASE", 160, 164], ["BAL", "ORGANISM_SUBSTANCE", 8, 11], ["BAL", "TEST", 8, 11], ["LRTI cases", "PROBLEM", 37, 47], ["other pathogens", "PROBLEM", 70, 85], ["the radiographic changes", "PROBLEM", 106, 130], ["true LRTI events", "PROBLEM", 155, 171]]], ["However, as stated above, in clinical practice BAL is often not attempted, and co\u2013pathogen data are not available, yet patients are considered to have LRTI.", [["LRTI", "DISEASE", 151, 155], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["clinical practice BAL", "TEST", 29, 50], ["co\u2013pathogen data", "TEST", 79, 95], ["LRTI", "PROBLEM", 151, 155], ["LRTI", "OBSERVATION", 151, 155]]], ["Thus, we included possible LRTI as an endpoint.", [["LRTI", "DISEASE", 27, 31], ["LRTI", "PROBLEM", 27, 31]]], ["Several epidemiologic studies and clinical trials of respiratory viruses in HCT recipients have used definitions of LRTI that include possible cases 4, 10, 35, 38, 39, 40, 41, 42.DiscussionIn summary, we describe the risk factors and development of a risk score for progression to LRTI in a large cohort of HCT recipients with HRV URTI.", [["respiratory viruses", "DISEASE", 53, 72], ["LRTI", "DISEASE", 116, 120], ["LRTI", "DISEASE", 281, 285], ["HRV URTI", "DISEASE", 327, 335], ["HCT", "CANCER", 307, 310], ["Several epidemiologic studies", "TEST", 0, 29], ["respiratory viruses", "PROBLEM", 53, 72], ["HCT recipients", "TREATMENT", 76, 90], ["LRTI", "PROBLEM", 116, 120], ["a risk score", "PROBLEM", 249, 261], ["LRTI", "PROBLEM", 281, 285], ["HCT recipients", "TREATMENT", 307, 321], ["HRV URTI", "PROBLEM", 327, 335], ["respiratory viruses", "OBSERVATION", 53, 72]]], ["The risk score proposed may have implications for risk stratifying patients for more intense clinical monitoring.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["The risk score", "PROBLEM", 0, 14], ["intense clinical monitoring", "TEST", 85, 112]]], ["Additionally, risk stratification will help inform the design of future randomized clinical trials of novel therapeutics, including the growing field of virus specific T cells, which are currently being evaluated for other respiratory viruses including PIV and hMPV 43, 44.", [["T cells", "ANATOMY", 168, 175], ["respiratory viruses", "DISEASE", 223, 242], ["T cells", "CELL", 168, 175], ["hMPV", "ORGANISM", 261, 265], ["virus specific T cells", "CELL_TYPE", 153, 175], ["hMPV", "SPECIES", 261, 265], ["novel therapeutics", "TREATMENT", 102, 120], ["virus specific T cells", "PROBLEM", 153, 175], ["other respiratory viruses", "PROBLEM", 217, 242], ["PIV", "TREATMENT", 253, 256], ["hMPV", "TEST", 261, 265], ["respiratory", "ANATOMY", 223, 234], ["viruses", "OBSERVATION", 235, 242]]]], "c8f6ad8f37e52b5d50ec73fc9296ffee7a27d778": [["IntroductionZika virus (ZIKV), a member of the genus Flavivirus of the Flaviviridae family, was first isolated from a sentinel monkey in the Zika forest of Uganda in 1947.", [["IntroductionZika virus", "ORGANISM", 0, 22], ["ZIKV", "GENE_OR_GENE_PRODUCT", 24, 28], ["Flaviviridae", "ORGANISM", 71, 83], ["monkey", "ORGANISM", 127, 133], ["IntroductionZika virus", "SPECIES", 0, 22], ["ZIKV", "SPECIES", 24, 28], ["IntroductionZika virus", "PROBLEM", 0, 22]]], ["Like other flaviviruses including dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese encephalitis (JEV) and tick-borne encephalitis (TBEV), ZIKV is an arbovirus, with mosquitoes of the Aedes genus, particularly Aedes aegypti, transmitting ZIKV between human and non-human primate (NHP) hosts.", [["flaviviruses including dengue (DENV)", "DISEASE", 11, 47], ["yellow fever", "DISEASE", 49, 61], ["YFV", "DISEASE", 63, 66], ["West Nile (WNV)", "DISEASE", 69, 84], ["Japanese encephalitis", "DISEASE", 86, 107], ["JEV", "DISEASE", 109, 112], ["tick-borne encephalitis", "DISEASE", 118, 141], ["TBEV", "DISEASE", 143, 147], ["arbovirus", "DISEASE", 161, 170], ["DENV", "ORGANISM", 42, 46], ["yellow fever", "ORGANISM", 49, 61], ["YFV", "ORGANISM", 63, 66], ["West Nile (WNV)", "ORGANISM", 69, 84], ["Japanese encephalitis", "ORGANISM", 86, 107], ["JEV", "ORGANISM", 109, 112], ["tick-borne encephalitis", "ORGANISM", 118, 141], ["TBEV", "ORGANISM", 143, 147], ["Aedes genus", "ORGANISM", 195, 206], ["Aedes aegypti", "ORGANISM", 221, 234], ["ZIKV", "GENE_OR_GENE_PRODUCT", 249, 253], ["human", "ORGANISM", 262, 267], ["non-human primate (NHP) hosts", "ORGANISM", 272, 301], ["yellow fever", "SPECIES", 49, 61], ["tick-borne encephalitis", "SPECIES", 118, 141], ["Aedes aegypti", "SPECIES", 221, 234], ["human", "SPECIES", 262, 267], ["non-human", "SPECIES", 272, 281], ["DENV", "SPECIES", 42, 46], ["yellow fever (", "SPECIES", 49, 63], ["YFV", "SPECIES", 63, 66], ["West Nile", "SPECIES", 69, 78], ["WNV", "SPECIES", 80, 83], ["Japanese encephalitis", "SPECIES", 86, 107], ["JEV", "SPECIES", 109, 112], ["tick-borne encephalitis", "SPECIES", 118, 141], ["TBEV", "SPECIES", 143, 147], ["ZIKV", "SPECIES", 150, 154], ["Aedes aegypti", "SPECIES", 221, 234], ["ZIKV", "SPECIES", 249, 253], ["human", "SPECIES", 262, 267], ["other flaviviruses", "PROBLEM", 5, 23], ["dengue (DENV)", "PROBLEM", 34, 47], ["yellow fever (YFV)", "PROBLEM", 49, 67], ["West Nile (WNV", "PROBLEM", 69, 83], ["Japanese encephalitis (JEV)", "PROBLEM", 86, 113], ["tick-borne encephalitis", "PROBLEM", 118, 141], ["ZIKV", "PROBLEM", 150, 154], ["an arbovirus", "PROBLEM", 158, 170], ["flaviviruses", "OBSERVATION", 11, 23], ["encephalitis", "OBSERVATION", 95, 107], ["arbovirus", "OBSERVATION", 161, 170]]], ["[1] [2] [3] Most ZIKV infections are asymptomatic, but some individuals develop mild symptoms after infection that include fever, headaches, lethargy, rash, arthralgia, and/or myalgia.", [["ZIKV infections", "DISEASE", 17, 32], ["infection", "DISEASE", 100, 109], ["fever", "DISEASE", 123, 128], ["headaches", "DISEASE", 130, 139], ["lethargy", "DISEASE", 141, 149], ["rash", "DISEASE", 151, 155], ["arthralgia", "DISEASE", 157, 167], ["myalgia", "DISEASE", 176, 183], ["[1] [2] [3", "SIMPLE_CHEMICAL", 0, 10], ["ZIKV", "ORGANISM", 17, 21], ["Most ZIKV infections", "PROBLEM", 12, 32], ["asymptomatic", "PROBLEM", 37, 49], ["mild symptoms", "PROBLEM", 80, 93], ["infection", "PROBLEM", 100, 109], ["fever", "PROBLEM", 123, 128], ["headaches", "PROBLEM", 130, 139], ["lethargy", "PROBLEM", 141, 149], ["rash", "PROBLEM", 151, 155], ["arthralgia", "PROBLEM", 157, 167], ["myalgia", "PROBLEM", 176, 183], ["infections", "OBSERVATION", 22, 32], ["infection", "OBSERVATION", 100, 109], ["arthralgia", "OBSERVATION", 157, 167], ["myalgia", "OBSERVATION", 176, 183]]], ["Outbreaks of ZIKV infections across islands in the Pacific Ocean and in the Americas (primarily Brazil) between 2007 and 2016, however, have indicated both previously unreported modes of transmission including sexual, vertical, and through blood transfusions/organ transplant as well as new, severe signs of ZIKV infection.", [["blood", "ANATOMY", 240, 245], ["organ", "ANATOMY", 259, 264], ["ZIKV infections", "DISEASE", 13, 28], ["ZIKV infection", "DISEASE", 308, 322], ["blood", "ORGANISM_SUBSTANCE", 240, 245], ["organ", "ORGAN", 259, 264], ["ZIKV", "SPECIES", 13, 17], ["ZIKV", "SPECIES", 308, 312], ["ZIKV infections", "PROBLEM", 13, 28], ["sexual, vertical, and through blood transfusions", "TREATMENT", 210, 258], ["organ transplant", "TREATMENT", 259, 275], ["ZIKV infection", "PROBLEM", 308, 322], ["ZIKV infections", "OBSERVATION", 13, 28], ["islands", "OBSERVATION_MODIFIER", 36, 43], ["Pacific", "OBSERVATION_MODIFIER", 51, 58], ["Ocean", "OBSERVATION_MODIFIER", 59, 64], ["organ", "ANATOMY", 259, 264], ["transplant", "OBSERVATION", 265, 275], ["severe", "OBSERVATION_MODIFIER", 292, 298], ["ZIKV infection", "OBSERVATION", 308, 322]]], ["[3] [4] [5] The most significant of these new manifestations is a dramatic increase in the incidence of microcephaly, congenital blindness, and other severe birth defects in babies born to mothers infected with ZIKV during pregnancy.", [["microcephaly", "DISEASE", 104, 116], ["congenital blindness", "DISEASE", 118, 138], ["birth defects", "DISEASE", 157, 170], ["ZIKV", "CHEMICAL", 211, 215], ["babies", "ORGANISM", 174, 180], ["mothers", "ORGANISM", 189, 196], ["ZIKV", "SPECIES", 211, 215], ["these new manifestations", "PROBLEM", 36, 60], ["microcephaly", "PROBLEM", 104, 116], ["congenital blindness", "PROBLEM", 118, 138], ["other severe birth defects", "PROBLEM", 144, 170], ["ZIKV during pregnancy", "PROBLEM", 211, 232], ["most significant", "OBSERVATION_MODIFIER", 16, 32], ["new", "OBSERVATION_MODIFIER", 42, 45], ["manifestations", "OBSERVATION", 46, 60], ["dramatic", "OBSERVATION_MODIFIER", 66, 74], ["increase", "OBSERVATION_MODIFIER", 75, 83], ["microcephaly", "OBSERVATION", 104, 116], ["congenital", "OBSERVATION_MODIFIER", 118, 128], ["blindness", "OBSERVATION", 129, 138], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["defects", "OBSERVATION", 163, 170]]], ["Subsequent studies in mice and humans have since confirmed that ZIKV is a teratogen.", [["ZIKV", "CHEMICAL", 64, 68], ["mice", "ORGANISM", 22, 26], ["humans", "ORGANISM", 31, 37], ["ZIKV", "GENE_OR_GENE_PRODUCT", 64, 68], ["mice", "SPECIES", 22, 26], ["humans", "SPECIES", 31, 37], ["mice", "SPECIES", 22, 26], ["humans", "SPECIES", 31, 37], ["ZIKV", "SPECIES", 64, 68], ["Subsequent studies", "TEST", 0, 18], ["ZIKV", "PROBLEM", 64, 68], ["ZIKV", "OBSERVATION", 64, 68]]], ["3, [6] [7] [8] [9] Additionally, ZIKV infection was also found to increase the risk for development of Guillain-Barr\u00e9 syndrome post recovery.", [["ZIKV infection", "DISEASE", 33, 47], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 103, 126], ["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 3, 18], ["ZIKV", "ORGANISM", 33, 37], ["Guillain-Barr\u00e9", "ORGANISM", 103, 117], ["ZIKV infection", "PROBLEM", 33, 47], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 103, 126], ["infection", "OBSERVATION", 38, 47], ["Barr\u00e9 syndrome", "OBSERVATION", 112, 126]]], ["8 This alarming increase in cases of microcephaly and other birth defects following ZIKV infections prompted the World Health Organization (WHO) to declare ZIKV infection a global health emergency in 2016.", [["microcephaly", "DISEASE", 37, 49], ["birth defects", "DISEASE", 60, 73], ["ZIKV infections", "DISEASE", 84, 99], ["infection", "DISEASE", 161, 170], ["ZIKV", "SPECIES", 84, 88], ["microcephaly", "PROBLEM", 37, 49], ["other birth defects", "PROBLEM", 54, 73], ["ZIKV infections", "PROBLEM", 84, 99], ["ZIKV infection", "PROBLEM", 156, 170], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["microcephaly", "OBSERVATION", 37, 49]]], ["4, 10 There are currently no licensed vaccines or treatments to prevent or ameliorate ZIKV infection and disease, but new findings about ZIKV infection have accelerated efforts to develop such therapeutics and vaccines.", [["infection", "DISEASE", 91, 100], ["ZIKV infection", "DISEASE", 137, 151], ["ZIKV", "ORGANISM", 137, 141], ["ZIKV", "SPECIES", 86, 90], ["ZIKV", "SPECIES", 137, 141], ["licensed vaccines", "TREATMENT", 29, 46], ["treatments", "TREATMENT", 50, 60], ["ZIKV infection", "PROBLEM", 86, 100], ["disease", "PROBLEM", 105, 112], ["ZIKV infection", "PROBLEM", 137, 151], ["such therapeutics", "TREATMENT", 188, 205], ["vaccines", "TREATMENT", 210, 218]]], ["Vaccines targeting ZIKV have been made in several formulations including purified inactivated virus, protein subunits, adenovirus vectors, DNA plasmids, and RNA.", [["plasmids", "ANATOMY", 143, 151], ["ZIKV", "GENE_OR_GENE_PRODUCT", 19, 23], ["adenovirus", "ORGANISM", 119, 129], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["protein subunits", "PROTEIN", 101, 117], ["DNA plasmids", "DNA", 139, 151], ["RNA", "RNA", 157, 160], ["ZIKV", "SPECIES", 19, 23], ["adenovirus", "SPECIES", 119, 129], ["Vaccines", "TREATMENT", 0, 8], ["ZIKV", "TREATMENT", 19, 23], ["several formulations", "TREATMENT", 42, 62], ["purified inactivated virus", "TREATMENT", 73, 99], ["protein subunits", "TREATMENT", 101, 117], ["adenovirus vectors", "TREATMENT", 119, 137], ["DNA plasmids", "TREATMENT", 139, 151], ["RNA", "ANATOMY", 157, 160]]], ["[11] [12] [13] [14] [15] [16] Each of these has been shown to induce ZIKV-specific immune responses in mice and NHPs that can protect these animal models against morbidity and mortality following ZIKV challenge.", [["[11] [12] [13] [14] [15]", "CHEMICAL", 0, 24], ["ZIKV", "CHEMICAL", 196, 200], ["[11] [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 0, 29], ["ZIKV", "GENE_OR_GENE_PRODUCT", 69, 73], ["mice", "ORGANISM", 103, 107], ["NHPs", "ORGANISM", 112, 116], ["mice", "SPECIES", 103, 107], ["ZIKV", "SPECIES", 69, 73], ["mice", "SPECIES", 103, 107], ["NHPs", "SPECIES", 112, 116], ["ZIKV", "SPECIES", 196, 200], ["ZIKV", "PROBLEM", 69, 73], ["ZIKV challenge", "TREATMENT", 196, 210]]], ["Some of these vaccines are now being evaluated in phase I clinical trials.", [["these vaccines", "TREATMENT", 8, 22]]], ["11 A second line of investigation for ZIKV therapeutics is the isolation and production of anti-ZIKV monoclonal antibodies (mAbs) for passive transfer into infected patients.", [["ZIKV", "CANCER", 38, 42], ["patients", "ORGANISM", 165, 173], ["anti-ZIKV monoclonal antibodies", "PROTEIN", 91, 122], ["mAbs", "PROTEIN", 124, 128], ["patients", "SPECIES", 165, 173], ["ZIKV", "SPECIES", 38, 42], ["anti-ZIKV", "SPECIES", 91, 100], ["ZIKV therapeutics", "TREATMENT", 38, 55], ["the isolation", "TREATMENT", 59, 72], ["anti-ZIKV monoclonal antibodies", "TREATMENT", 91, 122]]], ["Several antibodies have been identified and isolated from ZIKV-infected patients that are capable of neutralizing in vitro infection by a broad panel of ZIKV isolates from Africa, Asia, and the Americas.IntroductionTherapeutic mAbs can be an effective means of combating infectious diseases, but factors including a laborious production process and the need for repeated dosing to maintain protective serum levels make them cost-prohibitive, which limit their clinical application.", [["serum", "ANATOMY", 401, 406], ["ZIKV-infected", "DISEASE", 58, 71], ["infection", "DISEASE", 123, 132], ["infectious diseases", "DISEASE", 271, 290], ["ZIKV", "ORGANISM", 58, 62], ["patients", "ORGANISM", 72, 80], ["ZIKV", "ORGANISM", 153, 157], ["serum", "ORGANISM_SUBSTANCE", 401, 406], ["antibodies", "PROTEIN", 8, 18], ["patients", "SPECIES", 72, 80], ["ZIKV", "SPECIES", 58, 62], ["ZIKV", "SPECIES", 153, 157], ["Several antibodies", "TEST", 0, 18], ["ZIKV", "PROBLEM", 58, 62], ["neutralizing in vitro infection", "PROBLEM", 101, 132], ["ZIKV isolates", "PROBLEM", 153, 166], ["Therapeutic mAbs", "TREATMENT", 215, 231], ["infectious diseases", "PROBLEM", 271, 290], ["a laborious production process", "PROBLEM", 314, 344], ["repeated dosing", "TREATMENT", 362, 377], ["protective serum levels", "TEST", 390, 413], ["infected", "OBSERVATION_MODIFIER", 63, 71], ["neutralizing", "OBSERVATION_MODIFIER", 101, 113], ["infection", "OBSERVATION", 123, 132]]], ["To overcome some of these barriers, our group has pioneered a method that uses DNA plasmid technology as a delivery vehicle for these antibodies.", [["DNA", "CELLULAR_COMPONENT", 79, 82], ["DNA plasmid", "DNA", 79, 90], ["antibodies", "PROTEIN", 134, 144], ["DNA plasmid technology", "TREATMENT", 79, 101], ["a delivery vehicle", "TREATMENT", 105, 123]]], ["Delivery of DNA plasmids encoding genes of therapeutic monoclonal antibodies (dMAbs) into muscle followed by electroporation stimulates long-term, in vivo production of the mAbs which significantly reduces costs by eliminating both the need for ex vivo production and purification of protein mAbs and the need for repeated dosing.", [["muscle", "ANATOMY", 90, 96], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["monoclonal antibodies (dMAbs", "GENE_OR_GENE_PRODUCT", 55, 83], ["muscle", "ORGAN", 90, 96], ["DNA plasmids", "DNA", 12, 24], ["therapeutic monoclonal antibodies", "PROTEIN", 43, 76], ["dMAbs", "PROTEIN", 78, 83], ["mAbs", "PROTEIN", 173, 177], ["protein mAbs", "PROTEIN", 284, 296], ["Delivery", "TREATMENT", 0, 8], ["DNA plasmids", "TREATMENT", 12, 24], ["therapeutic monoclonal antibodies (dMAbs", "TREATMENT", 43, 83], ["the mAbs", "PROBLEM", 169, 177], ["ex vivo production", "TREATMENT", 245, 263], ["purification of protein mAbs", "TREATMENT", 268, 296], ["repeated dosing", "TREATMENT", 314, 329], ["muscle", "ANATOMY", 90, 96]]], ["Furthermore, using DNA plasmids as vectors for mAb gene delivery has additional advantages including; (i) a strong safety profile in numerous clinical trials; (ii) the ability for re-dosing since DNA vectors are non-immunogenic, and (iii) the possibility for long-term gene expression even though DNA vectors do not integrate into cellular DNA.", [["cellular", "ANATOMY", 331, 339], ["DNA", "CELLULAR_COMPONENT", 19, 22], ["mAb", "GENE_OR_GENE_PRODUCT", 47, 50], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["DNA", "CELLULAR_COMPONENT", 297, 300], ["cellular DNA", "CELLULAR_COMPONENT", 331, 343], ["DNA plasmids", "DNA", 19, 31], ["mAb gene", "DNA", 47, 55], ["DNA vectors", "DNA", 196, 207], ["DNA vectors", "DNA", 297, 308], ["cellular DNA", "DNA", 331, 343], ["DNA plasmids", "TREATMENT", 19, 31], ["mAb gene delivery", "TREATMENT", 47, 64], ["DNA vectors", "TREATMENT", 196, 207], ["non-immunogenic", "PROBLEM", 212, 227], ["long-term gene expression", "TREATMENT", 259, 284], ["DNA vectors", "TREATMENT", 297, 308], ["cellular DNA", "OBSERVATION", 331, 343]]], ["Synthetic DNA technology allows for manipulation of mAb sequences to improve in vivo expression levels and/or modify effector function(s) of the antibodies.", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["mAb sequences", "DNA", 52, 65], ["antibodies", "PROTEIN", 145, 155], ["Synthetic DNA technology", "TREATMENT", 0, 24], ["manipulation of mAb sequences", "TREATMENT", 36, 65], ["vivo expression levels", "TEST", 80, 102]]], ["We have demonstrated that delivery of dMAbs targeting Pseudomonas, Chikungunya, Dengue, and Influenza into mice produces biologically relevant mAb serum levels that can protect animals from challenge by each pathogen.", [["serum", "ANATOMY", 147, 152], ["dMAbs", "CHEMICAL", 38, 43], ["Chikungunya", "DISEASE", 67, 78], ["Dengue", "DISEASE", 80, 86], ["Influenza", "DISEASE", 92, 101], ["dMAbs", "GENE_OR_GENE_PRODUCT", 38, 43], ["Pseudomonas", "ORGANISM", 54, 65], ["Chikungunya", "ORGANISM", 67, 78], ["Dengue", "ORGANISM", 80, 86], ["Influenza", "ORGANISM", 92, 101], ["mice", "ORGANISM", 107, 111], ["serum", "ORGANISM_SUBSTANCE", 147, 152], ["mAb", "PROTEIN", 143, 146], ["Influenza", "SPECIES", 92, 101], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["dMAbs", "PROBLEM", 38, 43], ["Pseudomonas", "PROBLEM", 54, 65], ["Chikungunya", "PROBLEM", 67, 78], ["Dengue", "PROBLEM", 80, 86], ["Influenza", "PROBLEM", 92, 101], ["relevant mAb serum levels", "TEST", 134, 159]]], ["[17] [18] [19] [20] Additionally, dMAbs can be co-delivered with DNA vaccines to provide immediate protection during the eclipse period when conventional vaccine-induced immunity is developing.", [["[17] [18] [19] [20]", "SIMPLE_CHEMICAL", 0, 19], ["dMAbs", "SIMPLE_CHEMICAL", 34, 39], ["DNA", "CELLULAR_COMPONENT", 65, 68], ["DNA vaccines", "TREATMENT", 65, 77], ["immediate protection", "TREATMENT", 89, 109], ["conventional vaccine", "TREATMENT", 141, 161]]], ["19 Here we describe the identification and cloning of a panel of humanized IgG monoclonal antibodies isolated from ZIKV DNA vaccine-immunized mice as well as derived from ZIKVinfected rhesus macaque monkeys (RhMac).", [["ZIKV DNA", "ORGANISM", 115, 123], ["mice", "ORGANISM", 142, 146], ["rhesus", "ORGANISM", 184, 190], ["macaque", "ORGANISM", 191, 198], ["monkeys", "ORGANISM", 199, 206], ["RhMac", "ORGANISM", 208, 213], ["humanized IgG monoclonal antibodies", "PROTEIN", 65, 100], ["mice", "SPECIES", 142, 146], ["rhesus macaque monkeys", "SPECIES", 184, 206], ["ZIKV", "SPECIES", 115, 119], ["mice", "SPECIES", 142, 146], ["ZIKVinfected rhesus macaque monkeys", "SPECIES", 171, 206], ["a panel", "TEST", 54, 61], ["humanized IgG monoclonal antibodies", "TREATMENT", 65, 100], ["ZIKV DNA vaccine", "TREATMENT", 115, 131]]], ["The genetic sequences of the anti-ZIKV mAbs were modified to synthetically produce human IgGs while retaining each mAb's complementarity-determining region (CDR).", [["human", "ORGANISM", 83, 88], ["IgGs", "GENE_OR_GENE_PRODUCT", 89, 93], ["anti-ZIKV mAbs", "PROTEIN", 29, 43], ["human IgGs", "PROTEIN", 83, 93], ["mAb's complementarity-determining region", "PROTEIN", 115, 155], ["human", "SPECIES", 83, 88], ["anti-ZIKV", "SPECIES", 29, 38], ["human", "SPECIES", 83, 88], ["the anti-ZIKV mAbs", "TREATMENT", 25, 43], ["human IgGs", "TREATMENT", 83, 93]]], ["The genetic sequences were optimized to improve protein translation and then cloned into DNA vectors.", [["DNA", "CELLULAR_COMPONENT", 89, 92], ["DNA vectors", "DNA", 89, 100], ["The genetic sequences", "TEST", 0, 21], ["protein translation", "TREATMENT", 48, 67]]], ["The dMAb plasmids were shown to direct production of ZIKV-specific antibodies in vitro and in vivo.", [["dMAb plasmids", "ANATOMY", 4, 17], ["dMAb", "GENE_OR_GENE_PRODUCT", 4, 8], ["ZIKV", "GENE_OR_GENE_PRODUCT", 53, 57], ["dMAb plasmids", "DNA", 4, 17], ["ZIKV", "PROTEIN", 53, 57], ["specific antibodies", "PROTEIN", 58, 77], ["ZIKV", "SPECIES", 53, 57], ["The dMAb plasmids", "TREATMENT", 0, 17], ["ZIKV", "PROBLEM", 53, 57]]], ["Mice administered ZIKV-dMAb plasmids were protected from morbidity and mortality after challenge with a contemporary clinical ZIKV strain.", [["Mice", "ORGANISM", 0, 4], ["ZIKV-dMAb plasmids", "DNA", 18, 36], ["Mice", "SPECIES", 0, 4], ["ZIKV", "SPECIES", 126, 130], ["ZIKV-dMAb plasmids", "TREATMENT", 18, 36], ["a contemporary clinical ZIKV strain", "PROBLEM", 102, 137]]], ["Most importantly, the dMAb plasmids provide immediate protection from ZIKV which could be co-administered with a ZIKV DNA vaccine to provide comprehensive protection from ZIKV during the eclipse period of the vaccine-induced immune responses.", [["dMAb plasmids", "ANATOMY", 22, 35], ["ZIKV", "CHEMICAL", 70, 74], ["ZIKV", "CHEMICAL", 171, 175], ["dMAb", "GENE_OR_GENE_PRODUCT", 22, 26], ["ZIKV", "SIMPLE_CHEMICAL", 70, 74], ["ZIKV", "ORGANISM", 113, 117], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["ZIKV", "ORGANISM", 171, 175], ["dMAb plasmids", "DNA", 22, 35], ["ZIKV", "SPECIES", 70, 74], ["ZIKV", "SPECIES", 113, 117], ["ZIKV", "SPECIES", 171, 175], ["the dMAb plasmids", "TREATMENT", 18, 35], ["immediate protection", "TREATMENT", 44, 64], ["ZIKV", "TREATMENT", 70, 74], ["a ZIKV DNA vaccine", "TREATMENT", 111, 129], ["comprehensive protection", "TREATMENT", 141, 165], ["ZIKV", "PROBLEM", 171, 175], ["the vaccine", "TREATMENT", 205, 216]]], ["The anti-ZIKV mAbs described here may be useful in providing protection against this rapidly emerging virus.CellsHuman Embryonic Kidney 293T cells and Vero cells were maintained in Dulbecco's Modified Eagle's Medium (Gibco-Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 IU of penicillin per ml, 100 \u03bcg of streptomycin per ml and 2mM L-glutamine as described previously.", [["Embryonic Kidney 293T cells", "ANATOMY", 119, 146], ["Vero cells", "ANATOMY", 151, 161], ["fetal bovine serum", "ANATOMY", 257, 275], ["FBS", "ANATOMY", 277, 280], ["penicillin", "CHEMICAL", 293, 303], ["streptomycin", "CHEMICAL", 322, 334], ["L-glutamine", "CHEMICAL", 350, 361], ["penicillin", "CHEMICAL", 293, 303], ["streptomycin", "CHEMICAL", 322, 334], ["L-glutamine", "CHEMICAL", 350, 361], ["anti-ZIKV mAbs", "GENE_OR_GENE_PRODUCT", 4, 18], ["Embryonic Kidney 293T cells", "CELL", 119, 146], ["Vero cells", "CELL", 151, 161], ["bovine", "ORGANISM", 263, 269], ["serum", "ORGANISM_SUBSTANCE", 270, 275], ["FBS", "ORGANISM_SUBSTANCE", 277, 280], ["penicillin", "SIMPLE_CHEMICAL", 293, 303], ["streptomycin", "SIMPLE_CHEMICAL", 322, 334], ["L-glutamine", "SIMPLE_CHEMICAL", 350, 361], ["anti-ZIKV mAbs", "PROTEIN", 4, 18], ["CellsHuman Embryonic Kidney 293T cells", "CELL_LINE", 108, 146], ["Vero cells", "CELL_LINE", 151, 161], ["bovine", "SPECIES", 263, 269], ["anti-ZIKV", "SPECIES", 4, 13], ["The anti-ZIKV mAbs", "TREATMENT", 0, 18], ["this rapidly emerging virus", "PROBLEM", 80, 107], ["CellsHuman", "TEST", 108, 118], ["Vero cells", "TEST", 151, 161], ["Dulbecco", "TEST", 181, 189], ["Gibco", "TEST", 217, 222], ["FBS", "TEST", 277, 280], ["penicillin", "TREATMENT", 293, 303], ["streptomycin", "TREATMENT", 322, 334], ["2mM L-glutamine", "TREATMENT", 346, 361], ["Kidney", "ANATOMY", 129, 135], ["293T cells", "OBSERVATION", 136, 146], ["Vero cells", "OBSERVATION", 151, 161]]], ["19 Generation and evaluation of DNA-encoded monoclonal antibody (dMab) plasmids which express monoclonal antibodies (mAb) from generated and developed anti-ZIKV hybridomas For screening of antibody-producing mouse hybridoma clones, viral preparation and recombinant soluble ZIKV-Env protein was used as ZIKV antigens in an indirect ELISA.", [["hybridoma clones", "ANATOMY", 214, 230], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["mouse", "ORGANISM", 208, 213], ["hybridoma clones", "CELL", 214, 230], ["ZIKV", "GENE_OR_GENE_PRODUCT", 274, 278], ["DNA-encoded monoclonal antibody (dMab) plasmids", "DNA", 32, 79], ["monoclonal antibodies", "PROTEIN", 94, 115], ["mAb", "PROTEIN", 117, 120], ["anti-ZIKV hybridomas", "CELL_LINE", 151, 171], ["antibody-producing mouse hybridoma clones", "CELL_LINE", 189, 230], ["ZIKV", "PROTEIN", 274, 278], ["Env protein", "PROTEIN", 279, 290], ["ZIKV antigens", "PROTEIN", 303, 316], ["mouse", "SPECIES", 208, 213], ["anti-ZIKV", "SPECIES", 151, 160], ["mouse", "SPECIES", 208, 213], ["ZIKV", "SPECIES", 274, 278], ["ZIKV", "SPECIES", 303, 307], ["evaluation", "TEST", 18, 28], ["DNA", "TEST", 32, 35], ["encoded monoclonal antibody (dMab) plasmids", "TREATMENT", 36, 79], ["monoclonal antibodies", "TEST", 94, 115], ["anti-ZIKV hybridomas", "TREATMENT", 151, 171], ["screening", "TEST", 176, 185], ["antibody", "TEST", 189, 197], ["mouse hybridoma clones", "TREATMENT", 208, 230], ["viral preparation", "TREATMENT", 232, 249], ["recombinant soluble ZIKV", "TREATMENT", 254, 278], ["Env protein", "TREATMENT", 279, 290], ["ZIKV antigens", "TEST", 303, 316], ["anti-ZIKV hybridomas", "OBSERVATION", 151, 171], ["hybridoma clones", "OBSERVATION", 214, 230]]], ["Approximately 50-60 antibody-producing mouse hybridoma clones were identified as having antibody binding at least four-fold higher than the background level reactivity.", [["hybridoma clones", "ANATOMY", 45, 61], ["mouse", "ORGANISM", 39, 44], ["hybridoma clones", "CELL", 45, 61], ["50-60 antibody-producing mouse hybridoma clones", "CELL_LINE", 14, 61], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["60 antibody", "TEST", 17, 28], ["mouse hybridoma clones", "PROBLEM", 39, 61], ["antibody binding", "PROBLEM", 88, 104], ["hybridoma clones", "OBSERVATION", 45, 61]]], ["For the RhMac clones, we used phage display methods as outlined in Cold Spring Harbor Laboratory (CSHL) manual to generate mAb clones with high affinity for the ZIKV envelope protein.", [["RhMac clones", "ANATOMY", 8, 20], ["RhMac clones", "CELL", 8, 20], ["ZIKV", "GENE_OR_GENE_PRODUCT", 161, 165], ["RhMac clones", "CELL_LINE", 8, 20], ["mAb clones", "CELL_LINE", 123, 133], ["ZIKV envelope protein", "PROTEIN", 161, 182], ["ZIKV", "SPECIES", 161, 165], ["the RhMac clones", "PROBLEM", 4, 20], ["phage display methods", "TREATMENT", 30, 51], ["mAb clones", "TREATMENT", 123, 133], ["high affinity", "PROBLEM", 139, 152], ["the ZIKV envelope protein", "PROBLEM", 157, 182]]], ["Positive hybridoma clones reacting with sucrose-purified ZIKV virions, as well as recombinant soluble ZIKV-Env protein, were characterized by an indirect ELISA.", [["hybridoma clones", "ANATOMY", 9, 25], ["sucrose", "CHEMICAL", 40, 47], ["sucrose", "CHEMICAL", 40, 47], ["hybridoma clones", "CELL", 9, 25], ["sucrose", "SIMPLE_CHEMICAL", 40, 47], ["ZIKV virions", "ORGANISM", 57, 69], ["ZIKV", "GENE_OR_GENE_PRODUCT", 102, 106], ["hybridoma clones", "CELL_LINE", 9, 25], ["ZIKV", "PROTEIN", 102, 106], ["Env protein", "PROTEIN", 107, 118], ["Positive hybridoma clones", "PROBLEM", 0, 25], ["sucrose-purified ZIKV virions", "TREATMENT", 40, 69], ["an indirect ELISA", "TEST", 142, 159], ["hybridoma clones", "OBSERVATION", 9, 25]]], ["Positive clones were identified by nucleotide sequencing of the variable H chain (VH) and variable L chain (VL) sequences as described.", [["clones", "ANATOMY", 9, 15], ["nucleotide", "CHEMICAL", 35, 45], ["nucleotide", "CHEMICAL", 35, 45], ["variable H chain", "GENE_OR_GENE_PRODUCT", 64, 80], ["variable L chain", "GENE_OR_GENE_PRODUCT", 90, 106], ["H chain", "PROTEIN", 73, 80], ["variable L chain (VL) sequences", "DNA", 90, 121], ["Positive clones", "PROBLEM", 0, 15], ["nucleotide sequencing", "TEST", 35, 56], ["variable L chain (VL) sequences", "TREATMENT", 90, 121], ["clones", "OBSERVATION", 9, 15]]], ["[18] [19] [20] The coding sequences for the RhMac clone antibodies against ZIKV-Ig were obtained from the phage display assay.", [["ZIKV-Ig", "GENE_OR_GENE_PRODUCT", 75, 82], ["RhMac clone antibodies", "PROTEIN", 44, 66], ["ZIKV", "PROTEIN", 75, 79], ["Ig", "PROTEIN", 80, 82], ["The coding sequences", "TEST", 15, 35], ["the RhMac clone antibodies", "TEST", 40, 66], ["ZIKV", "PROBLEM", 75, 79]]], ["[21] [22] [23] We created synthetic antibody constructs (Ig) that encode VH and VL regions from anti-ZIKV-Ig and were utilized for the cloning organization of IgG constructs in a novel synthetic dual promoter plasmid strategy for developing anti-ZIKV-IgG.Measurement of expression of anti-ZIKV-Env antibody from ZIKV-dMAb by Western blot analysisSamples of anti-ZIKV-dMAb construct transfected cells (293T) were utilized for expression analysis using the GeneJammer transfection reagent (Agilent Technologies).", [["cells", "ANATOMY", 394, 399], ["293T", "ANATOMY", 401, 405], ["[21] [22] [23", "SIMPLE_CHEMICAL", 0, 13], ["Ig", "GENE_OR_GENE_PRODUCT", 57, 59], ["VH", "GENE_OR_GENE_PRODUCT", 73, 75], ["anti-ZIKV-Ig", "GENE_OR_GENE_PRODUCT", 96, 108], ["IgG", "GENE_OR_GENE_PRODUCT", 159, 162], ["anti-ZIKV-IgG", "GENE_OR_GENE_PRODUCT", 241, 254], ["anti-ZIKV", "GENE_OR_GENE_PRODUCT", 284, 293], ["ZIKV-dMAb", "GENE_OR_GENE_PRODUCT", 312, 321], ["anti-ZIKV-dMAb", "GENE_OR_GENE_PRODUCT", 357, 371], ["cells", "CELL", 394, 399], ["293T", "CELL", 401, 405], ["synthetic antibody constructs", "DNA", 26, 55], ["Ig", "PROTEIN", 57, 59], ["VH and VL regions", "DNA", 73, 90], ["anti-ZIKV-Ig", "DNA", 96, 108], ["IgG constructs", "DNA", 159, 173], ["anti-ZIKV", "PROTEIN", 241, 250], ["IgG", "PROTEIN", 251, 254], ["anti-ZIKV", "PROTEIN", 284, 293], ["Env antibody", "PROTEIN", 294, 306], ["ZIKV", "PROTEIN", 312, 316], ["dMAb", "DNA", 317, 321], ["anti-ZIKV-dMAb construct transfected cells", "CELL_LINE", 357, 399], ["293T", "CELL_LINE", 401, 405], ["anti-ZIKV", "SPECIES", 241, 250], ["synthetic antibody constructs", "TREATMENT", 26, 55], ["anti-ZIKV-Ig", "TREATMENT", 96, 108], ["IgG constructs", "TREATMENT", 159, 173], ["a novel synthetic dual promoter plasmid strategy", "TREATMENT", 177, 225], ["anti-ZIKV", "TEST", 284, 293], ["Env antibody", "TEST", 294, 306], ["ZIKV", "PROBLEM", 312, 316], ["anti-ZIKV-dMAb construct transfected cells", "TREATMENT", 357, 399], ["expression analysis", "TEST", 425, 444], ["the GeneJammer transfection reagent", "TREATMENT", 451, 486], ["VL", "ANATOMY", 80, 82]]], ["Samples were collected and compared to the control lysate from the empty vector control.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["the control lysate", "TREATMENT", 39, 57], ["the empty vector control", "TREATMENT", 63, 87], ["empty vector", "OBSERVATION", 67, 79]]], ["For each analysis, 20\u03bcg of sample were added to SDS loading buffer and loaded into each lane of a 4-12% Bis-Tris PAGE gel (Life Technologies).", [["sample", "ANATOMY", 27, 33], ["Bis-Tris", "CHEMICAL", 104, 112], ["Bis-Tris PAGE", "CHEMICAL", 104, 117], ["Bis-Tris PAGE", "SIMPLE_CHEMICAL", 104, 117], ["each analysis", "TEST", 4, 17], ["sample", "TREATMENT", 27, 33], ["SDS loading buffer", "TREATMENT", 48, 66], ["a 4-12% Bis-Tris PAGE gel", "TREATMENT", 96, 121]]], ["The gel was run and transferred onto a nitrocellulose membrane using iBlot2 (Life Technologies).", [["membrane", "ANATOMY", 54, 62], ["nitrocellulose", "CHEMICAL", 39, 53], ["membrane", "CELLULAR_COMPONENT", 54, 62], ["iBlot2", "SIMPLE_CHEMICAL", 69, 75], ["a nitrocellulose membrane", "TREATMENT", 37, 62], ["iBlot2 (Life Technologies", "TREATMENT", 69, 94]]], ["Samples were separated on a polyacrylamide gel (12% NuPAGE Novex, Invitrogen) and transferred to a PDF membrane (Invitrogen) that was blocked using a commercial buffer (Odyssey Blocking Buffer, LiCor BioSciences) and incubated overnight at 4\u00b0C with specific primary antibodies raised in mice as well as beta-actin (Santa Cruz).", [["Samples", "ANATOMY", 0, 7], ["PDF membrane", "ANATOMY", 99, 111], ["polyacrylamide", "CHEMICAL", 28, 42], ["NuPAGE", "CHEMICAL", 52, 58], ["PDF membrane", "MULTI-TISSUE_STRUCTURE", 99, 111], ["C", "GENE_OR_GENE_PRODUCT", 242, 243], ["mice", "ORGANISM", 287, 291], ["beta-actin", "GENE_OR_GENE_PRODUCT", 303, 313], ["primary antibodies", "PROTEIN", 258, 276], ["beta-actin", "PROTEIN", 303, 313], ["Santa Cruz", "PROTEIN", 315, 325], ["mice", "SPECIES", 287, 291], ["mice", "SPECIES", 287, 291], ["Samples", "TEST", 0, 7], ["a polyacrylamide gel", "TREATMENT", 26, 46], ["12% NuPAGE Novex", "TREATMENT", 48, 64], ["Invitrogen", "TREATMENT", 66, 76], ["a PDF membrane (Invitrogen)", "TREATMENT", 97, 124], ["a commercial buffer (Odyssey Blocking Buffer", "TREATMENT", 148, 192], ["LiCor BioSciences", "TREATMENT", 194, 211], ["specific primary antibodies", "TEST", 249, 276]]], ["IRDye800 and IRD700 goat antihuman or anti-mouse secondary antibodies were used for detection (LiCor Biosciences).Immunofluorescence analysisFor immunofluorescence analysis, chamber slides (Nalgene Nunc) were seeded with Vero cells (1x10 4 ) from stock cultures.", [["Vero cells", "ANATOMY", 221, 231], ["IRDye800", "CHEMICAL", 0, 8], ["IRDye800", "SIMPLE_CHEMICAL", 0, 8], ["Vero cells", "CELL", 221, 231], ["1x10 4", "CELL", 233, 239], ["IRDye800", "PROTEIN", 0, 8], ["IRD700 goat antihuman or anti-mouse secondary antibodies", "PROTEIN", 13, 69], ["Vero cells", "CELL_LINE", 221, 231], ["1x10 4", "CELL_LINE", 233, 239], ["goat", "SPECIES", 20, 24], ["antihuman", "SPECIES", 25, 34], ["anti-mouse", "SPECIES", 38, 48], ["goat", "SPECIES", 20, 24], ["IRDye800", "TREATMENT", 0, 8], ["IRD700 goat antihuman", "TREATMENT", 13, 34], ["anti-mouse secondary antibodies", "TREATMENT", 38, 69], ["Immunofluorescence analysis", "TEST", 114, 141], ["immunofluorescence analysis", "TEST", 145, 172], ["chamber slides (Nalgene Nunc)", "TREATMENT", 174, 203], ["Vero cells", "TREATMENT", 221, 231], ["stock cultures", "TEST", 247, 261]]], ["Cells were grown until they reached approximately 80% confluency after which cells were infected for 2 h with ZIKV at a multiplicity of infection (m.o.i.) of 0.01 so that cells expressed the antigens.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 77, 82], ["cells", "ANATOMY", 171, 176], ["ZIKV", "CHEMICAL", 110, 114], ["infection", "DISEASE", 136, 145], ["Cells", "CELL", 0, 5], ["cells", "CELL", 77, 82], ["cells", "CELL", 171, 176], ["antigens", "PROTEIN", 191, 199], ["ZIKV", "SPECIES", 110, 114], ["ZIKV", "PROBLEM", 110, 114], ["infection", "PROBLEM", 136, 145], ["infection", "OBSERVATION", 136, 145]]], ["Fixed cells on the slides were incubated for 1 h at 37\u00b0C with twofold dilutions of sera beginning at 1:100 dilution from the ZIKV-IgG administered mice for 90 min at 37\u00b0C in a humidified chamber.", [["cells", "ANATOMY", 6, 11], ["sera", "ANATOMY", 83, 87], ["cells", "CELL", 6, 11], ["sera", "ORGANISM_SUBSTANCE", 83, 87], ["ZIKV", "ORGANISM", 125, 129], ["IgG", "GENE_OR_GENE_PRODUCT", 130, 133], ["mice", "ORGANISM", 147, 151], ["ZIKV", "PROTEIN", 125, 129], ["IgG", "PROTEIN", 130, 133], ["mice", "SPECIES", 147, 151], ["ZIKV", "SPECIES", 125, 129], ["mice", "SPECIES", 147, 151], ["Fixed cells", "PROBLEM", 0, 11], ["the slides", "TEST", 15, 25], ["twofold dilutions of sera", "PROBLEM", 62, 87], ["a humidified chamber", "TREATMENT", 174, 194], ["humidified chamber", "OBSERVATION", 176, 194]]], ["After washing thrice with PBS, the cells were incubated for 60 min at 37\u00b0C with a FITC-conjugated goat anti-human IgG (Santa Cruz Biotechnology Inc).", [["cells", "ANATOMY", 35, 40], ["FITC", "CHEMICAL", 82, 86], ["cells", "CELL", 35, 40], ["FITC", "SIMPLE_CHEMICAL", 82, 86], ["FITC-conjugated goat anti-human IgG", "PROTEIN", 82, 117], ["Santa Cruz Biotechnology Inc", "PROTEIN", 119, 147], ["goat", "SPECIES", 98, 102], ["goat", "SPECIES", 98, 102], ["PBS", "TREATMENT", 26, 29], ["a FITC", "TEST", 80, 86]]], ["The additional nuclear staining with 4\u2032,6-diamidino-2-phenylindole (DAPI) was performed at room temperature for 20 min.", [["nuclear", "ANATOMY", 15, 22], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 37, 66], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 37, 66], ["DAPI", "CHEMICAL", 68, 72], ["nuclear", "CELLULAR_COMPONENT", 15, 22], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 37, 66], ["DAPI", "SIMPLE_CHEMICAL", 68, 72], ["The additional nuclear staining", "TEST", 0, 31], ["diamidino", "TEST", 42, 51], ["phenylindole (DAPI", "TREATMENT", 54, 72], ["nuclear staining", "OBSERVATION", 15, 31]]], ["After each incubation step, the samples were washed once with PBS.", [["samples", "ANATOMY", 32, 39], ["the samples", "TEST", 28, 39], ["PBS", "TREATMENT", 62, 65]]], ["The samples were subsequently mounted onto glass slides using DABCO and were viewed under a confocal microscope (LSM710; Carl Zeiss).", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["DABCO", "TREATMENT", 62, 67], ["a confocal microscope", "TEST", 90, 111]]], ["The resulting images were analyzed using the Zen software (Carl Zeiss).Quantitative and binding ELISAELISA assays were performed with sera from mice administered ZIKV-dMAb or pVax1 in order to measure the expression kinetics of the antibody construct and target antigen binding.", [["sera", "ANATOMY", 134, 138], ["sera", "ORGANISM_SUBSTANCE", 134, 138], ["mice", "ORGANISM", 144, 148], ["ZIKV-dMAb", "GENE_OR_GENE_PRODUCT", 162, 171], ["pVax1", "SIMPLE_CHEMICAL", 175, 180], ["ZIKV", "PROTEIN", 162, 166], ["dMAb", "PROTEIN", 167, 171], ["pVax1", "PROTEIN", 175, 180], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["ZIKV", "SPECIES", 162, 166], ["The resulting images", "TEST", 0, 20], ["Quantitative and binding ELISAELISA assays", "TEST", 71, 113], ["sera", "TEST", 134, 138], ["ZIKV-dMAb", "TREATMENT", 162, 171], ["pVax1", "TREATMENT", 175, 180], ["the antibody construct", "TEST", 228, 250], ["target antigen binding", "PROBLEM", 255, 277]]], ["Quantification of IgG in murine immunization studies was performed using 96-well black MaxiSorp plates (Nalgene Nunc) coated overnight at 4\u00b0C with 10 \u03bcg/mL goat anti-Human IgG (H + L) (Pierce).", [["IgG", "GENE_OR_GENE_PRODUCT", 18, 21], ["murine", "ORGANISM", 25, 31], ["goat", "ORGANISM", 156, 160], ["H + L", "SIMPLE_CHEMICAL", 177, 182], ["IgG", "PROTEIN", 18, 21], ["anti-Human IgG", "PROTEIN", 161, 175], ["H", "PROTEIN", 177, 178], ["murine", "SPECIES", 25, 31], ["goat", "SPECIES", 156, 160], ["goat", "SPECIES", 156, 160], ["IgG in murine immunization studies", "TEST", 18, 52], ["black MaxiSorp plates", "TREATMENT", 81, 102], ["Nalgene Nunc)", "TREATMENT", 104, 117], ["IgG", "OBSERVATION", 18, 21]]], ["Plates were blocked with Casein Blocker (Thermo), and serum samples and a standard curve (10 \u03bcg/mL of ChromPure Human IgG, whole molecule) (Jackson Labs) were serially diluted.", [["serum samples", "ANATOMY", 54, 67], ["Casein Blocker", "SIMPLE_CHEMICAL", 25, 39], ["serum samples", "ORGANISM_SUBSTANCE", 54, 67], ["Human", "ORGANISM", 112, 117], ["IgG", "GENE_OR_GENE_PRODUCT", 118, 121], ["Casein Blocker", "PROTEIN", 25, 39], ["ChromPure Human IgG", "PROTEIN", 102, 121], ["Human", "SPECIES", 112, 117], ["Human", "SPECIES", 112, 117], ["Casein Blocker", "TREATMENT", 25, 39], ["serum samples", "TEST", 54, 67], ["a standard curve", "TEST", 72, 88], ["ChromPure Human IgG", "TREATMENT", 102, 121], ["Jackson Labs", "TEST", 140, 152]]], ["Purified human IgG kappa or lambda (Bethyl Laboratories, Montgomery, TX) was used as a standard.", [["human", "ORGANISM", 9, 14], ["IgG kappa", "GENE_OR_GENE_PRODUCT", 15, 24], ["lambda", "GENE_OR_GENE_PRODUCT", 28, 34], ["Bethyl", "GENE_OR_GENE_PRODUCT", 36, 42], ["Purified human IgG kappa", "PROTEIN", 0, 24], ["lambda", "PROTEIN", 28, 34], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["TX)", "TREATMENT", 69, 72]]], ["Following incubation, samples were probed with an anti-human IgG antibody conjugated to horseradish peroxidase (Bethyl Laboratories) at a 1:20,000 dilution.", [["samples", "ANATOMY", 22, 29], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 88, 110], ["anti-human IgG antibody", "PROTEIN", 50, 73], ["horseradish peroxidase", "PROTEIN", 88, 110], ["Bethyl Laboratories", "PROTEIN", 112, 131], ["horseradish", "SPECIES", 88, 99], ["samples", "TEST", 22, 29], ["an anti-human IgG antibody", "TREATMENT", 47, 73]]], ["Plates were developed using o-phenylenediamine dihydrochloride substrate (OPD, Sigma Aldrich, St. Louis, MO) and stopped with 2 N H 2 SO 4 .", [["o-phenylenediamine dihydrochloride", "CHEMICAL", 28, 62], ["o-phenylenediamine dihydrochloride", "CHEMICAL", 28, 62], ["H 2 SO 4", "CHEMICAL", 130, 138], ["o-phenylenediamine dihydrochloride", "SIMPLE_CHEMICAL", 28, 62], ["o-phenylenediamine dihydrochloride substrate", "TREATMENT", 28, 72]]], ["Plates were then read at 450 nm using a Biotek EL312e quantification.", [["Plates", "TEST", 0, 6], ["a Biotek EL312e quantification", "TREATMENT", 38, 68]]], ["A standard curve was generated using purified human IgG/kappa (Bethyl Laboratories).", [["human", "ORGANISM", 46, 51], ["IgG/kappa", "GENE_OR_GENE_PRODUCT", 52, 61], ["Bethyl", "GENE_OR_GENE_PRODUCT", 63, 69], ["purified human IgG/kappa", "PROTEIN", 37, 61], ["Bethyl Laboratories", "PROTEIN", 63, 82], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["A standard curve", "TREATMENT", 0, 16]]], ["All sera samples were tested in duplicate.", [["sera samples", "ANATOMY", 4, 16], ["sera samples", "ORGANISM_SUBSTANCE", 4, 16], ["All sera samples", "TEST", 0, 16]]], ["For avidity ELISA, serum samples were applied to wells in duplicate.", [["serum samples", "ANATOMY", 19, 32], ["serum samples", "ORGANISM_SUBSTANCE", 19, 32], ["avidity ELISA", "TEST", 4, 17], ["serum samples", "TEST", 19, 32]]], ["After 1-h incubation, one set of samples was incubated with wash buffer and another with 4 M urea (Sigma Aldrich) for 5 min and washed twice with wash buffer, and the ELISA protocol was completed as described.ZIKV viral challenge studyFive-to-seven-week-old A129 mice deficient in interferon (IFN)-\u03b1/\u03b2 receptors were used for this study and were bred under specific pathogen-free conditions in an animal facility at The Wistar Institute.", [["samples", "ANATOMY", 33, 40], ["urea", "CHEMICAL", 93, 97], ["urea", "CHEMICAL", 93, 97], ["urea", "SIMPLE_CHEMICAL", 93, 97], ["Sigma Aldrich", "SIMPLE_CHEMICAL", 99, 112], ["ZIKV viral", "ORGANISM", 209, 219], ["A129", "ORGANISM", 258, 262], ["mice", "ORGANISM", 263, 267], ["interferon (IFN)-\u03b1", "GENE_OR_GENE_PRODUCT", 281, 299], ["\u03b2", "GENE_OR_GENE_PRODUCT", 300, 301], ["interferon (IFN)-\u03b1/\u03b2 receptors", "PROTEIN", 281, 311], ["mice", "SPECIES", 263, 267], ["ZIKV", "SPECIES", 209, 213], ["mice", "SPECIES", 263, 267], ["wash buffer", "TREATMENT", 60, 71], ["4 M urea (Sigma Aldrich)", "TREATMENT", 89, 113], ["wash buffer", "TREATMENT", 146, 157], ["the ELISA protocol", "TREATMENT", 163, 181], ["ZIKV viral challenge studyFive", "TEST", 209, 239], ["interferon (IFN)", "TREATMENT", 281, 297], ["receptors", "TREATMENT", 302, 311], ["this study", "TEST", 326, 336]]], ["Mice were injected with a total volume of 50\u03bcl of either pVax1 DNA (100 \u03bcg) or ZIKV-IgG (100 \u03bcg) diluted in sterile water in the quadriceps muscle using optimized electroporation (EP) for DNA delivery (CELLECTRA\u00ae; Inovio Pharmaceuticals, Inc., PA, USA).", [["quadriceps muscle", "ANATOMY", 129, 146], ["Mice", "ORGANISM", 0, 4], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["ZIKV-IgG", "GENE_OR_GENE_PRODUCT", 79, 87], ["quadriceps muscle", "TISSUE", 129, 146], ["DNA", "CELLULAR_COMPONENT", 188, 191], ["ZIKV", "PROTEIN", 79, 83], ["IgG", "PROTEIN", 84, 87], ["Mice", "SPECIES", 0, 4], ["a total volume", "TREATMENT", 24, 38], ["either pVax1 DNA", "TREATMENT", 50, 66], ["ZIKV-IgG", "TREATMENT", 79, 87], ["optimized electroporation (EP)", "TREATMENT", 153, 183], ["DNA delivery", "TREATMENT", 188, 200], ["Inovio Pharmaceuticals", "TREATMENT", 214, 236], ["quadriceps muscle", "ANATOMY", 129, 146]]], ["The pulsing parameters for EP delivery were as previously described.", [["The pulsing parameters", "TEST", 0, 22], ["EP delivery", "TREATMENT", 27, 38]]], ["19, 24 Mice were challenged with a total of 1 \u00d7 10 6 PFU (25\u03bcl) of ZIKV-PR209 virus in 50 \u03bcL of PBS by subcutaneous (s.c.) injection in the left hind footpad.", [["subcutaneous", "ANATOMY", 103, 115], ["left hind footpad", "ANATOMY", 140, 157], ["Mice", "ORGANISM", 7, 11], ["ZIKV-PR209 virus", "ORGANISM", 67, 83], ["hind footpad", "ORGANISM_SUBDIVISION", 145, 157], ["Mice", "SPECIES", 7, 11], ["ZIKV-PR209 virus", "SPECIES", 67, 83], ["ZIKV", "TREATMENT", 67, 71], ["virus", "TREATMENT", 78, 83], ["PBS", "TREATMENT", 96, 99], ["left", "ANATOMY_MODIFIER", 140, 144], ["hind", "ANATOMY", 145, 149]]], ["Following virus challenge, mouse weight, morbidity, and mortality were monitored daily.", [["mouse", "ORGANISM", 27, 32], ["mouse", "SPECIES", 27, 32], ["mouse", "SPECIES", 27, 32], ["virus challenge", "TEST", 10, 25], ["mouse weight", "TEST", 27, 39], ["morbidity", "PROBLEM", 41, 50]]], ["A 1-to-5 morbidity scale was adapted as described before: (1) Healthy (no disease); (2) Displaying mild signsdecreased mobility; (3) early signs of hunched posture and decreased mobility; (4) Fur ruffling, increased lethargy and limited mobility, and signs of paralysis in one hind limbs; and (5) Moribund, minimal mobility consistent with inability, paralysis or both hind limbs.", [["hind limbs", "ANATOMY", 277, 287], ["hind limbs", "ANATOMY", 369, 379], ["lethargy", "DISEASE", 216, 224], ["paralysis", "DISEASE", 260, 269], ["paralysis", "DISEASE", 351, 360], ["hind limbs", "ORGANISM_SUBDIVISION", 277, 287], ["hind limbs", "ORGANISM_SUBDIVISION", 369, 379], ["disease", "PROBLEM", 74, 81], ["mild signsdecreased mobility", "PROBLEM", 99, 127], ["early signs of hunched posture", "PROBLEM", 133, 163], ["decreased mobility", "PROBLEM", 168, 186], ["Fur ruffling", "PROBLEM", 192, 204], ["increased lethargy", "PROBLEM", 206, 224], ["limited mobility", "PROBLEM", 229, 245], ["paralysis in one hind limbs", "PROBLEM", 260, 287], ["minimal mobility", "PROBLEM", 307, 323], ["inability, paralysis or both hind limbs", "PROBLEM", 340, 379], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["paralysis", "OBSERVATION", 260, 269], ["hind limbs", "ANATOMY", 277, 287], ["paralysis", "OBSERVATION", 351, 360], ["hind limbs", "ANATOMY", 369, 379]]], ["Mice were euthanized if weight loss was equal to or greater than 20% of their original weight and/or if they scored \"5\" on the morbidity scale.", [["weight loss", "DISEASE", 24, 35], ["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["weight loss", "PROBLEM", 24, 35], ["the morbidity scale", "TREATMENT", 123, 142]]], ["Mice were monitored daily for survival and signs of infection (i.e., body weight and lethargy) over the 2week post-challenge observation period.", [["body", "ANATOMY", 69, 73], ["infection", "DISEASE", 52, 61], ["lethargy", "DISEASE", 85, 93], ["Mice", "ORGANISM", 0, 4], ["body", "ORGANISM_SUBDIVISION", 69, 73], ["Mice", "SPECIES", 0, 4], ["survival", "PROBLEM", 30, 38], ["infection", "PROBLEM", 52, 61], ["body weight", "TEST", 69, 80], ["lethargy", "PROBLEM", 85, 93], ["infection", "OBSERVATION", 52, 61]]], ["Blood samples were collected 7-14 d post-challenge.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["All animal experiments complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and were approved by the Animal Care and Use Committee of the Wistar Institute.Statistical analysisStatistical analyses, using either a Student t-test or the nonparametric Spearman's correlation test, were performed using Graph Pad Prism software (Prism Inc.).", [["Statistical analysisStatistical analyses", "TEST", 241, 281], ["a Student t-test", "TEST", 296, 312], ["the nonparametric Spearman's correlation test", "TEST", 316, 361]]], ["Correlations between the variables in the control and experimental groups were statistically evaluated using the Spearman rank correlation test.", [["the Spearman rank correlation test", "TEST", 109, 143]]], ["For all the tests, p values less than 0.05 were considered significant.Generation and characterization of antibodies targeting ZIKV envelopeThe major target of the host humoral immune response and of neutralizing Abs against flaviviruses is the envelope glycoprotein, which is a 56-kDa protein and the major antigen represented on the surface of virions.", [["surface", "ANATOMY", 335, 342], ["virions", "ANATOMY", 346, 353], ["ZIKV", "GENE_OR_GENE_PRODUCT", 127, 131], ["surface", "CELLULAR_COMPONENT", 335, 342], ["virions", "CELLULAR_COMPONENT", 346, 353], ["antibodies", "PROTEIN", 106, 116], ["ZIKV envelope", "PROTEIN", 127, 140], ["Abs", "PROTEIN", 213, 216], ["envelope glycoprotein", "PROTEIN", 245, 266], ["56-kDa protein", "PROTEIN", 279, 293], ["ZIKV", "SPECIES", 127, 131], ["all the tests", "TEST", 4, 17], ["p values", "TEST", 19, 27], ["antibodies", "TREATMENT", 106, 116], ["neutralizing", "TREATMENT", 200, 212], ["flaviviruses", "PROBLEM", 225, 237], ["the envelope glycoprotein", "TEST", 241, 266], ["host humoral immune response", "OBSERVATION", 164, 192], ["neutralizing", "OBSERVATION_MODIFIER", 200, 212], ["flaviviruses", "OBSERVATION", 225, 237], ["virions", "OBSERVATION", 346, 353]]], ["5, 25, 26 Our group has recently developed and tested in an animal model a DNA vaccine and passive antibody immunotherapy against ZIKV infection and disease.", [["ZIKV infection", "DISEASE", 130, 144], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["ZIKV", "CANCER", 130, 134], ["ZIKV", "SPECIES", 130, 134], ["an animal model a DNA vaccine", "TREATMENT", 57, 86], ["passive antibody immunotherapy", "TREATMENT", 91, 121], ["ZIKV infection", "PROBLEM", 130, 144], ["disease", "PROBLEM", 149, 156]]], ["12 This strategy has demonstrated protective efficacy in mice, non-human primates (NHP) and shows induction of protective immunity in passive transfer studies from vaccinated humans.", [["mice", "ORGANISM", 57, 61], ["non-human primates", "ORGANISM", 63, 81], ["NHP", "ORGANISM", 83, 86], ["humans", "ORGANISM", 175, 181], ["mice", "SPECIES", 57, 61], ["humans", "SPECIES", 175, 181], ["mice", "SPECIES", 57, 61], ["humans", "SPECIES", 175, 181], ["protective immunity", "TREATMENT", 111, 130], ["protective", "OBSERVATION_MODIFIER", 34, 44], ["efficacy", "OBSERVATION_MODIFIER", 45, 53]]], ["27 These studies and others [12] [13] [14] 28 support the role of antibodies directed against the pre-membrane: envelope protein complex (prM+Env) in mediating protection against infection and disease.", [["infection", "DISEASE", 179, 188], ["[12] [13] [14] 28", "SIMPLE_CHEMICAL", 28, 45], ["antibodies directed against the pre-membrane: envelope protein complex", "GENE_OR_GENE_PRODUCT", 66, 136], ["prM+Env", "GENE_OR_GENE_PRODUCT", 138, 145], ["antibodies", "PROTEIN", 66, 76], ["pre-membrane: envelope protein complex", "PROTEIN", 98, 136], ["prM", "PROTEIN", 138, 141], ["Env", "PROTEIN", 142, 145], ["These studies", "TEST", 3, 16], ["antibodies", "TREATMENT", 66, 76], ["envelope protein complex", "PROBLEM", 112, 136], ["infection", "PROBLEM", 179, 188], ["disease", "PROBLEM", 193, 200], ["infection", "OBSERVATION", 179, 188]]], ["7,12 Furthermore, within the prME complex antibodies targeting the E antigen are associated with the ability to transfer protection in animal models.", [["E antigen", "GENE_OR_GENE_PRODUCT", 67, 76], ["prME complex antibodies", "PROTEIN", 29, 52], ["E antigen", "PROTEIN", 67, 76]]], ["Passive antibodies may have value in therapy of infected persons to lower viral load as well as in rapid protection strategies to protect at risk women of childbearing years or the immune compromised.", [["persons", "ORGANISM", 57, 64], ["women", "ORGANISM", 146, 151], ["Passive antibodies", "PROTEIN", 0, 18], ["persons", "SPECIES", 57, 64], ["women", "SPECIES", 146, 151], ["Passive antibodies", "TREATMENT", 0, 18], ["infected persons", "PROBLEM", 48, 64], ["lower viral load", "PROBLEM", 68, 84], ["rapid protection strategies", "TREATMENT", 99, 126], ["the immune compromised", "PROBLEM", 177, 199], ["viral load", "OBSERVATION", 74, 84]]], ["Neutralizing monoclonal antibodies (mAbs) have been demonstrated to be effective in the treatment of several infectious diseases as well as in preliminary in vitro and in vivo models of flavivirus-related infections.", [["infectious diseases", "DISEASE", 109, 128], ["flavivirus", "DISEASE", 186, 196], ["infections", "DISEASE", 205, 215], ["flavivirus", "ORGANISM", 186, 196], ["Neutralizing monoclonal antibodies", "PROTEIN", 0, 34], ["mAbs", "PROTEIN", 36, 40], ["Neutralizing monoclonal antibodies", "TEST", 0, 34], ["several infectious diseases", "PROBLEM", 101, 128], ["flavivirus", "PROBLEM", 186, 196], ["related infections", "PROBLEM", 197, 215], ["infectious", "OBSERVATION", 109, 119], ["flavivirus", "OBSERVATION", 186, 196], ["infections", "OBSERVATION", 205, 215]]], ["25, 26, 28 Given their specific antiviral activity as being well-tolerated molecules with limited side effects, mAbs could represent a new therapeutic approach for the development of an effective treatment, as well as useful tools in the study of the host-virus interplay and in the development of more effective immunogens.Generation and characterization of antibodies targeting ZIKV envelopeTwo approaches were used to create antibodies in mice and RhMacs capable of binding to the ZIKV Envelope (Env) protein for protective studies.", [["ZIKV", "GENE_OR_GENE_PRODUCT", 380, 384], ["mice", "ORGANISM", 442, 446], ["RhMacs", "GENE_OR_GENE_PRODUCT", 451, 457], ["ZIKV", "GENE_OR_GENE_PRODUCT", 484, 488], ["Env", "GENE_OR_GENE_PRODUCT", 499, 502], ["mAbs", "PROTEIN", 112, 116], ["antibodies", "PROTEIN", 359, 369], ["ZIKV envelope", "PROTEIN", 380, 393], ["antibodies", "PROTEIN", 428, 438], ["ZIKV Envelope (Env) protein", "PROTEIN", 484, 511], ["mice", "SPECIES", 442, 446], ["ZIKV", "SPECIES", 380, 384], ["mice", "SPECIES", 442, 446], ["limited side effects", "PROBLEM", 90, 110], ["mAbs", "TREATMENT", 112, 116], ["a new therapeutic approach", "TREATMENT", 133, 159], ["an effective treatment", "TREATMENT", 183, 205], ["the study", "TEST", 234, 243], ["antibodies", "TREATMENT", 359, 369], ["Two approaches", "TREATMENT", 393, 407], ["antibodies in mice", "TREATMENT", 428, 446], ["protective studies", "TEST", 516, 534], ["effective", "OBSERVATION_MODIFIER", 186, 195], ["treatment", "OBSERVATION", 196, 205]]], ["In the first approach, C57/B6 mice were immunized three times by EP-enhanced vaccination using 50\u03bcg of a DNA vaccine encoding a synthetic, consensus sequence of ZIKV pre-membrane/membrane and envelope (prME) antigens.", [["membrane", "ANATOMY", 179, 187], ["EP", "CHEMICAL", 65, 67], ["C57/B6 mice", "ORGANISM", 23, 34], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["ZIKV", "GENE_OR_GENE_PRODUCT", 161, 165], ["membrane", "CELLULAR_COMPONENT", 179, 187], ["envelope (prME) antigens", "GENE_OR_GENE_PRODUCT", 192, 216], ["ZIKV pre-membrane/membrane and envelope (prME) antigens", "PROTEIN", 161, 216], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["C57/B6 mice", "TREATMENT", 23, 34], ["EP-enhanced vaccination", "TREATMENT", 65, 88], ["a DNA vaccine", "TREATMENT", 103, 116], ["ZIKV pre-membrane/membrane", "TREATMENT", 161, 187], ["envelope (prME) antigens", "TREATMENT", 192, 216]]], ["A similar DNA vaccine can induce robust antibody responses in mice and NHPs, that can protect mice from ZIKV challenge.", [["ZIKV", "CHEMICAL", 104, 108], ["DNA", "CELLULAR_COMPONENT", 10, 13], ["mice", "ORGANISM", 62, 66], ["NHPs", "ORGANISM", 71, 75], ["mice", "ORGANISM", 94, 98], ["ZIKV", "ORGANISM", 104, 108], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 62, 66], ["NHPs", "SPECIES", 71, 75], ["mice", "SPECIES", 94, 98], ["ZIKV", "SPECIES", 104, 108], ["A similar DNA vaccine", "TREATMENT", 0, 21], ["ZIKV challenge", "TREATMENT", 104, 118]]], ["12 Following the third immunization, sera from immunized mice were screened by ELISA to confirm the presence of antibodies targeting ZIKV Env.", [["sera", "ANATOMY", 37, 41], ["sera", "ORGANISM_SUBSTANCE", 37, 41], ["mice", "ORGANISM", 57, 61], ["antibodies", "PROTEIN", 112, 122], ["ZIKV", "PROTEIN", 133, 137], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 57, 61], ["ZIKV", "SPECIES", 133, 137], ["the third immunization", "TREATMENT", 13, 35], ["immunized mice", "TREATMENT", 47, 61], ["antibodies", "PROBLEM", 112, 122]]], ["Subsequently, B lymphocytes from immunized mice splenocytes were isolated and used to create hybridomas by conventional means.", [["B lymphocytes", "ANATOMY", 14, 27], ["splenocytes", "ANATOMY", 48, 59], ["hybridomas", "ANATOMY", 93, 103], ["B lymphocytes", "CELL", 14, 27], ["mice", "ORGANISM", 43, 47], ["splenocytes", "CELL", 48, 59], ["hybridomas", "CELL", 93, 103], ["B lymphocytes", "CELL_TYPE", 14, 27], ["splenocytes", "CELL_TYPE", 48, 59], ["hybridomas", "CELL_LINE", 93, 103], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["B lymphocytes", "TREATMENT", 14, 27], ["immunized mice splenocytes", "TREATMENT", 33, 59], ["lymphocytes", "ANATOMY", 16, 27]]], ["19 The hybridomas were screened to identify clones producing antibodies with the highest affinity against ZIKV-Env, resulting in 10 mouse mAbs: 1C2A6, 1D4G7, 3F12E9, 8D10F4, 8A9F9, 2B7D7, 4D6E8, 5E6D9, 6F9D1, and 9F7E1 being selected.", [["hybridomas", "ANATOMY", 7, 17], ["hybridomas", "CELL", 7, 17], ["ZIKV", "GENE_OR_GENE_PRODUCT", 106, 110], ["Env", "GENE_OR_GENE_PRODUCT", 111, 114], ["mouse", "ORGANISM", 132, 137], ["3F12E9", "GENE_OR_GENE_PRODUCT", 158, 164], ["8D10F4", "GENE_OR_GENE_PRODUCT", 166, 172], ["8A9F9", "GENE_OR_GENE_PRODUCT", 174, 179], ["4D6E8", "GENE_OR_GENE_PRODUCT", 188, 193], ["5E6D9", "GENE_OR_GENE_PRODUCT", 195, 200], ["6F9D1", "GENE_OR_GENE_PRODUCT", 202, 207], ["9F7E1", "GENE_OR_GENE_PRODUCT", 213, 218], ["hybridomas", "CELL_LINE", 7, 17], ["antibodies", "PROTEIN", 61, 71], ["ZIKV", "PROTEIN", 106, 110], ["Env", "PROTEIN", 111, 114], ["mouse mAbs", "PROTEIN", 132, 142], ["1C2A6", "PROTEIN", 144, 149], ["1D4G7", "PROTEIN", 151, 156], ["3F12E9", "PROTEIN", 158, 164], ["8D10F4", "PROTEIN", 166, 172], ["8A9F9", "PROTEIN", 174, 179], ["2B7D7", "PROTEIN", 181, 186], ["4D6E8", "PROTEIN", 188, 193], ["5E6D9", "PROTEIN", 195, 200], ["6F9D1", "PROTEIN", 202, 207], ["9F7E1", "PROTEIN", 213, 218], ["mouse", "SPECIES", 132, 137], ["mouse", "SPECIES", 132, 137], ["The hybridomas", "TEST", 3, 17], ["clones producing antibodies", "PROBLEM", 44, 71]]], ["Supernatants from each of these hybridoma clones bound purified recombinant soluble ZIKV-Env protein by indirect ELISA and western blot analysis, respectively (Figure 1a,b) .", [["Supernatants", "ANATOMY", 0, 12], ["hybridoma clones", "ANATOMY", 32, 48], ["hybridoma clones", "CELL", 32, 48], ["ZIKV", "GENE_OR_GENE_PRODUCT", 84, 88], ["hybridoma clones", "CELL_LINE", 32, 48], ["ZIKV", "PROTEIN", 84, 88], ["Env protein", "PROTEIN", 89, 100], ["these hybridoma clones", "TREATMENT", 26, 48], ["Env protein", "TEST", 89, 100], ["indirect ELISA", "TEST", 104, 118], ["western blot analysis", "TEST", 123, 144], ["hybridoma clones", "OBSERVATION", 32, 48]]], ["Anti-ZIKV ENV mAbs also bound to ZIKV-PR 209 virus-infected Vero cells as demonstrated via immunofluorescence assay (Figure 1c) .Generation and characterization of antibodies targeting ZIKV envelopeThe second approach used to generate anti-ZIKV Env mAbs utilized blood and splenic tissue collected from five RhMacs that were challenged twice with a contemporary strain of ZIKV, PR209.", [["Vero cells", "ANATOMY", 60, 70], ["blood", "ANATOMY", 263, 268], ["splenic tissue", "ANATOMY", 273, 287], ["RhMacs", "ANATOMY", 308, 314], ["ZIKV-PR 209", "CHEMICAL", 33, 44], ["PR209", "CHEMICAL", 378, 383], ["ZIKV-PR 209 virus", "ORGANISM", 33, 50], ["Vero cells", "CELL", 60, 70], ["ZIKV", "GENE_OR_GENE_PRODUCT", 185, 189], ["blood", "ORGANISM_SUBSTANCE", 263, 268], ["splenic tissue", "TISSUE", 273, 287], ["ZIKV", "ORGANISM", 372, 376], ["PR209", "SIMPLE_CHEMICAL", 378, 383], ["Anti-ZIKV ENV mAbs", "PROTEIN", 0, 18], ["ZIKV-PR 209 virus-infected Vero cells", "CELL_LINE", 33, 70], ["antibodies", "PROTEIN", 164, 174], ["ZIKV envelope", "PROTEIN", 185, 198], ["anti-ZIKV Env mAbs", "PROTEIN", 235, 253], ["Anti-ZIKV", "SPECIES", 0, 9], ["ENV", "SPECIES", 10, 13], ["ZIKV-PR 209 virus", "SPECIES", 33, 50], ["ZIKV", "SPECIES", 185, 189], ["anti-ZIKV", "SPECIES", 235, 244], ["ZIKV", "SPECIES", 372, 376], ["Anti-ZIKV ENV mAbs", "TREATMENT", 0, 18], ["ZIKV", "TEST", 33, 37], ["PR", "TEST", 38, 40], ["infected Vero cells", "PROBLEM", 51, 70], ["immunofluorescence assay", "TEST", 91, 115], ["antibodies", "TREATMENT", 164, 174], ["The second approach", "TREATMENT", 198, 217], ["anti-ZIKV Env mAbs", "TREATMENT", 235, 253], ["splenic tissue", "PROBLEM", 273, 287], ["ZIKV", "PROBLEM", 372, 376], ["Vero cells", "OBSERVATION", 60, 70], ["splenic", "ANATOMY", 273, 280], ["tissue", "ANATOMY_MODIFIER", 281, 287]]], ["All macaques developed viremia after the first challenge, but none had detectable viremia after re-challenge.", [["viremia", "DISEASE", 23, 30], ["viremia", "DISEASE", 82, 89], ["macaques", "ORGANISM", 4, 12], ["macaques", "SPECIES", 4, 12], ["viremia", "PROBLEM", 23, 30], ["detectable viremia", "PROBLEM", 71, 89], ["viremia", "OBSERVATION", 23, 30], ["viremia", "OBSERVATION", 82, 89]]], ["Spleen and whole blood mononuclear cells were harvested from the macaques 15 d-post re-challenge.", [["Spleen", "ANATOMY", 0, 6], ["whole blood mononuclear cells", "ANATOMY", 11, 40], ["Spleen", "CELL", 0, 6], ["whole blood mononuclear cells", "CELL", 11, 40], ["macaques", "ORGANISM", 65, 73], ["whole blood mononuclear cells", "CELL_TYPE", 11, 40], ["whole blood", "ANATOMY", 11, 22], ["mononuclear cells", "OBSERVATION", 23, 40]]], ["Subsequently, scFv/phage-display technology combined with solid-phase selection against immobilized Zika antigen was used.", [["scFv", "GENE_OR_GENE_PRODUCT", 14, 18], ["Zika antigen", "GENE_OR_GENE_PRODUCT", 100, 112], ["scFv", "PROTEIN", 14, 18], ["Zika antigen", "PROTEIN", 100, 112], ["scFv/phage", "TREATMENT", 14, 24], ["solid-phase selection", "TREATMENT", 58, 79], ["immobilized Zika antigen", "TREATMENT", 88, 112]]], ["RNA from peripheral blood B cells was prepared from each of the five macaques and pooled.", [["peripheral blood B cells", "ANATOMY", 9, 33], ["peripheral blood B cells", "CELL", 9, 33], ["macaques", "ORGANISM", 69, 77], ["RNA", "RNA", 0, 3], ["peripheral blood B cells", "CELL_TYPE", 9, 33], ["macaques", "SPECIES", 69, 77], ["peripheral blood B cells", "TEST", 9, 33], ["peripheral", "ANATOMY_MODIFIER", 9, 19], ["blood", "ANATOMY", 20, 25], ["B cells", "OBSERVATION", 26, 33]]], ["Similarly, splenic RNA was prepared from each macaque and pooled.", [["splenic", "ANATOMY", 11, 18], ["macaque", "ORGANISM", 46, 53], ["splenic RNA", "RNA", 11, 22], ["splenic RNA", "PROBLEM", 11, 22], ["splenic", "ANATOMY", 11, 18], ["RNA", "OBSERVATION", 19, 22]]], ["RT-PCR to amplify variable heavy (VH), variable kappa (V\u03ba), and variable lambda (V\u03bb) gene segments was performed separately on peripheral blood RNA and splenic RNA, and then VHs, V\u03bas, and V\u03bbs from each source of RNA were pooled.", [["peripheral blood", "ANATOMY", 127, 143], ["splenic", "ANATOMY", 152, 159], ["kappa", "GENE_OR_GENE_PRODUCT", 48, 53], ["V\u03ba", "GENE_OR_GENE_PRODUCT", 55, 57], ["lambda (V\u03bb)", "GENE_OR_GENE_PRODUCT", 73, 84], ["peripheral blood", "ORGANISM_SUBSTANCE", 127, 143], ["VHs", "GENE_OR_GENE_PRODUCT", 174, 177], ["V\u03bas", "GENE_OR_GENE_PRODUCT", 179, 182], ["V\u03bbs", "GENE_OR_GENE_PRODUCT", 188, 191], ["variable lambda (V\u03bb) gene segments", "DNA", 64, 98], ["peripheral blood RNA", "RNA", 127, 147], ["splenic RNA", "RNA", 152, 163], ["VHs", "PROTEIN", 174, 177], ["V\u03bas", "PROTEIN", 179, 182], ["V\u03bbs", "PROTEIN", 188, 191], ["RT-PCR", "TEST", 0, 6], ["variable lambda (V\u03bb) gene segments", "PROBLEM", 64, 98], ["peripheral blood RNA and splenic RNA", "PROBLEM", 127, 163], ["VHs", "TEST", 174, 177], ["V\u03bas", "TEST", 179, 182], ["peripheral", "ANATOMY_MODIFIER", 127, 137], ["blood RNA", "ANATOMY", 138, 147], ["splenic", "ANATOMY", 152, 159], ["RNA", "ANATOMY_MODIFIER", 160, 163]]], ["RT-PCR was performed as described 21-23 using a combination of human immunoglobulin primers previously described and supplemented with sets of macaque-specific VH, V\u03ba, and V\u03bb as summarized in supplementary data Table 1 .", [["human", "ORGANISM", 63, 68], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 69, 83], ["macaque", "ORGANISM", 143, 150], ["VH", "GENE_OR_GENE_PRODUCT", 160, 162], ["V\u03ba", "GENE_OR_GENE_PRODUCT", 164, 166], ["V\u03bb", "GENE_OR_GENE_PRODUCT", 172, 174], ["human immunoglobulin primers", "DNA", 63, 91], ["VH", "DNA", 160, 162], ["V\u03ba", "DNA", 164, 166], ["V\u03bb", "DNA", 172, 174], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["RT-PCR", "TEST", 0, 6], ["human immunoglobulin primers", "TREATMENT", 63, 91], ["macaque", "TEST", 143, 150]]], ["Separate VH/ V\u03ba and VH/V\u03bb scFv phage display libraries were constructed using the pComb3X vector as described 21, 22 using TG1 electrocompetent E. coli and comprised 1.6 \u00d7 10 9 and 1.5 \u00d7 10 9 independent transformants, respectively.", [["transformants", "ANATOMY", 204, 217], ["VH", "GENE_OR_GENE_PRODUCT", 9, 11], ["V\u03ba", "GENE_OR_GENE_PRODUCT", 13, 15], ["E. coli", "ORGANISM", 144, 151], ["transformants", "CELL", 204, 217], ["VH", "DNA", 9, 11], ["V\u03ba", "DNA", 13, 15], ["VH", "DNA", 20, 22], ["pComb3X vector", "DNA", 82, 96], ["E. coli", "SPECIES", 144, 151], ["E. coli", "SPECIES", 144, 151], ["Separate VH/ V\u03ba", "TEST", 0, 15], ["VH/V\u03bb scFv phage", "TREATMENT", 20, 36], ["the pComb3X vector", "TREATMENT", 78, 96], ["TG1 electrocompetent E. coli", "TEST", 123, 151]]], ["VH/V\u03ba and VH/V\u03bb libraries were panned separately on immobilized Zika ENV protein using solid-phase methods previously described.", [["VH/V\u03ba", "GENE_OR_GENE_PRODUCT", 0, 5], ["VH/V\u03ba and VH/V\u03bb libraries", "DNA", 0, 25], ["Zika ENV protein", "PROTEIN", 64, 80], ["VH", "TEST", 0, 2], ["VH/V\u03bb libraries", "TEST", 10, 25], ["solid-phase methods", "TREATMENT", 87, 106]]], ["21 Positive clones were identified using phage ELISA, and heavy and light chain scFv nucleotide sequences were identified as described 21, 23 and analyzed for homology to macaque immunoglobulin germline gene segments using IMGT/V-Quest.", [["clones", "ANATOMY", 12, 18], ["nucleotide", "CHEMICAL", 85, 95], ["nucleotide", "CHEMICAL", 85, 95], ["macaque", "ORGANISM", 171, 178], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 179, 193], ["heavy and light chain scFv nucleotide sequences", "DNA", 58, 105], ["macaque immunoglobulin germline gene segments", "DNA", 171, 216], ["phage ELISA", "TEST", 41, 52], ["light chain scFv nucleotide sequences", "TEST", 68, 105], ["Positive clones", "OBSERVATION", 3, 18]]], ["29 Of 44 randomly selected clones, 11 unique RhMac anti-ZIKV Env mAbs were isolated after screening: KP401, KP412, LP401, LP305, LP314, LP306, LP320, LP311, LP312, LP402 and LP408 where \"K\" and \"L\" designations indicate whether the scFv comprises a kappa or lambda light chain, respectively.", [["clones", "ANATOMY", 27, 33], ["clones", "CELL", 27, 33], ["RhMac", "GENE_OR_GENE_PRODUCT", 45, 50], ["lambda light chain", "GENE_OR_GENE_PRODUCT", 258, 276], ["RhMac anti-ZIKV Env mAbs", "PROTEIN", 45, 69], ["scFv", "PROTEIN", 232, 236], ["kappa or lambda light chain", "PROTEIN", 249, 276], ["unique RhMac anti-ZIKV Env mAbs", "TREATMENT", 38, 69], ["KP401", "TEST", 101, 106], ["KP412", "TEST", 108, 113], ["LP314", "TEST", 129, 134], ["LP306", "TEST", 136, 141], ["LP320", "TEST", 143, 148], ["LP311", "TEST", 150, 155], ["LP312", "TEST", 157, 162], ["LP402", "TEST", 164, 169], ["K\"", "TEST", 187, 189], ["the scFv", "PROBLEM", 228, 236]]], ["Clones LP305 and LP314 were clonally related (identical heavy chain and light chain CDR3 regions) as were clones LP311 and LP320 so only clones LP305 and LP311 were selected for dMAb conversion.Generation and characterization of antibodies targeting ZIKV envelopeThe nucleotide sequences of all mouse and RhMac anti-ZIKV mAbs were used for phylogenetic analysis and structural modeling of the antibody variable regions.", [["nucleotide", "CHEMICAL", 267, 277], ["LP305", "GENE_OR_GENE_PRODUCT", 7, 12], ["LP314", "GENE_OR_GENE_PRODUCT", 17, 22], ["LP320", "GENE_OR_GENE_PRODUCT", 123, 128], ["LP311", "GENE_OR_GENE_PRODUCT", 154, 159], ["dMAb", "SIMPLE_CHEMICAL", 178, 182], ["ZIKV", "GENE_OR_GENE_PRODUCT", 250, 254], ["mouse", "ORGANISM", 295, 300], ["LP305", "PROTEIN", 7, 12], ["LP314", "DNA", 17, 22], ["light chain CDR3 regions", "PROTEIN", 72, 96], ["LP320", "DNA", 123, 128], ["dMAb", "PROTEIN", 178, 182], ["antibodies", "PROTEIN", 229, 239], ["ZIKV envelope", "PROTEIN", 250, 263], ["mouse and RhMac anti-ZIKV mAbs", "PROTEIN", 295, 325], ["antibody variable regions", "PROTEIN", 393, 418], ["mouse", "SPECIES", 295, 300], ["ZIKV", "SPECIES", 250, 254], ["mouse", "SPECIES", 295, 300], ["anti-ZIKV", "SPECIES", 311, 320], ["Clones LP305", "TEST", 0, 12], ["identical heavy chain and light chain CDR3 regions", "PROBLEM", 46, 96], ["clones LP305", "TEST", 137, 149], ["dMAb conversion", "TREATMENT", 178, 193], ["antibodies", "TREATMENT", 229, 239], ["The nucleotide sequences", "TEST", 263, 287], ["RhMac anti-ZIKV mAbs", "TREATMENT", 305, 325], ["phylogenetic analysis", "TEST", 340, 361], ["structural modeling of the antibody variable regions", "PROBLEM", 366, 418], ["antibody", "OBSERVATION", 393, 401]]], ["An unrooted phylogenetic tree based on the CDR sequences of 16 mAbs (5 of the 10 murine antibodies and all 11 of the macaque antibodies) shows a high level of similarity between them suggesting they may all target the same or related epitopes.", [["murine", "ORGANISM", 81, 87], ["macaque", "ORGANISM", 117, 124], ["CDR sequences", "DNA", 43, 56], ["mAbs", "PROTEIN", 63, 67], ["murine antibodies", "PROTEIN", 81, 98], ["macaque antibodies", "PROTEIN", 117, 135], ["epitopes", "PROTEIN", 234, 242], ["murine", "SPECIES", 81, 87], ["An unrooted phylogenetic tree", "PROBLEM", 0, 29], ["the CDR sequences", "TEST", 39, 56], ["the 10 murine antibodies", "TEST", 74, 98], ["the macaque antibodies", "TEST", 113, 135], ["phylogenetic tree", "OBSERVATION", 12, 29]]], ["Predicted CDR structures of each mAb made using Discovery Studio software show similar CDR conformations between the most closely related mAbs as expected (Figure 2a) .", [["mAb", "PROTEIN", 33, 36], ["mAbs", "PROTEIN", 138, 142], ["Discovery Studio software", "TEST", 48, 73], ["similar CDR conformations", "PROBLEM", 79, 104], ["CDR conformations", "OBSERVATION", 87, 104], ["mAbs", "OBSERVATION", 138, 142]]], ["Docking analysis between the models of mAbs 8A9F9, LP314 and LP408 and the structure of ZIKV Env was performed using Discovery Studio software's ZDOCK function.", [["mAbs 8A9F9", "GENE_OR_GENE_PRODUCT", 39, 49], ["LP314", "GENE_OR_GENE_PRODUCT", 51, 56], ["LP408", "GENE_OR_GENE_PRODUCT", 61, 66], ["ZIKV", "GENE_OR_GENE_PRODUCT", 88, 92], ["mAbs 8A9F9", "PROTEIN", 39, 49], ["LP314", "PROTEIN", 51, 56], ["LP408", "PROTEIN", 61, 66], ["ZIKV Env", "PROTEIN", 88, 96], ["ZDOCK", "PROTEIN", 145, 150], ["ZIKV", "SPECIES", 88, 92], ["Docking analysis", "TEST", 0, 16], ["ZIKV Env", "OBSERVATION", 88, 96]]], ["This analysis suggests that each of these may bind to ZIKV Env Domain 3 (EDIII), a known target of neutralizing antibodies in related flaviviruses.", [["flaviviruses", "DISEASE", 134, 146], ["ZIKV Env Domain 3", "GENE_OR_GENE_PRODUCT", 54, 71], ["EDIII", "GENE_OR_GENE_PRODUCT", 73, 78], ["ZIKV Env Domain 3", "PROTEIN", 54, 71], ["EDIII", "PROTEIN", 73, 78], ["neutralizing antibodies", "PROTEIN", 99, 122], ["This analysis", "TEST", 0, 13], ["neutralizing antibodies in related flaviviruses", "PROBLEM", 99, 146], ["neutralizing antibodies", "OBSERVATION", 99, 122]]], ["26, [30] [31] [32] Construction and pharmacokinetic evaluation of anti-ZIKV-dMAbsGeneration and characterization of antibodies targeting ZIKV envelopeThe heavy and light chain sequences of each mouse and RhMac mAb were cloned as a single cassette into the pVax1 DNA plasmid to create dMAb plasmids (Figure 2b) .", [["plasmid", "ANATOMY", 266, 273], ["plasmids", "ANATOMY", 289, 297], ["mouse", "ORGANISM", 194, 199], ["RhMac mAb", "GENE_OR_GENE_PRODUCT", 204, 213], ["pVax1", "GENE_OR_GENE_PRODUCT", 256, 261], ["DNA", "CELLULAR_COMPONENT", 262, 265], ["antibodies", "PROTEIN", 116, 126], ["ZIKV envelope", "PROTEIN", 137, 150], ["heavy and light chain sequences", "DNA", 154, 185], ["RhMac mAb", "PROTEIN", 204, 213], ["pVax1 DNA plasmid", "DNA", 256, 273], ["dMAb plasmids", "DNA", 284, 297], ["mouse", "SPECIES", 194, 199], ["ZIKV", "SPECIES", 137, 141], ["mouse", "SPECIES", 194, 199], ["pharmacokinetic evaluation", "TEST", 36, 62], ["anti-ZIKV-dMAbsGeneration", "TREATMENT", 66, 91], ["antibodies", "PROBLEM", 116, 126], ["RhMac mAb", "TREATMENT", 204, 213], ["a single cassette", "TREATMENT", 229, 246], ["the pVax1 DNA plasmid", "TREATMENT", 252, 273], ["dMAb plasmids", "TREATMENT", 284, 297], ["heavy", "OBSERVATION_MODIFIER", 154, 159]]], ["Each antibody was cloned as a full-length human IgG1 constant region sequence to take advantage of IgG1 properties including longer circulating half-lives, better tissue penetration, lower retention times, and better recruitment of effector functions by the antibody constant (Fc) component.", [["tissue", "ANATOMY", 163, 169], ["human", "ORGANISM", 42, 47], ["IgG1", "GENE_OR_GENE_PRODUCT", 48, 52], ["IgG1", "GENE_OR_GENE_PRODUCT", 99, 103], ["tissue", "TISSUE", 163, 169], ["human IgG1 constant region sequence", "DNA", 42, 77], ["IgG1", "PROTEIN", 99, 103], ["antibody constant (Fc) component", "PROTEIN", 258, 290], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["a full-length human IgG1 constant region sequence", "TREATMENT", 28, 77], ["IgG1 properties", "TREATMENT", 99, 114]]], ["18, 19 Antibodies produced after transfection or injection of these plasmids will henceforth be referred to as dMAbs.", [["plasmids", "ANATOMY", 68, 76], ["dMAbs", "GENE_OR_GENE_PRODUCT", 111, 116], ["plasmids", "DNA", 68, 76], ["dMAbs", "PROTEIN", 111, 116], ["transfection", "TREATMENT", 33, 45], ["these plasmids", "TREATMENT", 62, 76]]], ["Each synthetically designed dMAb plasmid cassette consisted of an antibody sequence fused downstream of an enhanced leader sequence, and each cassette was codon and RNA structure optimized to drive increased in vivo protein production.", [["dMAb", "GENE_OR_GENE_PRODUCT", 28, 32], ["dMAb plasmid cassette", "DNA", 28, 49], ["antibody sequence", "DNA", 66, 83], ["enhanced leader sequence", "DNA", 107, 131], ["dMAb plasmid cassette", "TREATMENT", 28, 49], ["an antibody sequence", "TEST", 63, 83], ["an enhanced leader sequence", "TEST", 104, 131], ["codon and RNA structure", "PROBLEM", 155, 178], ["vivo protein production", "OBSERVATION", 211, 234]]], ["12, 18, 33 In vitro expression of antibody from each plasmid was evaluated by performing a quantitative ELISA for IgG concentration on cell lysates and supernatants collected from plasmid-transfected HEK293T cells.", [["plasmid", "ANATOMY", 53, 60], ["cell lysates", "ANATOMY", 135, 147], ["supernatants", "ANATOMY", 152, 164], ["HEK293T cells", "ANATOMY", 200, 213], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["cell lysates", "ORGANISM_SUBSTANCE", 135, 147], ["HEK293T cells", "CELL", 200, 213], ["IgG", "PROTEIN", 114, 117], ["HEK293T cells", "CELL_LINE", 200, 213], ["antibody from each plasmid", "TREATMENT", 34, 60], ["a quantitative ELISA", "TEST", 89, 109], ["IgG concentration", "TREATMENT", 114, 131], ["cell lysates", "TREATMENT", 135, 147], ["supernatants", "TEST", 152, 164], ["plasmid-transfected HEK293T cells", "TREATMENT", 180, 213], ["HEK293T cells", "OBSERVATION", 200, 213]]], ["Supernatants from cells transfected with either mouse or RhMac dMAb plasmids contained IgG at levels of 2000-9000 ng/ml at 48-h-post-transfections while lysates generally had lower levels at approximately 2000 ng/ml (Figure 2c,d) .Generation and characterization of antibodies targeting ZIKV envelopePharmacokinetic, binding and avidity activity of ZIKV-dMAbs in vivoGeneration and characterization of antibodies targeting ZIKV envelopeThe in vivo expression of dMAb was evaluated by injecting B6.", [["Supernatants", "ANATOMY", 0, 12], ["cells", "ANATOMY", 18, 23], ["lysates", "ANATOMY", 153, 160], ["ZIKV-dMAbs", "CHEMICAL", 349, 359], ["Supernatants", "CELL", 0, 12], ["cells", "CELL", 18, 23], ["mouse", "ORGANISM", 48, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["lysates", "ORGANISM_SUBSTANCE", 153, 160], ["ZIKV", "GENE_OR_GENE_PRODUCT", 287, 291], ["ZIKV-dMAbs", "SIMPLE_CHEMICAL", 349, 359], ["dMAb", "GENE_OR_GENE_PRODUCT", 462, 466], ["mouse or RhMac dMAb plasmids", "DNA", 48, 76], ["IgG", "PROTEIN", 87, 90], ["antibodies", "PROTEIN", 266, 276], ["ZIKV envelope", "PROTEIN", 287, 300], ["ZIKV", "PROTEIN", 349, 353], ["dMAbs", "PROTEIN", 354, 359], ["antibodies", "PROTEIN", 402, 412], ["ZIKV envelope", "PROTEIN", 423, 436], ["dMAb", "PROTEIN", 462, 466], ["mouse", "SPECIES", 48, 53], ["mouse", "SPECIES", 48, 53], ["ZIKV", "SPECIES", 287, 291], ["ZIKV", "SPECIES", 423, 427], ["Supernatants from cells", "PROBLEM", 0, 23], ["RhMac dMAb plasmids", "TREATMENT", 57, 76], ["IgG", "TEST", 87, 90], ["lysates", "TEST", 153, 160], ["lower levels", "PROBLEM", 175, 187], ["antibodies", "TREATMENT", 266, 276], ["Pharmacokinetic, binding", "PROBLEM", 300, 324], ["ZIKV", "PROBLEM", 349, 353], ["dMAbs", "PROBLEM", 354, 359], ["vivoGeneration", "TREATMENT", 363, 377], ["antibodies", "PROBLEM", 402, 412], ["dMAb", "OBSERVATION", 462, 466]]], ["Cg-Foxn1nu/J mice with 100 \u03bcg of dMAb plasmids intramuscularly followed by adaptive in vivo EP.", [["plasmids", "ANATOMY", 38, 46], ["Cg", "GENE_OR_GENE_PRODUCT", 0, 2], ["dMAb", "GENE_OR_GENE_PRODUCT", 33, 37], ["dMAb plasmids", "DNA", 33, 46], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["Cg", "TEST", 0, 2], ["Foxn1nu/J mice", "TREATMENT", 3, 17], ["dMAb plasmids", "TREATMENT", 33, 46]]], ["Sera collected from mice at various times post-injection and EP were evaluated by quantitative ELISA for chimeric human IgG to assess DMAb production and longevity.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["mice", "ORGANISM", 20, 24], ["human", "ORGANISM", 114, 119], ["IgG", "GENE_OR_GENE_PRODUCT", 120, 123], ["DMAb", "GENE_OR_GENE_PRODUCT", 134, 138], ["chimeric human IgG", "PROTEIN", 105, 123], ["mice", "SPECIES", 20, 24], ["human", "SPECIES", 114, 119], ["mice", "SPECIES", 20, 24], ["human", "SPECIES", 114, 119], ["Sera", "TEST", 0, 4], ["EP", "TEST", 61, 63], ["chimeric human IgG", "TREATMENT", 105, 123], ["longevity", "PROBLEM", 154, 163]]], ["As noted in Figure 3 , mouse and RhMac dMAb plasmids both were evaluated for production of IgG in vivo.", [["RhMac dMAb plasmids", "ANATOMY", 33, 52], ["mouse", "ORGANISM", 23, 28], ["RhMac", "GENE_OR_GENE_PRODUCT", 33, 38], ["IgG", "GENE_OR_GENE_PRODUCT", 91, 94], ["mouse and RhMac dMAb plasmids", "DNA", 23, 52], ["IgG", "PROTEIN", 91, 94], ["mouse", "SPECIES", 23, 28], ["mouse", "SPECIES", 23, 28], ["mouse and RhMac dMAb plasmids", "TREATMENT", 23, 52], ["IgG in vivo", "TREATMENT", 91, 102]]], ["Peak serum antibody levels varied between the different mouse-and RhMac dMAbs evaluated.", [["serum", "ANATOMY", 5, 10], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["mouse", "ORGANISM", 56, 61], ["RhMac dMAbs", "CELL", 66, 77], ["mouse", "SPECIES", 56, 61], ["mouse", "SPECIES", 56, 61], ["Peak serum antibody levels", "TEST", 0, 26]]], ["Mouse-derived ZIKV dMAb clones were observed at the highest serum concentration (ng/mL) between 15 and 25 dpost-injection ( Figure 3a) .", [["ZIKV dMAb clones", "ANATOMY", 14, 30], ["serum", "ANATOMY", 60, 65], ["Mouse", "ORGANISM", 0, 5], ["ZIKV dMAb clones", "CELL", 14, 30], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["Mouse-derived ZIKV dMAb clones", "CELL_LINE", 0, 30], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["ZIKV", "SPECIES", 14, 18], ["ZIKV dMAb clones", "TREATMENT", 14, 30]]], ["Importantly, these in vivo dMAbs retained the ability to bind to ZIKV Env protein by Western blot analyses (Figure 3b ).", [["dMAbs", "GENE_OR_GENE_PRODUCT", 27, 32], ["ZIKV Env", "GENE_OR_GENE_PRODUCT", 65, 73], ["dMAbs", "PROTEIN", 27, 32], ["ZIKV Env protein", "PROTEIN", 65, 81], ["ZIKV", "SPECIES", 65, 69], ["blot analyses", "TEST", 93, 106]]], ["The expression of RhMac dMAbs was detectable out to 60 dpost injection, and these in vivo dMAbs in circulation were also able to bind ZIKV Env protein (Figure 3c,d) .", [["RhMac", "GENE_OR_GENE_PRODUCT", 18, 23], ["dMAbs", "SIMPLE_CHEMICAL", 90, 95], ["RhMac dMAbs", "PROTEIN", 18, 29], ["ZIKV Env protein", "PROTEIN", 134, 150], ["Figure 3c,d)", "PROTEIN", 152, 164], ["RhMac dMAbs", "TEST", 18, 29]]], ["These results indicate that (a) An unrooted phylogenetic tree based on CDR comparisons (only) of 16 anti-Zika envelope antibodies was generated to demonstrate relatedness and by extension the potential for epitope targeting similarity.", [["16 anti", "PROTEIN", 97, 104], ["Zika envelope antibodies", "PROTEIN", 105, 129], ["An unrooted phylogenetic tree", "PROBLEM", 32, 61], ["CDR comparisons", "TEST", 71, 86], ["Zika envelope antibodies", "PROBLEM", 105, 129], ["epitope targeting similarity", "PROBLEM", 206, 234]]], ["Shown nearby to each antibody location on the tree is a molecular model generated with standard antibody modeling protocols as implemented in Discovery Studio.", [["standard antibody modeling protocols", "TREATMENT", 87, 123], ["antibody", "OBSERVATION", 21, 29], ["tree", "ANATOMY_MODIFIER", 46, 50]]], ["Models are shown in CPK format and CDRs are highlighted.", [["CPK", "GENE_OR_GENE_PRODUCT", 20, 23], ["CPK", "PROTEIN", 20, 23], ["CPK format", "TEST", 20, 30], ["CDRs", "TEST", 35, 39]]], ["As sequence relatedness translates to structural similarities, it can be noted that clusters of nearly or completely identical CDRs adopt similar conformations.", [["CDRs", "PROTEIN", 127, 131]]], ["Of the Fv models shown, LP408, LP314, and 8A9F9 have been subjected to docking analysis using ZDOCK as implemented in Discovery Studio and scored with ZRANK.", [["LP408", "GENE_OR_GENE_PRODUCT", 24, 29], ["LP314", "GENE_OR_GENE_PRODUCT", 31, 36], ["8A9F9", "GENE_OR_GENE_PRODUCT", 42, 47], ["ZDOCK", "SIMPLE_CHEMICAL", 94, 99], ["LP408", "PROTEIN", 24, 29], ["LP314", "PROTEIN", 31, 36], ["8A9F9", "PROTEIN", 42, 47], ["ZDOCK", "PROTEIN", 94, 99], ["ZRANK", "PROTEIN", 151, 156], ["the Fv models", "TEST", 3, 16], ["LP408", "TEST", 24, 29], ["LP314", "TEST", 31, 36], ["docking analysis", "TEST", 71, 87], ["ZDOCK", "TREATMENT", 94, 99]]], ["In all cases, the EDIII region (a known target for effective neutralizing antibodies) contains multiple top poses for the antibodies in question.", [["EDIII region", "DNA", 18, 30], ["neutralizing antibodies", "PROTEIN", 61, 84], ["antibodies", "PROTEIN", 122, 132], ["effective neutralizing antibodies", "TREATMENT", 51, 84], ["the antibodies", "TEST", 118, 132]]], ["In particular, LP408 and LP314 demonstrate the top 15 of 20 poses total in this region. * indicates similar CDR conformations between closely related mAbs and a potential ZIKV ENV Domain III (EDIII) binding for clones 8A9F9, LP314, and LP408. (b) Schematic diagram of ZIKV-specific antibody heavy and light chain encoded as a codon-optimized single cassette into the pVax1 DNA plasmid.", [["LP314", "CHEMICAL", 25, 30], ["LP408", "GENE_OR_GENE_PRODUCT", 15, 20], ["LP314", "GENE_OR_GENE_PRODUCT", 25, 30], ["ENV Domain III", "GENE_OR_GENE_PRODUCT", 176, 190], ["EDIII", "GENE_OR_GENE_PRODUCT", 192, 197], ["ZIKV", "GENE_OR_GENE_PRODUCT", 268, 272], ["antibody heavy and light chain", "GENE_OR_GENE_PRODUCT", 282, 312], ["pVax1", "GENE_OR_GENE_PRODUCT", 367, 372], ["DNA", "CELLULAR_COMPONENT", 373, 376], ["LP408", "PROTEIN", 15, 20], ["LP314", "PROTEIN", 25, 30], ["mAbs", "PROTEIN", 150, 154], ["EDIII", "PROTEIN", 192, 197], ["LP408", "CELL_LINE", 236, 241], ["ZIKV-specific antibody heavy and light chain", "PROTEIN", 268, 312], ["codon-optimized single cassette", "DNA", 326, 357], ["pVax1 DNA plasmid", "DNA", 367, 384], ["LP408", "TEST", 15, 20], ["similar CDR conformations", "PROBLEM", 100, 125], ["clones", "TEST", 211, 217], ["LP314", "TEST", 225, 230], ["ZIKV", "PROBLEM", 268, 272], ["a codon", "TREATMENT", 324, 331], ["the pVax1 DNA plasmid", "TREATMENT", 363, 384], ["top", "OBSERVATION_MODIFIER", 47, 50], ["CDR conformations", "OBSERVATION", 108, 125]]], ["Construction and expression of ZIKV-dMAb plasmid constructs from (c) ZIKV DNA plasmid-vaccinated murine spleen-derived and (d) ZIKV-infected RhMac spleenderived.", [["spleen", "ANATOMY", 104, 110], ["RhMac", "ANATOMY", 141, 146], ["ZIKV-dMAb", "GENE_OR_GENE_PRODUCT", 31, 40], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["murine", "ORGANISM", 97, 103], ["spleen", "ORGAN", 104, 110], ["ZIKV", "ORGANISM", 127, 131], ["RhMac", "CELL", 141, 146], ["ZIKV-dMAb plasmid constructs", "DNA", 31, 59], ["ZIKV DNA plasmid", "DNA", 69, 85], ["murine", "SPECIES", 97, 103], ["ZIKV", "SPECIES", 127, 131], ["ZIKV-dMAb plasmid constructs", "TREATMENT", 31, 59], ["ZIKV DNA plasmid", "TREATMENT", 69, 85], ["ZIKV", "PROBLEM", 127, 131], ["spleen", "ANATOMY", 104, 110]]], ["Each dMAb construct was transfected into 293T cells in order to determine in vitro expression via enzyme-linked immunosorbent assays (ELISAs).", [["293T cells", "ANATOMY", 41, 51], ["dMAb", "GENE_OR_GENE_PRODUCT", 5, 9], ["293T cells", "CELL", 41, 51], ["dMAb construct", "DNA", 5, 19], ["293T cells", "CELL_LINE", 41, 51], ["Each dMAb construct", "TREATMENT", 0, 19], ["enzyme", "TEST", 98, 104], ["immunosorbent assays", "TEST", 112, 132]]], ["The bar represents the level of IgG present at 48-h post transfection for both cell lysates and supernatants per construct.Generation and characterization of antibodies targeting ZIKV envelopeEP-enhanced intramuscular delivery of dMAb plasmids mediates in vivo production of functional ZIKV Env-specific monoclonal antibodies.Generation and characterization of antibodies targeting ZIKV envelopeThe binding affinity of an antibody to its target is defined by natural affinity and avidity.", [["cell lysates", "ANATOMY", 79, 91], ["supernatants", "ANATOMY", 96, 108], ["intramuscular", "ANATOMY", 204, 217], ["plasmids", "ANATOMY", 235, 243], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["cell lysates", "CELL", 79, 91], ["ZIKV", "GENE_OR_GENE_PRODUCT", 179, 183], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 204, 217], ["dMAb", "GENE_OR_GENE_PRODUCT", 230, 234], ["ZIKV", "GENE_OR_GENE_PRODUCT", 286, 290], ["ZIKV", "GENE_OR_GENE_PRODUCT", 382, 386], ["IgG", "PROTEIN", 32, 35], ["antibodies", "PROTEIN", 158, 168], ["ZIKV envelopeEP", "PROTEIN", 179, 194], ["dMAb plasmids", "DNA", 230, 243], ["ZIKV Env-specific monoclonal antibodies", "PROTEIN", 286, 325], ["antibodies", "PROTEIN", 361, 371], ["ZIKV envelope", "PROTEIN", 382, 395], ["ZIKV", "SPECIES", 179, 183], ["ZIKV", "SPECIES", 286, 290], ["ZIKV", "SPECIES", 382, 386], ["transfection", "TREATMENT", 57, 69], ["both cell lysates", "TREATMENT", 74, 91], ["antibodies", "TEST", 158, 168], ["ZIKV envelopeEP", "TREATMENT", 179, 194], ["enhanced intramuscular delivery", "TREATMENT", 195, 226], ["dMAb plasmids", "TREATMENT", 230, 243], ["functional ZIKV Env-specific monoclonal antibodies", "PROBLEM", 275, 325], ["antibodies", "TREATMENT", 361, 371], ["an antibody", "TREATMENT", 419, 430], ["bar", "OBSERVATION_MODIFIER", 4, 7], ["cell lysates", "OBSERVATION", 79, 91], ["natural affinity", "OBSERVATION", 459, 475]]], ["Natural affinity is the strength of monovalent binding between an antibody and an antigenic epitope, often measured by binding to IgG fragment to a target antigen.", [["IgG", "GENE_OR_GENE_PRODUCT", 130, 133], ["antigenic epitope", "PROTEIN", 82, 99], ["IgG fragment", "PROTEIN", 130, 142], ["monovalent binding", "PROBLEM", 36, 54], ["an antibody", "TEST", 63, 74], ["an antigenic epitope", "PROBLEM", 79, 99], ["IgG fragment", "PROBLEM", 130, 142], ["antigenic epitope", "OBSERVATION", 82, 99]]], ["Avidity is the supportive force of engaging multiple antibody paratope/antigen epitope pairs between one antibody and one antigen.", [["antibody paratope", "PROTEIN", 53, 70], ["antigen epitope pairs", "PROTEIN", 71, 92], ["engaging multiple antibody paratope/antigen epitope pairs", "PROBLEM", 35, 92], ["one antibody", "TEST", 101, 113]]], ["We therefore investigated IgG binding and avidity of these mAbs and analyzed in an indirect IgG and avidity ELISA.", [["IgG", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["IgG", "PROTEIN", 26, 29], ["mAbs", "PROTEIN", 59, 63], ["IgG", "PROTEIN", 92, 95], ["IgG binding", "PROBLEM", 26, 37], ["these mAbs", "TEST", 53, 63], ["an indirect IgG", "TEST", 80, 95]]], ["Using the traditional antigen-capture sandwich ELISA, all of these mAbs were tested.", [["mAbs", "GENE_OR_GENE_PRODUCT", 67, 71], ["mAbs", "PROTEIN", 67, 71], ["these mAbs", "TREATMENT", 61, 71]]], ["Shown are average ELISA signals plotted against input antibody concentration, a dose-dependent binding curve could be readily obtained, and the signals reached saturation at higher antibody concentrations (Figure 4a,b) .", [["average ELISA signals", "TEST", 10, 31], ["input antibody concentration", "TEST", 48, 76], ["a dose-dependent binding curve", "TEST", 78, 108], ["saturation", "TEST", 160, 170]]], ["Furthermore, we also assessed the monoclonal antibody activity of recombinant ZV-envelope III proteins by ELISA.", [["ZV-envelope III", "GENE_OR_GENE_PRODUCT", 78, 93], ["monoclonal antibody", "PROTEIN", 34, 53], ["recombinant ZV-envelope III proteins", "PROTEIN", 66, 102]]], ["EPenhanced intramuscular delivery of dMAb plasmids produced immune sera was tested by ELISA for detection and showed the presence-binding activity of the antibodies against DIII protein (Figure 4c ).Avidity characteristics of anti-ZIKV mAbsTo investigate whether the affinities of these interactions were engaging multiple antibodies, we studied each mAb's binding toward its Zika-Envelop recombinant antigen in using urea 4 M. ELISA titers for these ZIKV dMAbs exhibit high affinity to ZIKV antigen were also comparable, although the titer for 8D10F4, 3F12E9, 8A9F9, LP401, and LP312, were significantly stronger and higher whereas we found that low-avidity IgG antibodies namely ID4G7, KP401, KP412, LP305, LP306, LP311 and LP408 were detected (Figure 4d ).ZIKV-dMAbs protect mice against ZIKV challengeThe ZIKV-dMAbs were next evaluated for their ability to offer protection from ZIKV infection.", [["intramuscular", "ANATOMY", 11, 24], ["plasmids", "ANATOMY", 42, 50], ["immune sera", "ANATOMY", 60, 71], ["urea", "CHEMICAL", 418, 422], ["ZIKV", "CHEMICAL", 791, 795], ["ZIKV infection", "DISEASE", 883, 897], ["urea", "CHEMICAL", 418, 422], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["dMAb", "GENE_OR_GENE_PRODUCT", 37, 41], ["immune sera", "ORGANISM_SUBSTANCE", 60, 71], ["DIII", "GENE_OR_GENE_PRODUCT", 173, 177], ["anti-ZIKV mAbs", "GENE_OR_GENE_PRODUCT", 226, 240], ["ZIKV", "ORGANISM", 451, 455], ["ZIKV antigen", "GENE_OR_GENE_PRODUCT", 487, 499], ["8D10F4", "GENE_OR_GENE_PRODUCT", 545, 551], ["3F12E9", "GENE_OR_GENE_PRODUCT", 553, 559], ["8A9F9", "GENE_OR_GENE_PRODUCT", 561, 566], ["LP401", "GENE_OR_GENE_PRODUCT", 568, 573], ["LP312", "GENE_OR_GENE_PRODUCT", 579, 584], ["ID4G7", "GENE_OR_GENE_PRODUCT", 681, 686], ["KP401", "GENE_OR_GENE_PRODUCT", 688, 693], ["KP412", "GENE_OR_GENE_PRODUCT", 695, 700], ["LP305", "GENE_OR_GENE_PRODUCT", 702, 707], ["LP306", "GENE_OR_GENE_PRODUCT", 709, 714], ["LP311", "GENE_OR_GENE_PRODUCT", 716, 721], ["LP408", "GENE_OR_GENE_PRODUCT", 726, 731], ["ZIKV-dMAbs", "GENE_OR_GENE_PRODUCT", 759, 769], ["mice", "ORGANISM", 778, 782], ["ZIKV-dMAbs", "GENE_OR_GENE_PRODUCT", 809, 819], ["ZIKV", "ORGANISM", 883, 887], ["dMAb plasmids", "DNA", 37, 50], ["antibodies", "PROTEIN", 154, 164], ["DIII protein", "PROTEIN", 173, 185], ["anti-ZIKV mAbs", "PROTEIN", 226, 240], ["antibodies", "PROTEIN", 323, 333], ["mAb", "PROTEIN", 351, 354], ["Zika-Envelop recombinant antigen", "PROTEIN", 376, 408], ["ZIKV dMAbs", "PROTEIN", 451, 461], ["ZIKV antigen", "PROTEIN", 487, 499], ["8D10F4", "PROTEIN", 545, 551], ["3F12E9", "PROTEIN", 553, 559], ["8A9F9", "PROTEIN", 561, 566], ["LP401", "PROTEIN", 568, 573], ["LP312", "PROTEIN", 579, 584], ["IgG antibodies", "PROTEIN", 659, 673], ["ID4G7", "PROTEIN", 681, 686], ["KP401", "PROTEIN", 688, 693], ["KP412", "PROTEIN", 695, 700], ["LP305", "PROTEIN", 702, 707], ["LP306", "PROTEIN", 709, 714], ["LP311", "PROTEIN", 716, 721], ["LP408", "PROTEIN", 726, 731], ["ZIKV", "PROTEIN", 759, 763], ["dMAbs", "PROTEIN", 764, 769], ["ZIKV-dMAbs", "DNA", 809, 819], ["mice", "SPECIES", 778, 782], ["anti-ZIKV", "SPECIES", 226, 235], ["ZIKV", "SPECIES", 451, 455], ["ZIKV", "SPECIES", 487, 491], ["ZIKV", "SPECIES", 759, 763], ["mice", "SPECIES", 778, 782], ["ZIKV", "SPECIES", 791, 795], ["ZIKV", "SPECIES", 883, 887], ["EPenhanced intramuscular delivery", "TREATMENT", 0, 33], ["dMAb plasmids", "TREATMENT", 37, 50], ["immune sera", "TEST", 60, 71], ["detection", "TEST", 96, 105], ["the antibodies", "TEST", 150, 164], ["anti-ZIKV mAbs", "TREATMENT", 226, 240], ["multiple antibodies", "PROBLEM", 314, 333], ["its Zika", "PROBLEM", 372, 380], ["urea", "TEST", 418, 422], ["ELISA titers", "TEST", 428, 440], ["these ZIKV dMAbs", "TEST", 445, 461], ["high affinity", "PROBLEM", 470, 483], ["ZIKV antigen", "TEST", 487, 499], ["the titer", "TEST", 531, 540], ["low-avidity IgG antibodies", "PROBLEM", 647, 673], ["ID4G7", "TEST", 681, 686], ["KP401", "TEST", 688, 693], ["KP412", "TEST", 695, 700], ["LP305", "TEST", 702, 707], ["LP306", "TEST", 709, 714], ["LP311", "TEST", 716, 721], ["LP408", "TEST", 726, 731], ["ZIKV challenge", "TREATMENT", 791, 805], ["ZIKV infection", "PROBLEM", 883, 897], ["anti-ZIKV mAbs", "OBSERVATION", 226, 240], ["ZIKV", "OBSERVATION", 883, 887]]], ["For these studies, B6.129S2-Ifnar1 tm1Agt /Mmjax (A129) mice were used, as it has been demonstrated that the lack of functional type I interferon signaling in these mice allows for ZIKV replication and subsequent disease.", [["type I interferon", "GENE_OR_GENE_PRODUCT", 128, 145], ["mice", "ORGANISM", 165, 169], ["ZIKV", "GENE_OR_GENE_PRODUCT", 181, 185], ["129S2", "PROTEIN", 22, 27], ["interferon", "PROTEIN", 135, 145], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 165, 169], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 165, 169], ["ZIKV", "SPECIES", 181, 185], ["these studies", "TEST", 4, 17], ["Ifnar1 tm1Agt /Mmjax (A129)", "TREATMENT", 28, 55], ["functional type I interferon signaling", "PROBLEM", 117, 155], ["ZIKV replication", "TREATMENT", 181, 197], ["subsequent disease", "PROBLEM", 202, 220]]], ["12, 16, 34 Groups of A129 mice were injected intramuscularly with 100 \u03bcg of either a ZIKV-dMAb plasmid or an empty pVax1 vector, both formulated in sterile water, followed by EP.", [["intramuscularly", "ANATOMY", 45, 60], ["EP", "CHEMICAL", 175, 177], ["A129", "ORGANISM", 21, 25], ["mice", "ORGANISM", 26, 30], ["pVax1", "GENE_OR_GENE_PRODUCT", 115, 120], ["ZIKV-dMAb plasmid", "DNA", 85, 102], ["pVax1 vector", "DNA", 115, 127], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["a ZIKV-dMAb plasmid", "TREATMENT", 83, 102], ["an empty pVax1 vector", "TREATMENT", 106, 127], ["empty", "OBSERVATION", 109, 114]]], ["All mice were challenged 2 d later with 10 6 plaque-forming units (PFU) of ZIKV PR209.", [["plaque", "ANATOMY", 45, 51], ["mice", "ORGANISM", 4, 8], ["ZIKV", "ORGANISM", 75, 79], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["ZIKV", "SPECIES", 75, 79], ["ZIKV", "TREATMENT", 75, 79]]], ["Physical health indicators, including body weight and weakness, were monitored daily for 2 weeks post-infection.", [["body", "ANATOMY", 38, 42], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["body weight", "PROBLEM", 38, 49], ["weakness", "PROBLEM", 54, 62], ["weakness", "OBSERVATION", 54, 62]]], ["All mice injected with pVax1 experienced severe weight loss (data not shown) and eventually succumbed to ZIKV infection by d 9 post-challenge.", [["pVax1", "CHEMICAL", 23, 28], ["weight loss", "DISEASE", 48, 59], ["infection", "DISEASE", 110, 119], ["mice", "ORGANISM", 4, 8], ["pVax1", "GENE_OR_GENE_PRODUCT", 23, 28], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["ZIKV", "SPECIES", 105, 109], ["pVax1", "TREATMENT", 23, 28], ["severe weight loss", "PROBLEM", 41, 59], ["ZIKV infection", "PROBLEM", 105, 119], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["weight loss", "OBSERVATION", 48, 59]]], ["Most mice that received either mouse clones (Figure 5a ) or RhMac clones (Figure 5b ) of anti-ZIKV dMAb prior to challenge survived the infection.", [["anti-ZIKV dMAb", "CHEMICAL", 89, 103], ["infection", "DISEASE", 136, 145], ["mice", "ORGANISM", 5, 9], ["mouse", "ORGANISM", 31, 36], ["clones", "CELL", 37, 43], ["RhMac clones", "CELL", 60, 72], ["anti-ZIKV", "ORGANISM", 89, 98], ["mouse clones", "CELL_LINE", 31, 43], ["RhMac clones", "CELL_LINE", 60, 72], ["anti-ZIKV dMAb", "PROTEIN", 89, 103], ["mice", "SPECIES", 5, 9], ["mouse", "SPECIES", 31, 36], ["mice", "SPECIES", 5, 9], ["mouse", "SPECIES", 31, 36], ["anti-ZIKV", "SPECIES", 89, 98], ["RhMac clones", "TREATMENT", 60, 72], ["anti-ZIKV dMAb", "TREATMENT", 89, 103], ["the infection", "PROBLEM", 132, 145], ["infection", "OBSERVATION", 136, 145]]], ["Furthermore, there was notably less ZIKV-associated morbidity following viral challenge in mice pre-injected with either mouse clones (Figure 5c) or RhMac clones (Figure 5d ) compared to the pVax1-injected cohort exhibiting the most severe disease-state on average.In vivo evaluation of protective responses generated by co-delivery of anti-ZIKV-dMAb and ZIKV expressing DNA vaccine plasmidsCombinations of the synthetic ZIKV-DNA vaccines, ZIKV-dMAbs, and combination of both were evaluated systematically.", [["clones", "ANATOMY", 127, 133], ["RhMac clones", "ANATOMY", 149, 161], ["mice", "ORGANISM", 91, 95], ["mouse", "ORGANISM", 121, 126], ["RhMac clones", "CELL", 149, 161], ["pVax1", "GENE_OR_GENE_PRODUCT", 191, 196], ["anti-ZIKV-dMAb", "GENE_OR_GENE_PRODUCT", 336, 350], ["ZIKV", "GENE_OR_GENE_PRODUCT", 355, 359], ["DNA", "CELLULAR_COMPONENT", 371, 374], ["ZIKV", "GENE_OR_GENE_PRODUCT", 421, 425], ["DNA", "CELLULAR_COMPONENT", 426, 429], ["ZIKV-dMAbs", "ORGANISM", 440, 450], ["mouse clones", "CELL_LINE", 121, 133], ["RhMac clones", "CELL_LINE", 149, 161], ["pVax1", "PROTEIN", 191, 196], ["anti-ZIKV", "PROTEIN", 336, 345], ["dMAb", "PROTEIN", 346, 350], ["ZIKV", "PROTEIN", 355, 359], ["DNA vaccine plasmids", "DNA", 371, 391], ["mice", "SPECIES", 91, 95], ["mouse", "SPECIES", 121, 126], ["ZIKV", "SPECIES", 36, 40], ["mice", "SPECIES", 91, 95], ["mouse", "SPECIES", 121, 126], ["ZIKV", "SPECIES", 355, 359], ["viral challenge", "TREATMENT", 72, 87], ["mouse clones", "PROBLEM", 121, 133], ["RhMac clones", "PROBLEM", 149, 161], ["the pVax1", "TEST", 187, 196], ["the most severe disease", "PROBLEM", 224, 247], ["vivo evaluation", "TEST", 268, 283], ["anti-ZIKV", "TREATMENT", 336, 345], ["dMAb", "TREATMENT", 346, 350], ["ZIKV expressing DNA vaccine plasmids", "TREATMENT", 355, 391], ["the synthetic ZIKV", "TREATMENT", 407, 425], ["DNA vaccines", "TREATMENT", 426, 438], ["ZIKV", "PROBLEM", 440, 444], ["less", "OBSERVATION_MODIFIER", 31, 35], ["ZIKV", "OBSERVATION", 36, 40], ["most severe", "OBSERVATION_MODIFIER", 228, 239], ["disease", "OBSERVATION", 240, 247]]], ["We have previously reported on the effectiveness of a DNA vaccine containing a novel consensus prME ZIKV antigen in inducing protective humoral and cellular immune responses in mice, NHPs 12 and humans.", [["cellular", "ANATOMY", 148, 156], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["prME ZIKV antigen", "GENE_OR_GENE_PRODUCT", 95, 112], ["cellular", "CELL", 148, 156], ["mice", "ORGANISM", 177, 181], ["NHPs", "ORGANISM", 183, 187], ["humans", "ORGANISM", 195, 201], ["consensus prME ZIKV antigen", "PROTEIN", 85, 112], ["mice", "SPECIES", 177, 181], ["humans", "SPECIES", 195, 201], ["mice", "SPECIES", 177, 181], ["humans", "SPECIES", 195, 201], ["a DNA vaccine", "TREATMENT", 52, 65], ["a novel consensus prME ZIKV antigen", "PROBLEM", 77, 112], ["NHPs", "TEST", 183, 187], ["cellular immune responses", "OBSERVATION", 148, 173]]], ["27 As with most vaccines, optimal levels of protective immune responses are not achieved until at least a week post administration, and often, one or two boosting immunizations are needed to achieve durable, protective responses.", [["most vaccines", "TREATMENT", 11, 24], ["two boosting immunizations", "TREATMENT", 150, 176]]], ["In an outbreak situation, it is imperative to get health-care professionals and other personnel to hot zones rapidly, and often before they can receive a boost of any vaccine available to protect them from the threat.", [["any vaccine", "TREATMENT", 163, 174]]], ["33 For these situations, we hypothesized that formulating a dMAb plasmid with a DNA vaccine could create a novel field strategy capable of providing both immediate and persistent protective responses against a pathogen.", [["dMAb", "GENE_OR_GENE_PRODUCT", 60, 64], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["dMAb plasmid", "DNA", 60, 72], ["a dMAb plasmid", "TREATMENT", 58, 72], ["a DNA vaccine", "TREATMENT", 78, 91], ["a pathogen", "PROBLEM", 208, 218]]], ["DNA is a useful vector for this strategy as it is nonimmunogenic and allows for multiple administrations without loss of potency.", [["DNA", "CELLULAR_COMPONENT", 0, 3], ["this strategy", "TREATMENT", 27, 40], ["nonimmunogenic", "PROBLEM", 50, 64], ["loss of potency", "PROBLEM", 113, 128]]], ["17, 19 For this study, we injected groups of A129 mice intramuscularly + EP with ZIKV DNA vaccine plasmid coformulated with mouse-derived-or RhMac-derived-anti-ZIKV dMAb plasmids as described in Figure 6a .", [["plasmid", "ANATOMY", 98, 105], ["plasmids", "ANATOMY", 170, 178], ["EP", "CHEMICAL", 73, 75], ["A129", "ORGANISM", 45, 49], ["mice", "ORGANISM", 50, 54], ["ZIKV", "ORGANISM", 81, 85], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["mouse", "ORGANISM", 124, 129], ["ZIKV DNA vaccine plasmid", "DNA", 81, 105], ["mouse-derived-or RhMac-derived-anti-ZIKV dMAb plasmids", "DNA", 124, 178], ["mice", "SPECIES", 50, 54], ["mouse", "SPECIES", 124, 129], ["mice", "SPECIES", 50, 54], ["ZIKV", "SPECIES", 81, 85], ["mouse", "SPECIES", 124, 129], ["ZIKV", "SPECIES", 160, 164], ["this study", "TEST", 11, 21], ["A129 mice intramuscularly", "TREATMENT", 45, 70], ["EP", "TREATMENT", 73, 75], ["ZIKV DNA vaccine plasmid", "TREATMENT", 81, 105], ["RhMac-", "TREATMENT", 141, 147], ["anti-ZIKV dMAb plasmids", "TREATMENT", 155, 178]]], ["Half of the mice in each group were challenged with 10 6 PFU of ZIKV PR209 2 d later (D 2) while the other half in each group were challenged 3 weeks after the first immunization (D 21).", [["mice", "ORGANISM", 12, 16], ["mice", "SPECIES", 12, 16], ["mice", "SPECIES", 12, 16], ["ZIKV", "SPECIES", 64, 68], ["ZIKV", "TREATMENT", 64, 68]]], ["As expected, ZIKV challenge of vaccine+dMAb groups conducted 2 d post the first vaccine+dMAb injection was able to protect the mice from morbidity and mortality (90% protection).", [["ZIKV", "CHEMICAL", 13, 17], ["dMAb", "CHEMICAL", 88, 92], ["dMAb", "SIMPLE_CHEMICAL", 88, 92], ["mice", "ORGANISM", 127, 131], ["mice", "SPECIES", 127, 131], ["ZIKV", "SPECIES", 13, 17], ["mice", "SPECIES", 127, 131], ["ZIKV challenge of vaccine", "TREATMENT", 13, 38], ["dMAb groups", "TREATMENT", 39, 50], ["the first vaccine", "TREATMENT", 70, 87], ["dMAb injection", "TREATMENT", 88, 102], ["morbidity", "PROBLEM", 137, 146]]], ["The other half of each group that were challenged 3 weeks post the initial injection conferred 100% protection from ZIKV morbidity and mortality (Figure 6b,c) .", [["ZIKV", "DISEASE", 116, 120], ["ZIKV", "SPECIES", 116, 120], ["the initial injection", "TREATMENT", 63, 84], ["ZIKV morbidity", "PROBLEM", 116, 130]]], ["These results indicate that neither the mouse nor RhMac ZIKV dMAbs interfered with the induction of immune responses by the ZIKV DNA vaccine-making co-administration of these plasmids a viable strategy for providing immediate and persistent protection from ZIKV.DiscussionZIKV infection is an emerging disease threat worldwide for which there is currently no vaccine or drug therapy approved for human use.", [["plasmids", "ANATOMY", 175, 183], ["infection", "DISEASE", 277, 286], ["mouse", "ORGANISM", 40, 45], ["RhMac ZIKV dMAbs", "ORGANISM", 50, 66], ["ZIKV", "ORGANISM", 124, 128], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["human", "ORGANISM", 396, 401], ["mouse", "SPECIES", 40, 45], ["human", "SPECIES", 396, 401], ["mouse", "SPECIES", 40, 45], ["ZIKV", "SPECIES", 56, 60], ["ZIKV", "SPECIES", 124, 128], ["ZIKV", "SPECIES", 257, 261], ["human", "SPECIES", 396, 401], ["immune responses", "TREATMENT", 100, 116], ["the ZIKV DNA vaccine", "TREATMENT", 120, 140], ["these plasmids", "TREATMENT", 169, 183], ["ZIKV", "PROBLEM", 257, 261], ["DiscussionZIKV infection", "PROBLEM", 262, 286], ["vaccine", "TREATMENT", 359, 366], ["drug therapy", "TREATMENT", 370, 382], ["infection", "OBSERVATION", 277, 286]]], ["27, 35 As of January 2019, there are over 20 ZIKV vaccines in the pipeline in preclinical development and two candidates having entered phase II clinical trials (#NCT03110770, #NCT03014089).", [["ZIKV", "SPECIES", 45, 49], ["20 ZIKV vaccines", "TREATMENT", 42, 58]]], ["Current ZIKV vaccine platforms utilize various modalities including nucleic acids (both DNA and mRNA); purified, inactivated whole virus vaccines (PIV); viral-vectored vaccines; subunit proteins-virus-like particles (VLPs); and live-attenuated vaccines.", [["nucleic acids", "CHEMICAL", 68, 81], ["nucleic acids", "SIMPLE_CHEMICAL", 68, 81], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["whole virus vaccines", "ORGANISM", 125, 145], ["VLPs", "ORGANISM", 217, 221], ["mRNA", "RNA", 96, 100], ["subunit proteins", "PROTEIN", 178, 194], ["ZIKV", "SPECIES", 8, 12], ["PIV", "SPECIES", 147, 150], ["Current ZIKV vaccine platforms", "TREATMENT", 0, 30], ["various modalities", "TREATMENT", 39, 57], ["nucleic acids", "TREATMENT", 68, 81], ["both DNA and mRNA)", "TREATMENT", 83, 101], ["inactivated whole virus vaccines", "TREATMENT", 113, 145], ["PIV", "TREATMENT", 147, 150], ["viral-vectored vaccines", "TREATMENT", 153, 176], ["subunit proteins", "TEST", 178, 194], ["virus", "PROBLEM", 195, 200], ["live-attenuated vaccines", "TREATMENT", 228, 252]]], ["Developing ZIKV vaccines based on a single strain of virus is feasible because the two genetic lineages of ZIKV, African and Asian/American, have limited variability.", [["ZIKV", "ORGANISM", 11, 15], ["ZIKV", "ORGANISM", 107, 111], ["ZIKV", "SPECIES", 11, 15], ["ZIKV", "SPECIES", 107, 111], ["ZIKV vaccines", "TREATMENT", 11, 24], ["a single strain of virus", "PROBLEM", 34, 58], ["ZIKV", "OBSERVATION", 11, 15]]], ["36 As for ZIKV therapeutics, anti-ZIKV monoclonal antibodies for both prophylaxis and treatment have been developed including the EDIII-specific ZKA190 clone which is broadly neutralizing and the ZIKV-117 clone that reduces infection in pregnant and non-pregnant mice.", [["infection", "DISEASE", 224, 233], ["EDIII", "SIMPLE_CHEMICAL", 130, 135], ["ZKA190 clone", "CELL", 145, 157], ["ZIKV-117 clone", "CELL", 196, 210], ["mice", "ORGANISM", 263, 267], ["anti-ZIKV monoclonal antibodies", "PROTEIN", 29, 60], ["ZKA190 clone", "CELL_LINE", 145, 157], ["mice", "SPECIES", 263, 267], ["ZIKV", "SPECIES", 10, 14], ["anti-ZIKV", "SPECIES", 29, 38], ["ZIKV-117", "SPECIES", 196, 204], ["mice", "SPECIES", 263, 267], ["ZIKV therapeutics", "TREATMENT", 10, 27], ["anti-ZIKV monoclonal antibodies", "TREATMENT", 29, 60], ["both prophylaxis", "TREATMENT", 65, 81], ["treatment", "TREATMENT", 86, 95], ["the ZIKV", "TEST", 192, 200], ["infection", "PROBLEM", 224, 233], ["infection", "OBSERVATION", 224, 233]]], ["Small molecule antiviral agents have been tested that limit ZIKV infection in various ways including nucleoside analogs, peptidomimetic agents, adenosine analogs, antimalarials, anthelmintics, and cyclin-dependent kinase inhibitors (CDK).", [["infection", "DISEASE", 65, 74], ["nucleoside", "CHEMICAL", 101, 111], ["adenosine", "CHEMICAL", 144, 153], ["nucleoside", "CHEMICAL", 101, 111], ["adenosine", "CHEMICAL", 144, 153], ["nucleoside analogs", "SIMPLE_CHEMICAL", 101, 119], ["peptidomimetic agents", "SIMPLE_CHEMICAL", 121, 142], ["adenosine analogs", "SIMPLE_CHEMICAL", 144, 161], ["antimalarials", "SIMPLE_CHEMICAL", 163, 176], ["cyclin-dependent kinase inhibitors", "SIMPLE_CHEMICAL", 197, 231], ["CDK", "GENE_OR_GENE_PRODUCT", 233, 236], ["cyclin-dependent kinase inhibitors", "PROTEIN", 197, 231], ["CDK", "PROTEIN", 233, 236], ["ZIKV", "SPECIES", 60, 64], ["Small molecule antiviral agents", "TREATMENT", 0, 31], ["ZIKV infection", "PROBLEM", 60, 74], ["nucleoside analogs", "TREATMENT", 101, 119], ["peptidomimetic agents", "TREATMENT", 121, 142], ["adenosine analogs", "TREATMENT", 144, 161], ["antimalarials", "TREATMENT", 163, 176], ["anthelmintics", "TREATMENT", 178, 191], ["cyclin-dependent kinase inhibitors", "TREATMENT", 197, 231], ["molecule antiviral agents", "OBSERVATION", 6, 31]]], ["37 With both ZIKV vaccines and therapeutics for prophylactic and therapeutic usages, one of the biggest hurdles in advancing agents to the clinic has been the selection of the most suitable clinical endpoint.", [["ZIKV", "ORGANISM", 13, 17], ["ZIKV", "SPECIES", 13, 17], ["both ZIKV vaccines", "TREATMENT", 8, 26], ["therapeutics", "TREATMENT", 31, 43], ["prophylactic and therapeutic usages", "TREATMENT", 48, 83]]], ["37 Given the endemic potential of ZIKV encompassing several continents and the broad spectrum of clinical manifestations, it is difficult to discern a na\u00efve population without extensive laboratory testing.", [["ZIKV", "CANCER", 34, 38], ["ZIKV", "SPECIES", 34, 38], ["ZIKV", "PROBLEM", 34, 38], ["clinical manifestations", "PROBLEM", 97, 120], ["a na\u00efve population", "PROBLEM", 149, 167], ["extensive laboratory testing", "TEST", 176, 204], ["ZIKV", "OBSERVATION", 34, 38], ["broad spectrum", "OBSERVATION_MODIFIER", 79, 93]]], ["Ethical considerations for the inclusion of pregnant women and their safety related to ZIKV-related neurological complications, notably microcephaly and Guillain-Barr\u00e9 Syndrome, have also hindered the clinical evaluation of ZIKV vaccines and therapeutics.DiscussionIn this study, we used two distinct strategies to generate a panel of mouse and RhMac antibodies capable of binding to the Envelope protein of ZIKV.", [["neurological", "ANATOMY", 100, 112], ["ZIKV", "CHEMICAL", 87, 91], ["neurological complications", "DISEASE", 100, 126], ["microcephaly", "DISEASE", 136, 148], ["Guillain-Barr\u00e9 Syndrome", "DISEASE", 153, 176], ["women", "ORGANISM", 53, 58], ["ZIKV", "ORGANISM", 224, 228], ["mouse", "ORGANISM", 335, 340], ["RhMac", "GENE_OR_GENE_PRODUCT", 345, 350], ["ZIKV", "GENE_OR_GENE_PRODUCT", 408, 412], ["mouse and RhMac antibodies", "PROTEIN", 335, 361], ["Envelope protein", "PROTEIN", 388, 404], ["ZIKV", "PROTEIN", 408, 412], ["women", "SPECIES", 53, 58], ["mouse", "SPECIES", 335, 340], ["ZIKV", "SPECIES", 224, 228], ["mouse", "SPECIES", 335, 340], ["ZIKV", "SPECIES", 408, 412], ["ZIKV", "PROBLEM", 87, 91], ["neurological complications", "PROBLEM", 100, 126], ["microcephaly", "PROBLEM", 136, 148], ["Barr\u00e9 Syndrome", "PROBLEM", 162, 176], ["the clinical evaluation", "TEST", 197, 220], ["ZIKV vaccines", "TREATMENT", 224, 237], ["therapeutics", "TREATMENT", 242, 254], ["this study", "TEST", 268, 278], ["RhMac antibodies", "TEST", 345, 361], ["ZIKV", "PROBLEM", 408, 412], ["Barr\u00e9 Syndrome", "OBSERVATION", 162, 176]]], ["The antibody gene sequences were encoded into DNA plasmid vectors to create dMAb plasmids that were shown to drive production of significant serum levels of functional anti-ZIKV antibodies in mice after a single EPenhanced intramuscular injection.", [["plasmids", "ANATOMY", 81, 89], ["serum", "ANATOMY", 141, 146], ["intramuscular", "ANATOMY", 223, 236], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["dMAb", "GENE_OR_GENE_PRODUCT", 76, 80], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["anti-ZIKV antibodies", "GENE_OR_GENE_PRODUCT", 168, 188], ["mice", "ORGANISM", 192, 196], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 223, 236], ["antibody gene sequences", "DNA", 4, 27], ["DNA plasmid vectors", "DNA", 46, 65], ["dMAb plasmids", "DNA", 76, 89], ["anti-ZIKV antibodies", "PROTEIN", 168, 188], ["mice", "SPECIES", 192, 196], ["anti-ZIKV", "SPECIES", 168, 177], ["mice", "SPECIES", 192, 196], ["The antibody gene sequences", "TEST", 0, 27], ["DNA plasmid vectors", "TREATMENT", 46, 65], ["dMAb plasmids", "TREATMENT", 76, 89], ["significant serum levels", "PROBLEM", 129, 153], ["functional anti-ZIKV antibodies", "TREATMENT", 157, 188], ["a single EPenhanced intramuscular injection", "TREATMENT", 203, 246]]], ["Delivery of these anti-ZIKV dMAb plasmids protected mice from morbidity and mortality following ZIKV challenge.", [["ZIKV", "CHEMICAL", 96, 100], ["anti-ZIKV", "ORGANISM", 18, 27], ["dMAb", "GENE_OR_GENE_PRODUCT", 28, 32], ["mice", "ORGANISM", 52, 56], ["anti-ZIKV dMAb plasmids", "DNA", 18, 41], ["mice", "SPECIES", 52, 56], ["anti-ZIKV", "SPECIES", 18, 27], ["mice", "SPECIES", 52, 56], ["ZIKV", "SPECIES", 96, 100], ["Delivery", "TREATMENT", 0, 8], ["these anti-ZIKV dMAb plasmids", "TREATMENT", 12, 41], ["ZIKV challenge", "TREATMENT", 96, 110]]], ["Importantly, the ZIKV dMAb plasmids described here could be co-formulated with an anti-ZIKV DNA vaccine to provide immediate and persistent anti-ZIKV immune responses, respectively.", [["DNA", "CELLULAR_COMPONENT", 92, 95], ["ZIKV dMAb plasmids", "DNA", 17, 35], ["ZIKV", "SPECIES", 17, 21], ["anti-ZIKV", "SPECIES", 82, 91], ["anti-ZIKV", "SPECIES", 140, 149], ["the ZIKV dMAb plasmids", "TREATMENT", 13, 35], ["an anti-ZIKV DNA vaccine", "TREATMENT", 79, 103]]], ["As such, this can be a promising strategy for protecting individuals traveling to a ZIKV endemic region.", [["a promising strategy", "TREATMENT", 21, 41]]], ["8, 38 While the dMAb plasmids were constructed in a similar fashion, in vivo serum levels of ZIKV dMAbs varied greatly.", [["dMAb plasmids", "ANATOMY", 16, 29], ["serum", "ANATOMY", 77, 82], ["dMAb", "GENE_OR_GENE_PRODUCT", 16, 20], ["serum", "ORGANISM_SUBSTANCE", 77, 82], ["ZIKV", "GENE_OR_GENE_PRODUCT", 93, 97], ["dMAb plasmids", "DNA", 16, 29], ["ZIKV dMAbs", "PROTEIN", 93, 103], ["ZIKV", "SPECIES", 93, 97], ["the dMAb plasmids", "TREATMENT", 12, 29], ["vivo serum levels", "TEST", 72, 89], ["ZIKV dMAbs", "PROBLEM", 93, 103], ["ZIKV", "OBSERVATION", 93, 97]]], ["The clones producing peak serum antibody levels of 1\u221ag/ml or more include human IgGs 8A9F9 and 8D10F4 originated from mice, and the human IgGs LP301, LP311, LP312, and KP412 originating from RhMac.", [["clones", "ANATOMY", 4, 10], ["serum", "ANATOMY", 26, 31], ["clones", "CELL", 4, 10], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["human", "ORGANISM", 74, 79], ["IgGs 8A9F9", "GENE_OR_GENE_PRODUCT", 80, 90], ["8D10F4", "GENE_OR_GENE_PRODUCT", 95, 101], ["mice", "ORGANISM", 118, 122], ["human", "ORGANISM", 132, 137], ["IgGs", "GENE_OR_GENE_PRODUCT", 138, 142], ["LP301", "GENE_OR_GENE_PRODUCT", 143, 148], ["LP311", "GENE_OR_GENE_PRODUCT", 150, 155], ["LP312", "GENE_OR_GENE_PRODUCT", 157, 162], ["KP412", "GENE_OR_GENE_PRODUCT", 168, 173], ["RhMac", "GENE_OR_GENE_PRODUCT", 191, 196], ["human IgGs 8A9F9", "PROTEIN", 74, 90], ["8D10F4", "PROTEIN", 95, 101], ["human IgGs LP301", "PROTEIN", 132, 148], ["LP311", "PROTEIN", 150, 155], ["LP312", "PROTEIN", 157, 162], ["KP412", "PROTEIN", 168, 173], ["RhMac", "PROTEIN", 191, 196], ["human", "SPECIES", 74, 79], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 74, 79], ["mice", "SPECIES", 118, 122], ["human", "SPECIES", 132, 137], ["The clones", "TEST", 0, 10], ["peak serum antibody levels", "TEST", 21, 47], ["human IgGs", "TEST", 74, 84], ["the human IgGs", "TEST", 128, 142], ["KP412", "TREATMENT", 168, 173]]], ["There is no discernible pattern to explain the variable expression levels of each dMAb in vivo with factors including antibody folding, antibody charge, and antibody glycosylation all likely contributing factors.", [["dMAb", "GENE_OR_GENE_PRODUCT", 82, 86], ["dMAb", "PROTEIN", 82, 86], ["discernible pattern", "PROBLEM", 12, 31], ["the variable expression levels", "PROBLEM", 43, 73], ["antibody folding", "TREATMENT", 118, 134], ["antibody charge", "TEST", 136, 151], ["antibody glycosylation", "TREATMENT", 157, 179], ["no discernible", "UNCERTAINTY", 9, 23]]], ["To improve expression levels in vivo, changes in dMAb plasmid formulation are being explored along with two-plasmid strategies where the heavy and light chains of each antibody are delivered on separate plasmids.", [["plasmids", "ANATOMY", 203, 211], ["dMAb", "GENE_OR_GENE_PRODUCT", 49, 53], ["dMAb plasmid", "DNA", 49, 61], ["heavy and light chains", "PROTEIN", 137, 159], ["plasmids", "DNA", 203, 211], ["expression levels", "PROBLEM", 11, 28], ["changes in dMAb plasmid formulation", "TREATMENT", 38, 73], ["two-plasmid strategies", "TREATMENT", 104, 126], ["the heavy and light chains of each antibody", "TREATMENT", 133, 176], ["separate plasmids", "TREATMENT", 194, 211]]], ["DNA plasmids co-formulated with hyaluronidase have been shown to increase in vivo expression.", [["plasmids", "ANATOMY", 4, 12], ["hyaluronidase", "CHEMICAL", 32, 45], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["hyaluronidase", "GENE_OR_GENE_PRODUCT", 32, 45], ["DNA plasmids", "DNA", 0, 12], ["hyaluronidase", "PROTEIN", 32, 45], ["DNA plasmids", "TREATMENT", 0, 12], ["hyaluronidase", "TREATMENT", 32, 45], ["increase", "OBSERVATION_MODIFIER", 65, 73], ["vivo expression", "OBSERVATION", 77, 92]]], ["20, 39, 40 Despite variable expression levels, the ability of the different antibodies to bind to ZIKV envelope is similar at normalized serum concentrations.", [["serum", "ANATOMY", 137, 142], ["ZIKV", "GENE_OR_GENE_PRODUCT", 98, 102], ["serum", "ORGANISM_SUBSTANCE", 137, 142], ["antibodies", "PROTEIN", 76, 86], ["variable expression levels", "PROBLEM", 19, 45], ["the different antibodies", "TREATMENT", 62, 86], ["ZIKV envelope", "PROBLEM", 98, 111]]], ["An area of concern for antibody therapies for flaviviruses, particularly dengue virus, is the potential for antibody-dependent enhancement (ADE) of infection where sub-neutralizing levels of antibodies can mediate greater levels of infection by allowing uptake of virus into cells expressing the Fc receptor.", [["cells", "ANATOMY", 275, 280], ["flaviviruses", "DISEASE", 46, 58], ["dengue virus", "DISEASE", 73, 85], ["infection", "DISEASE", 148, 157], ["infection", "DISEASE", 232, 241], ["dengue virus", "ORGANISM", 73, 85], ["cells", "CELL", 275, 280], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 296, 307], ["antibodies", "PROTEIN", 191, 201], ["Fc receptor", "PROTEIN", 296, 307], ["dengue virus", "SPECIES", 73, 85], ["dengue virus", "SPECIES", 73, 85], ["antibody therapies", "TREATMENT", 23, 41], ["flaviviruses", "PROBLEM", 46, 58], ["dengue virus", "PROBLEM", 73, 85], ["antibody-dependent enhancement", "PROBLEM", 108, 138], ["infection", "PROBLEM", 148, 157], ["neutralizing levels", "TEST", 168, 187], ["antibodies", "PROBLEM", 191, 201], ["infection", "PROBLEM", 232, 241], ["uptake of virus into cells", "PROBLEM", 254, 280], ["concern for", "UNCERTAINTY", 11, 22], ["antibody therapies", "OBSERVATION", 23, 41], ["dependent", "OBSERVATION_MODIFIER", 117, 126], ["enhancement", "OBSERVATION", 127, 138], ["infection", "OBSERVATION", 148, 157], ["infection", "OBSERVATION", 232, 241]]], ["There are findings that cross-reactive dengue virus mAbs can exacerbate ZIKV infection of placental macrophages using Hoffbauer cells.", [["placental macrophages", "ANATOMY", 90, 111], ["Hoffbauer cells", "ANATOMY", 118, 133], ["dengue", "DISEASE", 39, 45], ["infection", "DISEASE", 77, 86], ["dengue virus mAbs", "ORGANISM", 39, 56], ["placental macrophages", "CELL", 90, 111], ["Hoffbauer cells", "CELL", 118, 133], ["cross-reactive dengue virus mAbs", "PROTEIN", 24, 56], ["placental macrophages", "CELL_TYPE", 90, 111], ["Hoffbauer cells", "CELL_LINE", 118, 133], ["dengue virus", "SPECIES", 39, 51], ["ZIKV", "SPECIES", 72, 76], ["cross-reactive dengue virus mAbs", "PROBLEM", 24, 56], ["ZIKV infection of placental macrophages", "PROBLEM", 72, 111], ["Hoffbauer cells", "TREATMENT", 118, 133], ["cross-reactive", "OBSERVATION_MODIFIER", 24, 38], ["dengue virus", "OBSERVATION", 39, 51], ["placental macrophages", "OBSERVATION", 90, 111]]], ["41 However, such effects had not been strongly demonstrated so far with ZIKV mAbs and increased ZIKV infections.", [["infections", "DISEASE", 101, 111], ["ZIKV mAbs", "PROTEIN", 72, 81], ["ZIKV", "SPECIES", 72, 76], ["ZIKV", "SPECIES", 96, 100], ["ZIKV mAbs", "TREATMENT", 72, 81], ["increased ZIKV infections", "PROBLEM", 86, 111], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["ZIKV infections", "OBSERVATION", 96, 111]]], ["Given the terminal disease state of severe ZIKV infections in humans, sub-neutralizing ZIKV mAbs with therapeutic efficacy warrants further investigation into higher animal models.DiscussionThese ZIKV dMAb studies have several limitations to address.", [["ZIKV infections", "DISEASE", 43, 58], ["humans", "ORGANISM", 62, 68], ["ZIKV", "ORGANISM", 87, 91], ["ZIKV mAbs", "PROTEIN", 87, 96], ["humans", "SPECIES", 62, 68], ["ZIKV", "SPECIES", 43, 47], ["humans", "SPECIES", 62, 68], ["ZIKV", "SPECIES", 87, 91], ["ZIKV", "SPECIES", 196, 200], ["the terminal disease state", "PROBLEM", 6, 32], ["severe ZIKV infections in humans", "PROBLEM", 36, 68], ["neutralizing ZIKV mAbs", "TREATMENT", 74, 96], ["therapeutic efficacy", "TREATMENT", 102, 122], ["further investigation", "TEST", 132, 153], ["These ZIKV dMAb studies", "TEST", 190, 213], ["terminal", "OBSERVATION_MODIFIER", 10, 18], ["disease", "OBSERVATION", 19, 26], ["severe", "OBSERVATION_MODIFIER", 36, 42], ["ZIKV infections", "OBSERVATION", 43, 58]]], ["Our efforts were concentrated on identifying myriad of potent anti-ZIKV clones that bind to the prM and envelope regions of ZIKV to mainly affect receptor binding targeting Domain III of envelope as well as the stem and transmembrane regions that alter virion entry, assembly, and membrane fusion.", [["stem", "ANATOMY", 211, 215], ["transmembrane", "ANATOMY", 220, 233], ["virion", "ANATOMY", 253, 259], ["membrane", "ANATOMY", 281, 289], ["anti-ZIKV clones", "CELL", 62, 78], ["prM", "GENE_OR_GENE_PRODUCT", 96, 99], ["ZIKV", "GENE_OR_GENE_PRODUCT", 124, 128], ["Domain III", "GENE_OR_GENE_PRODUCT", 173, 183], ["stem", "CELL", 211, 215], ["transmembrane", "CELLULAR_COMPONENT", 220, 233], ["virion", "CELLULAR_COMPONENT", 253, 259], ["membrane", "CELLULAR_COMPONENT", 281, 289], ["anti-ZIKV clones", "CELL_LINE", 62, 78], ["prM", "PROTEIN", 96, 99], ["envelope regions", "PROTEIN", 104, 120], ["ZIKV", "PROTEIN", 124, 128], ["Domain III", "PROTEIN", 173, 183], ["stem and transmembrane regions", "PROTEIN", 211, 241], ["potent anti-ZIKV clones", "TREATMENT", 55, 78], ["ZIKV", "PROBLEM", 124, 128], ["membrane fusion", "TREATMENT", 281, 296], ["ZIKV", "OBSERVATION", 124, 128], ["stem", "ANATOMY", 211, 215], ["virion entry", "OBSERVATION", 253, 265], ["membrane fusion", "OBSERVATION", 281, 296]]], ["42, 43 Yet other structural and non-structural proteins may also be targeted to prevent or treat ZIKV infections.", [["infections", "DISEASE", 102, 112], ["structural and non-structural proteins", "PROTEIN", 17, 55], ["ZIKV", "SPECIES", 97, 101], ["other structural and non-structural proteins", "PROBLEM", 11, 55], ["ZIKV infections", "PROBLEM", 97, 112], ["non-structural proteins", "OBSERVATION", 32, 55]]], ["Monoclonal antibodies binding to ZIKV-NS1 region may confer advantages during an active viral replication phase of ZIKV infection, whereas clones that bind to ZIKV capsid anchor (Ca) region may block proper virion assembly as the cis-binding of Ca with PrM is strictly required to produce infectious particles.", [["infection", "DISEASE", 120, 129], ["Ca", "CHEMICAL", 179, 181], ["Ca", "CHEMICAL", 245, 247], ["Ca", "CHEMICAL", 179, 181], ["Ca", "CHEMICAL", 245, 247], ["ZIKV", "GENE_OR_GENE_PRODUCT", 33, 37], ["ZIKV", "ORGANISM", 115, 119], ["PrM", "GENE_OR_GENE_PRODUCT", 253, 256], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["ZIKV-NS1 region", "DNA", 33, 48], ["ZIKV capsid anchor (Ca) region", "PROTEIN", 159, 189], ["PrM", "PROTEIN", 253, 256], ["ZIKV", "SPECIES", 115, 119], ["Monoclonal antibodies binding", "PROBLEM", 0, 29], ["ZIKV-NS1 region", "TREATMENT", 33, 48], ["ZIKV infection", "PROBLEM", 115, 129], ["ZIKV capsid anchor (Ca) region", "TREATMENT", 159, 189], ["block proper virion", "TREATMENT", 194, 213], ["Ca with PrM", "PROBLEM", 245, 256], ["infectious particles", "PROBLEM", 289, 309], ["ZIKV infection", "OBSERVATION", 115, 129], ["Ca", "OBSERVATION", 245, 247], ["infectious", "OBSERVATION", 289, 299]]], ["42 Broadly neutralizing capability of these anti-ZIKV clones has not been evaluated in this study since the dMAb-administered animals were challenged with a single strain of ZIKV-PR209.", [["dMAb", "CHEMICAL", 108, 112], ["ZIKV-PR209", "CHEMICAL", 174, 184], ["anti-ZIKV clones", "CELL", 44, 60], ["dMAb", "SIMPLE_CHEMICAL", 108, 112], ["animals", "ORGANISM", 126, 133], ["ZIKV-PR209", "ORGANISM", 174, 184], ["anti-ZIKV clones", "CELL_LINE", 44, 60], ["anti-ZIKV", "SPECIES", 44, 53], ["ZIKV", "SPECIES", 174, 178], ["these anti-ZIKV clones", "PROBLEM", 38, 60], ["this study", "TEST", 87, 97], ["the dMAb", "TREATMENT", 104, 112], ["neutralizing", "OBSERVATION", 11, 23]]], ["Despite the limitations in study designs, ZIKV has limited strain variability in which the African and Asian/American lineages are classified as a single serotype.", [["ZIKV", "CHEMICAL", 42, 46], ["ZIKV", "SPECIES", 42, 46], ["study designs", "TEST", 27, 40], ["ZIKV", "PROBLEM", 42, 46], ["limited strain variability", "PROBLEM", 51, 77], ["a single serotype", "PROBLEM", 145, 162]]], ["36 ZIKV-PR209 is of the Asian/American lineage and one of the most virulent strains of wild-type ZIKV in recent years, which has been used in numerous published studies to test neutralization and in animal challenges to validate therapeutic or prophylactic efficacy of ZIKV agents.", [["wild-type ZIKV", "ORGANISM", 87, 101], ["ZIKV agents", "SIMPLE_CHEMICAL", 269, 280], ["ZIKV", "SPECIES", 97, 101], ["ZIKV", "SPECIES", 269, 273], ["test neutralization", "TEST", 172, 191], ["ZIKV agents", "TREATMENT", 269, 280]]], ["12, 27, 44 Moreover, sequence alignments of 58 complete ZIKV genome and 5 ZIKV envelope sequences compiled as of April 2016 show highly conserved amino acid variations and only eight variation sites in the envelope region.", [["amino acid", "CHEMICAL", 146, 156], ["amino acid", "CHEMICAL", 146, 156], ["amino acid", "AMINO_ACID", 146, 156], ["ZIKV genome", "DNA", 56, 67], ["ZIKV envelope sequences", "DNA", 74, 97], ["envelope region", "DNA", 206, 221], ["ZIKV", "SPECIES", 74, 78], ["sequence alignments", "TEST", 21, 40], ["complete ZIKV genome", "TEST", 47, 67], ["ZIKV envelope sequences", "TEST", 74, 97], ["conserved amino acid variations", "PROBLEM", 136, 167], ["amino acid variations", "OBSERVATION", 146, 167], ["eight", "OBSERVATION_MODIFIER", 177, 182], ["variation", "OBSERVATION_MODIFIER", 183, 192], ["envelope", "ANATOMY_MODIFIER", 206, 214], ["region", "ANATOMY_MODIFIER", 215, 221]]], ["45 To our knowledge, these results are the first report of the in vivo expression of anti-ZIKV antibodies from a vector system.", [["anti-ZIKV antibodies", "GENE_OR_GENE_PRODUCT", 85, 105], ["anti-ZIKV antibodies", "PROTEIN", 85, 105], ["anti-ZIKV", "SPECIES", 85, 94], ["anti-ZIKV antibodies", "TREATMENT", 85, 105]]], ["As ZIKV has spread throughout the islands of the Pacific Ocean and into South and Central America over the last 10 y, more serious signs and symptoms of ZIKV infection including birth defects and Guillain-Barr\u00e9 syndrome have become evident and prompted a concerted effort to develop therapeutics that could protect from and/or treat ZIKV infection.", [["ZIKV", "CHEMICAL", 3, 7], ["infection", "DISEASE", 158, 167], ["birth defects", "DISEASE", 178, 191], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 196, 219], ["infection", "DISEASE", 338, 347], ["Guillain-Barr\u00e9", "ORGANISM", 196, 210], ["ZIKV", "ORGANISM", 333, 337], ["ZIKV", "SPECIES", 3, 7], ["ZIKV", "SPECIES", 153, 157], ["ZIKV", "SPECIES", 333, 337], ["ZIKV", "PROBLEM", 3, 7], ["symptoms", "PROBLEM", 141, 149], ["ZIKV infection", "PROBLEM", 153, 167], ["birth defects", "PROBLEM", 178, 191], ["Guillain", "TREATMENT", 196, 204], ["Barr\u00e9 syndrome", "PROBLEM", 205, 219], ["therapeutics", "TREATMENT", 283, 295], ["ZIKV infection", "PROBLEM", 333, 347], ["Central", "ANATOMY_MODIFIER", 82, 89], ["ZIKV infection", "OBSERVATION", 153, 167], ["Barr\u00e9 syndrome", "OBSERVATION", 205, 219]]], ["8 The mAbs described here have the potential to provide rapid prophylaxis against ZIKV infection and can be further combined with a ZIKV DNA vaccine to provide a durable protection to the virus.", [["infection", "DISEASE", 87, 96], ["ZIKV", "ORGANISM", 82, 86], ["ZIKV", "ORGANISM", 132, 136], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["mAbs", "PROTEIN", 6, 10], ["ZIKV", "SPECIES", 82, 86], ["ZIKV", "SPECIES", 132, 136], ["The mAbs", "TREATMENT", 2, 10], ["rapid prophylaxis", "TREATMENT", 56, 73], ["ZIKV infection", "PROBLEM", 82, 96], ["a ZIKV DNA vaccine", "TREATMENT", 130, 148], ["the virus", "PROBLEM", 184, 193]]], ["Furthermore, the mAb isolation process and the novel dMAb delivery strategy described here would be highly useful during an emerging infectious disease outbreak as the development and characterization stages are rapid and effective.", [["mAb", "GENE_OR_GENE_PRODUCT", 17, 20], ["dMAb", "SIMPLE_CHEMICAL", 53, 57], ["mAb", "PROTEIN", 17, 20], ["the mAb isolation process", "TREATMENT", 13, 38], ["the novel dMAb delivery strategy", "TREATMENT", 43, 75], ["an emerging infectious disease outbreak", "PROBLEM", 121, 160], ["mAb isolation", "OBSERVATION", 17, 30], ["infectious", "OBSERVATION", 133, 143], ["rapid", "OBSERVATION_MODIFIER", 212, 217]]], ["The potential to broaden the clinical use of this novel mAb delivery strategy as well as dMAb therapies to resource-poor regions of the world warrants further study.AcknowledgmentsThe studies described in this manuscript were funded by a grant from the Wistar Science Discovery Award to KM.", [["dMAb", "SIMPLE_CHEMICAL", 89, 93], ["this novel mAb delivery strategy", "TREATMENT", 45, 77], ["dMAb therapies", "TREATMENT", 89, 103], ["further study", "TEST", 151, 164], ["The studies", "TEST", 180, 191]]], ["The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.FundingThis work was supported by the Wistar Science Discovery fund awarded to K.M.Author ContributionsDBW and KM contributed to conceptualization.", [["data collection", "TEST", 41, 56], ["analysis", "TEST", 62, 70], ["no", "UNCERTAINTY", 16, 18]]], ["HC, SBK, ELR, KA, PB, SA, LVD, CCR, GG contributed to methodology, and investigation; SR, KEB, LMH, JJK, KEU, and DLS contributed to resources; HC, SBK, DBW, and KM contributed to writing-review and editing; KM contributed to supervision; SBK and HC contributed equally to this work.Conflict of InterestCCR, SR, KEB, LMH, and JJK are employees of Inovio Pharmaceuticals and as such receive salary and benefits, including ownership of stock and stock options.", [["KA", "CHEMICAL", 14, 16], ["KA", "SIMPLE_CHEMICAL", 14, 16], ["HC", "TEST", 0, 2], ["SBK", "TEST", 4, 7], ["ELR", "TEST", 9, 12], ["LVD", "PROBLEM", 26, 29], ["methodology", "TEST", 54, 65], ["investigation", "TEST", 71, 84], ["SR", "TEST", 86, 88], ["KEB", "TEST", 90, 93], ["JJK", "TEST", 100, 103], ["HC", "TEST", 144, 146], ["SBK", "TEST", 148, 151], ["SBK and HC", "PROBLEM", 239, 249], ["InterestCCR", "TEST", 295, 306], ["SR", "TEST", 308, 310], ["KEB", "TEST", 312, 315], ["Inovio Pharmaceuticals", "TREATMENT", 347, 369], ["PB", "ANATOMY", 18, 20], ["SA", "ANATOMY", 22, 24], ["LVD", "ANATOMY", 26, 29]]], ["KM discloses grant funding, industry collaborations, speaking honoraria, and fees for consulting.", [["honoraria", "ORGANISM", 62, 71], ["grant funding", "OBSERVATION", 13, 26]]], ["He has received consulting fees from Inovio Pharmaceuticals related to DNA and dMAb vaccine development.", [["He", "ORGANISM", 0, 2], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["Inovio Pharmaceuticals", "TREATMENT", 37, 59], ["DNA and dMAb vaccine", "TREATMENT", 71, 91]]], ["He has a patent application for DNA vaccine development and delivery of DNA-encoded monoclonal antibodies pending to Inovio Pharmaceuticals.", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["DNA-encoded monoclonal antibodies", "PROTEIN", 72, 105], ["a patent application", "TREATMENT", 7, 27], ["DNA vaccine development", "TREATMENT", 32, 55], ["DNA", "PROBLEM", 72, 75], ["monoclonal antibodies", "TEST", 84, 105], ["Inovio Pharmaceuticals", "TREATMENT", 117, 139], ["patent", "OBSERVATION", 9, 15]]], ["Remuneration includes direct payments.", [["direct payments", "TREATMENT", 22, 37]]], ["Remuneration includes direct payments and/or stock or stock options.", [["direct payments", "TREATMENT", 22, 37]]], ["He notes potential conflicts associated with this work with Pfizer, Bristol Myers Squibb, Inovio Pharmaceuticals, Merck, VGXI, Geneos, AstraZeneca, and potentially others.", [["AstraZeneca", "CHEMICAL", 135, 146], ["Inovio Pharmaceuticals", "TREATMENT", 90, 112], ["Merck", "TREATMENT", 114, 119], ["Geneos", "TREATMENT", 127, 133], ["AstraZeneca", "TREATMENT", 135, 146]]], ["Licensing of technology from this laboratory has created over 150 jobs in the biotech/pharma industry.", [["pharma", "ANATOMY", 86, 92]]]], "71c95bd39c649d3ba3fee28d11be98cd4019de7f": [["Accelerated gene family expansion, therefore, may provide hints for environmental forces on vertebrate species.", [["Accelerated gene family expansion", "PROBLEM", 0, 33], ["environmental forces on vertebrate species", "PROBLEM", 68, 110], ["expansion", "OBSERVATION_MODIFIER", 24, 33]]], ["For example, in species with an extraordinary large number of \u03b3/\u03b4 T-cells, like cattle, sheep and chicken, the CD163 family of immune receptors which are pivotal for the function of \u03b3/\u03b4 T-cells is expanded [1] .", [["\u03b3/\u03b4 T-cells", "ANATOMY", 62, 73], ["\u03b3/\u03b4 T-cells", "ANATOMY", 182, 193], ["\u03b3", "GENE_OR_GENE_PRODUCT", 62, 63], ["sheep", "ORGANISM", 88, 93], ["chicken", "ORGANISM", 98, 105], ["CD163", "GENE_OR_GENE_PRODUCT", 111, 116], ["\u03b3", "GENE_OR_GENE_PRODUCT", 182, 183], ["\u03b3/\u03b4 T-cells", "CELL_TYPE", 62, 73], ["CD163 family", "PROTEIN", 111, 123], ["immune receptors", "PROTEIN", 127, 143], ["\u03b3/\u03b4 T-cells", "CELL_TYPE", 182, 193], ["cattle", "SPECIES", 80, 86], ["sheep", "SPECIES", 88, 93], ["chicken", "SPECIES", 98, 105], ["cattle", "SPECIES", 80, 86], ["sheep", "SPECIES", 88, 93], ["chicken", "SPECIES", 98, 105], ["\u03b3/\u03b4 T-cells", "PROBLEM", 62, 73], ["immune receptors", "TREATMENT", 127, 143], ["the function", "TEST", 166, 178], ["extraordinary", "OBSERVATION_MODIFIER", 32, 45], ["large", "OBSERVATION_MODIFIER", 46, 51], ["number", "OBSERVATION_MODIFIER", 52, 58]]], ["Such a species-specific expansion is seen in various gene families, most of them being involved in immunity and/or reproduction.", [["a species", "PROBLEM", 5, 14]]], ["This is also true for the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily and represents one of the fastest evolving gene families in mammals [2] .", [["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 26, 50], ["CEA", "GENE_OR_GENE_PRODUCT", 52, 55], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 91, 105], ["carcinoembryonic antigen (CEA) gene family", "DNA", 26, 68], ["immunoglobulin superfamily", "PROTEIN", 91, 117], ["the carcinoembryonic antigen", "PROBLEM", 22, 50]]], ["In mammals, the ancestral CEA gene family was composed of five genes, i.e. CEACAM1, CEA-CAM16, CEACAM18, CEACAM19 and CEACAM20.", [["CEA", "GENE_OR_GENE_PRODUCT", 26, 29], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 75, 82], ["CEA-CAM16", "GENE_OR_GENE_PRODUCT", 84, 93], ["CEACAM18", "GENE_OR_GENE_PRODUCT", 95, 103], ["CEACAM19", "GENE_OR_GENE_PRODUCT", 105, 113], ["CEACAM20", "GENE_OR_GENE_PRODUCT", 118, 126], ["CEA gene family", "DNA", 26, 41], ["CEACAM1", "DNA", 75, 82], ["CEA", "DNA", 84, 87], ["CAM16", "DNA", 88, 93], ["CEACAM18", "DNA", 95, 103], ["CEACAM19", "DNA", 105, 113], ["CEACAM20", "DNA", 118, 126], ["CEA", "TEST", 84, 87], ["CEACAM18", "TREATMENT", 95, 103], ["CEACAM19", "TREATMENT", 105, 113], ["CEACAM20", "TREATMENT", 118, 126]]], ["These genes can be identified in almost all mammalian species.", [["mammalian species", "OBSERVATION", 44, 61]]], ["The ancestral CEACAM1 was subject to multiple duplications which led to species-specific expansion of CEACAM1-related members of the CEA gene family.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 14, 21], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 102, 109], ["CEA", "GENE_OR_GENE_PRODUCT", 133, 136], ["CEACAM1", "PROTEIN", 14, 21], ["CEACAM1", "PROTEIN", 102, 109], ["CEA gene family", "DNA", 133, 148], ["The ancestral CEACAM1", "TREATMENT", 0, 21], ["multiple duplications", "PROBLEM", 37, 58], ["species", "PROBLEM", 72, 79], ["CEACAM1", "OBSERVATION", 14, 21], ["CEA", "ANATOMY", 133, 136]]], ["CEA-CAM1 is a transmembrane inhibitory receptor composed of one N-terminal immunoglobulin variable (IgV)-like (also called N domain) and three Ig constant (IgC)-like extracellular domains (also named A1, B, and A2 domains).", [["transmembrane", "ANATOMY", 14, 27], ["extracellular", "ANATOMY", 166, 179], ["CEA-", "CHEMICAL", 0, 4], ["N", "CHEMICAL", 64, 65], ["CEA-CAM1", "GENE_OR_GENE_PRODUCT", 0, 8], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 75, 89], ["IgV", "GENE_OR_GENE_PRODUCT", 100, 103], ["Ig", "GENE_OR_GENE_PRODUCT", 143, 145], ["IgC", "GENE_OR_GENE_PRODUCT", 156, 159], ["B", "GENE_OR_GENE_PRODUCT", 204, 205], ["CAM1", "PROTEIN", 4, 8], ["transmembrane inhibitory receptor", "PROTEIN", 14, 47], ["N-terminal immunoglobulin variable", "PROTEIN", 64, 98], ["IgV", "PROTEIN", 100, 103], ["N domain", "PROTEIN", 123, 131], ["Ig constant (IgC)-like extracellular domains", "PROTEIN", 143, 187], ["A1", "PROTEIN", 200, 202], ["B", "PROTEIN", 204, 205], ["A2 domains", "PROTEIN", 211, 221], ["a transmembrane inhibitory receptor", "TEST", 12, 47], ["terminal immunoglobulin variable", "PROBLEM", 66, 98], ["extracellular domains", "PROBLEM", 166, 187]]], ["The IgV-like domain is the primary ligand-binding domain, which was shown to interact with other CEACAMs and other cell surface receptors such as galectins, integrins and TIM-3 as well as with various pathogen adhesins [3, 4] .", [["cell surface", "ANATOMY", 115, 127], ["IgV", "GENE_OR_GENE_PRODUCT", 4, 7], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 97, 104], ["cell", "CELL", 115, 119], ["galectins", "GENE_OR_GENE_PRODUCT", 146, 155], ["integrins", "GENE_OR_GENE_PRODUCT", 157, 166], ["TIM-3", "GENE_OR_GENE_PRODUCT", 171, 176], ["IgV-like domain", "PROTEIN", 4, 19], ["primary ligand-binding domain", "PROTEIN", 27, 56], ["CEACAMs", "PROTEIN", 97, 104], ["cell surface receptors", "PROTEIN", 115, 137], ["galectins", "PROTEIN", 146, 155], ["integrins", "PROTEIN", 157, 166], ["TIM-3", "PROTEIN", 171, 176], ["pathogen adhesins", "PROTEIN", 201, 218], ["other CEACAMs", "TREATMENT", 91, 104], ["other cell surface receptors", "TREATMENT", 109, 137]]], ["The cytoplasmic tail of CEACAM1 contains one to two immunoreceptor tyrosine-based inhibition motifs (ITIM).", [["cytoplasmic tail", "ANATOMY", 4, 20], ["tyrosine", "CHEMICAL", 67, 75], ["tyrosine", "CHEMICAL", 67, 75], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 24, 31], ["cytoplasmic tail", "PROTEIN", 4, 20], ["CEACAM1", "PROTEIN", 24, 31], ["immunoreceptor tyrosine-based inhibition motifs", "PROTEIN", 52, 99], ["ITIM", "PROTEIN", 101, 105], ["CEACAM1", "TEST", 24, 31], ["immunoreceptor tyrosine", "TREATMENT", 52, 75], ["cytoplasmic", "OBSERVATION_MODIFIER", 4, 15], ["tail", "OBSERVATION_MODIFIER", 16, 20]]], ["CEACAM1 is expressed by various cell types including, endothelial, epithelial and immune cells.", [["cell", "ANATOMY", 32, 36], ["endothelial", "ANATOMY", 54, 65], ["epithelial", "ANATOMY", 67, 77], ["immune cells", "ANATOMY", 82, 94], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 0, 7], ["cell", "CELL", 32, 36], ["endothelial", "CELL", 54, 65], ["epithelial", "CELL", 67, 77], ["immune cells", "CELL", 82, 94], ["CEACAM1", "PROTEIN", 0, 7], ["endothelial, epithelial and immune cells", "CELL_TYPE", 54, 94], ["CEACAM1", "PROBLEM", 0, 7], ["various cell types", "OBSERVATION", 24, 42], ["endothelial", "ANATOMY", 54, 65], ["epithelial", "ANATOMY", 67, 77], ["immune cells", "OBSERVATION", 82, 94]]], ["In immune cells CEACAM1 is an important regulator of cell activation [5] [6] [7] .", [["immune cells", "ANATOMY", 3, 15], ["cell", "ANATOMY", 53, 57], ["immune cells", "CELL", 3, 15], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 16, 23], ["cell", "CELL", 53, 57], ["immune cells", "CELL_TYPE", 3, 15], ["CEACAM1", "PROTEIN", 16, 23], ["immune cells CEACAM1", "OBSERVATION", 3, 23]]], ["In primates and rodents the CEACAM1-related genes belong either to the CEA-related cell adhesion molecule (CEACAM) or the pregnancy-specific glycoprotein (PSG) subgroups.", [["cell", "ANATOMY", 83, 87], ["primates", "ORGANISM", 3, 11], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 28, 35], ["CEA-related cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 71, 105], ["CEACAM", "GENE_OR_GENE_PRODUCT", 107, 113], ["CEACAM1", "PROTEIN", 28, 35], ["CEA", "PROTEIN", 71, 74], ["cell adhesion molecule", "PROTEIN", 83, 105], ["CEACAM", "PROTEIN", 107, 113], ["pregnancy-specific glycoprotein", "PROTEIN", 122, 153], ["PSG", "PROTEIN", 155, 158], ["the CEA", "TEST", 67, 74], ["cell adhesion molecule", "PROBLEM", 83, 105], ["the pregnancy", "PROBLEM", 118, 131], ["specific glycoprotein (PSG) subgroups", "TREATMENT", 132, 169], ["CEA", "ANATOMY", 71, 74], ["cell adhesion", "OBSERVATION", 83, 96]]], ["While several CEACAMs are receptors involved in immunity, PSGs are expressed nearly exclusively in trophoblast cells and most likely play a role in maternalfetal communication [8] .", [["trophoblast cells", "ANATOMY", 99, 116], ["maternalfetal", "ANATOMY", 148, 161], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 14, 21], ["PSGs", "GENE_OR_GENE_PRODUCT", 58, 62], ["trophoblast cells", "CELL", 99, 116], ["CEACAMs", "PROTEIN", 14, 21], ["PSGs", "PROTEIN", 58, 62], ["trophoblast cells", "CELL_TYPE", 99, 116], ["most likely", "UNCERTAINTY", 121, 132]]], ["Surprisingly, PSGs do not exist in various mammals including most of the members of the superorder Laurasiatheria [9] [10] [11] .", [["PSGs", "GENE_OR_GENE_PRODUCT", 14, 18], ["PSGs", "PROTEIN", 14, 18]]], ["However, more recently we and others found that in bats, namely in Myotis lucifugus (M. lucifugus) and Myotis davidii (M. davidii) which also belong to the superorder Laurasiatheria, a considerable gene amplification in the CEA gene family occurred [11, 12] .", [["Myotis lucifugus", "ORGANISM", 67, 83], ["M. lucifugus", "ORGANISM", 85, 97], ["Myotis davidii", "ORGANISM", 103, 117], ["M. davidii", "ORGANISM", 119, 129], ["CEA", "GENE_OR_GENE_PRODUCT", 224, 227], ["CEA gene family", "DNA", 224, 239], ["Myotis lucifugus", "SPECIES", 67, 83], ["M. lucifugus", "SPECIES", 85, 97], ["Myotis davidii", "SPECIES", 103, 117], ["M. davidii", "SPECIES", 119, 129], ["Myotis lucifugus", "SPECIES", 67, 83], ["M. lucifugus", "SPECIES", 85, 97], ["Myotis davidii", "SPECIES", 103, 117], ["M. davidii", "SPECIES", 119, 129], ["a considerable gene amplification", "TREATMENT", 183, 216]]], ["However, information on the structure and expression of the CEA family members in bats are completely missing.BackgroundBats belong to the order Chiroptera, which is the second largest order of mammals, only rodents contain more species.", [["CEA", "GENE_OR_GENE_PRODUCT", 60, 63], ["bats", "ORGANISM", 82, 86], ["Chiroptera", "GENE_OR_GENE_PRODUCT", 145, 155], ["CEA family members", "PROTEIN", 60, 78], ["more species", "OBSERVATION", 224, 236]]], ["Traditionally the order Chiroptera was divided into the two suborders Megachiroptera (fruit-eating, non-echolocating bats) and Microchiroptera (insectivorous, echolocating bats).", [["Megachiroptera", "CHEMICAL", 70, 84], ["Microchiroptera", "TREATMENT", 127, 142]]], ["However, current molecular evidence rather favors the division in the new subgroups Yinpterochiroptera and Yangochiroptera which have diverged approximately 60 million years ago [13, 14] .", [["new", "OBSERVATION_MODIFIER", 70, 73]]], ["Yinpterochiroptera contain in addition to the old world fruit bats (Pteropodidae), four families of echolocating insectivorous bats.", [["Yinpterochiroptera", "CHEMICAL", 0, 18], ["Yinpterochiroptera", "TREATMENT", 0, 18], ["fruit bats", "OBSERVATION", 56, 66], ["insectivorous bats", "OBSERVATION", 113, 131]]], ["Common to all bats is that they play an important role as reservoirs for viruses.", [["viruses", "PROBLEM", 73, 80]]], ["Currently more than 100 viruses have been detected in bats some of them, like lyssa, corona and ebola viruses, are of extraordinary importance for human health [15] .", [["lyssa", "GENE_OR_GENE_PRODUCT", 78, 83], ["ebola viruses", "ORGANISM", 96, 109], ["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["corona and ebola viruses", "PROBLEM", 85, 109], ["viruses", "OBSERVATION", 24, 31], ["corona", "ANATOMY_MODIFIER", 85, 91], ["ebola viruses", "OBSERVATION", 96, 109]]], ["As a consequence it has been speculated that the immune system of bats has unique features making them tolerant to several virus infections [16] .", [["immune system", "ANATOMY", 49, 62], ["infections", "DISEASE", 129, 139], ["bats", "ORGANISM", 66, 70], ["several virus infections", "PROBLEM", 115, 139]]], ["Indeed the continuous threat by various pathogens may have a strong influence on the evolution of immune proteins, including the CEACAM receptors of the CEA family.", [["CEACAM receptors", "GENE_OR_GENE_PRODUCT", 129, 145], ["CEA", "GENE_OR_GENE_PRODUCT", 153, 156], ["immune proteins", "PROTEIN", 98, 113], ["CEACAM receptors", "PROTEIN", 129, 145], ["CEA family", "PROTEIN", 153, 163], ["various pathogens", "PROBLEM", 32, 49], ["immune proteins", "PROBLEM", 98, 113], ["CEA", "ANATOMY", 153, 156]]], ["In addition, we have recently speculated that the expansion of the PSG subgroup of the CEA gene family requires the presence of a hemochorial placenta as it is found in primates and rodents.", [["hemochorial placenta", "ANATOMY", 130, 150], ["CEA", "GENE_OR_GENE_PRODUCT", 87, 90], ["hemochorial placenta", "TISSUE", 130, 150], ["primates", "ORGANISM", 169, 177], ["CEA gene family", "DNA", 87, 102], ["a hemochorial placenta", "PROBLEM", 128, 150], ["expansion", "OBSERVATION_MODIFIER", 50, 59], ["CEA", "ANATOMY", 87, 90]]], ["In contrast to endotheliochorial and epitheliochorial placentae the hemochorial placenta allows direct contact of fetal cells with maternal blood and immune cells [17] .", [["endotheliochorial", "ANATOMY", 15, 32], ["placentae", "ANATOMY", 54, 63], ["hemochorial placenta", "ANATOMY", 68, 88], ["fetal cells", "ANATOMY", 114, 125], ["blood", "ANATOMY", 140, 145], ["immune cells", "ANATOMY", 150, 162], ["endotheliochorial", "CANCER", 15, 32], ["epitheliochorial placentae", "TISSUE", 37, 63], ["hemochorial placenta", "TISSUE", 68, 88], ["fetal cells", "CELL", 114, 125], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["immune cells", "CELL", 150, 162], ["fetal cells", "CELL_TYPE", 114, 125], ["immune cells", "CELL_TYPE", 150, 162], ["fetal cells", "PROBLEM", 114, 125], ["maternal blood and immune cells", "PROBLEM", 131, 162]]], ["Bats have either an endotheliochorial or a hemochorial placenta, depending on the bat species.", [["endotheliochorial", "ANATOMY", 20, 37], ["hemochorial placenta", "ANATOMY", 43, 63], ["Bats", "CELL", 0, 4], ["hemochorial placenta", "TISSUE", 43, 63], ["a hemochorial placenta", "PROBLEM", 41, 63], ["hemochorial placenta", "OBSERVATION", 43, 63]]], ["Therefore, the high number of CEACAMs in certain bat species raises the question whether these CEACAMs may represent PSGs.BackgroundIn this report we show that the vast majority of CEA-CAMs in bats, which have an extended CEA family, are secreted glycoproteins.", [["CEACAMs", "DISEASE", 30, 37], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 30, 37], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 95, 102], ["PSGs", "PATHOLOGICAL_FORMATION", 117, 121], ["CEA-CAMs", "GENE_OR_GENE_PRODUCT", 181, 189], ["bats", "ORGANISM", 193, 197], ["CEA", "GENE_OR_GENE_PRODUCT", 222, 225], ["CEACAMs", "PROTEIN", 30, 37], ["CEACAMs", "PROTEIN", 95, 102], ["CEA", "PROTEIN", 181, 184], ["CAMs", "PROTEIN", 185, 189], ["CEA family", "PROTEIN", 222, 232], ["secreted glycoproteins", "PROTEIN", 238, 260], ["CEACAMs in certain bat species", "PROBLEM", 30, 60], ["these CEACAMs", "PROBLEM", 89, 102], ["PSGs", "PROBLEM", 117, 121], ["CEA", "TEST", 181, 184], ["secreted glycoproteins", "PROBLEM", 238, 260], ["high", "OBSERVATION_MODIFIER", 15, 19], ["number", "OBSERVATION_MODIFIER", 20, 26], ["PSGs", "OBSERVATION", 117, 121], ["CEA", "OBSERVATION", 181, 184], ["CEA", "OBSERVATION", 222, 225]]], ["These glycoproteins are not expressed in a number of tissues in which usually non-PSG CEACAMs are expressed suggesting that the secreted CEACAMs in bats have a restricted expression pattern.", [["tissues", "ANATOMY", 53, 60], ["tissues", "TISSUE", 53, 60], ["non-PSG", "GENE_OR_GENE_PRODUCT", 78, 85], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 86, 93], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 137, 144], ["bats", "ORGANISM", 148, 152], ["non-PSG CEACAMs", "PROTEIN", 78, 93], ["CEACAMs", "PROTEIN", 137, 144], ["the secreted CEACAMs", "PROBLEM", 124, 144], ["restricted expression", "OBSERVATION", 160, 181]]], ["Interestingly, the IgV-like domain which is responsible for the interaction with almost all extracellular ligands is under strong positive selection in bats.", [["extracellular", "ANATOMY", 92, 105], ["IgV", "GENE_OR_GENE_PRODUCT", 19, 22], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 105], ["IgV", "PROTEIN", 19, 22], ["responsible for", "UNCERTAINTY", 44, 59]]], ["Selection for diversification points to rapidly evolving ligands, like viruses and other microorganisms or to a family of closely related receptors, like members of a protein family.", [["protein family", "PROTEIN", 167, 181], ["diversification", "PROBLEM", 14, 29], ["rapidly evolving ligands", "PROBLEM", 40, 64], ["viruses", "PROBLEM", 71, 78], ["other microorganisms", "PROBLEM", 83, 103], ["ligands", "OBSERVATION", 57, 64], ["viruses", "OBSERVATION", 71, 78]]], ["We hypothesize that these PSG-like proteins (further referred to as PSGs) are expressed at the maternal-fetal interface and that they play a role either in counteracting infection or regulating maternal-fetal communication.Phylogeny of bat orthologous CEACAM genesFirst we searched for bat orthologous CEACAM genes CEACAM16, CEACAM18 and CEACAM19 in the \"whole-genome shotgun contigs (wgs)\" database at NCBI using cDNA sequences of individual exons of human orthologous genes.", [["fetal", "ANATOMY", 104, 109], ["fetal", "ANATOMY", 203, 208], ["infection", "DISEASE", 170, 179], ["PSG-like proteins", "GENE_OR_GENE_PRODUCT", 26, 43], ["PSGs", "GENE_OR_GENE_PRODUCT", 68, 72], ["fetal interface", "MULTI-TISSUE_STRUCTURE", 104, 119], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 203, 208], ["CEACAM", "GENE_OR_GENE_PRODUCT", 252, 258], ["CEACAM", "GENE_OR_GENE_PRODUCT", 302, 308], ["CEACAM16", "GENE_OR_GENE_PRODUCT", 315, 323], ["CEACAM18", "GENE_OR_GENE_PRODUCT", 325, 333], ["CEACAM19", "GENE_OR_GENE_PRODUCT", 338, 346], ["human", "ORGANISM", 452, 457], ["PSG", "PROTEIN", 26, 29], ["PSGs", "PROTEIN", 68, 72], ["bat orthologous CEACAM genes", "DNA", 236, 264], ["CEACAM genes", "DNA", 302, 314], ["CEACAM16", "DNA", 315, 323], ["CEACAM18", "DNA", 325, 333], ["CEACAM19", "DNA", 338, 346], ["\"whole-genome shotgun contigs", "DNA", 354, 383], ["wgs", "DNA", 385, 388], ["cDNA sequences", "DNA", 414, 428], ["exons", "DNA", 443, 448], ["human orthologous genes", "DNA", 452, 475], ["human", "SPECIES", 452, 457], ["human", "SPECIES", 452, 457], ["these PSG-like proteins", "PROBLEM", 20, 43], ["PSGs", "TEST", 68, 72], ["counteracting infection", "PROBLEM", 156, 179], ["bat orthologous CEACAM genes CEACAM16", "TREATMENT", 286, 323], ["CEACAM18", "TREATMENT", 325, 333], ["CEACAM19", "TREATMENT", 338, 346], ["cDNA sequences", "TEST", 414, 428], ["infection", "OBSERVATION", 170, 179]]], ["Significant hits (E value < e-20; Query cover >50%) were obtained for 12 bat species belonging to six families.", [["Significant hits (E value", "PROBLEM", 0, 25], ["Query cover", "TEST", 34, 45]]], ["Six species belong to the Yangochiroptera and six species to the Yinpterochiroptera subgroup including four megabat species.", [["Six species", "PROBLEM", 0, 11]]], ["Using sequences coding for extracellular domains (CEA-CAM16N1, A, B, N2, CEACAM18N, CEACAM19N) of orthologous CEACAMs we could identify all orthologous CEACAM genes in each species, except for M. lucifugus for which we did not find CEACAM16.", [["extracellular", "ANATOMY", 27, 40], ["CEA-CAM16N1", "GENE_OR_GENE_PRODUCT", 50, 61], ["B", "GENE_OR_GENE_PRODUCT", 66, 67], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 110, 117], ["CEACAM", "GENE_OR_GENE_PRODUCT", 152, 158], ["M. lucifugus", "ORGANISM", 193, 205], ["CEACAM16", "GENE_OR_GENE_PRODUCT", 232, 240], ["extracellular domains", "PROTEIN", 27, 48], ["CEA", "PROTEIN", 50, 53], ["CAM16N1", "PROTEIN", 54, 61], ["A", "PROTEIN", 63, 64], ["B", "PROTEIN", 66, 67], ["N2", "PROTEIN", 69, 71], ["CEACAM18N", "PROTEIN", 73, 82], ["CEACAM19N", "PROTEIN", 84, 93], ["orthologous CEACAMs", "DNA", 98, 117], ["CEACAM genes", "DNA", 152, 164], ["CEACAM16", "PROTEIN", 232, 240], ["M. lucifugus", "SPECIES", 193, 205], ["M. lucifugus", "SPECIES", 193, 205], ["extracellular domains", "TEST", 27, 48], ["CEA", "TEST", 50, 53], ["CAM16N1", "TEST", 54, 61], ["A", "TEST", 63, 64], ["CEACAM18N", "TEST", 73, 82], ["orthologous CEACAMs", "PROBLEM", 98, 117], ["all orthologous CEACAM genes in each species", "PROBLEM", 136, 180]]], ["The retrieved sequences were concatenated to construct a phylogenetic tree of these bat species (Fig. 1a) .", [["The retrieved sequences", "TEST", 0, 23]]], ["The phylogenetic tree based on orthologous CEACAM sequences, depicted very closely the phylogenetic relationship of bat families published previously based on other genetic data except for the relative position of Mormoopidae and Miniopteridae to Vespertilionidae [14, 18] .", [["CEACAM", "GENE_OR_GENE_PRODUCT", 43, 49], ["orthologous CEACAM sequences", "DNA", 31, 59], ["orthologous CEACAM sequences", "TEST", 31, 59], ["other genetic data", "TEST", 159, 177], ["Mormoopidae", "TREATMENT", 214, 225], ["Miniopteridae", "TREATMENT", 230, 243], ["phylogenetic tree", "OBSERVATION", 4, 21]]], ["While Miniopteridae and Vespertilionidae are considered to belong to the Vespertilionoides superfamily, Mormoopidae belong to the Noctilionoidea superfamily.", [["Miniopteridae", "CHEMICAL", 6, 19], ["Vespertilionidae", "CHEMICAL", 24, 40], ["Miniopteridae", "GENE_OR_GENE_PRODUCT", 6, 19], ["Vespertilionidae", "GENE_OR_GENE_PRODUCT", 24, 40], ["Vespertilionoides", "GENE_OR_GENE_PRODUCT", 73, 90], ["Mormoopidae", "GENE_OR_GENE_PRODUCT", 104, 115], ["Noctilionoidea", "GENE_OR_GENE_PRODUCT", 130, 144], ["Vespertilionoides superfamily", "PROTEIN", 73, 102], ["Mormoopidae", "PROTEIN", 104, 115], ["Noctilionoidea superfamily", "PROTEIN", 130, 156], ["Vespertilionidae", "TREATMENT", 24, 40]]], ["However, similar difficulties were reported by Agnarsson and colleagues who build a phylogenetic tree based on the single cytochrome b gene [19] .Phylogeny of bat orthologous CEACAM genesTremendous expansion of the CEA gene family in certain bat species of the Yangochiroptera subgroup Next we determined the number of CEACAM1 paralogs in each bat species as described in \"Materials and Methods\".", [["cytochrome b", "GENE_OR_GENE_PRODUCT", 122, 134], ["CEACAM", "GENE_OR_GENE_PRODUCT", 175, 181], ["CEA", "GENE_OR_GENE_PRODUCT", 215, 218], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 319, 326], ["cytochrome b gene", "DNA", 122, 139], ["bat orthologous CEACAM genes", "DNA", 159, 187], ["CEA gene family", "DNA", 215, 230], ["CEACAM1 paralogs", "PROTEIN", 319, 335], ["the single cytochrome b gene", "TREATMENT", 111, 139], ["CEACAM1 paralogs", "PROBLEM", 319, 335], ["expansion", "OBSERVATION_MODIFIER", 198, 207], ["CEA", "ANATOMY", 215, 218], ["CEACAM1 paralogs", "OBSERVATION", 319, 335]]], ["Sequences without an open reading frame (ORF) were considered to be part of a pseudogene.", [["open reading frame", "DNA", 21, 39], ["ORF", "DNA", 41, 44], ["Sequences", "TEST", 0, 9], ["a pseudogene", "PROBLEM", 76, 88], ["pseudogene", "OBSERVATION", 78, 88]]], ["Within Yinpterochiroptera maximally 11 N domain exon sequences were identified per species with a maximum of six N domain exons with an ORF within one species (Fig. 1b) .", [["N domain exon sequences", "DNA", 39, 62], ["N domain exons", "DNA", 113, 127], ["ORF", "DNA", 136, 139], ["N domain exon sequences", "TEST", 39, 62], ["six N domain exons", "TREATMENT", 109, 127], ["an ORF", "PROBLEM", 133, 139]]], ["Miniopterus natalensis (M. natalensis) a species of the Yangochiroptera suborder has also six N domain exon sequences with an ORF.", [["Miniopterus natalensis", "ORGANISM", 0, 22], ["M. natalensis", "ORGANISM", 24, 37], ["N domain exon sequences", "DNA", 94, 117], ["ORF", "DNA", 126, 129], ["Miniopterus natalensis", "SPECIES", 0, 22], ["M. natalensis", "SPECIES", 24, 37], ["Miniopterus natalensis", "SPECIES", 0, 22], ["M. natalensis", "SPECIES", 24, 37], ["Miniopterus natalensis", "PROBLEM", 0, 22], ["the Yangochiroptera suborder", "TREATMENT", 52, 80], ["an ORF", "PROBLEM", 123, 129]]], ["In all other species of the Yangochiroptera group investigated, a tremendous expansion of CEA family member N domain exons was observed.", [["CEA", "GENE_OR_GENE_PRODUCT", 90, 93], ["CEA family member N domain exons", "DNA", 90, 122], ["a tremendous expansion of CEA family member N domain exons", "PROBLEM", 64, 122], ["tremendous", "OBSERVATION_MODIFIER", 66, 76], ["expansion", "OBSERVATION_MODIFIER", 77, 86], ["CEA", "ANATOMY", 90, 93]]], ["In M. lucifugus 102 different N domain exons were found, nearly half of them contained an ORF (Fig. 1b) .", [["M. lucifugus", "ORGANISM", 3, 15], ["N domain exons", "DNA", 30, 44], ["ORF", "DNA", 90, 93], ["M. lucifugus", "SPECIES", 3, 15], ["M. lucifugus", "SPECIES", 3, 15], ["different N domain exons", "PROBLEM", 20, 44]]], ["Roughly, a one to one ratio of N domain exons with internal stop codons and N domain exons with an ORF were also found in Myotis brandii (M. brandii), while in M. davidii, Eptesicus fuscus (E. a b Fig. 1 The CEA gene family in microbats is the most populous so far found in mammals. a The phylogenetic tree of analyzed bats consisting of 12 species and six families was constructed using the nucleotide sequence of the exons coding for the extracellular domains of CEACAM16, CEACAM18 and CEACAM19.", [["extracellular", "ANATOMY", 440, 453], ["Myotis brandii", "ORGANISM", 122, 136], ["M. brandii", "ORGANISM", 138, 148], ["M. davidii", "ORGANISM", 160, 170], ["Eptesicus fuscus", "ORGANISM", 172, 188], ["CEA", "GENE_OR_GENE_PRODUCT", 208, 211], ["microbats", "CANCER", 227, 236], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 440, 453], ["CEACAM16", "GENE_OR_GENE_PRODUCT", 465, 473], ["CEACAM18", "GENE_OR_GENE_PRODUCT", 475, 483], ["CEACAM19", "GENE_OR_GENE_PRODUCT", 488, 496], ["N domain exons", "DNA", 31, 45], ["N domain exons", "DNA", 76, 90], ["ORF", "DNA", 99, 102], ["CEA gene family", "DNA", 208, 223], ["exons", "DNA", 419, 424], ["extracellular domains", "PROTEIN", 440, 461], ["CEACAM16", "PROTEIN", 465, 473], ["CEACAM18", "PROTEIN", 475, 483], ["CEACAM19", "PROTEIN", 488, 496], ["Myotis brandii", "SPECIES", 122, 136], ["M. brandii", "SPECIES", 138, 148], ["M. davidii", "SPECIES", 160, 170], ["Eptesicus fuscus", "SPECIES", 172, 188], ["Myotis brandii", "SPECIES", 122, 136], ["M. brandii", "SPECIES", 138, 148], ["M. davidii", "SPECIES", 160, 170], ["Eptesicus fuscus", "SPECIES", 172, 188], ["N domain exons", "TREATMENT", 31, 45], ["internal stop codons", "TREATMENT", 51, 71], ["N domain exons", "PROBLEM", 76, 90], ["an ORF", "PROBLEM", 96, 102], ["the extracellular domains of CEACAM16", "TREATMENT", 436, 473], ["CEACAM18", "TREATMENT", 475, 483], ["CEACAM19", "TREATMENT", 488, 496], ["phylogenetic", "OBSERVATION_MODIFIER", 289, 301], ["tree", "OBSERVATION_MODIFIER", 302, 306]]], ["Two main bat subgroups belonging to either Yinpterochiroptera or Yangochiroptera suborders (marked in blue) were identified.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["marked", "OBSERVATION_MODIFIER", 92, 98]]], ["Each suborder contains six species belonging to three bat families each. b The expansion of CEACAM1-like genes in different bat species is depicted.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 92, 99], ["CEACAM1", "PROTEIN", 92, 99], ["CEACAM1", "PROBLEM", 92, 99], ["six species", "OBSERVATION_MODIFIER", 23, 34], ["expansion", "OBSERVATION_MODIFIER", 79, 88], ["CEACAM1", "OBSERVATION", 92, 99], ["different", "OBSERVATION_MODIFIER", 114, 123], ["bat species", "OBSERVATION", 124, 135]]], ["Numbers indicate the number of N domain exons found in the indicated species: total number of N domain exons/number of N domain exons with ORF (bold).", [["N domain exons", "DNA", 31, 45], ["N domain exons", "PROTEIN", 94, 108], ["N domain exons", "DNA", 119, 133], ["ORF", "DNA", 139, 142], ["N domain exons", "PROBLEM", 31, 45], ["N domain exons", "TREATMENT", 94, 108], ["ORF", "PROBLEM", 139, 142]]], ["The base of the triangles is proportional to the total number of CEA gene family members.", [["CEA", "GENE_OR_GENE_PRODUCT", 65, 68], ["CEA gene family members", "PROTEIN", 65, 88], ["base", "ANATOMY_MODIFIER", 4, 8], ["triangles", "ANATOMY_MODIFIER", 16, 25], ["proportional", "OBSERVATION_MODIFIER", 29, 41], ["CEA", "OBSERVATION", 65, 68]]], ["Cut-off level for condensed tree is 50%.", [["Cut", "TEST", 0, 3], ["tree", "ANATOMY_MODIFIER", 28, 32]]], ["Importantly, every N domain exon sequence was separated from another N domain sequence by CEA family-related exon sequences encoding other domains, strongly indicating that in bats each CEA family gene contains only a single N domain exon.", [["CEA", "GENE_OR_GENE_PRODUCT", 90, 93], ["CEA", "GENE_OR_GENE_PRODUCT", 186, 189], ["N domain exon sequence", "DNA", 19, 41], ["N domain sequence", "DNA", 69, 86], ["CEA family-related exon sequences", "DNA", 90, 123], ["CEA family gene", "DNA", 186, 201], ["N domain exon", "DNA", 225, 238], ["every N domain exon sequence", "TEST", 13, 41], ["exon sequences", "TEST", 109, 123], ["a single N domain exon", "TREATMENT", 216, 238]]], ["Thus the number of N domain exons may indicate the number of CEA gene family members in bats.A balanced expansion of genes coding for inhibitory and activation CEACAM receptors frequently took place in batsMembers of the CEA family may be secreted or membrane-bound glycoproteins.", [["membrane", "ANATOMY", 251, 259], ["CEA", "GENE_OR_GENE_PRODUCT", 61, 64], ["CEACAM", "GENE_OR_GENE_PRODUCT", 160, 166], ["CEA", "GENE_OR_GENE_PRODUCT", 221, 224], ["membrane", "CELLULAR_COMPONENT", 251, 259], ["N domain exons", "DNA", 19, 33], ["CEA gene family members", "PROTEIN", 61, 84], ["inhibitory and activation CEACAM receptors", "PROTEIN", 134, 176], ["CEA family", "PROTEIN", 221, 231], ["membrane-bound glycoproteins", "PROTEIN", 251, 279], ["N domain exons", "TREATMENT", 19, 33], ["A balanced expansion of genes coding", "TREATMENT", 93, 129], ["inhibitory and activation CEACAM receptors", "TREATMENT", 134, 176]]], ["Membrane anchorage is accomplished by the presence of one of two types of transmembrane domain exons.", [["Membrane", "ANATOMY", 0, 8], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["transmembrane domain exons", "PROTEIN", 74, 100], ["Membrane anchorage", "TREATMENT", 0, 18], ["transmembrane domain exons", "TREATMENT", 74, 100], ["anchorage", "OBSERVATION", 9, 18], ["transmembrane domain exons", "OBSERVATION", 74, 100]]], ["One is derived from an ancestral CEACAM1 gene and is combined with exons encoding a cytoplasmic tail containing inhibitory signaling motifs, and the second is derived from an ancestral CEACAM gene which had exons encoding an activation signaling motif [9] .", [["cytoplasmic tail", "ANATOMY", 84, 100], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 33, 40], ["cytoplasmic", "ORGANISM_SUBSTANCE", 84, 95], ["CEACAM", "GENE_OR_GENE_PRODUCT", 185, 191], ["CEACAM1 gene", "DNA", 33, 45], ["exons", "DNA", 67, 72], ["cytoplasmic tail", "PROTEIN", 84, 100], ["inhibitory signaling motifs", "DNA", 112, 139], ["CEACAM gene", "DNA", 185, 196], ["exons", "DNA", 207, 212], ["activation signaling motif", "PROTEIN", 225, 251], ["an ancestral CEACAM1 gene", "TREATMENT", 20, 45], ["a cytoplasmic tail", "TREATMENT", 82, 100], ["inhibitory signaling motifs", "PROBLEM", 112, 139], ["an ancestral CEACAM gene", "TREATMENT", 172, 196], ["CEACAM1", "OBSERVATION", 33, 40]]], ["The function of CEACAMs largely depends on their type of membrane anchorage and their signaling capacity.", [["membrane", "ANATOMY", 57, 65], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 16, 23], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["CEACAMs", "PROTEIN", 16, 23], ["CEACAMs", "PROBLEM", 16, 23]]], ["Using nucleotide sequences from human CEACAM1 (encodes an inhibitory receptor) and human CEACAM3 (encodes an activating/endocytic receptor) transmembrane domain exons we searched for related sequences within the M. lucifugus genome.", [["nucleotide", "CHEMICAL", 6, 16], ["nucleotide", "CHEMICAL", 6, 16], ["human", "ORGANISM", 32, 37], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 38, 45], ["human", "ORGANISM", 83, 88], ["CEACAM3", "GENE_OR_GENE_PRODUCT", 89, 96], ["M. lucifugus", "ORGANISM", 212, 224], ["human CEACAM1", "PROTEIN", 32, 45], ["inhibitory receptor", "PROTEIN", 58, 77], ["human CEACAM3", "PROTEIN", 83, 96], ["activating/endocytic receptor", "PROTEIN", 109, 138], ["transmembrane domain exons", "PROTEIN", 140, 166], ["M. lucifugus genome", "DNA", 212, 231], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 83, 88], ["M. lucifugus", "SPECIES", 212, 224], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 83, 88], ["M. lucifugus", "SPECIES", 212, 224], ["nucleotide sequences", "TREATMENT", 6, 26], ["human CEACAM1", "TREATMENT", 32, 45], ["an inhibitory receptor)", "TREATMENT", 55, 78], ["human CEACAM3 (encodes an activating/endocytic receptor) transmembrane domain exons", "TREATMENT", 83, 166], ["lucifugus genome", "OBSERVATION", 215, 231]]], ["We were able to identify five sequences which were related to the transmembrane domain exon of CEACAM1 and five sequences which were related to the transmembrane domain exon of CEACAM3.", [["transmembrane", "ANATOMY", 66, 79], ["transmembrane", "ANATOMY", 148, 161], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 95, 102], ["CEACAM3", "GENE_OR_GENE_PRODUCT", 177, 184], ["transmembrane domain exon", "PROTEIN", 66, 91], ["CEACAM1", "PROTEIN", 95, 102], ["transmembrane domain exon", "PROTEIN", 148, 173], ["CEACAM3", "PROTEIN", 177, 184], ["five sequences", "TEST", 107, 121], ["the transmembrane domain exon of CEACAM3", "TREATMENT", 144, 184]]], ["Four sequences were next to exons encoding cytoplasmic tails with either two ITIM (three genes) or one ITIM and one immunoreceptor tyrosine-based switch motif (ITSM; one gene) while four transmembrane domain exons were coupled with cytoplasmic domain exons coding for immunoreceptor tyrosine-based activation motifs (ITAM).", [["cytoplasmic", "ANATOMY", 43, 54], ["cytoplasmic", "ANATOMY", 232, 243], ["tyrosine", "CHEMICAL", 131, 139], ["tyrosine", "CHEMICAL", 283, 291], ["tyrosine", "CHEMICAL", 131, 139], ["tyrosine", "CHEMICAL", 283, 291], ["cytoplasmic", "ORGANISM_SUBSTANCE", 43, 54], ["ITIM", "GENE_OR_GENE_PRODUCT", 77, 81], ["ITIM", "GENE_OR_GENE_PRODUCT", 103, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 232, 243], ["ITAM", "GENE_OR_GENE_PRODUCT", 317, 321], ["exons", "DNA", 28, 33], ["cytoplasmic tails", "PROTEIN", 43, 60], ["ITIM", "PROTEIN", 77, 81], ["ITIM", "PROTEIN", 103, 107], ["immunoreceptor tyrosine-based switch motif", "DNA", 116, 158], ["ITSM", "DNA", 160, 164], ["transmembrane domain exons", "DNA", 187, 213], ["cytoplasmic domain exons", "DNA", 232, 256], ["immunoreceptor tyrosine-based activation motifs", "PROTEIN", 268, 315], ["ITAM", "PROTEIN", 317, 321], ["Four sequences", "TEST", 0, 14], ["one ITIM", "TREATMENT", 99, 107], ["one immunoreceptor tyrosine", "TREATMENT", 112, 139], ["switch motif (ITSM", "TREATMENT", 146, 164], ["four transmembrane domain exons", "TREATMENT", 182, 213], ["cytoplasmic domain exons", "TREATMENT", 232, 256], ["immunoreceptor tyrosine", "TREATMENT", 268, 291]]], ["However, in three of these genes (two encoding ITIM and one ITAM) one splice donor site each is mutated indicating that these genes do not code for functional immunoreceptor tyrosine-based signaling motifs (Fig. 2a, b ).", [["tyrosine", "CHEMICAL", 174, 182], ["tyrosine", "CHEMICAL", 174, 182], ["ITIM", "GENE_OR_GENE_PRODUCT", 47, 51], ["ITAM", "GENE_OR_GENE_PRODUCT", 60, 64], ["ITIM", "PROTEIN", 47, 51], ["ITAM", "PROTEIN", 60, 64], ["splice donor site", "DNA", 70, 87], ["immunoreceptor tyrosine-based signaling motifs", "PROTEIN", 159, 205], ["two encoding ITIM and one ITAM)", "TREATMENT", 34, 65], ["functional immunoreceptor tyrosine", "TREATMENT", 148, 182]]], ["For two of these genes the corresponding N domain sequence could not be identified.", [["N domain sequence", "DNA", 41, 58], ["the corresponding N domain sequence", "TEST", 23, 58]]], ["As shown in Fig. 2c such a balanced expansion took place in 50% of the bat species analyzed.", [["a balanced expansion", "TREATMENT", 25, 45], ["Fig", "OBSERVATION", 12, 15], ["expansion", "OBSERVATION_MODIFIER", 36, 45]]], ["The relatively small fraction of sequences that code for transmembrane domains (10 out of 102) in M. lucifugus was surprising and indicates that the majority of CEA family members in that species are not fixed to the cell membrane.A balanced expansion of genes coding for inhibitory and activation CEACAM receptors frequently took place in batsGenes encoding secreted CEA family members expanded in bat species of the Yangochiroptera suborderA balanced expansion of genes coding for inhibitory and activation CEACAM receptors frequently took place in batsThe predicted exon composition and order of most bat CEA gene family members without a transmembrane domain exon is as follows: a leader, IgV-like domain, and one IgC-like domain exon.", [["transmembrane", "ANATOMY", 57, 70], ["cell membrane", "ANATOMY", 217, 230], ["transmembrane", "ANATOMY", 642, 655], ["M. lucifugus", "ORGANISM", 98, 110], ["CEA", "GENE_OR_GENE_PRODUCT", 161, 164], ["cell membrane", "CELLULAR_COMPONENT", 217, 230], ["CEACAM", "GENE_OR_GENE_PRODUCT", 298, 304], ["CEA", "GENE_OR_GENE_PRODUCT", 368, 371], ["bat species", "ORGANISM", 399, 410], ["Yangochiroptera suborderA", "ORGANISM", 418, 443], ["CEACAM receptors", "GENE_OR_GENE_PRODUCT", 509, 525], ["CEA", "GENE_OR_GENE_PRODUCT", 608, 611], ["IgV", "GENE_OR_GENE_PRODUCT", 693, 696], ["IgC", "GENE_OR_GENE_PRODUCT", 718, 721], ["transmembrane domains", "PROTEIN", 57, 78], ["CEA family members", "PROTEIN", 161, 179], ["inhibitory and activation CEACAM receptors", "PROTEIN", 272, 314], ["CEA family members", "PROTEIN", 368, 386], ["inhibitory and activation CEACAM receptors", "PROTEIN", 483, 525], ["bat CEA gene family members", "PROTEIN", 604, 631], ["transmembrane domain exon", "PROTEIN", 642, 667], ["IgV", "PROTEIN", 693, 696], ["IgC-like domain exon", "DNA", 718, 738], ["M. lucifugus", "SPECIES", 98, 110], ["M. lucifugus", "SPECIES", 98, 110], ["transmembrane domains", "TEST", 57, 78], ["A balanced expansion of genes coding", "TREATMENT", 231, 267], ["inhibitory and activation CEACAM receptors", "TREATMENT", 272, 314], ["inhibitory and activation CEACAM receptors", "TREATMENT", 483, 525], ["The predicted exon composition", "TREATMENT", 555, 585], ["a transmembrane domain exon", "PROBLEM", 640, 667], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["small", "OBSERVATION_MODIFIER", 15, 20], ["fraction", "OBSERVATION", 21, 29], ["CEA", "OBSERVATION", 161, 164], ["cell membrane", "OBSERVATION", 217, 230]]], ["In all of these genes, the latter exon has an internal stop codon either at the end of the IgC-like domain exon (PSGs with two immunoglobulin domains) or somewhere within the IgC-like domain (PSGs with only one immunoglobulin domain ( Fig. 3a) .", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 127, 141], ["exon", "DNA", 34, 38], ["internal stop codon", "DNA", 46, 65], ["IgC-like domain exon", "DNA", 91, 111], ["PSGs", "DNA", 113, 117], ["immunoglobulin domains", "DNA", 127, 149], ["IgC-like domain", "DNA", 175, 190], ["PSGs", "DNA", 192, 196], ["immunoglobulin domain", "DNA", 211, 232], ["an internal stop codon", "PROBLEM", 43, 65], ["the IgC", "TEST", 87, 94], ["two immunoglobulin domains", "TEST", 123, 149], ["the IgC", "TEST", 171, 178], ["PSGs", "TEST", 192, 196]]], ["Comparison of the IgC-like domains of secreted CEACAMs from M. lucifugus and P. parnellii with the IgC domains of CEACAM1 of M. lucifugus (i.e. A1, B, A2) revealed that they are most closely related with the A2-type IgC-like domains (Fig. 3b ).", [["IgC", "GENE_OR_GENE_PRODUCT", 18, 21], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 47, 54], ["M. lucifugus", "ORGANISM", 60, 72], ["P. parnellii", "ORGANISM", 77, 89], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 114, 121], ["M. lucifugus", "ORGANISM", 125, 137], ["B", "GENE_OR_GENE_PRODUCT", 148, 149], ["A2", "GENE_OR_GENE_PRODUCT", 151, 153], ["A2", "GENE_OR_GENE_PRODUCT", 208, 210], ["IgC", "PROTEIN", 18, 21], ["secreted CEACAMs", "PROTEIN", 38, 54], ["IgC domains", "PROTEIN", 99, 110], ["CEACAM1", "PROTEIN", 114, 121], ["A1", "PROTEIN", 144, 146], ["B", "PROTEIN", 148, 149], ["A2", "PROTEIN", 151, 153], ["A2", "PROTEIN", 208, 210], ["IgC", "PROTEIN", 216, 219], ["M. lucifugus", "SPECIES", 60, 72], ["P. parnellii", "SPECIES", 77, 89], ["M. lucifugus", "SPECIES", 125, 137], ["M. lucifugus", "SPECIES", 60, 72], ["P. parnellii", "SPECIES", 77, 89], ["M. lucifugus", "SPECIES", 125, 137], ["the IgC", "TEST", 14, 21], ["secreted CEACAMs", "PROBLEM", 38, 54], ["M. lucifugus", "PROBLEM", 60, 72], ["M. lucifugus", "TEST", 125, 137], ["the A2-type IgC", "PROBLEM", 204, 219]]], ["Such exon arrangement and stop codon localization as found in the one domain PSGs was previously also found in equine PSGs (Fig. 3c) .", [["PSGs", "ANATOMY", 118, 122], ["equine", "ORGANISM", 111, 117], ["PSGs", "PATHOLOGICAL_FORMATION", 118, 122], ["PSGs", "PROTEIN", 77, 81], ["Such exon arrangement", "TREATMENT", 0, 21], ["stop codon localization", "TREATMENT", 26, 49]]], ["N glycosylation sites of the IgV-like domains varied between zero and two.", [["N", "CHEMICAL", 0, 1], ["IgV", "GENE_OR_GENE_PRODUCT", 29, 32], ["N glycosylation sites", "PROTEIN", 0, 21], ["IgV", "PROTEIN", 29, 32], ["glycosylation sites", "TREATMENT", 2, 21]]], ["This indicates that the majority of CEA gene family members in certain Yangochiroptera species codes for secreted proteins.A balanced expansion of genes coding for inhibitory and activation CEACAM receptors frequently took place in batsPSG N domains are more closely related with each other than with N domains of membrane anchored CEACAMs in M. lucifugusA balanced expansion of genes coding for inhibitory and activation CEACAM receptors frequently took place in batsNext we wanted to know how the presumed ligand-binding domains (the IgV-like domains) of the CEA family members in M. lucifugus are related.", [["membrane", "ANATOMY", 314, 322], ["CEA", "GENE_OR_GENE_PRODUCT", 36, 39], ["Yangochiroptera", "GENE_OR_GENE_PRODUCT", 71, 86], ["CEACAM", "GENE_OR_GENE_PRODUCT", 190, 196], ["membrane", "CELLULAR_COMPONENT", 314, 322], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 332, 339], ["M. lucifugusA", "ORGANISM", 343, 356], ["CEACAM receptors", "GENE_OR_GENE_PRODUCT", 422, 438], ["IgV", "GENE_OR_GENE_PRODUCT", 536, 539], ["CEA", "GENE_OR_GENE_PRODUCT", 561, 564], ["M. lucifugus", "ORGANISM", 583, 595], ["CEA gene family members", "DNA", 36, 59], ["Yangochiroptera species", "PROTEIN", 71, 94], ["secreted proteins", "PROTEIN", 105, 122], ["inhibitory and activation CEACAM receptors", "PROTEIN", 164, 206], ["PSG N domains", "PROTEIN", 236, 249], ["N domains", "PROTEIN", 301, 310], ["membrane anchored CEACAMs", "PROTEIN", 314, 339], ["inhibitory and activation CEACAM receptors", "PROTEIN", 396, 438], ["ligand-binding domains", "PROTEIN", 508, 530], ["IgV", "PROTEIN", 536, 539], ["CEA family members", "PROTEIN", 561, 579], ["M. lucifugusA", "SPECIES", 343, 356], ["M. lucifugus", "SPECIES", 583, 595], ["M. lucifugusA", "SPECIES", 343, 356], ["M. lucifugus", "SPECIES", 583, 595], ["secreted proteins", "PROBLEM", 105, 122], ["A balanced expansion of genes coding", "TREATMENT", 123, 159], ["inhibitory and activation CEACAM receptors", "TREATMENT", 164, 206], ["PSG N domains", "TREATMENT", 236, 249], ["membrane anchored CEACAMs", "PROBLEM", 314, 339], ["inhibitory and activation CEACAM receptors", "TREATMENT", 396, 438], ["ligand-binding domains", "PROBLEM", 508, 530], ["CEA", "ANATOMY", 561, 564]]], ["In humans, the ligandbinding domains of PSGs form a separate cluster within the CEA family.", [["humans", "ORGANISM", 3, 9], ["PSGs", "GENE_OR_GENE_PRODUCT", 40, 44], ["CEA", "GENE_OR_GENE_PRODUCT", 80, 83], ["ligandbinding domains", "PROTEIN", 15, 36], ["PSGs", "PROTEIN", 40, 44], ["CEA family", "PROTEIN", 80, 90], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["CEA", "ANATOMY", 80, 83]]], ["In M. lucifugus phylogenetic studies revealed that the ligand-binding domains form also two clusters separating the secreted PSGs and the transmembraneanchored CEACAMs (Fig. 4) .", [["PSGs", "GENE_OR_GENE_PRODUCT", 125, 129], ["ligand-binding domains", "PROTEIN", 55, 77], ["PSGs", "PROTEIN", 125, 129], ["transmembraneanchored CEACAMs", "PROTEIN", 138, 167], ["Fig. 4", "PROTEIN", 169, 175], ["M. lucifugus", "SPECIES", 3, 15], ["M. lucifugus", "SPECIES", 3, 15], ["M. lucifugus phylogenetic studies", "TEST", 3, 36], ["the ligand-binding domains", "PROBLEM", 51, 77], ["secreted PSGs", "OBSERVATION", 116, 129]]], ["Interestingly, the ligandbinding domains of PSG in M. lucifugus formed two separated clusters further referred to as PSG I and PSG II.PSG N domains of Yangochiroptera bat speciesWe next analyzed CEA families in additional microbat species belonging to different families of Yangochiroptera (Fig. 6) .The ligand-binding domains of PSGs exhibit positive selectionRapid expansion of gene families is due to selection for a higher gene dosage or for functional diversification of the gene repertoire.", [["PSG", "GENE_OR_GENE_PRODUCT", 44, 47], ["M. lucifugus", "ORGANISM", 51, 63], ["PSG I", "GENE_OR_GENE_PRODUCT", 117, 122], ["PSG II", "GENE_OR_GENE_PRODUCT", 127, 133], ["Yangochiroptera bat", "ORGANISM", 151, 170], ["CEA", "GENE_OR_GENE_PRODUCT", 195, 198], ["PSGs", "GENE_OR_GENE_PRODUCT", 330, 334], ["ligandbinding domains", "PROTEIN", 19, 40], ["PSG", "PROTEIN", 44, 47], ["PSG I", "PROTEIN", 117, 122], ["PSG II", "PROTEIN", 127, 133], ["PSG N domains", "PROTEIN", 134, 147], ["CEA families", "PROTEIN", 195, 207], ["ligand-binding domains", "PROTEIN", 304, 326], ["PSGs", "PROTEIN", 330, 334], ["M. lucifugus", "SPECIES", 51, 63], ["M. lucifugus", "SPECIES", 51, 63], ["PSG N domains", "TREATMENT", 134, 147], ["Yangochiroptera bat species", "PROBLEM", 151, 178], ["Yangochiroptera (Fig", "TREATMENT", 274, 294], ["PSGs", "TEST", 330, 334], ["a higher gene dosage", "TREATMENT", 418, 438], ["functional diversification of the gene repertoire", "TREATMENT", 446, 495], ["positive selection", "OBSERVATION", 343, 361], ["Rapid", "OBSERVATION_MODIFIER", 361, 366], ["expansion", "OBSERVATION_MODIFIER", 367, 376]]], ["Selection for diversification is accompanied by adaptive evolution, i.e. a high ratio of nonsynonymous to synonymous nucleotide substitutions is observed.", [["nucleotide", "CHEMICAL", 117, 127], ["nucleotide", "CHEMICAL", 117, 127], ["diversification", "PROBLEM", 14, 29], ["a high ratio of nonsynonymous to synonymous nucleotide substitutions", "PROBLEM", 73, 141], ["synonymous nucleotide substitutions", "OBSERVATION", 106, 141]]], ["Therefore, we analyzed the evolution of the presumed ligand-binding domains (IgV-like domains) of bat PSGs using the SLAC and the BUSTED software (see \"Material and Methods\" section).", [["bat", "ORGANISM", 98, 101], ["PSGs", "PATHOLOGICAL_FORMATION", 102, 106], ["ligand-binding domains", "PROTEIN", 53, 75], ["IgV", "PROTEIN", 77, 80], ["bat PSGs", "PROTEIN", 98, 106], ["SLAC", "PROTEIN", 117, 121], ["ligand-binding domains", "PROBLEM", 53, 75]]], ["A mean ratio of nonsynonymous mutations per nonsynonymous site and synonymous mutations per synonymous site (dN/dS) of 1.66 was indicative for positive selection on the IgV-like domains of bat PSGs, which was confirmed by the detection of evidence of episodic diversifying selection using the likelihood ratio test (LRT) in the BUSTED software package (p-value <0.001).", [["IgV", "GENE_OR_GENE_PRODUCT", 169, 172], ["bat", "ORGANISM", 189, 192], ["PSGs", "PATHOLOGICAL_FORMATION", 193, 197], ["IgV-like domains", "DNA", 169, 185], ["bat PSGs", "DNA", 189, 197], ["A mean ratio", "TEST", 0, 12], ["nonsynonymous mutations", "PROBLEM", 16, 39], ["nonsynonymous site", "PROBLEM", 44, 62], ["synonymous mutations", "PROBLEM", 67, 87], ["positive selection", "PROBLEM", 143, 161], ["bat PSGs", "TEST", 189, 197], ["episodic diversifying selection", "PROBLEM", 251, 282], ["the likelihood ratio test", "TEST", 289, 314], ["p-value", "TEST", 353, 360], ["nonsynonymous mutations", "OBSERVATION", 16, 39], ["synonymous mutations", "OBSERVATION", 67, 87], ["indicative for", "UNCERTAINTY", 128, 142], ["bat PSGs", "ANATOMY", 189, 197]]], ["We further determined the selection pressure at individual sites using BUSTED and MEME software.", [["pressure", "OBSERVATION_MODIFIER", 36, 44]]], ["It turned out that multiple amino acid positions are under positive selection indicating that the ligand binding domain is selected for diversification (Fig. 7a-c) .", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["ligand binding domain", "PROTEIN", 98, 119], ["multiple amino acid positions", "TREATMENT", 19, 48], ["positive selection", "TREATMENT", 59, 77], ["the ligand binding domain", "PROBLEM", 94, 119]]], ["Interestingly, most of the amino acids under positive selection are located at the molecular surface of the IgVlike domains as determined by three-dimensional modeling (Fig. 7d) .The ligand-binding domains of PSGs exhibit positive selectionSites under positive selection differ between PSG I, PSG II and CEACAM N domains and CEACAMs (M. davidii) were aligned separately using \"Muscle\" (codon alignment) and MEGA6.", [["Muscle", "ANATOMY", 377, 383], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "AMINO_ACID", 27, 38], ["molecular surface", "CELLULAR_COMPONENT", 83, 100], ["PSGs", "GENE_OR_GENE_PRODUCT", 209, 213], ["PSG I", "GENE_OR_GENE_PRODUCT", 286, 291], ["PSG II", "GENE_OR_GENE_PRODUCT", 293, 299], ["CEACAM N domains", "GENE_OR_GENE_PRODUCT", 304, 320], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 325, 332], ["M. davidii", "ORGANISM", 334, 344], ["Muscle", "TISSUE", 377, 383], ["MEGA6", "GENE_OR_GENE_PRODUCT", 407, 412], ["IgVlike domains", "PROTEIN", 108, 123], ["ligand-binding domains", "PROTEIN", 183, 205], ["PSGs", "PROTEIN", 209, 213], ["PSG I", "PROTEIN", 286, 291], ["PSG II", "PROTEIN", 293, 299], ["CEACAM N domains", "PROTEIN", 304, 320], ["CEACAMs", "PROTEIN", 325, 332], ["MEGA6", "DNA", 407, 412], ["M. davidii", "SPECIES", 334, 344], ["M. davidii", "SPECIES", 334, 344], ["the amino acids", "TEST", 23, 38], ["positive selection", "PROBLEM", 45, 63], ["PSGs", "TEST", 209, 213], ["positive selectionSites", "PROBLEM", 222, 245], ["positive selection", "TREATMENT", 252, 270], ["PSG I", "TEST", 286, 291], ["CEACAM N domains", "TREATMENT", 304, 320], ["CEACAMs", "PROBLEM", 325, 332], ["Muscle\" (codon alignment", "TREATMENT", 377, 401], ["MEGA6", "TREATMENT", 407, 412], ["molecular", "ANATOMY_MODIFIER", 83, 92], ["surface", "ANATOMY_MODIFIER", 93, 100], ["positive selectionSites", "OBSERVATION", 222, 245], ["positive selection", "OBSERVATION", 252, 270], ["Muscle", "ANATOMY", 377, 383]]], ["Alignments were analyzed for N exon-wide episodic selection using BUSTED.", [["N exon-wide episodic selection", "TREATMENT", 29, 59]]], ["In all groups evidence for positive selection was found.", [["positive selection", "PROBLEM", 27, 45]]], ["We further compared sites of positive selection with a level of significance <0.1 (default parameter BUSTED) (Fig. 8a) of PSG I and PSG II of M. lucifugus and noticed that positive selection occurs at different sites in both PSG groups (Fig. 8a) .", [["PSG I", "GENE_OR_GENE_PRODUCT", 122, 127], ["M. lucifugus", "ORGANISM", 142, 154], ["PSG I", "PROTEIN", 122, 127], ["PSG II", "PROTEIN", 132, 138], ["M. lucifugus", "SPECIES", 142, 154], ["M. lucifugus", "SPECIES", 142, 154], ["positive selection", "PROBLEM", 29, 47], ["PSG I", "TREATMENT", 122, 127], ["positive selection", "PROBLEM", 172, 190], ["positive selection", "OBSERVATION", 172, 190], ["both", "ANATOMY_MODIFIER", 220, 224]]], ["In addition sites of positive selection of PSGs differ from positively selected sites in CEACAM N domains (Fig. 8a) .", [["PSGs", "GENE_OR_GENE_PRODUCT", 43, 47], ["PSGs", "DNA", 43, 47], ["CEACAM N domains", "DNA", 89, 105], ["positive selection of PSGs", "PROBLEM", 21, 47], ["positive selection", "OBSERVATION", 21, 39], ["PSGs", "OBSERVATION", 43, 47], ["positively", "OBSERVATION_MODIFIER", 60, 70], ["selected", "OBSERVATION_MODIFIER", 71, 79], ["sites", "OBSERVATION_MODIFIER", 80, 85]]], ["As assumed for a group of diverging genes, individual sites were under different modes of selection in different PSG genes (Fig. 8b-d) .Bat PSGs have a restricted expression patternVariation of the ligand-binding domains may be interpreted as a characteristic feature of decoy receptors for pathogen adhesins, therefore, we wondered if secreted PSGs are expressed in the placenta or by immune cells.", [["placenta", "ANATOMY", 371, 379], ["immune cells", "ANATOMY", 386, 398], ["PSGs", "GENE_OR_GENE_PRODUCT", 140, 144], ["PSGs", "GENE_OR_GENE_PRODUCT", 345, 349], ["placenta", "ORGAN", 371, 379], ["immune cells", "CELL", 386, 398], ["diverging genes", "DNA", 26, 41], ["PSG genes", "DNA", 113, 122], ["Bat PSGs", "DNA", 136, 144], ["ligand-binding domains", "PROTEIN", 198, 220], ["decoy receptors", "PROTEIN", 271, 286], ["pathogen adhesins", "PROTEIN", 291, 308], ["PSGs", "PROTEIN", 345, 349], ["immune cells", "CELL_TYPE", 386, 398], ["diverging genes", "PROBLEM", 26, 41], ["individual sites", "PROBLEM", 43, 59], ["Bat PSGs", "TREATMENT", 136, 144], ["pathogen adhesins", "PROBLEM", 291, 308], ["secreted PSGs", "PROBLEM", 336, 349], ["placenta", "ANATOMY", 371, 379]]], ["Unfortunately, we were not able to get placental tissue from microbats.", [["placental tissue", "ANATOMY", 39, 55], ["placental tissue", "TISSUE", 39, 55]]], ["Therefore, we focused our expression analyses on immune cells and determined the transcriptome of lymphoid tissues.", [["immune cells", "ANATOMY", 49, 61], ["lymphoid tissues", "ANATOMY", 98, 114], ["immune cells", "CELL", 49, 61], ["lymphoid tissues", "TISSUE", 98, 114], ["immune cells", "CELL_TYPE", 49, 61], ["immune cells", "TREATMENT", 49, 61], ["lymphoid tissues", "OBSERVATION", 98, 114]]], ["Total RNA was isolated from the spleen, thymus, intestine and lymph nodes of one individual of the species Myotis myotis which is very closely related to Myotis davidii [20] and analyzed by RNA sequencing.", [["spleen", "ANATOMY", 32, 38], ["thymus", "ANATOMY", 40, 46], ["intestine", "ANATOMY", 48, 57], ["lymph nodes", "ANATOMY", 62, 73], ["spleen", "ORGAN", 32, 38], ["thymus", "ORGAN", 40, 46], ["intestine", "ORGAN", 48, 57], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 62, 73], ["Myotis myotis", "ORGANISM", 107, 120], ["Myotis davidii", "ORGANISM", 154, 168], ["Myotis myotis", "SPECIES", 107, 120], ["Myotis davidii", "SPECIES", 154, 168], ["Myotis myotis", "SPECIES", 107, 120], ["Myotis davidii", "SPECIES", 154, 168], ["Total RNA", "TEST", 0, 9], ["lymph nodes", "PROBLEM", 62, 73], ["the species Myotis myotis", "PROBLEM", 95, 120], ["Myotis davidii", "TREATMENT", 154, 168], ["spleen", "ANATOMY", 32, 38], ["thymus", "ANATOMY", 40, 46], ["intestine", "ANATOMY", 48, 57], ["lymph nodes", "OBSERVATION", 62, 73], ["species", "OBSERVATION_MODIFIER", 99, 106], ["Myotis myotis", "OBSERVATION", 107, 120]]], ["All reads related to genes of the CEA gene family were analyzed.", [["CEA", "GENE_OR_GENE_PRODUCT", 34, 37], ["CEA gene family", "DNA", 34, 49]]], ["Remarkably only sequences belonging to the CEACAM-related subgroup could be found and none of the expressed genes belonged to the PSG group (Table 1 ).DiscussionIn most species of the superorder Laurasiatheria, the CEA gene family is relatively small [11] .", [["CEACAM", "GENE_OR_GENE_PRODUCT", 43, 49], ["CEA", "GENE_OR_GENE_PRODUCT", 215, 218], ["CEACAM", "DNA", 43, 49], ["CEA gene family", "DNA", 215, 230], ["the CEACAM", "TEST", 39, 49], ["small", "OBSERVATION_MODIFIER", 245, 250]]], ["However, a few exceptions of this rule exist [11] .", [["few", "OBSERVATION_MODIFIER", 11, 14]]], ["Recently, we have identified an expanded CEA gene family in the horse the expansion of which is due to the amplification of genes coding for secreted PSG-like CEACAMs [21] .", [["CEA", "GENE_OR_GENE_PRODUCT", 41, 44], ["horse", "ORGANISM", 64, 69], ["PSG", "GENE_OR_GENE_PRODUCT", 150, 153], ["CEA gene family", "DNA", 41, 56], ["PSG", "PROTEIN", 150, 153], ["CEACAMs", "PROTEIN", 159, 166], ["horse", "SPECIES", 64, 69], ["secreted PSG", "TEST", 141, 153], ["expanded", "OBSERVATION_MODIFIER", 32, 40], ["CEA", "OBSERVATION", 41, 44]]], ["In addition, there are reports indicating that the CEA gene family has been expanded in certain microbats [22] , namely in Myotis lucifugus [11] and in Myotis davidii [12] .", [["CEA", "GENE_OR_GENE_PRODUCT", 51, 54], ["Myotis lucifugus", "ORGANISM", 123, 139], ["CEA gene family", "DNA", 51, 66], ["Myotis lucifugus", "SPECIES", 123, 139], ["Myotis davidii", "SPECIES", 152, 166], ["Myotis lucifugus", "SPECIES", 123, 139], ["Myotis davidii", "SPECIES", 152, 166]]], ["Such a co-expansion of a gene family in otherwise distantly related species may point to similar selective pressures working on these species during evolution and thereby may provide clues to the function of the gene family.", [["selective", "OBSERVATION_MODIFIER", 97, 106], ["pressures", "OBSERVATION", 107, 116]]], ["In order to get a comprehensive knowledge of the CEA gene family in bats we have analyzed the CEA gene family in 12 different bat species.", [["CEA", "GENE_OR_GENE_PRODUCT", 49, 52], ["CEA", "GENE_OR_GENE_PRODUCT", 94, 97], ["CEA gene family", "DNA", 49, 64], ["CEA gene family", "DNA", 94, 109]]], ["According to the phylogenetic tree based on the sequences of orthologous CEACAMs six of these species belong to the Yangochiroptera and six to the Yinpterochiroptera suborders which is in accordance with phylogenetic trees previously reported by other authors [19, 23] .", [["orthologous CEACAMs", "DNA", 61, 80], ["Yinpterochiroptera suborders", "DNA", 147, 175], ["orthologous CEACAMs", "TREATMENT", 61, 80], ["these species", "PROBLEM", 88, 101]]], ["The maximal number of CEA family-related N domains containing an open reading frame in a single species of Yinpterochiroptera suborder was six.", [["CEA", "GENE_OR_GENE_PRODUCT", 22, 25], ["CEA family", "PROTEIN", 22, 32], ["N domains", "PROTEIN", 41, 50], ["open reading frame", "DNA", 65, 83], ["related N domains", "PROBLEM", 33, 50], ["an open reading frame", "TREATMENT", 62, 83], ["maximal", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["CEA", "OBSERVATION", 22, 25]]], ["In contrast in Yangochiroptera in particular in the Myotis genus up to tenfold as many CEA family member N domains were found.", [["CEA", "GENE_OR_GENE_PRODUCT", 87, 90], ["CEA family member N domains", "PROTEIN", 87, 114], ["Myotis", "ANATOMY", 52, 58]]], ["According to the currently proposed phylogeny of Yangochiroptera Miniopteridae are more closely related to Vespertilionidae than to Mormoopidae [19, 24] .", [["Yangochiroptera Miniopteridae", "ORGANISM", 49, 78], ["Yangochiroptera Miniopteridae", "SPECIES", 49, 78], ["Yangochiroptera Miniopteridae", "TREATMENT", 49, 78]]], ["Therefore, it is surprising that we found more CEA gene family members in P. parnellii than in M. natalensis.", [["CEA", "GENE_OR_GENE_PRODUCT", 47, 50], ["P. parnellii", "ORGANISM", 74, 86], ["M. natalensis", "ORGANISM", 95, 108], ["CEA gene family members", "PROTEIN", 47, 70], ["P. parnellii", "SPECIES", 74, 86], ["M. natalensis", "SPECIES", 95, 108], ["P. parnellii", "SPECIES", 74, 86], ["M. natalensis", "SPECIES", 95, 108]]], ["The most plausible explanation is that the expansion of the CEA gene family occurred in both linages independently.", [["CEA", "GENE_OR_GENE_PRODUCT", 60, 63], ["CEA gene family", "DNA", 60, 75], ["CEA", "ANATOMY", 60, 63]]], ["Furthermore the difference in the size of the CEA gene family in Myotis and Eptesicus indicates that a second boost of CEA gene family expansion occurred between 20 and 25 Mya years ago in the Vespertilionidae [19, 24] .DiscussionMultiple CEACAM genes were found to code for transmembrane proteins with signaling capacities through ITIMs and ITAMs in the cytoplasmic tails.", [["transmembrane", "ANATOMY", 275, 288], ["cytoplasmic", "ANATOMY", 355, 366], ["CEA", "GENE_OR_GENE_PRODUCT", 46, 49], ["CEA", "GENE_OR_GENE_PRODUCT", 119, 122], ["CEACAM", "GENE_OR_GENE_PRODUCT", 239, 245], ["transmembrane", "CELLULAR_COMPONENT", 275, 288], ["ITIMs", "GENE_OR_GENE_PRODUCT", 332, 337], ["ITAMs", "GENE_OR_GENE_PRODUCT", 342, 347], ["cytoplasmic", "ORGANISM_SUBSTANCE", 355, 366], ["CEA gene family", "DNA", 46, 61], ["CEA gene family", "DNA", 119, 134], ["CEACAM genes", "DNA", 239, 251], ["transmembrane proteins", "PROTEIN", 275, 297], ["ITIMs", "PROTEIN", 332, 337], ["ITAMs", "PROTEIN", 342, 347], ["cytoplasmic tails", "PROTEIN", 355, 372], ["CEA gene family expansion", "PROBLEM", 119, 144], ["transmembrane proteins", "PROBLEM", 275, 297], ["signaling capacities", "PROBLEM", 303, 323], ["ITIMs", "TREATMENT", 332, 337], ["ITAMs", "TREATMENT", 342, 347], ["difference", "OBSERVATION_MODIFIER", 16, 26], ["size", "OBSERVATION_MODIFIER", 34, 38], ["CEA", "ANATOMY", 46, 49], ["cytoplasmic tails", "OBSERVATION", 355, 372]]], ["Interestingly, amplification of both gene types coding for ITAM-and ITIM-containing CEACAMs occurred.", [["ITAM", "GENE_OR_GENE_PRODUCT", 59, 63], ["ITIM", "GENE_OR_GENE_PRODUCT", 68, 72], ["CEACAMs", "PATHOLOGICAL_FORMATION", 84, 91], ["ITAM", "PROTEIN", 59, 63], ["ITIM", "PROTEIN", 68, 72], ["CEACAMs", "PROTEIN", 84, 91], ["ITAM", "TEST", 59, 63], ["ITIM", "TREATMENT", 68, 72], ["CEACAMs", "TREATMENT", 84, 91]]], ["In the CEA gene families of other mammals described previously, a preferential expansion of either genes coding for ITAM-containing proteins (dog) or for ITIMcontaining proteins occurred (mouse, horse and, opossum) [9, 11] .", [["CEA", "GENE_OR_GENE_PRODUCT", 7, 10], ["ITAM-containing proteins", "GENE_OR_GENE_PRODUCT", 116, 140], ["dog", "ORGANISM", 142, 145], ["ITIMcontaining", "GENE_OR_GENE_PRODUCT", 154, 168], ["mouse", "ORGANISM", 188, 193], ["horse", "ORGANISM_SUBDIVISION", 195, 200], ["CEA gene families", "DNA", 7, 24], ["ITAM", "PROTEIN", 116, 120], ["ITIMcontaining proteins", "PROTEIN", 154, 177], ["mouse", "SPECIES", 188, 193], ["horse", "SPECIES", 195, 200], ["mouse", "SPECIES", 188, 193], ["ITIMcontaining proteins", "PROBLEM", 154, 177], ["CEA", "ANATOMY", 7, 10]]], ["Interestingly, a balanced expansion of transmembrane CEACAMs could be found in both Yangochiroptera and Yinpterochiroptera.", [["transmembrane", "ANATOMY", 39, 52], ["transmembrane", "CELLULAR_COMPONENT", 39, 52], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 53, 60], ["transmembrane CEACAMs", "PROTEIN", 39, 60], ["transmembrane CEACAMs", "PROBLEM", 39, 60], ["expansion", "OBSERVATION_MODIFIER", 26, 35]]], ["This may be explained by the fact that multiple ITIM-and ITAMcontaining signaling CEACAMs were already present in the last common ancestor of Yangochiroptera and Yinpterochiroptera bat suborders.", [["ITIM", "GENE_OR_GENE_PRODUCT", 48, 52], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 82, 89], ["Yangochiroptera", "GENE_OR_GENE_PRODUCT", 142, 157], ["Yinpterochiroptera bat", "ORGANISM", 162, 184], ["ITIM", "PROTEIN", 48, 52], ["CEACAMs", "PROTEIN", 82, 89], ["Yinpterochiroptera bat", "SPECIES", 162, 184], ["multiple ITIM", "PROBLEM", 39, 52], ["ITAMcontaining signaling CEACAMs", "PROBLEM", 57, 89], ["may be explained", "UNCERTAINTY", 5, 21], ["multiple", "OBSERVATION_MODIFIER", 39, 47], ["ITIM", "OBSERVATION", 48, 52]]], ["In the pooled tissues including spleen, thymus, lymph node and intestine we found strong mRNA expression of these signaling CEA-CAMs, consistent with the view that these CEACAMs Positively selected sides are shown in green.", [["tissues", "ANATOMY", 14, 21], ["spleen", "ANATOMY", 32, 38], ["thymus", "ANATOMY", 40, 46], ["lymph node", "ANATOMY", 48, 58], ["intestine", "ANATOMY", 63, 72], ["tissues", "TISSUE", 14, 21], ["spleen", "ORGAN", 32, 38], ["thymus", "ORGAN", 40, 46], ["lymph node", "MULTI-TISSUE_STRUCTURE", 48, 58], ["intestine", "ORGAN", 63, 72], ["CEA-CAMs", "GENE_OR_GENE_PRODUCT", 124, 132], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 170, 177], ["CEA", "PROTEIN", 124, 127], ["CAMs", "PROTEIN", 128, 132], ["CEACAMs", "PROTEIN", 170, 177], ["pooled tissues", "ANATOMY", 7, 21], ["spleen", "ANATOMY", 32, 38], ["thymus", "ANATOMY", 40, 46], ["lymph node", "OBSERVATION", 48, 58], ["intestine", "ANATOMY", 63, 72], ["strong", "OBSERVATION_MODIFIER", 82, 88], ["mRNA expression", "OBSERVATION", 89, 104], ["signaling", "OBSERVATION_MODIFIER", 114, 123], ["CEA", "OBSERVATION", 124, 127], ["consistent with", "UNCERTAINTY", 134, 149], ["green", "OBSERVATION_MODIFIER", 217, 222]]], ["Note that multiple positively selected sides are located in the CFG face which is known to interact homo-and heterotypically in other CEACAMs are important for immune function.", [["CFG face", "ANATOMY", 64, 72], ["CFG", "GENE_OR_GENE_PRODUCT", 64, 67], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 134, 141], ["CEACAMs", "PROTEIN", 134, 141], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["positively", "OBSERVATION_MODIFIER", 19, 29], ["CFG face", "ANATOMY", 64, 72]]], ["We have previously reported that pairs of ITIM-and ITAM-containing CEACAMs with very similar ligand-binding domains exist in most mammals and even in amphibians [11, 25] .", [["ITIM", "GENE_OR_GENE_PRODUCT", 42, 46], ["ITAM", "GENE_OR_GENE_PRODUCT", 51, 55], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 67, 74], ["ITIM", "PROTEIN", 42, 46], ["ITAM", "PROTEIN", 51, 55], ["CEACAMs", "PROTEIN", 67, 74], ["ligand-binding domains", "PROTEIN", 93, 115], ["ITIM", "TEST", 42, 46], ["CEACAMs", "TREATMENT", 67, 74], ["very similar ligand-binding domains", "PROBLEM", 80, 115], ["most mammals", "OBSERVATION_MODIFIER", 125, 137]]], ["The most plausible explanation for the evolution of these paired receptors is that activation receptors evolved as a countermeasure to the use of the inhibitory receptor by pathogens as cellular receptors.", [["cellular", "ANATOMY", 186, 194], ["cellular", "CELL", 186, 194], ["paired receptors", "PROTEIN", 58, 74], ["activation receptors", "PROTEIN", 83, 103], ["inhibitory receptor", "PROTEIN", 150, 169], ["cellular receptors", "PROTEIN", 186, 204], ["activation receptors", "PROBLEM", 83, 103], ["most plausible explanation for", "UNCERTAINTY", 4, 34]]], ["One indication for such a mechanism is that the ligand-binding domain is most similar between ITIM-containing CEA-CAMs and an ITAM-containing CEACAM which is the case for CEACAMs of Myotis lucifugus (CEACAM1L1/ CEACAM1L2 and CEACAM3L1) (Fig. 4) .DiscussionHowever, the enormous expansion of the CEA gene family in certain bat species is due to the amplification of genes coding for a single IgV-like domain followed by an IgC-like domain.", [["ITIM", "GENE_OR_GENE_PRODUCT", 94, 98], ["CEA-CAMs", "GENE_OR_GENE_PRODUCT", 110, 118], ["ITAM", "GENE_OR_GENE_PRODUCT", 126, 130], ["CEACAM", "GENE_OR_GENE_PRODUCT", 142, 148], ["Myotis lucifugus", "ORGANISM", 182, 198], ["CEACAM1L1", "GENE_OR_GENE_PRODUCT", 200, 209], ["CEACAM1L2", "GENE_OR_GENE_PRODUCT", 211, 220], ["CEACAM3L1", "GENE_OR_GENE_PRODUCT", 225, 234], ["CEA", "GENE_OR_GENE_PRODUCT", 295, 298], ["IgV", "GENE_OR_GENE_PRODUCT", 391, 394], ["IgC", "GENE_OR_GENE_PRODUCT", 422, 425], ["ligand-binding domain", "PROTEIN", 48, 69], ["ITIM", "PROTEIN", 94, 98], ["CEA", "PROTEIN", 110, 113], ["CAMs", "PROTEIN", 114, 118], ["ITAM", "PROTEIN", 126, 130], ["CEACAM", "PROTEIN", 142, 148], ["CEACAMs", "PROTEIN", 171, 178], ["CEACAM1L1", "PROTEIN", 200, 209], ["CEACAM1L2", "PROTEIN", 211, 220], ["CEACAM3L1", "PROTEIN", 225, 234], ["CEA gene family", "DNA", 295, 310], ["IgV", "PROTEIN", 391, 394], ["IgC", "PROTEIN", 422, 425], ["Myotis lucifugus", "SPECIES", 182, 198], ["Myotis lucifugus", "SPECIES", 182, 198], ["the ligand-binding domain", "PROBLEM", 44, 69], ["ITIM", "TEST", 94, 98], ["CEA", "TEST", 110, 113], ["an ITAM", "TEST", 123, 130], ["CEACAM", "TREATMENT", 142, 148], ["Myotis lucifugus", "PROBLEM", 182, 198], ["CEACAM1L1/ CEACAM1L2 and CEACAM3L1)", "TREATMENT", 200, 235], ["a single IgV-like domain", "PROBLEM", 382, 406], ["enormous", "OBSERVATION_MODIFIER", 269, 277], ["expansion", "OBSERVATION_MODIFIER", 278, 287], ["CEA", "ANATOMY", 295, 298]]], ["The IgC-like domains are of the A2 type (named according to the most similar IgC-like domain of CEACAM1) and are encoded by exons which have either stop codons (at the beginning of the exon) or mutated splice donor sites.", [["IgC", "GENE_OR_GENE_PRODUCT", 4, 7], ["A2", "GENE_OR_GENE_PRODUCT", 32, 34], ["IgC", "GENE_OR_GENE_PRODUCT", 77, 80], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 96, 103], ["IgC", "PROTEIN", 4, 7], ["A2 type", "PROTEIN", 32, 39], ["IgC", "PROTEIN", 77, 80], ["CEACAM1", "PROTEIN", 96, 103], ["exons", "DNA", 124, 129], ["exon", "DNA", 185, 189], ["mutated splice donor sites", "DNA", 194, 220], ["The IgC", "TEST", 0, 7], ["stop codons", "PROBLEM", 148, 159], ["mutated splice donor sites", "PROBLEM", 194, 220], ["A2 type", "OBSERVATION_MODIFIER", 32, 39]]], ["The mutation of the splice donor site creates a stop codon which is followed in near proximity by a polyadenylation signal.", [["splice donor site", "DNA", 20, 37], ["stop codon", "DNA", 48, 58], ["The mutation of the splice donor site", "PROBLEM", 0, 37], ["a stop codon", "PROBLEM", 46, 58], ["a polyadenylation signal", "PROBLEM", 98, 122], ["stop codon", "OBSERVATION", 48, 58], ["polyadenylation signal", "OBSERVATION", 100, 122]]], ["The presence of a leader sequence indicates that these molecules are secreted.", [["a leader sequence", "TEST", 16, 33]]], ["Indeed, this is besides expression by trophoblast cells (which could not be demonstrated directly due to lack of bat placental tissues), the most important classification criterion for PSGs.", [["trophoblast cells", "ANATOMY", 38, 55], ["placental tissues", "ANATOMY", 117, 134], ["PSGs", "DISEASE", 185, 189], ["trophoblast cells", "CELL", 38, 55], ["bat", "ORGANISM", 113, 116], ["placental tissues", "TISSUE", 117, 134], ["PSGs", "CANCER", 185, 189], ["trophoblast cells", "CELL_TYPE", 38, 55], ["trophoblast cells", "PROBLEM", 38, 55], ["lack of bat placental tissues", "PROBLEM", 105, 134], ["trophoblast cells", "OBSERVATION", 38, 55], ["placental tissues", "ANATOMY", 117, 134]]], ["The closer relationship of the ligand-binding domains (IgV-like domain) between PSGs than to other CEACAMs in a given species represents a b c d an additional criterion.", [["PSGs", "CANCER", 80, 84], ["CEACAMs", "CANCER", 99, 106], ["ligand-binding domains", "PROTEIN", 31, 53], ["IgV", "PROTEIN", 55, 58], ["like domain", "PROTEIN", 59, 70], ["PSGs", "PROTEIN", 80, 84], ["CEACAMs", "PROTEIN", 99, 106], ["the ligand-binding domains", "PROBLEM", 27, 53], ["PSGs", "TREATMENT", 80, 84], ["other CEACAMs", "PROBLEM", 93, 106]]], ["Indeed this is the case for bat PSGs.", [["bat", "ORGANISM", 28, 31], ["PSGs", "PATHOLOGICAL_FORMATION", 32, 36], ["bat PSGs", "TREATMENT", 28, 36]]], ["Remarkably, the structure of bat PSGs is very similar to the PSGs recently found in the horse [21] suggesting that both have a common ancestor.", [["bat", "ORGANISM", 29, 32], ["PSGs", "GENE_OR_GENE_PRODUCT", 33, 37], ["PSGs", "GENE_OR_GENE_PRODUCT", 61, 65], ["bat PSGs", "PROTEIN", 29, 37], ["PSGs", "PROTEIN", 61, 65], ["horse", "SPECIES", 88, 93], ["bat PSGs", "OBSERVATION", 29, 37]]], ["Indeed the phylogenetic relationship of bats within Laurasiatheria is still a matter of debate, however several lines of evidence point to a close relationship of bats and horses [23] .", [["Laurasiatheria", "CHEMICAL", 52, 66]]], ["For example, Zhang and colleagues used 2492 nuclearencoded genes to perform maximum-likelihood and Bayesian phylogenomic analysis.", [["2492 nuclearencoded genes", "DNA", 39, 64], ["Bayesian phylogenomic analysis", "TEST", 99, 129]]], ["Their results vigorously supported bats as a member of Pegasoferae (Chiroptera + Perissodactyla + Carnivora), with the bat lineage diverging from the Equus (horse) lineage~88 million years ago [12] .", [["bats", "ORGANISM", 35, 39], ["Pegasoferae", "ORGANISM", 55, 66], ["Chiroptera + Perissodactyla + Carnivora", "ORGANISM", 68, 107], ["horse", "ORGANISM_SUBDIVISION", 157, 162], ["horse", "SPECIES", 157, 162], ["Pegasoferae (Chiroptera + Perissodactyla + Carnivora", "TREATMENT", 55, 107]]], ["Interestingly, phylogenetic analysis indicated that two main groups of PSGs exist in bats.", [["PSGs", "GENE_OR_GENE_PRODUCT", 71, 75], ["bats", "ORGANISM", 85, 89], ["PSGs", "PROTEIN", 71, 75], ["phylogenetic analysis", "TEST", 15, 36]]], ["Both groups contain an almost equal number of PSGs in Vespertilionidae.", [["PSGs", "DISEASE", 46, 50], ["PSGs", "GENE_OR_GENE_PRODUCT", 46, 50], ["PSGs in Vespertilionidae", "TREATMENT", 46, 70]]], ["In the more distantly related Pteronotus parnellii PSGs of subgroup II expanded preferentially (Fig. 5) .", [["Pteronotus parnellii", "ORGANISM", 30, 50], ["Pteronotus parnellii PSGs", "CELL_LINE", 30, 55], ["Pteronotus parnellii", "SPECIES", 30, 50], ["Pteronotus parnellii", "SPECIES", 30, 50], ["Pteronotus parnellii", "OBSERVATION", 30, 50], ["subgroup II", "OBSERVATION_MODIFIER", 59, 70], ["expanded", "OBSERVATION_MODIFIER", 71, 79], ["preferentially", "OBSERVATION_MODIFIER", 80, 94]]], ["Taken together our data imply that the PSG group II is the more primordial PSG group being present in all analyzed representatives of the Yangochiroptera.", [["PSG group II", "PROTEIN", 39, 51], ["primordial PSG", "OBSERVATION", 64, 78]]], ["The ancestor of PSGs group I may have arisen in a common ancestor of the Miniopteridae and the Vespertilionidae.DiscussionWhat is the reason for the selective expansion of the PSGs in certain families of Yangochiroptera?", [["PSGs", "GENE_OR_GENE_PRODUCT", 16, 20], ["Miniopteridae", "CANCER", 73, 86], ["PSGs", "CANCER", 176, 180], ["Yangochiroptera", "GENE_OR_GENE_PRODUCT", 204, 219], ["the Miniopteridae", "TREATMENT", 69, 86], ["the Vespertilionidae", "TREATMENT", 91, 111]]], ["Until now PSGs are only described in species having a hemochorial placenta [11] .", [["hemochorial placenta", "ANATOMY", 54, 74], ["PSGs", "GENE_OR_GENE_PRODUCT", 10, 14], ["PSGs", "PROTEIN", 10, 14], ["PSGs", "PROBLEM", 10, 14], ["a hemochorial placenta", "PROBLEM", 52, 74]]], ["This is the case for all bat species with PSGs.", [["PSGs", "CANCER", 42, 46]]], ["However, hemochorial placentae are also common within the Yinpterochiroptera suborder; this may suggest that a second prerequisite is needed to lead to PSG expansion.", [["hemochorial placentae", "ANATOMY", 9, 30], ["hemochorial placentae", "ORGANISM", 9, 30], ["hemochorial placentae", "PROBLEM", 9, 30], ["PSG expansion", "TEST", 152, 165], ["hemochorial placentae", "OBSERVATION", 9, 30], ["may suggest", "UNCERTAINTY", 92, 103]]], ["This view is further supported by our previous observation that PSGs did not evolve in hedgehogs, which have also a hemochorial placenta [11] .", [["hemochorial placenta", "ANATOMY", 116, 136], ["PSGs", "GENE_OR_GENE_PRODUCT", 64, 68], ["a hemochorial placenta", "PROBLEM", 114, 136]]], ["The most obvious prerequisite is that a primordial PSG is created by duplication of a CEA gene family member.", [["CEA", "GENE_OR_GENE_PRODUCT", 86, 89], ["CEA gene family member", "DNA", 86, 108], ["a primordial PSG", "PROBLEM", 38, 54], ["most obvious", "OBSERVATION_MODIFIER", 4, 16], ["primordial PSG", "OBSERVATION", 40, 54]]], ["This would be a random event with a limited frequency, only occurring in restricted number of mammals with a hemochorial placenta.", [["hemochorial placenta", "ANATOMY", 109, 129], ["hemochorial placenta", "TISSUE", 109, 129], ["a random event", "PROBLEM", 14, 28], ["a hemochorial placenta", "PROBLEM", 107, 129], ["hemochorial placenta", "OBSERVATION", 109, 129]]], ["A second possibility is that a hemochorial placenta is not sufficient to drive PSG evolution but additional specific features of the hemochorial placenta, like special blood flow conditions, invasion depth or immunological challenges are necessary.", [["hemochorial placenta", "ANATOMY", 31, 51], ["hemochorial placenta", "ANATOMY", 133, 153], ["blood", "ANATOMY", 168, 173], ["hemochorial placenta", "TISSUE", 31, 51], ["hemochorial placenta", "MULTI-TISSUE_STRUCTURE", 133, 153], ["blood", "ORGANISM_SUBSTANCE", 168, 173], ["a hemochorial placenta", "PROBLEM", 29, 51], ["the hemochorial placenta", "PROBLEM", 129, 153], ["special blood flow conditions", "PROBLEM", 160, 189], ["invasion depth", "PROBLEM", 191, 205], ["immunological challenges", "TREATMENT", 209, 233], ["hemochorial placenta", "OBSERVATION", 31, 51], ["hemochorial placenta", "ANATOMY", 133, 153]]], ["Indeed, it is well known that placentation of bats is extremely diverse and therefore even placentae with a hemochorial interface may differ considerably [27, 28] .DiscussionOn the other hand the very recent and massive expansion of PSGs makes maternal-fetal communication as the only driving force for PSG evolution in microbats questionable.", [["placentae", "ANATOMY", 91, 100], ["fetal", "ANATOMY", 253, 258], ["PSGs", "DISEASE", 233, 237], ["bats", "ORGANISM", 46, 50], ["placentae", "ORGAN", 91, 100], ["PSGs", "CANCER", 233, 237], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 253, 258], ["microbats", "CANCER", 320, 329], ["a hemochorial interface", "PROBLEM", 106, 129], ["massive expansion of PSGs", "PROBLEM", 212, 237], ["PSG evolution", "TEST", 303, 316], ["massive", "OBSERVATION_MODIFIER", 212, 219], ["expansion", "OBSERVATION", 220, 229]]], ["In particular, positive selection point to an interaction with fast evolving ligands.", [["positive", "OBSERVATION_MODIFIER", 15, 23], ["selection", "OBSERVATION", 24, 33]]], ["Ligands fulfilling such requirements are for example pathogen receptors.", [["pathogen receptors", "PROTEIN", 53, 71], ["example pathogen receptors", "PROBLEM", 45, 71]]], ["Indeed several pathogens were described to bind to certain CEACAMs.", [["CEACAMs", "GENE_OR_GENE_PRODUCT", 59, 66], ["CEACAMs", "PROTEIN", 59, 66], ["several pathogens", "PROBLEM", 7, 24], ["several", "OBSERVATION_MODIFIER", 7, 14], ["pathogens", "OBSERVATION", 15, 24]]], ["In humans a variety of bacterial pathogens were identified that bind to various human CEACAMs [29] [30] [31] [32] [33] [34] [35] .", [["humans", "ORGANISM", 3, 9], ["human", "ORGANISM", 80, 85], ["CEACAMs [29] [30] [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 86, 128], ["humans", "SPECIES", 3, 9], ["human", "SPECIES", 80, 85], ["humans", "SPECIES", 3, 9], ["human", "SPECIES", 80, 85], ["bacterial pathogens", "PROBLEM", 23, 42], ["various human CEACAMs", "TEST", 72, 93]]], ["Furthermore, mouse hepatitis virus, which belongs to the corona viridae group 2 uses CEA-CAM1 as a cellular receptor to infect susceptible hosts [36, 37] .", [["cellular", "ANATOMY", 99, 107], ["hepatitis virus", "DISEASE", 19, 34], ["mouse hepatitis virus", "ORGANISM", 13, 34], ["CEA-CAM1", "GENE_OR_GENE_PRODUCT", 85, 93], ["cellular", "CELL", 99, 107], ["CEA", "PROTEIN", 85, 88], ["CAM1", "PROTEIN", 89, 93], ["cellular receptor", "PROTEIN", 99, 116], ["mouse", "SPECIES", 13, 18], ["hepatitis virus", "SPECIES", 19, 34], ["mouse hepatitis virus", "SPECIES", 13, 34], ["mouse hepatitis virus", "PROBLEM", 13, 34], ["CEA", "TEST", 85, 88], ["hepatitis virus", "OBSERVATION", 19, 34]]], ["Bats are known to be prominent reservoirs for corona viruses and therefore it is worthwhile to speculate that in microbats viruses exist or have existed that interact with bat CEACAMs.", [["Bats", "CELL", 0, 4], ["corona viruses", "ORGANISM", 46, 60], ["microbats viruses", "ORGANISM", 113, 130], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 176, 183], ["bat CEACAMs", "PROTEIN", 172, 183], ["corona viruses", "PROBLEM", 46, 60], ["microbats viruses", "PROBLEM", 113, 130], ["known to be", "UNCERTAINTY", 9, 20], ["prominent", "OBSERVATION_MODIFIER", 21, 30], ["reservoirs", "OBSERVATION", 31, 41], ["corona", "OBSERVATION_MODIFIER", 46, 52], ["viruses", "OBSERVATION", 53, 60]]], ["Indeed, recently a bat corona virus of group 2 was isolated from the common vampire bat Desmodus rotundus [38] .", [["bat corona virus", "ORGANISM", 19, 35], ["Desmodus rotundus", "ORGANISM", 88, 105], ["Desmodus rotundus", "SPECIES", 88, 105], ["bat corona virus", "SPECIES", 19, 35], ["Desmodus rotundus", "SPECIES", 88, 105], ["a bat corona virus of group 2", "PROBLEM", 17, 46]]], ["Secreted proteins with some similarities to these CEACAMs may function as decoy receptors and thereby limit virus binding to their cellular receptor.", [["cellular", "ANATOMY", 131, 139], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 50, 57], ["cellular", "CELL", 131, 139], ["Secreted proteins", "PROTEIN", 0, 17], ["CEACAMs", "PROTEIN", 50, 57], ["decoy receptors", "PROTEIN", 74, 89], ["cellular receptor", "PROTEIN", 131, 148], ["Secreted proteins", "PROBLEM", 0, 17], ["decoy receptors", "PROBLEM", 74, 89], ["thereby limit virus binding", "PROBLEM", 94, 121]]], ["Such an interpretation would be consistent with a rapid expansion and a positive selection of the decoy receptors.", [["decoy receptors", "PROTEIN", 98, 113], ["a rapid expansion", "PROBLEM", 48, 65], ["consistent with", "UNCERTAINTY", 32, 47], ["rapid", "OBSERVATION_MODIFIER", 50, 55], ["expansion", "OBSERVATION", 56, 65]]], ["This hypothesis is even more exciting for secreted proteins at the maternal-fetal interface, which could be involved in the prevention of transplacental infection.", [["fetal", "ANATOMY", 76, 81], ["transplacental infection", "DISEASE", 138, 162], ["fetal interface", "MULTI-TISSUE_STRUCTURE", 76, 91], ["secreted proteins", "PROTEIN", 42, 59], ["secreted proteins", "PROBLEM", 42, 59], ["transplacental infection", "PROBLEM", 138, 162], ["fetal interface", "OBSERVATION", 76, 91], ["transplacental", "OBSERVATION_MODIFIER", 138, 152], ["infection", "OBSERVATION", 153, 162]]], ["We further speculate that such a mechanism of innate immunity may be especially beneficial for an order of mammals that live in large colonies with synchronized pregnancies and an extraordinary close contact to other individuals.", [["colonies", "ANATOMY", 134, 142], ["large colonies", "PROBLEM", 128, 142], ["synchronized pregnancies", "PROBLEM", 148, 172], ["large", "OBSERVATION_MODIFIER", 128, 133], ["colonies", "OBSERVATION", 134, 142]]], ["The rapid expansion of PSGs in certain bat species together with selection for diversification suggest that bat PSGs could be part of a pathogen defense system by serving as decoy receptors and/or regulators of fetomaternal interactions.ConclusionsPSGs are a subgroup of the CEA family.", [["PSGs", "CHEMICAL", 112, 116], ["PSGs", "GENE_OR_GENE_PRODUCT", 23, 27], ["bat", "ORGANISM", 108, 111], ["PSGs", "GENE_OR_GENE_PRODUCT", 112, 116], ["CEA", "GENE_OR_GENE_PRODUCT", 275, 278], ["PSGs", "PROTEIN", 23, 27], ["decoy receptors", "PROTEIN", 174, 189], ["CEA family", "PROTEIN", 275, 285], ["The rapid expansion of PSGs", "PROBLEM", 0, 27], ["diversification", "TREATMENT", 79, 94], ["bat PSGs", "PROBLEM", 108, 116], ["a pathogen defense system", "PROBLEM", 134, 159], ["fetomaternal interactions", "PROBLEM", 211, 236], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["expansion", "OBSERVATION_MODIFIER", 10, 19], ["PSGs", "OBSERVATION", 23, 27], ["CEA", "ANATOMY", 275, 278]]], ["We and others have suggested that maternal-fetal interactions are the drivers of the expansion of PSGs in some mammalian species, including humans and rodents.", [["fetal", "ANATOMY", 43, 48], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 43, 48], ["PSGs", "GENE_OR_GENE_PRODUCT", 98, 102], ["humans", "ORGANISM", 140, 146], ["humans", "SPECIES", 140, 146], ["humans", "SPECIES", 140, 146], ["maternal-fetal interactions", "PROBLEM", 34, 61], ["the expansion of PSGs", "PROBLEM", 81, 102], ["some mammalian species", "PROBLEM", 106, 128], ["mammalian species", "OBSERVATION", 111, 128]]], ["Both higher primates and rodents have a hemochorialData sets and nomenclature of genesSequence similarity searches were performed using the NCBI BLAST tools \"blastn\" http://blast.ncbi.nlm.nih.gov/ Blast.cgi and Ensembl BLAST/BLAT search programs http://www.ensembl.org/Multi/Tools/Blast?db=core using default parameters.", [["NCBI BLAST tools", "DNA", 140, 156], ["Blast.cgi and Ensembl BLAST", "DNA", 197, 224], ["a hemochorialData sets", "PROBLEM", 38, 60], ["Sequence similarity searches", "TEST", 86, 114], ["Ensembl BLAST", "TEST", 211, 224], ["default parameters", "TEST", 301, 319], ["Ensembl BLAST", "OBSERVATION", 211, 224]]], ["For identification of bat CEACAM exons, exon and cDNA sequences from known CEACAM and PSG genes were used to search \"whole-genome shotgun contigs (wgs)\" databases limited to organism \"Chiroptera (taxid:9397)\".", [["CEACAM", "GENE_OR_GENE_PRODUCT", 26, 32], ["CEACAM", "GENE_OR_GENE_PRODUCT", 75, 81], ["bat CEACAM exons", "DNA", 22, 38], ["cDNA sequences", "DNA", 49, 63], ["CEACAM and PSG genes", "DNA", 75, 95], ["bat CEACAM exons", "TREATMENT", 22, 38], ["exon and cDNA sequences", "TEST", 40, 63], ["known CEACAM", "PROBLEM", 69, 81], ["PSG genes", "TREATMENT", 86, 95]]], ["Hits were considered to be significant if the E-value was < e-10 and the query cover was >50%.", [["the E-value", "TEST", 42, 53]]], ["Once a wgs contig was identified that contained CEACAM-related sequences we confirmed manually the presence of the complete exon by the number of nucleotides and identification of CEACAM-typical splice site sequences.", [["nucleotides", "CHEMICAL", 146, 157], ["CEACAM", "GENE_OR_GENE_PRODUCT", 48, 54], ["CEACAM", "GENE_OR_GENE_PRODUCT", 180, 186], ["wgs contig", "DNA", 7, 17], ["CEACAM-related sequences", "DNA", 48, 72], ["exon", "DNA", 124, 128], ["CEACAM-typical splice site sequences", "DNA", 180, 216], ["a wgs contig", "TEST", 5, 17], ["CEACAM", "TEST", 48, 54], ["CEACAM", "TEST", 180, 186]]], ["Only sequences which were considered to be complete exons were used for further analyses.", [["exons", "DNA", 52, 57], ["further analyses", "TEST", 72, 88]]], ["In a second step we used the identified exon sequences to search the database limited to this bat species in order to identify all existing paralogous CEACAM genes.", [["CEACAM", "GENE_OR_GENE_PRODUCT", 151, 157], ["exon sequences", "DNA", 40, 54], ["CEACAM genes", "DNA", 151, 163], ["exon sequences", "TEST", 40, 54], ["the database", "TEST", 65, 77], ["this bat species", "PROBLEM", 89, 105], ["CEACAM genes", "OBSERVATION", 151, 163]]], ["In some species we performed several rounds of searches using sequences of distantly related CEACAMs in a given species.", [["CEACAMs", "GENE_OR_GENE_PRODUCT", 93, 100], ["CEACAMs", "DNA", 93, 100], ["searches", "TREATMENT", 47, 55], ["distantly related CEACAMs", "PROBLEM", 75, 100]]], ["Once we had identified individual exons we predicted the gene structure according to known CEACAMs.", [["CEACAMs", "GENE_OR_GENE_PRODUCT", 91, 98], ["exons", "DNA", 34, 39], ["CEACAMs", "DNA", 91, 98], ["individual exons", "PROBLEM", 23, 39]]], ["The location of different exons on the same contig was a prerequisite for considering that these exons belong to the same gene.", [["exons", "DNA", 26, 31], ["exons", "DNA", 97, 102], ["these exons", "TREATMENT", 91, 102], ["different", "OBSERVATION_MODIFIER", 16, 25], ["exons", "OBSERVATION_MODIFIER", 26, 31]]], ["Short exons, like exons coding for the cytoplasmic tail, were identified by alignments of downstream sequences of identified transmembrane exons with cytoplasmic exon sequences of human CEACAMs.Data sets and nomenclature of genesSequence alignments for exon identification was performed using clustalw (http://www.genome.jp/tools/clustalw/).", [["cytoplasmic tail", "ANATOMY", 39, 55], ["transmembrane", "ANATOMY", 125, 138], ["cytoplasmic", "ANATOMY", 150, 161], ["cytoplasmic tail", "CELLULAR_COMPONENT", 39, 55], ["transmembrane", "CELLULAR_COMPONENT", 125, 138], ["cytoplasmic", "ORGANISM_SUBSTANCE", 150, 161], ["human", "ORGANISM", 180, 185], ["CEACAMs", "CANCER", 186, 193], ["exons", "DNA", 6, 11], ["exons", "DNA", 18, 23], ["cytoplasmic tail", "PROTEIN", 39, 55], ["downstream sequences", "DNA", 90, 110], ["transmembrane exons", "DNA", 125, 144], ["cytoplasmic exon sequences", "DNA", 150, 176], ["human CEACAMs", "PROTEIN", 180, 193], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["Short exons", "PROBLEM", 0, 11], ["the cytoplasmic tail", "TEST", 35, 55], ["transmembrane exons", "PROBLEM", 125, 144], ["cytoplasmic exon sequences of human CEACAMs", "PROBLEM", 150, 193], ["Data sets", "TEST", 194, 203], ["Sequence alignments", "TEST", 229, 248], ["exon identification", "TEST", 253, 272], ["tail", "ANATOMY", 51, 55], ["transmembrane exons", "OBSERVATION", 125, 144], ["cytoplasmic exon", "OBSERVATION", 150, 166]]], ["The following wgs data sets were used: The CEA gene family in bats is not well annotated; therefore, we adopted the nomenclature according to the one previously used for the CEA gene family of other mammals [11] .", [["CEA", "GENE_OR_GENE_PRODUCT", 43, 46], ["CEA", "GENE_OR_GENE_PRODUCT", 174, 177], ["CEA gene family", "DNA", 43, 58], ["CEA gene family", "DNA", 174, 189]]], ["Gene names and corresponding sequences are summarized in (Additional file 1).Phylogenetic analysesPhylogenetic analyses based on nucleotide and amino acid sequences were conducted using MEGA5 and MEGA6.", [["nucleotide", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 144, 154], ["nucleotide", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 144, 154], ["amino acid", "AMINO_ACID", 144, 154], ["MEGA5", "GENE_OR_GENE_PRODUCT", 186, 191], ["MEGA6", "GENE_OR_GENE_PRODUCT", 196, 201], ["MEGA5", "PROTEIN", 186, 191], ["MEGA6", "PROTEIN", 196, 201], ["Phylogenetic analyses", "TEST", 77, 98], ["Phylogenetic analyses", "TEST", 98, 119], ["nucleotide and amino acid sequences", "TEST", 129, 164], ["MEGA5", "TREATMENT", 186, 191], ["MEGA6", "TREATMENT", 196, 201]]], ["Sequence alignments were performed using \"Muscle\".", [["Muscle", "ANATOMY", 42, 48], ["Muscle", "TISSUE", 42, 48], ["Sequence alignments", "TEST", 0, 19], ["Muscle", "ANATOMY", 42, 48]]], ["The maximum likelihood (ML) method with bootstrap testing (500 replicates) was applied for the construction of phylogenetic trees.", [["The maximum likelihood (ML) method", "TREATMENT", 0, 34], ["bootstrap testing", "TEST", 40, 57], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["phylogenetic trees", "OBSERVATION", 111, 129]]], ["To determine the selective pressure on the maintenance of the nucleotide sequences, the number of nonsynonymous nucleotide substitution per nonsynonymous site (dN) and the number of synonymous substitutions per synonymous site (dS) were determined for N domain exons.", [["nucleotide", "CHEMICAL", 62, 72], ["nucleotide", "CHEMICAL", 112, 122], ["nucleotide", "CHEMICAL", 62, 72], ["nucleotide", "CHEMICAL", 112, 122], ["nucleotide sequences", "DNA", 62, 82], ["N domain exons", "DNA", 252, 266], ["the nucleotide sequences", "TEST", 58, 82], ["nonsynonymous nucleotide substitution", "TREATMENT", 98, 135], ["synonymous substitutions", "TREATMENT", 182, 206], ["N domain exons", "PROBLEM", 252, 266], ["selective", "OBSERVATION_MODIFIER", 17, 26], ["pressure", "OBSERVATION", 27, 35], ["nonsynonymous", "OBSERVATION", 98, 111], ["nucleotide substitution", "OBSERVATION", 112, 135], ["nonsynonymous site", "OBSERVATION", 140, 158], ["synonymous substitutions", "OBSERVATION", 182, 206]]], ["The dN/dS ratios were calculated after manual editing of sequence gaps or insertions guided by the amino acid sequences for all branches of the resulting phylogenetic trees using the Datamonkey web interface.", [["amino acid", "CHEMICAL", 99, 109], ["amino acid", "CHEMICAL", 99, 109], ["amino acid", "AMINO_ACID", 99, 109], ["The dN/dS ratios", "TEST", 0, 16], ["the amino acid sequences", "TEST", 95, 119], ["branches", "ANATOMY_MODIFIER", 128, 136], ["phylogenetic trees", "OBSERVATION", 154, 172]]], ["The mean dN/dS ratios were calculated using the single likelihood ancestor counting (SLAC) algorithm.", [["The mean dN/dS ratios", "TEST", 0, 21]]], ["The synonymous nonsynonymous analysis program (SNAP; http://www.hiv.lanl.gov/ content/sequence/SNAP/SNAP.html) allowed the calculation of cumulative average synonymous and nonsynonymous substitutions along coding regions of N domain exons from paralogous and orthologous genes.", [["N domain exons", "DNA", 224, 238], ["paralogous and orthologous genes", "DNA", 244, 276], ["The synonymous nonsynonymous analysis", "TEST", 0, 37], ["SNAP", "TEST", 47, 51], ["cumulative average synonymous", "TREATMENT", 138, 167], ["nonsynonymous substitutions", "PROBLEM", 172, 199], ["N domain exons from paralogous and orthologous genes", "PROBLEM", 224, 276], ["nonsynonymous substitutions", "OBSERVATION", 172, 199], ["orthologous genes", "OBSERVATION", 259, 276]]], ["For the identification of N domain-wide episodic selection we used a branch-site unrestricted statistical test for episodic diversification (BUSTED) approach [39] .", [["N domain", "PROTEIN", 26, 34], ["N domain", "PROBLEM", 26, 34], ["wide episodic selection", "TREATMENT", 35, 58], ["episodic diversification (BUSTED) approach", "TREATMENT", 115, 157]]], ["For the detection of individual sites under positive selection we used the mixed effects model of evolution software (MEME) [40] after screening for recombination using the genetic algorithm for recombination detection (GARD) software [41] .", [["individual sites", "PROBLEM", 21, 37], ["positive selection", "TREATMENT", 44, 62], ["screening", "TEST", 135, 144], ["the genetic algorithm", "TEST", 169, 190]]]], "PMC7256909": [], "e9a2f6758ce1aeaf80f826a1ca87c85190d3228c": [["IntroductionLungs are repeatedly divulged to several environmental stimuli including chemicals, dust, pollen along with numerous microorganisms.", [["pollen", "ANATOMY", 102, 108], ["dust", "PROBLEM", 96, 100], ["numerous microorganisms", "PROBLEM", 120, 143]]], ["Composite nasal passage geometry, airways branching pattern, secretion of mucus and soluble mediators like surfactant proteins, lysozyme, secretory IgA and antimicrobial peptides are the exemplifications of host defences.", [["nasal", "ANATOMY", 10, 15], ["airways", "ANATOMY", 34, 41], ["mucus", "ANATOMY", 74, 79], ["airways", "MULTI-TISSUE_STRUCTURE", 34, 41], ["mucus", "ORGANISM_SUBSTANCE", 74, 79], ["soluble mediators like surfactant proteins", "GENE_OR_GENE_PRODUCT", 84, 126], ["lysozyme", "GENE_OR_GENE_PRODUCT", 128, 136], ["secretory IgA", "GENE_OR_GENE_PRODUCT", 138, 151], ["antimicrobial peptides", "GENE_OR_GENE_PRODUCT", 156, 178], ["soluble mediators", "PROTEIN", 84, 101], ["surfactant proteins", "PROTEIN", 107, 126], ["lysozyme", "PROTEIN", 128, 136], ["secretory IgA", "PROTEIN", 138, 151], ["Composite nasal passage geometry", "TREATMENT", 0, 32], ["mucus and soluble mediators", "TREATMENT", 74, 101], ["surfactant proteins", "TREATMENT", 107, 126], ["lysozyme", "TREATMENT", 128, 136], ["antimicrobial peptides", "TREATMENT", 156, 178], ["nasal", "ANATOMY", 10, 15], ["passage geometry", "OBSERVATION", 16, 32], ["airways", "ANATOMY", 34, 41], ["branching", "ANATOMY_MODIFIER", 42, 51], ["host defences", "OBSERVATION", 207, 220]]], ["Furthermore, alveolar macrophages and dendritic cells provide a perpetual vigilance for pathogenic components.", [["alveolar macrophages", "ANATOMY", 13, 33], ["dendritic cells", "ANATOMY", 38, 53], ["alveolar macrophages", "CELL", 13, 33], ["dendritic cells", "CELL", 38, 53], ["alveolar macrophages", "CELL_TYPE", 13, 33], ["dendritic cells", "CELL_TYPE", 38, 53], ["alveolar macrophages", "PROBLEM", 13, 33], ["dendritic cells", "PROBLEM", 38, 53], ["pathogenic components", "PROBLEM", 88, 109], ["alveolar macrophages", "OBSERVATION", 13, 33], ["dendritic cells", "OBSERVATION", 38, 53]]], ["At the same time, they are also implicated in inhibiting T cell responses against non-pathogenic antigens [1] .", [["T cell", "ANATOMY", 57, 63], ["T cell", "CELL", 57, 63], ["non-pathogenic antigens", "PROTEIN", 82, 105], ["non-pathogenic antigens", "PROBLEM", 82, 105]]], ["These normal processes of host defences are trivial, but an inflammatory response is anticipated in case of a prolonged exposure to pathogenic antigens or highly virulent microbes.", [["pathogenic antigens", "PROTEIN", 132, 151], ["an inflammatory response", "PROBLEM", 57, 81], ["a prolonged exposure to pathogenic antigens", "PROBLEM", 108, 151], ["normal", "OBSERVATION", 6, 12], ["host defences", "OBSERVATION", 26, 39], ["trivial", "OBSERVATION_MODIFIER", 44, 51], ["inflammatory", "OBSERVATION", 60, 72], ["highly", "OBSERVATION_MODIFIER", 155, 161], ["virulent", "OBSERVATION_MODIFIER", 162, 170]]], ["Prompt commencement of an inflammatory response is accomplished with the help of unique and conserved Pattern recognition receptors (PRRs) present on the surface of myeloid cells, lung epithelial cells and lymphoid tissue.", [["surface", "ANATOMY", 154, 161], ["myeloid cells", "ANATOMY", 165, 178], ["lung epithelial cells", "ANATOMY", 180, 201], ["lymphoid tissue", "ANATOMY", 206, 221], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 102, 131], ["PRRs", "GENE_OR_GENE_PRODUCT", 133, 137], ["surface", "CELLULAR_COMPONENT", 154, 161], ["myeloid cells", "CELL", 165, 178], ["lung epithelial cells", "CELL", 180, 201], ["lymphoid tissue", "TISSUE", 206, 221], ["Pattern recognition receptors", "PROTEIN", 102, 131], ["PRRs", "PROTEIN", 133, 137], ["myeloid cells", "CELL_TYPE", 165, 178], ["lung epithelial cells", "CELL_TYPE", 180, 201], ["an inflammatory response", "PROBLEM", 23, 47], ["myeloid cells", "PROBLEM", 165, 178], ["lung epithelial cells", "PROBLEM", 180, 201], ["lymphoid tissue", "PROBLEM", 206, 221], ["inflammatory", "OBSERVATION", 26, 38], ["myeloid cells", "OBSERVATION", 165, 178], ["lung", "ANATOMY", 180, 184], ["epithelial cells", "OBSERVATION", 185, 201], ["lymphoid tissue", "OBSERVATION", 206, 221]]], ["PRRs comprise of Toll like receptors (TLRs), RIG-I like receptors (RLRs) and NOD like receptors (NLRs).", [["Toll like receptors", "GENE_OR_GENE_PRODUCT", 17, 36], ["TLRs", "GENE_OR_GENE_PRODUCT", 38, 42], ["RIG-I like receptors", "GENE_OR_GENE_PRODUCT", 45, 65], ["RLRs", "GENE_OR_GENE_PRODUCT", 67, 71], ["NOD like receptors", "GENE_OR_GENE_PRODUCT", 77, 95], ["NLRs", "GENE_OR_GENE_PRODUCT", 97, 101], ["PRRs", "PROTEIN", 0, 4], ["Toll like receptors", "PROTEIN", 17, 36], ["TLRs", "PROTEIN", 38, 42], ["RIG-I like receptors", "PROTEIN", 45, 65], ["RLRs", "PROTEIN", 67, 71], ["NOD like receptors", "PROTEIN", 77, 95], ["NLRs", "PROTEIN", 97, 101]]], ["These receptors are activated upon binding to their respective ligands, which trigger the release of cytokines and chemokines that calls for recruitment of antigen presenting cells and leukocytes at the site of infection and consequently induces the adaptive immunity [2] .IntroductionPerpetual communication of respiratory tract with the environmental stimuli put a constraint on the host immune system to differentiate innoxious and pathogenic exposures in a robust manner.", [["antigen presenting cells", "ANATOMY", 156, 180], ["leukocytes", "ANATOMY", 185, 195], ["respiratory tract", "ANATOMY", 312, 329], ["infection", "DISEASE", 211, 220], ["cells", "CELL", 175, 180], ["leukocytes", "CELL", 185, 195], ["respiratory tract", "ORGANISM_SUBDIVISION", 312, 329], ["cytokines", "PROTEIN", 101, 110], ["chemokines", "PROTEIN", 115, 125], ["antigen presenting cells", "CELL_TYPE", 156, 180], ["leukocytes", "CELL_TYPE", 185, 195], ["cytokines and chemokines", "TREATMENT", 101, 125], ["antigen presenting cells", "PROBLEM", 156, 180], ["leukocytes", "PROBLEM", 185, 195], ["infection", "PROBLEM", 211, 220], ["respiratory tract", "TREATMENT", 312, 329], ["the environmental stimuli", "TEST", 335, 360], ["infection", "OBSERVATION", 211, 220], ["respiratory tract", "ANATOMY", 312, 329], ["pathogenic exposures", "OBSERVATION", 435, 455]]], ["To accomplish this, TLRs selectively recognize unique microbial patterns called Pathogen associated molecular patterns (PAMPs) [3, 4] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 20, 24], ["Pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 80, 118], ["TLRs", "PROTEIN", 20, 24], ["Pathogen associated molecular patterns", "PROTEIN", 80, 118]]], ["Lipopolysaccharide (LPS) in outer membrane of gram-negative bacteria, lipoteichoic acid and peptidoglycan in cell wall of gram-positive bacteria, flagellin of bacterial flagella, dsRNA and ssRNA of viruses etc. act as PAMPs [5] [6] [7] .", [["outer membrane", "ANATOMY", 28, 42], ["cell wall", "ANATOMY", 109, 118], ["flagella", "ANATOMY", 169, 177], ["Lipopolysaccharide", "CHEMICAL", 0, 18], ["LPS", "CHEMICAL", 20, 23], ["lipoteichoic acid", "CHEMICAL", 70, 87], ["peptidoglycan", "CHEMICAL", 92, 105], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 0, 18], ["LPS", "SIMPLE_CHEMICAL", 20, 23], ["outer membrane", "CELLULAR_COMPONENT", 28, 42], ["lipoteichoic acid", "SIMPLE_CHEMICAL", 70, 87], ["peptidoglycan", "SIMPLE_CHEMICAL", 92, 105], ["cell wall", "CELLULAR_COMPONENT", 109, 118], ["flagellin", "GENE_OR_GENE_PRODUCT", 146, 155], ["PAMPs [5] [6] [7]", "SIMPLE_CHEMICAL", 218, 235], ["flagellin", "PROTEIN", 146, 155], ["bacterial flagella", "PROTEIN", 159, 177], ["Lipopolysaccharide (LPS", "TEST", 0, 23], ["outer membrane", "TEST", 28, 42], ["gram", "TEST", 46, 50], ["negative bacteria", "PROBLEM", 51, 68], ["lipoteichoic acid", "TEST", 70, 87], ["peptidoglycan in cell wall", "TEST", 92, 118], ["gram", "TEST", 122, 126], ["positive bacteria", "PROBLEM", 127, 144], ["bacterial flagella", "PROBLEM", 159, 177], ["dsRNA", "PROBLEM", 179, 184], ["ssRNA of viruses etc", "PROBLEM", 189, 209], ["outer membrane", "ANATOMY", 28, 42], ["negative bacteria", "OBSERVATION", 51, 68], ["lipoteichoic acid", "OBSERVATION", 70, 87], ["cell", "OBSERVATION", 109, 113], ["wall", "ANATOMY_MODIFIER", 114, 118], ["positive bacteria", "OBSERVATION", 127, 144], ["bacterial flagella", "OBSERVATION", 159, 177], ["ssRNA of viruses", "OBSERVATION", 189, 205]]], ["PAMPs are recognized by the receptor called Pattern recognition receptors or PRRs present on the cells of the innate immunity, i.e. monocytes, macrophages, dendritic cells, neutrophils etc., non-immune cells like fibroblasts, endothelial cells, epithelial cells etc., and in various intercellular compartments like endosome and lysosome.", [["cells", "ANATOMY", 97, 102], ["monocytes", "ANATOMY", 132, 141], ["macrophages", "ANATOMY", 143, 154], ["dendritic cells", "ANATOMY", 156, 171], ["neutrophils", "ANATOMY", 173, 184], ["non-immune cells", "ANATOMY", 191, 207], ["fibroblasts", "ANATOMY", 213, 224], ["endothelial cells", "ANATOMY", 226, 243], ["epithelial cells", "ANATOMY", 245, 261], ["intercellular compartments", "ANATOMY", 283, 309], ["endosome", "ANATOMY", 315, 323], ["lysosome", "ANATOMY", 328, 336], ["PAMPs", "GENE_OR_GENE_PRODUCT", 0, 5], ["Pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 44, 73], ["PRRs", "GENE_OR_GENE_PRODUCT", 77, 81], ["cells", "CELL", 97, 102], ["monocytes", "CELL", 132, 141], ["macrophages", "CELL", 143, 154], ["dendritic cells", "CELL", 156, 171], ["neutrophils", "CELL", 173, 184], ["non-immune cells", "CELL", 191, 207], ["fibroblasts", "CELL", 213, 224], ["endothelial cells", "CELL", 226, 243], ["epithelial cells", "CELL", 245, 261], ["intercellular compartments", "CELLULAR_COMPONENT", 283, 309], ["endosome", "CELLULAR_COMPONENT", 315, 323], ["lysosome", "CELLULAR_COMPONENT", 328, 336], ["PAMPs", "PROTEIN", 0, 5], ["Pattern recognition receptors", "PROTEIN", 44, 73], ["PRRs", "PROTEIN", 77, 81], ["monocytes", "CELL_TYPE", 132, 141], ["macrophages", "CELL_TYPE", 143, 154], ["dendritic cells", "CELL_TYPE", 156, 171], ["neutrophils", "CELL_TYPE", 173, 184], ["non-immune cells", "CELL_TYPE", 191, 207], ["fibroblasts", "CELL_TYPE", 213, 224], ["endothelial cells", "CELL_TYPE", 226, 243], ["epithelial cells", "CELL_TYPE", 245, 261], ["PRRs", "PROBLEM", 77, 81], ["monocytes", "TEST", 132, 141], ["macrophages", "PROBLEM", 143, 154], ["dendritic cells", "PROBLEM", 156, 171], ["neutrophils", "TEST", 173, 184], ["non-immune cells", "PROBLEM", 191, 207], ["fibroblasts", "PROBLEM", 213, 224], ["endothelial cells", "TEST", 226, 243], ["epithelial cells", "PROBLEM", 245, 261], ["monocytes", "ANATOMY", 132, 141], ["macrophages", "ANATOMY", 143, 154], ["dendritic cells", "OBSERVATION", 156, 171], ["non-immune cells", "OBSERVATION", 191, 207], ["endothelial cells", "OBSERVATION", 226, 243], ["epithelial cells", "OBSERVATION", 245, 261], ["intercellular", "ANATOMY_MODIFIER", 283, 296], ["compartments", "ANATOMY_MODIFIER", 297, 309], ["endosome", "OBSERVATION", 315, 323], ["lysosome", "OBSERVATION", 328, 336]]], ["Thus, PRRs can detect extracellular as well as intracellular pathogens.", [["extracellular", "ANATOMY", 22, 35], ["intracellular", "ANATOMY", 47, 60], ["PRRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["PRRs", "PROTEIN", 6, 10], ["intracellular pathogens", "PROBLEM", 47, 70], ["pathogens", "OBSERVATION", 61, 70]]], ["There are different types of PRRs and each type can recognize multiple pathogenic species that share a particular type of PRR and TLR is one among them [3] .", [["PRRs", "GENE_OR_GENE_PRODUCT", 29, 33], ["PRR", "GENE_OR_GENE_PRODUCT", 122, 125], ["TLR", "GENE_OR_GENE_PRODUCT", 130, 133], ["PRRs", "PROTEIN", 29, 33], ["PRR", "PROTEIN", 122, 125], ["TLR", "PROTEIN", 130, 133], ["multiple pathogenic species", "PROBLEM", 62, 89], ["multiple", "OBSERVATION_MODIFIER", 62, 70], ["pathogenic species", "OBSERVATION", 71, 89]]], ["TLRs are crucial components of the innate immune system, used to recognize and defend against invading pathogens.", [["immune system", "ANATOMY", 42, 55], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "PROTEIN", 0, 4], ["the innate immune system", "TREATMENT", 31, 55], ["invading pathogens", "PROBLEM", 94, 112]]], ["Toll is a gene in fruit fly and toll-like proteins have been found in animals and are known as TLRs.", [["fruit fly", "ANATOMY", 18, 27], ["Toll", "GENE_OR_GENE_PRODUCT", 0, 4], ["fruit fly", "ORGANISM", 18, 27], ["toll-like proteins", "GENE_OR_GENE_PRODUCT", 32, 50], ["TLRs", "GENE_OR_GENE_PRODUCT", 95, 99], ["Toll", "PROTEIN", 0, 4], ["fruit fly and toll-like proteins", "PROTEIN", 18, 50], ["TLRs", "PROTEIN", 95, 99]]], ["They are conserved and there are about 10 functional TLRs (TLR1 to TLR10) in humans and 12 (TLR1 to TLR9, TLR11 to TLR13) in mice.", [["TLRs", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR1", "GENE_OR_GENE_PRODUCT", 59, 63], ["TLR10", "GENE_OR_GENE_PRODUCT", 67, 72], ["humans", "ORGANISM", 77, 83], ["TLR1", "GENE_OR_GENE_PRODUCT", 92, 96], ["TLR9", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR11", "GENE_OR_GENE_PRODUCT", 106, 111], ["TLR13", "GENE_OR_GENE_PRODUCT", 115, 120], ["mice", "ORGANISM", 125, 129], ["TLRs", "PROTEIN", 53, 57], ["TLR1", "PROTEIN", 59, 63], ["TLR10", "PROTEIN", 67, 72], ["TLR1", "PROTEIN", 92, 96], ["TLR9", "PROTEIN", 100, 104], ["TLR11", "PROTEIN", 106, 111], ["TLR13", "PROTEIN", 115, 120], ["humans", "SPECIES", 77, 83], ["mice", "SPECIES", 125, 129], ["humans", "SPECIES", 77, 83], ["mice", "SPECIES", 125, 129]]], ["Human TLRs; TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 are expressed on cell surface, while TLR3, TLR7, TLR8 and TLR9 are expressed on the membrane of intracellular vesicles [5] [6] [7] [8] .IntroductionOther than PAMPs, studies have reported the existence of Damage associated molecular patterns (DAMPs), which are known to be the ligands of TLRs.", [["cell surface", "ANATOMY", 68, 80], ["membrane", "ANATOMY", 135, 143], ["intracellular vesicles", "ANATOMY", 147, 169], ["Human", "ORGANISM", 0, 5], ["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR1", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR2", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR4", "GENE_OR_GENE_PRODUCT", 24, 28], ["TLR5", "GENE_OR_GENE_PRODUCT", 30, 34], ["TLR6", "GENE_OR_GENE_PRODUCT", 36, 40], ["TLR10", "GENE_OR_GENE_PRODUCT", 45, 50], ["cell surface", "CELLULAR_COMPONENT", 68, 80], ["TLR3", "GENE_OR_GENE_PRODUCT", 88, 92], ["TLR7", "GENE_OR_GENE_PRODUCT", 94, 98], ["TLR8", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR9", "GENE_OR_GENE_PRODUCT", 109, 113], ["membrane", "CELLULAR_COMPONENT", 135, 143], ["intracellular vesicles", "CELLULAR_COMPONENT", 147, 169], ["DAMPs", "GENE_OR_GENE_PRODUCT", 294, 299], ["TLRs", "GENE_OR_GENE_PRODUCT", 339, 343], ["Human TLRs", "PROTEIN", 0, 10], ["TLR1", "PROTEIN", 12, 16], ["TLR2", "PROTEIN", 18, 22], ["TLR4", "PROTEIN", 24, 28], ["TLR5", "PROTEIN", 30, 34], ["TLR6", "PROTEIN", 36, 40], ["TLR10", "PROTEIN", 45, 50], ["TLR3", "PROTEIN", 88, 92], ["TLR7", "PROTEIN", 94, 98], ["TLR8", "PROTEIN", 100, 104], ["TLR9", "PROTEIN", 109, 113], ["PAMPs", "PROTEIN", 210, 215], ["TLRs", "PROTEIN", 339, 343], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["TLR1", "TEST", 12, 16], ["TLR2", "TEST", 18, 22], ["TLR4", "TEST", 24, 28], ["TLR5", "TEST", 30, 34], ["TLR6", "TEST", 36, 40], ["TLR10", "TREATMENT", 45, 50], ["TLR3, TLR7, TLR8 and TLR9", "TREATMENT", 88, 113], ["studies", "TEST", 217, 224], ["Damage associated molecular patterns (DAMPs)", "PROBLEM", 256, 300]]], ["It was first suggested by studies on heat shock proteins [9] .", [["heat shock proteins", "GENE_OR_GENE_PRODUCT", 37, 56], ["heat shock proteins", "PROTEIN", 37, 56], ["heat shock proteins", "TREATMENT", 37, 56]]], ["These DAMPs originate from the host such as high mobility group box 1 (HMGB1), hyaluronan and heat shock proteins as they are released from damaged tissues [5] [6] [7] , act as danger signals to alert the cells.", [["tissues", "ANATOMY", 148, 155], ["cells", "ANATOMY", 205, 210], ["DAMPs", "GENE_OR_GENE_PRODUCT", 6, 11], ["high mobility group box 1", "GENE_OR_GENE_PRODUCT", 44, 69], ["HMGB1", "GENE_OR_GENE_PRODUCT", 71, 76], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 79, 89], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 94, 113], ["tissues", "TISSUE", 148, 155], ["cells", "CELL", 205, 210], ["DAMPs", "PROTEIN", 6, 11], ["high mobility group box 1", "PROTEIN", 44, 69], ["HMGB1", "PROTEIN", 71, 76], ["hyaluronan and heat shock proteins", "PROTEIN", 79, 113], ["These DAMPs", "PROBLEM", 0, 11], ["high mobility group box", "PROBLEM", 44, 67], ["hyaluronan and heat shock proteins", "TREATMENT", 79, 113]]], ["In case of an injury, damaged tissues release certain intracellular components into the surroundings, some of which specifically activate TLRs.", [["tissues", "ANATOMY", 30, 37], ["intracellular", "ANATOMY", 54, 67], ["tissues", "TISSUE", 30, 37], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 54, 67], ["components", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 78], ["TLRs", "GENE_OR_GENE_PRODUCT", 138, 142], ["TLRs", "PROTEIN", 138, 142], ["an injury", "PROBLEM", 11, 20], ["damaged tissues", "PROBLEM", 22, 37], ["injury", "OBSERVATION", 14, 20]]], ["Detection of endogenous ligands may also lead to the incipience of autoimmune responses.", [["endogenous ligands", "PROBLEM", 13, 31], ["autoimmune responses", "PROBLEM", 67, 87], ["endogenous ligands", "OBSERVATION", 13, 31]]], ["For instance, HMGB1 proteins normally reside in the nucleus, but when released from apoptotic cells in a complex with nucleosomes can give rise to lupus like symptoms upon activation of TLR2 [10] .", [["nucleus", "ANATOMY", 52, 59], ["cells", "ANATOMY", 94, 99], ["nucleosomes", "ANATOMY", 118, 129], ["lupus", "DISEASE", 147, 152], ["HMGB1", "GENE_OR_GENE_PRODUCT", 14, 19], ["nucleus", "CELLULAR_COMPONENT", 52, 59], ["cells", "CELL", 94, 99], ["nucleosomes", "CELLULAR_COMPONENT", 118, 129], ["TLR2", "GENE_OR_GENE_PRODUCT", 186, 190], ["HMGB1 proteins", "PROTEIN", 14, 28], ["apoptotic cells", "CELL_TYPE", 84, 99], ["nucleosomes", "PROTEIN", 118, 129], ["TLR2", "PROTEIN", 186, 190], ["HMGB1 proteins", "TEST", 14, 28], ["apoptotic cells", "PROBLEM", 84, 99], ["lupus like symptoms", "PROBLEM", 147, 166], ["nucleus", "ANATOMY", 52, 59], ["apoptotic cells", "OBSERVATION", 84, 99], ["lupus", "OBSERVATION", 147, 152]]], ["Breakdown of extracellular matrix also act as damage signals.", [["extracellular matrix", "ANATOMY", 13, 33], ["extracellular matrix", "CELLULAR_COMPONENT", 13, 33], ["Breakdown of extracellular matrix", "PROBLEM", 0, 33], ["damage signals", "TEST", 46, 60], ["extracellular matrix", "OBSERVATION", 13, 33]]], ["Similarly, ischemic injury results from temporary blood flow loss and oxygen supply.", [["blood", "ANATOMY", 50, 55], ["ischemic injury", "DISEASE", 11, 26], ["oxygen", "CHEMICAL", 70, 76], ["oxygen", "CHEMICAL", 70, 76], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["oxygen", "SIMPLE_CHEMICAL", 70, 76], ["ischemic injury", "PROBLEM", 11, 26], ["temporary blood flow loss", "TREATMENT", 40, 65], ["oxygen supply", "TREATMENT", 70, 83], ["ischemic", "OBSERVATION_MODIFIER", 11, 19], ["injury", "OBSERVATION", 20, 26], ["temporary blood", "OBSERVATION", 40, 55], ["flow loss", "OBSERVATION", 56, 65], ["oxygen supply", "OBSERVATION", 70, 83]]], ["Cell deaths during ischemia release damage signal and allow influx of WBCs, which instigate more detrimental and highly exaggerated inflammatory response [8] .IntroductionEach TLR is a horse shoe like structure with variable number of Leucine rich repeats (LRRs) at N-terminal facing the extracellular matrix, if present, on surface of the cell; while face lumen if present in intracellular vesicles.", [["Cell", "ANATOMY", 0, 4], ["WBCs", "ANATOMY", 70, 74], ["extracellular matrix", "ANATOMY", 288, 308], ["surface", "ANATOMY", 325, 332], ["cell", "ANATOMY", 340, 344], ["face lumen", "ANATOMY", 352, 362], ["intracellular vesicles", "ANATOMY", 377, 399], ["deaths", "DISEASE", 5, 11], ["ischemia", "DISEASE", 19, 27], ["Leucine", "CHEMICAL", 235, 242], ["N", "CHEMICAL", 266, 267], ["Cell", "CELL", 0, 4], ["WBCs", "CELL", 70, 74], ["TLR", "GENE_OR_GENE_PRODUCT", 176, 179], ["extracellular matrix", "CELLULAR_COMPONENT", 288, 308], ["surface", "CELLULAR_COMPONENT", 325, 332], ["cell", "CELL", 340, 344], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 357, 362], ["intracellular vesicles", "CELLULAR_COMPONENT", 377, 399], ["WBCs", "CELL_TYPE", 70, 74], ["TLR", "PROTEIN", 176, 179], ["Leucine rich repeats", "PROTEIN", 235, 255], ["LRRs", "PROTEIN", 257, 261], ["N-terminal", "PROTEIN", 266, 276], ["Cell deaths", "PROBLEM", 0, 11], ["ischemia release damage signal", "PROBLEM", 19, 49], ["influx of WBCs", "PROBLEM", 60, 74], ["highly exaggerated inflammatory response", "PROBLEM", 113, 153], ["a horse shoe like structure", "PROBLEM", 183, 210], ["Leucine rich repeats (LRRs", "TREATMENT", 235, 261], ["exaggerated", "OBSERVATION_MODIFIER", 120, 131], ["inflammatory", "OBSERVATION_MODIFIER", 132, 144], ["horse shoe", "OBSERVATION", 185, 195], ["extracellular matrix", "ANATOMY", 288, 308], ["intracellular vesicles", "ANATOMY", 377, 399]]], ["The intracellular or cytoplasmic domain is designated as Toll/IL-1R (TIR) as it shares similarity with Interleukin-1 receptor (IL-1R).", [["intracellular", "ANATOMY", 4, 17], ["cytoplasmic", "ANATOMY", 21, 32], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["cytoplasmic", "ORGANISM_SUBSTANCE", 21, 32], ["Toll", "GENE_OR_GENE_PRODUCT", 57, 61], ["IL-1R", "GENE_OR_GENE_PRODUCT", 62, 67], ["TIR", "GENE_OR_GENE_PRODUCT", 69, 72], ["Interleukin-1 receptor", "GENE_OR_GENE_PRODUCT", 103, 125], ["IL-1R", "GENE_OR_GENE_PRODUCT", 127, 132], ["intracellular or cytoplasmic domain", "PROTEIN", 4, 39], ["Toll/IL-1R", "PROTEIN", 57, 67], ["TIR", "PROTEIN", 69, 72], ["Interleukin-1 receptor (IL-1R", "PROTEIN", 103, 132], ["Interleukin", "TEST", 103, 114], ["cytoplasmic domain", "OBSERVATION", 21, 39]]], ["TIR is involved in mediating the interaction between TLR and adaptor proteins and transducing signal while LRRs is believed to recognize ligands [11] .", [["TLR", "GENE_OR_GENE_PRODUCT", 53, 56], ["LRRs", "GENE_OR_GENE_PRODUCT", 107, 111], ["TIR", "PROTEIN", 0, 3], ["TLR", "PROTEIN", 53, 56], ["adaptor proteins", "PROTEIN", 61, 77], ["LRRs", "PROTEIN", 107, 111], ["TLR and adaptor proteins", "TREATMENT", 53, 77]]], ["Signalling pathways activated downstream of the adaptor molecule interacting with TIR domain promote the expression of cytokines, chemokines, interferons, which assist in pathogen removal by recruitment of other immune cells and activation of specific adaptive immunity.", [["immune cells", "ANATOMY", 212, 224], ["interferons", "GENE_OR_GENE_PRODUCT", 142, 153], ["immune cells", "CELL", 212, 224], ["adaptor molecule", "PROTEIN", 48, 64], ["TIR domain", "PROTEIN", 82, 92], ["cytokines", "PROTEIN", 119, 128], ["chemokines", "PROTEIN", 130, 140], ["interferons", "PROTEIN", 142, 153], ["immune cells", "CELL_TYPE", 212, 224], ["Signalling pathways", "PROBLEM", 0, 19], ["the adaptor molecule", "TREATMENT", 44, 64], ["TIR domain", "TREATMENT", 82, 92], ["cytokines", "TREATMENT", 119, 128], ["chemokines", "TREATMENT", 130, 140], ["interferons", "TREATMENT", 142, 153], ["pathogen removal", "TREATMENT", 171, 187], ["other immune cells", "TREATMENT", 206, 224], ["immune cells", "OBSERVATION", 212, 224]]], ["Some TLRs work in dimer form, either homodimer or heterodimer [12] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 5, 9], ["TLRs", "PROTEIN", 5, 9], ["dimer form", "PROTEIN", 18, 28], ["homodimer", "PROTEIN", 37, 46]]], ["It is also associated with other protein families like MD2 and CD14 to increase ligand diversity (Table 1) [13, 14] .", [["MD2", "GENE_OR_GENE_PRODUCT", 55, 58], ["CD14", "GENE_OR_GENE_PRODUCT", 63, 67], ["protein families", "PROTEIN", 33, 49], ["MD2", "PROTEIN", 55, 58], ["CD14", "PROTEIN", 63, 67]]], ["After the binding of ligand to the receptor, TIR interact with intracellular adaptor proteins like MyD88, TRIF (TICAM-1), TIRAP (MAL), TRAM (TICAM-2) and activate the downstream signalling pathways.", [["intracellular", "ANATOMY", 63, 76], ["TIR", "GENE_OR_GENE_PRODUCT", 45, 48], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["MyD88", "GENE_OR_GENE_PRODUCT", 99, 104], ["TRIF", "GENE_OR_GENE_PRODUCT", 106, 110], ["TICAM-1", "GENE_OR_GENE_PRODUCT", 112, 119], ["TIRAP", "GENE_OR_GENE_PRODUCT", 122, 127], ["MAL", "GENE_OR_GENE_PRODUCT", 129, 132], ["TRAM", "GENE_OR_GENE_PRODUCT", 135, 139], ["TICAM-2", "GENE_OR_GENE_PRODUCT", 141, 148], ["TIR", "PROTEIN", 45, 48], ["intracellular adaptor proteins", "PROTEIN", 63, 93], ["MyD88", "PROTEIN", 99, 104], ["TRIF", "PROTEIN", 106, 110], ["TICAM", "PROTEIN", 112, 117], ["TIRAP", "PROTEIN", 122, 127], ["MAL", "PROTEIN", 129, 132], ["TRAM", "PROTEIN", 135, 139], ["TICAM", "PROTEIN", 141, 146], ["intracellular adaptor proteins", "TREATMENT", 63, 93], ["TRIF (TICAM", "TREATMENT", 106, 117], ["TIRAP (MAL)", "TREATMENT", 122, 133]]], ["MyD88 dependent pathway and TRIF dependent pathways are the two primarily involved signalling pathways, however, other adaptor proteins act as bridge molecules.", [["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["TRIF", "GENE_OR_GENE_PRODUCT", 28, 32], ["MyD88", "PROTEIN", 0, 5], ["TRIF", "PROTEIN", 28, 32], ["adaptor proteins", "PROTEIN", 119, 135], ["bridge molecules", "PROTEIN", 143, 159], ["MyD88 dependent pathway", "PROBLEM", 0, 23], ["TRIF dependent pathways", "PROBLEM", 28, 51]]], ["MyD88 acquires three domains: an amino-(N-) terminal death domain (DD), a carboxy-(C-) terminal Toll/IL-1R (TIR) domain and a short linker sequence.", [["amino", "CHEMICAL", 33, 38], ["carboxy", "CHEMICAL", 74, 81], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1R", "GENE_OR_GENE_PRODUCT", 101, 106], ["MyD88", "PROTEIN", 0, 5], ["amino-(N-) terminal death domain", "PROTEIN", 33, 65], ["DD", "PROTEIN", 67, 69], ["carboxy-(C-) terminal Toll/IL-1R (TIR) domain", "PROTEIN", 74, 119], ["short linker sequence", "PROTEIN", 126, 147], ["an amino-(N-) terminal death domain", "TREATMENT", 30, 65], ["a carboxy-(C-) terminal Toll/IL", "TREATMENT", 72, 103], ["a short linker sequence", "TREATMENT", 124, 147]]], ["One of its intermediate domain (ID) is in connection with IL-1R-associated kinases 4 (IRAK4) involved in TLR signalling [15, 16] .", [["IL-1R-associated kinases 4", "GENE_OR_GENE_PRODUCT", 58, 84], ["IRAK4", "GENE_OR_GENE_PRODUCT", 86, 91], ["TLR", "GENE_OR_GENE_PRODUCT", 105, 108], ["intermediate domain", "PROTEIN", 11, 30], ["ID", "PROTEIN", 32, 34], ["IL-1R-associated kinases 4", "PROTEIN", 58, 84], ["IRAK4", "PROTEIN", 86, 91], ["TLR", "PROTEIN", 105, 108], ["IL", "TEST", 58, 60], ["intermediate", "OBSERVATION_MODIFIER", 11, 23], ["domain", "OBSERVATION_MODIFIER", 24, 30]]], ["All TLRs except TLR3 use MyD88-dependent signalling.", [["TLRs", "GENE_OR_GENE_PRODUCT", 4, 8], ["TLR3", "GENE_OR_GENE_PRODUCT", 16, 20], ["MyD88", "GENE_OR_GENE_PRODUCT", 25, 30], ["TLRs", "PROTEIN", 4, 8], ["TLR3", "PROTEIN", 16, 20], ["MyD88", "PROTEIN", 25, 30]]], ["On the other hand, TRIF (a large protein consisting of 712 amino acids in humans) binds to TLR3 directly and indirectly to TLR4 by means of an adaptor protein, TRIF related adaptor molecule (TRAM) [15] .", [["amino acids", "CHEMICAL", 59, 70], ["amino acids", "CHEMICAL", 59, 70], ["TRIF", "GENE_OR_GENE_PRODUCT", 19, 23], ["amino acids", "AMINO_ACID", 59, 70], ["humans", "ORGANISM", 74, 80], ["TLR3", "GENE_OR_GENE_PRODUCT", 91, 95], ["TLR4", "GENE_OR_GENE_PRODUCT", 123, 127], ["TRIF related adaptor molecule", "GENE_OR_GENE_PRODUCT", 160, 189], ["TRIF", "PROTEIN", 19, 23], ["TLR3", "PROTEIN", 91, 95], ["TLR4", "PROTEIN", 123, 127], ["adaptor protein", "PROTEIN", 143, 158], ["TRIF related adaptor molecule", "PROTEIN", 160, 189], ["TRAM", "PROTEIN", 191, 195], ["humans", "SPECIES", 74, 80], ["humans", "SPECIES", 74, 80], ["a large protein", "TREATMENT", 25, 40], ["amino acids", "TREATMENT", 59, 70], ["an adaptor protein", "TREATMENT", 140, 158], ["TRIF related adaptor molecule", "TREATMENT", 160, 189]]], ["It is known to possess a significant role in induction of inflammatory mediators, that consequently induce antiviral innate immune responses via TLR3 and TLR4 mediated signalling.", [["TLR3", "GENE_OR_GENE_PRODUCT", 145, 149], ["TLR4", "GENE_OR_GENE_PRODUCT", 154, 158], ["inflammatory mediators", "PROTEIN", 58, 80], ["TLR3", "PROTEIN", 145, 149], ["TLR4", "PROTEIN", 154, 158], ["inflammatory mediators", "PROBLEM", 58, 80], ["antiviral innate immune responses", "TREATMENT", 107, 140], ["TLR3 and TLR4 mediated signalling", "TREATMENT", 145, 178], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["This was confirmed upon defective expression of IFN-related genes, mediated by TLR3 and TLR4 in TRIF knockout mice.", [["IFN", "GENE_OR_GENE_PRODUCT", 48, 51], ["TLR3", "GENE_OR_GENE_PRODUCT", 79, 83], ["TLR4", "GENE_OR_GENE_PRODUCT", 88, 92], ["TRIF", "GENE_OR_GENE_PRODUCT", 96, 100], ["mice", "ORGANISM", 110, 114], ["IFN-related genes", "DNA", 48, 65], ["TLR3", "PROTEIN", 79, 83], ["TLR4", "PROTEIN", 88, 92], ["TRIF", "PROTEIN", 96, 100], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["IFN", "PROBLEM", 48, 51], ["defective expression", "OBSERVATION", 24, 44]]], ["However, TLR4 mediated MyD88 pathway activation and early phase activation of NF-\u03ba\u03b2 was also observed.", [["TLR4", "GENE_OR_GENE_PRODUCT", 9, 13], ["MyD88", "GENE_OR_GENE_PRODUCT", 23, 28], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 78, 83], ["TLR4", "PROTEIN", 9, 13], ["MyD88", "PROTEIN", 23, 28], ["NF-\u03ba\u03b2", "PROTEIN", 78, 83], ["TLR4 mediated MyD88 pathway activation", "TREATMENT", 9, 47], ["early phase activation of NF", "TREATMENT", 52, 80]]], ["Thus, TLR4 is unique as it uses both pathways [3] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR4", "PROTEIN", 6, 10]]], ["Activated TLRs initiate a cascade of events which involves variety of protein kinases that eventually leads to the activation of certain transcription factors like NF-\u03ba\u03b2, MAPKs, IRFs, AP1 [4, 12] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 10, 14], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 164, 169], ["MAPKs", "GENE_OR_GENE_PRODUCT", 171, 176], ["IRFs", "GENE_OR_GENE_PRODUCT", 178, 182], ["AP1", "GENE_OR_GENE_PRODUCT", 184, 187], ["TLRs", "PROTEIN", 10, 14], ["protein kinases", "PROTEIN", 70, 85], ["transcription factors", "PROTEIN", 137, 158], ["NF-\u03ba\u03b2", "PROTEIN", 164, 169], ["MAPKs", "PROTEIN", 171, 176], ["IRFs", "PROTEIN", 178, 182], ["AP1", "PROTEIN", 184, 187], ["protein kinases", "PROBLEM", 70, 85], ["certain transcription factors", "PROBLEM", 129, 158]]], ["These factors enter the nucleus, binds DNA, transcribe and translate proteins that consequently enhance innate immune response and initiate adaptive immune responses against the pathogen ( Fig. 1) [7, 17, 18] .", [["nucleus", "ANATOMY", 24, 31], ["nucleus", "CELLULAR_COMPONENT", 24, 31], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["adaptive immune responses", "TREATMENT", 140, 165], ["nucleus", "ANATOMY_MODIFIER", 24, 31]]], ["Inappropriate or unregulated activation of TLR signalling can lead to chronic inflammation and autoimmune disorders.IntroductionTLRs are extensively expressed on resident as well as infiltrating myeloid and lymphoid cells in the lung tissue.", [["infiltrating myeloid", "ANATOMY", 182, 202], ["lymphoid cells", "ANATOMY", 207, 221], ["lung tissue", "ANATOMY", 229, 240], ["inflammation", "DISEASE", 78, 90], ["autoimmune disorders", "DISEASE", 95, 115], ["TLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["myeloid", "CELL", 195, 202], ["lymphoid cells", "CELL", 207, 221], ["lung tissue", "TISSUE", 229, 240], ["TLR", "PROTEIN", 43, 46], ["IntroductionTLRs", "PROTEIN", 116, 132], ["infiltrating myeloid and lymphoid cells", "CELL_TYPE", 182, 221], ["TLR signalling", "PROBLEM", 43, 57], ["chronic inflammation", "PROBLEM", 70, 90], ["autoimmune disorders", "PROBLEM", 95, 115], ["IntroductionTLRs", "TREATMENT", 116, 132], ["infiltrating myeloid and lymphoid cells in the lung tissue", "PROBLEM", 182, 240], ["chronic", "OBSERVATION_MODIFIER", 70, 77], ["inflammation", "OBSERVATION", 78, 90], ["autoimmune", "OBSERVATION", 95, 105], ["infiltrating myeloid", "OBSERVATION", 182, 202], ["lymphoid cells", "OBSERVATION", 207, 221], ["lung", "ANATOMY", 229, 233], ["tissue", "ANATOMY_MODIFIER", 234, 240]]], ["TLR1 to TLR10 are expressed on primary bronchial epithelial cells, and consequently release CXCL8 (IL-8) upon activation of TLRs by several ligands [19] .", [["primary bronchial epithelial cells", "ANATOMY", 31, 65], ["TLR1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR10", "GENE_OR_GENE_PRODUCT", 8, 13], ["bronchial epithelial cells", "CELL", 39, 65], ["CXCL8", "GENE_OR_GENE_PRODUCT", 92, 97], ["IL-8", "GENE_OR_GENE_PRODUCT", 99, 103], ["TLRs", "GENE_OR_GENE_PRODUCT", 124, 128], ["TLR1", "PROTEIN", 0, 4], ["TLR10", "PROTEIN", 8, 13], ["primary bronchial epithelial cells", "CELL_TYPE", 31, 65], ["CXCL8", "PROTEIN", 92, 97], ["IL-8", "PROTEIN", 99, 103], ["TLRs", "PROTEIN", 124, 128], ["TLR1 to TLR10", "TREATMENT", 0, 13], ["primary bronchial epithelial cells", "PROBLEM", 31, 65], ["CXCL8", "TEST", 92, 97], ["IL", "TEST", 99, 101], ["bronchial", "ANATOMY", 39, 48], ["epithelial cells", "OBSERVATION", 49, 65]]], ["Lower levels of TLR3, TLR5, TLR9 and higher levels of TLR1, TLR2, TLR4, TLR7 and TLR8 have been found to be expressed on the surface of human alveolar macrophages [20] .", [["surface", "ANATOMY", 125, 132], ["alveolar macrophages", "ANATOMY", 142, 162], ["TLR3", "GENE_OR_GENE_PRODUCT", 16, 20], ["TLR5", "GENE_OR_GENE_PRODUCT", 22, 26], ["TLR9", "GENE_OR_GENE_PRODUCT", 28, 32], ["TLR1", "GENE_OR_GENE_PRODUCT", 54, 58], ["TLR2", "GENE_OR_GENE_PRODUCT", 60, 64], ["TLR4", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR7", "GENE_OR_GENE_PRODUCT", 72, 76], ["TLR8", "GENE_OR_GENE_PRODUCT", 81, 85], ["surface", "CELLULAR_COMPONENT", 125, 132], ["human", "ORGANISM", 136, 141], ["alveolar macrophages", "CELL", 142, 162], ["TLR3", "PROTEIN", 16, 20], ["TLR5", "PROTEIN", 22, 26], ["TLR9", "PROTEIN", 28, 32], ["TLR1", "PROTEIN", 54, 58], ["TLR2", "PROTEIN", 60, 64], ["TLR4", "PROTEIN", 66, 70], ["TLR7", "PROTEIN", 72, 76], ["TLR8", "PROTEIN", 81, 85], ["human alveolar macrophages", "CELL_TYPE", 136, 162], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 136, 141], ["TLR3", "TEST", 16, 20], ["TLR5", "TEST", 22, 26], ["TLR9", "TEST", 28, 32], ["TLR1", "TEST", 54, 58], ["TLR2", "TEST", 60, 64], ["TLR4", "TEST", 66, 70], ["TLR7", "TEST", 72, 76], ["TLR8", "TREATMENT", 81, 85], ["TLR3", "ANATOMY", 16, 20], ["TLR1", "ANATOMY", 54, 58], ["alveolar macrophages", "OBSERVATION", 142, 162]]], ["TLR4 is expressed on lung endothelial cells and is imperative for capillary concealment and neutrophil recruitment after systemic administration of LPS [21] .", [["lung endothelial cells", "ANATOMY", 21, 43], ["capillary", "ANATOMY", 66, 75], ["neutrophil", "ANATOMY", 92, 102], ["LPS", "CHEMICAL", 148, 151], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung endothelial cells", "CELL", 21, 43], ["capillary", "TISSUE", 66, 75], ["neutrophil", "CELL", 92, 102], ["LPS", "SIMPLE_CHEMICAL", 148, 151], ["TLR4", "PROTEIN", 0, 4], ["lung endothelial cells", "CELL_TYPE", 21, 43], ["lung endothelial cells", "TREATMENT", 21, 43], ["capillary concealment", "TREATMENT", 66, 87], ["neutrophil recruitment", "TREATMENT", 92, 114], ["systemic administration of LPS", "TREATMENT", 121, 151], ["lung", "ANATOMY", 21, 25], ["endothelial cells", "OBSERVATION", 26, 43], ["neutrophil recruitment", "OBSERVATION", 92, 114]]], ["Recruited neutrophils also express TLR1, TLR2, TLR4, TLR5 and TLR9 [22] .", [["neutrophils", "ANATOMY", 10, 21], ["neutrophils", "CELL", 10, 21], ["TLR1", "GENE_OR_GENE_PRODUCT", 35, 39], ["TLR2", "GENE_OR_GENE_PRODUCT", 41, 45], ["TLR4", "GENE_OR_GENE_PRODUCT", 47, 51], ["TLR5", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLR9", "GENE_OR_GENE_PRODUCT", 62, 66], ["neutrophils", "CELL_TYPE", 10, 21], ["TLR1", "PROTEIN", 35, 39], ["TLR2", "PROTEIN", 41, 45], ["TLR4", "PROTEIN", 47, 51], ["TLR5", "PROTEIN", 53, 57], ["TLR9", "PROTEIN", 62, 66], ["TLR1", "TEST", 35, 39], ["TLR2", "TEST", 41, 45], ["TLR4", "TEST", 47, 51], ["TLR9", "TEST", 62, 66], ["TLR1", "ANATOMY_MODIFIER", 35, 39]]], ["These markers and anatomical locations can be used to distinguish different subsets of dendritic cells (DCs) [23] .", [["dendritic cells", "ANATOMY", 87, 102], ["DCs", "ANATOMY", 104, 107], ["dendritic cells", "CELL", 87, 102], ["DCs", "CELL", 104, 107], ["dendritic cells", "CELL_TYPE", 87, 102], ["DCs", "CELL_TYPE", 104, 107], ["These markers", "TEST", 0, 13], ["dendritic cells", "PROBLEM", 87, 102], ["dendritic cells", "OBSERVATION", 87, 102]]], ["Significantly high levels of TLR7 and TLR9 have been found to be expressed on lung plasmacytoid DCs (pDCs), which give rise to regulatory T cells and are also involved in suppressing allergic response [24] .IntroductionTLR mediated responses are cell or tissue location dependent.", [["lung plasmacytoid DCs", "ANATOMY", 78, 99], ["pDCs", "ANATOMY", 101, 105], ["regulatory T cells", "ANATOMY", 127, 145], ["cell", "ANATOMY", 246, 250], ["tissue", "ANATOMY", 254, 260], ["allergic", "DISEASE", 183, 191], ["TLR7", "GENE_OR_GENE_PRODUCT", 29, 33], ["TLR9", "GENE_OR_GENE_PRODUCT", 38, 42], ["lung plasmacytoid DCs", "CELL", 78, 99], ["pDCs", "CELL", 101, 105], ["T cells", "CELL", 138, 145], ["cell", "CELL", 246, 250], ["tissue", "TISSUE", 254, 260], ["TLR7", "PROTEIN", 29, 33], ["TLR9", "PROTEIN", 38, 42], ["lung plasmacytoid DCs", "CELL_TYPE", 78, 99], ["pDCs", "CELL_TYPE", 101, 105], ["regulatory T cells", "CELL_TYPE", 127, 145], ["IntroductionTLR", "PROTEIN", 207, 222], ["Significantly high levels of TLR7 and TLR9", "PROBLEM", 0, 42], ["suppressing allergic response", "PROBLEM", 171, 200], ["lung", "ANATOMY", 78, 82], ["plasmacytoid", "OBSERVATION", 83, 95], ["cell", "OBSERVATION", 246, 250]]], ["This can be illustrated as -In the basal layers of airway epithelium, TLR2 and TLR4 are most relevant and maintained at low expression levels, but in inflamed cells and pathogenic infection, there is an upsurge in their MyD88, TIRAP MyD88 TLR-3 Intracellular CD14, TRIL dsRNA Viruses TRIF TRIF Poly(I:C) Synthetic analogue of dsRNA TLR-4 Cell surface CD14, MD-2 LPS, F-Prot Bacteria MyD88, TIRAF, TRIF, TRAM MyD88, TRIF RSV, VSV, Env-prot, MMTV others.", [["basal layers", "ANATOMY", 35, 47], ["airway epithelium", "ANATOMY", 51, 68], ["cells", "ANATOMY", 159, 164], ["Cell surface", "ANATOMY", 338, 350], ["infection", "DISEASE", 180, 189], ["basal layers", "TISSUE", 35, 47], ["airway epithelium", "TISSUE", 51, 68], ["TLR2", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR4", "GENE_OR_GENE_PRODUCT", 79, 83], ["cells", "CELL", 159, 164], ["MyD88", "GENE_OR_GENE_PRODUCT", 220, 225], ["TLR-3", "GENE_OR_GENE_PRODUCT", 239, 244], ["CD14", "GENE_OR_GENE_PRODUCT", 259, 263], ["TRIL", "GENE_OR_GENE_PRODUCT", 265, 269], ["TRIF", "GENE_OR_GENE_PRODUCT", 284, 288], ["TLR-4", "GENE_OR_GENE_PRODUCT", 332, 337], ["CD14", "GENE_OR_GENE_PRODUCT", 351, 355], ["MD-2", "GENE_OR_GENE_PRODUCT", 357, 361], ["F-Prot", "GENE_OR_GENE_PRODUCT", 367, 373], ["MyD88", "GENE_OR_GENE_PRODUCT", 383, 388], ["TIRAF", "GENE_OR_GENE_PRODUCT", 390, 395], ["TRIF", "GENE_OR_GENE_PRODUCT", 397, 401], ["TRAM", "GENE_OR_GENE_PRODUCT", 403, 407], ["MyD88", "GENE_OR_GENE_PRODUCT", 408, 413], ["TRIF", "GENE_OR_GENE_PRODUCT", 415, 419], ["VSV", "ORGANISM", 425, 428], ["Env-prot", "GENE_OR_GENE_PRODUCT", 430, 438], ["MMTV", "ORGANISM", 440, 444], ["TLR2", "PROTEIN", 70, 74], ["TLR4", "PROTEIN", 79, 83], ["inflamed cells", "CELL_TYPE", 150, 164], ["MyD88", "PROTEIN", 220, 225], ["TIRAP", "PROTEIN", 227, 232], ["D88 TLR-3", "PROTEIN", 235, 244], ["CD14", "PROTEIN", 259, 263], ["TRIL", "PROTEIN", 265, 269], ["TRIF", "PROTEIN", 284, 288], ["TRIF", "PROTEIN", 289, 293], ["I:C", "PROTEIN", 299, 302], ["dsRNA TLR-4", "PROTEIN", 326, 337], ["Cell surface CD14, MD-2 LPS, F-Prot Bacteria", "PROTEIN", 338, 382], ["MyD88", "PROTEIN", 383, 388], ["TIRAF", "PROTEIN", 390, 395], ["TRIF", "PROTEIN", 397, 401], ["TRAM", "PROTEIN", 403, 407], ["MyD88", "PROTEIN", 408, 413], ["TRIF", "PROTEIN", 415, 419], ["Env-prot", "PROTEIN", 430, 438], ["RSV", "SPECIES", 420, 423], ["VSV", "SPECIES", 425, 428], ["TLR2 and TLR4", "TREATMENT", 70, 83], ["inflamed cells", "PROBLEM", 150, 164], ["pathogenic infection", "PROBLEM", 169, 189], ["TIRAP", "TEST", 227, 232], ["TLR", "TEST", 239, 242], ["Intracellular CD14", "TEST", 245, 263], ["TRIL", "TEST", 265, 269], ["TLR", "TEST", 332, 335], ["CD14", "TEST", 351, 355], ["MD", "TEST", 357, 359], ["LPS", "TEST", 362, 365], ["TIRAF", "TREATMENT", 390, 395], ["basal", "ANATOMY_MODIFIER", 35, 40], ["layers", "ANATOMY_MODIFIER", 41, 47], ["airway", "ANATOMY", 51, 57], ["epithelium", "ANATOMY_MODIFIER", 58, 68], ["low expression", "OBSERVATION_MODIFIER", 120, 134], ["inflamed cells", "OBSERVATION", 150, 164], ["pathogenic", "OBSERVATION_MODIFIER", 169, 179], ["infection", "OBSERVATION", 180, 189]]], ["Viruses TLR-5 Cell surface Flagellin Bacteria MyD88 MyD88 TLR-7 Intracellular CD14 ssRNA Viruses MyD88 MyD88 TLR-8 Intracellular CD14 ssRNA Viruses MyD88 TLR-9 Intracellular CD14, HMGB1 Unmethylated CpG DNA Bacteria, protozoa and viruses MyD88 MyD88 Mitochondrial DNA Endogenous expression levels [25, 26] .", [["TLR-7", "GENE_OR_GENE_PRODUCT", 58, 63], ["CD14", "GENE_OR_GENE_PRODUCT", 78, 82], ["TLR-8", "GENE_OR_GENE_PRODUCT", 109, 114], ["CD14", "GENE_OR_GENE_PRODUCT", 129, 133], ["TLR-9", "GENE_OR_GENE_PRODUCT", 154, 159], ["CD14", "GENE_OR_GENE_PRODUCT", 174, 178], ["HMGB1", "GENE_OR_GENE_PRODUCT", 180, 185], ["DNA", "CELLULAR_COMPONENT", 203, 206], ["MyD88", "GENE_OR_GENE_PRODUCT", 238, 243], ["DNA", "CELLULAR_COMPONENT", 264, 267], ["TLR-5 Cell surface Flagellin Bacteria MyD88 MyD88 TLR-7", "PROTEIN", 8, 63], ["CD14", "PROTEIN", 78, 82], ["MyD88 MyD88 TLR-8", "PROTEIN", 97, 114], ["CD14", "PROTEIN", 129, 133], ["MyD88 TLR-9", "PROTEIN", 148, 159], ["CD14", "PROTEIN", 174, 178], ["HMGB1", "PROTEIN", 180, 185], ["MyD88", "PROTEIN", 238, 243], ["MyD88", "PROTEIN", 244, 249], ["Viruses", "TEST", 0, 7], ["TLR", "TEST", 8, 11], ["Cell surface", "TEST", 14, 26], ["Flagellin", "TEST", 27, 36], ["Bacteria", "TEST", 37, 45], ["MyD88", "TEST", 46, 51], ["MyD88", "TEST", 52, 57], ["TLR", "TEST", 58, 61], ["Intracellular CD14", "TEST", 64, 82], ["ssRNA", "TEST", 83, 88], ["Viruses", "TEST", 89, 96], ["MyD88", "TEST", 97, 102], ["MyD88", "TEST", 103, 108], ["TLR", "TEST", 109, 112], ["Intracellular CD14 ssRNA", "TREATMENT", 115, 139], ["Viruses", "TEST", 140, 147], ["MyD88", "TEST", 148, 153], ["TLR", "TEST", 154, 157], ["Intracellular CD14", "TEST", 160, 178], ["HMGB1 Unmethylated CpG", "TREATMENT", 180, 202], ["Bacteria", "PROBLEM", 207, 215], ["protozoa", "PROBLEM", 217, 225], ["Mitochondrial DNA", "TEST", 250, 267], ["Endogenous expression levels", "TEST", 268, 296]]], ["Moreover, TLR4 is intracellular but can be willingly transferred to the surface of the cell for pathogen recognition [27] .", [["intracellular", "ANATOMY", 18, 31], ["surface", "ANATOMY", 72, 79], ["cell", "ANATOMY", 87, 91], ["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["surface", "CELLULAR_COMPONENT", 72, 79], ["cell", "CELL", 87, 91], ["TLR4", "PROTEIN", 10, 14]]], ["It has been found that TLR4 is one of the host extracellular and cellular proteins, along with MD-2, HBD-2, CD14 and LBP (LPS binding protein); required for a precise response to several endotoxins.", [["extracellular", "ANATOMY", 47, 60], ["cellular", "ANATOMY", 65, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["cellular", "CELL", 65, 73], ["MD-2", "GENE_OR_GENE_PRODUCT", 95, 99], ["HBD-2", "GENE_OR_GENE_PRODUCT", 101, 106], ["CD14", "GENE_OR_GENE_PRODUCT", 108, 112], ["LBP", "GENE_OR_GENE_PRODUCT", 117, 120], ["LPS binding protein", "GENE_OR_GENE_PRODUCT", 122, 141], ["TLR4", "PROTEIN", 23, 27], ["host extracellular and cellular proteins", "PROTEIN", 42, 82], ["MD", "PROTEIN", 95, 97], ["HBD", "PROTEIN", 101, 104], ["CD14", "PROTEIN", 108, 112], ["LBP", "PROTEIN", 117, 120], ["LPS binding protein", "PROTEIN", 122, 141], ["MD", "TEST", 95, 97], ["HBD", "TEST", 101, 104], ["CD14", "TEST", 108, 112], ["LBP", "PROBLEM", 117, 120], ["LPS binding protein", "TEST", 122, 141], ["TLR4", "OBSERVATION", 23, 27], ["cellular proteins", "OBSERVATION", 65, 82], ["LBP", "ANATOMY", 117, 120]]], ["Human airway epithelial cells abundantly express TLR4 very little HBD-2 and little or no MD-2, thus they have to induced in these cells upon exposure to specific bacterial or host products in order to generate an appropriate response against the endotoxins [28] .", [["airway epithelial cells", "ANATOMY", 6, 29], ["cells", "ANATOMY", 130, 135], ["Human", "ORGANISM", 0, 5], ["airway epithelial cells", "CELL", 6, 29], ["TLR4", "GENE_OR_GENE_PRODUCT", 49, 53], ["HBD-2", "GENE_OR_GENE_PRODUCT", 66, 71], ["MD-2", "GENE_OR_GENE_PRODUCT", 89, 93], ["cells", "CELL", 130, 135], ["Human airway epithelial cells", "CELL_TYPE", 0, 29], ["TLR4", "PROTEIN", 49, 53], ["HBD", "PROTEIN", 66, 69], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human airway epithelial cells", "PROBLEM", 0, 29], ["TLR4 very little HBD", "PROBLEM", 49, 69], ["specific bacterial or host products", "TREATMENT", 153, 188], ["airway", "ANATOMY", 6, 12], ["epithelial cells", "OBSERVATION", 13, 29]]], ["In addition, TLR3 and TLR5 in the human airway epithelia also play important roles in ligand recognition [11, 29, 30] .", [["airway epithelia", "ANATOMY", 40, 56], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR5", "GENE_OR_GENE_PRODUCT", 22, 26], ["human", "ORGANISM", 34, 39], ["airway epithelia", "TISSUE", 40, 56], ["TLR3", "PROTEIN", 13, 17], ["TLR5", "PROTEIN", 22, 26], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["TLR3 and TLR5 in the human airway epithelia", "TREATMENT", 13, 56], ["airway", "ANATOMY", 40, 46]]], ["Additionally, levels of TLR expression in cells cannot always be coordinated with the functional response [20, 31] .", [["cells", "ANATOMY", 42, 47], ["TLR", "GENE_OR_GENE_PRODUCT", 24, 27], ["cells", "CELL", 42, 47], ["TLR", "PROTEIN", 24, 27], ["TLR expression in cells", "PROBLEM", 24, 47]]], ["This can be explained as enhanced secretion of TNF-\u03b1 by alveolar macrophages, IL-6 and IL-10 by interstitial macrophages has been observed even when the levels of TLR mRNA are comparable [20] .", [["alveolar macrophages", "ANATOMY", 56, 76], ["interstitial macrophages", "ANATOMY", 96, 120], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 47, 52], ["alveolar macrophages", "CELL", 56, 76], ["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL-10", "GENE_OR_GENE_PRODUCT", 87, 92], ["interstitial macrophages", "CELL", 96, 120], ["TLR", "GENE_OR_GENE_PRODUCT", 163, 166], ["TNF-\u03b1", "PROTEIN", 47, 52], ["alveolar macrophages", "CELL_TYPE", 56, 76], ["IL-6 and IL-10", "PROTEIN", 78, 92], ["interstitial macrophages", "CELL_TYPE", 96, 120], ["TLR mRNA", "RNA", 163, 171], ["TNF", "TEST", 47, 50], ["alveolar macrophages", "PROBLEM", 56, 76], ["IL", "TEST", 78, 80], ["IL", "TREATMENT", 87, 89], ["interstitial macrophages", "PROBLEM", 96, 120], ["TLR mRNA", "TEST", 163, 171], ["alveolar macrophages", "ANATOMY", 56, 76], ["interstitial", "ANATOMY_MODIFIER", 96, 108], ["macrophages", "OBSERVATION", 109, 120]]], ["Moreover, cellular activation of lung tissue can also be achieved via co-operative interactions with TLR expressing lymphoid cells.", [["cellular", "ANATOMY", 10, 18], ["lung tissue", "ANATOMY", 33, 44], ["lymphoid cells", "ANATOMY", 116, 130], ["cellular", "CELL", 10, 18], ["lung tissue", "TISSUE", 33, 44], ["TLR", "GENE_OR_GENE_PRODUCT", 101, 104], ["lymphoid cells", "CELL", 116, 130], ["TLR expressing lymphoid cells", "CELL_TYPE", 101, 130], ["cellular activation of lung tissue", "PROBLEM", 10, 44], ["TLR expressing lymphoid cells", "TREATMENT", 101, 130], ["cellular activation", "OBSERVATION", 10, 29], ["lung", "ANATOMY", 33, 37], ["lymphoid cells", "OBSERVATION", 116, 130]]], ["This was demonstrated by activation of airway smooth muscle cells, by IL-1\u03b2 released by monocytes stimulated by LPS.", [["airway smooth muscle cells", "ANATOMY", 39, 65], ["monocytes", "ANATOMY", 88, 97], ["LPS", "CHEMICAL", 112, 115], ["airway smooth muscle cells", "CELL", 39, 65], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 70, 75], ["monocytes", "CELL", 88, 97], ["LPS", "SIMPLE_CHEMICAL", 112, 115], ["airway smooth muscle cells", "CELL_TYPE", 39, 65], ["IL-1\u03b2", "PROTEIN", 70, 75], ["monocytes", "CELL_TYPE", 88, 97], ["airway", "ANATOMY", 39, 45], ["smooth muscle cells", "OBSERVATION", 46, 65]]], ["Therefore, both intrinsic cellular mechanisms and co-operative interactions between resident and recruited cells play a significant role in determination of response to TLR ligands in the lung.TLR signalling in respiratory tractA large number of commensal organisms are in continuous contact with the upper epithelium of respiratory tract which includes nasal cavity, pharynx, larynx [32] .", [["cellular", "ANATOMY", 26, 34], ["cells", "ANATOMY", 107, 112], ["lung", "ANATOMY", 188, 192], ["respiratory tract", "ANATOMY", 211, 228], ["upper epithelium", "ANATOMY", 301, 317], ["respiratory tract", "ANATOMY", 321, 338], ["nasal cavity", "ANATOMY", 354, 366], ["pharynx", "ANATOMY", 368, 375], ["larynx", "ANATOMY", 377, 383], ["cellular", "CELL", 26, 34], ["cells", "CELL", 107, 112], ["TLR ligands", "GENE_OR_GENE_PRODUCT", 169, 180], ["lung", "ORGAN", 188, 192], ["TLR", "GENE_OR_GENE_PRODUCT", 193, 196], ["upper epithelium", "TISSUE", 301, 317], ["respiratory tract", "ORGANISM_SUBDIVISION", 321, 338], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 354, 366], ["pharynx", "ORGAN", 368, 375], ["larynx", "ORGAN", 377, 383], ["resident and recruited cells", "CELL_TYPE", 84, 112], ["TLR", "PROTEIN", 169, 172], ["TLR", "PROTEIN", 193, 196], ["TLR signalling in respiratory tract", "PROBLEM", 193, 228], ["commensal organisms", "PROBLEM", 246, 265], ["nasal cavity, pharynx, larynx", "PROBLEM", 354, 383], ["cellular mechanisms", "OBSERVATION", 26, 45], ["lung", "ANATOMY", 188, 192], ["respiratory tract", "ANATOMY", 211, 228], ["large", "OBSERVATION_MODIFIER", 230, 235], ["number", "OBSERVATION_MODIFIER", 236, 242], ["commensal organisms", "OBSERVATION", 246, 265], ["upper", "ANATOMY_MODIFIER", 301, 306], ["epithelium", "ANATOMY_MODIFIER", 307, 317], ["respiratory tract", "ANATOMY", 321, 338], ["nasal cavity", "ANATOMY", 354, 366], ["pharynx", "ANATOMY", 368, 375], ["larynx", "ANATOMY", 377, 383]]], ["In case of a respiratory disease or allergic conditions, production of mucus and anti-microbial substances is the primitive response of epithelial cells [11, 17] .", [["respiratory", "ANATOMY", 13, 24], ["mucus", "ANATOMY", 71, 76], ["epithelial cells", "ANATOMY", 136, 152], ["respiratory disease", "DISEASE", 13, 32], ["allergic conditions", "DISEASE", 36, 55], ["mucus", "ORGANISM_SUBSTANCE", 71, 76], ["epithelial cells", "CELL", 136, 152], ["epithelial cells", "CELL_TYPE", 136, 152], ["a respiratory disease", "PROBLEM", 11, 32], ["allergic conditions", "PROBLEM", 36, 55], ["mucus and anti-microbial substances", "PROBLEM", 71, 106], ["epithelial cells", "PROBLEM", 136, 152], ["respiratory disease", "OBSERVATION", 13, 32], ["allergic", "OBSERVATION", 36, 44], ["epithelial cells", "OBSERVATION", 136, 152]]], ["Mucins (protein component of mucus) expression is induced either directly or indirectly by TLR signalling [11, 33] .", [["Mucins", "GENE_OR_GENE_PRODUCT", 0, 6], ["protein component of mucus", "GENE_OR_GENE_PRODUCT", 8, 34], ["TLR", "GENE_OR_GENE_PRODUCT", 91, 94], ["Mucins", "PROTEIN", 0, 6], ["TLR", "PROTEIN", 91, 94], ["Mucins (protein component of mucus) expression", "PROBLEM", 0, 46]]], ["In the lower respiratory tract; trachea, bronchi, and lungs express TLR3 on the luminal and basal side, whereas TLR2, TLR6 and TLR1 on basolateral side.", [["lower respiratory tract", "ANATOMY", 7, 30], ["trachea", "ANATOMY", 32, 39], ["bronchi", "ANATOMY", 41, 48], ["lungs", "ANATOMY", 54, 59], ["luminal", "ANATOMY", 80, 87], ["basal side", "ANATOMY", 92, 102], ["basolateral", "ANATOMY", 135, 146], ["lower", "ORGANISM_SUBDIVISION", 7, 12], ["respiratory tract", "ORGANISM_SUBDIVISION", 13, 30], ["trachea", "MULTI-TISSUE_STRUCTURE", 32, 39], ["bronchi", "MULTI-TISSUE_STRUCTURE", 41, 48], ["lungs", "ORGAN", 54, 59], ["TLR3", "GENE_OR_GENE_PRODUCT", 68, 72], ["luminal", "MULTI-TISSUE_STRUCTURE", 80, 87], ["basal side", "CELLULAR_COMPONENT", 92, 102], ["TLR2", "GENE_OR_GENE_PRODUCT", 112, 116], ["TLR6", "GENE_OR_GENE_PRODUCT", 118, 122], ["TLR1", "GENE_OR_GENE_PRODUCT", 127, 131], ["TLR3", "PROTEIN", 68, 72], ["TLR2", "PROTEIN", 112, 116], ["TLR6", "PROTEIN", 118, 122], ["TLR1", "PROTEIN", 127, 131], ["TLR2", "TEST", 112, 116], ["TLR6 and TLR1 on basolateral side", "TREATMENT", 118, 151], ["lower", "ANATOMY_MODIFIER", 7, 12], ["respiratory tract", "ANATOMY", 13, 30], ["trachea", "ANATOMY", 32, 39], ["bronchi", "ANATOMY", 41, 48], ["lungs", "ANATOMY", 54, 59], ["TLR3", "OBSERVATION", 68, 72], ["luminal", "ANATOMY_MODIFIER", 80, 87], ["basal", "ANATOMY_MODIFIER", 92, 97], ["TLR2", "ANATOMY_MODIFIER", 112, 116], ["TLR6", "ANATOMY_MODIFIER", 118, 122], ["TLR1", "ANATOMY_MODIFIER", 127, 131]]], ["TLR6 are present in high levels, lower levels of TLR2, TLR4, TLR5 and TLR10 along with TLR3, TLR7 and TLR9 are present on both cell surface as well as intracellular compartments [34] .", [["cell surface", "ANATOMY", 127, 139], ["intracellular compartments", "ANATOMY", 151, 177], ["TLR6", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "GENE_OR_GENE_PRODUCT", 49, 53], ["TLR4", "GENE_OR_GENE_PRODUCT", 55, 59], ["TLR5", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR10", "GENE_OR_GENE_PRODUCT", 70, 75], ["TLR3", "GENE_OR_GENE_PRODUCT", 87, 91], ["TLR7", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR9", "GENE_OR_GENE_PRODUCT", 102, 106], ["cell surface", "CELLULAR_COMPONENT", 127, 139], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 151, 164], ["TLR6", "PROTEIN", 0, 4], ["TLR2", "PROTEIN", 49, 53], ["TLR4", "PROTEIN", 55, 59], ["TLR5", "PROTEIN", 61, 65], ["TLR10", "PROTEIN", 70, 75], ["TLR3", "PROTEIN", 87, 91], ["TLR7", "PROTEIN", 93, 97], ["TLR9", "PROTEIN", 102, 106], ["TLR6", "TEST", 0, 4], ["TLR2", "TEST", 49, 53], ["TLR4", "TEST", 55, 59], ["TLR5", "TEST", 61, 65], ["TLR10", "TEST", 70, 75], ["TLR3, TLR7 and TLR9", "TREATMENT", 87, 106], ["high levels", "OBSERVATION_MODIFIER", 20, 31], ["lower", "ANATOMY_MODIFIER", 33, 38], ["TLR2", "ANATOMY", 49, 53], ["TLR4", "ANATOMY", 55, 59], ["both", "ANATOMY_MODIFIER", 122, 126], ["cell", "ANATOMY_MODIFIER", 127, 131], ["surface", "ANATOMY_MODIFIER", 132, 139]]], ["In response to various TLR ligands, primary bronchial epithelial cells express TLR1 to TLR10 and secrete the chemokine CXCL8 (IL-8) [3, 19] .", [["primary bronchial epithelial cells", "ANATOMY", 36, 70], ["TLR", "GENE_OR_GENE_PRODUCT", 23, 26], ["bronchial epithelial cells", "CELL", 44, 70], ["TLR1", "GENE_OR_GENE_PRODUCT", 79, 83], ["TLR10", "GENE_OR_GENE_PRODUCT", 87, 92], ["CXCL8", "GENE_OR_GENE_PRODUCT", 119, 124], ["IL-8", "GENE_OR_GENE_PRODUCT", 126, 130], ["TLR ligands", "PROTEIN", 23, 34], ["primary bronchial epithelial cells", "CELL_TYPE", 36, 70], ["TLR1", "PROTEIN", 79, 83], ["TLR10", "PROTEIN", 87, 92], ["chemokine", "PROTEIN", 109, 118], ["CXCL8", "PROTEIN", 119, 124], ["IL", "PROTEIN", 126, 128], ["various TLR ligands", "TEST", 15, 34], ["primary bronchial epithelial cells", "PROBLEM", 36, 70], ["TLR1", "TEST", 79, 83], ["TLR10", "TEST", 87, 92], ["secrete the chemokine CXCL8", "TEST", 97, 124], ["IL", "TEST", 126, 128], ["bronchial", "ANATOMY", 44, 53], ["epithelial cells", "OBSERVATION", 54, 70], ["TLR1", "ANATOMY_MODIFIER", 79, 83], ["chemokine CXCL8", "ANATOMY", 109, 124]]], ["TLR4 expressed in lung endothelial cells is crucial for neutrophil recruitment [22] and capillary sequestration [3, 21] .", [["lung endothelial cells", "ANATOMY", 18, 40], ["neutrophil", "ANATOMY", 56, 66], ["capillary", "ANATOMY", 88, 97], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung endothelial cells", "CELL", 18, 40], ["neutrophil", "CELL", 56, 66], ["capillary", "TISSUE", 88, 97], ["TLR4", "PROTEIN", 0, 4], ["lung endothelial cells", "CELL_TYPE", 18, 40], ["neutrophil", "CELL_TYPE", 56, 66], ["lung endothelial cells", "TREATMENT", 18, 40], ["neutrophil recruitment", "TEST", 56, 78], ["capillary sequestration", "TEST", 88, 111], ["lung", "ANATOMY", 18, 22], ["endothelial cells", "OBSERVATION", 23, 40]]], ["Dendritic cells of lungs act as sentinels and bridge innate and adaptive immunity.", [["Dendritic cells", "ANATOMY", 0, 15], ["lungs", "ANATOMY", 19, 24], ["Dendritic cells", "CELL", 0, 15], ["lungs", "ORGAN", 19, 24], ["Dendritic cells", "CELL_TYPE", 0, 15], ["Dendritic cells of lungs act", "PROBLEM", 0, 28], ["bridge innate and adaptive immunity", "TREATMENT", 46, 81], ["lungs", "ANATOMY", 19, 24]]], ["TLR7 and TLR9 are highly expressed by lung pDCs (plasmacytoid DCs) that suppress the allergic response and regulatory T cells are raised by regulatory lung DCs [3, 24] .", [["lung pDCs", "ANATOMY", 38, 47], ["plasmacytoid DCs", "ANATOMY", 49, 65], ["T cells", "ANATOMY", 118, 125], ["lung DCs", "ANATOMY", 151, 159], ["allergic", "DISEASE", 85, 93], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["lung pDCs", "CELL", 38, 47], ["plasmacytoid DCs", "CELL", 49, 65], ["T cells", "CELL", 118, 125], ["lung DCs", "CELL", 151, 159], ["TLR7", "PROTEIN", 0, 4], ["TLR9", "PROTEIN", 9, 13], ["lung pDCs", "CELL_TYPE", 38, 47], ["plasmacytoid DCs", "CELL_TYPE", 49, 65], ["regulatory T cells", "CELL_TYPE", 107, 125], ["regulatory lung DCs", "CELL_TYPE", 140, 159], ["TLR7 and TLR9", "TREATMENT", 0, 13], ["lung pDCs (plasmacytoid DCs)", "TREATMENT", 38, 66], ["the allergic response", "PROBLEM", 81, 102], ["regulatory T cells", "PROBLEM", 107, 125], ["lung", "ANATOMY", 38, 42], ["pDCs", "OBSERVATION", 43, 47], ["allergic response", "OBSERVATION", 85, 102], ["lung", "ANATOMY", 151, 155]]], ["It has been shown that alveolar macrophages express TLR3, TLR5 and TLR9 and higher levels of TLR1, TLR2, TLR4, TLR7 and TLR8 [3, 20, 31] .", [["alveolar macrophages", "ANATOMY", 23, 43], ["alveolar macrophages", "CELL", 23, 43], ["TLR3", "GENE_OR_GENE_PRODUCT", 52, 56], ["TLR5", "GENE_OR_GENE_PRODUCT", 58, 62], ["TLR9", "GENE_OR_GENE_PRODUCT", 67, 71], ["TLR1", "GENE_OR_GENE_PRODUCT", 93, 97], ["TLR2", "GENE_OR_GENE_PRODUCT", 99, 103], ["TLR4", "GENE_OR_GENE_PRODUCT", 105, 109], ["TLR7", "GENE_OR_GENE_PRODUCT", 111, 115], ["TLR8", "GENE_OR_GENE_PRODUCT", 120, 124], ["alveolar macrophages", "CELL_TYPE", 23, 43], ["TLR3", "PROTEIN", 52, 56], ["TLR5", "PROTEIN", 58, 62], ["TLR9", "PROTEIN", 67, 71], ["TLR1", "PROTEIN", 93, 97], ["TLR2", "PROTEIN", 99, 103], ["TLR4", "PROTEIN", 105, 109], ["TLR7", "PROTEIN", 111, 115], ["TLR8", "PROTEIN", 120, 124], ["alveolar macrophages", "TEST", 23, 43], ["TLR3", "TEST", 52, 56], ["TLR5", "TEST", 58, 62], ["TLR9", "TEST", 67, 71], ["TLR1", "TEST", 93, 97], ["TLR2", "TEST", 99, 103], ["TLR4", "TEST", 105, 109], ["TLR8", "TEST", 120, 124], ["alveolar", "ANATOMY_MODIFIER", 23, 31], ["macrophages", "OBSERVATION", 32, 43], ["TLR3", "ANATOMY_MODIFIER", 52, 56], ["TLR1", "ANATOMY_MODIFIER", 93, 97], ["TLR2", "ANATOMY", 99, 103]]], ["Thus, TLR signalling is implicated in secretion of cytokines, chemokines, interferons like TNF\u03b1, IL-8, MIP-1\u03b1, MIP-1\u03b2, RANTES, GRO-\u03b1, -\u03b2 and -\u03b3, IL-6, IL-5 and TGF\u03b2 which are necessary for promoting influx of professional phagocytic/ killing cells such as neutrophils, eosinophils, monocytes, NK cells, macrophages and DCs that are ultimately responsible for removal of pathogen [11, 35, 36] .", [["phagocytic", "ANATOMY", 222, 232], ["cells", "ANATOMY", 242, 247], ["neutrophils", "ANATOMY", 256, 267], ["eosinophils", "ANATOMY", 269, 280], ["monocytes", "ANATOMY", 282, 291], ["NK cells", "ANATOMY", 293, 301], ["macrophages", "ANATOMY", 303, 314], ["DCs", "ANATOMY", 319, 322], ["TLR", "GENE_OR_GENE_PRODUCT", 6, 9], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-8", "GENE_OR_GENE_PRODUCT", 97, 101], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 103, 109], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 111, 117], ["RANTES", "GENE_OR_GENE_PRODUCT", 119, 125], ["GRO-\u03b1", "GENE_OR_GENE_PRODUCT", 127, 132], ["-\u03b2", "GENE_OR_GENE_PRODUCT", 134, 136], ["-\u03b3", "GENE_OR_GENE_PRODUCT", 141, 143], ["IL-6", "GENE_OR_GENE_PRODUCT", 145, 149], ["IL-5", "GENE_OR_GENE_PRODUCT", 151, 155], ["TGF\u03b2", "GENE_OR_GENE_PRODUCT", 160, 164], ["cells", "CELL", 242, 247], ["neutrophils", "CELL", 256, 267], ["eosinophils", "CELL", 269, 280], ["monocytes", "CELL", 282, 291], ["NK cells", "CELL", 293, 301], ["macrophages", "CELL", 303, 314], ["DCs", "CELL", 319, 322], ["TLR", "PROTEIN", 6, 9], ["cytokines", "PROTEIN", 51, 60], ["chemokines", "PROTEIN", 62, 72], ["interferons", "PROTEIN", 74, 85], ["TNF\u03b1", "PROTEIN", 91, 95], ["IL-8", "PROTEIN", 97, 101], ["MIP-1\u03b1", "PROTEIN", 103, 109], ["MIP-1\u03b2", "PROTEIN", 111, 117], ["RANTES", "PROTEIN", 119, 125], ["GRO-\u03b1, -\u03b2 and -\u03b3, IL-6, IL-5", "PROTEIN", 127, 155], ["TGF\u03b2", "PROTEIN", 160, 164], ["killing cells", "CELL_TYPE", 234, 247], ["neutrophils", "CELL_TYPE", 256, 267], ["eosinophils", "CELL_TYPE", 269, 280], ["monocytes", "CELL_TYPE", 282, 291], ["NK cells", "CELL_TYPE", 293, 301], ["macrophages", "CELL_TYPE", 303, 314], ["DCs", "CELL_TYPE", 319, 322], ["cytokines", "TEST", 51, 60], ["chemokines", "TEST", 62, 72], ["interferons", "TEST", 74, 85], ["TNF", "TEST", 91, 94], ["IL", "TEST", 97, 99], ["MIP", "TEST", 103, 106], ["MIP", "TEST", 111, 114], ["RANTES", "TEST", 119, 125], ["GRO", "TEST", 127, 130], ["-\u03b2", "TEST", 134, 136], ["-\u03b3", "TEST", 141, 143], ["IL", "TEST", 145, 147], ["IL", "TEST", 151, 153], ["TGF", "TEST", 160, 163], ["professional phagocytic/ killing cells", "PROBLEM", 209, 247], ["neutrophils", "TEST", 256, 267], ["eosinophils", "TEST", 269, 280], ["monocytes", "TEST", 282, 291], ["NK cells", "TEST", 293, 301], ["macrophages", "PROBLEM", 303, 314], ["DCs", "PROBLEM", 319, 322], ["pathogen", "PROBLEM", 370, 378], ["killing cells", "OBSERVATION", 234, 247], ["monocytes", "ANATOMY", 282, 291], ["NK cells", "OBSERVATION", 293, 301]]], ["In addition, TLR signalling is also involved in production of anti-microbial substances such as defensins, lysozyme, nitric oxide (NO) and IL-37 in lower respiratory tract [11] .", [["lower respiratory tract", "ANATOMY", 148, 171], ["nitric oxide", "CHEMICAL", 117, 129], ["NO", "CHEMICAL", 131, 133], ["nitric oxide", "CHEMICAL", 117, 129], ["NO", "CHEMICAL", 131, 133], ["TLR", "GENE_OR_GENE_PRODUCT", 13, 16], ["defensins", "GENE_OR_GENE_PRODUCT", 96, 105], ["lysozyme", "GENE_OR_GENE_PRODUCT", 107, 115], ["nitric oxide", "SIMPLE_CHEMICAL", 117, 129], ["NO", "SIMPLE_CHEMICAL", 131, 133], ["IL-37", "GENE_OR_GENE_PRODUCT", 139, 144], ["TLR", "PROTEIN", 13, 16], ["defensins", "PROTEIN", 96, 105], ["lysozyme", "PROTEIN", 107, 115], ["IL", "PROTEIN", 139, 141], ["anti-microbial substances", "TREATMENT", 62, 87], ["defensins", "TREATMENT", 96, 105], ["lysozyme", "TREATMENT", 107, 115], ["nitric oxide", "TREATMENT", 117, 129], ["IL", "TEST", 139, 141], ["anti-microbial substances", "OBSERVATION", 62, 87], ["lower", "ANATOMY_MODIFIER", 148, 153], ["respiratory tract", "ANATOMY", 154, 171]]], ["Boron has been found to equilibrate the LPS-CD14/TLR4/MD2 complex in a study, leading to release of pro inflammatory cytokines by M1 macrophages [37] .", [["M1 macrophages", "ANATOMY", 130, 144], ["Boron", "CHEMICAL", 0, 5], ["Boron", "CHEMICAL", 0, 5], ["Boron", "SIMPLE_CHEMICAL", 0, 5], ["CD14", "GENE_OR_GENE_PRODUCT", 44, 48], ["TLR4", "GENE_OR_GENE_PRODUCT", 49, 53], ["MD2", "GENE_OR_GENE_PRODUCT", 54, 57], ["M1 macrophages", "CELL", 130, 144], ["CD14", "PROTEIN", 44, 48], ["TLR4", "PROTEIN", 49, 53], ["MD2 complex", "PROTEIN", 54, 65], ["pro inflammatory cytokines", "PROTEIN", 100, 126], ["M1 macrophages", "CELL_TYPE", 130, 144], ["Boron", "TREATMENT", 0, 5], ["the LPS", "TEST", 36, 43], ["a study", "TEST", 69, 76], ["pro inflammatory cytokines", "PROBLEM", 100, 126]]], ["TLR signalling -TLR1, TLR2, TLR4, TLR5, TLR6 and TLR10 are expressed on the surface of the cell whereas TLR3, TLR7, TLR8 and TLR9 in intracellular vesicles like endosome and lysosomes.", [["surface", "ANATOMY", 76, 83], ["cell", "ANATOMY", 91, 95], ["intracellular vesicles", "ANATOMY", 133, 155], ["endosome", "ANATOMY", 161, 169], ["lysosomes", "ANATOMY", 174, 183], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["TLR1", "GENE_OR_GENE_PRODUCT", 16, 20], ["TLR2", "GENE_OR_GENE_PRODUCT", 22, 26], ["TLR4", "GENE_OR_GENE_PRODUCT", 28, 32], ["TLR5", "GENE_OR_GENE_PRODUCT", 34, 38], ["TLR6", "GENE_OR_GENE_PRODUCT", 40, 44], ["TLR10", "GENE_OR_GENE_PRODUCT", 49, 54], ["surface", "CELLULAR_COMPONENT", 76, 83], ["cell", "CELL", 91, 95], ["TLR3", "GENE_OR_GENE_PRODUCT", 104, 108], ["TLR7", "GENE_OR_GENE_PRODUCT", 110, 114], ["TLR8", "GENE_OR_GENE_PRODUCT", 116, 120], ["TLR9", "GENE_OR_GENE_PRODUCT", 125, 129], ["intracellular vesicles", "CELLULAR_COMPONENT", 133, 155], ["endosome", "CELLULAR_COMPONENT", 161, 169], ["lysosomes", "CELLULAR_COMPONENT", 174, 183], ["TLR", "PROTEIN", 0, 3], ["TLR1", "PROTEIN", 16, 20], ["TLR2", "PROTEIN", 22, 26], ["TLR4", "PROTEIN", 28, 32], ["TLR5", "PROTEIN", 34, 38], ["TLR6", "PROTEIN", 40, 44], ["TLR10", "PROTEIN", 49, 54], ["TLR3", "PROTEIN", 104, 108], ["TLR7", "PROTEIN", 110, 114], ["TLR8", "PROTEIN", 116, 120], ["TLR9", "PROTEIN", 125, 129], ["TLR signalling", "TEST", 0, 14], ["TLR2", "TEST", 22, 26], ["TLR4", "TEST", 28, 32], ["TLR5", "TEST", 34, 38], ["TLR6", "TEST", 40, 44], ["TLR10", "TREATMENT", 49, 54], ["TLR3", "TEST", 104, 108], ["TLR7", "TEST", 110, 114], ["TLR8", "TEST", 116, 120], ["TLR1", "ANATOMY_MODIFIER", 16, 20], ["TLR2", "ANATOMY_MODIFIER", 22, 26], ["TLR4", "ANATOMY_MODIFIER", 28, 32], ["cell", "ANATOMY_MODIFIER", 91, 95], ["TLR7", "ANATOMY", 110, 114], ["TLR8", "ANATOMY", 116, 120], ["TLR9", "ANATOMY_MODIFIER", 125, 129], ["intracellular vesicles", "OBSERVATION", 133, 155], ["endosome", "OBSERVATION", 161, 169]]], ["All TLRs except TLR3 activates MyD88 pathway, TLR3 and TLR4 activate TRIF pathway.", [["TLRs", "GENE_OR_GENE_PRODUCT", 4, 8], ["TLR3", "GENE_OR_GENE_PRODUCT", 16, 20], ["MyD88", "GENE_OR_GENE_PRODUCT", 31, 36], ["TLR3", "GENE_OR_GENE_PRODUCT", 46, 50], ["TLR4", "GENE_OR_GENE_PRODUCT", 55, 59], ["TRIF", "GENE_OR_GENE_PRODUCT", 69, 73], ["TLRs", "PROTEIN", 4, 8], ["TLR3", "PROTEIN", 16, 20], ["MyD88", "PROTEIN", 31, 36], ["TLR3", "PROTEIN", 46, 50], ["TLR4", "PROTEIN", 55, 59], ["TRIF", "PROTEIN", 69, 73], ["TLR3 and TLR4 activate TRIF pathway", "TREATMENT", 46, 81]]], ["When ligand binds to the TLR receptors, adaptor molecules MyD88 and TRIF bind to the TIR domain either directly or indirectly via bridge molecules TIRAP and TRAM.", [["TLR", "GENE_OR_GENE_PRODUCT", 25, 28], ["MyD88", "GENE_OR_GENE_PRODUCT", 58, 63], ["TRIF", "GENE_OR_GENE_PRODUCT", 68, 72], ["TIRAP", "GENE_OR_GENE_PRODUCT", 147, 152], ["TRAM", "GENE_OR_GENE_PRODUCT", 157, 161], ["TLR receptors", "PROTEIN", 25, 38], ["adaptor molecules", "PROTEIN", 40, 57], ["MyD88", "PROTEIN", 58, 63], ["TRIF", "PROTEIN", 68, 72], ["TIR domain", "PROTEIN", 85, 95], ["bridge molecules", "PROTEIN", 130, 146], ["TIRAP", "PROTEIN", 147, 152], ["TRAM", "PROTEIN", 157, 161], ["the TLR receptors", "TREATMENT", 21, 38], ["adaptor molecules MyD88", "TREATMENT", 40, 63], ["TRIF bind", "TREATMENT", 68, 77], ["the TIR domain", "TREATMENT", 81, 95], ["TRAM", "TREATMENT", 157, 161]]], ["MyD88 now recruits IRAK4 which in turn phosphorylate and activate IRAK1/2.", [["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["IRAK4", "GENE_OR_GENE_PRODUCT", 19, 24], ["IRAK1/2", "GENE_OR_GENE_PRODUCT", 66, 73], ["MyD88", "PROTEIN", 0, 5], ["IRAK4", "PROTEIN", 19, 24], ["IRAK1/2", "PROTEIN", 66, 73], ["IRAK4", "PROBLEM", 19, 24], ["phosphorylate and activate IRAK1", "TREATMENT", 39, 71], ["IRAK4", "OBSERVATION", 19, 24]]], ["The activated IRAKs now interact with TRAF6.", [["IRAKs", "GENE_OR_GENE_PRODUCT", 14, 19], ["TRAF6", "GENE_OR_GENE_PRODUCT", 38, 43], ["IRAKs", "PROTEIN", 14, 19], ["TRAF6", "PROTEIN", 38, 43], ["The activated IRAKs", "TREATMENT", 0, 19], ["TRAF6", "TREATMENT", 38, 43]]], ["This IRAK-TRAF6 complex recruits and activates TAK1.", [["IRAK", "GENE_OR_GENE_PRODUCT", 5, 9], ["TRAF6", "GENE_OR_GENE_PRODUCT", 10, 15], ["TAK1", "GENE_OR_GENE_PRODUCT", 47, 51], ["IRAK", "PROTEIN", 5, 9], ["TRAF6 complex", "PROTEIN", 10, 23], ["TAK1", "PROTEIN", 47, 51], ["This IRAK", "TEST", 0, 9]]], ["It also gets activated directly by MyD88 and RIP1.", [["MyD88", "GENE_OR_GENE_PRODUCT", 35, 40], ["RIP1", "GENE_OR_GENE_PRODUCT", 45, 49], ["MyD88", "PROTEIN", 35, 40], ["RIP1", "PROTEIN", 45, 49]]], ["Activated TAK1 activates IKK complex and MAPKs.", [["TAK1", "GENE_OR_GENE_PRODUCT", 10, 14], ["IKK", "GENE_OR_GENE_PRODUCT", 25, 28], ["MAPKs", "GENE_OR_GENE_PRODUCT", 41, 46], ["TAK1", "PROTEIN", 10, 14], ["IKK complex", "PROTEIN", 25, 36], ["MAPKs", "PROTEIN", 41, 46]]], ["IKK complex phosphorylates and subsequently degrade I\u03ba\u03b2 by proteasomes leading to release of transcription factor (TF) NF-\u03ba\u03b2 whereas activated MAPKs releases transcription factor AP1 by activating JNK1/2 and p38.", [["IKK", "GENE_OR_GENE_PRODUCT", 0, 3], ["I\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 52, 55], ["TF", "GENE_OR_GENE_PRODUCT", 115, 117], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 119, 124], ["MAPKs", "GENE_OR_GENE_PRODUCT", 143, 148], ["AP1", "GENE_OR_GENE_PRODUCT", 179, 182], ["JNK1/2", "GENE_OR_GENE_PRODUCT", 197, 203], ["p38", "GENE_OR_GENE_PRODUCT", 208, 211], ["IKK complex", "PROTEIN", 0, 11], ["I\u03ba\u03b2", "PROTEIN", 52, 55], ["proteasomes", "PROTEIN", 59, 70], ["transcription factor (TF) NF-\u03ba\u03b2", "PROTEIN", 93, 124], ["MAPKs", "PROTEIN", 143, 148], ["transcription factor", "PROTEIN", 158, 178], ["AP1", "PROTEIN", 179, 182], ["JNK1/2", "PROTEIN", 197, 203], ["p38", "PROTEIN", 208, 211], ["IKK complex phosphorylates", "PROBLEM", 0, 26], ["transcription factor", "PROBLEM", 93, 113], ["JNK1", "TEST", 197, 201]]], ["These TFs translocate into the nucleus and bind to their corresponding TF binding segment on the DNA to induce transcription of cytokines, chemokines, interferons, interleukins etc. In TRIF pathway, TRIF binds to TIR domain via bridge molecule TRAM.", [["TFs", "ANATOMY", 6, 9], ["nucleus", "ANATOMY", 31, 38], ["TF", "ANATOMY", 71, 73], ["TFs", "CELL", 6, 9], ["nucleus", "CELLULAR_COMPONENT", 31, 38], ["TF", "GENE_OR_GENE_PRODUCT", 71, 73], ["DNA", "CELLULAR_COMPONENT", 97, 100], ["interferons", "GENE_OR_GENE_PRODUCT", 151, 162], ["interleukins etc", "GENE_OR_GENE_PRODUCT", 164, 180], ["TRIF", "GENE_OR_GENE_PRODUCT", 185, 189], ["TRIF", "GENE_OR_GENE_PRODUCT", 199, 203], ["TFs", "PROTEIN", 6, 9], ["TF binding segment", "DNA", 71, 89], ["cytokines", "PROTEIN", 128, 137], ["chemokines", "PROTEIN", 139, 149], ["interferons", "PROTEIN", 151, 162], ["interleukins", "PROTEIN", 164, 176], ["TRIF", "PROTEIN", 185, 189], ["TRIF", "PROTEIN", 199, 203], ["TIR domain", "PROTEIN", 213, 223], ["bridge molecule", "PROTEIN", 228, 243], ["TRAM", "PROTEIN", 244, 248], ["the DNA", "TREATMENT", 93, 100], ["cytokines", "TREATMENT", 128, 137], ["chemokines", "TREATMENT", 139, 149], ["interferons", "TREATMENT", 151, 162], ["interleukins etc", "TREATMENT", 164, 180], ["bridge molecule TRAM", "TREATMENT", 228, 248]]], ["TRIF binds TRAF3 and TRAF6.", [["TRIF", "GENE_OR_GENE_PRODUCT", 0, 4], ["TRAF3", "GENE_OR_GENE_PRODUCT", 11, 16], ["TRAF6", "GENE_OR_GENE_PRODUCT", 21, 26], ["TRIF", "PROTEIN", 0, 4], ["TRAF3", "PROTEIN", 11, 16], ["TRAF6", "PROTEIN", 21, 26]]], ["By binding to TRAF6 it normally activates MyD88 pathway whereas by binding with TRAF3 it activates TKB1 which further phosphorylates and activates IRF3 and IRF7.", [["TRAF6", "GENE_OR_GENE_PRODUCT", 14, 19], ["MyD88", "GENE_OR_GENE_PRODUCT", 42, 47], ["TRAF3", "GENE_OR_GENE_PRODUCT", 80, 85], ["TKB1", "GENE_OR_GENE_PRODUCT", 99, 103], ["IRF3", "GENE_OR_GENE_PRODUCT", 147, 151], ["IRF7", "GENE_OR_GENE_PRODUCT", 156, 160], ["TRAF6", "PROTEIN", 14, 19], ["MyD88", "PROTEIN", 42, 47], ["TRAF3", "PROTEIN", 80, 85], ["TKB1", "PROTEIN", 99, 103], ["IRF3", "PROTEIN", 147, 151], ["IRF7", "PROTEIN", 156, 160], ["TRAF3", "TREATMENT", 80, 85], ["further phosphorylates", "TREATMENT", 110, 132]]], ["Their homodimers enter nucleus and binds to its binding segment on DNA and transcribe IFN-\u03b1 and IFN-\u03b2.TLRs in infectious diseasesPathogen identification is a crucial component for induction of innate immune system in case of inflammation and is moderated through receptors termed PRRs, the pattern recognition receptors, which detect conserved molecular motifs on pathogens called PAMPs (pathogen associated molecular patterns) [38] .", [["nucleus", "ANATOMY", 23, 30], ["immune system", "ANATOMY", 200, 213], ["infectious diseases", "DISEASE", 110, 129], ["inflammation", "DISEASE", 225, 237], ["nucleus", "CELLULAR_COMPONENT", 23, 30], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 86, 91], ["IFN-\u03b2.", "GENE_OR_GENE_PRODUCT", 96, 102], ["TLRs", "GENE_OR_GENE_PRODUCT", 102, 106], ["PRRs", "GENE_OR_GENE_PRODUCT", 280, 284], ["PAMPs", "GENE_OR_GENE_PRODUCT", 381, 386], ["pathogen associated molecular patterns", "GENE_OR_GENE_PRODUCT", 388, 426], ["homodimers", "PROTEIN", 6, 16], ["IFN", "PROTEIN", 86, 89], ["IFN", "PROTEIN", 96, 99], ["TLRs", "PROTEIN", 102, 106], ["PRRs", "PROTEIN", 280, 284], ["pattern recognition receptors", "PROTEIN", 290, 319], ["PAMPs", "PROTEIN", 381, 386], ["IFN", "TEST", 96, 99], ["innate immune system", "TREATMENT", 193, 213], ["inflammation", "PROBLEM", 225, 237], ["PAMPs", "PROBLEM", 381, 386], ["nucleus", "ANATOMY_MODIFIER", 23, 30], ["infectious", "OBSERVATION", 110, 120], ["inflammation", "OBSERVATION", 225, 237]]], ["PRRs induce multitude of signalling pathways for accomplishment of early host response upon PAMP recognition, which is essential to kill infectious pathogens.TLRs in infectious diseasesThe first recognized PRRs were TLRs.", [["infectious diseases", "DISEASE", 166, 185], ["PRRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PAMP", "GENE_OR_GENE_PRODUCT", 92, 96], ["TLRs", "GENE_OR_GENE_PRODUCT", 158, 162], ["PRRs", "GENE_OR_GENE_PRODUCT", 206, 210], ["TLRs", "GENE_OR_GENE_PRODUCT", 216, 220], ["PRRs", "PROTEIN", 0, 4], ["PAMP", "PROTEIN", 92, 96], ["TLRs", "PROTEIN", 158, 162], ["PRRs", "PROTEIN", 206, 210], ["TLRs", "PROTEIN", 216, 220], ["PAMP recognition", "TEST", 92, 108], ["kill infectious pathogens", "PROBLEM", 132, 157], ["infectious", "OBSERVATION", 166, 176]]], ["TLRs identify broad array of PAMPs [13, [39] [40] [41] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["[39] [40] [41]", "SIMPLE_CHEMICAL", 40, 54], ["TLRs", "PROTEIN", 0, 4], ["PAMPs", "PROTEIN", 29, 34], ["PAMPs", "TEST", 29, 34]]], ["In humans, ten members of TLR family have been recognized and each one sense specific PAMPs derived from several pathogens such as bacteria, viruses, fungi, mycobacteria (Table 2 ) [4, 39] .", [["humans", "ORGANISM", 3, 9], ["TLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["PAMPs", "GENE_OR_GENE_PRODUCT", 86, 91], ["TLR family", "PROTEIN", 26, 36], ["PAMPs", "PROTEIN", 86, 91], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["several pathogens", "PROBLEM", 105, 122], ["bacteria", "PROBLEM", 131, 139], ["viruses", "PROBLEM", 141, 148], ["mycobacteria", "PROBLEM", 157, 169]]], ["Identification of particular PAMPs by TLR initiate signalling cascade, upon recruitment of adaptor molecule (for example MyD88), leading to discharge of interferon, chemokines and host defence peptides; which initiate macrophage activation, stimulation of interferonstimulated genes (ISGs) and recruitment of neutrophils causing infected microbe killing [4, 42] .", [["macrophage", "ANATOMY", 218, 228], ["neutrophils", "ANATOMY", 309, 320], ["PAMPs", "GENE_OR_GENE_PRODUCT", 29, 34], ["TLR", "GENE_OR_GENE_PRODUCT", 38, 41], ["MyD88", "GENE_OR_GENE_PRODUCT", 121, 126], ["interferon", "GENE_OR_GENE_PRODUCT", 153, 163], ["macrophage", "CELL", 218, 228], ["ISGs", "GENE_OR_GENE_PRODUCT", 284, 288], ["neutrophils", "CELL", 309, 320], ["PAMPs", "PROTEIN", 29, 34], ["TLR", "PROTEIN", 38, 41], ["adaptor molecule", "PROTEIN", 91, 107], ["MyD88", "PROTEIN", 121, 126], ["interferon", "PROTEIN", 153, 163], ["chemokines", "PROTEIN", 165, 175], ["interferonstimulated genes", "DNA", 256, 282], ["ISGs", "DNA", 284, 288], ["neutrophils", "CELL_TYPE", 309, 320], ["particular PAMPs", "TREATMENT", 18, 34], ["signalling cascade", "PROBLEM", 51, 69], ["interferon", "TREATMENT", 153, 163], ["chemokines", "TREATMENT", 165, 175], ["host defence peptides", "TREATMENT", 180, 201], ["macrophage activation", "TREATMENT", 218, 239], ["stimulation of interferonstimulated genes", "TREATMENT", 241, 282], ["neutrophils", "PROBLEM", 309, 320]]], ["Certain TLRs are localized to intracellular vesicles while some are localized to the cell surface.", [["intracellular vesicles", "ANATOMY", 30, 52], ["cell surface", "ANATOMY", 85, 97], ["TLRs", "GENE_OR_GENE_PRODUCT", 8, 12], ["intracellular vesicles", "CELLULAR_COMPONENT", 30, 52], ["cell surface", "CELLULAR_COMPONENT", 85, 97], ["TLRs", "PROTEIN", 8, 12], ["intracellular vesicles", "OBSERVATION", 30, 52], ["cell", "OBSERVATION_MODIFIER", 85, 89], ["surface", "OBSERVATION_MODIFIER", 90, 97]]], ["TLR9, TLR8, TLR7 and TLR3 sense nucleic acids and are localized in intracellular vesicles.", [["intracellular vesicles", "ANATOMY", 67, 89], ["nucleic acids", "CHEMICAL", 32, 45], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR8", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR7", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR3", "GENE_OR_GENE_PRODUCT", 21, 25], ["intracellular vesicles", "CELLULAR_COMPONENT", 67, 89], ["TLR9", "PROTEIN", 0, 4], ["TLR8", "PROTEIN", 6, 10], ["TLR7", "PROTEIN", 12, 16], ["TLR3", "PROTEIN", 21, 25], ["TLR9", "TEST", 0, 4], ["TLR8", "TEST", 6, 10], ["TLR7 and TLR3 sense nucleic acids", "TREATMENT", 12, 45], ["TLR8", "ANATOMY_MODIFIER", 6, 10], ["nucleic acids", "OBSERVATION", 32, 45], ["intracellular vesicles", "OBSERVATION", 67, 89]]], ["Cell surface TLRs such as TLR6, TLR5, TLR4, TLR2 and TLR1 sense microbial structures [43] .TLRs in microbial infectionsTLR-deficient mice have been used to study the role of TLRs in bacterial infections.", [["Cell surface", "ANATOMY", 0, 12], ["bacterial infections", "DISEASE", 182, 202], ["Cell", "CELL", 0, 4], ["TLRs", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR6", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLR5", "GENE_OR_GENE_PRODUCT", 32, 36], ["TLR4", "GENE_OR_GENE_PRODUCT", 38, 42], ["TLR2", "GENE_OR_GENE_PRODUCT", 44, 48], ["TLR1", "GENE_OR_GENE_PRODUCT", 53, 57], ["TLRs", "GENE_OR_GENE_PRODUCT", 91, 95], ["microbial infectionsTLR", "GENE_OR_GENE_PRODUCT", 99, 122], ["mice", "ORGANISM", 133, 137], ["TLRs", "GENE_OR_GENE_PRODUCT", 174, 178], ["Cell surface TLRs", "PROTEIN", 0, 17], ["TLR6", "PROTEIN", 26, 30], ["TLR5", "PROTEIN", 32, 36], ["TLR4", "PROTEIN", 38, 42], ["TLR2", "PROTEIN", 44, 48], ["TLR1", "PROTEIN", 53, 57], ["TLRs", "PROTEIN", 91, 95], ["TLRs", "PROTEIN", 174, 178], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 133, 137], ["Cell surface TLRs", "TEST", 0, 17], ["TLR6", "TEST", 26, 30], ["TLR5", "TEST", 32, 36], ["TLR4", "TEST", 38, 42], ["TLR2", "TEST", 44, 48], ["TLRs", "TREATMENT", 91, 95], ["microbial infectionsTLR-deficient mice", "TREATMENT", 99, 137], ["bacterial infections", "PROBLEM", 182, 202], ["TLR6", "ANATOMY_MODIFIER", 26, 30], ["bacterial", "OBSERVATION_MODIFIER", 182, 191], ["infections", "OBSERVATION", 192, 202]]], ["The gram-positive bacterium Staphylococcus aureus comprises numerous TLR PAMPs.", [["gram-", "GENE_OR_GENE_PRODUCT", 4, 9], ["Staphylococcus aureus", "ORGANISM", 28, 49], ["TLR PAMPs", "GENE_OR_GENE_PRODUCT", 69, 78], ["TLR PAMPs", "PROTEIN", 69, 78], ["Staphylococcus aureus", "SPECIES", 28, 49], ["Staphylococcus aureus", "SPECIES", 28, 49], ["The gram-positive bacterium Staphylococcus aureus", "PROBLEM", 0, 49], ["positive bacterium Staphylococcus aureus", "OBSERVATION", 9, 49], ["numerous", "OBSERVATION_MODIFIER", 60, 68], ["TLR PAMPs", "OBSERVATION", 69, 78]]], ["Lipoteichoic acid and lipoprotein are sensed by the TLR6-TLR2 heterodimer.", [["Lipoteichoic acid", "CHEMICAL", 0, 17], ["Lipoteichoic acid", "CHEMICAL", 0, 17], ["Lipoteichoic acid", "SIMPLE_CHEMICAL", 0, 17], ["lipoprotein", "SIMPLE_CHEMICAL", 22, 33], ["TLR6", "GENE_OR_GENE_PRODUCT", 52, 56], ["TLR2", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR6", "PROTEIN", 52, 56], ["TLR2 heterodimer", "PROTEIN", 57, 73], ["Lipoteichoic acid", "TEST", 0, 17], ["lipoprotein", "TEST", 22, 33], ["the TLR6-TLR2 heterodimer", "TREATMENT", 48, 73]]], ["After the infection with Staphylococcus aureus, there was decline in TLR2 deficient mice survival [44] .", [["infection", "DISEASE", 10, 19], ["Staphylococcus aureus", "DISEASE", 25, 46], ["Staphylococcus aureus", "ORGANISM", 25, 46], ["TLR2", "GENE_OR_GENE_PRODUCT", 69, 73], ["mice", "ORGANISM", 84, 88], ["TLR2", "PROTEIN", 69, 73], ["Staphylococcus aureus", "SPECIES", 25, 46], ["mice", "SPECIES", 84, 88], ["Staphylococcus aureus", "SPECIES", 25, 46], ["mice", "SPECIES", 84, 88], ["the infection", "PROBLEM", 6, 19], ["Staphylococcus aureus", "PROBLEM", 25, 46], ["infection", "OBSERVATION", 10, 19], ["Staphylococcus aureus", "OBSERVATION", 25, 46]]], ["After sinus and eye infection, TLR2 deficient mice signify increase in disease severeness and bio burden [45] suggesting that the TLR2 mediated sensing of the bacterial lipoproteins stimulates an immune response against Staphylococcus aureus.", [["sinus", "ANATOMY", 6, 11], ["eye", "ANATOMY", 16, 19], ["sinus and eye infection", "DISEASE", 6, 29], ["Staphylococcus aureus", "DISEASE", 220, 241], ["sinus", "MULTI-TISSUE_STRUCTURE", 6, 11], ["eye", "ORGAN", 16, 19], ["TLR2", "GENE_OR_GENE_PRODUCT", 31, 35], ["mice", "ORGANISM", 46, 50], ["TLR2", "GENE_OR_GENE_PRODUCT", 130, 134], ["Staphylococcus aureus", "ORGANISM", 220, 241], ["TLR2", "PROTEIN", 31, 35], ["TLR2", "PROTEIN", 130, 134], ["bacterial lipoproteins", "PROTEIN", 159, 181], ["mice", "SPECIES", 46, 50], ["Staphylococcus aureus", "SPECIES", 220, 241], ["mice", "SPECIES", 46, 50], ["Staphylococcus aureus", "SPECIES", 220, 241], ["sinus and eye infection", "PROBLEM", 6, 29], ["TLR2 deficient mice", "PROBLEM", 31, 50], ["increase in disease severeness", "PROBLEM", 59, 89], ["bio burden", "PROBLEM", 94, 104], ["the bacterial lipoproteins", "TREATMENT", 155, 181], ["Staphylococcus aureus", "PROBLEM", 220, 241], ["sinus", "ANATOMY", 6, 11], ["eye", "ANATOMY", 16, 19], ["infection", "OBSERVATION", 20, 29], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["disease", "OBSERVATION", 71, 78], ["Staphylococcus aureus", "OBSERVATION", 220, 241]]], ["But in case of bacterial brain abscess, both mice groups (control and TLR2 deficient) showed indistinguishable responses on bioburden and survival [46] .", [["brain abscess", "ANATOMY", 25, 38], ["brain abscess", "DISEASE", 25, 38], ["brain abscess", "PATHOLOGICAL_FORMATION", 25, 38], ["mice", "ORGANISM", 45, 49], ["TLR2", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR2", "PROTEIN", 70, 74], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["bacterial brain abscess", "PROBLEM", 15, 38], ["indistinguishable responses on bioburden", "PROBLEM", 93, 133], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["brain", "ANATOMY", 25, 30], ["abscess", "OBSERVATION", 31, 38]]], ["According to study of Miller et al. and Takeuchi et al 2000, in several mice infection groups, TLR2-deficient mice group was less vulnerable to bacterial infection than MyD88 deficient mice group, which proposed the role of another TLRs and IL-1R family members in stimulating immune responses [44, 46] .", [["infection", "DISEASE", 77, 86], ["bacterial infection", "DISEASE", 144, 163], ["mice", "ORGANISM", 72, 76], ["TLR2", "GENE_OR_GENE_PRODUCT", 95, 99], ["mice", "ORGANISM", 110, 114], ["MyD88", "GENE_OR_GENE_PRODUCT", 169, 174], ["mice", "ORGANISM", 185, 189], ["TLRs", "GENE_OR_GENE_PRODUCT", 232, 236], ["IL-1R", "GENE_OR_GENE_PRODUCT", 241, 246], ["TLR2", "PROTEIN", 95, 99], ["MyD88", "PROTEIN", 169, 174], ["TLRs", "PROTEIN", 232, 236], ["IL-1R family members", "PROTEIN", 241, 261], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 185, 189], ["bacterial infection", "PROBLEM", 144, 163], ["bacterial", "OBSERVATION_MODIFIER", 144, 153], ["infection", "OBSERVATION", 154, 163]]], ["Thus, both TLR2 signalling and IL-1R, in conjoint have been found to initiate immune responses against Staphylococcus aureus infection.TLRs in microbial infectionsThe gram-negative bacterium Salmonella typhimurium comprise numerous PAMPs sensed by TLRs.", [["Staphylococcus aureus infection", "DISEASE", 103, 134], ["microbial infections", "DISEASE", 143, 163], ["TLR2", "GENE_OR_GENE_PRODUCT", 11, 15], ["IL-1R", "GENE_OR_GENE_PRODUCT", 31, 36], ["Staphylococcus aureus", "ORGANISM", 103, 124], ["TLRs", "GENE_OR_GENE_PRODUCT", 135, 139], ["Salmonella typhimurium", "ORGANISM", 191, 213], ["PAMPs", "GENE_OR_GENE_PRODUCT", 232, 237], ["TLRs", "GENE_OR_GENE_PRODUCT", 248, 252], ["TLR2", "PROTEIN", 11, 15], ["IL-1R", "PROTEIN", 31, 36], ["TLRs", "PROTEIN", 135, 139], ["PAMPs", "PROTEIN", 232, 237], ["TLRs", "PROTEIN", 248, 252], ["Staphylococcus aureus", "SPECIES", 103, 124], ["Salmonella typhimurium", "SPECIES", 191, 213], ["Staphylococcus aureus", "SPECIES", 103, 124], ["Salmonella typhimurium", "SPECIES", 191, 213], ["Staphylococcus aureus infection", "PROBLEM", 103, 134], ["microbial infections", "PROBLEM", 143, 163], ["The gram", "TEST", 163, 171], ["negative bacterium Salmonella typhimurium", "PROBLEM", 172, 213], ["Staphylococcus aureus", "OBSERVATION", 103, 124], ["infection", "OBSERVATION", 125, 134], ["microbial", "OBSERVATION_MODIFIER", 143, 152], ["infections", "OBSERVATION", 153, 163], ["negative bacterium", "OBSERVATION_MODIFIER", 172, 190], ["Salmonella typhimurium", "OBSERVATION", 191, 213]]], ["Cytidine-phosphate-guanosine (CpG) DNA sensed by TLR9, lipoprotein sensed by TLR2, flagellin sensed by TLR5 and LPS sensed by TLR4 [45] .", [["Cytidine-phosphate", "CHEMICAL", 0, 18], ["guanosine", "CHEMICAL", 19, 28], ["CpG", "CHEMICAL", 30, 33], ["Cytidine-phosphate", "CHEMICAL", 0, 18], ["guanosine", "CHEMICAL", 19, 28], ["CpG", "CHEMICAL", 30, 33], ["Cytidine-phosphate-guanosine", "SIMPLE_CHEMICAL", 0, 28], ["CpG", "SIMPLE_CHEMICAL", 30, 33], ["DNA", "CELLULAR_COMPONENT", 35, 38], ["TLR9", "GENE_OR_GENE_PRODUCT", 49, 53], ["lipoprotein", "GENE_OR_GENE_PRODUCT", 55, 66], ["TLR2", "GENE_OR_GENE_PRODUCT", 77, 81], ["flagellin", "GENE_OR_GENE_PRODUCT", 83, 92], ["TLR5", "GENE_OR_GENE_PRODUCT", 103, 107], ["LPS", "GENE_OR_GENE_PRODUCT", 112, 115], ["TLR4", "GENE_OR_GENE_PRODUCT", 126, 130], ["Cytidine-phosphate-guanosine (CpG) DNA", "DNA", 0, 38], ["TLR9", "PROTEIN", 49, 53], ["TLR2", "PROTEIN", 77, 81], ["flagellin", "PROTEIN", 83, 92], ["TLR5", "PROTEIN", 103, 107], ["TLR4", "PROTEIN", 126, 130], ["Cytidine-phosphate", "TREATMENT", 0, 18], ["guanosine (CpG)", "TREATMENT", 19, 34], ["lipoprotein", "TEST", 55, 66]]], ["After the infection with Salmonella typhimurium, TLR4-deficient mice indicated growth and Salmonella typhimurium accumulation inside Mesenteric lymphadenitis and was found to be more vulnerable to bacterial infection than control group.", [["Mesenteric lymphadenitis", "ANATOMY", 133, 157], ["infection", "DISEASE", 10, 19], ["Mesenteric lymphadenitis", "DISEASE", 133, 157], ["bacterial infection", "DISEASE", 197, 216], ["Salmonella typhimurium", "ORGANISM", 25, 47], ["TLR4", "GENE_OR_GENE_PRODUCT", 49, 53], ["mice", "ORGANISM", 64, 68], ["Salmonella typhimurium", "ORGANISM", 90, 112], ["Mesenteric lymphadenitis", "PATHOLOGICAL_FORMATION", 133, 157], ["TLR4", "PROTEIN", 49, 53], ["Salmonella typhimurium", "SPECIES", 25, 47], ["mice", "SPECIES", 64, 68], ["Salmonella typhimurium", "SPECIES", 90, 112], ["Salmonella typhimurium", "SPECIES", 25, 47], ["mice", "SPECIES", 64, 68], ["Salmonella typhimurium", "SPECIES", 90, 112], ["the infection", "PROBLEM", 6, 19], ["Salmonella typhimurium", "TREATMENT", 25, 47], ["TLR4-deficient mice", "TREATMENT", 49, 68], ["Salmonella typhimurium accumulation", "PROBLEM", 90, 125], ["Mesenteric lymphadenitis", "PROBLEM", 133, 157], ["bacterial infection", "PROBLEM", 197, 216], ["infection", "OBSERVATION", 10, 19], ["growth", "OBSERVATION_MODIFIER", 79, 85], ["Salmonella typhimurium", "OBSERVATION", 90, 112], ["Mesenteric", "ANATOMY", 133, 143], ["lymphadenitis", "OBSERVATION", 144, 157], ["bacterial", "OBSERVATION_MODIFIER", 197, 206], ["infection", "OBSERVATION", 207, 216]]], ["Weiss et al. reported that even during lack of functional TLR4, TLR2 efficiently respond to the infection as TLR4 and TLR2-deficient group was more vulnerable to the infection than TLR4 knock-out group [47] .TLRs in microbial infectionsMycobacterium tuberculosis (M. tuberculosis), the causative pathogen of tuberculosis is present in aerosol particles.", [["infection", "DISEASE", 96, 105], ["infection", "DISEASE", 166, 175], ["microbial infections", "DISEASE", 216, 236], ["Mycobacterium tuberculosis", "DISEASE", 236, 262], ["M. tuberculosis", "DISEASE", 264, 279], ["tuberculosis", "DISEASE", 308, 320], ["TLR4", "GENE_OR_GENE_PRODUCT", 58, 62], ["TLR2", "GENE_OR_GENE_PRODUCT", 64, 68], ["TLR4", "GENE_OR_GENE_PRODUCT", 109, 113], ["TLR2", "GENE_OR_GENE_PRODUCT", 118, 122], ["TLR4", "GENE_OR_GENE_PRODUCT", 181, 185], ["TLRs", "GENE_OR_GENE_PRODUCT", 208, 212], ["microbial infections", "ORGANISM", 216, 236], ["Mycobacterium tuberculosis", "ORGANISM", 236, 262], ["M. tuberculosis", "ORGANISM", 264, 279], ["TLR4", "PROTEIN", 58, 62], ["TLR2", "PROTEIN", 64, 68], ["TLR4", "PROTEIN", 109, 113], ["TLR2", "PROTEIN", 118, 122], ["TLR4", "PROTEIN", 181, 185], ["TLRs", "PROTEIN", 208, 212], ["Mycobacterium tuberculosis", "SPECIES", 236, 262], ["M. tuberculosis", "SPECIES", 264, 279], ["Mycobacterium tuberculosis", "SPECIES", 236, 262], ["M. tuberculosis", "SPECIES", 264, 279], ["the infection", "PROBLEM", 92, 105], ["TLR4 and TLR2-deficient group", "TREATMENT", 109, 138], ["the infection", "PROBLEM", 162, 175], ["TLR4 knock", "TEST", 181, 191], ["TLRs", "TREATMENT", 208, 212], ["microbial infections", "PROBLEM", 216, 236], ["Mycobacterium tuberculosis (M. tuberculosis", "PROBLEM", 236, 279], ["the causative pathogen of tuberculosis", "PROBLEM", 282, 320], ["infection", "OBSERVATION", 96, 105], ["infection", "OBSERVATION", 166, 175], ["microbial", "OBSERVATION_MODIFIER", 216, 225], ["infections", "OBSERVATION_MODIFIER", 226, 236], ["Mycobacterium tuberculosis", "OBSERVATION", 236, 262], ["pathogen", "OBSERVATION_MODIFIER", 296, 304], ["tuberculosis", "OBSERVATION", 308, 320], ["aerosol particles", "OBSERVATION", 335, 352]]], ["M. tuberculosis reproduce in the phagosome of dust cells (alveolar macrophages).", [["phagosome", "ANATOMY", 33, 42], ["dust cells", "ANATOMY", 46, 56], ["alveolar macrophages", "ANATOMY", 58, 78], ["M. tuberculosis", "ORGANISM", 0, 15], ["phagosome", "CELLULAR_COMPONENT", 33, 42], ["dust cells", "CELL", 46, 56], ["alveolar macrophages", "CELL", 58, 78], ["dust cells", "CELL_TYPE", 46, 56], ["alveolar macrophages", "CELL_TYPE", 58, 78], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis", "SPECIES", 0, 15], ["M. tuberculosis", "PROBLEM", 0, 15], ["tuberculosis", "OBSERVATION", 3, 15], ["phagosome", "OBSERVATION_MODIFIER", 33, 42], ["dust cells", "OBSERVATION", 46, 56], ["alveolar macrophages", "OBSERVATION", 58, 78]]], ["TLR9, TLR4 and TLR2, expressed on the surface of alveolar macrophages recognize the primary Mycobacterium infection and initiate transcription of IL-6, TNF\u03b1 and IL-12 inflammatory cytokines in order to regulate infection [45, 48] .", [["surface", "ANATOMY", 38, 45], ["alveolar macrophages", "ANATOMY", 49, 69], ["Mycobacterium infection", "DISEASE", 92, 115], ["infection", "DISEASE", 211, 220], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR2", "GENE_OR_GENE_PRODUCT", 15, 19], ["surface", "CELLULAR_COMPONENT", 38, 45], ["alveolar macrophages", "CELL", 49, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 146, 150], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 152, 156], ["IL-12", "GENE_OR_GENE_PRODUCT", 161, 166], ["TLR9", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 6, 10], ["TLR2", "PROTEIN", 15, 19], ["alveolar macrophages", "CELL_TYPE", 49, 69], ["IL-6", "PROTEIN", 146, 150], ["TNF\u03b1", "PROTEIN", 152, 156], ["inflammatory cytokines", "PROTEIN", 167, 189], ["TLR2", "TREATMENT", 15, 19], ["alveolar macrophages", "PROBLEM", 49, 69], ["the primary Mycobacterium infection", "PROBLEM", 80, 115], ["transcription of IL", "TREATMENT", 129, 148], ["TNF", "TREATMENT", 152, 155], ["IL", "TREATMENT", 161, 163], ["inflammatory cytokines", "TREATMENT", 167, 189], ["infection", "PROBLEM", 211, 220], ["alveolar macrophages", "OBSERVATION", 49, 69], ["primary", "OBSERVATION_MODIFIER", 84, 91], ["Mycobacterium infection", "OBSERVATION", 92, 115], ["infection", "OBSERVATION", 211, 220]]], ["According to some reports, M. tuberculosis inhibited the MyD88 dependent TLR2 signalling [4, 49] .", [["tuberculosis", "DISEASE", 30, 42], ["M. tuberculosis", "ORGANISM", 27, 42], ["MyD88", "GENE_OR_GENE_PRODUCT", 57, 62], ["TLR2", "GENE_OR_GENE_PRODUCT", 73, 77], ["MyD88", "PROTEIN", 57, 62], ["TLR2", "PROTEIN", 73, 77], ["M. tuberculosis", "SPECIES", 27, 42], ["M. tuberculosis", "SPECIES", 27, 42], ["tuberculosis", "OBSERVATION", 30, 42]]], ["MyD88 deficient mice group infected with M. tuberculosis was highly vulnerable to the infection and exhibited high bioburden and reduced secretion of TNF-\u03b1 and IL-12, suggesting that sensing of M. tuberculosis by TLR generated innate immunity against Mycobacterium infection [48] .", [["M. tuberculosis", "DISEASE", 41, 56], ["infection", "DISEASE", 86, 95], ["tuberculosis", "DISEASE", 197, 209], ["Mycobacterium infection", "DISEASE", 251, 274], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 16, 20], ["M. tuberculosis", "ORGANISM", 41, 56], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 150, 155], ["IL-12", "GENE_OR_GENE_PRODUCT", 160, 165], ["M. tuberculosis", "ORGANISM", 194, 209], ["TLR", "GENE_OR_GENE_PRODUCT", 213, 216], ["MyD88", "PROTEIN", 0, 5], ["TNF", "PROTEIN", 150, 153], ["IL-12", "PROTEIN", 160, 165], ["TLR", "PROTEIN", 213, 216], ["mice", "SPECIES", 16, 20], ["M. tuberculosis", "SPECIES", 41, 56], ["M. tuberculosis", "SPECIES", 194, 209], ["mice", "SPECIES", 16, 20], ["M. tuberculosis", "SPECIES", 41, 56], ["M. tuberculosis", "SPECIES", 194, 209], ["M. tuberculosis", "PROBLEM", 41, 56], ["the infection", "PROBLEM", 82, 95], ["high bioburden", "PROBLEM", 110, 124], ["reduced secretion of TNF", "PROBLEM", 129, 153], ["IL", "TEST", 160, 162], ["M. tuberculosis", "PROBLEM", 194, 209], ["Mycobacterium infection", "PROBLEM", 251, 274], ["tuberculosis", "OBSERVATION", 44, 56], ["infection", "OBSERVATION", 86, 95], ["high", "OBSERVATION_MODIFIER", 110, 114], ["bioburden", "OBSERVATION", 115, 124]]], ["According to several reports, high dosage of Mycobacterium infection into TLR9 and TLR2 deficient mice groups showed high vulnerability to infection but some reports suggested that low dosage of Mycobacterium infection into TLR9, TLR4 or TLR2 deficient mice group showed very less vulnerability to infection [48] .", [["Mycobacterium infection", "DISEASE", 45, 68], ["infection", "DISEASE", 139, 148], ["Mycobacterium infection", "DISEASE", 195, 218], ["infection", "DISEASE", 298, 307], ["TLR9", "GENE_OR_GENE_PRODUCT", 74, 78], ["TLR2", "GENE_OR_GENE_PRODUCT", 83, 87], ["mice", "ORGANISM", 98, 102], ["TLR9", "GENE_OR_GENE_PRODUCT", 224, 228], ["TLR4", "GENE_OR_GENE_PRODUCT", 230, 234], ["TLR2", "GENE_OR_GENE_PRODUCT", 238, 242], ["TLR9", "PROTEIN", 74, 78], ["TLR2", "PROTEIN", 83, 87], ["TLR9", "PROTEIN", 224, 228], ["TLR4", "PROTEIN", 230, 234], ["TLR2", "PROTEIN", 238, 242], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 98, 102], ["Mycobacterium infection", "PROBLEM", 45, 68], ["high vulnerability to infection", "PROBLEM", 117, 148], ["Mycobacterium infection into TLR9", "PROBLEM", 195, 228], ["very less vulnerability to infection", "PROBLEM", 271, 307], ["Mycobacterium", "OBSERVATION", 45, 58], ["high vulnerability", "OBSERVATION_MODIFIER", 117, 135], ["infection", "OBSERVATION", 139, 148], ["low dosage", "OBSERVATION_MODIFIER", 181, 191], ["Mycobacterium", "OBSERVATION", 195, 208], ["infection", "OBSERVATION", 298, 307]]], ["According to Holscher et al. [270] , both control and TLR9-TLR4-TLR2 deficient mice groups infected with Mycobacterium exhibited controlled growth of M. tuberculosis in lung.", [["lung", "ANATOMY", 169, 173], ["Mycobacterium", "CHEMICAL", 105, 118], ["tuberculosis", "DISEASE", 153, 165], ["TLR9", "GENE_OR_GENE_PRODUCT", 54, 58], ["TLR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["TLR2", "GENE_OR_GENE_PRODUCT", 64, 68], ["mice", "ORGANISM", 79, 83], ["M. tuberculosis", "ORGANISM", 150, 165], ["lung", "ORGAN", 169, 173], ["TLR9", "PROTEIN", 54, 58], ["TLR4", "PROTEIN", 59, 63], ["TLR2", "PROTEIN", 64, 68], ["mice", "SPECIES", 79, 83], ["M. tuberculosis", "SPECIES", 150, 165], ["mice", "SPECIES", 79, 83], ["M. tuberculosis", "SPECIES", 150, 165], ["TLR9", "TEST", 54, 58], ["Mycobacterium", "PROBLEM", 105, 118], ["M. tuberculosis in lung", "PROBLEM", 150, 173], ["growth", "OBSERVATION_MODIFIER", 140, 146], ["M.", "OBSERVATION_MODIFIER", 150, 152], ["tuberculosis", "OBSERVATION", 153, 165], ["lung", "ANATOMY", 169, 173]]], ["Hence, TLRs sensing discrete M. tuberculosis PAMP are mostly superfluous in stimulating the innate immune response against low dose aerosol infection of M. tuberculosis.TLRs in microbial infectionsInvasive candidiasis is an infection caused by fungus Candida and is a life-threatening infection for immunosuppressed individuals.", [["infection", "DISEASE", 140, 149], ["tuberculosis", "DISEASE", 156, 168], ["microbial infections", "DISEASE", 177, 197], ["Invasive candidiasis", "DISEASE", 197, 217], ["infection", "DISEASE", 224, 233], ["infection", "DISEASE", 285, 294], ["TLRs", "GENE_OR_GENE_PRODUCT", 7, 11], ["M. tuberculosis", "ORGANISM", 29, 44], ["PAMP", "GENE_OR_GENE_PRODUCT", 45, 49], ["M. tuberculosis", "ORGANISM", 153, 168], ["TLRs", "GENE_OR_GENE_PRODUCT", 169, 173], ["TLRs", "PROTEIN", 7, 11], ["TLRs", "PROTEIN", 169, 173], ["M. tuberculosis", "SPECIES", 29, 44], ["M. tuberculosis", "SPECIES", 153, 168], ["M. tuberculosis", "SPECIES", 29, 44], ["M. tuberculosis", "SPECIES", 153, 168], ["tuberculosis PAMP", "PROBLEM", 32, 49], ["low dose aerosol infection", "PROBLEM", 123, 149], ["M. tuberculosis", "PROBLEM", 153, 168], ["microbial infections", "PROBLEM", 177, 197], ["Invasive candidiasis", "PROBLEM", 197, 217], ["an infection", "PROBLEM", 221, 233], ["fungus Candida", "PROBLEM", 244, 258], ["a life-threatening infection", "PROBLEM", 266, 294], ["immunosuppressed individuals", "PROBLEM", 299, 327], ["tuberculosis", "OBSERVATION", 32, 44], ["mostly", "OBSERVATION_MODIFIER", 54, 60], ["superfluous", "OBSERVATION_MODIFIER", 61, 72], ["tuberculosis", "OBSERVATION", 156, 168], ["microbial", "OBSERVATION_MODIFIER", 177, 186], ["infections", "OBSERVATION", 187, 197], ["candidiasis", "OBSERVATION", 206, 217], ["infection", "OBSERVATION", 224, 233], ["fungus Candida", "OBSERVATION", 244, 258], ["infection", "OBSERVATION", 285, 294]]], ["Dendritic cells recognize the Candida infection and initiate the secretion of cytokines as well as the upregulation of molecules that cause na\u00efve T cells differentiation in T helper 17 cell (Th17), T helper 2 cell (Th2), T helper 1 cell (Th1) and Regulatory T (Treg) cells.", [["Dendritic cells", "ANATOMY", 0, 15], ["na\u00efve T cells", "ANATOMY", 140, 153], ["T helper 17 cell", "ANATOMY", 173, 189], ["Th17", "ANATOMY", 191, 195], ["T helper 2 cell", "ANATOMY", 198, 213], ["T helper 1 cell", "ANATOMY", 221, 236], ["Regulatory T (Treg) cells", "ANATOMY", 247, 272], ["Candida infection", "DISEASE", 30, 47], ["Dendritic cells", "CELL", 0, 15], ["na\u00efve T cells", "CELL", 140, 153], ["T helper 17 cell", "CELL", 173, 189], ["Th17", "CELL", 191, 195], ["T helper 2 cell", "CELL", 198, 213], ["Th2", "CELL", 215, 218], ["T helper 1 cell", "CELL", 221, 236], ["Th1", "CELL", 238, 241], ["Regulatory T (Treg) cells", "CELL", 247, 272], ["Dendritic cells", "CELL_TYPE", 0, 15], ["cytokines", "PROTEIN", 78, 87], ["na\u00efve T cells", "CELL_TYPE", 140, 153], ["T helper 17 cell", "CELL_TYPE", 173, 189], ["Th17", "CELL_TYPE", 191, 195], ["T helper 2 cell (Th2), T helper 1 cell (Th1) and Regulatory T (Treg) cells", "CELL_TYPE", 198, 272], ["Dendritic cells", "PROBLEM", 0, 15], ["the Candida infection", "PROBLEM", 26, 47], ["the secretion of cytokines", "TREATMENT", 61, 87], ["the upregulation of molecules", "PROBLEM", 99, 128], ["na\u00efve T cells differentiation", "PROBLEM", 140, 169], ["Regulatory T (Treg) cells", "TREATMENT", 247, 272], ["Candida infection", "OBSERVATION", 30, 47]]], ["It has been reported that innate immunity is repressed by inducing a detrimental Treg and Th2 cells response in a mouse model infected with Candida albicans.", [["Treg", "ANATOMY", 81, 85], ["Th2 cells", "ANATOMY", 90, 99], ["Candida albicans", "DISEASE", 140, 156], ["Treg", "CELL", 81, 85], ["Th2 cells", "CELL", 90, 99], ["mouse", "ORGANISM", 114, 119], ["Candida albicans", "ORGANISM", 140, 156], ["Th2 cells", "CELL_TYPE", 90, 99], ["mouse", "SPECIES", 114, 119], ["Candida albicans", "SPECIES", 140, 156], ["mouse", "SPECIES", 114, 119], ["Candida albicans", "SPECIES", 140, 156], ["a detrimental Treg and Th2 cells response", "TREATMENT", 67, 108], ["Candida albicans", "PROBLEM", 140, 156], ["Th2 cells", "OBSERVATION", 90, 99], ["infected", "OBSERVATION_MODIFIER", 126, 134], ["Candida albicans", "OBSERVATION", 140, 156]]], ["However, Th17 and Th1 cell responses play a vital role in protection against Candida albicans infection.", [["Th17", "ANATOMY", 9, 13], ["Th1 cell", "ANATOMY", 18, 26], ["Candida albicans infection", "DISEASE", 77, 103], ["Th17", "CELL", 9, 13], ["Th1 cell", "CELL", 18, 26], ["Candida albicans", "ORGANISM", 77, 93], ["Candida albicans", "SPECIES", 77, 93], ["Candida albicans", "SPECIES", 77, 93], ["Candida albicans infection", "PROBLEM", 77, 103], ["Th1 cell", "OBSERVATION", 18, 26]]], ["Candida species comprise numerous PAMPs such as mannan, nucleic acids, chitin and \u03b2-glucan and these PAMPs are sensed by TLR9, TLR7, TLR6, TLR4 and TLR2 [50, 51] .TLRs in microbial infectionsPAMP such as mannans is expressed through Candida albicans (C. albicans) and Saccharomyces cerevisiae (S. cerevisiae) is sensed by TLR4 leading to the secretion of TNF-\u03b1 [50] .", [["nucleic acids", "CHEMICAL", 56, 69], ["chitin", "CHEMICAL", 71, 77], ["\u03b2-glucan", "CHEMICAL", 82, 90], ["infections", "DISEASE", 181, 191], ["mannans", "CHEMICAL", 204, 211], ["Candida species", "ORGANISM", 0, 15], ["PAMPs", "GENE_OR_GENE_PRODUCT", 34, 39], ["mannan", "SIMPLE_CHEMICAL", 48, 54], ["nucleic acids", "SIMPLE_CHEMICAL", 56, 69], ["chitin", "SIMPLE_CHEMICAL", 71, 77], ["\u03b2-glucan", "SIMPLE_CHEMICAL", 82, 90], ["PAMPs", "GENE_OR_GENE_PRODUCT", 101, 106], ["TLR9", "GENE_OR_GENE_PRODUCT", 121, 125], ["TLR7", "GENE_OR_GENE_PRODUCT", 127, 131], ["TLR6", "GENE_OR_GENE_PRODUCT", 133, 137], ["TLR4", "GENE_OR_GENE_PRODUCT", 139, 143], ["TLR2", "GENE_OR_GENE_PRODUCT", 148, 152], ["TLRs", "GENE_OR_GENE_PRODUCT", 163, 167], ["PAMP", "GENE_OR_GENE_PRODUCT", 191, 195], ["mannans", "GENE_OR_GENE_PRODUCT", 204, 211], ["Candida albicans", "ORGANISM", 233, 249], ["C. albicans", "ORGANISM", 251, 262], ["Saccharomyces cerevisiae", "ORGANISM", 268, 292], ["S. cerevisiae", "ORGANISM", 294, 307], ["TLR4", "GENE_OR_GENE_PRODUCT", 322, 326], ["TNF", "GENE_OR_GENE_PRODUCT", 355, 358], ["PAMPs", "PROTEIN", 34, 39], ["mannan", "PROTEIN", 48, 54], ["chitin", "PROTEIN", 71, 77], ["\u03b2-glucan", "PROTEIN", 82, 90], ["PAMPs", "PROTEIN", 101, 106], ["TLR9", "PROTEIN", 121, 125], ["TLR7", "PROTEIN", 127, 131], ["TLR6", "PROTEIN", 133, 137], ["TLR4", "PROTEIN", 139, 143], ["TLR2", "PROTEIN", 148, 152], ["TLRs", "PROTEIN", 163, 167], ["TLR4", "PROTEIN", 322, 326], ["TNF", "PROTEIN", 355, 358], ["Candida albicans", "SPECIES", 233, 249], ["C. albicans", "SPECIES", 251, 262], ["Saccharomyces cerevisiae", "SPECIES", 268, 292], ["S. cerevisiae", "SPECIES", 294, 307], ["Candida albicans", "SPECIES", 233, 249], ["C. albicans", "SPECIES", 251, 262], ["Saccharomyces cerevisiae", "SPECIES", 268, 292], ["S. cerevisiae", "SPECIES", 294, 307], ["Candida species", "PROBLEM", 0, 15], ["numerous PAMPs", "PROBLEM", 25, 39], ["mannan", "TEST", 48, 54], ["nucleic acids", "TEST", 56, 69], ["chitin and \u03b2-glucan", "TEST", 71, 90], ["these PAMPs", "TEST", 95, 106], ["TLR9", "TEST", 121, 125], ["TLR7", "TEST", 127, 131], ["TLR6", "TEST", 133, 137], ["TLR4", "TEST", 139, 143], ["TLR2", "TEST", 148, 152], ["TLRs", "TREATMENT", 163, 167], ["microbial infectionsPAMP", "PROBLEM", 171, 195], ["Candida albicans", "PROBLEM", 233, 249], ["Saccharomyces cerevisiae", "TREATMENT", 268, 292], ["microbial", "OBSERVATION_MODIFIER", 171, 180], ["infections", "OBSERVATION", 181, 191]]], ["According to the Netea and Marodi, TLR4 defective C3H/HeJ mice infected with C. albicans exhibit reduced secretion of cytokines and chemokines through macrophages and the group was more vulnerable to the infection than control mice.", [["macrophages", "ANATOMY", 151, 162], ["infection", "DISEASE", 204, 213], ["Marodi", "GENE_OR_GENE_PRODUCT", 27, 33], ["TLR4", "GENE_OR_GENE_PRODUCT", 35, 39], ["C3H/HeJ mice", "ORGANISM", 50, 62], ["C. albicans", "ORGANISM", 77, 88], ["macrophages", "CELL", 151, 162], ["mice", "ORGANISM", 227, 231], ["TLR4", "PROTEIN", 35, 39], ["cytokines", "PROTEIN", 118, 127], ["chemokines", "PROTEIN", 132, 142], ["macrophages", "CELL_TYPE", 151, 162], ["mice", "SPECIES", 58, 62], ["C. albicans", "SPECIES", 77, 88], ["mice", "SPECIES", 227, 231], ["mice", "SPECIES", 58, 62], ["C. albicans", "SPECIES", 77, 88], ["mice", "SPECIES", 227, 231], ["C. albicans", "PROBLEM", 77, 88], ["reduced secretion of cytokines", "PROBLEM", 97, 127], ["chemokines through macrophages", "TREATMENT", 132, 162], ["the infection", "PROBLEM", 200, 213], ["infection", "OBSERVATION", 204, 213]]], ["Moreover, TLR4 deficient mice group primarily infected with less virulent Candida yeast and re-infected with Candida hyphae exhibited vulnerability to the infection.", [["hyphae", "ANATOMY", 117, 123], ["infection", "DISEASE", 155, 164], ["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["mice", "ORGANISM", 25, 29], ["Candida yeast", "ORGANISM", 74, 87], ["Candida hyphae", "ORGANISM", 109, 123], ["TLR4", "PROTEIN", 10, 14], ["mice", "SPECIES", 25, 29], ["Candida yeast", "SPECIES", 74, 87], ["mice", "SPECIES", 25, 29], ["Candida yeast", "SPECIES", 74, 87], ["less virulent Candida yeast", "PROBLEM", 60, 87], ["Candida hyphae", "PROBLEM", 109, 123], ["the infection", "PROBLEM", 151, 164], ["less virulent", "OBSERVATION_MODIFIER", 60, 73], ["Candida yeast", "OBSERVATION", 74, 87], ["Candida hyphae", "OBSERVATION", 109, 123], ["infection", "OBSERVATION", 155, 164]]], ["But some reports also suggested that when TLR4-deficient mice are infected with Candida hyphae, they live more than control mice group [50] .TLRs in microbial infectionsMyD88 deficient mice infected with Candida albicans show high vulnerability to the infection.", [["hyphae", "ANATOMY", 88, 94], ["microbial infections", "DISEASE", 149, 169], ["infection", "DISEASE", 252, 261], ["TLR4", "GENE_OR_GENE_PRODUCT", 42, 46], ["mice", "ORGANISM", 57, 61], ["Candida hyphae", "ORGANISM", 80, 94], ["mice", "ORGANISM", 124, 128], ["TLRs", "GENE_OR_GENE_PRODUCT", 141, 145], ["MyD88", "GENE_OR_GENE_PRODUCT", 169, 174], ["mice", "ORGANISM", 185, 189], ["Candida albicans", "ORGANISM", 204, 220], ["TLR4", "PROTEIN", 42, 46], ["TLRs", "PROTEIN", 141, 145], ["MyD88", "PROTEIN", 169, 174], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 185, 189], ["Candida albicans", "SPECIES", 204, 220], ["mice", "SPECIES", 57, 61], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 185, 189], ["Candida albicans", "SPECIES", 204, 220], ["Candida hyphae", "PROBLEM", 80, 94], ["TLRs", "TREATMENT", 141, 145], ["Candida albicans", "PROBLEM", 204, 220], ["the infection", "PROBLEM", 248, 261], ["high vulnerability", "OBSERVATION_MODIFIER", 226, 244], ["infection", "OBSERVATION", 252, 261]]], ["The role of IL-1R/TLR mediated responses has been owed to the high vulnerability of mice [52] .", [["IL-1R", "GENE_OR_GENE_PRODUCT", 12, 17], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["mice", "ORGANISM", 84, 88], ["IL-1R", "PROTEIN", 12, 17], ["TLR", "PROTEIN", 18, 21], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["IL-1R/TLR mediated responses", "TREATMENT", 12, 40]]], ["There are some conflicting studies on specific TLRs function to stimulate host immune responses against Candida spp.", [["TLRs", "GENE_OR_GENE_PRODUCT", 47, 51], ["Candida spp", "ORGANISM", 104, 115], ["TLRs", "PROTEIN", 47, 51], ["Candida spp", "PROBLEM", 104, 115], ["some", "OBSERVATION_MODIFIER", 10, 14], ["conflicting", "OBSERVATION", 15, 26]]], ["According to some reports, TLR2 plays redundant role against fungal infection in in vivo conditions.", [["fungal infection", "DISEASE", 61, 77], ["TLR2", "GENE_OR_GENE_PRODUCT", 27, 31], ["TLR2", "PROTEIN", 27, 31], ["fungal infection in in vivo conditions", "PROBLEM", 61, 99], ["fungal", "OBSERVATION_MODIFIER", 61, 67], ["infection", "OBSERVATION", 68, 77]]], ["TLR2 deficient mice group is more vulnerable to the Candida fungal infection than the control mice group and secrete low level of chemokines and TNF-\u03b1.", [["fungal infection", "DISEASE", 60, 76], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 15, 19], ["Candida fungal", "ORGANISM", 52, 66], ["mice", "ORGANISM", 94, 98], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 145, 151], ["TLR2", "PROTEIN", 0, 4], ["chemokines", "PROTEIN", 130, 140], ["TNF", "PROTEIN", 145, 148], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 94, 98], ["TLR2 deficient mice group", "TREATMENT", 0, 25], ["the Candida fungal infection", "PROBLEM", 48, 76], ["secrete low level of chemokines", "PROBLEM", 109, 140], ["TNF", "TEST", 145, 148], ["Candida", "OBSERVATION_MODIFIER", 52, 59], ["fungal", "OBSERVATION_MODIFIER", 60, 66], ["infection", "OBSERVATION", 67, 76]]], ["Furthermore, Both TLR2 deficient mice group and control mice group are defended against another challenge with virulent Candida albicans, even though, TLR2 deficient mice group exhibit reduced production of antibody against less virulent Candida species than control mice group [50] .", [["Candida albicans", "DISEASE", 120, 136], ["TLR2", "GENE_OR_GENE_PRODUCT", 18, 22], ["mice", "ORGANISM", 33, 37], ["control mice", "ORGANISM", 48, 60], ["Candida albicans", "ORGANISM", 120, 136], ["TLR2", "GENE_OR_GENE_PRODUCT", 151, 155], ["mice", "ORGANISM", 166, 170], ["Candida species", "ORGANISM", 238, 253], ["mice", "ORGANISM", 267, 271], ["TLR2", "PROTEIN", 18, 22], ["TLR2", "PROTEIN", 151, 155], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 56, 60], ["Candida albicans", "SPECIES", 120, 136], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 267, 271], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 56, 60], ["Candida albicans", "SPECIES", 120, 136], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 267, 271], ["Both TLR2 deficient mice group", "TREATMENT", 13, 43], ["virulent Candida albicans", "PROBLEM", 111, 136], ["reduced production of antibody", "PROBLEM", 185, 215], ["less virulent Candida species", "PROBLEM", 224, 253]]], ["Several reports suggested that, TLR2 mediated sensing of Candida species can be detrimental for the host species, as TLR2 deficient mice show reduced production of IL-10 and elevated secretion of IFN-\u03b3 and IL-12 and due to this, TLR2 deficient mice exhibit more resistance against Candida species infection Fungus TLR7 RNA TLR4, TLR2 Mannan TLR6, TLR2 \u03b2-Glucan, zymosan TLR9 DNA Mycobacteria, bacteria TLR7 RNA TLR4 Lipopolysaccharide TLR9 DNA TLR6, TLR2, TLR1 Lipoproteins TLR5 Flagellin Viruses TLR8, TLR7, TLR3 RNA TLR9 DNA TLR4, TLR2 Structural protein than control group [53, 54] .TLRs in microbial infectionsIn viruses, nucleotides act as PAMPs and are sensed by several TLRs.", [["infection", "DISEASE", 297, 306], ["microbial infections", "DISEASE", 594, 614], ["nucleotides", "CHEMICAL", 626, 637], ["TLR2", "GENE_OR_GENE_PRODUCT", 32, 36], ["Candida species", "ORGANISM", 57, 72], ["TLR2", "GENE_OR_GENE_PRODUCT", 117, 121], ["mice", "ORGANISM", 132, 136], ["IL-10", "GENE_OR_GENE_PRODUCT", 164, 169], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 196, 201], ["IL-12", "GENE_OR_GENE_PRODUCT", 206, 211], ["TLR2", "GENE_OR_GENE_PRODUCT", 229, 233], ["mice", "ORGANISM", 244, 248], ["Candida species", "ORGANISM", 281, 296], ["TLR7", "GENE_OR_GENE_PRODUCT", 314, 318], ["TLR4", "GENE_OR_GENE_PRODUCT", 323, 327], ["TLR2", "GENE_OR_GENE_PRODUCT", 329, 333], ["TLR6", "GENE_OR_GENE_PRODUCT", 341, 345], ["TLR2 \u03b2-Glucan", "GENE_OR_GENE_PRODUCT", 347, 360], ["zymosan TLR9", "GENE_OR_GENE_PRODUCT", 362, 374], ["DNA", "CELLULAR_COMPONENT", 375, 378], ["TLR7", "GENE_OR_GENE_PRODUCT", 402, 406], ["TLR4 Lipopolysaccharide TLR9", "GENE_OR_GENE_PRODUCT", 411, 439], ["DNA", "CELLULAR_COMPONENT", 440, 443], ["TLR6", "GENE_OR_GENE_PRODUCT", 444, 448], ["TLR2", "GENE_OR_GENE_PRODUCT", 450, 454], ["TLR1", "GENE_OR_GENE_PRODUCT", 456, 460], ["TLR5", "GENE_OR_GENE_PRODUCT", 474, 478], ["TLR8", "GENE_OR_GENE_PRODUCT", 497, 501], ["TLR7", "GENE_OR_GENE_PRODUCT", 503, 507], ["TLR3", "GENE_OR_GENE_PRODUCT", 509, 513], ["TLR9", "GENE_OR_GENE_PRODUCT", 518, 522], ["DNA", "CELLULAR_COMPONENT", 523, 526], ["TLR4", "GENE_OR_GENE_PRODUCT", 527, 531], ["TLR2", "GENE_OR_GENE_PRODUCT", 533, 537], ["TLRs", "GENE_OR_GENE_PRODUCT", 586, 590], ["PAMPs", "GENE_OR_GENE_PRODUCT", 645, 650], ["TLRs", "GENE_OR_GENE_PRODUCT", 677, 681], ["TLR2", "PROTEIN", 32, 36], ["TLR2", "PROTEIN", 117, 121], ["IL-10", "PROTEIN", 164, 169], ["IFN-\u03b3 and IL-12", "PROTEIN", 196, 211], ["TLR2", "PROTEIN", 229, 233], ["TLR7 RNA", "RNA", 314, 322], ["TLR4", "PROTEIN", 323, 327], ["TLR2", "PROTEIN", 329, 333], ["TLR6", "PROTEIN", 341, 345], ["TLR2", "PROTEIN", 347, 351], ["TLR9", "PROTEIN", 370, 374], ["TLR7 RNA", "RNA", 402, 410], ["TLR4", "PROTEIN", 411, 415], ["TLR9", "PROTEIN", 435, 439], ["TLR6", "PROTEIN", 444, 448], ["TLR2", "PROTEIN", 450, 454], ["TLR1", "PROTEIN", 456, 460], ["TLR5", "PROTEIN", 474, 478], ["TLR8", "PROTEIN", 497, 501], ["TLR7", "PROTEIN", 503, 507], ["TLR3 RNA TLR9 DNA TLR4", "PROTEIN", 509, 531], ["TLR2", "PROTEIN", 533, 537], ["TLRs", "PROTEIN", 586, 590], ["PAMPs", "PROTEIN", 645, 650], ["TLRs", "PROTEIN", 677, 681], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 244, 248], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 244, 248], ["Candida species", "PROBLEM", 57, 72], ["the host species", "PROBLEM", 96, 112], ["reduced production of IL", "PROBLEM", 142, 166], ["elevated secretion of IFN", "PROBLEM", 174, 199], ["IL", "TEST", 206, 208], ["Candida species infection", "PROBLEM", 281, 306], ["Fungus", "TEST", 307, 313], ["TLR4", "TEST", 323, 327], ["TLR2", "TEST", 329, 333], ["Mannan", "TEST", 334, 340], ["TLR6", "TEST", 341, 345], ["TLR2", "TEST", 347, 351], ["\u03b2-", "TEST", 352, 354], ["Glucan", "TEST", 354, 360], ["zymosan", "TEST", 362, 369], ["TLR9", "TEST", 370, 374], ["DNA", "TEST", 375, 378], ["Mycobacteria", "TEST", 379, 391], ["bacteria", "TEST", 393, 401], ["TLR7 RNA", "TREATMENT", 402, 410], ["TLR4", "TEST", 411, 415], ["Lipopolysaccharide", "TEST", 416, 434], ["TLR9", "TEST", 435, 439], ["DNA", "TEST", 440, 443], ["TLR6", "TEST", 444, 448], ["TLR2", "TEST", 450, 454], ["TLR1", "TEST", 456, 460], ["Lipoproteins", "TEST", 461, 473], ["TLR5 Flagellin Viruses", "TREATMENT", 474, 496], ["TLR8", "TEST", 497, 501], ["TLR7", "TEST", 503, 507], ["TLR3 RNA", "TREATMENT", 509, 517], ["TLR4", "TEST", 527, 531], ["Structural protein", "TEST", 538, 556], ["microbial infections", "PROBLEM", 594, 614], ["nucleotides", "TREATMENT", 626, 637], ["microbial", "OBSERVATION_MODIFIER", 594, 603], ["infections", "OBSERVATION", 604, 614], ["viruses", "OBSERVATION", 617, 624]]], ["Viral nucleic acids like DNA is sensed by TLR9, dsRNA is sensed by TLR3, and ssRNA is sensed by TLR8-TLR7 [7] .", [["nucleic acids", "CHEMICAL", 6, 19], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["TLR9", "GENE_OR_GENE_PRODUCT", 42, 46], ["TLR3", "GENE_OR_GENE_PRODUCT", 67, 71], ["TLR8", "GENE_OR_GENE_PRODUCT", 96, 100], ["TLR7", "GENE_OR_GENE_PRODUCT", 101, 105], ["TLR9", "PROTEIN", 42, 46], ["TLR3", "PROTEIN", 67, 71], ["TLR8", "PROTEIN", 96, 100], ["TLR7", "PROTEIN", 101, 105], ["Viral nucleic acids", "TEST", 0, 19], ["DNA", "PROBLEM", 25, 28], ["dsRNA", "PROBLEM", 48, 53], ["TLR3", "TEST", 67, 71], ["ssRNA", "TREATMENT", 77, 82], ["nucleic acids", "OBSERVATION", 6, 19]]], ["Viral DNA rich in CpG domains are sensed by TLR9 [39, 43, 55, 56] .", [["CpG", "CHEMICAL", 18, 21], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["TLR9", "GENE_OR_GENE_PRODUCT", 44, 48], ["Viral DNA", "DNA", 0, 9], ["CpG domains", "DNA", 18, 29], ["TLR9", "PROTEIN", 44, 48], ["Viral DNA rich in CpG domains", "PROBLEM", 0, 29], ["TLR9", "TEST", 44, 48]]], ["The TLR-mediated recognition of viral nucleotides stimulates the secretion of cytokines and IFN type-1 [57] .TLRs in microbial infectionsTLR4 and TLR2 are the cell surface TLRs which detect viruses.", [["cell surface", "ANATOMY", 159, 171], ["infections", "DISEASE", 127, 137], ["nucleotides", "CHEMICAL", 38, 49], ["TLR", "GENE_OR_GENE_PRODUCT", 4, 7], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 92, 102], ["TLRs", "GENE_OR_GENE_PRODUCT", 109, 113], ["TLR4", "GENE_OR_GENE_PRODUCT", 137, 141], ["TLR2", "GENE_OR_GENE_PRODUCT", 146, 150], ["cell", "CELL", 159, 163], ["TLRs", "GENE_OR_GENE_PRODUCT", 172, 176], ["TLR", "PROTEIN", 4, 7], ["cytokines", "PROTEIN", 78, 87], ["TLRs", "PROTEIN", 109, 113], ["TLR4", "PROTEIN", 137, 141], ["TLR2", "PROTEIN", 146, 150], ["cell surface TLRs", "PROTEIN", 159, 176], ["viral nucleotides", "TREATMENT", 32, 49], ["IFN type", "TEST", 92, 100], ["the cell surface TLRs", "TEST", 155, 176], ["viruses", "PROBLEM", 190, 197], ["viral nucleotides", "OBSERVATION", 32, 49], ["microbial", "OBSERVATION_MODIFIER", 117, 126], ["infections", "OBSERVATION", 127, 137], ["viruses", "OBSERVATION", 190, 197]]], ["Respiratory syncytial virus (RSV) fusion proteins are sensed by TLR4 and initiate secretion of cytokines.", [["Respiratory syncytial virus", "DISEASE", 0, 27], ["Respiratory syncytial virus", "ORGANISM", 0, 27], ["RSV", "ORGANISM", 29, 32], ["TLR4", "GENE_OR_GENE_PRODUCT", 64, 68], ["Respiratory syncytial virus (RSV) fusion proteins", "PROTEIN", 0, 49], ["TLR4", "PROTEIN", 64, 68], ["cytokines", "PROTEIN", 95, 104], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["Respiratory syncytial virus", "SPECIES", 0, 27], ["RSV", "SPECIES", 29, 32], ["Respiratory syncytial virus", "PROBLEM", 0, 27], ["RSV) fusion proteins", "TREATMENT", 29, 49], ["cytokines", "PROBLEM", 95, 104], ["syncytial virus", "OBSERVATION", 12, 27]]], ["TLR4 also senses envelop protein of mouse mammary tumor virus (MMTV).", [["mammary tumor", "ANATOMY", 42, 55], ["mammary tumor", "DISEASE", 42, 55], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["mouse mammary tumor virus", "ORGANISM", 36, 61], ["MMTV", "ORGANISM", 63, 67], ["TLR4", "PROTEIN", 0, 4], ["envelop protein", "PROTEIN", 17, 32], ["mouse", "SPECIES", 36, 41], ["mouse mammary tumor virus", "SPECIES", 36, 61], ["MMTV", "SPECIES", 63, 67], ["TLR4", "TREATMENT", 0, 4], ["mouse mammary tumor virus", "PROBLEM", 36, 61], ["mammary", "ANATOMY", 42, 49], ["tumor", "OBSERVATION", 50, 55]]], ["TLR4 deficient mice exhibit reduction in IL-12 secretion and reduced levels of mononuclear cells infiltration leading to the reduction in viral clearance [39] .", [["mononuclear cells", "ANATOMY", 79, 96], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 15, 19], ["IL-12", "GENE_OR_GENE_PRODUCT", 41, 46], ["mononuclear cells", "CELL", 79, 96], ["TLR4", "PROTEIN", 0, 4], ["IL-12", "PROTEIN", 41, 46], ["mononuclear cells", "CELL_TYPE", 79, 96], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["TLR4 deficient mice", "TREATMENT", 0, 19], ["reduction in IL", "TREATMENT", 28, 43], ["mononuclear cells infiltration", "PROBLEM", 79, 109], ["the reduction in viral clearance", "PROBLEM", 121, 153], ["reduction", "OBSERVATION_MODIFIER", 28, 37], ["mononuclear cells infiltration", "OBSERVATION", 79, 109], ["reduction", "OBSERVATION_MODIFIER", 125, 134], ["viral clearance", "OBSERVATION", 138, 153]]], ["Inactivated H5N1 avian influenza virus causes acute lung injury into mice and TLR4 deficient mice group is defended against the injury.", [["lung", "ANATOMY", 52, 56], ["influenza virus", "DISEASE", 23, 38], ["lung injury", "DISEASE", 52, 63], ["Inactivated", "ORGANISM", 0, 11], ["H5N1 avian influenza virus", "ORGANISM", 12, 38], ["lung", "ORGAN", 52, 56], ["mice", "ORGANISM", 69, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 78, 82], ["mice", "ORGANISM", 93, 97], ["TLR4", "PROTEIN", 78, 82], ["H5N1 avian influenza virus", "SPECIES", 12, 38], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 93, 97], ["H5N1 avian influenza virus", "SPECIES", 12, 38], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 93, 97], ["Inactivated H5N1 avian influenza virus", "TREATMENT", 0, 38], ["acute lung injury", "PROBLEM", 46, 63], ["TLR4 deficient mice group", "TREATMENT", 78, 103], ["the injury", "PROBLEM", 124, 134], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["lung", "ANATOMY", 52, 56], ["injury", "OBSERVATION", 57, 63], ["injury", "OBSERVATION", 128, 134]]], ["Oxidative stress recognized by TLR4 also play role in inflammation [58] .", [["inflammation", "DISEASE", 54, 66], ["TLR4", "GENE_OR_GENE_PRODUCT", 31, 35], ["TLR4", "PROTEIN", 31, 35], ["Oxidative stress", "PROBLEM", 0, 16]]], ["Viral products like Herpes simplex virus 1 (HSV1), Human cytomegalovirus (CMV) and Measles virus hemagglutinin (MV-H) glycoproteins are recognized by TLR2 and produce inflammatory cytokines [2] .", [["Herpes simplex virus", "DISEASE", 20, 40], ["Viral", "ORGANISM", 0, 5], ["Herpes simplex virus 1", "ORGANISM", 20, 42], ["HSV1", "ORGANISM", 44, 48], ["Human cytomegalovirus", "ORGANISM", 51, 72], ["CMV", "ORGANISM", 74, 77], ["Measles virus hemagglutinin", "ORGANISM", 83, 110], ["MV-H) glycoproteins", "GENE_OR_GENE_PRODUCT", 112, 131], ["TLR2", "GENE_OR_GENE_PRODUCT", 150, 154], ["Measles virus hemagglutinin (MV-H) glycoproteins", "PROTEIN", 83, 131], ["TLR2", "PROTEIN", 150, 154], ["inflammatory cytokines", "PROTEIN", 167, 189], ["Herpes simplex virus 1", "SPECIES", 20, 42], ["Human", "SPECIES", 51, 56], ["Measles virus hemagglutinin", "SPECIES", 83, 110], ["Herpes simplex virus 1", "SPECIES", 20, 42], ["HSV1", "SPECIES", 44, 48], ["Human cytomegalovirus", "SPECIES", 51, 72], ["CMV", "SPECIES", 74, 77], ["Measles virus hemagglutinin", "SPECIES", 83, 110], ["MV", "SPECIES", 112, 114], ["Viral products", "TEST", 0, 14], ["Herpes simplex virus", "PROBLEM", 20, 40], ["HSV1", "TEST", 44, 48], ["Human cytomegalovirus (CMV)", "TREATMENT", 51, 78], ["Measles virus hemagglutinin (MV-H) glycoproteins", "TREATMENT", 83, 131], ["inflammatory cytokines", "PROBLEM", 167, 189], ["Herpes simplex virus", "OBSERVATION", 20, 40], ["inflammatory", "OBSERVATION_MODIFIER", 167, 179]]], ["Moreover, TLR2 also initiate IFN type-1 production in cell type specific manner.", [["cell", "ANATOMY", 54, 58], ["TLR2", "GENE_OR_GENE_PRODUCT", 10, 14], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 29, 39], ["cell type", "CELL", 54, 63], ["TLR2", "PROTEIN", 10, 14]]], ["After infection with inactivated vaccinia virus (VV), dendritic cells and macrophages produce inflammatory cytokines but not IFN type-1 via TLR2 whereas inflammatory monocytes induce IFN type-1 through TLR2 [59] .", [["dendritic cells", "ANATOMY", 54, 69], ["macrophages", "ANATOMY", 74, 85], ["monocytes", "ANATOMY", 166, 175], ["infection", "DISEASE", 6, 15], ["vaccinia virus", "ORGANISM", 33, 47], ["VV", "ORGANISM", 49, 51], ["dendritic cells", "CELL", 54, 69], ["macrophages", "CELL", 74, 85], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 125, 135], ["TLR2", "GENE_OR_GENE_PRODUCT", 140, 144], ["monocytes", "CELL", 166, 175], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 183, 193], ["TLR2", "GENE_OR_GENE_PRODUCT", 202, 206], ["dendritic cells", "CELL_TYPE", 54, 69], ["macrophages", "CELL_TYPE", 74, 85], ["inflammatory cytokines", "PROTEIN", 94, 116], ["IFN type-1", "PROTEIN", 125, 135], ["TLR2", "PROTEIN", 140, 144], ["inflammatory monocytes", "CELL_TYPE", 153, 175], ["IFN type-1", "PROTEIN", 183, 193], ["TLR2", "PROTEIN", 202, 206], ["vaccinia virus", "SPECIES", 33, 47], ["vaccinia virus", "SPECIES", 33, 47], ["VV", "SPECIES", 49, 51], ["infection", "PROBLEM", 6, 15], ["inactivated vaccinia virus", "PROBLEM", 21, 47], ["dendritic cells", "PROBLEM", 54, 69], ["macrophages", "PROBLEM", 74, 85], ["inflammatory cytokines", "PROBLEM", 94, 116], ["IFN type", "TEST", 125, 133], ["inflammatory monocytes", "TEST", 153, 175], ["IFN type", "TEST", 183, 191], ["infection", "OBSERVATION", 6, 15], ["vaccinia virus", "OBSERVATION", 33, 47], ["dendritic cells", "OBSERVATION", 54, 69], ["macrophages", "ANATOMY", 74, 85], ["inflammatory", "OBSERVATION_MODIFIER", 94, 106], ["inflammatory", "OBSERVATION_MODIFIER", 153, 165]]], ["Furthermore, TLR2 mediated stimulation of IFN type-1 does not need nucleotides [60] .TLRs in microbial infectionsTLR3 induces secretion of IFN type-1 and inflammatory cytokines needed for virus elimination.", [["infections", "DISEASE", 103, 113], ["nucleotides", "CHEMICAL", 67, 78], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 42, 52], ["TLRs", "GENE_OR_GENE_PRODUCT", 85, 89], ["TLR3", "GENE_OR_GENE_PRODUCT", 113, 117], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 139, 149], ["TLR2", "PROTEIN", 13, 17], ["IFN type-1", "PROTEIN", 42, 52], ["TLRs", "PROTEIN", 85, 89], ["TLR3", "PROTEIN", 113, 117], ["IFN type-1", "PROTEIN", 139, 149], ["inflammatory cytokines", "PROTEIN", 154, 176], ["TLR2 mediated stimulation of IFN type", "TREATMENT", 13, 50], ["nucleotides", "TREATMENT", 67, 78], ["TLRs", "TREATMENT", 85, 89], ["IFN type", "TEST", 139, 147], ["inflammatory cytokines", "PROBLEM", 154, 176], ["virus elimination", "PROBLEM", 188, 205], ["microbial", "OBSERVATION_MODIFIER", 93, 102], ["infections", "OBSERVATION", 103, 113]]], ["However, there are conflicting reports regarding the demand of TLR3 in in vivo conditions for protection against viral infection.", [["viral infection", "DISEASE", 113, 128], ["TLR3", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR3", "PROTEIN", 63, 67], ["vivo conditions", "TREATMENT", 74, 89], ["viral infection", "PROBLEM", 113, 128], ["infection", "OBSERVATION", 119, 128]]], ["When TLR3 deficient mice group is infected with mouse cytomegalovirus (MCMV), it exhibits depletion in IFN type-1, IFN-\u03b3 and IL-12p40 secretion and depletion in activation of Natural Killer and Natural Killer T cells.", [["Natural Killer T cells", "ANATOMY", 194, 216], ["TLR3", "GENE_OR_GENE_PRODUCT", 5, 9], ["mice", "ORGANISM", 20, 24], ["mouse cytomegalovirus", "ORGANISM", 48, 69], ["MCMV", "ORGANISM", 71, 75], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 103, 113], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 115, 120], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 125, 133], ["Natural Killer", "CELL", 175, 189], ["Natural Killer T cells", "CELL", 194, 216], ["TLR3", "PROTEIN", 5, 9], ["IFN", "PROTEIN", 115, 118], ["Natural Killer and Natural Killer T cells", "CELL_TYPE", 175, 216], ["mice", "SPECIES", 20, 24], ["mouse", "SPECIES", 48, 53], ["mice", "SPECIES", 20, 24], ["mouse cytomegalovirus", "SPECIES", 48, 69], ["MCMV", "SPECIES", 71, 75], ["mouse cytomegalovirus (MCMV", "PROBLEM", 48, 75], ["IFN type", "TEST", 103, 111], ["IFN", "TEST", 115, 118], ["IL", "TEST", 125, 127], ["depletion", "PROBLEM", 148, 157], ["Natural Killer", "TREATMENT", 175, 189], ["Natural Killer T cells", "TREATMENT", 194, 216], ["depletion", "OBSERVATION", 90, 99], ["Natural Killer", "OBSERVATION", 175, 189]]], ["Due to this, TLR3 deficient mice group is more vulnerable to viral infection than control mice group [61] .", [["viral infection", "DISEASE", 61, 76], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["mice", "ORGANISM", 28, 32], ["mice", "ORGANISM", 90, 94], ["TLR3", "PROTEIN", 13, 17], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 90, 94], ["viral infection", "PROBLEM", 61, 76]]], ["Negishi et al., reported that, in Coxsackie B3 virus (CVB3) infection, TLR3 dependent IFN-\u03b3 signalling is required for protection against the infection whereas IFN type-1 signalling is not required for protection [62] .", [["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 142, 151], ["Coxsackie B3 virus", "ORGANISM", 34, 52], ["CVB3", "ORGANISM", 54, 58], ["TLR3", "GENE_OR_GENE_PRODUCT", 71, 75], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 86, 91], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 160, 170], ["TLR3", "PROTEIN", 71, 75], ["IFN", "PROTEIN", 86, 89], ["\u03b3", "PROTEIN", 90, 91], ["Coxsackie B3 virus", "SPECIES", 34, 52], ["Coxsackie B3 virus", "SPECIES", 34, 52], ["CVB3", "SPECIES", 54, 58], ["Coxsackie B3 virus (CVB3) infection", "PROBLEM", 34, 69], ["TLR3 dependent IFN", "PROBLEM", 71, 89], ["protection", "TREATMENT", 119, 129], ["the infection", "PROBLEM", 138, 151], ["infection", "OBSERVATION", 60, 69], ["TLR3 dependent", "OBSERVATION_MODIFIER", 71, 85], ["infection", "OBSERVATION", 142, 151]]], ["Furthermore, TLR3 deficient mice group is more vulnerable to the virulent West Nile virus (WNV) infection than the control mice group [63] .", [["West Nile virus (WNV) infection", "DISEASE", 74, 105], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["mice", "ORGANISM", 28, 32], ["West Nile virus", "ORGANISM", 74, 89], ["WNV", "ORGANISM", 91, 94], ["mice", "ORGANISM", 123, 127], ["TLR3", "PROTEIN", 13, 17], ["mice", "SPECIES", 28, 32], ["West Nile virus", "SPECIES", 74, 89], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 28, 32], ["West Nile virus", "SPECIES", 74, 89], ["WNV", "SPECIES", 91, 94], ["mice", "SPECIES", 123, 127], ["infection", "PROBLEM", 96, 105]]], ["Wang et al. [271] reported that TLR3 deficient group exhibits more survival rate against the WNV infection than the control group.", [["WNV infection", "DISEASE", 93, 106], ["TLR3", "GENE_OR_GENE_PRODUCT", 32, 36], ["WNV", "ORGANISM", 93, 96], ["TLR3", "PROTEIN", 32, 36], ["WNV", "SPECIES", 93, 96], ["TLR3 deficient group", "PROBLEM", 32, 52], ["the WNV infection", "PROBLEM", 89, 106], ["WNV", "OBSERVATION_MODIFIER", 93, 96], ["infection", "OBSERVATION", 97, 106]]], ["Although, some reports suggested that, after infection with viruses like MCMV, Vesicular stomatitis virus (VSV), Reoviruses and Lymphocytic choriomeningitis virus (LCMV), deficiency of TLR3 does not influence CD8+ T and CD4+ T cells.", [["CD8+ T", "ANATOMY", 209, 215], ["CD4+ T cells", "ANATOMY", 220, 232], ["infection", "DISEASE", 45, 54], ["Vesicular stomatitis", "DISEASE", 79, 99], ["Lymphocytic choriomeningitis virus", "DISEASE", 128, 162], ["MCMV", "ORGANISM", 73, 77], ["Vesicular stomatitis virus", "ORGANISM", 79, 105], ["VSV", "ORGANISM", 107, 110], ["Reoviruses", "ORGANISM", 113, 123], ["Lymphocytic choriomeningitis virus", "ORGANISM", 128, 162], ["LCMV", "ORGANISM", 164, 168], ["TLR3", "GENE_OR_GENE_PRODUCT", 185, 189], ["CD8", "GENE_OR_GENE_PRODUCT", 209, 212], ["CD4", "GENE_OR_GENE_PRODUCT", 220, 223], ["TLR3", "PROTEIN", 185, 189], ["CD8+ T and CD4+ T cells", "CELL_TYPE", 209, 232], ["MCMV", "SPECIES", 73, 77], ["Vesicular stomatitis virus", "SPECIES", 79, 105], ["Lymphocytic choriomeningitis virus", "SPECIES", 128, 162], ["MCMV", "SPECIES", 73, 77], ["Vesicular stomatitis virus", "SPECIES", 79, 105], ["VSV", "SPECIES", 107, 110], ["Lymphocytic choriomeningitis virus", "SPECIES", 128, 162], ["LCMV", "SPECIES", 164, 168], ["infection", "PROBLEM", 45, 54], ["viruses", "PROBLEM", 60, 67], ["MCMV", "PROBLEM", 73, 77], ["Vesicular stomatitis virus (VSV)", "PROBLEM", 79, 111], ["Reoviruses", "PROBLEM", 113, 123], ["Lymphocytic choriomeningitis virus", "PROBLEM", 128, 162], ["deficiency of TLR3", "PROBLEM", 171, 189], ["CD8", "TEST", 209, 212], ["CD4+ T cells", "PROBLEM", 220, 232], ["Vesicular stomatitis virus", "OBSERVATION", 79, 105], ["Lymphocytic choriomeningitis", "OBSERVATION", 128, 156]]], ["Thus, it can be said that TLR3 is not required for protection against viruses [64] .TLRs in acute lung injury/acute respiratory distress syndrome (ARDS)Acute lung injury (ALI) is a lethal disease described by an exaggerated host defence immune response in which influx of inflammatory cells, such as neutrophils and macrophages, into the lung tissue perpetuates a vicious cycle of inflammation that amplifies the accumulation of these cells [65] .", [["lung", "ANATOMY", 98, 102], ["lung", "ANATOMY", 158, 162], ["inflammatory cells", "ANATOMY", 272, 290], ["neutrophils", "ANATOMY", 300, 311], ["macrophages", "ANATOMY", 316, 327], ["lung tissue", "ANATOMY", 338, 349], ["cells", "ANATOMY", 435, 440], ["acute lung injury", "DISEASE", 92, 109], ["acute respiratory distress syndrome", "DISEASE", 110, 145], ["ARDS", "DISEASE", 147, 151], ["Acute lung injury", "DISEASE", 152, 169], ["ALI", "DISEASE", 171, 174], ["inflammation", "DISEASE", 381, 393], ["TLR3", "GENE_OR_GENE_PRODUCT", 26, 30], ["TLRs", "GENE_OR_GENE_PRODUCT", 84, 88], ["lung", "ORGAN", 98, 102], ["lung", "ORGAN", 158, 162], ["inflammatory cells", "CELL", 272, 290], ["neutrophils", "CELL", 300, 311], ["macrophages", "CELL", 316, 327], ["lung tissue", "TISSUE", 338, 349], ["cells", "CELL", 435, 440], ["TLR3", "PROTEIN", 26, 30], ["TLRs", "PROTEIN", 84, 88], ["inflammatory cells", "CELL_TYPE", 272, 290], ["neutrophils", "CELL_TYPE", 300, 311], ["macrophages", "CELL_TYPE", 316, 327], ["TLR3", "TREATMENT", 26, 30], ["viruses", "PROBLEM", 70, 77], ["acute lung injury", "PROBLEM", 92, 109], ["acute respiratory distress syndrome", "PROBLEM", 110, 145], ["ARDS)", "PROBLEM", 147, 152], ["Acute lung injury", "PROBLEM", 152, 169], ["a lethal disease", "PROBLEM", 179, 195], ["an exaggerated host defence immune response", "PROBLEM", 209, 252], ["inflammatory cells", "PROBLEM", 272, 290], ["neutrophils", "TEST", 300, 311], ["macrophages", "PROBLEM", 316, 327], ["the lung tissue", "PROBLEM", 334, 349], ["inflammation", "PROBLEM", 381, 393], ["the accumulation of these cells", "PROBLEM", 409, 440], ["acute", "OBSERVATION_MODIFIER", 92, 97], ["lung", "ANATOMY", 98, 102], ["injury", "OBSERVATION", 103, 109], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory distress", "OBSERVATION", 116, 136], ["ARDS", "OBSERVATION", 147, 151], ["Acute", "OBSERVATION_MODIFIER", 152, 157], ["lung", "ANATOMY", 158, 162], ["injury", "OBSERVATION", 163, 169], ["ALI", "ANATOMY", 171, 174], ["exaggerated", "OBSERVATION_MODIFIER", 212, 223], ["host defence", "OBSERVATION_MODIFIER", 224, 236], ["immune response", "OBSERVATION", 237, 252], ["inflammatory cells", "OBSERVATION", 272, 290], ["lung", "ANATOMY", 338, 342], ["tissue", "ANATOMY_MODIFIER", 343, 349], ["vicious", "OBSERVATION_MODIFIER", 364, 371], ["inflammation", "OBSERVATION", 381, 393]]], ["A central pathogenic feature underlying ALI is the breakdown of lung epithelial-endothelial barrier function due to widespread cell death and disassembly of endothelial adherens junctions [65] [66] [67] .", [["lung epithelial", "ANATOMY", 64, 79], ["endothelial barrier", "ANATOMY", 80, 99], ["cell", "ANATOMY", 127, 131], ["endothelial adherens junctions", "ANATOMY", 157, 187], ["ALI", "DISEASE", 40, 43], ["death", "DISEASE", 132, 137], ["lung epithelial-endothelial barrier", "TISSUE", 64, 99], ["cell", "CELL", 127, 131], ["endothelial adherens", "CELLULAR_COMPONENT", 157, 177], ["junctions", "CELLULAR_COMPONENT", 178, 187], ["A central pathogenic feature underlying ALI", "PROBLEM", 0, 43], ["the breakdown of lung epithelial", "PROBLEM", 47, 79], ["endothelial barrier function", "TREATMENT", 80, 108], ["widespread cell death", "PROBLEM", 116, 137], ["central", "OBSERVATION_MODIFIER", 2, 9], ["pathogenic", "OBSERVATION", 10, 20], ["ALI", "OBSERVATION", 40, 43], ["lung", "ANATOMY", 64, 68], ["epithelial", "ANATOMY_MODIFIER", 69, 79], ["endothelial", "ANATOMY", 80, 91], ["widespread", "OBSERVATION_MODIFIER", 116, 126], ["cell death", "OBSERVATION", 127, 137], ["endothelial", "ANATOMY", 157, 168]]], ["An intact barrier tightly controls lung vascular permeability [66] and leukocyte recruitment [68] , whereas its disruption results in tissue oedema, neutrophil influx, activation of procoagulant pathways, and release of proinflammatory cytokines such as IL-1\u03b2 [65] .", [["lung vascular", "ANATOMY", 35, 48], ["leukocyte", "ANATOMY", 71, 80], ["tissue", "ANATOMY", 134, 140], ["neutrophil", "ANATOMY", 149, 159], ["oedema", "DISEASE", 141, 147], ["lung vascular", "MULTI-TISSUE_STRUCTURE", 35, 48], ["leukocyte", "CELL", 71, 80], ["tissue", "TISSUE", 134, 140], ["neutrophil", "CELL", 149, 159], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 254, 259], ["proinflammatory cytokines", "PROTEIN", 220, 245], ["IL", "PROTEIN", 254, 256], ["An intact barrier", "TREATMENT", 0, 17], ["lung vascular permeability", "TEST", 35, 61], ["leukocyte recruitment", "TEST", 71, 92], ["tissue oedema", "PROBLEM", 134, 147], ["neutrophil influx", "TREATMENT", 149, 166], ["procoagulant pathways", "TREATMENT", 182, 203], ["proinflammatory cytokines", "TREATMENT", 220, 245], ["intact", "OBSERVATION", 3, 9], ["barrier tightly", "OBSERVATION_MODIFIER", 10, 25], ["vascular", "ANATOMY", 40, 48], ["tissue", "ANATOMY", 134, 140], ["oedema", "OBSERVATION", 141, 147], ["neutrophil influx", "OBSERVATION", 149, 166]]], ["ALI may be caused by bacterial or viral infection or could be a repercussion of non-infectious outrage including hyperoxia, trauma or environmental toxins such as ozone, heavy metals.", [["ALI", "DISEASE", 0, 3], ["infection", "DISEASE", 40, 49], ["hyperoxia", "DISEASE", 113, 122], ["trauma", "DISEASE", 124, 130], ["ozone", "CHEMICAL", 163, 168], ["ozone", "CHEMICAL", 163, 168], ["ozone", "SIMPLE_CHEMICAL", 163, 168], ["heavy metals", "SIMPLE_CHEMICAL", 170, 182], ["ALI", "PROBLEM", 0, 3], ["bacterial or viral infection", "PROBLEM", 21, 49], ["non-infectious outrage", "PROBLEM", 80, 102], ["hyperoxia", "PROBLEM", 113, 122], ["trauma", "PROBLEM", 124, 130], ["environmental toxins", "PROBLEM", 134, 154], ["may be caused", "UNCERTAINTY", 4, 17], ["bacterial", "OBSERVATION_MODIFIER", 21, 30], ["viral", "OBSERVATION_MODIFIER", 34, 39], ["infection", "OBSERVATION", 40, 49], ["non-infectious", "OBSERVATION", 80, 94]]], ["Also, lungs are invariably exposed to circulating pathogens and bacterial endotoxins such as the LPS, which are known to induce inflammatory responses and are key for the pathogenesis of ALI [69] .", [["lungs", "ANATOMY", 6, 11], ["LPS", "CHEMICAL", 97, 100], ["ALI", "DISEASE", 187, 190], ["lungs", "ORGAN", 6, 11], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["circulating pathogens", "PROBLEM", 38, 59], ["bacterial endotoxins", "PROBLEM", 64, 84], ["the LPS", "TEST", 93, 100], ["ALI", "PROBLEM", 187, 190], ["lungs", "ANATOMY", 6, 11], ["circulating", "OBSERVATION_MODIFIER", 38, 49], ["pathogens", "OBSERVATION", 50, 59], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["endotoxins", "OBSERVATION", 74, 84], ["inflammatory", "OBSERVATION", 128, 140]]], ["TLRs conciliate ALI by identifying specific PAMPs such as LPS or endogenous DAMPs such as HMGB1, heat shock proteins, fibrinogen or hyaluronan [70, 71] , which, in turn activates inflammation [72] [73] [74] .", [["ALI", "DISEASE", 16, 19], ["LPS", "CHEMICAL", 58, 61], ["inflammation", "DISEASE", 179, 191], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PAMPs", "GENE_OR_GENE_PRODUCT", 44, 49], ["LPS", "SIMPLE_CHEMICAL", 58, 61], ["DAMPs", "GENE_OR_GENE_PRODUCT", 76, 81], ["HMGB1", "GENE_OR_GENE_PRODUCT", 90, 95], ["heat shock proteins", "GENE_OR_GENE_PRODUCT", 97, 116], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 118, 128], ["hyaluronan [70, 71]", "SIMPLE_CHEMICAL", 132, 151], ["TLRs", "PROTEIN", 0, 4], ["PAMPs", "PROTEIN", 44, 49], ["endogenous DAMPs", "PROTEIN", 65, 81], ["HMGB1", "PROTEIN", 90, 95], ["heat shock proteins", "PROTEIN", 97, 116], ["fibrinogen", "PROTEIN", 118, 128], ["ALI", "PROBLEM", 16, 19], ["specific PAMPs", "PROBLEM", 35, 49], ["LPS", "PROBLEM", 58, 61], ["endogenous DAMPs", "PROBLEM", 65, 81], ["HMGB1", "PROBLEM", 90, 95], ["heat shock proteins", "TEST", 97, 116], ["fibrinogen", "TEST", 118, 128], ["hyaluronan", "TEST", 132, 142]]], ["The inflammatory response could be benign or adverse for host, depends upon the nature and severity of the instigating stimulus.", [["the instigating stimulus", "PROBLEM", 103, 127], ["inflammatory", "OBSERVATION_MODIFIER", 4, 16]]], ["Alterations in macrophage polarization may also influence the severity of acute inflammation in lung [75] .", [["macrophage", "ANATOMY", 15, 25], ["lung", "ANATOMY", 96, 100], ["inflammation", "DISEASE", 80, 92], ["macrophage", "CELL", 15, 25], ["lung", "ORGAN", 96, 100], ["Alterations in macrophage polarization", "PROBLEM", 0, 38], ["acute inflammation in lung", "PROBLEM", 74, 100], ["macrophage polarization", "OBSERVATION", 15, 38], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["inflammation", "OBSERVATION", 80, 92], ["lung", "ANATOMY", 96, 100]]], ["It could be beneficial for the preservation of tissue integrity and repair of host tissues but prolonged inflammatory responses may lead to aggravated fibrosis and accumulation of fluid in the lungs which could be detrimental for the lung tissue [58, 76] .", [["tissue", "ANATOMY", 47, 53], ["tissues", "ANATOMY", 83, 90], ["fluid", "ANATOMY", 180, 185], ["lungs", "ANATOMY", 193, 198], ["lung tissue", "ANATOMY", 234, 245], ["fibrosis", "DISEASE", 151, 159], ["tissue", "TISSUE", 47, 53], ["tissues", "TISSUE", 83, 90], ["fluid", "ORGANISM_SUBSTANCE", 180, 185], ["lungs", "ORGAN", 193, 198], ["lung tissue", "TISSUE", 234, 245], ["tissue integrity", "TREATMENT", 47, 63], ["repair", "TREATMENT", 68, 74], ["host tissues", "PROBLEM", 78, 90], ["prolonged inflammatory responses", "PROBLEM", 95, 127], ["aggravated fibrosis", "PROBLEM", 140, 159], ["accumulation of fluid in the lungs", "PROBLEM", 164, 198], ["the lung tissue", "PROBLEM", 230, 245], ["tissue integrity", "OBSERVATION", 47, 63], ["host tissues", "OBSERVATION", 78, 90], ["prolonged", "OBSERVATION_MODIFIER", 95, 104], ["inflammatory", "OBSERVATION", 105, 117], ["aggravated", "OBSERVATION_MODIFIER", 140, 150], ["fibrosis", "OBSERVATION", 151, 159], ["accumulation", "OBSERVATION_MODIFIER", 164, 176], ["fluid", "OBSERVATION", 180, 185], ["lungs", "ANATOMY", 193, 198], ["lung", "ANATOMY", 234, 238]]], ["Severe bacterial pneumonia is one of the most common causative factor of ALI, ARDS and lung injury leading to enhanced pneumonia associated mortality and morbidity.", [["lung", "ANATOMY", 87, 91], ["bacterial pneumonia", "DISEASE", 7, 26], ["ALI", "DISEASE", 73, 76], ["ARDS", "DISEASE", 78, 82], ["lung injury", "DISEASE", 87, 98], ["pneumonia", "DISEASE", 119, 128], ["lung", "ORGAN", 87, 91], ["Severe bacterial pneumonia", "PROBLEM", 0, 26], ["ALI", "PROBLEM", 73, 76], ["ARDS", "PROBLEM", 78, 82], ["lung injury", "PROBLEM", 87, 98], ["enhanced pneumonia associated mortality", "PROBLEM", 110, 149], ["morbidity", "PROBLEM", 154, 163], ["bacterial", "OBSERVATION_MODIFIER", 7, 16], ["pneumonia", "OBSERVATION", 17, 26], ["one of the most common", "OBSERVATION_MODIFIER", 30, 52], ["ALI", "OBSERVATION", 73, 76], ["ARDS", "OBSERVATION", 78, 82], ["lung", "ANATOMY", 87, 91], ["injury", "OBSERVATION", 92, 98], ["enhanced", "OBSERVATION_MODIFIER", 110, 118], ["pneumonia", "OBSERVATION", 119, 128], ["morbidity", "OBSERVATION", 154, 163]]], ["TLR4 plays an important role in bacterial clearance in case of Pseudomonas pneumonia as well as Klebsiella pneumonia.", [["Pseudomonas pneumonia", "DISEASE", 63, 84], ["Klebsiella pneumonia", "DISEASE", 96, 116], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["Pseudomonas pneumonia", "ORGANISM", 63, 84], ["TLR4", "PROTEIN", 0, 4], ["Pseudomonas pneumonia", "SPECIES", 63, 84], ["Pseudomonas pneumonia", "SPECIES", 63, 84], ["Klebsiella pneumonia", "SPECIES", 96, 116], ["bacterial clearance", "TREATMENT", 32, 51], ["Pseudomonas pneumonia", "PROBLEM", 63, 84], ["Klebsiella pneumonia", "PROBLEM", 96, 116], ["Pseudomonas", "OBSERVATION_MODIFIER", 63, 74], ["pneumonia", "OBSERVATION", 75, 84], ["Klebsiella", "OBSERVATION_MODIFIER", 96, 106], ["pneumonia", "OBSERVATION", 107, 116]]], ["This effect is mediated by GM-CSF (Granulocyte -macrophage colony stimulating factor), a pleiotropic growth factor that possess cytoprotective effects on alveolar epithelium [77] .", [["alveolar epithelium", "ANATOMY", 154, 173], ["GM", "CHEMICAL", 27, 29], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 27, 33], ["Granulocyte -macrophage colony stimulating factor", "GENE_OR_GENE_PRODUCT", 35, 84], ["alveolar epithelium", "TISSUE", 154, 173], ["GM", "PROTEIN", 27, 29], ["CSF", "PROTEIN", 30, 33], ["Granulocyte -macrophage colony stimulating factor", "PROTEIN", 35, 84], ["pleiotropic growth factor", "PROTEIN", 89, 114], ["GM", "TEST", 27, 29], ["CSF", "TEST", 30, 33], ["Granulocyte", "TEST", 35, 46], ["a pleiotropic growth factor", "PROBLEM", 87, 114], ["cytoprotective effects on alveolar epithelium", "PROBLEM", 128, 173], ["CSF", "ANATOMY", 30, 33], ["alveolar epithelium", "OBSERVATION", 154, 173]]], ["GM-CSF is responsible for governing the intensity of inflammation by regulating the activation of Akt and Erk kinases, leading to activation of NF-\u03ba\u03b2 and AP-1transcription factor complex respectively.", [["GM", "CHEMICAL", 0, 2], ["inflammation", "DISEASE", 53, 65], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 0, 6], ["Akt", "GENE_OR_GENE_PRODUCT", 98, 101], ["Erk", "GENE_OR_GENE_PRODUCT", 106, 109], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 144, 149], ["AP-1transcription factor complex", "GENE_OR_GENE_PRODUCT", 154, 186], ["CSF", "PROTEIN", 3, 6], ["Akt", "PROTEIN", 98, 101], ["Erk kinases", "PROTEIN", 106, 117], ["NF-\u03ba\u03b2", "PROTEIN", 144, 149], ["AP-1transcription factor complex", "PROTEIN", 154, 186], ["GM-CSF", "TEST", 0, 6], ["inflammation", "PROBLEM", 53, 65], ["Erk kinases", "TEST", 106, 117], ["NF", "TEST", 144, 146], ["AP", "TEST", 154, 156], ["CSF", "OBSERVATION", 3, 6], ["inflammation", "OBSERVATION", 53, 65]]], ["Moreover, suppression of GM-CSF has direct effects on activation of these kinases, generating anti -inflammatory effects, which could have clinical implications too in inflammatory diseases [78] .TLRs in acute lung injury/acute respiratory distress syndrome (ARDS)It has been found that Hemorrhagic shock (HS), customarily seen in trauma patients leads to excessive inflammatory responses resulting in development of ALI [79] .", [["lung", "ANATOMY", 210, 214], ["GM", "CHEMICAL", 25, 27], ["acute lung injury", "DISEASE", 204, 221], ["acute respiratory distress syndrome", "DISEASE", 222, 257], ["ARDS", "DISEASE", 259, 263], ["Hemorrhagic shock", "DISEASE", 287, 304], ["HS", "DISEASE", 306, 308], ["trauma", "DISEASE", 331, 337], ["ALI", "DISEASE", 417, 420], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 25, 31], ["TLRs", "GENE_OR_GENE_PRODUCT", 196, 200], ["lung", "ORGAN", 210, 214], ["patients", "ORGANISM", 338, 346], ["GM", "PROTEIN", 25, 27], ["CSF", "PROTEIN", 28, 31], ["kinases", "PROTEIN", 74, 81], ["TLRs", "PROTEIN", 196, 200], ["patients", "SPECIES", 338, 346], ["GM-CSF", "PROBLEM", 25, 31], ["these kinases", "TEST", 68, 81], ["anti -inflammatory effects", "PROBLEM", 94, 120], ["inflammatory diseases", "PROBLEM", 168, 189], ["TLRs", "TREATMENT", 196, 200], ["acute lung injury", "PROBLEM", 204, 221], ["acute respiratory distress syndrome", "PROBLEM", 222, 257], ["ARDS", "PROBLEM", 259, 263], ["Hemorrhagic shock (HS)", "PROBLEM", 287, 309], ["trauma", "PROBLEM", 331, 337], ["excessive inflammatory responses", "PROBLEM", 356, 388], ["ALI", "PROBLEM", 417, 420], ["inflammatory effects", "OBSERVATION", 100, 120], ["inflammatory", "OBSERVATION_MODIFIER", 168, 180], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["lung", "ANATOMY", 210, 214], ["injury", "OBSERVATION", 215, 221], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["respiratory distress", "OBSERVATION", 228, 248], ["Hemorrhagic", "OBSERVATION_MODIFIER", 287, 298], ["shock", "OBSERVATION", 299, 304], ["excessive", "OBSERVATION_MODIFIER", 356, 365], ["inflammatory", "OBSERVATION", 366, 378], ["ALI", "OBSERVATION", 417, 420]]], ["Studies based on mouse models of HS-induced ALI with LPS as the secondary stimulus have demonstrated that increased secretion of inflammatory mediator CXCL8, pulmonary oedema and enhanced neutrophils incursion are a result of cross talk between TLR2 and TLR4 [73, 79, 80] .", [["pulmonary", "ANATOMY", 158, 167], ["neutrophils", "ANATOMY", 188, 199], ["ALI", "DISEASE", 44, 47], ["LPS", "CHEMICAL", 53, 56], ["pulmonary oedema", "DISEASE", 158, 174], ["mouse", "ORGANISM", 17, 22], ["LPS", "SIMPLE_CHEMICAL", 53, 56], ["CXCL8", "GENE_OR_GENE_PRODUCT", 151, 156], ["pulmonary", "ORGAN", 158, 167], ["neutrophils", "CELL", 188, 199], ["TLR2", "GENE_OR_GENE_PRODUCT", 245, 249], ["TLR4", "GENE_OR_GENE_PRODUCT", 254, 258], ["inflammatory mediator", "PROTEIN", 129, 150], ["CXCL8", "PROTEIN", 151, 156], ["neutrophils", "CELL_TYPE", 188, 199], ["TLR2", "PROTEIN", 245, 249], ["TLR4", "PROTEIN", 254, 258], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 17, 22], ["LPS", "TREATMENT", 53, 56], ["the secondary stimulus", "TEST", 60, 82], ["increased secretion of inflammatory mediator CXCL8", "PROBLEM", 106, 156], ["pulmonary oedema", "PROBLEM", 158, 174], ["enhanced neutrophils incursion", "PROBLEM", 179, 209], ["TLR4", "TEST", 254, 258], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["secretion", "OBSERVATION_MODIFIER", 116, 125], ["inflammatory", "OBSERVATION_MODIFIER", 129, 141], ["pulmonary", "ANATOMY", 158, 167], ["oedema", "OBSERVATION", 168, 174], ["enhanced neutrophils", "OBSERVATION", 179, 199]]], ["Similarly, TLR4 is implicated in protection against hyperoxia-induced ALI by promoting the expression of Bcl-2 and Phospho Akt (anti apoptotic factors) [81] .", [["hyperoxia", "CHEMICAL", 52, 61], ["ALI", "DISEASE", 70, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 11, 15], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["Phospho", "GENE_OR_GENE_PRODUCT", 115, 122], ["Akt", "GENE_OR_GENE_PRODUCT", 123, 126], ["anti apoptotic factors", "GENE_OR_GENE_PRODUCT", 128, 150], ["TLR4", "PROTEIN", 11, 15], ["Bcl-2", "PROTEIN", 105, 110], ["Phospho Akt", "PROTEIN", 115, 126], ["anti apoptotic factors", "PROTEIN", 128, 150], ["hyperoxia", "PROBLEM", 52, 61], ["ALI", "PROBLEM", 70, 73], ["Bcl", "TEST", 105, 108], ["Phospho Akt", "TEST", 115, 126], ["TLR4", "OBSERVATION", 11, 15]]], ["On the other hand, TLR3 promotes ALI as evident from study demonstrating that TLR3 deficient mice show reduced neutrophil influx, increased expression of surfactant proteins and stimulation of pro-apoptotic factors which protects them from ALI [82] .", [["neutrophil", "ANATOMY", 111, 121], ["ALI", "DISEASE", 33, 36], ["ALI", "DISEASE", 240, 243], ["TLR3", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR3", "GENE_OR_GENE_PRODUCT", 78, 82], ["mice", "ORGANISM", 93, 97], ["neutrophil", "CELL", 111, 121], ["TLR3", "PROTEIN", 19, 23], ["TLR3", "PROTEIN", 78, 82], ["surfactant proteins", "PROTEIN", 154, 173], ["pro-apoptotic factors", "PROTEIN", 193, 214], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["study", "TEST", 53, 58], ["TLR3 deficient mice", "PROBLEM", 78, 97], ["reduced neutrophil influx", "PROBLEM", 103, 128], ["surfactant proteins", "TREATMENT", 154, 173], ["pro-apoptotic factors", "PROBLEM", 193, 214], ["ALI", "OBSERVATION", 33, 36], ["reduced", "OBSERVATION_MODIFIER", 103, 110], ["neutrophil influx", "OBSERVATION", 111, 128]]], ["Furthermore, TLR2 and TLR4 are also involved in mediating macrophage inflammatory responses to hyaluronan fragments in case of Bleomycin-induced lung injury [83] .TLRs in acute lung injury/acute respiratory distress syndrome (ARDS)TLR7 has been associated with production of IFN type-1, important for clearance of viruses such as the severe acute respiratory syndrome coronavirus (SARS CoV).", [["macrophage", "ANATOMY", 58, 68], ["lung", "ANATOMY", 145, 149], ["lung", "ANATOMY", 177, 181], ["Bleomycin", "CHEMICAL", 127, 136], ["lung injury", "DISEASE", 145, 156], ["lung injury", "DISEASE", 177, 188], ["acute respiratory distress syndrome", "DISEASE", 189, 224], ["ARDS", "DISEASE", 226, 230], ["TLR7", "CHEMICAL", 231, 235], ["acute respiratory syndrome coronavirus", "DISEASE", 341, 379], ["SARS", "DISEASE", 381, 385], ["Bleomycin", "CHEMICAL", 127, 136], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 22, 26], ["macrophage", "CELL", 58, 68], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 95, 105], ["Bleomycin", "SIMPLE_CHEMICAL", 127, 136], ["lung", "ORGAN", 145, 149], ["TLRs", "GENE_OR_GENE_PRODUCT", 163, 167], ["lung", "ORGAN", 177, 181], ["TLR7", "GENE_OR_GENE_PRODUCT", 231, 235], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 275, 285], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 334, 379], ["SARS CoV", "ORGANISM", 381, 389], ["TLR2", "PROTEIN", 13, 17], ["TLR4", "PROTEIN", 22, 26], ["TLRs", "PROTEIN", 163, 167], ["TLR7", "PROTEIN", 231, 235], ["IFN type-1", "PROTEIN", 275, 285], ["severe acute respiratory syndrome coronavirus", "SPECIES", 334, 379], ["SARS CoV", "SPECIES", 381, 389], ["TLR2 and TLR4", "TREATMENT", 13, 26], ["hyaluronan fragments", "PROBLEM", 95, 115], ["Bleomycin", "TREATMENT", 127, 136], ["lung injury", "PROBLEM", 145, 156], ["TLRs", "TREATMENT", 163, 167], ["acute lung injury", "PROBLEM", 171, 188], ["acute respiratory distress syndrome", "PROBLEM", 189, 224], ["ARDS)TLR7", "PROBLEM", 226, 235], ["IFN type-1", "PROBLEM", 275, 285], ["clearance of viruses", "PROBLEM", 301, 321], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 330, 379], ["macrophage", "OBSERVATION_MODIFIER", 58, 68], ["inflammatory", "OBSERVATION", 69, 81], ["hyaluronan fragments", "OBSERVATION", 95, 115], ["Bleomycin", "OBSERVATION", 127, 136], ["lung", "ANATOMY", 145, 149], ["injury", "OBSERVATION", 150, 156], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["lung", "ANATOMY", 177, 181], ["injury", "OBSERVATION", 182, 188], ["acute", "OBSERVATION_MODIFIER", 189, 194], ["respiratory distress", "OBSERVATION", 195, 215], ["ARDS", "OBSERVATION", 226, 230], ["viruses", "OBSERVATION", 314, 321], ["severe", "OBSERVATION_MODIFIER", 334, 340], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["respiratory syndrome coronavirus", "OBSERVATION", 347, 379]]], ["TLR4 and MyD88 also possess a protective role in case of SARS infection [84, 85] .", [["SARS infection", "DISEASE", 57, 71], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["MyD88", "GENE_OR_GENE_PRODUCT", 9, 14], ["TLR4", "PROTEIN", 0, 4], ["MyD88", "PROTEIN", 9, 14], ["TLR4 and MyD88", "TREATMENT", 0, 14], ["SARS infection", "PROBLEM", 57, 71]]], ["TLR7 also plays a significant role in case of influenza infection.", [["influenza infection", "DISEASE", 46, 65], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["influenza", "ORGANISM", 46, 55], ["TLR7", "PROTEIN", 0, 4], ["influenza infection", "PROBLEM", 46, 65], ["infection", "OBSERVATION", 56, 65]]], ["They are expressed on pDCs and mediate cell specific immune response via MyD88-dependent IFN induction.", [["pDCs", "ANATOMY", 22, 26], ["cell", "ANATOMY", 39, 43], ["pDCs", "CELL", 22, 26], ["cell", "CELL", 39, 43], ["MyD88", "GENE_OR_GENE_PRODUCT", 73, 78], ["IFN", "GENE_OR_GENE_PRODUCT", 89, 92], ["pDCs", "CELL_TYPE", 22, 26], ["MyD88", "PROTEIN", 73, 78], ["IFN", "PROTEIN", 89, 92], ["MyD88-dependent IFN induction", "TREATMENT", 73, 102]]], ["Bcell isotype switching is also observed in case of influenza infection and is mediated by MyD88 and IPS-1 (adaptor molecule involved in cytosolic RIG-I pathway) [86] .", [["cytosolic", "ANATOMY", 137, 146], ["influenza infection", "DISEASE", 52, 71], ["MyD88", "GENE_OR_GENE_PRODUCT", 91, 96], ["IPS-1", "GENE_OR_GENE_PRODUCT", 101, 106], ["RIG-I", "GENE_OR_GENE_PRODUCT", 147, 152], ["Bcell isotype", "PROTEIN", 0, 13], ["MyD88", "PROTEIN", 91, 96], ["IPS-1", "PROTEIN", 101, 106], ["adaptor molecule", "PROTEIN", 108, 124], ["cytosolic RIG-I", "PROTEIN", 137, 152], ["Bcell isotype switching", "PROBLEM", 0, 23], ["influenza infection", "PROBLEM", 52, 71], ["IPS", "TEST", 101, 104], ["isotype switching", "OBSERVATION", 6, 23], ["influenza", "OBSERVATION", 52, 61]]], ["TLR3 is seen to be highly upregulated in human alveolar bronchial and epithelial cells during influenza infection.", [["alveolar bronchial", "ANATOMY", 47, 65], ["epithelial cells", "ANATOMY", 70, 86], ["influenza infection", "DISEASE", 94, 113], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 41, 46], ["alveolar bronchial", "CELL", 47, 65], ["epithelial cells", "CELL", 70, 86], ["TLR3", "PROTEIN", 0, 4], ["human alveolar bronchial and epithelial cells", "CELL_TYPE", 41, 86], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["human alveolar bronchial and epithelial cells", "PROBLEM", 41, 86], ["influenza infection", "PROBLEM", 94, 113], ["highly", "OBSERVATION_MODIFIER", 19, 25], ["upregulated", "OBSERVATION", 26, 37], ["human", "ANATOMY_MODIFIER", 41, 46], ["alveolar", "ANATOMY_MODIFIER", 47, 55], ["bronchial", "ANATOMY", 56, 65], ["epithelial cells", "OBSERVATION", 70, 86], ["influenza", "OBSERVATION_MODIFIER", 94, 103], ["infection", "OBSERVATION", 104, 113]]], ["Moreover, RIG-I, NLRP3 and NOD-2 have also been found to be associated with immune response against influenza infections [87] [88] [89] [90] [91] .TLRs in cystic fibrosisCystic Fibrosis, an autosomal recessive genetic disorder is described by chronic inflammation, caused by prolonged bacterial colonization.", [["cystic", "ANATOMY", 155, 161], ["influenza infections", "DISEASE", 100, 120], ["Fibrosis", "DISEASE", 177, 185], ["autosomal recessive genetic disorder", "DISEASE", 190, 226], ["inflammation", "DISEASE", 251, 263], ["RIG-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["NLRP3", "GENE_OR_GENE_PRODUCT", 17, 22], ["NOD-2", "GENE_OR_GENE_PRODUCT", 27, 32], ["TLRs", "GENE_OR_GENE_PRODUCT", 147, 151], ["RIG", "PROTEIN", 10, 13], ["NLRP3", "PROTEIN", 17, 22], ["NOD", "PROTEIN", 27, 30], ["TLRs", "PROTEIN", 147, 151], ["influenza infections", "PROBLEM", 100, 120], ["cystic fibrosisCystic Fibrosis", "PROBLEM", 155, 185], ["an autosomal recessive genetic disorder", "PROBLEM", 187, 226], ["chronic inflammation", "PROBLEM", 243, 263], ["prolonged bacterial colonization", "PROBLEM", 275, 307], ["cystic", "OBSERVATION_MODIFIER", 155, 161], ["fibrosisCystic Fibrosis", "OBSERVATION", 162, 185], ["autosomal", "OBSERVATION_MODIFIER", 190, 199], ["recessive", "OBSERVATION_MODIFIER", 200, 209], ["genetic disorder", "OBSERVATION", 210, 226], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["inflammation", "OBSERVATION", 251, 263], ["prolonged", "OBSERVATION_MODIFIER", 275, 284], ["bacterial colonization", "OBSERVATION", 285, 307]]], ["Acute pneumonia or chronic lung disease with sharp, intermittent aggravations, as a result of Pseudomonas aeruginosa infection are the major causes of mortality and morbidity in cystic fibrosis [92] [93] [94] [95] .", [["lung", "ANATOMY", 27, 31], ["cystic", "ANATOMY", 178, 184], ["pneumonia", "DISEASE", 6, 15], ["chronic lung disease", "DISEASE", 19, 39], ["Pseudomonas aeruginosa infection", "DISEASE", 94, 126], ["fibrosis", "DISEASE", 185, 193], ["lung", "ORGAN", 27, 31], ["Pseudomonas aeruginosa", "ORGANISM", 94, 116], ["cystic", "ORGAN", 178, 184], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["Pseudomonas aeruginosa", "SPECIES", 94, 116], ["Acute pneumonia", "PROBLEM", 0, 15], ["chronic lung disease", "PROBLEM", 19, 39], ["sharp, intermittent aggravations", "PROBLEM", 45, 77], ["Pseudomonas aeruginosa infection", "PROBLEM", 94, 126], ["morbidity in cystic fibrosis", "PROBLEM", 165, 193], ["pneumonia", "OBSERVATION", 6, 15], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["lung", "ANATOMY", 27, 31], ["disease", "OBSERVATION", 32, 39], ["sharp", "OBSERVATION_MODIFIER", 45, 50], ["intermittent", "OBSERVATION_MODIFIER", 52, 64], ["Pseudomonas", "OBSERVATION_MODIFIER", 94, 105], ["aeruginosa", "OBSERVATION", 106, 116], ["cystic", "OBSERVATION_MODIFIER", 178, 184], ["fibrosis", "OBSERVATION", 185, 193]]], ["It has been observed that functional TLRs are expressed on both CF and non-CF lung epithelial cells but does not affect the susceptibility of chronic and gradual P. aeruginosa infection [96] .", [["CF", "ANATOMY", 64, 66], ["non-CF lung epithelial cells", "ANATOMY", 71, 99], ["P. aeruginosa infection", "DISEASE", 162, 185], ["TLRs", "GENE_OR_GENE_PRODUCT", 37, 41], ["CF", "CELL", 64, 66], ["non-CF lung epithelial cells", "CELL", 71, 99], ["P. aeruginosa", "ORGANISM", 162, 175], ["TLRs", "PROTEIN", 37, 41], ["CF and non-CF lung epithelial cells", "CELL_TYPE", 64, 99], ["P. aeruginosa", "SPECIES", 162, 175], ["P. aeruginosa", "SPECIES", 162, 175], ["non-CF lung epithelial cells", "PROBLEM", 71, 99], ["chronic and gradual P. aeruginosa infection", "PROBLEM", 142, 185], ["lung", "ANATOMY", 78, 82], ["epithelial cells", "OBSERVATION", 83, 99], ["chronic", "OBSERVATION_MODIFIER", 142, 149], ["gradual", "OBSERVATION_MODIFIER", 154, 161], ["aeruginosa", "OBSERVATION_MODIFIER", 165, 175]]], ["This has been confirmed by a study in which expression of surface TLR1 to TLR5 and TLR9 was observed in both human CFTE29o (CFTR) and 16HBE14o (bronchial non CF) cell lines [96] .", [["surface", "ANATOMY", 58, 65], ["bronchial non CF) cell lines", "ANATOMY", 144, 172], ["TLR1", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR5", "GENE_OR_GENE_PRODUCT", 74, 78], ["TLR9", "GENE_OR_GENE_PRODUCT", 83, 87], ["human", "ORGANISM", 109, 114], ["CFTE29o", "GENE_OR_GENE_PRODUCT", 115, 122], ["CFTR", "GENE_OR_GENE_PRODUCT", 124, 128], ["bronchial non CF) cell lines [96", "CELL", 144, 176], ["TLR1", "PROTEIN", 66, 70], ["TLR5", "PROTEIN", 74, 78], ["TLR9", "PROTEIN", 83, 87], ["human CFTE29o (CFTR) and 16HBE14o (bronchial non CF) cell lines", "CELL_LINE", 109, 172], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["a study", "TEST", 27, 34], ["surface TLR1 to TLR5 and TLR9", "TREATMENT", 58, 87], ["cell lines", "TEST", 162, 172], ["bronchial", "ANATOMY", 144, 153], ["cell lines", "OBSERVATION", 162, 172]]], ["TLR6 mRNA was found to be expressed in both cell lines but only CF cells retorted to MALP-2, a TLR2/TLR6 agonist [96] .", [["cell lines", "ANATOMY", 44, 54], ["CF cells", "ANATOMY", 64, 72], ["TLR6", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell lines", "CELL", 44, 54], ["CF cells", "CELL", 64, 72], ["MALP-2", "GENE_OR_GENE_PRODUCT", 85, 91], ["TLR2", "GENE_OR_GENE_PRODUCT", 95, 99], ["TLR6", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR6 mRNA", "RNA", 0, 9], ["cell lines", "CELL_LINE", 44, 54], ["CF cells", "CELL_TYPE", 64, 72], ["MALP", "PROTEIN", 85, 89], ["TLR2", "PROTEIN", 95, 99], ["TLR6", "PROTEIN", 100, 104], ["TLR6 mRNA", "TEST", 0, 9], ["CF cells", "PROBLEM", 64, 72], ["MALP", "TEST", 85, 89], ["a TLR2/TLR6 agonist", "TREATMENT", 93, 112], ["both cell lines", "OBSERVATION", 39, 54]]], ["Recently, it has been shown that bacterial flagellin and expression of TLR5 plays a significant role in enhanced inflammatory responses, observed upon stimulation of IB3-1 cells (CF airway epithelial cells) with clinical Pseudomonas isolates as compared to cell line expressing wild type CFTR gene.", [["IB3-1 cells", "ANATOMY", 166, 177], ["CF airway epithelial cells", "ANATOMY", 179, 205], ["cell line", "ANATOMY", 257, 266], ["flagellin", "GENE_OR_GENE_PRODUCT", 43, 52], ["TLR5", "GENE_OR_GENE_PRODUCT", 71, 75], ["IB3-1 cells", "CELL", 166, 177], ["CF airway epithelial cells", "CELL", 179, 205], ["cell line", "CELL", 257, 266], ["CFTR", "GENE_OR_GENE_PRODUCT", 288, 292], ["bacterial flagellin", "PROTEIN", 33, 52], ["TLR5", "PROTEIN", 71, 75], ["IB3-1 cells", "CELL_LINE", 166, 177], ["CF airway epithelial cells", "CELL_TYPE", 179, 205], ["wild type CFTR gene", "DNA", 278, 297], ["bacterial flagellin", "TREATMENT", 33, 52], ["enhanced inflammatory responses", "PROBLEM", 104, 135], ["IB3", "TEST", 166, 169], ["CF airway epithelial cells", "PROBLEM", 179, 205], ["clinical Pseudomonas isolates", "PROBLEM", 212, 241], ["cell line", "TREATMENT", 257, 266], ["bacterial flagellin", "OBSERVATION", 33, 52], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["enhanced", "OBSERVATION_MODIFIER", 104, 112], ["inflammatory", "OBSERVATION", 113, 125], ["airway", "ANATOMY", 182, 188], ["epithelial cells", "OBSERVATION", 189, 205]]], ["Moreover, peripheral blood mononuclear cells from CF patients also displayed aggravated inflammatory response upon stimulation with TLR ligands and P. aeruginosa in comparison to healthy controls.", [["peripheral blood mononuclear cells", "ANATOMY", 10, 44], ["peripheral blood mononuclear cells", "CELL", 10, 44], ["patients", "ORGANISM", 53, 61], ["TLR", "GENE_OR_GENE_PRODUCT", 132, 135], ["P. aeruginosa", "ORGANISM", 148, 161], ["peripheral blood mononuclear cells", "CELL_TYPE", 10, 44], ["TLR", "PROTEIN", 132, 135], ["patients", "SPECIES", 53, 61], ["P. aeruginosa", "SPECIES", 148, 161], ["P. aeruginosa", "SPECIES", 148, 161], ["peripheral blood mononuclear cells", "TEST", 10, 44], ["aggravated inflammatory response", "PROBLEM", 77, 109], ["TLR ligands", "TREATMENT", 132, 143], ["P. aeruginosa", "PROBLEM", 148, 161], ["peripheral", "ANATOMY_MODIFIER", 10, 20], ["blood", "ANATOMY", 21, 26], ["mononuclear cells", "OBSERVATION", 27, 44], ["aggravated", "OBSERVATION_MODIFIER", 77, 87], ["inflammatory response", "OBSERVATION", 88, 109]]], ["They also expressed higher levels of TLR5, suggesting the role of TLR5 in modulating host immune response via an undetermined mechanism.", [["TLR5", "GENE_OR_GENE_PRODUCT", 37, 41], ["TLR5", "GENE_OR_GENE_PRODUCT", 66, 70], ["TLR5", "PROTEIN", 37, 41], ["TLR5", "PROTEIN", 66, 70]]], ["TLR5 was also selectively increased in airway but not circulating neutrophils from CF patients, but not in patients with Bronchiectasis and healthy controls [22] .", [["airway", "ANATOMY", 39, 45], ["neutrophils", "ANATOMY", 66, 77], ["Bronchiectasis", "DISEASE", 121, 135], ["TLR5", "GENE_OR_GENE_PRODUCT", 0, 4], ["airway", "MULTI-TISSUE_STRUCTURE", 39, 45], ["neutrophils", "CELL", 66, 77], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 107, 115], ["TLR5", "PROTEIN", 0, 4], ["circulating neutrophils", "CELL_TYPE", 54, 77], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 107, 115], ["TLR5", "TREATMENT", 0, 4], ["Bronchiectasis", "PROBLEM", 121, 135], ["selectively", "OBSERVATION_MODIFIER", 14, 25], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["airway", "ANATOMY", 39, 45], ["Bronchiectasis", "OBSERVATION", 121, 135]]], ["TLR5 expression on neutrophils can be functionally related to chronic infection as they are implicated in phagocytosis, respiratory burst and flagellin dependent IL-8 secretion [22] .", [["neutrophils", "ANATOMY", 19, 30], ["respiratory", "ANATOMY", 120, 131], ["infection", "DISEASE", 70, 79], ["TLR5", "GENE_OR_GENE_PRODUCT", 0, 4], ["neutrophils", "CELL", 19, 30], ["flagellin", "GENE_OR_GENE_PRODUCT", 142, 151], ["IL-8", "GENE_OR_GENE_PRODUCT", 162, 166], ["TLR5", "PROTEIN", 0, 4], ["neutrophils", "CELL_TYPE", 19, 30], ["TLR5 expression on neutrophils", "PROBLEM", 0, 30], ["chronic infection", "PROBLEM", 62, 79], ["phagocytosis", "TEST", 106, 118], ["respiratory burst", "PROBLEM", 120, 137], ["flagellin dependent IL", "TREATMENT", 142, 164], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["infection", "OBSERVATION", 70, 79], ["respiratory burst", "OBSERVATION", 120, 137]]], ["This association was confirmed by a study which showed abbreviated neutrophil recruitment, MCP-1 production and bacterial clearance, upon low dose stimulation with flagellated P. aeruginosa as compared to isotypic non flagellated strains [97] .", [["neutrophil", "ANATOMY", 67, 77], ["neutrophil", "CELL", 67, 77], ["MCP-1", "GENE_OR_GENE_PRODUCT", 91, 96], ["P. aeruginosa", "ORGANISM", 176, 189], ["MCP", "PROTEIN", 91, 94], ["P. aeruginosa", "SPECIES", 176, 189], ["P. aeruginosa", "SPECIES", 176, 189], ["a study", "TEST", 34, 41], ["abbreviated neutrophil recruitment", "PROBLEM", 55, 89], ["MCP", "TEST", 91, 94], ["bacterial clearance", "PROBLEM", 112, 131], ["low dose stimulation", "TREATMENT", 138, 158], ["flagellated P. aeruginosa", "PROBLEM", 164, 189], ["isotypic non flagellated strains", "PROBLEM", 205, 237], ["neutrophil recruitment", "OBSERVATION", 67, 89]]], ["In addition, TLR 4 detects LPS and TLR2/TLR4 detects ExoS toxin of P. aeruginosa [16, 30, 98] .", [["TLR 4", "GENE_OR_GENE_PRODUCT", 13, 18], ["LPS", "GENE_OR_GENE_PRODUCT", 27, 30], ["TLR2", "GENE_OR_GENE_PRODUCT", 35, 39], ["TLR4", "GENE_OR_GENE_PRODUCT", 40, 44], ["ExoS", "GENE_OR_GENE_PRODUCT", 53, 57], ["P. aeruginosa", "ORGANISM", 67, 80], ["TLR 4", "PROTEIN", 13, 18], ["TLR2", "PROTEIN", 35, 39], ["TLR4", "PROTEIN", 40, 44], ["ExoS toxin", "PROTEIN", 53, 63], ["P. aeruginosa", "SPECIES", 67, 80], ["P. aeruginosa", "SPECIES", 67, 80], ["TLR", "TEST", 13, 16], ["LPS", "TEST", 27, 30], ["TLR2/TLR4", "TEST", 35, 44], ["ExoS toxin", "TEST", 53, 63], ["P. aeruginosa", "TEST", 67, 80]]], ["Similarly, MyD88 also exhibit a momentous role during the early phase of inflammation as loss of MyD88 may confer hyper-susceptibility, enhanced bacterial load, reduced neutrophil influx while TLR deficiency does not collogue susceptibility to P. aeruginosa infection [97, 99, 100] .", [["neutrophil", "ANATOMY", 169, 179], ["inflammation", "DISEASE", 73, 85], ["P. aeruginosa infection", "DISEASE", 244, 267], ["MyD88", "GENE_OR_GENE_PRODUCT", 11, 16], ["MyD88", "GENE_OR_GENE_PRODUCT", 97, 102], ["neutrophil", "CELL", 169, 179], ["TLR", "GENE_OR_GENE_PRODUCT", 193, 196], ["P. aeruginosa", "ORGANISM", 244, 257], ["MyD88", "PROTEIN", 11, 16], ["MyD88", "PROTEIN", 97, 102], ["neutrophil", "CELL_TYPE", 169, 179], ["TLR", "PROTEIN", 193, 196], ["P. aeruginosa", "SPECIES", 244, 257], ["P. aeruginosa", "SPECIES", 244, 257], ["inflammation", "PROBLEM", 73, 85], ["loss of MyD88", "PROBLEM", 89, 102], ["hyper-susceptibility", "PROBLEM", 114, 134], ["enhanced bacterial load", "PROBLEM", 136, 159], ["reduced neutrophil influx", "PROBLEM", 161, 186], ["TLR deficiency", "PROBLEM", 193, 207], ["P. aeruginosa infection", "PROBLEM", 244, 267], ["inflammation", "OBSERVATION", 73, 85], ["bacterial load", "OBSERVATION", 145, 159], ["neutrophil influx", "OBSERVATION", 169, 186]]], ["TLR2 and TLR4 signal via MyD88 dependent and independent pathways, whereas TLR5 signals via MyD88 exclusively.", [["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 9, 13], ["MyD88", "GENE_OR_GENE_PRODUCT", 25, 30], ["TLR5", "GENE_OR_GENE_PRODUCT", 75, 79], ["MyD88", "GENE_OR_GENE_PRODUCT", 92, 97], ["TLR2", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 9, 13], ["MyD88", "PROTEIN", 25, 30], ["TLR5", "PROTEIN", 75, 79], ["MyD88", "PROTEIN", 92, 97]]], ["However, the complicated pathogenesis of P. aeruginosa infection leads to inconsistent results in studies for determination of relative contribution of TLR2, TLR4 and TLR5 [101] .TLRs in cystic fibrosisOther than P. aeruginosa, Staphylococcus aureus and Burkholderia cenocepacia are also correlated with early and progressive lung disease associated with CF, respectively [102, 103] .", [["cystic", "ANATOMY", 187, 193], ["lung", "ANATOMY", 326, 330], ["P. aeruginosa infection", "DISEASE", 41, 64], ["lung disease", "DISEASE", 326, 338], ["P. aeruginosa", "ORGANISM", 41, 54], ["TLR2", "GENE_OR_GENE_PRODUCT", 152, 156], ["TLR4", "GENE_OR_GENE_PRODUCT", 158, 162], ["TLR5", "GENE_OR_GENE_PRODUCT", 167, 171], ["TLRs", "GENE_OR_GENE_PRODUCT", 179, 183], ["P. aeruginosa", "ORGANISM", 213, 226], ["Staphylococcus aureus", "ORGANISM", 228, 249], ["Burkholderia cenocepacia", "ORGANISM", 254, 278], ["lung", "ORGAN", 326, 330], ["TLR2", "PROTEIN", 152, 156], ["TLR4", "PROTEIN", 158, 162], ["TLR5", "PROTEIN", 167, 171], ["TLRs", "PROTEIN", 179, 183], ["P. aeruginosa", "SPECIES", 41, 54], ["P. aeruginosa", "SPECIES", 213, 226], ["Staphylococcus aureus", "SPECIES", 228, 249], ["Burkholderia cenocepacia", "SPECIES", 254, 278], ["P. aeruginosa", "SPECIES", 41, 54], ["P. aeruginosa", "SPECIES", 213, 226], ["Staphylococcus aureus", "SPECIES", 228, 249], ["Burkholderia cenocepacia", "SPECIES", 254, 278], ["P. aeruginosa infection", "PROBLEM", 41, 64], ["P. aeruginosa", "PROBLEM", 213, 226], ["Staphylococcus aureus", "PROBLEM", 228, 249], ["Burkholderia cenocepacia", "PROBLEM", 254, 278], ["progressive lung disease", "PROBLEM", 314, 338], ["CF", "PROBLEM", 355, 357], ["P. aeruginosa", "OBSERVATION", 41, 54], ["TLR2", "ANATOMY", 152, 156], ["cystic", "OBSERVATION_MODIFIER", 187, 193], ["Staphylococcus aureus", "OBSERVATION", 228, 249], ["Burkholderia cenocepacia", "OBSERVATION", 254, 278], ["progressive", "OBSERVATION_MODIFIER", 314, 325], ["lung", "ANATOMY", 326, 330], ["disease", "OBSERVATION", 331, 338]]], ["Severe pneumonia and sepsis in CF patients is a result of B. cenocepacia infection and stimulates damage to lung epithelial cells along with secretion of TNF-\u03b1 [104, 105] .", [["lung epithelial cells", "ANATOMY", 108, 129], ["pneumonia", "DISEASE", 7, 16], ["sepsis", "DISEASE", 21, 27], ["CF", "DISEASE", 31, 33], ["B. cenocepacia infection", "DISEASE", 58, 82], ["patients", "ORGANISM", 34, 42], ["B. cenocepacia", "ORGANISM", 58, 72], ["lung epithelial cells", "CELL", 108, 129], ["TNF", "GENE_OR_GENE_PRODUCT", 154, 157], ["lung epithelial cells", "CELL_TYPE", 108, 129], ["TNF", "PROTEIN", 154, 157], ["patients", "SPECIES", 34, 42], ["B. cenocepacia", "SPECIES", 58, 72], ["B. cenocepacia", "SPECIES", 58, 72], ["Severe pneumonia", "PROBLEM", 0, 16], ["sepsis", "PROBLEM", 21, 27], ["B. cenocepacia infection", "PROBLEM", 58, 82], ["stimulates damage to lung epithelial cells", "PROBLEM", 87, 129], ["secretion of TNF", "PROBLEM", 141, 157], ["pneumonia", "OBSERVATION", 7, 16], ["sepsis", "OBSERVATION", 21, 27], ["cenocepacia", "OBSERVATION_MODIFIER", 61, 72], ["infection", "OBSERVATION", 73, 82], ["lung", "ANATOMY", 108, 112], ["epithelial cells", "OBSERVATION", 113, 129]]], ["Higher mortality has been observed due to flagellin mediated activation of TLR5 and MyD88 in case of B. cenocepacia infection [105] .", [["B. cenocepacia infection", "DISEASE", 101, 125], ["flagellin", "GENE_OR_GENE_PRODUCT", 42, 51], ["TLR5", "GENE_OR_GENE_PRODUCT", 75, 79], ["MyD88", "GENE_OR_GENE_PRODUCT", 84, 89], ["B. cenocepacia", "ORGANISM", 101, 115], ["flagellin", "PROTEIN", 42, 51], ["TLR5", "PROTEIN", 75, 79], ["MyD88", "PROTEIN", 84, 89], ["B. cenocepacia", "SPECIES", 101, 115], ["B. cenocepacia", "SPECIES", 101, 115], ["Higher mortality", "PROBLEM", 0, 16], ["flagellin mediated activation of TLR5 and MyD88", "TREATMENT", 42, 89], ["B. cenocepacia infection", "PROBLEM", 101, 125], ["cenocepacia", "OBSERVATION_MODIFIER", 104, 115], ["infection", "OBSERVATION", 116, 125]]], ["MyD88 plays a very important role in inflammation associated with B. cenocepacia also, as demonstrated by a study which showed that loss of MyD88 decreased inflammation and mortality of mice despite higher loads of infection [106] .TLRs in chronic obstructive pulmonary disease (COPD)COPD is a respiratory disorder designated by irreversible limited expiratory airflow and aberrant inflammation [4] .", [["pulmonary", "ANATOMY", 260, 269], ["inflammation", "DISEASE", 37, 49], ["inflammation", "DISEASE", 156, 168], ["infection", "DISEASE", 215, 224], ["chronic obstructive pulmonary disease", "DISEASE", 240, 277], ["COPD", "DISEASE", 279, 283], ["COPD", "DISEASE", 284, 288], ["respiratory disorder", "DISEASE", 294, 314], ["inflammation", "DISEASE", 382, 394], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["B. cenocepacia", "ORGANISM", 66, 80], ["MyD88", "GENE_OR_GENE_PRODUCT", 140, 145], ["mice", "ORGANISM", 186, 190], ["TLRs", "GENE_OR_GENE_PRODUCT", 232, 236], ["pulmonary", "ORGAN", 260, 269], ["MyD88", "PROTEIN", 0, 5], ["MyD88", "PROTEIN", 140, 145], ["TLRs", "PROTEIN", 232, 236], ["B. cenocepacia", "SPECIES", 66, 80], ["mice", "SPECIES", 186, 190], ["B. cenocepacia", "SPECIES", 66, 80], ["mice", "SPECIES", 186, 190], ["inflammation", "PROBLEM", 37, 49], ["B. cenocepacia", "PROBLEM", 66, 80], ["a study", "TEST", 106, 113], ["loss of MyD88 decreased inflammation", "PROBLEM", 132, 168], ["infection", "PROBLEM", 215, 224], ["chronic obstructive pulmonary disease", "PROBLEM", 240, 277], ["COPD)", "PROBLEM", 279, 284], ["COPD", "PROBLEM", 284, 288], ["a respiratory disorder", "PROBLEM", 292, 314], ["irreversible limited expiratory airflow", "PROBLEM", 329, 368], ["aberrant inflammation", "PROBLEM", 373, 394], ["inflammation", "OBSERVATION", 37, 49], ["cenocepacia", "OBSERVATION", 69, 80], ["infection", "OBSERVATION", 215, 224], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["obstructive", "OBSERVATION_MODIFIER", 248, 259], ["pulmonary", "ANATOMY", 260, 269], ["disease", "OBSERVATION", 270, 277], ["COPD", "OBSERVATION", 279, 283], ["COPD", "OBSERVATION", 284, 288], ["respiratory disorder", "OBSERVATION", 294, 314], ["irreversible", "OBSERVATION_MODIFIER", 329, 341], ["expiratory airflow", "OBSERVATION", 350, 368], ["aberrant", "OBSERVATION_MODIFIER", 373, 381], ["inflammation", "OBSERVATION", 382, 394]]], ["Smoking is the most provocative risk factor for COPD in humans and the disease prevalence is age associated [107] .", [["Smoking", "DISEASE", 0, 7], ["COPD", "DISEASE", 48, 52], ["humans", "ORGANISM", 56, 62], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 56, 62], ["COPD in humans", "PROBLEM", 48, 62], ["COPD", "OBSERVATION", 48, 52]]], ["Disease pathogenesis is not well appreciated but impaired function of alveolar macrophages, defective mucociliary clearance and aberrant expression of airway antimicrobial polypeptides are customarily observed in COPD [108] .", [["alveolar macrophages", "ANATOMY", 70, 90], ["mucociliary", "ANATOMY", 102, 113], ["airway", "ANATOMY", 151, 157], ["COPD", "DISEASE", 213, 217], ["alveolar macrophages", "CELL", 70, 90], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 102, 113], ["airway antimicrobial polypeptides", "GENE_OR_GENE_PRODUCT", 151, 184], ["alveolar macrophages", "CELL_TYPE", 70, 90], ["Disease pathogenesis", "PROBLEM", 0, 20], ["alveolar macrophages", "PROBLEM", 70, 90], ["defective mucociliary clearance", "PROBLEM", 92, 123], ["aberrant expression of airway antimicrobial polypeptides", "PROBLEM", 128, 184], ["COPD", "PROBLEM", 213, 217], ["not well", "UNCERTAINTY", 24, 32], ["alveolar macrophages", "OBSERVATION", 70, 90], ["mucociliary clearance", "OBSERVATION", 102, 123], ["airway", "ANATOMY", 151, 157], ["antimicrobial polypeptides", "OBSERVATION", 158, 184], ["COPD", "OBSERVATION", 213, 217]]], ["Consequently, there is a gradual loss of lung function, due to an atrocious circle of inflammation generated upon establishment of pathogens in the lower respiratory tract [109] .", [["lung", "ANATOMY", 41, 45], ["lower respiratory tract", "ANATOMY", 148, 171], ["loss of lung function", "DISEASE", 33, 54], ["inflammation", "DISEASE", 86, 98], ["lung", "ORGAN", 41, 45], ["a gradual loss of lung function", "PROBLEM", 23, 54], ["an atrocious circle of inflammation", "PROBLEM", 63, 98], ["pathogens in the lower respiratory tract", "PROBLEM", 131, 171], ["gradual", "OBSERVATION_MODIFIER", 25, 32], ["loss", "OBSERVATION_MODIFIER", 33, 37], ["lung", "ANATOMY", 41, 45], ["function", "OBSERVATION", 46, 54], ["inflammation", "OBSERVATION", 86, 98], ["pathogens", "OBSERVATION_MODIFIER", 131, 140], ["lower", "ANATOMY_MODIFIER", 148, 153], ["respiratory tract", "ANATOMY", 154, 171]]], ["Evidences have suggested that a typical innate immunity contributes to the disease pathogenesis [110] .", [["the disease pathogenesis", "PROBLEM", 71, 95]]], ["Recent studies show that TLR4 perpetuates the lung oxidant/antioxidant balance by regulating the expression of NADPH oxidase 3 in structural cells.", [["lung", "ANATOMY", 46, 50], ["cells", "ANATOMY", 141, 146], ["NADPH", "CHEMICAL", 111, 116], ["NADPH", "CHEMICAL", 111, 116], ["TLR4", "GENE_OR_GENE_PRODUCT", 25, 29], ["lung", "ORGAN", 46, 50], ["NADPH oxidase 3", "GENE_OR_GENE_PRODUCT", 111, 126], ["cells", "CELL", 141, 146], ["TLR4", "PROTEIN", 25, 29], ["NADPH oxidase 3", "PROTEIN", 111, 126], ["structural cells", "CELL_TYPE", 130, 146], ["Recent studies", "TEST", 0, 14], ["TLR4", "TREATMENT", 25, 29], ["the lung oxidant/antioxidant balance", "TREATMENT", 42, 78], ["NADPH oxidase", "TREATMENT", 111, 124], ["TLR4", "OBSERVATION", 25, 29], ["lung", "ANATOMY", 46, 50], ["oxidant", "OBSERVATION", 51, 58], ["antioxidant balance", "OBSERVATION", 59, 78], ["structural cells", "OBSERVATION", 130, 146]]], ["This was confirmed when increased oxidant stress, elastolysis and tissue necrosis (all features of age-related emphysema) were observed in TLR4 and MyD88 deficient mice.", [["tissue", "ANATOMY", 66, 72], ["necrosis", "DISEASE", 73, 81], ["emphysema", "DISEASE", 111, 120], ["tissue", "TISSUE", 66, 72], ["emphysema", "PATHOLOGICAL_FORMATION", 111, 120], ["TLR4", "GENE_OR_GENE_PRODUCT", 139, 143], ["MyD88", "GENE_OR_GENE_PRODUCT", 148, 153], ["TLR4", "PROTEIN", 139, 143], ["MyD88", "PROTEIN", 148, 153], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 164, 168], ["increased oxidant stress", "PROBLEM", 24, 48], ["elastolysis", "PROBLEM", 50, 61], ["tissue necrosis", "PROBLEM", 66, 81], ["emphysema", "PROBLEM", 111, 120], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["oxidant stress", "OBSERVATION", 34, 48], ["elastolysis", "OBSERVATION_MODIFIER", 50, 61], ["tissue", "ANATOMY", 66, 72], ["necrosis", "OBSERVATION", 73, 81], ["emphysema", "OBSERVATION", 111, 120]]], ["Thus, it was also hypothesized that free radicals and oxidants of tobacco smoke may supersede innate immunity, resulting in cell necrosis and damage to lung tissue [111] .", [["cell", "ANATOMY", 124, 128], ["lung tissue", "ANATOMY", 152, 163], ["smoke", "CHEMICAL", 74, 79], ["necrosis", "DISEASE", 129, 137], ["free radicals", "SIMPLE_CHEMICAL", 36, 49], ["tobacco", "ORGANISM", 66, 73], ["cell", "CELL", 124, 128], ["lung tissue", "TISSUE", 152, 163], ["tobacco", "SPECIES", 66, 73], ["cell necrosis", "PROBLEM", 124, 137], ["damage to lung tissue", "PROBLEM", 142, 163], ["cell necrosis", "OBSERVATION", 124, 137], ["lung", "ANATOMY", 152, 156]]], ["A brief exposure of cigarette smoke leads to TLR4, MyD88 and IL-1R1 mediated neutrophilic airway inflammation in mice [112, 113] .", [["airway", "ANATOMY", 90, 96], ["airway inflammation", "DISEASE", 90, 109], ["cigarette", "ORGANISM", 20, 29], ["TLR4", "GENE_OR_GENE_PRODUCT", 45, 49], ["MyD88", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-1R1", "GENE_OR_GENE_PRODUCT", 61, 67], ["neutrophilic airway", "PATHOLOGICAL_FORMATION", 77, 96], ["mice", "ORGANISM", 113, 117], ["TLR4", "PROTEIN", 45, 49], ["MyD88", "PROTEIN", 51, 56], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["IL", "TEST", 61, 63], ["neutrophilic airway inflammation", "PROBLEM", 77, 109], ["neutrophilic", "OBSERVATION_MODIFIER", 77, 89], ["airway", "ANATOMY", 90, 96], ["inflammation", "OBSERVATION", 97, 109]]], ["However, C3H/HeJ mice having naturally impaired TLR4 signalling establish less chronic inflammation after cigarette smoke exposure for 5 weeks [114] .", [["inflammation", "DISEASE", 87, 99], ["smoke", "CHEMICAL", 116, 121], ["C3H/HeJ mice", "ORGANISM", 9, 21], ["TLR4", "GENE_OR_GENE_PRODUCT", 48, 52], ["TLR4", "PROTEIN", 48, 52], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 17, 21], ["naturally impaired TLR4 signalling", "PROBLEM", 29, 63], ["less chronic inflammation", "PROBLEM", 74, 99], ["less", "OBSERVATION_MODIFIER", 74, 78], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["inflammation", "OBSERVATION", 87, 99]]], ["Cigarette smoke exposure in for the long haul induced strain dependent emphysema in mice, while no association with TLRs was established [115] .", [["smoke", "CHEMICAL", 10, 15], ["emphysema", "DISEASE", 71, 80], ["Cigarette", "ORGANISM", 0, 9], ["emphysema", "PATHOLOGICAL_FORMATION", 71, 80], ["mice", "ORGANISM", 84, 88], ["TLRs", "GENE_OR_GENE_PRODUCT", 116, 120], ["TLRs", "PROTEIN", 116, 120], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["strain dependent emphysema", "PROBLEM", 54, 80], ["dependent", "OBSERVATION_MODIFIER", 61, 70], ["emphysema", "OBSERVATION", 71, 80]]], ["There are several studies discussing the association of TLR function and expression in smokers, non-smokers and COPD patients.", [["COPD", "DISEASE", 112, 116], ["TLR", "GENE_OR_GENE_PRODUCT", 56, 59], ["patients", "ORGANISM", 117, 125], ["TLR", "PROTEIN", 56, 59], ["patients", "SPECIES", 117, 125], ["several studies", "TEST", 10, 25], ["COPD patients", "PROBLEM", 112, 125]]], ["One of the studies has shown that the expression of TLR2 reduces in alveolar macrophages of smokers and COPD patients upon ex vivo ligand stimulation.", [["alveolar macrophages", "ANATOMY", 68, 88], ["COPD", "DISEASE", 104, 108], ["TLR2", "GENE_OR_GENE_PRODUCT", 52, 56], ["alveolar macrophages", "CELL", 68, 88], ["patients", "ORGANISM", 109, 117], ["TLR2", "PROTEIN", 52, 56], ["alveolar macrophages", "CELL_TYPE", 68, 88], ["patients", "SPECIES", 109, 117], ["the studies", "TEST", 7, 18], ["TLR2 reduces", "PROBLEM", 52, 64], ["COPD", "PROBLEM", 104, 108], ["ex vivo ligand stimulation", "TREATMENT", 123, 149], ["TLR2", "OBSERVATION_MODIFIER", 52, 56], ["reduces", "OBSERVATION_MODIFIER", 57, 64], ["alveolar macrophages", "OBSERVATION", 68, 88], ["COPD", "OBSERVATION", 104, 108]]], ["However, the relative expression of TLR4 was insignificant.", [["TLR4", "GENE_OR_GENE_PRODUCT", 36, 40], ["TLR4", "PROTEIN", 36, 40]]], ["Other study reported the commensurate level of expression of TLR2, TLR4, CD14 or MD2 but stimulation of alveolar macrophages with ligands of both TLR2 or TLR4 decreases the expression of mRNA and protein of inflammatory cytokines (such as IL-6, TNF-\u03b1, IL-1\u03b2) and chemokines (such as RANTES and IL-8), exhibit defective NF-\u03ba\u03b2 activation, concealed IRAK-1 and p38 phosphorylation in smokers [116] .", [["alveolar macrophages", "ANATOMY", 104, 124], ["TLR2", "GENE_OR_GENE_PRODUCT", 61, 65], ["TLR4", "GENE_OR_GENE_PRODUCT", 67, 71], ["CD14", "GENE_OR_GENE_PRODUCT", 73, 77], ["MD2", "GENE_OR_GENE_PRODUCT", 81, 84], ["alveolar macrophages", "CELL", 104, 124], ["TLR2", "GENE_OR_GENE_PRODUCT", 146, 150], ["TLR4", "GENE_OR_GENE_PRODUCT", 154, 158], ["IL-6", "GENE_OR_GENE_PRODUCT", 239, 243], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 245, 250], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 252, 257], ["RANTES", "GENE_OR_GENE_PRODUCT", 283, 289], ["IL-8", "GENE_OR_GENE_PRODUCT", 294, 298], ["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 319, 324], ["IRAK-1", "GENE_OR_GENE_PRODUCT", 347, 353], ["p38", "GENE_OR_GENE_PRODUCT", 358, 361], ["TLR2", "PROTEIN", 61, 65], ["TLR4", "PROTEIN", 67, 71], ["CD14", "PROTEIN", 73, 77], ["MD2", "PROTEIN", 81, 84], ["alveolar macrophages", "CELL_TYPE", 104, 124], ["TLR2", "PROTEIN", 146, 150], ["TLR4", "PROTEIN", 154, 158], ["mRNA", "RNA", 187, 191], ["inflammatory cytokines", "PROTEIN", 207, 229], ["IL-6", "PROTEIN", 239, 243], ["TNF", "PROTEIN", 245, 248], ["IL-1\u03b2", "PROTEIN", 252, 257], ["chemokines", "PROTEIN", 263, 273], ["RANTES", "PROTEIN", 283, 289], ["IL-8", "PROTEIN", 294, 298], ["NF-\u03ba\u03b2", "PROTEIN", 319, 324], ["IRAK", "PROTEIN", 347, 351], ["p38", "PROTEIN", 358, 361], ["Other study", "TEST", 0, 11], ["CD14", "TEST", 73, 77], ["MD2", "TREATMENT", 81, 84], ["alveolar macrophages", "PROBLEM", 104, 124], ["TLR4", "PROBLEM", 154, 158], ["inflammatory cytokines", "PROBLEM", 207, 229], ["IL", "TEST", 239, 241], ["TNF", "TEST", 245, 248], ["IL", "TEST", 252, 254], ["chemokines", "TEST", 263, 273], ["RANTES", "TEST", 283, 289], ["IL", "TEST", 294, 296], ["defective NF", "PROBLEM", 309, 321], ["IRAK", "TEST", 347, 351], ["TLR2", "ANATOMY", 61, 65], ["alveolar macrophages", "OBSERVATION", 104, 124], ["both", "ANATOMY_MODIFIER", 141, 145], ["TLR2", "ANATOMY", 146, 150], ["inflammatory", "OBSERVATION_MODIFIER", 207, 219]]], ["Therefore, it was suggested by authors that TLR2 and TLR4 mediated inflammatory response is dependent upon exposure time of LPS via cigarette smoking that selectively reprograms alveolar macrophages [117] .", [["alveolar macrophages", "ANATOMY", 178, 198], ["LPS", "CHEMICAL", 124, 127], ["smoking", "CHEMICAL", 142, 149], ["TLR2", "GENE_OR_GENE_PRODUCT", 44, 48], ["TLR4", "GENE_OR_GENE_PRODUCT", 53, 57], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["cigarette", "ORGANISM", 132, 141], ["alveolar macrophages", "CELL", 178, 198], ["TLR2", "PROTEIN", 44, 48], ["TLR4", "PROTEIN", 53, 57], ["alveolar macrophages", "CELL_TYPE", 178, 198], ["TLR4 mediated inflammatory response", "PROBLEM", 53, 88], ["inflammatory", "OBSERVATION", 67, 79], ["alveolar macrophages", "OBSERVATION", 178, 198]]], ["Another study reported decreased expression of TLR2 mRNA with no changes in TLR4 expression in nasal and tracheal epithelial cells of smokers in comparison to non-smokers [118] .", [["nasal", "ANATOMY", 95, 100], ["tracheal epithelial cells", "ANATOMY", 105, 130], ["TLR2", "GENE_OR_GENE_PRODUCT", 47, 51], ["TLR4", "GENE_OR_GENE_PRODUCT", 76, 80], ["nasal", "CELL", 95, 100], ["tracheal epithelial cells", "CELL", 105, 130], ["TLR2 mRNA", "RNA", 47, 56], ["TLR4", "PROTEIN", 76, 80], ["nasal and tracheal epithelial cells", "CELL_TYPE", 95, 130], ["Another study", "TEST", 0, 13], ["TLR2 mRNA", "PROBLEM", 47, 56], ["changes in TLR4 expression in nasal and tracheal epithelial cells", "PROBLEM", 65, 130], ["TLR2 mRNA", "OBSERVATION", 47, 56], ["no", "UNCERTAINTY", 62, 64], ["TLR4 expression", "OBSERVATION", 76, 91], ["nasal", "ANATOMY", 95, 100], ["tracheal", "ANATOMY", 105, 113], ["epithelial cells", "OBSERVATION", 114, 130]]], ["However, expression of TLR4 and HBD-2 (an inducible antimicrobial peptide) is found to be increased in case of mild COPD.", [["COPD", "DISEASE", 116, 120], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["HBD-2", "GENE_OR_GENE_PRODUCT", 32, 37], ["TLR4", "PROTEIN", 23, 27], ["HBD-2", "PROTEIN", 32, 37], ["TLR4", "TEST", 23, 27], ["HBD", "TEST", 32, 35], ["an inducible antimicrobial peptide", "TREATMENT", 39, 73], ["mild COPD", "PROBLEM", 111, 120], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["mild", "OBSERVATION_MODIFIER", 111, 115], ["COPD", "OBSERVATION", 116, 120]]], ["On the other hand, advanced COPD reduces their levels of expression [118] .", [["COPD", "DISEASE", 28, 32], ["advanced COPD", "PROBLEM", 19, 32], ["advanced", "OBSERVATION_MODIFIER", 19, 27], ["COPD", "OBSERVATION", 28, 32]]], ["Thus, several studies have been carried out to determine the inflection of TLR expression upon exposure to cigarette smoke and it was concluded that various factors such as degree of bacterial colonization, content of LPS in cigarette smoke and persistent inflammatory conditions, account for modulation of levels of TLR expression.", [["LPS", "CHEMICAL", 218, 221], ["TLR", "GENE_OR_GENE_PRODUCT", 75, 78], ["cigarette", "ORGANISM", 107, 116], ["LPS", "SIMPLE_CHEMICAL", 218, 221], ["TLR", "GENE_OR_GENE_PRODUCT", 317, 320], ["TLR", "PROTEIN", 75, 78], ["TLR", "PROTEIN", 317, 320], ["several studies", "TEST", 6, 21], ["various factors", "PROBLEM", 149, 164], ["bacterial colonization", "PROBLEM", 183, 205], ["LPS", "PROBLEM", 218, 221], ["persistent inflammatory conditions", "PROBLEM", 245, 279], ["TLR expression", "PROBLEM", 317, 331], ["bacterial colonization", "OBSERVATION", 183, 205], ["persistent", "OBSERVATION_MODIFIER", 245, 255], ["inflammatory", "OBSERVATION", 256, 268]]], ["Hence, a more powerful host response in case of mild COPD corresponds to enhanced TLR4 expression, and reduced expression in case of severe COPD can be correlated with impaired innate immunity [118] .TLRs in chronic obstructive pulmonary disease (COPD)Moreover, cigarette smoke gaseous and particulate phase contains 4500 or more components encompassing noxious particles, reactive chemicals and free radicals and an overly studied risk factor for COPD.", [["pulmonary", "ANATOMY", 228, 237], ["COPD", "DISEASE", 53, 57], ["COPD", "DISEASE", 140, 144], ["chronic obstructive pulmonary disease", "DISEASE", 208, 245], ["COPD", "DISEASE", 247, 251], ["COPD", "DISEASE", 448, 452], ["TLR4", "GENE_OR_GENE_PRODUCT", 82, 86], ["pulmonary", "ORGAN", 228, 237], ["TLR4", "PROTEIN", 82, 86], ["TLRs", "PROTEIN", 200, 204], ["mild COPD", "PROBLEM", 48, 57], ["enhanced TLR4 expression", "PROBLEM", 73, 97], ["severe COPD", "PROBLEM", 133, 144], ["chronic obstructive pulmonary disease", "PROBLEM", 208, 245], ["COPD)", "PROBLEM", 247, 252], ["noxious particles", "PROBLEM", 354, 371], ["reactive chemicals", "PROBLEM", 373, 391], ["free radicals", "PROBLEM", 396, 409], ["COPD", "PROBLEM", 448, 452], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["COPD", "OBSERVATION", 53, 57], ["TLR4 expression", "OBSERVATION", 82, 97], ["severe", "OBSERVATION_MODIFIER", 133, 139], ["COPD", "OBSERVATION", 140, 144], ["chronic", "OBSERVATION_MODIFIER", 208, 215], ["obstructive", "OBSERVATION_MODIFIER", 216, 227], ["pulmonary", "ANATOMY", 228, 237], ["disease", "OBSERVATION", 238, 245], ["COPD", "OBSERVATION", 247, 251], ["reactive chemicals", "OBSERVATION", 373, 391], ["COPD", "OBSERVATION", 448, 452]]], ["The components of cigarette smoke instigate and augment immune cells such as the macrophages [119] .", [["immune cells", "ANATOMY", 56, 68], ["macrophages", "ANATOMY", 81, 92], ["cigarette", "ORGANISM", 18, 27], ["immune cells", "CELL", 56, 68], ["macrophages", "CELL", 81, 92], ["immune cells", "CELL_TYPE", 56, 68], ["macrophages", "CELL_TYPE", 81, 92], ["augment immune cells", "PROBLEM", 48, 68], ["cigarette smoke", "OBSERVATION", 18, 33], ["immune cells", "OBSERVATION", 56, 68], ["macrophages", "ANATOMY", 81, 92]]], ["Damage to lung tissue occurs due to hypersecretion of mucus, mucociliary malfunction and inflammation.", [["lung tissue", "ANATOMY", 10, 21], ["mucus", "ANATOMY", 54, 59], ["mucociliary", "ANATOMY", 61, 72], ["inflammation", "DISEASE", 89, 101], ["lung tissue", "TISSUE", 10, 21], ["mucus", "ORGANISM_SUBSTANCE", 54, 59], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 61, 72], ["Damage to lung tissue", "PROBLEM", 0, 21], ["hypersecretion of mucus", "PROBLEM", 36, 59], ["mucociliary malfunction", "PROBLEM", 61, 84], ["inflammation", "PROBLEM", 89, 101], ["lung", "ANATOMY", 10, 14], ["tissue", "OBSERVATION", 15, 21], ["hypersecretion", "OBSERVATION", 36, 50], ["mucus", "OBSERVATION", 54, 59], ["mucociliary malfunction", "OBSERVATION", 61, 84], ["inflammation", "OBSERVATION", 89, 101]]], ["The cigarette smoke provocative response accumulates neutrophils, monocyte, dendritic cells, proinflammatory mediators, ROS, factors attracting T-lymphocyte and proteolytic enzymes.", [["neutrophils", "ANATOMY", 53, 64], ["monocyte", "ANATOMY", 66, 74], ["dendritic cells", "ANATOMY", 76, 91], ["T-lymphocyte", "ANATOMY", 144, 156], ["cigarette", "ORGANISM", 4, 13], ["neutrophils", "CELL", 53, 64], ["monocyte", "CELL", 66, 74], ["dendritic cells", "CELL", 76, 91], ["ROS", "SIMPLE_CHEMICAL", 120, 123], ["T-lymphocyte", "CELL", 144, 156], ["neutrophils", "CELL_TYPE", 53, 64], ["monocyte", "CELL_TYPE", 66, 74], ["dendritic cells", "CELL_TYPE", 76, 91], ["proinflammatory mediators", "PROTEIN", 93, 118], ["T-lymphocyte and proteolytic enzymes", "PROTEIN", 144, 180], ["proinflammatory mediators", "TEST", 93, 118], ["proteolytic enzymes", "TEST", 161, 180], ["accumulates neutrophils", "OBSERVATION", 41, 64], ["dendritic cells", "OBSERVATION", 76, 91]]], ["These responsive features are crucial players in COPD [120, 121] .TLRs in chronic obstructive pulmonary disease (COPD)Toll like receptors associated to cigarette smoke-induced inflammation are TLR2, TLR4 and TLR9.", [["pulmonary", "ANATOMY", 94, 103], ["COPD", "DISEASE", 49, 53], ["chronic obstructive pulmonary disease", "DISEASE", 74, 111], ["COPD", "DISEASE", 113, 117], ["smoke", "CHEMICAL", 162, 167], ["inflammation", "DISEASE", 176, 188], ["TLRs", "GENE_OR_GENE_PRODUCT", 66, 70], ["pulmonary", "ORGAN", 94, 103], ["Toll like receptors", "GENE_OR_GENE_PRODUCT", 118, 137], ["cigarette", "ORGANISM", 152, 161], ["TLR2", "GENE_OR_GENE_PRODUCT", 193, 197], ["TLR4", "GENE_OR_GENE_PRODUCT", 199, 203], ["TLR9", "GENE_OR_GENE_PRODUCT", 208, 212], ["TLRs", "PROTEIN", 66, 70], ["Toll like receptors", "PROTEIN", 118, 137], ["TLR2", "PROTEIN", 193, 197], ["TLR4", "PROTEIN", 199, 203], ["TLR9", "PROTEIN", 208, 212], ["COPD", "PROBLEM", 49, 53], ["chronic obstructive pulmonary disease", "PROBLEM", 74, 111], ["COPD)", "PROBLEM", 113, 118], ["inflammation", "PROBLEM", 176, 188], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["obstructive", "OBSERVATION_MODIFIER", 82, 93], ["pulmonary", "ANATOMY", 94, 103], ["disease", "OBSERVATION", 104, 111], ["COPD", "OBSERVATION", 113, 117], ["inflammation", "OBSERVATION", 176, 188]]], ["An extensive research has been done on TLR4 function such as by Karimi et al., who showed TLR4 involvement in cigarette smoke-persuaded cytokine production [122] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 39, 43], ["TLR4", "GENE_OR_GENE_PRODUCT", 90, 94], ["TLR4", "PROTEIN", 39, 43], ["TLR4", "PROTEIN", 90, 94], ["cytokine", "PROTEIN", 136, 144], ["TLR4 function", "TREATMENT", 39, 52]]], ["Sarir et al. revealed that TLR4 surface manifestation is reduced upon brief exposure of cigarette smoke [123] .", [["surface", "ANATOMY", 32, 39], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["cigarette", "ORGANISM", 88, 97], ["TLR4", "PROTEIN", 27, 31], ["TLR4 surface manifestation", "PROBLEM", 27, 53], ["TLR4 surface", "OBSERVATION_MODIFIER", 27, 39], ["reduced", "OBSERVATION_MODIFIER", 57, 64]]], ["Pace et al. corroborated TLR4 involvement in cigarette smoke-inciting CXCL8-lung inflammation employing epithelial cells [124] .", [["lung", "ANATOMY", 76, 80], ["epithelial cells", "ANATOMY", 104, 120], ["inflammation", "DISEASE", 81, 93], ["TLR4", "GENE_OR_GENE_PRODUCT", 25, 29], ["cigarette", "ORGANISM_SUBDIVISION", 45, 54], ["CXCL8", "GENE_OR_GENE_PRODUCT", 70, 75], ["lung", "ORGAN", 76, 80], ["epithelial cells", "CELL", 104, 120], ["TLR4", "PROTEIN", 25, 29], ["CXCL8", "PROTEIN", 70, 75], ["epithelial cells", "CELL_TYPE", 104, 120], ["CXCL8", "TEST", 70, 75], ["lung inflammation", "PROBLEM", 76, 93], ["epithelial cells", "PROBLEM", 104, 120], ["TLR4", "OBSERVATION", 25, 29], ["cigarette smoke", "OBSERVATION", 45, 60], ["lung", "ANATOMY", 76, 80], ["inflammation", "OBSERVATION", 81, 93], ["epithelial cells", "OBSERVATION", 104, 120]]], ["Maes et al. demonstrated that on subacute cigarette exposure neutrophils, lymphocyte levels in BALF were reduced in TLR4 knockout mice when compared with control wild type mice [115] .", [["neutrophils", "ANATOMY", 61, 72], ["lymphocyte", "ANATOMY", 74, 84], ["BALF", "ANATOMY", 95, 99], ["neutrophils", "CELL", 61, 72], ["lymphocyte", "CELL", 74, 84], ["BALF", "ORGANISM_SUBSTANCE", 95, 99], ["TLR4", "GENE_OR_GENE_PRODUCT", 116, 120], ["mice", "ORGANISM", 130, 134], ["mice", "ORGANISM", 172, 176], ["neutrophils", "CELL_TYPE", 61, 72], ["BALF", "CELL_TYPE", 95, 99], ["TLR4", "PROTEIN", 116, 120], ["mice", "SPECIES", 130, 134], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 130, 134], ["subacute cigarette exposure neutrophils", "TEST", 33, 72], ["lymphocyte levels", "TEST", 74, 91], ["BALF", "TEST", 95, 99], ["subacute", "OBSERVATION_MODIFIER", 33, 41], ["reduced", "OBSERVATION_MODIFIER", 105, 112], ["TLR4 knockout", "OBSERVATION", 116, 129]]], ["TLR4 role in COPD evidence comes from a population study which reported connotation between TLR4 polymorphism (TLRD299G, TLR2R753Q, TLR4T3991) and in 240 heavy smokers COPD development was investigated [125] .", [["COPD", "DISEASE", 13, 17], ["COPD", "DISEASE", 168, 172], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 92, 96], ["TLR4", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 92, 96], ["COPD evidence", "PROBLEM", 13, 26], ["a population study", "TEST", 38, 56], ["TLR4 polymorphism (TLRD299G", "TREATMENT", 92, 119], ["COPD", "OBSERVATION", 13, 17]]], ["Deteriorated polymorphic TLR4T3991 contribute to COPD development in smokers, an exposition to upsurge susceptibility to infections whereas polymorphism of D299G TLR4 has been linked to reduce COPD severity due to LPS hypo reactivity.", [["COPD", "DISEASE", 49, 53], ["infections", "DISEASE", 121, 131], ["COPD", "DISEASE", 193, 197], ["LPS", "CHEMICAL", 214, 217], ["TLR4T3991", "GENE_OR_GENE_PRODUCT", 25, 34], ["D299G TLR4", "GENE_OR_GENE_PRODUCT", 156, 166], ["LPS", "SIMPLE_CHEMICAL", 214, 217], ["TLR4T3991", "DNA", 25, 34], ["D299G TLR4", "PROTEIN", 156, 166], ["Deteriorated polymorphic TLR4T3991", "PROBLEM", 0, 34], ["COPD development", "PROBLEM", 49, 65], ["infections", "PROBLEM", 121, 131], ["polymorphism of D299G TLR4", "TREATMENT", 140, 166], ["COPD severity", "PROBLEM", 193, 206], ["LPS hypo reactivity", "PROBLEM", 214, 233], ["COPD", "OBSERVATION", 49, 53], ["hypo reactivity", "OBSERVATION", 218, 233]]], ["To fully explicate the function of TLR-polymorphism in COPD, more research is needed.", [["COPD", "DISEASE", 55, 59], ["TLR", "GENE_OR_GENE_PRODUCT", 35, 38], ["TLR", "PROTEIN", 35, 38], ["polymorphism", "PROBLEM", 39, 51], ["COPD", "PROBLEM", 55, 59], ["COPD", "OBSERVATION", 55, 59]]], ["Deficiency of TLR4 in mice results in pulmonary emphysema [111] .", [["pulmonary", "ANATOMY", 38, 47], ["pulmonary emphysema", "DISEASE", 38, 57], ["TLR4", "GENE_OR_GENE_PRODUCT", 14, 18], ["mice", "ORGANISM", 22, 26], ["pulmonary", "ORGAN", 38, 47], ["TLR4", "PROTEIN", 14, 18], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["Deficiency of TLR4", "PROBLEM", 0, 18], ["pulmonary emphysema", "PROBLEM", 38, 57], ["TLR4", "ANATOMY_MODIFIER", 14, 18], ["pulmonary", "ANATOMY", 38, 47], ["emphysema", "OBSERVATION", 48, 57]]], ["This shows TLR4 participation in healthy tissue homeostasis.", [["tissue", "ANATOMY", 41, 47], ["TLR4", "GENE_OR_GENE_PRODUCT", 11, 15], ["tissue", "TISSUE", 41, 47], ["TLR4", "PROTEIN", 11, 15], ["TLR4 participation", "OBSERVATION", 11, 29], ["healthy tissue homeostasis", "OBSERVATION", 33, 59]]], ["Overall, above knowledge summarizes TLR4 mediated inflammation generated by components of environment as well as deregulated TLR4 in disease.TLRs in chronic obstructive pulmonary disease (COPD)TLR2 altered function and expression, upon exposure of cigarette smoke has also been linked to COPD.", [["pulmonary", "ANATOMY", 169, 178], ["inflammation", "DISEASE", 50, 62], ["chronic obstructive pulmonary disease", "DISEASE", 149, 186], ["COPD", "DISEASE", 188, 192], ["COPD", "DISEASE", 288, 292], ["TLR4", "GENE_OR_GENE_PRODUCT", 36, 40], ["TLR4", "GENE_OR_GENE_PRODUCT", 125, 129], ["TLRs", "GENE_OR_GENE_PRODUCT", 141, 145], ["pulmonary", "ORGAN", 169, 178], ["TLR2", "GENE_OR_GENE_PRODUCT", 193, 197], ["cigarette", "ORGANISM", 248, 257], ["TLR4", "PROTEIN", 36, 40], ["TLR4", "PROTEIN", 125, 129], ["TLRs", "PROTEIN", 141, 145], ["TLR2", "PROTEIN", 193, 197], ["TLR4 mediated inflammation", "PROBLEM", 36, 62], ["deregulated TLR4 in disease", "PROBLEM", 113, 140], ["chronic obstructive pulmonary disease", "PROBLEM", 149, 186], ["COPD)", "PROBLEM", 188, 193], ["TLR2 altered function", "PROBLEM", 193, 214], ["COPD", "PROBLEM", 288, 292], ["inflammation", "OBSERVATION", 50, 62], ["TLR4", "OBSERVATION_MODIFIER", 125, 129], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["obstructive", "OBSERVATION_MODIFIER", 157, 168], ["pulmonary", "ANATOMY", 169, 178], ["disease", "OBSERVATION", 179, 186], ["COPD", "OBSERVATION", 188, 192], ["COPD", "OBSERVATION", 288, 292]]], ["When COPD patients and cigarette smokers were compared with wild type, a decreased expression of TLR2 on macrophages were observed [117] .", [["macrophages", "ANATOMY", 105, 116], ["COPD", "DISEASE", 5, 9], ["patients", "ORGANISM", 10, 18], ["cigarette", "ORGANISM", 23, 32], ["TLR2", "GENE_OR_GENE_PRODUCT", 97, 101], ["macrophages", "CELL", 105, 116], ["TLR2", "PROTEIN", 97, 101], ["macrophages", "CELL_TYPE", 105, 116], ["patients", "SPECIES", 10, 18], ["COPD", "PROBLEM", 5, 9], ["a decreased expression of TLR2 on macrophages", "PROBLEM", 71, 116], ["TLR2", "ANATOMY", 97, 101]]], ["Moreover, mRNA and protein expression of TLR2 was not elevated after triggering macrophages with LPS in smokers and COPD patients.", [["macrophages", "ANATOMY", 80, 91], ["LPS", "CHEMICAL", 97, 100], ["COPD", "DISEASE", 116, 120], ["TLR2", "GENE_OR_GENE_PRODUCT", 41, 45], ["macrophages", "CELL", 80, 91], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["patients", "ORGANISM", 121, 129], ["mRNA", "RNA", 10, 14], ["TLR2", "PROTEIN", 41, 45], ["macrophages", "CELL_TYPE", 80, 91], ["patients", "SPECIES", 121, 129], ["mRNA and protein expression", "TEST", 10, 37], ["TLR2", "TEST", 41, 45], ["elevated", "PROBLEM", 54, 62], ["LPS", "PROBLEM", 97, 100], ["COPD patients", "PROBLEM", 116, 129], ["COPD", "OBSERVATION", 116, 120]]], ["Howbeit, Pons et al. reported increased TLR2 expression on monocytes from COPD patients [126] .", [["monocytes", "ANATOMY", 59, 68], ["COPD", "DISEASE", 74, 78], ["TLR2", "GENE_OR_GENE_PRODUCT", 40, 44], ["monocytes", "CELL", 59, 68], ["patients", "ORGANISM", 79, 87], ["TLR2", "PROTEIN", 40, 44], ["monocytes", "CELL_TYPE", 59, 68], ["patients", "SPECIES", 79, 87], ["increased TLR2 expression on monocytes", "PROBLEM", 30, 68], ["COPD", "PROBLEM", 74, 78], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["TLR2 expression", "OBSERVATION", 40, 55], ["monocytes", "OBSERVATION_MODIFIER", 59, 68]]], ["This shows disagreement with the Droemann et al. findings [117] , but Pons study was on peripheral blood mononuclear cells (PBMCs), signifying a dissimilarity in TLR2 expression in terms of alveolar and systemic effects.TLRs in chronic obstructive pulmonary disease (COPD)Role of TLR9 in cigarette smoke-persuading signalling has been elaborated by a group who established in vitro, implication of TLR9 in cigarette-induced production of CXCL8 by neutrophils and plasmacytoid dendritic cells [127] .", [["peripheral blood mononuclear cells", "ANATOMY", 88, 122], ["PBMCs", "ANATOMY", 124, 129], ["alveolar", "ANATOMY", 190, 198], ["pulmonary", "ANATOMY", 248, 257], ["neutrophils", "ANATOMY", 447, 458], ["plasmacytoid dendritic cells", "ANATOMY", 463, 491], ["chronic obstructive pulmonary disease", "DISEASE", 228, 265], ["COPD", "DISEASE", 267, 271], ["smoke", "CHEMICAL", 298, 303], ["peripheral blood mononuclear cells", "CELL", 88, 122], ["PBMCs", "CELL", 124, 129], ["TLR2", "GENE_OR_GENE_PRODUCT", 162, 166], ["alveolar", "MULTI-TISSUE_STRUCTURE", 190, 198], ["TLRs", "GENE_OR_GENE_PRODUCT", 220, 224], ["pulmonary", "ORGAN", 248, 257], ["TLR9", "GENE_OR_GENE_PRODUCT", 280, 284], ["cigarette", "ORGANISM", 288, 297], ["TLR9", "GENE_OR_GENE_PRODUCT", 398, 402], ["cigarette", "ORGANISM", 406, 415], ["CXCL8", "GENE_OR_GENE_PRODUCT", 438, 443], ["neutrophils", "CELL", 447, 458], ["plasmacytoid dendritic cells", "CELL", 463, 491], ["peripheral blood mononuclear cells", "CELL_TYPE", 88, 122], ["PBMCs", "CELL_TYPE", 124, 129], ["TLR2", "PROTEIN", 162, 166], ["TLRs", "PROTEIN", 220, 224], ["TLR9", "PROTEIN", 280, 284], ["TLR9", "PROTEIN", 398, 402], ["CXCL8", "PROTEIN", 438, 443], ["neutrophils", "CELL_TYPE", 447, 458], ["plasmacytoid dendritic cells", "CELL_TYPE", 463, 491], ["Pons study", "TEST", 70, 80], ["peripheral blood mononuclear cells", "PROBLEM", 88, 122], ["PBMCs", "TEST", 124, 129], ["a dissimilarity in TLR2 expression", "PROBLEM", 143, 177], ["alveolar and systemic effects", "PROBLEM", 190, 219], ["chronic obstructive pulmonary disease", "PROBLEM", 228, 265], ["COPD", "PROBLEM", 267, 271], ["neutrophils", "TEST", 447, 458], ["plasmacytoid dendritic cells", "PROBLEM", 463, 491], ["peripheral", "ANATOMY_MODIFIER", 88, 98], ["blood", "ANATOMY", 99, 104], ["mononuclear cells", "OBSERVATION", 105, 122], ["TLR2 expression", "OBSERVATION", 162, 177], ["alveolar", "ANATOMY_MODIFIER", 190, 198], ["systemic effects", "OBSERVATION", 203, 219], ["chronic", "OBSERVATION_MODIFIER", 228, 235], ["obstructive", "OBSERVATION_MODIFIER", 236, 247], ["pulmonary", "ANATOMY", 248, 257], ["disease", "OBSERVATION", 258, 265], ["COPD", "OBSERVATION", 267, 271], ["plasmacytoid dendritic cells", "OBSERVATION", 463, 491]]], ["Evidence supporting role of TLR9 instigation in cigarette smoke-persuading inflammation invent from a study in which transfected cell line TLR9 human embryonic kidney (HEK) were used.", [["cell line", "ANATOMY", 129, 138], ["embryonic kidney", "ANATOMY", 150, 166], ["HEK", "ANATOMY", 168, 171], ["inflammation", "DISEASE", 75, 87], ["TLR9", "GENE_OR_GENE_PRODUCT", 28, 32], ["cigarette", "ORGANISM", 48, 57], ["cell line", "CELL", 129, 138], ["TLR9", "GENE_OR_GENE_PRODUCT", 139, 143], ["human", "ORGANISM", 144, 149], ["embryonic kidney", "CELL", 150, 166], ["HEK", "CELL", 168, 171], ["TLR9", "PROTEIN", 28, 32], ["transfected cell line TLR9 human embryonic kidney (HEK)", "CELL_LINE", 117, 172], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 144, 149], ["TLR9 instigation", "TREATMENT", 28, 44], ["persuading inflammation", "PROBLEM", 64, 87], ["a study", "TEST", 100, 107], ["transfected cell line TLR9 human embryonic kidney (HEK)", "TREATMENT", 117, 172], ["cell line", "OBSERVATION", 129, 138], ["kidney", "ANATOMY", 160, 166]]], ["TLR9 deficient cells showed decrease production of CXCL8.", [["cells", "ANATOMY", 15, 20], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 15, 20], ["CXCL8", "GENE_OR_GENE_PRODUCT", 51, 56], ["TLR9", "PROTEIN", 0, 4], ["CXCL8", "PROTEIN", 51, 56], ["TLR9 deficient cells", "PROBLEM", 0, 20], ["decrease production of CXCL8", "PROBLEM", 28, 56], ["deficient cells", "OBSERVATION", 5, 20], ["decrease", "OBSERVATION_MODIFIER", 28, 36], ["production", "OBSERVATION_MODIFIER", 37, 47], ["CXCL8", "OBSERVATION_MODIFIER", 51, 56]]], ["Synthetic CpG-oligodeoxynucleotides (ODNs), a TLR9 ligand targeting mice lung gave rise to infiltration of neutrophils, systemic inflammation along with increased pulmonary permeability [128, 129] .", [["lung", "ANATOMY", 73, 77], ["neutrophils", "ANATOMY", 107, 118], ["pulmonary", "ANATOMY", 163, 172], ["CpG-oligodeoxynucleotides", "CHEMICAL", 10, 35], ["inflammation", "DISEASE", 129, 141], ["CpG-oligodeoxynucleotides", "CHEMICAL", 10, 35], ["CpG-oligodeoxynucleotides", "SIMPLE_CHEMICAL", 10, 35], ["ODNs", "SIMPLE_CHEMICAL", 37, 41], ["TLR9", "GENE_OR_GENE_PRODUCT", 46, 50], ["mice", "ORGANISM", 68, 72], ["lung", "ORGAN", 73, 77], ["neutrophils", "CELL", 107, 118], ["pulmonary", "ORGAN", 163, 172], ["TLR9 ligand", "PROTEIN", 46, 57], ["neutrophils", "CELL_TYPE", 107, 118], ["mice", "SPECIES", 68, 72], ["mice", "SPECIES", 68, 72], ["Synthetic CpG-oligodeoxynucleotides (ODNs)", "TREATMENT", 0, 42], ["a TLR9 ligand targeting mice lung", "TREATMENT", 44, 77], ["infiltration of neutrophils", "PROBLEM", 91, 118], ["systemic inflammation", "PROBLEM", 120, 141], ["increased pulmonary permeability", "PROBLEM", 153, 185], ["lung", "ANATOMY", 73, 77], ["infiltration", "OBSERVATION", 91, 103], ["neutrophils", "OBSERVATION", 107, 118], ["systemic", "OBSERVATION_MODIFIER", 120, 128], ["inflammation", "OBSERVATION", 129, 141], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["pulmonary", "ANATOMY", 163, 172], ["permeability", "OBSERVATION_MODIFIER", 173, 185]]], ["This oligonucleotide inciting inflammation has been implied to be based on TNF\u03b1.", [["inflammation", "DISEASE", 30, 42], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 75, 79], ["TNF", "PROTEIN", 75, 78], ["This oligonucleotide inciting inflammation", "PROBLEM", 0, 42], ["inflammation", "OBSERVATION", 30, 42]]], ["TLR9 was also found to be rodent specific due to increased transcription of TLR9 in rodent lung [130] .", [["lung", "ANATOMY", 91, 95], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR9", "GENE_OR_GENE_PRODUCT", 76, 80], ["lung", "ORGAN", 91, 95], ["TLR9", "PROTEIN", 0, 4], ["TLR9", "PROTEIN", 76, 80], ["rodent", "SPECIES", 84, 90], ["increased transcription of TLR9 in rodent lung", "PROBLEM", 49, 95], ["TLR9", "ANATOMY_MODIFIER", 76, 80], ["lung", "ANATOMY", 91, 95]]], ["On the other hand, LPS treatment can upregulate TLR9 expression in lungs of horses.", [["lungs", "ANATOMY", 67, 72], ["LPS", "CHEMICAL", 19, 22], ["LPS", "SIMPLE_CHEMICAL", 19, 22], ["TLR9", "GENE_OR_GENE_PRODUCT", 48, 52], ["lungs", "ORGAN", 67, 72], ["horses", "ORGANISM", 76, 82], ["TLR9", "PROTEIN", 48, 52], ["LPS treatment", "TREATMENT", 19, 32], ["TLR9 expression in lungs of horses", "PROBLEM", 48, 82], ["lungs", "ANATOMY", 67, 72]]], ["Henceforth, in non-rodent mammals, the expression of TLR9 and CpG-ODNs response might increase due to specific co-stimulatory patterns [131] .", [["TLR9", "GENE_OR_GENE_PRODUCT", 53, 57], ["CpG-ODNs", "GENE_OR_GENE_PRODUCT", 62, 70], ["TLR9", "PROTEIN", 53, 57], ["TLR9 and CpG-ODNs response", "TREATMENT", 53, 79]]], ["TLR9 stimulation induces various host defence genes expression, including IFN-\u03b1/\u03b2, which is required for antimicrobial immunity.", [["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 74, 79], ["\u03b2", "GENE_OR_GENE_PRODUCT", 80, 81], ["TLR9", "PROTEIN", 0, 4], ["IFN", "PROTEIN", 74, 77], ["\u03b1", "PROTEIN", 78, 79], ["\u03b2", "PROTEIN", 80, 81], ["TLR9 stimulation", "TREATMENT", 0, 16], ["IFN", "TEST", 74, 77], ["\u03b2", "PROBLEM", 80, 81], ["antimicrobial immunity", "TREATMENT", 105, 127]]], ["Howbeit, on exposure of cigarette smoke extract, this effect is suppressed in vitro.", [["Howbeit", "CHEMICAL", 0, 7], ["cigarette", "ORGANISM", 24, 33]]], ["Surprisingly cigarette smoke stimulates TLR9 mediated IL-8 expression and influx of neutrophils implying that ongoing smoking potentiates detrimental inflammation in airways in response to infection, in addition to impaired host airway defence.TLRs in chronic obstructive pulmonary disease (COPD)Among viral ligands, TLR4 also interacts with viral pneumococci toxin pneumolysin [132] However, TLR4 interactions seems to be specific for nasopharynx as indicated by a study in which TLR4 deficient mice possessed very mild impairment of host immune response, upon direct infection of lower respiratory tract with pneumococcal toxin [133, 134] .", [["neutrophils", "ANATOMY", 84, 95], ["airways", "ANATOMY", 166, 173], ["airway", "ANATOMY", 229, 235], ["pulmonary", "ANATOMY", 272, 281], ["nasopharynx", "ANATOMY", 436, 447], ["lower respiratory tract", "ANATOMY", 582, 605], ["smoke", "CHEMICAL", 23, 28], ["smoking", "CHEMICAL", 118, 125], ["inflammation", "DISEASE", 150, 162], ["infection", "DISEASE", 189, 198], ["chronic obstructive pulmonary disease", "DISEASE", 252, 289], ["COPD", "DISEASE", 291, 295], ["infection of lower respiratory tract", "DISEASE", 569, 605], ["cigarette", "ORGANISM", 13, 22], ["TLR9", "GENE_OR_GENE_PRODUCT", 40, 44], ["IL-8", "GENE_OR_GENE_PRODUCT", 54, 58], ["neutrophils", "CELL", 84, 95], ["airways", "MULTI-TISSUE_STRUCTURE", 166, 173], ["airway", "MULTI-TISSUE_STRUCTURE", 229, 235], ["TLRs", "GENE_OR_GENE_PRODUCT", 244, 248], ["pulmonary", "ORGAN", 272, 281], ["TLR4", "GENE_OR_GENE_PRODUCT", 317, 321], ["pneumococci toxin pneumolysin", "GENE_OR_GENE_PRODUCT", 348, 377], ["TLR4", "GENE_OR_GENE_PRODUCT", 393, 397], ["nasopharynx", "ORGAN", 436, 447], ["TLR4", "GENE_OR_GENE_PRODUCT", 481, 485], ["mice", "ORGANISM", 496, 500], ["lower", "ORGANISM_SUBDIVISION", 582, 587], ["respiratory tract", "ORGANISM_SUBDIVISION", 588, 605], ["TLR9", "PROTEIN", 40, 44], ["IL-8", "PROTEIN", 54, 58], ["neutrophils", "CELL_TYPE", 84, 95], ["TLRs", "PROTEIN", 244, 248], ["TLR4", "PROTEIN", 317, 321], ["TLR4", "PROTEIN", 393, 397], ["TLR4", "PROTEIN", 481, 485], ["mice", "SPECIES", 496, 500], ["mice", "SPECIES", 496, 500], ["pneumococcal", "SPECIES", 611, 623], ["TLR9 mediated IL", "TREATMENT", 40, 56], ["influx of neutrophils", "PROBLEM", 74, 95], ["detrimental inflammation in airways", "PROBLEM", 138, 173], ["infection", "PROBLEM", 189, 198], ["impaired host airway defence", "PROBLEM", 215, 243], ["chronic obstructive pulmonary disease", "PROBLEM", 252, 289], ["COPD)", "PROBLEM", 291, 296], ["Among viral ligands", "PROBLEM", 296, 315], ["viral pneumococci toxin pneumolysin", "PROBLEM", 342, 377], ["nasopharynx", "PROBLEM", 436, 447], ["a study", "TEST", 464, 471], ["very mild impairment of host immune response", "PROBLEM", 511, 555], ["direct infection of lower respiratory tract", "PROBLEM", 562, 605], ["pneumococcal toxin", "TEST", 611, 629], ["detrimental", "OBSERVATION_MODIFIER", 138, 149], ["inflammation", "OBSERVATION", 150, 162], ["airways", "ANATOMY", 166, 173], ["infection", "OBSERVATION", 189, 198], ["impaired", "OBSERVATION_MODIFIER", 215, 223], ["host airway defence", "OBSERVATION", 224, 243], ["chronic", "OBSERVATION_MODIFIER", 252, 259], ["obstructive", "OBSERVATION_MODIFIER", 260, 271], ["pulmonary", "ANATOMY", 272, 281], ["disease", "OBSERVATION", 282, 289], ["COPD", "OBSERVATION", 291, 295], ["viral ligands", "OBSERVATION", 302, 315], ["mild", "OBSERVATION_MODIFIER", 516, 520], ["lower", "ANATOMY_MODIFIER", 582, 587], ["respiratory tract", "ANATOMY", 588, 605]]], ["Pneumococcal infection also upregulates the expression of TLR2 and aggravates the host inflammatory response [135, 136] .", [["Pneumococcal infection", "DISEASE", 0, 22], ["TLR2", "GENE_OR_GENE_PRODUCT", 58, 62], ["TLR2", "PROTEIN", 58, 62], ["Pneumococcal infection", "PROBLEM", 0, 22], ["infection", "OBSERVATION", 13, 22], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99]]], ["Other PRRs are also involved in case of Streptococcus pneumoniae infections as indicated by a study wherein there is clearance of high and low infectious doses of S. pneumoniae with a moderate reduction in production of inflammatory mediators in TLR2 deficient mice [134, 137] .", [["Streptococcus pneumoniae infections", "DISEASE", 40, 75], ["PRRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["Streptococcus pneumoniae", "ORGANISM", 40, 64], ["S. pneumoniae", "ORGANISM", 163, 176], ["TLR2", "GENE_OR_GENE_PRODUCT", 246, 250], ["mice", "ORGANISM", 261, 265], ["PRRs", "PROTEIN", 6, 10], ["inflammatory mediators", "PROTEIN", 220, 242], ["TLR2", "PROTEIN", 246, 250], ["Streptococcus pneumoniae", "SPECIES", 40, 64], ["S. pneumoniae", "SPECIES", 163, 176], ["mice", "SPECIES", 261, 265], ["Streptococcus pneumoniae", "SPECIES", 40, 64], ["S. pneumoniae", "SPECIES", 163, 176], ["mice", "SPECIES", 261, 265], ["Streptococcus pneumoniae infections", "PROBLEM", 40, 75], ["a study", "TEST", 92, 99], ["high and low infectious doses", "PROBLEM", 130, 159], ["S. pneumoniae", "PROBLEM", 163, 176], ["a moderate reduction", "PROBLEM", 182, 202], ["inflammatory mediators", "PROBLEM", 220, 242], ["Streptococcus pneumoniae", "OBSERVATION", 40, 64], ["high", "OBSERVATION_MODIFIER", 130, 134], ["low infectious", "OBSERVATION_MODIFIER", 139, 153], ["pneumoniae", "OBSERVATION", 166, 176], ["moderate", "OBSERVATION_MODIFIER", 184, 192], ["reduction", "OBSERVATION_MODIFIER", 193, 202], ["production", "OBSERVATION_MODIFIER", 206, 216], ["inflammatory", "OBSERVATION_MODIFIER", 220, 232]]], ["TLR4 recognizes pneumolysin, an intracellular toxin secreted by Streptococcus pneumonia.", [["intracellular", "ANATOMY", 32, 45], ["Streptococcus pneumonia", "DISEASE", 64, 87], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["pneumolysin", "GENE_OR_GENE_PRODUCT", 16, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 45], ["Streptococcus pneumonia", "ORGANISM", 64, 87], ["TLR4", "PROTEIN", 0, 4], ["pneumolysin", "PROTEIN", 16, 27], ["intracellular toxin", "PROTEIN", 32, 51], ["Streptococcus pneumonia", "SPECIES", 64, 87], ["pneumolysin", "PROBLEM", 16, 27], ["an intracellular toxin", "TEST", 29, 51], ["Streptococcus pneumonia", "PROBLEM", 64, 87], ["pneumolysin", "OBSERVATION", 16, 27], ["Streptococcus", "OBSERVATION_MODIFIER", 64, 77], ["pneumonia", "OBSERVATION", 78, 87]]], ["Despite TLR2 plays a decisive role in host defence against gram positive bacteria, nevertheless S. pneumoniae can be perceived by TLR4, even in the absence of TLR2 [138] .", [["TLR2", "GENE_OR_GENE_PRODUCT", 8, 12], ["S. pneumoniae", "ORGANISM", 96, 109], ["TLR4", "GENE_OR_GENE_PRODUCT", 130, 134], ["TLR2", "GENE_OR_GENE_PRODUCT", 159, 163], ["TLR2", "PROTEIN", 8, 12], ["TLR4", "PROTEIN", 130, 134], ["TLR2", "PROTEIN", 159, 163], ["S. pneumoniae", "SPECIES", 96, 109], ["S. pneumoniae", "SPECIES", 96, 109], ["gram positive bacteria", "PROBLEM", 59, 81], ["S. pneumoniae", "PROBLEM", 96, 109], ["pneumoniae", "OBSERVATION", 99, 109]]], ["TLR9 also plays a role, as TLR9 deficiency increases the susceptibility to pneumococcal infection [139] .", [["pneumococcal infection", "DISEASE", 75, 97], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR9", "GENE_OR_GENE_PRODUCT", 27, 31], ["TLR9", "PROTEIN", 0, 4], ["TLR9", "PROTEIN", 27, 31], ["pneumococcal", "SPECIES", 75, 87], ["TLR9 deficiency", "PROBLEM", 27, 42], ["pneumococcal infection", "PROBLEM", 75, 97], ["pneumococcal", "OBSERVATION_MODIFIER", 75, 87], ["infection", "OBSERVATION", 88, 97]]], ["On the contrary, reduced production of inflammatory mediators (IL-6 and TNF-\u03b1), unconstrained systemic bacterial dissemination and airway pneumococcal growth has also been observed in case of rescission of MyD88 signalling [140] .", [["airway", "ANATOMY", 131, 137], ["IL-6", "GENE_OR_GENE_PRODUCT", 63, 67], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["airway", "MULTI-TISSUE_STRUCTURE", 131, 137], ["MyD88", "GENE_OR_GENE_PRODUCT", 206, 211], ["inflammatory mediators", "PROTEIN", 39, 61], ["IL-6", "PROTEIN", 63, 67], ["TNF", "PROTEIN", 72, 75], ["MyD88", "PROTEIN", 206, 211], ["pneumococcal", "SPECIES", 138, 150], ["inflammatory mediators", "PROBLEM", 39, 61], ["IL", "TEST", 63, 65], ["TNF", "TEST", 72, 75], ["unconstrained systemic bacterial dissemination", "PROBLEM", 80, 126], ["airway pneumococcal growth", "PROBLEM", 131, 157], ["MyD88 signalling", "TEST", 206, 222], ["reduced", "OBSERVATION_MODIFIER", 17, 24], ["production", "OBSERVATION_MODIFIER", 25, 35], ["inflammatory", "OBSERVATION_MODIFIER", 39, 51], ["systemic", "OBSERVATION_MODIFIER", 94, 102], ["bacterial dissemination", "OBSERVATION", 103, 126], ["airway", "ANATOMY", 131, 137], ["pneumococcal", "OBSERVATION", 138, 150]]], ["The severity of response against S. pneumonia is enormously increased in case of MyD88 deficiency rather than single or combined deletion of TLR2 and TLR4 respectively [141] .TLRs in chronic obstructive pulmonary disease (COPD)COPD aggravations are also associated with non-typeable H. influenza (NTHi) infection.", [["pulmonary", "ANATOMY", 203, 212], ["pneumonia", "DISEASE", 36, 45], ["chronic obstructive pulmonary disease", "DISEASE", 183, 220], ["COPD", "DISEASE", 222, 226], ["COPD", "DISEASE", 227, 231], ["H. influenza (NTHi) infection", "DISEASE", 283, 312], ["MyD88", "GENE_OR_GENE_PRODUCT", 81, 86], ["TLR2", "GENE_OR_GENE_PRODUCT", 141, 145], ["TLR4", "GENE_OR_GENE_PRODUCT", 150, 154], ["TLRs", "GENE_OR_GENE_PRODUCT", 175, 179], ["pulmonary", "ORGAN", 203, 212], ["H. influenza", "ORGANISM", 283, 295], ["NTHi", "ORGANISM", 297, 301], ["MyD88", "PROTEIN", 81, 86], ["TLR2", "PROTEIN", 141, 145], ["TLR4", "PROTEIN", 150, 154], ["TLRs", "PROTEIN", 175, 179], ["H. influenza", "SPECIES", 283, 295], ["S. pneumonia", "SPECIES", 33, 45], ["S. pneumonia", "PROBLEM", 33, 45], ["MyD88 deficiency", "PROBLEM", 81, 97], ["single or combined deletion of TLR2", "PROBLEM", 110, 145], ["chronic obstructive pulmonary disease", "PROBLEM", 183, 220], ["COPD)", "PROBLEM", 222, 227], ["COPD aggravations", "PROBLEM", 227, 244], ["non-typeable H. influenza (NTHi) infection", "PROBLEM", 270, 312], ["pneumonia", "OBSERVATION", 36, 45], ["enormously", "OBSERVATION_MODIFIER", 49, 59], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["MyD88 deficiency", "OBSERVATION", 81, 97], ["TLR2", "ANATOMY", 141, 145], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["obstructive", "OBSERVATION_MODIFIER", 191, 202], ["pulmonary", "ANATOMY", 203, 212], ["disease", "OBSERVATION", 213, 220], ["COPD", "OBSERVATION", 222, 226], ["COPD", "OBSERVATION", 227, 231], ["influenza", "OBSERVATION", 286, 295], ["infection", "OBSERVATION", 303, 312]]], ["Although both TLR2 and TLR4 ligands are involved, but TLR4/MyD88 is the most assertive immune signalling pathway involved in in vitro and in vivo bacterial clearance.", [["TLR2", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["TLR4", "GENE_OR_GENE_PRODUCT", 54, 58], ["MyD88", "GENE_OR_GENE_PRODUCT", 59, 64], ["TLR2", "PROTEIN", 14, 18], ["TLR4", "PROTEIN", 23, 27], ["TLR4", "PROTEIN", 54, 58], ["MyD88", "PROTEIN", 59, 64], ["TLR2", "ANATOMY_MODIFIER", 14, 18], ["bacterial clearance", "OBSERVATION", 146, 165]]], ["TLR3 also exhibit a role in production of inflammatory mediators but their bestowal in bacterial clearance is ambiguous [142] .TLRs in asthmaAsthma is a deadly disease that causes chronic airway inflammation described by discursive bronchoconstriction, hyperplasia of goblet cells, excessive secretion of mucus and tissue remodelling that eventuates in childhood.", [["asthmaAsthma", "ANATOMY", 135, 147], ["airway", "ANATOMY", 188, 194], ["goblet cells", "ANATOMY", 268, 280], ["mucus", "ANATOMY", 305, 310], ["tissue", "ANATOMY", 315, 321], ["asthmaAsthma", "DISEASE", 135, 147], ["airway inflammation", "DISEASE", 188, 207], ["hyperplasia", "DISEASE", 253, 264], ["TLR3", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["asthmaAsthma", "CANCER", 135, 147], ["airway", "MULTI-TISSUE_STRUCTURE", 188, 194], ["goblet cells", "CELL", 268, 280], ["mucus", "TISSUE", 305, 310], ["tissue", "TISSUE", 315, 321], ["TLR3", "PROTEIN", 0, 4], ["inflammatory mediators", "PROTEIN", 42, 64], ["TLRs", "PROTEIN", 127, 131], ["goblet cells", "CELL_TYPE", 268, 280], ["inflammatory mediators", "PROBLEM", 42, 64], ["bacterial clearance", "TEST", 87, 106], ["a deadly disease", "PROBLEM", 151, 167], ["chronic airway inflammation", "PROBLEM", 180, 207], ["discursive bronchoconstriction", "PROBLEM", 221, 251], ["hyperplasia of goblet cells", "PROBLEM", 253, 280], ["excessive secretion of mucus and tissue remodelling", "PROBLEM", 282, 333], ["inflammatory", "OBSERVATION_MODIFIER", 42, 54], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["airway", "ANATOMY", 188, 194], ["inflammation", "OBSERVATION", 195, 207], ["bronchoconstriction", "OBSERVATION", 232, 251], ["hyperplasia", "OBSERVATION", 253, 264], ["goblet cells", "OBSERVATION", 268, 280], ["excessive", "OBSERVATION_MODIFIER", 282, 291], ["secretion", "OBSERVATION_MODIFIER", 292, 301], ["mucus", "OBSERVATION_MODIFIER", 305, 310], ["tissue", "OBSERVATION", 315, 321], ["remodelling", "OBSERVATION_MODIFIER", 322, 333]]], ["Host immune response against environmental stimuli of asthma i.e. pollen or dust particles constitutes the inhabitance of antigen specific Th2 cells secreting antigen specific IgE in lung [143, 144] .TLRs in asthmaInnate immunity plays a significant role in pathogenesis of disease as viral and bacterial infections can be correlated with stimulation or defence against asthma [145] .", [["pollen", "ANATOMY", 66, 72], ["Th2 cells", "ANATOMY", 139, 148], ["lung", "ANATOMY", 183, 187], ["asthma", "DISEASE", 54, 60], ["viral and bacterial infections", "DISEASE", 285, 315], ["asthma", "DISEASE", 370, 376], ["pollen", "ORGANISM_SUBDIVISION", 66, 72], ["Th2 cells", "CELL", 139, 148], ["IgE", "GENE_OR_GENE_PRODUCT", 176, 179], ["lung", "ORGAN", 183, 187], ["TLRs", "GENE_OR_GENE_PRODUCT", 200, 204], ["asthmaInnate", "CANCER", 208, 220], ["antigen specific Th2 cells", "CELL_TYPE", 122, 148], ["IgE", "PROTEIN", 176, 179], ["TLRs", "PROTEIN", 200, 204], ["environmental stimuli", "TEST", 29, 50], ["asthma", "PROBLEM", 54, 60], ["pollen", "PROBLEM", 66, 72], ["dust particles", "PROBLEM", 76, 90], ["secreting antigen", "TEST", 149, 166], ["disease", "PROBLEM", 274, 281], ["viral and bacterial infections", "PROBLEM", 285, 315], ["asthma", "PROBLEM", 370, 376], ["asthma", "OBSERVATION", 54, 60], ["lung", "ANATOMY", 183, 187]]], ["It has been reported by several epidemiological, human and animal studies that time and degree of LPS exposure and hence activation of TLR4 determines the type of response i.e. whether a defensive Th1 response or an acquiescent Th2 response is generated [146] .", [["LPS", "CHEMICAL", 98, 101], ["human", "ORGANISM", 49, 54], ["LPS", "SIMPLE_CHEMICAL", 98, 101], ["TLR4", "GENE_OR_GENE_PRODUCT", 135, 139], ["TLR4", "PROTEIN", 135, 139], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 49, 54], ["animal studies", "TEST", 59, 73], ["LPS exposure", "PROBLEM", 98, 110], ["a defensive Th1 response", "PROBLEM", 185, 209], ["an acquiescent Th2 response", "TEST", 213, 240], ["LPS exposure", "OBSERVATION", 98, 110]]], ["This can be illustrated as Th2 response develops upon intranasal administration of low dose of LPS in lung whereas a robust Th1 response is generated upon administration of LPS elsewhere in the body.", [["lung", "ANATOMY", 102, 106], ["body", "ANATOMY", 194, 198], ["LPS", "CHEMICAL", 95, 98], ["LPS", "CHEMICAL", 173, 176], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["lung", "ORGAN", 102, 106], ["LPS", "SIMPLE_CHEMICAL", 173, 176], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["intranasal administration", "TREATMENT", 54, 79], ["low dose of LPS in lung", "TREATMENT", 83, 106], ["LPS", "TREATMENT", 173, 176], ["lung", "ANATOMY", 102, 106], ["body", "ANATOMY", 194, 198]]], ["Nonetheless, airway hyperresponsiveness, allergic sensitization and eosinophilic inflammation is repressed upon treatment with TLR agonists or microbes [147] [148] [149] .", [["airway", "ANATOMY", 13, 19], ["eosinophilic", "ANATOMY", 68, 80], ["allergic sensitization", "DISEASE", 41, 63], ["inflammation", "DISEASE", 81, 93], ["airway", "MULTI-TISSUE_STRUCTURE", 13, 19], ["TLR agonists", "GENE_OR_GENE_PRODUCT", 127, 139], ["TLR", "PROTEIN", 127, 130], ["airway hyperresponsiveness", "PROBLEM", 13, 39], ["allergic sensitization", "PROBLEM", 41, 63], ["eosinophilic inflammation", "PROBLEM", 68, 93], ["TLR agonists", "TREATMENT", 127, 139], ["airway", "ANATOMY", 13, 19], ["hyperresponsiveness", "OBSERVATION", 20, 39], ["eosinophilic inflammation", "OBSERVATION", 68, 93]]], ["Recent studies have shown that intranasal administration of Acinetobacter lwoffii F78 into pregnant mice provides protection against ovalbumin-induced asthma in the progeny.", [["Acinetobacter lwoffii F78", "CHEMICAL", 60, 85], ["ovalbumin", "CHEMICAL", 133, 142], ["asthma", "DISEASE", 151, 157], ["Acinetobacter lwoffii F78", "ORGANISM", 60, 85], ["mice", "ORGANISM", 100, 104], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 133, 142], ["Acinetobacter lwoffii", "SPECIES", 60, 81], ["mice", "SPECIES", 100, 104], ["Acinetobacter lwoffii", "SPECIES", 60, 81], ["mice", "SPECIES", 100, 104], ["Recent studies", "TEST", 0, 14], ["intranasal administration", "TREATMENT", 31, 56], ["Acinetobacter lwoffii", "TREATMENT", 60, 81], ["ovalbumin", "PROBLEM", 133, 142], ["asthma", "PROBLEM", 151, 157], ["asthma", "OBSERVATION", 151, 157]]], ["The protective effect depends upon maternal pattern of TLR expression and recognition of microbes by maternal TLRs during pregnancy primes the foetal lung environment for a later Th1 response against these antigens [150] .", [["foetal lung", "ANATOMY", 143, 154], ["TLR", "GENE_OR_GENE_PRODUCT", 55, 58], ["TLRs", "GENE_OR_GENE_PRODUCT", 110, 114], ["foetal", "MULTI-TISSUE_STRUCTURE", 143, 149], ["lung", "ORGAN", 150, 154], ["TLR", "PROTEIN", 55, 58], ["maternal TLRs", "PROTEIN", 101, 114], ["TLR expression", "TREATMENT", 55, 69], ["maternal TLRs during pregnancy", "PROBLEM", 101, 131], ["the foetal lung environment", "PROBLEM", 139, 166], ["lung", "ANATOMY", 150, 154]]], ["TLR4 expressing lung resident cells recognize house dust mite (a pervasive home allergen) and induces Th2 cell response to produce IL-25, IL-33, granulocyte-macrophage colony stimulating factor and thymic stromal lymphopoietin.", [["lung resident cells", "ANATOMY", 16, 35], ["Th2 cell", "ANATOMY", 102, 110], ["thymic stromal lymphopoietin", "ANATOMY", 198, 226], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["lung resident cells", "CELL", 16, 35], ["mite", "ORGANISM_SUBSTANCE", 57, 61], ["Th2 cell", "CELL", 102, 110], ["IL-25", "GENE_OR_GENE_PRODUCT", 131, 136], ["IL-33", "GENE_OR_GENE_PRODUCT", 138, 143], ["granulocyte-macrophage colony stimulating factor", "GENE_OR_GENE_PRODUCT", 145, 193], ["thymic stromal lymphopoietin", "CANCER", 198, 226], ["TLR4", "PROTEIN", 0, 4], ["lung resident cells", "CELL_TYPE", 16, 35], ["IL", "PROTEIN", 131, 133], ["IL-33", "PROTEIN", 138, 143], ["granulocyte-macrophage colony stimulating factor", "PROTEIN", 145, 193], ["house dust mite", "SPECIES", 46, 61], ["a pervasive home allergen", "TREATMENT", 63, 88], ["IL", "TEST", 131, 133], ["IL", "TEST", 138, 140], ["granulocyte", "TEST", 145, 156], ["thymic stromal lymphopoietin", "TREATMENT", 198, 226], ["lung", "ANATOMY", 16, 20], ["granulocyte", "ANATOMY", 145, 156], ["macrophage colony", "OBSERVATION", 157, 174], ["thymic", "ANATOMY", 198, 204], ["stromal lymphopoietin", "OBSERVATION", 205, 226]]], ["These cytokines leads to activation and polarization of ingenuous lymphocytes.", [["ingenuous lymphocytes", "ANATOMY", 56, 77], ["lymphocytes", "CELL", 66, 77], ["cytokines", "PROTEIN", 6, 15], ["ingenuous lymphocytes", "CELL_TYPE", 56, 77], ["ingenuous lymphocytes", "PROBLEM", 56, 77], ["polarization", "OBSERVATION_MODIFIER", 40, 52], ["ingenuous lymphocytes", "OBSERVATION", 56, 77]]], ["Also, neurotoxin derived from eosinophil stimulates TLR2 activation, that eventually leads to enormous secretion of IL-6, IL-10 and Th2 polarization [152] .", [["eosinophil", "ANATOMY", 30, 40], ["eosinophil", "CELL", 30, 40], ["TLR2", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["IL-10", "GENE_OR_GENE_PRODUCT", 122, 127], ["Th2", "GENE_OR_GENE_PRODUCT", 132, 135], ["eosinophil", "CELL_TYPE", 30, 40], ["TLR2", "PROTEIN", 52, 56], ["neurotoxin", "PROBLEM", 6, 16], ["eosinophil stimulates TLR2 activation", "TREATMENT", 30, 67], ["IL", "TEST", 116, 118]]], ["Similarly, basophils also lead to Th2 cell activation [153] .TLRs in asthmaTLRs are also implicated in augmentation of allergic asthma as shown by numerous genetic association studies.", [["basophils", "ANATOMY", 11, 20], ["Th2 cell", "ANATOMY", 34, 42], ["allergic asthma", "DISEASE", 119, 134], ["basophils", "CELL", 11, 20], ["Th2 cell", "CELL", 34, 42], ["TLRs", "GENE_OR_GENE_PRODUCT", 61, 65], ["asthmaTLRs", "GENE_OR_GENE_PRODUCT", 69, 79], ["basophils", "CELL_TYPE", 11, 20], ["TLRs", "PROTEIN", 61, 65], ["basophils", "TEST", 11, 20], ["Th2 cell activation", "TEST", 34, 53], ["allergic asthma", "PROBLEM", 119, 134], ["basophils", "ANATOMY", 11, 20], ["Th2 cell activation", "OBSERVATION", 34, 53], ["allergic asthma", "OBSERVATION", 119, 134]]], ["For instance, TLR7 and TLR8 are correlated with progression of asthma whereas their ligands safeguard against airway remodelling in experimentally lured asthma [154] .", [["airway", "ANATOMY", 110, 116], ["asthma", "DISEASE", 63, 69], ["airway remodelling", "DISEASE", 110, 128], ["asthma", "DISEASE", 153, 159], ["TLR7", "GENE_OR_GENE_PRODUCT", 14, 18], ["TLR8", "GENE_OR_GENE_PRODUCT", 23, 27], ["airway", "MULTI-TISSUE_STRUCTURE", 110, 116], ["TLR7", "PROTEIN", 14, 18], ["TLR8", "PROTEIN", 23, 27], ["TLR7 and TLR8", "TREATMENT", 14, 27], ["asthma", "PROBLEM", 63, 69], ["airway remodelling", "PROBLEM", 110, 128], ["experimentally lured asthma", "PROBLEM", 132, 159], ["asthma", "OBSERVATION", 63, 69], ["airway", "ANATOMY", 110, 116]]], ["The ligands for TLR10 are not defined yet, but their SNPs share correlation with asthma in two independent samples.", [["samples", "ANATOMY", 107, 114], ["asthma", "DISEASE", 81, 87], ["TLR10", "GENE_OR_GENE_PRODUCT", 16, 21], ["TLR10", "PROTEIN", 16, 21], ["TLR10", "TREATMENT", 16, 21], ["asthma", "PROBLEM", 81, 87], ["asthma", "OBSERVATION", 81, 87]]], ["TLR4 and TLR9 are associated with wheezing, while TLR4 is related to secretion of allergen specific IgE [155] .", [["wheezing", "DISEASE", 34, 42], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["TLR4", "GENE_OR_GENE_PRODUCT", 50, 54], ["IgE", "GENE_OR_GENE_PRODUCT", 100, 103], ["TLR4", "PROTEIN", 0, 4], ["TLR9", "PROTEIN", 9, 13], ["TLR4", "PROTEIN", 50, 54], ["IgE", "PROTEIN", 100, 103], ["TLR4 and TLR9", "TREATMENT", 0, 13], ["wheezing", "PROBLEM", 34, 42], ["wheezing", "OBSERVATION", 34, 42]]], ["Hence, TLR9 ligands are in clinical trials for prevention or treatment of asthma at present [156] .", [["asthma", "DISEASE", 74, 80], ["TLR9", "GENE_OR_GENE_PRODUCT", 7, 11], ["TLR9", "PROTEIN", 7, 11], ["TLR9 ligands", "TREATMENT", 7, 19], ["clinical trials", "TREATMENT", 27, 42], ["treatment", "TREATMENT", 61, 70], ["asthma", "PROBLEM", 74, 80], ["asthma", "OBSERVATION", 74, 80]]], ["Furthermore, bacterial infections such as Mycoplasma pneumonia, Chlamydia pneumoniae and Streptococcus pneumonia may worsen the disease conditions [157] .", [["bacterial infections", "DISEASE", 13, 33], ["Mycoplasma pneumonia", "DISEASE", 42, 62], ["Chlamydia pneumoniae", "DISEASE", 64, 84], ["Streptococcus pneumonia", "DISEASE", 89, 112], ["Mycoplasma pneumonia", "ORGANISM", 42, 62], ["Chlamydia pneumoniae", "ORGANISM", 64, 84], ["Streptococcus pneumonia", "ORGANISM", 89, 112], ["Mycoplasma pneumonia", "SPECIES", 42, 62], ["Chlamydia pneumoniae", "SPECIES", 64, 84], ["Streptococcus pneumonia", "SPECIES", 89, 112], ["Mycoplasma pneumonia", "SPECIES", 42, 62], ["Chlamydia pneumoniae", "SPECIES", 64, 84], ["bacterial infections", "PROBLEM", 13, 33], ["Mycoplasma pneumonia", "PROBLEM", 42, 62], ["Chlamydia pneumoniae", "PROBLEM", 64, 84], ["Streptococcus pneumonia", "PROBLEM", 89, 112], ["the disease conditions", "PROBLEM", 124, 146], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["infections", "OBSERVATION", 23, 33], ["Mycoplasma", "OBSERVATION_MODIFIER", 42, 52], ["pneumonia", "OBSERVATION", 53, 62], ["Chlamydia pneumoniae", "OBSERVATION", 64, 84], ["Streptococcus", "OBSERVATION_MODIFIER", 89, 102], ["pneumonia", "OBSERVATION", 103, 112]]], ["It was shown that MyD88 deficient mice infected with C. pneumonia exhibited reduced cytokine and chemokine expression, deferred recruitment of CD4+ and CD8+ cells, and inability to clear lung bacterium resulting in chronic inflammation and high mortality [158] .", [["CD4+ and CD8+ cells", "ANATOMY", 143, 162], ["lung bacterium", "ANATOMY", 187, 201], ["C. pneumonia", "DISEASE", 53, 65], ["inflammation", "DISEASE", 223, 235], ["MyD88", "GENE_OR_GENE_PRODUCT", 18, 23], ["mice", "ORGANISM", 34, 38], ["C. pneumonia", "ORGANISM", 53, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 143, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 152, 155], ["lung", "ORGAN", 187, 191], ["MyD88", "PROTEIN", 18, 23], ["cytokine", "PROTEIN", 84, 92], ["chemokine", "PROTEIN", 97, 106], ["CD4", "PROTEIN", 143, 146], ["CD8", "PROTEIN", 152, 155], ["mice", "SPECIES", 34, 38], ["C. pneumonia", "SPECIES", 53, 65], ["mice", "SPECIES", 34, 38], ["C. pneumonia", "SPECIES", 53, 65], ["MyD88 deficient mice infected", "PROBLEM", 18, 47], ["C. pneumonia", "PROBLEM", 53, 65], ["reduced cytokine and chemokine expression", "PROBLEM", 76, 117], ["CD4", "TEST", 143, 146], ["CD8+ cells", "PROBLEM", 152, 162], ["inability to clear lung bacterium", "PROBLEM", 168, 201], ["chronic inflammation", "PROBLEM", 215, 235], ["high mortality", "PROBLEM", 240, 254], ["pneumonia", "OBSERVATION", 56, 65], ["reduced", "OBSERVATION_MODIFIER", 76, 83], ["cytokine", "OBSERVATION_MODIFIER", 84, 92], ["chemokine expression", "OBSERVATION", 97, 117], ["lung", "ANATOMY", 187, 191], ["bacterium", "OBSERVATION", 192, 201], ["chronic", "OBSERVATION_MODIFIER", 215, 222], ["inflammation", "OBSERVATION", 223, 235], ["high", "OBSERVATION_MODIFIER", 240, 244]]], ["However, secretion of IL-1\u03b2, IFN-\u03b3 and other inflammatory mediators may be enhanced at later stages through MyD88 independent pathway but that are incompetent to preclude C. pneumonia associated mortality [159] .TLRs in asthmaTLR2 and TLR4 either act in concert or other PRRs are also involved in C. pneumoniae infection as indicated by normal recovery of TLR2 and TLR4 deficient mice with proper bacterial clearance from C. pneumoniae infection [160] .", [["pneumonia", "DISEASE", 174, 183], ["C. pneumoniae infection", "DISEASE", 297, 320], ["C. pneumoniae infection", "DISEASE", 422, 445], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 22, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 29, 34], ["MyD88", "GENE_OR_GENE_PRODUCT", 108, 113], ["TLRs", "GENE_OR_GENE_PRODUCT", 212, 216], ["asthmaTLR2", "GENE_OR_GENE_PRODUCT", 220, 230], ["TLR4", "GENE_OR_GENE_PRODUCT", 235, 239], ["PRRs", "GENE_OR_GENE_PRODUCT", 271, 275], ["C. pneumoniae", "ORGANISM", 297, 310], ["TLR2", "GENE_OR_GENE_PRODUCT", 356, 360], ["TLR4", "GENE_OR_GENE_PRODUCT", 365, 369], ["mice", "ORGANISM", 380, 384], ["C. pneumoniae", "ORGANISM", 422, 435], ["IL-1\u03b2", "PROTEIN", 22, 27], ["IFN", "PROTEIN", 29, 32], ["inflammatory mediators", "PROTEIN", 45, 67], ["MyD88", "PROTEIN", 108, 113], ["TLRs", "PROTEIN", 212, 216], ["asthmaTLR2", "PROTEIN", 220, 230], ["TLR4", "PROTEIN", 235, 239], ["PRRs", "PROTEIN", 271, 275], ["TLR2", "PROTEIN", 356, 360], ["TLR4", "PROTEIN", 365, 369], ["C. pneumoniae", "SPECIES", 297, 310], ["mice", "SPECIES", 380, 384], ["C. pneumoniae", "SPECIES", 422, 435], ["C. pneumoniae", "SPECIES", 297, 310], ["mice", "SPECIES", 380, 384], ["C. pneumoniae", "SPECIES", 422, 435], ["IL", "TEST", 22, 24], ["other inflammatory mediators", "PROBLEM", 39, 67], ["C. pneumonia", "PROBLEM", 171, 183], ["TLRs in asthmaTLR2", "TREATMENT", 212, 230], ["TLR4", "TREATMENT", 235, 239], ["C. pneumoniae infection", "PROBLEM", 297, 320], ["TLR2 and TLR4 deficient mice", "TREATMENT", 356, 384], ["proper bacterial clearance", "PROBLEM", 390, 416], ["C. pneumoniae infection", "PROBLEM", 422, 445], ["inflammatory", "OBSERVATION", 45, 57], ["pneumonia", "OBSERVATION", 174, 183], ["pneumoniae", "OBSERVATION", 300, 310], ["pneumoniae", "OBSERVATION_MODIFIER", 425, 435], ["infection", "OBSERVATION", 436, 445]]], ["M. pneumoniae infection leads to hypersecretion of airway mucin and upregulation of TLR2.", [["airway mucin", "ANATOMY", 51, 63], ["infection", "DISEASE", 14, 23], ["M. pneumoniae", "ORGANISM", 0, 13], ["airway mucin", "GENE_OR_GENE_PRODUCT", 51, 63], ["TLR2", "GENE_OR_GENE_PRODUCT", 84, 88], ["TLR2", "PROTEIN", 84, 88], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae", "SPECIES", 0, 13], ["M. pneumoniae infection", "PROBLEM", 0, 23], ["hypersecretion of airway mucin", "PROBLEM", 33, 63], ["upregulation of TLR2", "TREATMENT", 68, 88], ["pneumoniae", "OBSERVATION", 3, 13], ["airway", "ANATOMY", 51, 57], ["TLR2", "ANATOMY", 84, 88]]], ["However, TLR2 is inhibited during allergic inflammation caused by M. pneumoniae infection, along with reduced production of IL-6 and other mediators, needed for bacterial clearance [161] .", [["allergic inflammation", "DISEASE", 34, 55], ["M. pneumoniae infection", "DISEASE", 66, 89], ["TLR2", "GENE_OR_GENE_PRODUCT", 9, 13], ["M. pneumoniae", "ORGANISM", 66, 79], ["IL-6", "GENE_OR_GENE_PRODUCT", 124, 128], ["TLR2", "PROTEIN", 9, 13], ["IL-6", "PROTEIN", 124, 128], ["M. pneumoniae", "SPECIES", 66, 79], ["M. pneumoniae", "SPECIES", 66, 79], ["TLR2", "PROBLEM", 9, 13], ["allergic inflammation", "PROBLEM", 34, 55], ["M. pneumoniae infection", "PROBLEM", 66, 89], ["reduced production of IL", "TREATMENT", 102, 126], ["bacterial clearance", "PROBLEM", 161, 180], ["pneumoniae", "OBSERVATION_MODIFIER", 69, 79], ["infection", "OBSERVATION", 80, 89]]], ["Antibiotic treatments are highly effective in treating asthmatic patients with M. pneumoniae infections as they improve their pulmonary function and are suggestive of the contributions of bacterial interactions with the host immune system in asthma aggravations and mortality [162, 163] .", [["pulmonary", "ANATOMY", 126, 135], ["asthmatic", "DISEASE", 55, 64], ["M. pneumoniae infections", "DISEASE", 79, 103], ["asthma", "DISEASE", 242, 248], ["patients", "ORGANISM", 65, 73], ["M. pneumoniae", "ORGANISM", 79, 92], ["pulmonary", "ORGAN", 126, 135], ["patients", "SPECIES", 65, 73], ["M. pneumoniae", "SPECIES", 79, 92], ["M. pneumoniae", "SPECIES", 79, 92], ["Antibiotic treatments", "TREATMENT", 0, 21], ["M. pneumoniae infections", "PROBLEM", 79, 103], ["bacterial interactions", "PROBLEM", 188, 210], ["asthma aggravations", "PROBLEM", 242, 261], ["pneumoniae", "OBSERVATION", 82, 92], ["pulmonary", "ANATOMY", 126, 135], ["suggestive of", "UNCERTAINTY", 153, 166], ["bacterial interactions", "OBSERVATION", 188, 210]]], ["Other PRRs are also involved in case of Streptococcus pneumonia infections as indicated by a study wherein there is clearance of high and low infectious doses of S. pneumonia with a moderate reduction in production of inflammatory mediators in TLR2 deficient mice (Cite reference [118, 121] ).", [["Streptococcus pneumonia infections", "DISEASE", 40, 74], ["pneumonia", "DISEASE", 165, 174], ["PRRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["Streptococcus pneumonia", "ORGANISM", 40, 63], ["TLR2", "GENE_OR_GENE_PRODUCT", 244, 248], ["mice", "ORGANISM", 259, 263], ["PRRs", "PROTEIN", 6, 10], ["inflammatory mediators", "PROTEIN", 218, 240], ["TLR2", "PROTEIN", 244, 248], ["Streptococcus pneumonia", "SPECIES", 40, 63], ["S. pneumonia", "SPECIES", 162, 174], ["mice", "SPECIES", 259, 263], ["mice", "SPECIES", 259, 263], ["Streptococcus pneumonia infections", "PROBLEM", 40, 74], ["a study", "TEST", 91, 98], ["high and low infectious doses", "PROBLEM", 129, 158], ["S. pneumonia", "PROBLEM", 162, 174], ["a moderate reduction", "PROBLEM", 180, 200], ["inflammatory mediators", "PROBLEM", 218, 240], ["Streptococcus", "OBSERVATION_MODIFIER", 40, 53], ["pneumonia", "OBSERVATION", 54, 63], ["high", "OBSERVATION_MODIFIER", 129, 133], ["low infectious", "OBSERVATION_MODIFIER", 138, 152], ["pneumonia", "OBSERVATION", 165, 174], ["moderate", "OBSERVATION_MODIFIER", 182, 190], ["reduction", "OBSERVATION_MODIFIER", 191, 200], ["inflammatory", "OBSERVATION_MODIFIER", 218, 230]]], ["The severity of response against S. pneumonia is enormously increased in case of MyD88 deficiency rather than single or combined deletion of TLR2 and TLR4 respectively (cite reference [124] ).TLRs in asthmaViruses such as Respiratory Syncytial Virus (RSV) also contribute to development and aggravations associated with asthma.", [["pneumonia", "DISEASE", 36, 45], ["Respiratory Syncytial Virus", "DISEASE", 222, 249], ["asthma", "DISEASE", 320, 326], ["MyD88", "GENE_OR_GENE_PRODUCT", 81, 86], ["TLR2", "GENE_OR_GENE_PRODUCT", 141, 145], ["TLR4", "GENE_OR_GENE_PRODUCT", 150, 154], ["TLRs", "GENE_OR_GENE_PRODUCT", 192, 196], ["asthmaViruses", "GENE_OR_GENE_PRODUCT", 200, 213], ["Respiratory Syncytial Virus", "ORGANISM", 222, 249], ["RSV", "ORGANISM", 251, 254], ["MyD88", "PROTEIN", 81, 86], ["TLR2", "PROTEIN", 141, 145], ["TLR4", "PROTEIN", 150, 154], ["TLRs", "PROTEIN", 192, 196], ["Respiratory Syncytial Virus", "SPECIES", 222, 249], ["S. pneumonia", "SPECIES", 33, 45], ["Respiratory Syncytial Virus", "SPECIES", 222, 249], ["RSV", "SPECIES", 251, 254], ["S. pneumonia", "PROBLEM", 33, 45], ["MyD88 deficiency", "PROBLEM", 81, 97], ["single or combined deletion of TLR2 and TLR4", "PROBLEM", 110, 154], ["TLRs in asthmaViruses", "TREATMENT", 192, 213], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 222, 255], ["aggravations", "PROBLEM", 291, 303], ["asthma", "PROBLEM", 320, 326], ["pneumonia", "OBSERVATION", 36, 45], ["enormously", "OBSERVATION_MODIFIER", 49, 59], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["MyD88 deficiency", "OBSERVATION", 81, 97], ["TLR2", "ANATOMY_MODIFIER", 141, 145], ["Respiratory Syncytial", "ANATOMY", 222, 243], ["asthma", "OBSERVATION", 320, 326]]], ["RSV, in particular causes acute bronchiolitis and wheezing in children, that subsequently progresses into asthma [164, 165] .", [["RSV", "DISEASE", 0, 3], ["bronchiolitis", "DISEASE", 32, 45], ["wheezing", "DISEASE", 50, 58], ["asthma", "DISEASE", 106, 112], ["RSV", "ORGANISM", 0, 3], ["children", "ORGANISM", 62, 70], ["children", "SPECIES", 62, 70], ["RSV", "SPECIES", 0, 3], ["RSV", "PROBLEM", 0, 3], ["acute bronchiolitis", "PROBLEM", 26, 45], ["wheezing", "PROBLEM", 50, 58], ["asthma", "PROBLEM", 106, 112], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["bronchiolitis", "OBSERVATION", 32, 45], ["wheezing", "OBSERVATION", 50, 58]]], ["Wheezing due to serious infection with RSV in early years of life is associated with enhanced Th2 response, IL-10 secretion and eosinophilia [166, 167] .", [["Wheezing", "DISEASE", 0, 8], ["infection", "DISEASE", 24, 33], ["RSV", "DISEASE", 39, 42], ["eosinophilia", "DISEASE", 128, 140], ["RSV", "ORGANISM", 39, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 108, 113], ["RSV", "SPECIES", 39, 42], ["Wheezing", "PROBLEM", 0, 8], ["serious infection", "PROBLEM", 16, 33], ["RSV", "PROBLEM", 39, 42], ["IL", "TEST", 108, 110], ["eosinophilia", "TEST", 128, 140], ["serious", "OBSERVATION_MODIFIER", 16, 23], ["infection", "OBSERVATION", 24, 33], ["RSV", "OBSERVATION", 39, 42], ["eosinophilia", "OBSERVATION", 128, 140]]], ["As a result, TLRs are found to be extensively upregulated in human tracheal epithelial (9HTEo) cells.", [["tracheal epithelial (9HTEo) cells", "ANATOMY", 67, 100], ["TLRs", "GENE_OR_GENE_PRODUCT", 13, 17], ["human", "ORGANISM", 61, 66], ["tracheal epithelial (9HTEo) cells", "CELL", 67, 100], ["TLRs", "PROTEIN", 13, 17], ["human tracheal epithelial (9HTEo) cells", "CELL_TYPE", 61, 100], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 61, 66], ["tracheal epithelial", "ANATOMY", 67, 86]]], ["In the course of RSV infection, virus attaches to the lung epithelial cells via G protein, followed by fusion of viral envelope with host cell plasma membrane mediated by F protein [168, 169] .", [["lung epithelial cells", "ANATOMY", 54, 75], ["cell plasma membrane", "ANATOMY", 138, 158], ["RSV infection", "DISEASE", 17, 30], ["RSV", "ORGANISM", 17, 20], ["lung epithelial cells", "CELL", 54, 75], ["G protein", "GENE_OR_GENE_PRODUCT", 80, 89], ["host cell", "CELLULAR_COMPONENT", 133, 142], ["plasma membrane", "CELLULAR_COMPONENT", 143, 158], ["F protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["lung epithelial cells", "CELL_TYPE", 54, 75], ["G protein", "PROTEIN", 80, 89], ["F protein", "PROTEIN", 171, 180], ["RSV", "SPECIES", 17, 20], ["RSV infection", "PROBLEM", 17, 30], ["virus attaches", "PROBLEM", 32, 46], ["G protein", "TEST", 80, 89], ["viral envelope", "PROBLEM", 113, 127], ["host cell plasma membrane", "TREATMENT", 133, 158], ["RSV", "ANATOMY", 17, 20], ["infection", "OBSERVATION", 21, 30], ["lung", "ANATOMY", 54, 58], ["epithelial cells", "OBSERVATION", 59, 75], ["host cell", "OBSERVATION", 133, 142]]], ["TLR4 recognizes the viral F protein and stimulate NK cells [164, 170] .", [["NK cells", "ANATOMY", 50, 58], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["viral F", "GENE_OR_GENE_PRODUCT", 20, 27], ["NK cells", "CELL", 50, 58], ["TLR4", "PROTEIN", 0, 4], ["viral F protein", "PROTEIN", 20, 35], ["NK cells", "CELL_TYPE", 50, 58], ["the viral F protein", "TEST", 16, 35], ["NK cells", "TEST", 50, 58]]], ["Thus, TLR4 deficient mice possess elevated viral load and defective NK cells [171, 172] .", [["NK cells", "ANATOMY", 68, 76], ["TLR4", "GENE_OR_GENE_PRODUCT", 6, 10], ["mice", "ORGANISM", 21, 25], ["NK cells", "CELL", 68, 76], ["TLR4", "PROTEIN", 6, 10], ["NK cells", "CELL_TYPE", 68, 76], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["elevated viral load", "PROBLEM", 34, 53], ["defective NK cells", "PROBLEM", 58, 76], ["elevated", "OBSERVATION_MODIFIER", 34, 42], ["viral load", "OBSERVATION", 43, 53], ["defective NK cells", "OBSERVATION", 58, 76]]], ["According to a study, inadequate TLR4 signalling is also associated with enhanced worsening in pre-term infants [173] .", [["TLR4", "GENE_OR_GENE_PRODUCT", 33, 37], ["TLR4", "PROTEIN", 33, 37], ["infants", "SPECIES", 104, 111], ["a study", "TEST", 13, 20], ["enhanced worsening in pre-term infants", "PROBLEM", 73, 111], ["enhanced", "OBSERVATION_MODIFIER", 73, 81], ["worsening", "OBSERVATION_MODIFIER", 82, 91]]], ["Additionally, dsRNA formed during RSV replication stimulates TLR3 mediated signalling in human lung fibroblasts and epithelial cells, resulting in exaggerated secretion of the chemokines RANTES and IP-10 [170] .", [["lung fibroblasts", "ANATOMY", 95, 111], ["epithelial cells", "ANATOMY", 116, 132], ["RSV", "ORGANISM", 34, 37], ["TLR3", "GENE_OR_GENE_PRODUCT", 61, 65], ["human", "ORGANISM", 89, 94], ["lung fibroblasts", "CELL", 95, 111], ["epithelial cells", "CELL", 116, 132], ["RANTES", "GENE_OR_GENE_PRODUCT", 187, 193], ["IP-10", "GENE_OR_GENE_PRODUCT", 198, 203], ["TLR3", "PROTEIN", 61, 65], ["human lung fibroblasts", "CELL_TYPE", 89, 111], ["epithelial cells", "CELL_TYPE", 116, 132], ["chemokines", "PROTEIN", 176, 186], ["RANTES", "PROTEIN", 187, 193], ["human", "SPECIES", 89, 94], ["RSV", "SPECIES", 34, 37], ["human", "SPECIES", 89, 94], ["dsRNA", "PROBLEM", 14, 19], ["RSV replication", "TREATMENT", 34, 49], ["signalling in human lung fibroblasts", "PROBLEM", 75, 111], ["epithelial cells", "PROBLEM", 116, 132], ["exaggerated secretion of the chemokines RANTES", "PROBLEM", 147, 193], ["IP", "TEST", 198, 200], ["RSV replication", "OBSERVATION", 34, 49], ["lung", "ANATOMY", 95, 99], ["fibroblasts", "OBSERVATION", 100, 111], ["epithelial cells", "OBSERVATION", 116, 132], ["exaggerated", "OBSERVATION_MODIFIER", 147, 158], ["secretion", "OBSERVATION_MODIFIER", 159, 168]]], ["Deficiency of TLR3 signalling leads to enhanced mucus secretion, airway eosinophilia and increased expression of IL-5 and IL-13.", [["mucus", "ANATOMY", 48, 53], ["airway", "ANATOMY", 65, 71], ["eosinophilia", "DISEASE", 72, 84], ["TLR3", "GENE_OR_GENE_PRODUCT", 14, 18], ["mucus", "ORGANISM_SUBSTANCE", 48, 53], ["IL-5", "GENE_OR_GENE_PRODUCT", 113, 117], ["IL-13", "GENE_OR_GENE_PRODUCT", 122, 127], ["TLR3", "PROTEIN", 14, 18], ["IL-5 and IL-13", "PROTEIN", 113, 127], ["Deficiency of TLR3 signalling", "PROBLEM", 0, 29], ["enhanced mucus secretion", "PROBLEM", 39, 63], ["airway eosinophilia", "PROBLEM", 65, 84], ["increased expression of IL", "TREATMENT", 89, 115], ["TLR3 signalling", "OBSERVATION", 14, 29], ["mucus secretion", "OBSERVATION", 48, 63], ["airway", "ANATOMY", 65, 71], ["eosinophilia", "OBSERVATION", 72, 84], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["expression", "OBSERVATION_MODIFIER", 99, 109]]], ["Recently, it has been demonstrated that expression of IFN-\u03b2 induced by RIG-I, in the time of RSV infection, brings about TLR3 activation, suggesting the role of TLR3 in mediating secondary immune signalling pathway.", [["RSV infection", "DISEASE", 93, 106], ["IFN-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["RIG-I", "GENE_OR_GENE_PRODUCT", 71, 76], ["RSV", "ORGANISM", 93, 96], ["TLR3", "GENE_OR_GENE_PRODUCT", 121, 125], ["TLR3", "GENE_OR_GENE_PRODUCT", 161, 165], ["IFN", "PROTEIN", 54, 57], ["\u03b2", "PROTEIN", 58, 59], ["RIG-I", "PROTEIN", 71, 76], ["TLR3", "PROTEIN", 121, 125], ["TLR3", "PROTEIN", 161, 165], ["RSV", "SPECIES", 93, 96], ["IFN", "PROBLEM", 54, 57], ["RSV infection", "PROBLEM", 93, 106], ["TLR3 activation", "TREATMENT", 121, 136], ["TLR3", "TREATMENT", 161, 165], ["RSV", "ANATOMY", 93, 96], ["infection", "OBSERVATION", 97, 106]]], ["Contrastingly, RSV viral clearance is totally mediated by TLR2/TLR6 heterodimers.", [["RSV", "ORGANISM", 15, 18], ["TLR2", "GENE_OR_GENE_PRODUCT", 58, 62], ["TLR6", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR2", "PROTEIN", 58, 62], ["TLR6 heterodimers", "PROTEIN", 63, 80], ["RSV", "SPECIES", 15, 18], ["RSV viral clearance", "PROBLEM", 15, 34], ["TLR2/TLR6 heterodimers", "TREATMENT", 58, 80], ["RSV", "OBSERVATION", 15, 18], ["viral clearance", "OBSERVATION", 19, 34]]], ["Thus, allergic asthma can be mediated by infection and worsened by genetic predispositions.", [["allergic asthma", "DISEASE", 6, 21], ["infection", "DISEASE", 41, 50], ["allergic asthma", "PROBLEM", 6, 21], ["infection", "PROBLEM", 41, 50], ["allergic asthma", "OBSERVATION", 6, 21], ["infection", "OBSERVATION", 41, 50], ["worsened", "OBSERVATION_MODIFIER", 55, 63]]], ["These infections may lead to protective inflammatory responses in some cases or acute allergic responses in other cases or may be permissive towards prolonged Th2 response.TLRs in lung cancerLung cancer is one of the foremost causes of cancer associated deaths all over the world.", [["lung cancerLung cancer", "ANATOMY", 180, 202], ["cancer", "ANATOMY", 236, 242], ["infections", "DISEASE", 6, 16], ["allergic", "DISEASE", 86, 94], ["lung cancerLung cancer", "DISEASE", 180, 202], ["cancer", "DISEASE", 236, 242], ["deaths", "DISEASE", 254, 260], ["TLRs", "GENE_OR_GENE_PRODUCT", 172, 176], ["lung cancerLung cancer", "CANCER", 180, 202], ["cancer", "CANCER", 236, 242], ["TLRs", "PROTEIN", 172, 176], ["These infections", "PROBLEM", 0, 16], ["protective inflammatory responses", "PROBLEM", 29, 62], ["acute allergic responses", "PROBLEM", 80, 104], ["prolonged Th2 response", "PROBLEM", 149, 171], ["lung cancerLung cancer", "PROBLEM", 180, 202], ["cancer associated deaths", "PROBLEM", 236, 260], ["infections", "OBSERVATION", 6, 16], ["may lead to", "UNCERTAINTY", 17, 28], ["protective", "OBSERVATION_MODIFIER", 29, 39], ["inflammatory", "OBSERVATION", 40, 52], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["allergic", "OBSERVATION", 86, 94], ["lung", "ANATOMY", 180, 184], ["cancerLung", "OBSERVATION_MODIFIER", 185, 195], ["cancer", "OBSERVATION", 196, 202], ["cancer", "OBSERVATION", 236, 242]]], ["Inflammation is one of the hallmarks of cancer and tumor microenvironment also consists of cells that play highly significant roles in inflammation.", [["cancer", "ANATOMY", 40, 46], ["tumor", "ANATOMY", 51, 56], ["cells", "ANATOMY", 91, 96], ["Inflammation", "DISEASE", 0, 12], ["cancer", "DISEASE", 40, 46], ["tumor", "DISEASE", 51, 56], ["inflammation", "DISEASE", 135, 147], ["cancer", "CANCER", 40, 46], ["tumor", "CANCER", 51, 56], ["cells", "CELL", 91, 96], ["Inflammation", "PROBLEM", 0, 12], ["cancer", "PROBLEM", 40, 46], ["tumor microenvironment", "PROBLEM", 51, 73], ["cells", "PROBLEM", 91, 96], ["inflammation", "PROBLEM", 135, 147], ["cancer", "OBSERVATION", 40, 46], ["tumor", "OBSERVATION", 51, 56], ["highly", "OBSERVATION_MODIFIER", 107, 113], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["inflammation", "OBSERVATION", 135, 147]]], ["These cells thus, actively participate in innate immune responses, wherein TLRs also play key roles.", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["TLRs", "GENE_OR_GENE_PRODUCT", 75, 79], ["TLRs", "PROTEIN", 75, 79]]], ["TLRs present on cells of the innate immune system are activated upon recognition of specific ligands and induce host adaptive immune responses consequently.", [["cells", "ANATOMY", 16, 21], ["immune system", "ANATOMY", 36, 49], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 16, 21], ["innate", "ANATOMICAL_SYSTEM", 29, 35], ["immune system", "ANATOMICAL_SYSTEM", 36, 49], ["TLRs", "PROTEIN", 0, 4], ["the innate immune system", "TREATMENT", 25, 49]]], ["Thus, TLRs act as a double edged sword where on one side identify cancer specific antigens and activate innate responses and on the other side, promote latent chronic inflammation by inducing persistent adaptive responses which promote the process of tumorigenesis [174] [175] [176] .", [["cancer", "ANATOMY", 66, 72], ["cancer", "DISEASE", 66, 72], ["inflammation", "DISEASE", 167, 179], ["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["cancer", "CANCER", 66, 72], ["TLRs", "PROTEIN", 6, 10], ["cancer specific antigens", "PROTEIN", 66, 90], ["cancer specific antigens", "PROBLEM", 66, 90], ["latent chronic inflammation", "PROBLEM", 152, 179], ["cancer", "OBSERVATION", 66, 72], ["latent", "OBSERVATION_MODIFIER", 152, 158], ["chronic", "OBSERVATION_MODIFIER", 159, 166], ["inflammation", "OBSERVATION", 167, 179]]], ["Since TLRs are extensively expressed on resident as well as infiltrating myeloid and lymphoid cells (responsible for activation of adaptive responses), the maintenance of a fine equilibrium between stromal and haematopoietic cells become very crucial in case of cancer.", [["infiltrating myeloid", "ANATOMY", 60, 80], ["lymphoid cells", "ANATOMY", 85, 99], ["stromal", "ANATOMY", 198, 205], ["haematopoietic cells", "ANATOMY", 210, 230], ["cancer", "ANATOMY", 262, 268], ["cancer", "DISEASE", 262, 268], ["TLRs", "GENE_OR_GENE_PRODUCT", 6, 10], ["myeloid", "CELL", 73, 80], ["lymphoid cells", "CELL", 85, 99], ["stromal", "CELL", 198, 205], ["haematopoietic cells", "CELL", 210, 230], ["cancer", "CANCER", 262, 268], ["TLRs", "PROTEIN", 6, 10], ["infiltrating myeloid and lymphoid cells", "CELL_TYPE", 60, 99], ["stromal and haematopoietic cells", "CELL_TYPE", 198, 230], ["infiltrating myeloid and lymphoid cells", "PROBLEM", 60, 99], ["stromal and haematopoietic cells", "TREATMENT", 198, 230], ["cancer", "PROBLEM", 262, 268], ["infiltrating myeloid", "OBSERVATION", 60, 80], ["lymphoid cells", "OBSERVATION", 85, 99], ["haematopoietic cells", "OBSERVATION", 210, 230], ["cancer", "OBSERVATION", 262, 268]]], ["TLR activation on both types of cells calls for recruitment of immune stimulating or tolerogenic cells, both of which participate in the process of oncogenesis.", [["cells", "ANATOMY", 32, 37], ["cells", "ANATOMY", 97, 102], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 32, 37], ["cells", "CELL", 97, 102], ["TLR", "PROTEIN", 0, 3], ["tolerogenic cells", "CELL_TYPE", 85, 102], ["immune stimulating or tolerogenic cells", "TREATMENT", 63, 102]]], ["This can be explained as -activation of TLRs present on epithelial cells induce production of chemokines (such as IL-8, a strong neutrophils chemoattractant) and growth factors such as the Vascular endothelium-derived growth factor (VEGF) that is a key factor of angiogenesis [177] [178] [179] [180] .", [["epithelial cells", "ANATOMY", 56, 72], ["neutrophils", "ANATOMY", 129, 140], ["TLRs", "GENE_OR_GENE_PRODUCT", 40, 44], ["epithelial cells", "CELL", 56, 72], ["IL-8", "GENE_OR_GENE_PRODUCT", 114, 118], ["neutrophils", "CELL", 129, 140], ["Vascular endothelium-derived growth factor", "GENE_OR_GENE_PRODUCT", 189, 231], ["VEGF", "GENE_OR_GENE_PRODUCT", 233, 237], ["TLRs", "PROTEIN", 40, 44], ["epithelial cells", "CELL_TYPE", 56, 72], ["chemokines", "PROTEIN", 94, 104], ["IL-8", "PROTEIN", 114, 118], ["strong neutrophils chemoattractant", "PROTEIN", 122, 156], ["growth factors", "PROTEIN", 162, 176], ["Vascular endothelium-derived growth factor", "PROTEIN", 189, 231], ["VEGF", "PROTEIN", 233, 237], ["epithelial cells", "PROBLEM", 56, 72], ["chemokines", "PROBLEM", 94, 104], ["IL", "TEST", 114, 116], ["a strong neutrophils chemoattractant", "TREATMENT", 120, 156], ["growth factors", "PROBLEM", 162, 176], ["the Vascular endothelium", "TEST", 185, 209], ["epithelial cells", "OBSERVATION", 56, 72], ["Vascular endothelium", "ANATOMY", 189, 209]]], ["Similarly, TLR activation on innate immune cells helps in processing of antigens and their presentation, promotes the expression of CD80/86 (co-stimulatory molecules) which are involved in activation of T cells and finally secretes IL-6 that modulates the activity of Treg cells [181, 182] .", [["immune cells", "ANATOMY", 36, 48], ["T cells", "ANATOMY", 203, 210], ["Treg cells", "ANATOMY", 268, 278], ["TLR", "GENE_OR_GENE_PRODUCT", 11, 14], ["innate immune cells", "CELL", 29, 48], ["CD80/86", "GENE_OR_GENE_PRODUCT", 132, 139], ["co-stimulatory molecules", "GENE_OR_GENE_PRODUCT", 141, 165], ["T cells", "CELL", 203, 210], ["IL-6", "GENE_OR_GENE_PRODUCT", 232, 236], ["Treg cells", "CELL", 268, 278], ["TLR", "PROTEIN", 11, 14], ["innate immune cells", "CELL_TYPE", 29, 48], ["antigens", "PROTEIN", 72, 80], ["CD80/86", "PROTEIN", 132, 139], ["co-stimulatory molecules", "PROTEIN", 141, 165], ["T cells", "CELL_TYPE", 203, 210], ["IL-6", "PROTEIN", 232, 236], ["Treg cells", "CELL_TYPE", 268, 278], ["innate immune cells", "TREATMENT", 29, 48], ["secretes IL", "TEST", 223, 234]]], ["Activation of TLRs also promotes the production of IL-12p19 or IL-12p35 and IL-27, favouring Th1 or Th17 immunity, respectively [183] .", [["TLRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["IL-12p19", "GENE_OR_GENE_PRODUCT", 51, 59], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 63, 71], ["IL-27", "GENE_OR_GENE_PRODUCT", 76, 81], ["Th1", "GENE_OR_GENE_PRODUCT", 93, 96], ["Th17", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLRs", "PROTEIN", 14, 18], ["IL", "TEST", 51, 53], ["IL", "TEST", 63, 65]]], ["Th1 exerts anti tumor immunity while Th17 can possess either pro-tumor or anti tumor activity, that is tissue or organ dependent [184] .", [["tumor", "ANATOMY", 16, 21], ["pro-tumor", "ANATOMY", 61, 70], ["tumor", "ANATOMY", 79, 84], ["tissue", "ANATOMY", 103, 109], ["organ", "ANATOMY", 113, 118], ["tumor", "DISEASE", 16, 21], ["tumor", "DISEASE", 79, 84], ["tumor", "CANCER", 16, 21], ["Th17", "GENE_OR_GENE_PRODUCT", 37, 41], ["tumor", "CANCER", 79, 84], ["tissue", "TISSUE", 103, 109], ["organ", "ORGAN", 113, 118], ["Th17", "CELL_TYPE", 37, 41], ["anti tumor immunity", "TREATMENT", 11, 30], ["anti tumor activity", "PROBLEM", 74, 93], ["anti tumor", "OBSERVATION_MODIFIER", 11, 21], ["tumor", "OBSERVATION", 79, 84]]], ["One of the study has demonstrated the anti tumor activity of Th17 immunity in IL-17 knockout mice [185] .", [["tumor", "ANATOMY", 43, 48], ["tumor", "DISEASE", 43, 48], ["tumor", "CANCER", 43, 48], ["Th17", "CELL", 61, 65], ["IL-17", "GENE_OR_GENE_PRODUCT", 78, 83], ["mice", "ORGANISM", 93, 97], ["IL", "PROTEIN", 78, 80], ["mice", "SPECIES", 93, 97], ["the study", "TEST", 7, 16], ["anti", "OBSERVATION_MODIFIER", 38, 42], ["tumor", "OBSERVATION", 43, 48]]], ["Thus, Th1 response generates a protective response, however, Th2 response bedews the host immune response, promoting latent chronic inflammation.", [["inflammation", "DISEASE", 132, 144], ["latent chronic inflammation", "PROBLEM", 117, 144], ["latent", "OBSERVATION_MODIFIER", 117, 123], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["inflammation", "OBSERVATION", 132, 144]]], ["This chronic inflammation can lead to the proliferation of transformed cells that can evade the immune system in cancer conditions.", [["cells", "ANATOMY", 71, 76], ["immune system", "ANATOMY", 96, 109], ["cancer", "ANATOMY", 113, 119], ["inflammation", "DISEASE", 13, 25], ["cancer", "DISEASE", 113, 119], ["cells", "CELL", 71, 76], ["cancer", "CANCER", 113, 119], ["transformed cells", "CELL_LINE", 59, 76], ["This chronic inflammation", "PROBLEM", 0, 25], ["the proliferation of transformed cells", "PROBLEM", 38, 76], ["cancer conditions", "PROBLEM", 113, 130], ["chronic", "OBSERVATION_MODIFIER", 5, 12], ["inflammation", "OBSERVATION", 13, 25], ["transformed cells", "OBSERVATION", 59, 76], ["cancer", "OBSERVATION", 113, 119]]], ["Interestingly, Treg cells are involved in these alterations of Th2 responses and hence play crucial roles in tumor immunology, determining the destiny of lung cancer cells.", [["Treg cells", "ANATOMY", 15, 25], ["tumor", "ANATOMY", 109, 114], ["lung cancer cells", "ANATOMY", 154, 171], ["tumor", "DISEASE", 109, 114], ["lung cancer", "DISEASE", 154, 165], ["Treg cells", "CELL", 15, 25], ["tumor", "CANCER", 109, 114], ["lung cancer cells", "CELL", 154, 171], ["Treg cells", "CELL_TYPE", 15, 25], ["lung cancer cells", "CELL_TYPE", 154, 171], ["lung cancer cells", "PROBLEM", 154, 171], ["Treg cells", "OBSERVATION", 15, 25], ["tumor", "OBSERVATION", 109, 114], ["lung", "ANATOMY", 154, 158], ["cancer cells", "OBSERVATION", 159, 171]]], ["Moreover, several studies have displayed the role of TLRs in cancer development and progression [177] .", [["cancer", "ANATOMY", 61, 67], ["cancer", "DISEASE", 61, 67], ["TLRs", "GENE_OR_GENE_PRODUCT", 53, 57], ["cancer", "CANCER", 61, 67], ["TLRs", "PROTEIN", 53, 57], ["several studies", "TEST", 10, 25], ["cancer", "OBSERVATION", 61, 67]]], ["Nonetheless, the debate on their protective role in immune system activation to fight against cancer and their cancer promoting role by facilitating chronic inflammation is still on [186] .TLRs in lung cancerAs in other cases, TLRs expressed on dendritic cells play equally important roles in lung cancer too as upon TLR ligation and activation, they act as guards to look for antigens which are then presented and processed by T cells to generate adaptive immune responses.", [["immune system", "ANATOMY", 52, 65], ["cancer", "ANATOMY", 94, 100], ["cancer", "ANATOMY", 111, 117], ["lung cancerAs", "ANATOMY", 197, 210], ["dendritic cells", "ANATOMY", 245, 260], ["lung cancer", "ANATOMY", 293, 304], ["T cells", "ANATOMY", 428, 435], ["cancer", "DISEASE", 94, 100], ["cancer", "DISEASE", 111, 117], ["inflammation", "DISEASE", 157, 169], ["lung cancerAs", "DISEASE", 197, 210], ["lung cancer", "DISEASE", 293, 304], ["cancer", "CANCER", 94, 100], ["cancer", "CANCER", 111, 117], ["TLRs", "GENE_OR_GENE_PRODUCT", 189, 193], ["lung cancerAs", "CANCER", 197, 210], ["TLRs", "GENE_OR_GENE_PRODUCT", 227, 231], ["dendritic cells", "CELL", 245, 260], ["lung cancer", "CANCER", 293, 304], ["TLR", "GENE_OR_GENE_PRODUCT", 317, 320], ["T cells", "CELL", 428, 435], ["TLRs", "PROTEIN", 189, 193], ["TLRs", "PROTEIN", 227, 231], ["dendritic cells", "CELL_TYPE", 245, 260], ["TLR", "PROTEIN", 317, 320], ["antigens", "PROTEIN", 377, 385], ["T cells", "CELL_TYPE", 428, 435], ["cancer", "PROBLEM", 94, 100], ["their cancer", "PROBLEM", 105, 117], ["chronic inflammation", "PROBLEM", 149, 169], ["lung cancer", "PROBLEM", 293, 304], ["TLR ligation", "TREATMENT", 317, 329], ["antigens", "PROBLEM", 377, 385], ["cancer", "OBSERVATION", 111, 117], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["inflammation", "OBSERVATION", 157, 169], ["lung", "ANATOMY", 197, 201], ["cancerAs", "OBSERVATION", 202, 210], ["dendritic cells", "OBSERVATION", 245, 260], ["lung", "ANATOMY", 293, 297], ["cancer", "OBSERVATION", 298, 304]]], ["Thus, they act as a bridge between innate and adaptive immune system [187] .", [["a bridge between innate and adaptive immune system", "TREATMENT", 18, 68]]], ["TLR 1 to TLR9 are expressed on both human and mouse myeloid dendritic cells, but their roles in lung carcinoma have not been elucidated yet. pDCs express TLR7/8 and TLR9 responsible for the production of IFN\u03b1/\u03b2 in MyD88 dependent manner [188, 189] .", [["myeloid dendritic cells", "ANATOMY", 52, 75], ["lung carcinoma", "ANATOMY", 96, 110], ["pDCs", "ANATOMY", 141, 145], ["lung carcinoma", "DISEASE", 96, 110], ["TLR 1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["human", "ORGANISM", 36, 41], ["mouse", "ORGANISM", 46, 51], ["myeloid dendritic cells", "CELL", 52, 75], ["lung carcinoma", "CANCER", 96, 110], ["pDCs", "CELL", 141, 145], ["TLR7", "GENE_OR_GENE_PRODUCT", 154, 158], ["8", "GENE_OR_GENE_PRODUCT", 159, 160], ["TLR9", "GENE_OR_GENE_PRODUCT", 165, 169], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 204, 208], ["\u03b2", "GENE_OR_GENE_PRODUCT", 209, 210], ["MyD88", "GENE_OR_GENE_PRODUCT", 214, 219], ["TLR 1", "PROTEIN", 0, 5], ["TLR9", "PROTEIN", 9, 13], ["human and mouse myeloid dendritic cells", "CELL_TYPE", 36, 75], ["pDCs", "CELL_TYPE", 141, 145], ["TLR7/8", "PROTEIN", 154, 160], ["TLR9", "PROTEIN", 165, 169], ["IFN\u03b1", "PROTEIN", 204, 208], ["\u03b2", "PROTEIN", 209, 210], ["MyD88", "PROTEIN", 214, 219], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 46, 51], ["human", "SPECIES", 36, 41], ["mouse", "SPECIES", 46, 51], ["mouse myeloid dendritic cells", "PROBLEM", 46, 75], ["lung carcinoma", "PROBLEM", 96, 110], ["mouse myeloid", "OBSERVATION", 46, 59], ["dendritic cells", "OBSERVATION", 60, 75], ["lung", "ANATOMY", 96, 100], ["carcinoma", "OBSERVATION", 101, 110]]], ["IFN type-1 plays significant role in CD8+ T cell cytotoxicity, NK cell activation and proliferation, production of cytokines and TRAIL-mediated cell death [190] , but their functions in lung carcinoma have not been defined yet.", [["CD8+ T cell", "ANATOMY", 37, 48], ["NK cell", "ANATOMY", 63, 70], ["cell", "ANATOMY", 144, 148], ["lung carcinoma", "ANATOMY", 186, 200], ["death", "DISEASE", 149, 154], ["lung carcinoma", "DISEASE", 186, 200], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 0, 10], ["CD8", "GENE_OR_GENE_PRODUCT", 37, 40], ["NK cell", "CELL", 63, 70], ["TRAIL", "GENE_OR_GENE_PRODUCT", 129, 134], ["cell", "CELL", 144, 148], ["lung carcinoma", "CANCER", 186, 200], ["IFN type-1", "PROTEIN", 0, 10], ["CD8", "PROTEIN", 37, 40], ["cytokines", "PROTEIN", 115, 124], ["TRAIL", "PROTEIN", 129, 134], ["CD8", "TEST", 37, 40], ["T cell cytotoxicity", "PROBLEM", 42, 61], ["NK cell activation", "PROBLEM", 63, 81], ["proliferation", "PROBLEM", 86, 99], ["cytokines", "PROBLEM", 115, 124], ["TRAIL", "TREATMENT", 129, 134], ["cell death", "PROBLEM", 144, 154], ["lung carcinoma", "PROBLEM", 186, 200], ["cell cytotoxicity", "OBSERVATION", 44, 61], ["NK cell", "OBSERVATION", 63, 70], ["lung", "ANATOMY", 186, 190], ["carcinoma", "OBSERVATION", 191, 200]]], ["However, it is speculated that tumor microenvironment debilitates their anti tumor functions [191] .", [["tumor", "ANATOMY", 31, 36], ["tumor", "ANATOMY", 77, 82], ["tumor", "DISEASE", 31, 36], ["tumor", "DISEASE", 77, 82], ["tumor", "CANCER", 31, 36], ["tumor", "CANCER", 77, 82], ["tumor microenvironment", "PROBLEM", 31, 53], ["tumor", "OBSERVATION", 31, 36]]], ["In addition, TLR2, TLR4, TLR7/8 and TLR9 are highly expressed in lung carcinoma tissues, and stimulate the production of IFN type-1 and IFN-\u03b3, which in turn, promotes the production of IL-10, TGF-\u03b2 (immunosuppressive cytokines) and tolerogenic enzyme indoleamine-2,3-dioxygenase (IDO) [189, 192] .", [["lung carcinoma tissues", "ANATOMY", 65, 87], ["lung carcinoma", "DISEASE", 65, 79], ["indoleamine-2,3-dioxygenase", "CHEMICAL", 251, 278], ["indoleamine", "CHEMICAL", 251, 262], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 19, 23], ["TLR7", "GENE_OR_GENE_PRODUCT", 25, 29], ["8", "GENE_OR_GENE_PRODUCT", 30, 31], ["TLR9", "GENE_OR_GENE_PRODUCT", 36, 40], ["lung carcinoma tissues", "TISSUE", 65, 87], ["IFN type-1", "GENE_OR_GENE_PRODUCT", 121, 131], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 136, 141], ["IL-10", "GENE_OR_GENE_PRODUCT", 185, 190], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 192, 197], ["indoleamine-2,3-dioxygenase", "GENE_OR_GENE_PRODUCT", 251, 278], ["IDO", "GENE_OR_GENE_PRODUCT", 280, 283], ["TLR2", "PROTEIN", 13, 17], ["TLR4", "PROTEIN", 19, 23], ["TLR7/8", "PROTEIN", 25, 31], ["TLR9", "PROTEIN", 36, 40], ["IFN type-1", "PROTEIN", 121, 131], ["IFN-\u03b3", "PROTEIN", 136, 141], ["IL-10", "PROTEIN", 185, 190], ["TGF-\u03b2", "PROTEIN", 192, 197], ["immunosuppressive cytokines", "PROTEIN", 199, 226], ["tolerogenic enzyme indoleamine-2,3-dioxygenase", "PROTEIN", 232, 278], ["IDO", "PROTEIN", 280, 283], ["TLR2", "TEST", 13, 17], ["TLR4", "TEST", 19, 23], ["TLR7", "TEST", 25, 29], ["TLR9", "TREATMENT", 36, 40], ["lung carcinoma tissues", "PROBLEM", 65, 87], ["IFN type", "TEST", 121, 129], ["IFN", "TEST", 136, 139], ["IL", "TEST", 185, 187], ["TGF", "TEST", 192, 195], ["immunosuppressive cytokines", "TREATMENT", 199, 226], ["tolerogenic enzyme indoleamine", "TEST", 232, 262], ["TLR2", "ANATOMY", 13, 17], ["lung", "ANATOMY", 65, 69], ["carcinoma", "OBSERVATION", 70, 79]]], ["As a consequence, these cytokines and tolerogenic enzyme induces the production of adaptive and natural Tregs, involved in host immune alterations [193] . pDCs bind Treg through PD-1/PD-L1 (immune checkpoint regulators) while TGF-\u03b2 (induced by TLR4, TLR7 and TLR9) stimulates production of Treg or Th17 [194, 195] .", [["Tregs", "ANATOMY", 104, 109], ["pDCs", "ANATOMY", 155, 159], ["Treg", "ANATOMY", 165, 169], ["Treg", "ANATOMY", 290, 294], ["Tregs", "CELL", 104, 109], ["pDCs", "CELL", 155, 159], ["Treg", "CELL", 165, 169], ["PD-1", "GENE_OR_GENE_PRODUCT", 178, 182], ["PD-L1", "GENE_OR_GENE_PRODUCT", 183, 188], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 226, 231], ["TLR4", "GENE_OR_GENE_PRODUCT", 244, 248], ["TLR7", "GENE_OR_GENE_PRODUCT", 250, 254], ["TLR9", "GENE_OR_GENE_PRODUCT", 259, 263], ["Treg", "CELL", 290, 294], ["cytokines", "PROTEIN", 24, 33], ["tolerogenic enzyme", "PROTEIN", 38, 56], ["natural Tregs", "CELL_TYPE", 96, 109], ["pDCs", "CELL_TYPE", 155, 159], ["Treg", "CELL_TYPE", 165, 169], ["PD-1/PD-L1", "PROTEIN", 178, 188], ["immune checkpoint regulators", "PROTEIN", 190, 218], ["TGF-\u03b2", "PROTEIN", 226, 231], ["TLR4", "PROTEIN", 244, 248], ["TLR7", "PROTEIN", 250, 254], ["TLR9", "PROTEIN", 259, 263], ["Treg", "CELL_TYPE", 290, 294], ["these cytokines", "TEST", 18, 33], ["tolerogenic enzyme", "TREATMENT", 38, 56], ["adaptive and natural Tregs", "TREATMENT", 83, 109], ["PD", "TEST", 178, 180], ["PD", "TEST", 183, 185], ["L1 (immune checkpoint regulators", "TREATMENT", 186, 218], ["TGF", "TEST", 226, 229], ["TLR4", "TEST", 244, 248], ["L1", "ANATOMY", 186, 188]]], ["TLR9 activation by CpG-ODN enhances lung metastasis in IL-17 knockout mice, however tumor burden reduces in other tumor models [185] .", [["lung", "ANATOMY", 36, 40], ["tumor", "ANATOMY", 84, 89], ["tumor", "ANATOMY", 114, 119], ["CpG-ODN", "CHEMICAL", 19, 26], ["tumor", "DISEASE", 84, 89], ["tumor", "DISEASE", 114, 119], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["CpG-ODN", "SIMPLE_CHEMICAL", 19, 26], ["lung", "ORGAN", 36, 40], ["IL-17", "GENE_OR_GENE_PRODUCT", 55, 60], ["mice", "ORGANISM", 70, 74], ["tumor", "CANCER", 84, 89], ["tumor", "CANCER", 114, 119], ["TLR9", "PROTEIN", 0, 4], ["mice", "SPECIES", 70, 74], ["mice", "SPECIES", 70, 74], ["TLR9 activation", "TREATMENT", 0, 15], ["lung metastasis", "PROBLEM", 36, 51], ["tumor burden", "PROBLEM", 84, 96], ["lung", "ANATOMY", 36, 40], ["metastasis", "OBSERVATION", 41, 51], ["tumor", "OBSERVATION", 84, 89], ["tumor", "OBSERVATION", 114, 119]]], ["This discrepancy could be due to tissue specificity.TLRs in lung cancerOn the other hand, B cells express TLR7 and TLR9 in an enormous level.", [["tissue", "ANATOMY", 33, 39], ["lung cancerOn", "ANATOMY", 60, 73], ["hand", "ANATOMY", 84, 88], ["B cells", "ANATOMY", 90, 97], ["tissue", "TISSUE", 33, 39], ["TLRs", "GENE_OR_GENE_PRODUCT", 52, 56], ["lung cancerOn", "CANCER", 60, 73], ["B cells", "CELL", 90, 97], ["TLR7", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR9", "GENE_OR_GENE_PRODUCT", 115, 119], ["TLRs", "PROTEIN", 52, 56], ["B cells", "CELL_TYPE", 90, 97], ["TLR7", "PROTEIN", 106, 110], ["TLR9", "PROTEIN", 115, 119], ["tissue specificity", "TEST", 33, 51], ["could be due to", "UNCERTAINTY", 17, 32], ["lung", "ANATOMY", 60, 64], ["cancerOn", "OBSERVATION", 65, 73], ["hand", "ANATOMY", 84, 88], ["TLR7", "ANATOMY", 106, 110]]], ["TLR9 binds to CpG and causes B-cell polarization to acquire B-1 phenotype, which promotes tumor regression in mice [189, 196] .", [["B-cell", "ANATOMY", 29, 35], ["tumor", "ANATOMY", 90, 95], ["tumor", "DISEASE", 90, 95], ["CpG", "CHEMICAL", 14, 17], ["TLR9", "GENE_OR_GENE_PRODUCT", 0, 4], ["B-cell", "CELL", 29, 35], ["B-1", "GENE_OR_GENE_PRODUCT", 60, 63], ["tumor", "CANCER", 90, 95], ["mice", "ORGANISM", 110, 114], ["TLR9", "PROTEIN", 0, 4], ["CpG", "DNA", 14, 17], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["TLR9 binds to CpG", "TREATMENT", 0, 17], ["B-cell polarization", "TREATMENT", 29, 48], ["tumor", "OBSERVATION", 90, 95]]], ["However, in other study B cells act as antigen presenting cells and immunoglobulin producing cells, leading to tumor regression in mouse model [197] .", [["B cells", "ANATOMY", 24, 31], ["antigen presenting cells", "ANATOMY", 39, 63], ["cells", "ANATOMY", 93, 98], ["tumor", "ANATOMY", 111, 116], ["tumor", "DISEASE", 111, 116], ["B cells", "CELL", 24, 31], ["cells", "CELL", 58, 63], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 68, 82], ["cells", "CELL", 93, 98], ["tumor", "CANCER", 111, 116], ["mouse", "ORGANISM", 131, 136], ["B cells", "CELL_TYPE", 24, 31], ["antigen presenting cells", "CELL_TYPE", 39, 63], ["immunoglobulin producing cells", "CELL_TYPE", 68, 98], ["mouse", "SPECIES", 131, 136], ["mouse", "SPECIES", 131, 136], ["other study B cells", "TEST", 12, 31], ["immunoglobulin producing cells", "PROBLEM", 68, 98], ["tumor regression in mouse model", "PROBLEM", 111, 142], ["tumor", "OBSERVATION", 111, 116]]], ["Moreover, roles of other TLRs in B-cell derived immunity needs further elucidation.", [["B-cell", "ANATOMY", 33, 39], ["TLRs", "GENE_OR_GENE_PRODUCT", 25, 29], ["B-cell", "CELL", 33, 39], ["TLRs", "PROTEIN", 25, 29]]], ["Similarly, lung macrophages express high levels of TLR2, TLR3, TLR4 and TLR6 as compared to TLR7 and TLR9.", [["lung macrophages", "ANATOMY", 11, 27], ["lung macrophages", "CELL", 11, 27], ["TLR2", "GENE_OR_GENE_PRODUCT", 51, 55], ["TLR3", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR4", "GENE_OR_GENE_PRODUCT", 63, 67], ["TLR6", "GENE_OR_GENE_PRODUCT", 72, 76], ["TLR7", "GENE_OR_GENE_PRODUCT", 92, 96], ["TLR9", "GENE_OR_GENE_PRODUCT", 101, 105], ["lung macrophages", "CELL_TYPE", 11, 27], ["TLR2", "PROTEIN", 51, 55], ["TLR3", "PROTEIN", 57, 61], ["TLR4", "PROTEIN", 63, 67], ["TLR6", "PROTEIN", 72, 76], ["TLR7", "PROTEIN", 92, 96], ["TLR9", "PROTEIN", 101, 105], ["lung macrophages", "TEST", 11, 27], ["TLR2", "TEST", 51, 55], ["TLR3", "TEST", 57, 61], ["TLR6", "TEST", 72, 76], ["TLR7", "TEST", 92, 96], ["lung", "ANATOMY", 11, 15], ["macrophages", "OBSERVATION", 16, 27], ["high", "OBSERVATION_MODIFIER", 36, 40], ["levels", "OBSERVATION_MODIFIER", 41, 47], ["TLR2", "ANATOMY_MODIFIER", 51, 55]]], ["Tumor macrophages are polarized to M2 phenotype, upon TLR stimulation.", [["Tumor macrophages", "ANATOMY", 0, 17], ["Tumor macrophages", "CELL", 0, 17], ["M2", "GENE_OR_GENE_PRODUCT", 35, 37], ["TLR", "GENE_OR_GENE_PRODUCT", 54, 57], ["Tumor macrophages", "CELL_TYPE", 0, 17], ["TLR", "PROTEIN", 54, 57], ["Tumor macrophages", "PROBLEM", 0, 17], ["TLR stimulation", "TREATMENT", 54, 69], ["macrophages", "OBSERVATION", 6, 17], ["M2 phenotype", "OBSERVATION", 35, 47]]], ["These macrophages are termed as Tumor associated macrophages (TAMs), expressing high levels of TLR2.", [["macrophages", "ANATOMY", 6, 17], ["Tumor", "ANATOMY", 32, 37], ["macrophages", "ANATOMY", 49, 60], ["TAMs", "ANATOMY", 62, 66], ["macrophages", "CELL", 6, 17], ["Tumor associated macrophages", "CELL", 32, 60], ["TAMs", "CELL", 62, 66], ["TLR2", "GENE_OR_GENE_PRODUCT", 95, 99], ["macrophages", "CELL_TYPE", 6, 17], ["Tumor associated macrophages", "CELL_TYPE", 32, 60], ["TAMs", "CELL_TYPE", 62, 66], ["TLR2", "PROTEIN", 95, 99], ["Tumor associated macrophages", "PROBLEM", 32, 60], ["expressing high levels of TLR2", "PROBLEM", 69, 99], ["macrophages", "OBSERVATION", 6, 17], ["Tumor", "OBSERVATION", 32, 37], ["macrophages", "OBSERVATION_MODIFIER", 49, 60], ["high", "OBSERVATION_MODIFIER", 80, 84]]], ["Stimulation of TLR2 signalling pathway promotes lung metastasis [198] .", [["lung", "ANATOMY", 48, 52], ["TLR2", "GENE_OR_GENE_PRODUCT", 15, 19], ["lung", "ORGAN", 48, 52], ["TLR2", "PROTEIN", 15, 19], ["Stimulation of TLR2 signalling pathway", "TREATMENT", 0, 38], ["lung metastasis", "PROBLEM", 48, 63], ["lung", "ANATOMY", 48, 52], ["metastasis", "OBSERVATION", 53, 63]]], ["Likewise, TLR4 signalling in TAMs also increases cancerous lesions [199] .", [["TAMs", "ANATOMY", 29, 33], ["cancerous lesions", "ANATOMY", 49, 66], ["TLR4", "GENE_OR_GENE_PRODUCT", 10, 14], ["TAMs", "CELL", 29, 33], ["cancerous lesions", "CANCER", 49, 66], ["TLR4", "PROTEIN", 10, 14], ["TAMs", "CELL_TYPE", 29, 33], ["cancerous lesions", "PROBLEM", 49, 66], ["TLR4", "OBSERVATION_MODIFIER", 10, 14], ["increases", "OBSERVATION_MODIFIER", 39, 48], ["cancerous", "OBSERVATION_MODIFIER", 49, 58], ["lesions", "OBSERVATION", 59, 66]]], ["CpG-ODN (type B) activation of TLR9, recruits an enormous amount of macrophages into the lungs of mice poised with tumor [200] .", [["macrophages", "ANATOMY", 68, 79], ["lungs", "ANATOMY", 89, 94], ["tumor", "ANATOMY", 115, 120], ["CpG-ODN", "CHEMICAL", 0, 7], ["tumor", "DISEASE", 115, 120], ["CpG", "CHEMICAL", 0, 3], ["CpG-ODN", "GENE_OR_GENE_PRODUCT", 0, 7], ["type B", "GENE_OR_GENE_PRODUCT", 9, 15], ["TLR9", "GENE_OR_GENE_PRODUCT", 31, 35], ["macrophages", "CELL", 68, 79], ["lungs", "ORGAN", 89, 94], ["mice", "ORGANISM", 98, 102], ["tumor", "CANCER", 115, 120], ["TLR9", "PROTEIN", 31, 35], ["macrophages", "CELL_TYPE", 68, 79], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["CpG-ODN (type B) activation of TLR9", "TREATMENT", 0, 35], ["tumor", "PROBLEM", 115, 120], ["lungs", "ANATOMY", 89, 94], ["tumor", "OBSERVATION", 115, 120]]], ["Deficiency of MyD88 reduces tumor growth owing to reduced incursion of macrophages to the tumor microenvironment [201] .", [["tumor", "ANATOMY", 28, 33], ["macrophages", "ANATOMY", 71, 82], ["tumor", "ANATOMY", 90, 95], ["tumor", "DISEASE", 28, 33], ["tumor", "DISEASE", 90, 95], ["MyD88", "GENE_OR_GENE_PRODUCT", 14, 19], ["tumor", "CANCER", 28, 33], ["macrophages", "CELL", 71, 82], ["tumor", "CANCER", 90, 95], ["MyD88", "PROTEIN", 14, 19], ["macrophages", "CELL_TYPE", 71, 82], ["Deficiency of MyD88", "PROBLEM", 0, 19], ["tumor growth", "PROBLEM", 28, 40], ["tumor", "OBSERVATION", 90, 95]]], ["MyD88 mediated signalling activates M2 phenotype while TRIF dependent signalling, strongly induced by TLR3 activation, stimulates M1 phenotype of macrophages.", [["macrophages", "ANATOMY", 146, 157], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["M2", "GENE_OR_GENE_PRODUCT", 36, 38], ["TRIF", "GENE_OR_GENE_PRODUCT", 55, 59], ["TLR3", "GENE_OR_GENE_PRODUCT", 102, 106], ["M1", "CELL", 130, 132], ["macrophages", "CELL", 146, 157], ["MyD88", "PROTEIN", 0, 5], ["TRIF", "PROTEIN", 55, 59], ["TLR3", "PROTEIN", 102, 106], ["macrophages", "CELL_TYPE", 146, 157], ["TRIF dependent signalling", "PROBLEM", 55, 80], ["macrophages", "OBSERVATION", 146, 157]]], ["TLR activation on macrophages and myeloid-derived suppressor cells (MDSCs) repress immune surveillance of tumor cells [202] .", [["macrophages", "ANATOMY", 18, 29], ["myeloid-derived suppressor cells", "ANATOMY", 34, 66], ["MDSCs", "ANATOMY", 68, 73], ["tumor cells", "ANATOMY", 106, 117], ["tumor", "DISEASE", 106, 111], ["TLR", "GENE_OR_GENE_PRODUCT", 0, 3], ["macrophages", "CELL", 18, 29], ["myeloid-derived suppressor cells", "CELL", 34, 66], ["MDSCs", "CELL", 68, 73], ["tumor cells", "CELL", 106, 117], ["TLR", "PROTEIN", 0, 3], ["macrophages", "CELL_TYPE", 18, 29], ["myeloid-derived suppressor cells", "CELL_TYPE", 34, 66], ["MDSCs", "CELL_TYPE", 68, 73], ["tumor cells", "CELL_TYPE", 106, 117], ["macrophages", "PROBLEM", 18, 29], ["myeloid-derived suppressor cells", "TREATMENT", 34, 66], ["tumor cells", "PROBLEM", 106, 117], ["macrophages", "ANATOMY", 18, 29], ["myeloid", "ANATOMY", 34, 41], ["tumor cells", "OBSERVATION", 106, 117]]], ["It was confirmed in a recent study wherein TLR2 activation on MDSCs promotes tumor immune evasion, thereby enhancing tumor growth in lung adenocarcinoma, lymphoma and colon carcinoma [203] .", [["MDSCs", "ANATOMY", 62, 67], ["tumor", "ANATOMY", 77, 82], ["tumor", "ANATOMY", 117, 122], ["lung adenocarcinoma", "ANATOMY", 133, 152], ["lymphoma", "ANATOMY", 154, 162], ["colon carcinoma", "ANATOMY", 167, 182], ["tumor", "DISEASE", 77, 82], ["tumor", "DISEASE", 117, 122], ["lung adenocarcinoma, lymphoma", "DISEASE", 133, 162], ["colon carcinoma", "DISEASE", 167, 182], ["TLR2", "GENE_OR_GENE_PRODUCT", 43, 47], ["MDSCs", "CELL", 62, 67], ["tumor", "CANCER", 77, 82], ["tumor", "CANCER", 117, 122], ["lung adenocarcinoma", "CANCER", 133, 152], ["lymphoma", "CANCER", 154, 162], ["colon carcinoma", "CANCER", 167, 182], ["TLR2", "PROTEIN", 43, 47], ["MDSCs", "CELL_TYPE", 62, 67], ["a recent study", "TEST", 20, 34], ["TLR2 activation on MDSCs", "TREATMENT", 43, 67], ["tumor immune evasion", "TREATMENT", 77, 97], ["enhancing tumor growth", "PROBLEM", 107, 129], ["lung adenocarcinoma", "PROBLEM", 133, 152], ["lymphoma", "PROBLEM", 154, 162], ["colon carcinoma", "PROBLEM", 167, 182], ["enhancing", "OBSERVATION_MODIFIER", 107, 116], ["tumor", "OBSERVATION_MODIFIER", 117, 122], ["growth", "OBSERVATION_MODIFIER", 123, 129], ["lung", "ANATOMY", 133, 137], ["adenocarcinoma", "OBSERVATION", 138, 152], ["lymphoma", "OBSERVATION", 154, 162], ["colon", "ANATOMY", 167, 172], ["carcinoma", "OBSERVATION", 173, 182]]], ["Additionally, MDSCs are recruited to the lung upon administration of CpG-ODN (ligand of TLR9) into the mice bearing tumor [197] .", [["MDSCs", "ANATOMY", 14, 19], ["lung", "ANATOMY", 41, 45], ["tumor", "ANATOMY", 116, 121], ["CpG-ODN", "CHEMICAL", 69, 76], ["tumor", "DISEASE", 116, 121], ["CpG", "CHEMICAL", 69, 72], ["MDSCs", "CELL", 14, 19], ["lung", "ORGAN", 41, 45], ["CpG-ODN", "SIMPLE_CHEMICAL", 69, 76], ["TLR9", "GENE_OR_GENE_PRODUCT", 88, 92], ["mice", "ORGANISM", 103, 107], ["tumor", "CANCER", 116, 121], ["MDSCs", "CELL_TYPE", 14, 19], ["TLR9", "PROTEIN", 88, 92], ["mice", "SPECIES", 103, 107], ["CpG-ODN (ligand of TLR9)", "TREATMENT", 69, 93], ["MDSCs", "OBSERVATION", 14, 19], ["lung", "ANATOMY", 41, 45], ["tumor", "OBSERVATION", 116, 121]]], ["Thus, MDSCs and Tregs, both have important contributions in progression of lung tumors and are swayed by activation of TLRs; elucidation of their roles in lung cancer would be therapeutically very beneficial.TLRs in lung cancerNK cells, one of the leading effector cells against tumors are scarcely activated by MyD88 dependent pathway, but TRIF dependent pathway lures their cytotoxicity.", [["MDSCs", "ANATOMY", 6, 11], ["Tregs", "ANATOMY", 16, 21], ["lung tumors", "ANATOMY", 75, 86], ["lung cancer", "ANATOMY", 155, 166], ["lung cancerNK cells", "ANATOMY", 216, 235], ["effector cells", "ANATOMY", 256, 270], ["tumors", "ANATOMY", 279, 285], ["lung tumors", "DISEASE", 75, 86], ["lung cancer", "DISEASE", 155, 166], ["tumors", "DISEASE", 279, 285], ["MDSCs", "CELL", 6, 11], ["Tregs", "CELL", 16, 21], ["lung tumors", "CANCER", 75, 86], ["TLRs", "GENE_OR_GENE_PRODUCT", 119, 123], ["lung cancer", "CANCER", 155, 166], ["TLRs", "GENE_OR_GENE_PRODUCT", 208, 212], ["lung cancerNK cells", "CELL", 216, 235], ["cells", "CELL", 265, 270], ["tumors", "CANCER", 279, 285], ["MyD88", "GENE_OR_GENE_PRODUCT", 312, 317], ["TRIF", "GENE_OR_GENE_PRODUCT", 341, 345], ["MDSCs", "CELL_TYPE", 6, 11], ["Tregs", "CELL_TYPE", 16, 21], ["TLRs", "PROTEIN", 119, 123], ["TLRs", "PROTEIN", 208, 212], ["lung cancerNK cells", "CELL_TYPE", 216, 235], ["effector cells", "CELL_TYPE", 256, 270], ["MyD88", "PROTEIN", 312, 317], ["TRIF", "PROTEIN", 341, 345], ["lung tumors", "PROBLEM", 75, 86], ["lung cancer", "PROBLEM", 155, 166], ["TLRs in lung cancerNK cells", "PROBLEM", 208, 235], ["tumors", "PROBLEM", 279, 285], ["MyD88 dependent pathway", "TREATMENT", 312, 335], ["TRIF dependent pathway", "PROBLEM", 341, 363], ["their cytotoxicity", "PROBLEM", 370, 388], ["progression", "OBSERVATION_MODIFIER", 60, 71], ["lung", "ANATOMY", 75, 79], ["tumors", "OBSERVATION", 80, 86], ["lung", "ANATOMY", 155, 159], ["cancer", "OBSERVATION", 160, 166], ["lung", "ANATOMY", 216, 220], ["cancerNK cells", "OBSERVATION", 221, 235], ["effector cells", "OBSERVATION", 256, 270]]], ["It has been found that absence of TRIF mediates tumor progression upon administration of Poly I:C (a ligand of TLR3) [204] .", [["tumor", "ANATOMY", 48, 53], ["tumor", "DISEASE", 48, 53], ["Poly I:C", "CHEMICAL", 89, 97], ["TRIF", "GENE_OR_GENE_PRODUCT", 34, 38], ["tumor", "CANCER", 48, 53], ["Poly I:C", "SIMPLE_CHEMICAL", 89, 97], ["TLR3", "GENE_OR_GENE_PRODUCT", 111, 115], ["TRIF", "PROTEIN", 34, 38], ["Poly I:C", "PROTEIN", 89, 97], ["TLR3", "PROTEIN", 111, 115], ["TRIF mediates tumor progression", "PROBLEM", 34, 65], ["tumor", "OBSERVATION", 48, 53]]], ["However, in case of prostate cancer, Poly I:C administration regresses tumor growth as activation of TLR3 can also result in apoptotic cascade [205] .", [["prostate cancer", "ANATOMY", 20, 35], ["tumor", "ANATOMY", 71, 76], ["prostate cancer", "DISEASE", 20, 35], ["Poly I:C", "CHEMICAL", 37, 45], ["tumor", "DISEASE", 71, 76], ["Poly I:C", "CHEMICAL", 37, 45], ["prostate cancer", "CANCER", 20, 35], ["Poly I:C", "SIMPLE_CHEMICAL", 37, 45], ["tumor", "CANCER", 71, 76], ["TLR3", "GENE_OR_GENE_PRODUCT", 101, 105], ["TLR3", "PROTEIN", 101, 105], ["prostate cancer", "PROBLEM", 20, 35], ["Poly I:C administration", "TREATMENT", 37, 60], ["tumor growth", "PROBLEM", 71, 83], ["activation of TLR3", "TREATMENT", 87, 105], ["apoptotic cascade", "PROBLEM", 125, 142], ["prostate", "ANATOMY", 20, 28], ["cancer", "OBSERVATION", 29, 35]]], ["TLR7 and TLR9 signalling reduces upon viral infection [206] , thereby reducing innate immune response in the course of tumorigenesis.", [["infection", "DISEASE", 44, 53], ["TLR7", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["TLR7", "PROTEIN", 0, 4], ["TLR9", "PROTEIN", 9, 13], ["TLR7", "TREATMENT", 0, 4], ["viral infection", "PROBLEM", 38, 53], ["tumorigenesis", "PROBLEM", 119, 132], ["viral", "OBSERVATION_MODIFIER", 38, 43], ["infection", "OBSERVATION", 44, 53], ["immune response", "OBSERVATION", 86, 101]]], ["NK cells are also activated upon activation of TLR2-MyD88 on mDCs.", [["NK cells", "ANATOMY", 0, 8], ["mDCs", "ANATOMY", 61, 65], ["NK cells", "CELL", 0, 8], ["TLR2", "GENE_OR_GENE_PRODUCT", 47, 51], ["MyD88", "GENE_OR_GENE_PRODUCT", 52, 57], ["mDCs", "CELL", 61, 65], ["NK cells", "CELL_TYPE", 0, 8], ["TLR2", "PROTEIN", 47, 51], ["MyD88", "PROTEIN", 52, 57], ["mDCs", "CELL_TYPE", 61, 65], ["NK cells", "PROBLEM", 0, 8]]], ["However, reduced lung metastases have been observed due to NK cell activation upon administration of ligands of TLR3, TLR7/8 [207] [208] [209] .", [["lung metastases", "ANATOMY", 17, 32], ["NK cell", "ANATOMY", 59, 66], ["lung metastases", "DISEASE", 17, 32], ["lung", "ORGAN", 17, 21], ["NK cell", "CELL", 59, 66], ["TLR3", "GENE_OR_GENE_PRODUCT", 112, 116], ["TLR7/8", "GENE_OR_GENE_PRODUCT", 118, 124], ["TLR3", "PROTEIN", 112, 116], ["reduced lung metastases", "PROBLEM", 9, 32], ["NK cell activation", "PROBLEM", 59, 77], ["reduced", "OBSERVATION_MODIFIER", 9, 16], ["lung", "ANATOMY", 17, 21], ["metastases", "OBSERVATION", 22, 32], ["NK cell activation", "OBSERVATION", 59, 77]]], ["Similarly, mast cells are also present in several tumor types and the activation of mast cell receptors and TLRs stimulate a number of growth stimulatory mediators and pro-angiogenic factors that enhance tumor proliferation.", [["mast cells", "ANATOMY", 11, 21], ["tumor", "ANATOMY", 50, 55], ["mast cell", "ANATOMY", 84, 93], ["tumor", "ANATOMY", 204, 209], ["tumor", "DISEASE", 50, 55], ["tumor", "DISEASE", 204, 209], ["mast cells", "CELL", 11, 21], ["tumor", "CANCER", 50, 55], ["mast cell", "CELL", 84, 93], ["TLRs", "GENE_OR_GENE_PRODUCT", 108, 112], ["tumor", "CANCER", 204, 209], ["mast cells", "CELL_TYPE", 11, 21], ["mast cell receptors", "PROTEIN", 84, 103], ["TLRs", "PROTEIN", 108, 112], ["growth stimulatory mediators", "PROTEIN", 135, 163], ["pro-angiogenic factors", "PROTEIN", 168, 190], ["mast cells", "PROBLEM", 11, 21], ["mast cell receptors", "TREATMENT", 84, 103], ["TLRs stimulate", "TREATMENT", 108, 122], ["pro-angiogenic factors", "PROBLEM", 168, 190], ["tumor proliferation", "PROBLEM", 204, 223], ["mast cells", "OBSERVATION", 11, 21], ["several", "OBSERVATION_MODIFIER", 42, 49], ["tumor", "OBSERVATION", 50, 55], ["mast cell receptors", "OBSERVATION", 84, 103], ["pro-angiogenic", "OBSERVATION_MODIFIER", 168, 182], ["tumor proliferation", "OBSERVATION", 204, 223]]], ["Contrastingly, TLR2 activation on mast cells reduced lung carcinoma growth upon subcutaneous implantation of LLC1 cells in mouse model [210] .", [["mast cells", "ANATOMY", 34, 44], ["lung carcinoma", "ANATOMY", 53, 67], ["subcutaneous", "ANATOMY", 80, 92], ["LLC1 cells", "ANATOMY", 109, 119], ["lung carcinoma", "DISEASE", 53, 67], ["TLR2", "GENE_OR_GENE_PRODUCT", 15, 19], ["mast cells", "CELL", 34, 44], ["lung carcinoma", "CANCER", 53, 67], ["LLC1 cells", "CELL", 109, 119], ["mouse", "ORGANISM", 123, 128], ["TLR2", "PROTEIN", 15, 19], ["mast cells", "CELL_TYPE", 34, 44], ["LLC1 cells", "CELL_LINE", 109, 119], ["mouse", "SPECIES", 123, 128], ["mouse", "SPECIES", 123, 128], ["mast cells", "PROBLEM", 34, 44], ["lung carcinoma growth", "PROBLEM", 53, 74], ["subcutaneous implantation of LLC1 cells", "TREATMENT", 80, 119], ["TLR2 activation", "OBSERVATION", 15, 30], ["mast cells", "OBSERVATION", 34, 44], ["reduced", "OBSERVATION_MODIFIER", 45, 52], ["lung", "ANATOMY", 53, 57], ["carcinoma", "OBSERVATION", 58, 67], ["subcutaneous", "OBSERVATION_MODIFIER", 80, 92], ["implantation", "OBSERVATION", 93, 105], ["LLC1 cells", "OBSERVATION", 109, 119]]], ["Oldford et al. have demonstrated that TLR2 activation on mast cells facilitate release of IL-6 and CCL1, responsible for consequent increase in antitumor activities and recruitment of NK and CD8+ cytotoxic T cells [200, 211] .", [["mast cells", "ANATOMY", 57, 67], ["antitumor", "ANATOMY", 144, 153], ["NK", "ANATOMY", 184, 186], ["CD8+ cytotoxic T cells", "ANATOMY", 191, 213], ["TLR2", "GENE_OR_GENE_PRODUCT", 38, 42], ["mast cells", "CELL", 57, 67], ["IL-6", "GENE_OR_GENE_PRODUCT", 90, 94], ["CCL1", "GENE_OR_GENE_PRODUCT", 99, 103], ["antitumor", "CANCER", 144, 153], ["NK", "CELL", 184, 186], ["CD8", "GENE_OR_GENE_PRODUCT", 191, 194], ["TLR2", "PROTEIN", 38, 42], ["mast cells", "CELL_TYPE", 57, 67], ["IL-6", "PROTEIN", 90, 94], ["CCL1", "PROTEIN", 99, 103], ["NK and CD8+ cytotoxic T cells", "CELL_TYPE", 184, 213], ["TLR2 activation", "PROBLEM", 38, 53], ["mast cells", "TREATMENT", 57, 67], ["IL", "TEST", 90, 92], ["CCL1", "TREATMENT", 99, 103], ["consequent increase in antitumor activities", "PROBLEM", 121, 164], ["NK", "TEST", 184, 186], ["CD8", "TEST", 191, 194], ["cytotoxic T cells", "TEST", 196, 213], ["increase", "OBSERVATION_MODIFIER", 132, 140], ["antitumor activities", "OBSERVATION", 144, 164]]], ["Although lung cancer bears Th2 based pathology, the role of mast cells in tumor progression remains elusive.TLRs in lung cancerDevelopment and progression of lung cancer involves anti-inflammatory cytokines such as TGF-\u03b2 [212] , IL-10 and growth factors such as VEGF and Fibroblast growth factor 2 (FGF2), which are induced by activation of TLR2, TLR4 and TLR9.", [["lung cancer", "ANATOMY", 9, 20], ["mast cells", "ANATOMY", 60, 70], ["tumor", "ANATOMY", 74, 79], ["lung", "ANATOMY", 116, 120], ["lung cancer", "ANATOMY", 158, 169], ["lung cancer", "DISEASE", 9, 20], ["tumor", "DISEASE", 74, 79], ["lung cancer", "DISEASE", 158, 169], ["lung cancer", "CANCER", 9, 20], ["mast cells", "CELL", 60, 70], ["tumor", "CANCER", 74, 79], ["TLRs", "GENE_OR_GENE_PRODUCT", 108, 112], ["lung", "ORGAN", 116, 120], ["lung cancer", "CANCER", 158, 169], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 215, 220], ["IL-10", "GENE_OR_GENE_PRODUCT", 229, 234], ["VEGF", "GENE_OR_GENE_PRODUCT", 262, 266], ["Fibroblast growth factor 2", "GENE_OR_GENE_PRODUCT", 271, 297], ["FGF2", "GENE_OR_GENE_PRODUCT", 299, 303], ["TLR2", "GENE_OR_GENE_PRODUCT", 341, 345], ["TLR4", "GENE_OR_GENE_PRODUCT", 347, 351], ["TLR9", "GENE_OR_GENE_PRODUCT", 356, 360], ["mast cells", "CELL_TYPE", 60, 70], ["TLRs", "PROTEIN", 108, 112], ["anti-inflammatory cytokines", "PROTEIN", 179, 206], ["TGF", "PROTEIN", 215, 218], ["IL-10", "PROTEIN", 229, 234], ["growth factors", "PROTEIN", 239, 253], ["VEGF", "PROTEIN", 262, 266], ["Fibroblast growth factor 2", "PROTEIN", 271, 297], ["FGF2", "PROTEIN", 299, 303], ["TLR2", "PROTEIN", 341, 345], ["TLR4", "PROTEIN", 347, 351], ["TLR9", "PROTEIN", 356, 360], ["lung cancer", "PROBLEM", 9, 20], ["Th2 based pathology", "PROBLEM", 27, 46], ["mast cells", "PROBLEM", 60, 70], ["tumor progression", "PROBLEM", 74, 91], ["TLRs in lung cancerDevelopment", "TREATMENT", 108, 138], ["lung cancer", "PROBLEM", 158, 169], ["anti-inflammatory cytokines", "TEST", 179, 206], ["TGF", "TEST", 215, 218], ["IL", "TEST", 229, 231], ["growth factors", "PROBLEM", 239, 253], ["VEGF", "PROBLEM", 262, 266], ["Fibroblast growth factor", "TEST", 271, 295], ["TLR4 and TLR9", "TREATMENT", 347, 360], ["lung", "ANATOMY", 9, 13], ["cancer", "OBSERVATION", 14, 20], ["mast cells", "OBSERVATION", 60, 70], ["tumor", "OBSERVATION", 74, 79], ["lung", "ANATOMY", 116, 120], ["cancerDevelopment", "OBSERVATION", 121, 138], ["progression", "OBSERVATION_MODIFIER", 143, 154], ["lung", "ANATOMY", 158, 162], ["cancer", "OBSERVATION", 163, 169], ["anti-inflammatory", "OBSERVATION_MODIFIER", 179, 196]]], ["In lung epithelial cells, TGF-\u03b21 has been recognized to facilitate apoptosis and inflammation [212] .", [["lung epithelial cells", "ANATOMY", 3, 24], ["inflammation", "DISEASE", 81, 93], ["lung epithelial cells", "CELL", 3, 24], ["TGF-\u03b21", "GENE_OR_GENE_PRODUCT", 26, 32], ["lung epithelial cells", "CELL_TYPE", 3, 24], ["TGF-\u03b21", "PROTEIN", 26, 32], ["lung epithelial cells", "TEST", 3, 24], ["TGF", "TEST", 26, 29], ["apoptosis", "PROBLEM", 67, 76], ["inflammation", "PROBLEM", 81, 93], ["lung", "ANATOMY", 3, 7], ["epithelial cells", "OBSERVATION", 8, 24], ["apoptosis", "OBSERVATION_MODIFIER", 67, 76], ["inflammation", "OBSERVATION_MODIFIER", 81, 93]]], ["However, TLR2 and TLR4 activation induces extracellular matrix remodelling and EGFR-mediated signalling, respectively, stimulating progression of lung carcinoma [213, 214] .", [["extracellular matrix", "ANATOMY", 42, 62], ["lung carcinoma", "ANATOMY", 146, 160], ["lung carcinoma", "DISEASE", 146, 160], ["TLR2", "GENE_OR_GENE_PRODUCT", 9, 13], ["TLR4", "GENE_OR_GENE_PRODUCT", 18, 22], ["extracellular matrix", "CELLULAR_COMPONENT", 42, 62], ["EGFR", "GENE_OR_GENE_PRODUCT", 79, 83], ["lung carcinoma", "CANCER", 146, 160], ["TLR2", "PROTEIN", 9, 13], ["TLR4", "PROTEIN", 18, 22], ["EGFR", "PROTEIN", 79, 83], ["TLR2 and TLR4 activation", "TREATMENT", 9, 33], ["extracellular matrix remodelling", "TREATMENT", 42, 74], ["EGFR", "TEST", 79, 83], ["lung carcinoma", "PROBLEM", 146, 160], ["lung", "ANATOMY", 146, 150], ["carcinoma", "OBSERVATION", 151, 160]]], ["Exceptionally, TLR9 signalling along with cetuximab (an inhibitor of EGFR signalling) regresses tumor growth [215] .", [["tumor", "ANATOMY", 96, 101], ["cetuximab", "CHEMICAL", 42, 51], ["tumor", "DISEASE", 96, 101], ["TLR9", "GENE_OR_GENE_PRODUCT", 15, 19], ["cetuximab", "SIMPLE_CHEMICAL", 42, 51], ["EGFR", "GENE_OR_GENE_PRODUCT", 69, 73], ["tumor", "CANCER", 96, 101], ["TLR9", "PROTEIN", 15, 19], ["EGFR", "PROTEIN", 69, 73], ["cetuximab", "TREATMENT", 42, 51], ["an inhibitor of EGFR signalling", "TREATMENT", 53, 84], ["tumor growth", "PROBLEM", 96, 108]]], ["However, activation of TLR9 by CpG-ODN promotes the growth of human tumor epithelial lung cells [216] .", [["tumor epithelial lung cells", "ANATOMY", 68, 95], ["CpG-ODN", "CHEMICAL", 31, 38], ["tumor", "DISEASE", 68, 73], ["TLR9", "GENE_OR_GENE_PRODUCT", 23, 27], ["CpG-ODN", "SIMPLE_CHEMICAL", 31, 38], ["human", "ORGANISM", 62, 67], ["tumor epithelial lung cells [216]", "CELL", 68, 101], ["TLR9", "PROTEIN", 23, 27], ["human tumor epithelial lung cells", "CELL_TYPE", 62, 95], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["TLR9 by CpG", "TREATMENT", 23, 34], ["human tumor epithelial lung cells", "PROBLEM", 62, 95], ["epithelial", "ANATOMY_MODIFIER", 74, 84], ["lung", "ANATOMY", 85, 89]]], ["Further, TLR9 activation induces release of VEGF, thereby promoting the growth of tumor cells [217] .", [["tumor cells", "ANATOMY", 82, 93], ["tumor", "DISEASE", 82, 87], ["TLR9", "GENE_OR_GENE_PRODUCT", 9, 13], ["VEGF", "GENE_OR_GENE_PRODUCT", 44, 48], ["tumor cells", "CELL", 82, 93], ["TLR9", "PROTEIN", 9, 13], ["VEGF", "PROTEIN", 44, 48], ["tumor cells", "CELL_TYPE", 82, 93], ["VEGF", "PROBLEM", 44, 48], ["tumor cells", "PROBLEM", 82, 93], ["growth", "OBSERVATION_MODIFIER", 72, 78], ["tumor cells", "OBSERVATION", 82, 93]]], ["The role of TLR3 and TLR7 signalling has not been yet explored in lung carcinoma.", [["lung carcinoma", "ANATOMY", 66, 80], ["lung carcinoma", "DISEASE", 66, 80], ["TLR3", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR7", "GENE_OR_GENE_PRODUCT", 21, 25], ["lung carcinoma", "CANCER", 66, 80], ["TLR3", "PROTEIN", 12, 16], ["TLR7", "PROTEIN", 21, 25], ["TLR3 and TLR7 signalling", "TREATMENT", 12, 36], ["lung carcinoma", "PROBLEM", 66, 80], ["lung", "ANATOMY", 66, 70], ["carcinoma", "OBSERVATION", 71, 80]]], ["Although, TLR3 and TLR7 activation induces apoptosis and hence facilitate tumor regression in prostate and melanoma models of mouse as well as in in vitro studies conducted on human lung cancer cell line treated with imiquimod, a TLR7 ligand [218] .", [["tumor", "ANATOMY", 74, 79], ["prostate", "ANATOMY", 94, 102], ["melanoma", "ANATOMY", 107, 115], ["lung cancer cell line", "ANATOMY", 182, 203], ["tumor", "DISEASE", 74, 79], ["prostate and melanoma", "DISEASE", 94, 115], ["lung cancer", "DISEASE", 182, 193], ["imiquimod", "CHEMICAL", 217, 226], ["imiquimod", "CHEMICAL", 217, 226], ["TLR3", "GENE_OR_GENE_PRODUCT", 10, 14], ["TLR7", "GENE_OR_GENE_PRODUCT", 19, 23], ["tumor", "CANCER", 74, 79], ["prostate", "CANCER", 94, 102], ["melanoma", "CANCER", 107, 115], ["mouse", "ORGANISM", 126, 131], ["human", "ORGANISM", 176, 181], ["lung cancer cell line", "CELL", 182, 203], ["imiquimod", "SIMPLE_CHEMICAL", 217, 226], ["TLR7", "GENE_OR_GENE_PRODUCT", 230, 234], ["TLR3", "PROTEIN", 10, 14], ["TLR7", "PROTEIN", 19, 23], ["human lung cancer cell line", "CELL_LINE", 176, 203], ["TLR7 ligand", "PROTEIN", 230, 241], ["mouse", "SPECIES", 126, 131], ["human", "SPECIES", 176, 181], ["mouse", "SPECIES", 126, 131], ["human", "SPECIES", 176, 181], ["TLR3 and TLR7 activation", "TREATMENT", 10, 34], ["apoptosis", "PROBLEM", 43, 52], ["tumor regression in prostate", "PROBLEM", 74, 102], ["melanoma models of mouse", "PROBLEM", 107, 131], ["vitro studies", "TEST", 149, 162], ["human lung cancer cell line", "TREATMENT", 176, 203], ["imiquimod", "TREATMENT", 217, 226], ["a TLR7 ligand", "TREATMENT", 228, 241], ["tumor", "OBSERVATION", 74, 79], ["prostate", "ANATOMY", 94, 102], ["melanoma", "OBSERVATION", 107, 115], ["lung", "ANATOMY", 182, 186], ["cancer", "OBSERVATION", 187, 193], ["cell line", "OBSERVATION", 194, 203]]], ["VEGF released from CpG-ODN induced lung carcinoma, acts as a pro-tumor factor, expediting the angiogenesis of cancer cells and recruitment of inflammatory cells, favouring anti-tumor activity [213, 217, 219] .", [["lung carcinoma", "ANATOMY", 35, 49], ["cancer cells", "ANATOMY", 110, 122], ["inflammatory cells", "ANATOMY", 142, 160], ["ODN", "CHEMICAL", 23, 26], ["lung carcinoma", "DISEASE", 35, 49], ["cancer", "DISEASE", 110, 116], ["VEGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["CpG-ODN", "SIMPLE_CHEMICAL", 19, 26], ["lung carcinoma", "CANCER", 35, 49], ["cancer cells", "CELL", 110, 122], ["inflammatory cells", "CELL", 142, 160], ["anti-tumor", "CANCER", 172, 182], ["VEGF", "PROTEIN", 0, 4], ["pro-tumor factor", "PROTEIN", 61, 77], ["cancer cells", "CELL_TYPE", 110, 122], ["inflammatory cells", "CELL_TYPE", 142, 160], ["VEGF", "PROBLEM", 0, 4], ["CpG-ODN", "TREATMENT", 19, 26], ["lung carcinoma", "PROBLEM", 35, 49], ["a pro-tumor factor", "PROBLEM", 59, 77], ["cancer cells", "PROBLEM", 110, 122], ["inflammatory cells", "PROBLEM", 142, 160], ["anti-tumor activity", "PROBLEM", 172, 191], ["lung", "ANATOMY", 35, 39], ["carcinoma", "OBSERVATION", 40, 49], ["cancer cells", "OBSERVATION", 110, 122], ["recruitment", "OBSERVATION_MODIFIER", 127, 138], ["inflammatory cells", "OBSERVATION", 142, 160]]], ["Thus, VEGF may act as both pro-tumorigenic and antitumorigenic.", [["VEGF", "GENE_OR_GENE_PRODUCT", 6, 10], ["VEGF", "PROTEIN", 6, 10], ["pro-tumorigenic", "OBSERVATION", 27, 42], ["antitumorigenic", "OBSERVATION_MODIFIER", 47, 62]]], ["More significantly, TLR2 and TLR4 activation also causes the extradition of extracellular matrix proteins such as fibrin and hyaluronan, which may act as DAMPs, exaggerating the inflammatory processes [213, 220] .", [["extracellular matrix", "ANATOMY", 76, 96], ["TLR2", "GENE_OR_GENE_PRODUCT", 20, 24], ["TLR4", "GENE_OR_GENE_PRODUCT", 29, 33], ["extracellular matrix", "CELLULAR_COMPONENT", 76, 96], ["fibrin", "GENE_OR_GENE_PRODUCT", 114, 120], ["hyaluronan", "GENE_OR_GENE_PRODUCT", 125, 135], ["DAMPs", "GENE_OR_GENE_PRODUCT", 154, 159], ["TLR2", "PROTEIN", 20, 24], ["TLR4", "PROTEIN", 29, 33], ["extracellular matrix proteins", "PROTEIN", 76, 105], ["fibrin", "PROTEIN", 114, 120], ["DAMPs", "PROTEIN", 154, 159], ["TLR2 and TLR4 activation", "TREATMENT", 20, 44], ["extracellular matrix proteins", "PROBLEM", 76, 105], ["fibrin and hyaluronan", "PROBLEM", 114, 135], ["the inflammatory processes", "PROBLEM", 174, 200], ["extracellular matrix", "OBSERVATION", 76, 96], ["fibrin", "OBSERVATION", 114, 120], ["hyaluronan", "OBSERVATION", 125, 135], ["inflammatory", "OBSERVATION_MODIFIER", 178, 190]]], ["Pro-inflammatory cytokines such as IL-1, IL-6 and chemokines such as IL-8, and ICAM-1 are released upon activation of TLRs present on endothelial cells, and bolsters the recruitment of leukocytes to the lung [221] .", [["endothelial cells", "ANATOMY", 134, 151], ["leukocytes", "ANATOMY", 185, 195], ["lung", "ANATOMY", 203, 207], ["IL-1", "GENE_OR_GENE_PRODUCT", 35, 39], ["IL-6", "GENE_OR_GENE_PRODUCT", 41, 45], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["ICAM-1", "GENE_OR_GENE_PRODUCT", 79, 85], ["TLRs", "GENE_OR_GENE_PRODUCT", 118, 122], ["endothelial cells", "CELL", 134, 151], ["leukocytes", "CELL", 185, 195], ["lung", "ORGAN", 203, 207], ["Pro-inflammatory cytokines", "PROTEIN", 0, 26], ["IL-1, IL-6", "PROTEIN", 35, 45], ["chemokines", "PROTEIN", 50, 60], ["IL-8", "PROTEIN", 69, 73], ["ICAM-1", "PROTEIN", 79, 85], ["TLRs", "PROTEIN", 118, 122], ["endothelial cells", "CELL_TYPE", 134, 151], ["leukocytes", "CELL_TYPE", 185, 195], ["Pro-inflammatory cytokines", "TEST", 0, 26], ["IL", "TEST", 35, 37], ["IL", "TEST", 41, 43], ["chemokines", "TREATMENT", 50, 60], ["IL", "TEST", 69, 71], ["ICAM", "TEST", 79, 83], ["endothelial cells", "TREATMENT", 134, 151], ["endothelial cells", "OBSERVATION", 134, 151], ["recruitment", "OBSERVATION_MODIFIER", 170, 181], ["leukocytes", "OBSERVATION", 185, 195], ["lung", "ANATOMY", 203, 207]]], ["Surprisingly, endothelial cells upregulate PD-1 and secrete high levels of IL-10, TGF-\u03b1, TGF-\u03b2 and IFN-\u03b3, thereby promoting recruitment of immunosuppressive cells such as pDCs which interacts with Tregs, to the lung, and hence enhance the immunosuppressive abeyants of activated Tregs [222] .", [["endothelial cells", "ANATOMY", 14, 31], ["cells", "ANATOMY", 157, 162], ["pDCs", "ANATOMY", 171, 175], ["Tregs", "ANATOMY", 197, 202], ["lung", "ANATOMY", 211, 215], ["Tregs", "ANATOMY", 279, 284], ["endothelial cells", "CELL", 14, 31], ["PD-1", "GENE_OR_GENE_PRODUCT", 43, 47], ["IL-10", "GENE_OR_GENE_PRODUCT", 75, 80], ["TGF-\u03b1", "GENE_OR_GENE_PRODUCT", 82, 87], ["TGF-\u03b2", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 99, 104], ["immunosuppressive cells", "CELL", 139, 162], ["pDCs", "CELL", 171, 175], ["Tregs", "CELL", 197, 202], ["lung", "ORGAN", 211, 215], ["Tregs", "CELL", 279, 284], ["endothelial cells", "CELL_TYPE", 14, 31], ["IL-10", "PROTEIN", 75, 80], ["TGF-\u03b1", "PROTEIN", 82, 87], ["TGF", "PROTEIN", 89, 92], ["IFN-\u03b3", "PROTEIN", 99, 104], ["immunosuppressive cells", "CELL_TYPE", 139, 162], ["pDCs", "CELL_TYPE", 171, 175], ["Tregs", "CELL_TYPE", 197, 202], ["activated Tregs", "CELL_TYPE", 269, 284], ["endothelial cells", "TEST", 14, 31], ["PD", "TEST", 43, 45], ["IL", "TEST", 75, 77], ["TGF", "TEST", 82, 85], ["TGF", "TEST", 89, 92], ["IFN", "TEST", 99, 102], ["immunosuppressive cells", "TREATMENT", 139, 162], ["pDCs", "PROBLEM", 171, 175], ["endothelial", "ANATOMY", 14, 25], ["immunosuppressive cells", "OBSERVATION", 139, 162], ["lung", "ANATOMY", 211, 215]]], ["Immunosuppressive effects could also arise from activation of MDSCs mediated by MyD88 signalling.", [["MDSCs", "ANATOMY", 62, 67], ["MDSCs", "CELL", 62, 67], ["MyD88", "GENE_OR_GENE_PRODUCT", 80, 85], ["MDSCs", "CELL_TYPE", 62, 67], ["MyD88", "PROTEIN", 80, 85], ["Immunosuppressive effects", "TREATMENT", 0, 25]]], ["These MDSCs are also associated with release of DAMPs such as HMGB1, vimentin, hsp72 into the tumor microenvironment.", [["MDSCs", "ANATOMY", 6, 11], ["tumor", "ANATOMY", 94, 99], ["tumor", "DISEASE", 94, 99], ["MDSCs", "CELL", 6, 11], ["DAMPs", "GENE_OR_GENE_PRODUCT", 48, 53], ["HMGB1", "GENE_OR_GENE_PRODUCT", 62, 67], ["vimentin", "GENE_OR_GENE_PRODUCT", 69, 77], ["hsp72", "GENE_OR_GENE_PRODUCT", 79, 84], ["tumor", "CANCER", 94, 99], ["MDSCs", "CELL_TYPE", 6, 11], ["DAMPs", "PROTEIN", 48, 53], ["HMGB1", "PROTEIN", 62, 67], ["vimentin", "PROTEIN", 69, 77], ["hsp72", "PROTEIN", 79, 84], ["DAMPs", "PROBLEM", 48, 53], ["HMGB1", "TEST", 62, 67], ["vimentin", "TREATMENT", 69, 77], ["MDSCs", "OBSERVATION", 6, 11], ["DAMPs", "OBSERVATION", 48, 53], ["tumor", "OBSERVATION", 94, 99]]], ["HMGB1 is recognized by TLR4 and TLR9, whereas hsp72, vimentin and HMGB1, all act as ligands for TLR2, which upon activation initiate a series of inflammatory processes associated with cancer development and progression [176, 203] .TLRs as therapeutic targetsExtensive studies over the years have revealed a broad array of role played by TLRs in activation of innate immune response against various infectious agents and intrinsic molecules suggesting its potential as a therapeutic target.", [["cancer", "ANATOMY", 184, 190], ["cancer", "DISEASE", 184, 190], ["HMGB1", "GENE_OR_GENE_PRODUCT", 0, 5], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["TLR9", "GENE_OR_GENE_PRODUCT", 32, 36], ["hsp72", "GENE_OR_GENE_PRODUCT", 46, 51], ["vimentin", "GENE_OR_GENE_PRODUCT", 53, 61], ["HMGB1", "GENE_OR_GENE_PRODUCT", 66, 71], ["TLR2", "GENE_OR_GENE_PRODUCT", 96, 100], ["cancer", "CANCER", 184, 190], ["TLRs", "GENE_OR_GENE_PRODUCT", 231, 235], ["TLRs", "GENE_OR_GENE_PRODUCT", 337, 341], ["HMGB1", "PROTEIN", 0, 5], ["TLR4", "PROTEIN", 23, 27], ["TLR9", "PROTEIN", 32, 36], ["hsp72", "PROTEIN", 46, 51], ["vimentin", "PROTEIN", 53, 61], ["HMGB1", "PROTEIN", 66, 71], ["TLR2", "PROTEIN", 96, 100], ["TLRs", "PROTEIN", 231, 235], ["TLRs", "PROTEIN", 337, 341], ["HMGB1", "TEST", 0, 5], ["TLR9", "TEST", 32, 36], ["hsp72", "TEST", 46, 51], ["vimentin", "TEST", 53, 61], ["HMGB1", "TEST", 66, 71], ["TLR2", "TEST", 96, 100], ["inflammatory processes", "PROBLEM", 145, 167], ["cancer development", "PROBLEM", 184, 202], ["TLRs", "TREATMENT", 231, 235], ["Extensive studies", "TEST", 258, 275], ["innate immune response", "TREATMENT", 359, 381], ["various infectious agents", "TREATMENT", 390, 415], ["intrinsic molecules", "PROBLEM", 420, 439], ["TLR4", "OBSERVATION_MODIFIER", 23, 27], ["inflammatory", "OBSERVATION", 145, 157], ["cancer", "OBSERVATION", 184, 190]]], ["Dysregulation of TLR in induction of pro-inflammatory signalling cascade leads to continued cytokines and chemokines secretion.", [["TLR", "GENE_OR_GENE_PRODUCT", 17, 20], ["TLR", "PROTEIN", 17, 20], ["cytokines", "PROTEIN", 92, 101], ["chemokines", "PROTEIN", 106, 116], ["Dysregulation of TLR", "PROBLEM", 0, 20], ["pro-inflammatory signalling cascade", "TREATMENT", 37, 72], ["chemokines secretion", "PROBLEM", 106, 126], ["TLR", "OBSERVATION_MODIFIER", 17, 20]]], ["This makes TLRs a causative reason for several diseases such as auto-immune disorders, systemic lupus erythematosus (SLE), asthma, allergic rhinitis and ischemia reperfusion injury [223] .TLRs as therapeutic targetsConsequently, TLRs are being targeted in a dual way -by development of small molecule ligands (agonists) which have the ability to bind with TLRs and augment host immune capabilities and also act as adjuvants in vaccine therapies and by inhibiting TLRs through specific antibodies, small molecule inhibitors, oligopeptides and by improving endogenous anti-TLR molecules.", [["auto-immune disorders", "DISEASE", 64, 85], ["systemic lupus erythematosus", "DISEASE", 87, 115], ["SLE", "DISEASE", 117, 120], ["asthma", "DISEASE", 123, 129], ["allergic rhinitis", "DISEASE", 131, 148], ["ischemia reperfusion injury", "DISEASE", 153, 180], ["TLRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["TLRs", "GENE_OR_GENE_PRODUCT", 188, 192], ["TLRs", "GENE_OR_GENE_PRODUCT", 229, 233], ["TLRs", "GENE_OR_GENE_PRODUCT", 356, 360], ["TLRs", "GENE_OR_GENE_PRODUCT", 463, 467], ["anti-TLR", "GENE_OR_GENE_PRODUCT", 566, 574], ["TLRs", "PROTEIN", 11, 15], ["TLRs", "PROTEIN", 188, 192], ["TLRs", "PROTEIN", 229, 233], ["TLRs", "PROTEIN", 356, 360], ["TLRs", "PROTEIN", 463, 467], ["antibodies", "PROTEIN", 485, 495], ["anti-TLR molecules", "PROTEIN", 566, 584], ["several diseases", "PROBLEM", 39, 55], ["auto-immune disorders", "PROBLEM", 64, 85], ["systemic lupus erythematosus", "PROBLEM", 87, 115], ["SLE)", "PROBLEM", 117, 121], ["asthma", "PROBLEM", 123, 129], ["allergic rhinitis", "PROBLEM", 131, 148], ["ischemia reperfusion injury", "PROBLEM", 153, 180], ["TLRs", "TREATMENT", 188, 192], ["small molecule ligands", "PROBLEM", 286, 308], ["TLRs and augment host immune capabilities", "TREATMENT", 356, 397], ["vaccine therapies", "TREATMENT", 427, 444], ["specific antibodies", "TEST", 476, 495], ["small molecule inhibitors", "TREATMENT", 497, 522], ["oligopeptides", "TREATMENT", 524, 537], ["improving endogenous anti-TLR molecules", "PROBLEM", 545, 584], ["systemic", "OBSERVATION_MODIFIER", 87, 95], ["lupus erythematosus", "OBSERVATION", 96, 115], ["allergic rhinitis", "OBSERVATION", 131, 148], ["ischemia", "OBSERVATION_MODIFIER", 153, 161], ["reperfusion", "OBSERVATION_MODIFIER", 162, 173], ["small", "OBSERVATION_MODIFIER", 286, 291], ["molecule ligands", "OBSERVATION", 292, 308]]], ["Also, negative regulation of signalling pathways involving TLRs are also gaining interest as a novel therapeutic strategy.", [["TLRs", "GENE_OR_GENE_PRODUCT", 59, 63], ["TLRs", "PROTEIN", 59, 63], ["a novel therapeutic strategy", "TREATMENT", 93, 121]]], ["Apart from infectious and inflammatory diseases, targeting TLRs have demonstrated promising effects in non-infectious diseases, including lung airway disease, ALI, and interstitial lung disease (ILD) [224] .TLR agonistsEmerging data have shown that TLRs like TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 are linked with various diseases and could be activated by agonists making them compelling immunomodulators and adjuvants.", [["lung airway", "ANATOMY", 138, 149], ["interstitial lung", "ANATOMY", 168, 185], ["infectious and inflammatory diseases", "DISEASE", 11, 47], ["non-infectious diseases", "DISEASE", 103, 126], ["lung airway disease", "DISEASE", 138, 157], ["ALI", "DISEASE", 159, 162], ["interstitial lung disease", "DISEASE", 168, 193], ["ILD", "DISEASE", 195, 198], ["TLRs", "GENE_OR_GENE_PRODUCT", 59, 63], ["lung airway", "MULTI-TISSUE_STRUCTURE", 138, 149], ["lung", "ORGAN", 181, 185], ["TLR", "GENE_OR_GENE_PRODUCT", 207, 210], ["TLRs", "GENE_OR_GENE_PRODUCT", 249, 253], ["TLR2", "GENE_OR_GENE_PRODUCT", 259, 263], ["TLR3", "GENE_OR_GENE_PRODUCT", 265, 269], ["TLR4", "GENE_OR_GENE_PRODUCT", 271, 275], ["TLR5", "GENE_OR_GENE_PRODUCT", 277, 281], ["TLR7", "GENE_OR_GENE_PRODUCT", 283, 287], ["TLR9", "GENE_OR_GENE_PRODUCT", 292, 296], ["TLRs", "PROTEIN", 59, 63], ["TLR", "PROTEIN", 207, 210], ["TLRs", "PROTEIN", 249, 253], ["TLR2", "PROTEIN", 259, 263], ["TLR3", "PROTEIN", 265, 269], ["TLR4", "PROTEIN", 271, 275], ["TLR5", "PROTEIN", 277, 281], ["TLR7", "PROTEIN", 283, 287], ["TLR9", "PROTEIN", 292, 296], ["infectious and inflammatory diseases", "PROBLEM", 11, 47], ["non-infectious diseases", "PROBLEM", 103, 126], ["lung airway disease", "PROBLEM", 138, 157], ["ALI", "PROBLEM", 159, 162], ["interstitial lung disease (ILD)", "PROBLEM", 168, 199], ["Emerging data", "TEST", 219, 232], ["TLR5", "TREATMENT", 277, 281], ["TLR7", "TREATMENT", 283, 287], ["TLR9", "TREATMENT", 292, 296], ["various diseases", "PROBLEM", 313, 329], ["compelling immunomodulators", "TREATMENT", 377, 404], ["adjuvants", "TREATMENT", 409, 418], ["infectious", "OBSERVATION_MODIFIER", 11, 21], ["inflammatory", "OBSERVATION_MODIFIER", 26, 38], ["promising", "OBSERVATION_MODIFIER", 82, 91], ["effects", "OBSERVATION_MODIFIER", 92, 99], ["non-infectious", "OBSERVATION_MODIFIER", 103, 117], ["lung", "ANATOMY", 138, 142], ["airway disease", "OBSERVATION", 143, 157], ["ALI", "OBSERVATION", 159, 162], ["interstitial", "ANATOMY_MODIFIER", 168, 180], ["lung", "ANATOMY", 181, 185], ["disease", "OBSERVATION", 186, 193]]], ["These agonists are catalogued either as cell surface or intracellular molecules on the basis of TLRs location.", [["cell surface", "ANATOMY", 40, 52], ["intracellular", "ANATOMY", 56, 69], ["cell surface", "CELLULAR_COMPONENT", 40, 52], ["intracellular molecules", "CELLULAR_COMPONENT", 56, 79], ["TLRs", "GENE_OR_GENE_PRODUCT", 96, 100], ["intracellular molecules", "PROTEIN", 56, 79], ["TLRs", "PROTEIN", 96, 100], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["intracellular molecules", "OBSERVATION", 56, 79]]], ["TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are cell surface TLRs whereas TLR3, TLR7, TLR8 and TLR9 are included in intracellular TLRs [225] .", [["cell surface", "ANATOMY", 44, 56], ["intracellular", "ANATOMY", 112, 125], ["TLR1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR2", "GENE_OR_GENE_PRODUCT", 6, 10], ["TLR4", "GENE_OR_GENE_PRODUCT", 12, 16], ["TLR5", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR6", "GENE_OR_GENE_PRODUCT", 24, 28], ["TLR10", "GENE_OR_GENE_PRODUCT", 34, 39], ["cell", "CELL", 44, 48], ["TLRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR3", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR7", "GENE_OR_GENE_PRODUCT", 76, 80], ["TLR8", "GENE_OR_GENE_PRODUCT", 82, 86], ["TLR9", "GENE_OR_GENE_PRODUCT", 91, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 125], ["TLR1", "PROTEIN", 0, 4], ["TLR2", "PROTEIN", 6, 10], ["TLR4", "PROTEIN", 12, 16], ["TLR5", "PROTEIN", 18, 22], ["TLR6", "PROTEIN", 24, 28], ["TLR10", "PROTEIN", 34, 39], ["cell surface TLRs", "PROTEIN", 44, 61], ["TLR3", "PROTEIN", 70, 74], ["TLR7", "PROTEIN", 76, 80], ["TLR8", "PROTEIN", 82, 86], ["TLR9", "PROTEIN", 91, 95], ["intracellular TLRs", "PROTEIN", 112, 130], ["TLR1", "TEST", 0, 4], ["TLR2", "TEST", 6, 10], ["TLR4", "TEST", 12, 16], ["TLR5", "TEST", 18, 22], ["TLR6", "TEST", 24, 28], ["cell surface TLRs", "TEST", 44, 61], ["TLR3", "TEST", 70, 74], ["TLR7", "TEST", 76, 80], ["TLR8", "TEST", 82, 86], ["TLR9", "TEST", 91, 95], ["TLR2", "ANATOMY_MODIFIER", 6, 10], ["TLR7", "ANATOMY", 76, 80], ["TLR8", "ANATOMY", 82, 86]]], ["TLR4 is unique in itself as it can be active on the cell surface and also intracellularly in specific cells [225] .", [["cell surface", "ANATOMY", 52, 64], ["cells", "ANATOMY", 102, 107], ["TLR4", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell surface", "CELLULAR_COMPONENT", 52, 64], ["cells", "CELL", 102, 107], ["TLR4", "PROTEIN", 0, 4], ["active", "OBSERVATION_MODIFIER", 38, 44]]], ["The microbial component, LPS, can activate TLR4 and its signalling by inducing the formation of a symmetric M-shaped TLR4-MD-2-LPS multimer which, in turn stimulates the production of TNF-\u03b1, as well as increase the production of inducible nitric oxide synthase (iNOS) in tumor cells, making it a possible therapeutic strategy for lung cancer treatment [226] .", [["tumor cells", "ANATOMY", 271, 282], ["lung cancer", "ANATOMY", 330, 341], ["LPS", "CHEMICAL", 25, 28], ["nitric oxide", "CHEMICAL", 239, 251], ["tumor", "DISEASE", 271, 276], ["lung cancer", "DISEASE", 330, 341], ["nitric oxide", "CHEMICAL", 239, 251], ["LPS", "SIMPLE_CHEMICAL", 25, 28], ["TLR4", "GENE_OR_GENE_PRODUCT", 43, 47], ["TLR4", "GENE_OR_GENE_PRODUCT", 117, 121], ["MD-2", "GENE_OR_GENE_PRODUCT", 122, 126], ["LPS multimer", "GENE_OR_GENE_PRODUCT", 127, 139], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 184, 189], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 229, 260], ["iNOS", "GENE_OR_GENE_PRODUCT", 262, 266], ["tumor cells", "CELL", 271, 282], ["lung cancer", "CANCER", 330, 341], ["TLR4", "PROTEIN", 43, 47], ["TLR4", "PROTEIN", 117, 121], ["LPS multimer", "PROTEIN", 127, 139], ["TNF-\u03b1", "PROTEIN", 184, 189], ["nitric oxide synthase", "PROTEIN", 239, 260], ["iNOS", "PROTEIN", 262, 266], ["tumor cells", "CELL_TYPE", 271, 282], ["TNF", "TEST", 184, 187], ["inducible nitric oxide synthase", "TREATMENT", 229, 260], ["iNOS) in tumor cells", "PROBLEM", 262, 282], ["lung cancer treatment", "TREATMENT", 330, 351], ["microbial", "OBSERVATION_MODIFIER", 4, 13], ["component", "OBSERVATION_MODIFIER", 14, 23], ["LPS", "OBSERVATION_MODIFIER", 25, 28], ["symmetric", "OBSERVATION_MODIFIER", 98, 107], ["shaped", "OBSERVATION_MODIFIER", 110, 116], ["TLR4", "OBSERVATION_MODIFIER", 117, 121], ["nitric oxide synthase", "OBSERVATION", 239, 260], ["tumor cells", "OBSERVATION", 271, 282], ["lung", "ANATOMY", 330, 334], ["cancer", "OBSERVATION", 335, 341]]], ["A TLR4 agonist MPL (monophosphoryl lipid A), derived from lipid A of Salmonella minnesota is an approved vaccine adjuvant in the Europe for hepatitis B and HPV virus [227] .", [["MPL", "CHEMICAL", 15, 18], ["monophosphoryl lipid A", "CHEMICAL", 20, 42], ["hepatitis B", "DISEASE", 140, 151], ["monophosphoryl lipid A", "CHEMICAL", 20, 42], ["TLR4", "GENE_OR_GENE_PRODUCT", 2, 6], ["MPL", "SIMPLE_CHEMICAL", 15, 18], ["monophosphoryl lipid A", "SIMPLE_CHEMICAL", 20, 42], ["lipid A", "SIMPLE_CHEMICAL", 58, 65], ["Salmonella minnesota", "ORGANISM", 69, 89], ["hepatitis B", "ORGANISM", 140, 151], ["HPV virus", "ORGANISM", 156, 165], ["TLR4", "PROTEIN", 2, 6], ["Salmonella minnesota", "SPECIES", 69, 89], ["HPV virus", "SPECIES", 156, 165], ["Salmonella minnesota", "SPECIES", 69, 89], ["hepatitis B", "SPECIES", 140, 151], ["HPV virus", "SPECIES", 156, 165], ["A TLR4 agonist MPL (monophosphoryl lipid A", "TREATMENT", 0, 42], ["Salmonella minnesota", "TREATMENT", 69, 89], ["an approved vaccine adjuvant", "TREATMENT", 93, 121], ["hepatitis B", "PROBLEM", 140, 151], ["HPV virus", "PROBLEM", 156, 165]]], ["Further, MPL works potently as an adjuvant in allergy vaccines and is used to treat asthma as it specifically activates the TRAM/TRIF pathway in TLR4 signalling and regulates CD80/86 complex which is vital for conferring MPL vaccine adjuvant ability [228] .", [["allergy", "DISEASE", 46, 53], ["asthma", "DISEASE", 84, 90], ["MPL", "GENE_OR_GENE_PRODUCT", 9, 12], ["TRAM", "GENE_OR_GENE_PRODUCT", 124, 128], ["TRIF", "GENE_OR_GENE_PRODUCT", 129, 133], ["TLR4", "GENE_OR_GENE_PRODUCT", 145, 149], ["CD80", "GENE_OR_GENE_PRODUCT", 175, 179], ["86", "GENE_OR_GENE_PRODUCT", 180, 182], ["MPL", "GENE_OR_GENE_PRODUCT", 221, 224], ["TRAM", "PROTEIN", 124, 128], ["TRIF", "PROTEIN", 129, 133], ["TLR4", "PROTEIN", 145, 149], ["CD80", "PROTEIN", 175, 179], ["86 complex", "PROTEIN", 180, 190], ["an adjuvant in allergy vaccines", "TREATMENT", 31, 62], ["asthma", "PROBLEM", 84, 90], ["the TRAM/TRIF pathway", "TREATMENT", 120, 141], ["conferring MPL vaccine adjuvant", "TREATMENT", 210, 241]]], ["MPL is also recently being used in combination with other molecules to synthesize novel vaccines such as Pollinex Quattro, which is currently in a Phase III clinical trial against seasonal airway allergies [229, 230] .", [["airway", "ANATOMY", 189, 195], ["Pollinex Quattro", "CHEMICAL", 105, 121], ["airway allergies", "DISEASE", 189, 205], ["MPL", "GENE_OR_GENE_PRODUCT", 0, 3], ["airway", "ORGAN", 189, 195], ["other molecules", "TREATMENT", 52, 67], ["synthesize novel vaccines", "TREATMENT", 71, 96], ["Pollinex Quattro", "TREATMENT", 105, 121], ["seasonal airway allergies", "PROBLEM", 180, 205], ["airway", "ANATOMY", 189, 195]]], ["In addition, OM-174, a TLR4 agonist which is a purified form of lipid-A developed from E. coli has demonstrated anti-tumor activity in mice models by increasing IFN-\u03b3 production [231, 232] .", [["OM-174", "CHEMICAL", 13, 19], ["lipid-A", "CHEMICAL", 64, 71], ["OM-174", "CHEMICAL", 13, 19], ["OM-174", "SIMPLE_CHEMICAL", 13, 19], ["TLR4", "GENE_OR_GENE_PRODUCT", 23, 27], ["lipid-A", "SIMPLE_CHEMICAL", 64, 71], ["E. coli", "ORGANISM", 87, 94], ["anti-tumor", "CANCER", 112, 122], ["mice", "ORGANISM", 135, 139], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 161, 166], ["TLR4", "PROTEIN", 23, 27], ["IFN", "PROTEIN", 161, 164], ["\u03b3", "PROTEIN", 165, 166], ["E. coli", "SPECIES", 87, 94], ["mice", "SPECIES", 135, 139], ["E. coli", "SPECIES", 87, 94], ["mice", "SPECIES", 135, 139], ["OM", "TEST", 13, 15], ["a TLR4 agonist", "TREATMENT", 21, 35], ["E. coli", "PROBLEM", 87, 94], ["anti-tumor activity in mice models", "PROBLEM", 112, 146], ["increasing IFN", "PROBLEM", 150, 164], ["anti-tumor activity", "OBSERVATION", 112, 131], ["increasing", "OBSERVATION_MODIFIER", 150, 160]]], ["Few chemically synthesized TLR4 agonists, for example E6020 are vaccine adjuvants [233, 234] .", [["E6020", "CHEMICAL", 54, 59], ["TLR4", "GENE_OR_GENE_PRODUCT", 27, 31], ["E6020", "SIMPLE_CHEMICAL", 54, 59], ["TLR4", "PROTEIN", 27, 31], ["Few chemically synthesized TLR4 agonists", "TREATMENT", 0, 40], ["vaccine adjuvants", "TREATMENT", 64, 81], ["TLR4 agonists", "OBSERVATION", 27, 40]]], ["Apart from this, the aminoalkyl glucosaminide phosphates which are lipid A derivatives, are safe and effective adjuvants for influenza virus vaccine [235, 236] .", [["aminoalkyl glucosaminide phosphates", "CHEMICAL", 21, 56], ["influenza virus", "DISEASE", 125, 140], ["aminoalkyl glucosaminide phosphates", "CHEMICAL", 21, 56], ["aminoalkyl glucosaminide phosphates", "SIMPLE_CHEMICAL", 21, 56], ["lipid A derivatives", "SIMPLE_CHEMICAL", 67, 86], ["influenza virus", "ORGANISM", 125, 140], ["influenza virus vaccine", "SPECIES", 125, 148], ["the aminoalkyl glucosaminide phosphates", "TREATMENT", 17, 56], ["lipid A derivatives", "TREATMENT", 67, 86], ["safe and effective adjuvants", "TREATMENT", 92, 120], ["influenza virus vaccine", "TREATMENT", 125, 148]]], ["In a murine model of allergic type lung inflammation, poly-\u03b3-glutamic acid (\u03b3-PGA) which is a TLR4 agonist is seen to cause downregulation of Th2 cytokines, airway inflammation and eosinophilia while increasing the manifestation of co-stimulatory molecules, CD80, CD86 and CD40 on dendritic cells [237] .", [["lung", "ANATOMY", 35, 39], ["airway", "ANATOMY", 157, 163], ["dendritic cells", "ANATOMY", 281, 296], ["allergic type lung inflammation", "DISEASE", 21, 52], ["poly-\u03b3-glutamic acid", "CHEMICAL", 54, 74], ["\u03b3-PGA", "CHEMICAL", 76, 81], ["airway inflammation", "DISEASE", 157, 176], ["eosinophilia", "DISEASE", 181, 193], ["poly-\u03b3-glutamic acid", "CHEMICAL", 54, 74], ["\u03b3-PGA", "CHEMICAL", 76, 81], ["murine", "ORGANISM", 5, 11], ["lung", "ORGAN", 35, 39], ["poly-\u03b3-glutamic acid", "SIMPLE_CHEMICAL", 54, 74], ["\u03b3-PGA", "SIMPLE_CHEMICAL", 76, 81], ["TLR4", "GENE_OR_GENE_PRODUCT", 94, 98], ["Th2", "GENE_OR_GENE_PRODUCT", 142, 145], ["airway", "MULTI-TISSUE_STRUCTURE", 157, 163], ["CD80", "GENE_OR_GENE_PRODUCT", 258, 262], ["CD86", "GENE_OR_GENE_PRODUCT", 264, 268], ["CD40", "GENE_OR_GENE_PRODUCT", 273, 277], ["dendritic cells", "CELL", 281, 296], ["TLR4", "PROTEIN", 94, 98], ["Th2 cytokines", "PROTEIN", 142, 155], ["co-stimulatory molecules", "PROTEIN", 232, 256], ["CD80", "PROTEIN", 258, 262], ["CD86", "PROTEIN", 264, 268], ["CD40", "PROTEIN", 273, 277], ["dendritic cells", "CELL_TYPE", 281, 296], ["murine", "SPECIES", 5, 11], ["allergic type lung inflammation", "PROBLEM", 21, 52], ["poly", "TEST", 54, 58], ["glutamic acid", "TEST", 61, 74], ["a TLR4 agonist", "TREATMENT", 92, 106], ["Th2 cytokines", "PROBLEM", 142, 155], ["airway inflammation", "PROBLEM", 157, 176], ["eosinophilia", "PROBLEM", 181, 193], ["co-stimulatory molecules", "TEST", 232, 256], ["CD80", "TEST", 258, 262], ["CD86", "TEST", 264, 268], ["dendritic cells", "PROBLEM", 281, 296], ["allergic type", "OBSERVATION", 21, 34], ["lung", "ANATOMY", 35, 39], ["inflammation", "OBSERVATION", 40, 52], ["Th2 cytokines", "OBSERVATION", 142, 155], ["airway", "ANATOMY", 157, 163], ["inflammation", "OBSERVATION", 164, 176], ["eosinophilia", "OBSERVATION", 181, 193], ["dendritic cells", "OBSERVATION", 281, 296]]], ["Recently, a synthetic TLR4 agonist (ER803022) has been developed which shows potential against asthma in mouse models in a TLR-dependent MyD88 activation and IL-12/IFN-\u03b3 production [238] .", [["ER803022", "CHEMICAL", 36, 44], ["asthma", "DISEASE", 95, 101], ["ER803022", "CHEMICAL", 36, 44], ["TLR4", "GENE_OR_GENE_PRODUCT", 22, 26], ["ER803022", "SIMPLE_CHEMICAL", 36, 44], ["mouse", "ORGANISM", 105, 110], ["TLR", "GENE_OR_GENE_PRODUCT", 123, 126], ["MyD88", "GENE_OR_GENE_PRODUCT", 137, 142], ["IL-12", "GENE_OR_GENE_PRODUCT", 158, 163], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 164, 169], ["TLR4", "PROTEIN", 22, 26], ["TLR", "PROTEIN", 123, 126], ["MyD88", "PROTEIN", 137, 142], ["IFN", "PROTEIN", 164, 167], ["mouse", "SPECIES", 105, 110], ["mouse", "SPECIES", 105, 110], ["asthma in mouse models", "PROBLEM", 95, 117], ["IL", "TEST", 158, 160], ["IFN", "PROBLEM", 164, 167], ["potential against", "UNCERTAINTY", 77, 94], ["asthma", "OBSERVATION", 95, 101]]], ["TLR2 is LPS receptor and identifies several ligands especially that of Gram-positive bacteria, a synthetic TLR2 agonist known as Pam3CSK4 shows anti-asthmatic properties by reducing Th2 cytokine release, airway inflammation and other symptom.", [["airway", "ANATOMY", 204, 210], ["Pam3CSK4", "CHEMICAL", 129, 137], ["airway inflammation", "DISEASE", 204, 223], ["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["LPS receptor", "GENE_OR_GENE_PRODUCT", 8, 20], ["Gram", "GENE_OR_GENE_PRODUCT", 71, 75], ["TLR2", "GENE_OR_GENE_PRODUCT", 107, 111], ["Pam3CSK4", "SIMPLE_CHEMICAL", 129, 137], ["Th2 cytokine", "GENE_OR_GENE_PRODUCT", 182, 194], ["airway", "MULTI-TISSUE_STRUCTURE", 204, 210], ["TLR2", "PROTEIN", 0, 4], ["LPS receptor", "PROTEIN", 8, 20], ["TLR2", "PROTEIN", 107, 111], ["Th2 cytokine", "PROTEIN", 182, 194], ["LPS receptor", "TEST", 8, 20], ["several ligands", "PROBLEM", 36, 51], ["Gram", "TEST", 71, 75], ["positive bacteria", "PROBLEM", 76, 93], ["a synthetic TLR2 agonist", "TREATMENT", 95, 119], ["Pam3CSK4", "TEST", 129, 137], ["anti-asthmatic properties", "TREATMENT", 144, 169], ["Th2 cytokine release", "TREATMENT", 182, 202], ["airway inflammation", "PROBLEM", 204, 223], ["other symptom", "PROBLEM", 228, 241], ["positive bacteria", "OBSERVATION_MODIFIER", 76, 93], ["anti-asthmatic properties", "OBSERVATION", 144, 169], ["airway", "ANATOMY", 204, 210], ["inflammation", "OBSERVATION", 211, 223]]], ["Pam3CSK4 has two thioester linked lipid chains through which it binds to a TLR2 pocket and a small channel of TLR1, hence forming a bridge between the two molecules [239] .", [["Pam3CSK4", "CHEMICAL", 0, 8], ["thioester", "CHEMICAL", 17, 26], ["Pam3CSK4", "SIMPLE_CHEMICAL", 0, 8], ["TLR2", "GENE_OR_GENE_PRODUCT", 75, 79], ["TLR1", "GENE_OR_GENE_PRODUCT", 110, 114], ["TLR2 pocket", "PROTEIN", 75, 86], ["TLR1", "PROTEIN", 110, 114], ["Pam3CSK4", "TREATMENT", 0, 8], ["two thioester linked lipid chains", "TREATMENT", 13, 46], ["a TLR2 pocket", "TREATMENT", 73, 86], ["a small channel of TLR1", "TREATMENT", 91, 114], ["lipid chains", "OBSERVATION", 34, 46], ["small channel", "OBSERVATION_MODIFIER", 93, 106]]], ["SMP-105 is a TLR2 agonist from Mycobacterium bovis that consists of mycolic acids, and peptidoglycans is an approved drug for bladder cancer [240] .", [["bladder cancer", "ANATOMY", 126, 140], ["SMP-105", "CHEMICAL", 0, 7], ["mycolic acids", "CHEMICAL", 68, 81], ["peptidoglycans", "CHEMICAL", 87, 101], ["bladder cancer", "DISEASE", 126, 140], ["mycolic acids", "CHEMICAL", 68, 81], ["SMP-105", "GENE_OR_GENE_PRODUCT", 0, 7], ["TLR2", "GENE_OR_GENE_PRODUCT", 13, 17], ["Mycobacterium bovis", "ORGANISM", 31, 50], ["mycolic acids", "SIMPLE_CHEMICAL", 68, 81], ["peptidoglycans", "SIMPLE_CHEMICAL", 87, 101], ["bladder cancer", "CANCER", 126, 140], ["TLR2", "PROTEIN", 13, 17], ["Mycobacterium bovis", "SPECIES", 31, 50], ["Mycobacterium bovis", "SPECIES", 31, 50], ["SMP", "TEST", 0, 3], ["a TLR2 agonist", "TREATMENT", 11, 25], ["Mycobacterium bovis", "PROBLEM", 31, 50], ["mycolic acids", "PROBLEM", 68, 81], ["peptidoglycans", "PROBLEM", 87, 101], ["bladder cancer", "PROBLEM", 126, 140], ["Mycobacterium bovis", "OBSERVATION", 31, 50], ["mycolic acids", "OBSERVATION", 68, 81], ["bladder", "ANATOMY", 126, 133], ["cancer", "OBSERVATION", 134, 140]]], ["This compound upregulates NF-\u03ba\u03b2 in a TLR2 dependent and TLR4 independent manner leading to decrease in TNF-\u03b1 and IL-6 levels and can be used as an adjuvant as anti-inflammatory agent [240] .", [["NF-\u03ba\u03b2", "GENE_OR_GENE_PRODUCT", 26, 31], ["TLR2", "GENE_OR_GENE_PRODUCT", 37, 41], ["TLR4", "GENE_OR_GENE_PRODUCT", 56, 60], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-6", "GENE_OR_GENE_PRODUCT", 113, 117], ["NF-\u03ba\u03b2", "PROTEIN", 26, 31], ["TLR2", "PROTEIN", 37, 41], ["TLR4", "PROTEIN", 56, 60], ["TNF", "PROTEIN", 103, 106], ["This compound upregulates NF", "PROBLEM", 0, 28], ["TNF", "TEST", 103, 106], ["IL", "TEST", 113, 115], ["an adjuvant as anti-inflammatory agent", "TREATMENT", 144, 182], ["upregulates", "OBSERVATION_MODIFIER", 14, 25], ["NF", "OBSERVATION_MODIFIER", 26, 28], ["TLR2 dependent", "OBSERVATION_MODIFIER", 37, 51], ["TLR4 independent", "OBSERVATION_MODIFIER", 56, 72], ["decrease", "OBSERVATION_MODIFIER", 91, 99]]], ["Another ligand, Macrophage activating lipopeptide-2 (MALP-2) binds to TLR2/ TLR6 heterodimer and is effective against asthma.", [["asthma", "DISEASE", 118, 124], ["Macrophage activating lipopeptide-2", "GENE_OR_GENE_PRODUCT", 16, 51], ["MALP-2", "GENE_OR_GENE_PRODUCT", 53, 59], ["TLR2", "GENE_OR_GENE_PRODUCT", 70, 74], ["TLR6", "GENE_OR_GENE_PRODUCT", 76, 80], ["Macrophage activating lipopeptide-2 (MALP-2", "PROTEIN", 16, 59], ["TLR2", "PROTEIN", 70, 74], ["TLR6 heterodimer", "PROTEIN", 76, 92], ["Another ligand", "TREATMENT", 0, 14], ["Macrophage activating lipopeptide", "TREATMENT", 16, 49], ["MALP", "TEST", 53, 57], ["TLR2/ TLR6 heterodimer", "TREATMENT", 70, 92], ["asthma", "PROBLEM", 118, 124], ["asthma", "OBSERVATION", 118, 124]]], ["It is acquired from Mycoplasma fermentans and induces IFN-\u03b3, CD80 (B7-1), CD86 (B7-2), MHC I and II in response to allergies [241] .", [["allergies", "DISEASE", 115, 124], ["Mycoplasma fermentans", "ORGANISM", 20, 41], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 54, 59], ["CD80", "GENE_OR_GENE_PRODUCT", 61, 65], ["B7-1", "GENE_OR_GENE_PRODUCT", 67, 71], ["CD86", "GENE_OR_GENE_PRODUCT", 74, 78], ["B7-2", "GENE_OR_GENE_PRODUCT", 80, 84], ["MHC I", "GENE_OR_GENE_PRODUCT", 87, 92], ["IFN", "PROTEIN", 54, 57], ["\u03b3", "PROTEIN", 58, 59], ["CD80", "PROTEIN", 61, 65], ["B7", "PROTEIN", 67, 69], ["CD86", "PROTEIN", 74, 78], ["B7", "PROTEIN", 80, 82], ["MHC I and II", "PROTEIN", 87, 99], ["Mycoplasma fermentans", "SPECIES", 20, 41], ["Mycoplasma fermentans", "SPECIES", 20, 41], ["Mycoplasma fermentans", "TEST", 20, 41], ["IFN", "TEST", 54, 57], ["CD80", "TEST", 61, 65], ["B7", "TEST", 67, 69], ["CD86", "TEST", 74, 78], ["B7", "TEST", 80, 82], ["Mycoplasma fermentans", "OBSERVATION", 20, 41]]], ["A study showed that in a murine model of asthma, MALP-2 causes the decrease of AHR, eosinophilia and Th2 cytokines.", [["asthma", "DISEASE", 41, 47], ["eosinophilia", "DISEASE", 84, 96], ["murine", "ORGANISM", 25, 31], ["MALP-2", "GENE_OR_GENE_PRODUCT", 49, 55], ["AHR", "GENE_OR_GENE_PRODUCT", 79, 82], ["AHR", "PROTEIN", 79, 82], ["Th2 cytokines", "PROTEIN", 101, 114], ["murine", "SPECIES", 25, 31], ["A study", "TEST", 0, 7], ["asthma", "PROBLEM", 41, 47], ["MALP", "TEST", 49, 53], ["the decrease of AHR", "PROBLEM", 63, 82], ["eosinophilia", "PROBLEM", 84, 96], ["Th2 cytokines", "PROBLEM", 101, 114], ["asthma", "OBSERVATION", 41, 47], ["decrease", "OBSERVATION_MODIFIER", 67, 75], ["eosinophilia", "OBSERVATION", 84, 96], ["Th2 cytokines", "OBSERVATION", 101, 114]]], ["In addition, it stimulates T cell, B cell and natural killer cell accumulation in lungs of adult mice [242] .", [["T cell", "ANATOMY", 27, 33], ["B cell", "ANATOMY", 35, 41], ["natural killer cell", "ANATOMY", 46, 65], ["lungs", "ANATOMY", 82, 87], ["T cell", "CELL", 27, 33], ["B cell", "CELL", 35, 41], ["natural killer cell", "CELL", 46, 65], ["lungs", "ORGAN", 82, 87], ["mice", "ORGANISM", 97, 101], ["T cell", "CELL_TYPE", 27, 33], ["B cell", "CELL_TYPE", 35, 41], ["natural killer cell", "CELL_TYPE", 46, 65], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 97, 101], ["natural killer cell accumulation", "TREATMENT", 46, 78], ["natural killer cell accumulation", "OBSERVATION", 46, 78], ["lungs", "ANATOMY", 82, 87]]], ["Similarly, Lipoprotein 1 and Lipopeptide-CGP40774 are TLR2 agonists capable of controlling asthma and airway inflammation by suppressing IgE production, IL-4 and IL-13 production [243, 244] .", [["airway", "ANATOMY", 102, 108], ["CGP40774", "CHEMICAL", 41, 49], ["asthma", "DISEASE", 91, 97], ["airway inflammation", "DISEASE", 102, 121], ["Lipoprotein 1", "GENE_OR_GENE_PRODUCT", 11, 24], ["Lipopeptide-CGP40774", "GENE_OR_GENE_PRODUCT", 29, 49], ["TLR2", "GENE_OR_GENE_PRODUCT", 54, 58], ["airway", "MULTI-TISSUE_STRUCTURE", 102, 108], ["IgE", "GENE_OR_GENE_PRODUCT", 137, 140], ["IL-4", "GENE_OR_GENE_PRODUCT", 153, 157], ["IL-13", "GENE_OR_GENE_PRODUCT", 162, 167], ["TLR2", "PROTEIN", 54, 58], ["IgE", "PROTEIN", 137, 140], ["Lipoprotein", "TEST", 11, 22], ["Lipopeptide", "TREATMENT", 29, 40], ["TLR2 agonists", "TREATMENT", 54, 67], ["controlling asthma", "PROBLEM", 79, 97], ["airway inflammation", "PROBLEM", 102, 121], ["suppressing IgE production", "PROBLEM", 125, 151], ["IL", "TEST", 153, 155], ["asthma", "OBSERVATION", 91, 97], ["airway", "ANATOMY", 102, 108], ["inflammation", "OBSERVATION", 109, 121]]], ["Accumulating evidence have indicated that activating TLR7 not only suppresses Th2mediated airway inflammation but also decreases the manifestation of IgE, additionally it significantly inhibits IL-17 and IL-13 production through IL-10 mediated pathway [245] .", [["airway", "ANATOMY", 90, 96], ["inflammation", "DISEASE", 97, 109], ["TLR7", "GENE_OR_GENE_PRODUCT", 53, 57], ["airway", "MULTI-TISSUE_STRUCTURE", 90, 96], ["IgE", "GENE_OR_GENE_PRODUCT", 150, 153], ["IL-17", "GENE_OR_GENE_PRODUCT", 194, 199], ["IL-13", "GENE_OR_GENE_PRODUCT", 204, 209], ["IL-10", "GENE_OR_GENE_PRODUCT", 229, 234], ["TLR7", "PROTEIN", 53, 57], ["IgE", "PROTEIN", 150, 153], ["activating TLR7", "PROBLEM", 42, 57], ["Th2mediated airway inflammation", "PROBLEM", 78, 109], ["IgE", "PROBLEM", 150, 153], ["IL", "TEST", 194, 196], ["IL", "TEST", 204, 206], ["airway", "ANATOMY", 90, 96], ["inflammation", "OBSERVATION", 97, 109], ["decreases", "OBSERVATION_MODIFIER", 119, 128]]], ["Therefore, TLR7 is thought to recuperate airway diseases such as asthma and allergic rhinitis.", [["airway", "ANATOMY", 41, 47], ["TLR7", "CHEMICAL", 11, 15], ["airway diseases", "DISEASE", 41, 56], ["asthma", "DISEASE", 65, 71], ["allergic rhinitis", "DISEASE", 76, 93], ["TLR7", "GENE_OR_GENE_PRODUCT", 11, 15], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["TLR7", "PROTEIN", 11, 15], ["TLR7", "TREATMENT", 11, 15], ["airway diseases", "PROBLEM", 41, 56], ["asthma", "PROBLEM", 65, 71], ["allergic rhinitis", "PROBLEM", 76, 93], ["thought to", "UNCERTAINTY", 19, 29], ["airway", "ANATOMY", 41, 47], ["diseases", "OBSERVATION", 48, 56], ["asthma", "OBSERVATION", 65, 71], ["allergic rhinitis", "OBSERVATION", 76, 93]]], ["Indeed, Imiquimod is a clinically approved TLR7 agonist for basal cell carcinoma, actinic keratosis and external genital wart [246, 247] .", [["basal cell carcinoma", "ANATOMY", 60, 80], ["actinic keratosis", "ANATOMY", 82, 99], ["genital wart", "ANATOMY", 113, 125], ["Imiquimod", "CHEMICAL", 8, 17], ["basal cell carcinoma", "DISEASE", 60, 80], ["actinic keratosis", "DISEASE", 82, 99], ["Imiquimod", "CHEMICAL", 8, 17], ["Imiquimod", "SIMPLE_CHEMICAL", 8, 17], ["TLR7", "GENE_OR_GENE_PRODUCT", 43, 47], ["basal cell carcinoma", "CANCER", 60, 80], ["TLR7", "PROTEIN", 43, 47], ["Imiquimod", "TREATMENT", 8, 17], ["a clinically approved TLR7 agonist", "TREATMENT", 21, 55], ["basal cell carcinoma", "PROBLEM", 60, 80], ["actinic keratosis", "PROBLEM", 82, 99], ["external genital wart", "PROBLEM", 104, 125], ["basal cell carcinoma", "OBSERVATION", 60, 80], ["external genital", "ANATOMY", 104, 120]]], ["This drug also works against asthma and viral induced lung and airway infection by increasing IFN-\u03b1 via TLR7-MYD88 dependent pathway.", [["lung", "ANATOMY", 54, 58], ["airway", "ANATOMY", 63, 69], ["asthma", "DISEASE", 29, 35], ["viral induced lung and airway infection", "DISEASE", 40, 79], ["lung", "ORGAN", 54, 58], ["airway", "MULTI-TISSUE_STRUCTURE", 63, 69], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 94, 99], ["TLR7", "GENE_OR_GENE_PRODUCT", 104, 108], ["MYD88", "GENE_OR_GENE_PRODUCT", 109, 114], ["IFN", "PROTEIN", 94, 97], ["TLR7", "PROTEIN", 104, 108], ["MYD88", "PROTEIN", 109, 114], ["asthma", "PROBLEM", 29, 35], ["viral induced lung and airway infection", "PROBLEM", 40, 79], ["increasing IFN", "TREATMENT", 83, 97], ["TLR7-MYD88 dependent pathway", "TREATMENT", 104, 132], ["lung", "ANATOMY", 54, 58], ["airway", "ANATOMY", 63, 69], ["infection", "OBSERVATION", 70, 79]]], ["Another compound Resiquimod (R-848), a TLR7 and TLR8 agonist displayed great tendency to induce IFN-\u03b1, IL-12 and TNF-\u03b1 production while reducing lung eosinophilia and airway inflammation in in vivo models [248, 249] .", [["lung", "ANATOMY", 145, 149], ["airway", "ANATOMY", 167, 173], ["Resiquimod", "CHEMICAL", 17, 27], ["R-848", "CHEMICAL", 29, 34], ["lung eosinophilia", "DISEASE", 145, 162], ["airway inflammation", "DISEASE", 167, 186], ["Resiquimod", "CHEMICAL", 17, 27], ["Resiquimod", "SIMPLE_CHEMICAL", 17, 27], ["R-848", "SIMPLE_CHEMICAL", 29, 34], ["TLR7", "GENE_OR_GENE_PRODUCT", 39, 43], ["TLR8", "GENE_OR_GENE_PRODUCT", 48, 52], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 96, 101], ["IL-12", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 113, 118], ["lung", "ORGAN", 145, 149], ["airway", "MULTI-TISSUE_STRUCTURE", 167, 173], ["TLR7", "PROTEIN", 39, 43], ["TLR8", "PROTEIN", 48, 52], ["IFN", "PROTEIN", 96, 99], ["TNF", "PROTEIN", 113, 116], ["a TLR7 and TLR8 agonist", "TREATMENT", 37, 60], ["great tendency", "PROBLEM", 71, 85], ["IFN", "TEST", 96, 99], ["IL", "TEST", 103, 105], ["TNF", "TEST", 113, 116], ["lung eosinophilia", "PROBLEM", 145, 162], ["airway inflammation", "PROBLEM", 167, 186], ["lung", "ANATOMY", 145, 149], ["eosinophilia", "OBSERVATION", 150, 162], ["airway", "ANATOMY", 167, 173], ["inflammation", "OBSERVATION", 174, 186]]], ["A synthetic TLR7 agonist SA-2 regulates T cell production through IFN-\u03b1, IL-27 and IL-10 and shows promising therapeutic potential [250] .", [["T cell", "ANATOMY", 40, 46], ["SA-2", "CHEMICAL", 25, 29], ["TLR7", "GENE_OR_GENE_PRODUCT", 12, 16], ["SA-2", "GENE_OR_GENE_PRODUCT", 25, 29], ["T cell", "CELL", 40, 46], ["IFN-\u03b1", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-27", "GENE_OR_GENE_PRODUCT", 73, 78], ["IL-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["TLR7", "PROTEIN", 12, 16], ["IFN", "PROTEIN", 66, 69], ["IL", "PROTEIN", 83, 85], ["A synthetic TLR7 agonist SA", "TEST", 0, 27], ["IFN", "TEST", 66, 69], ["IL", "TEST", 73, 75], ["IL", "TEST", 83, 85]]], ["ANA773 is a small molecule TLR7 agonist which is under phase I clinical trial for its anti-viral potential [251] .", [["ANA773", "CHEMICAL", 0, 6], ["ANA773", "CHEMICAL", 0, 6], ["ANA773", "SIMPLE_CHEMICAL", 0, 6], ["TLR7", "GENE_OR_GENE_PRODUCT", 27, 31], ["a small molecule TLR7 agonist", "TREATMENT", 10, 39]]], ["One of the most investigated class of compound developed for exacerbation of asthma known as CpG-ODN, is a TLR9 agonist [252] .", [["asthma", "DISEASE", 77, 83], ["CpG-ODN", "CHEMICAL", 93, 100], ["CpG", "CHEMICAL", 93, 96], ["CpG-ODN", "SIMPLE_CHEMICAL", 93, 100], ["TLR9", "GENE_OR_GENE_PRODUCT", 107, 111], ["TLR9", "PROTEIN", 107, 111], ["exacerbation", "PROBLEM", 61, 73], ["asthma", "PROBLEM", 77, 83], ["asthma", "OBSERVATION", 77, 83]]], ["It interacts with TLR9 present on leukocytes, B cells and T cells and stimulates the secretion of IL-6, IFN-\u03b3, IL-12 and CD4 T lymphocytes, in turn eliciting a Th1 type of inflammatory response along with enhanced IL-12 and IL-10 production [253] .", [["leukocytes", "ANATOMY", 34, 44], ["B cells", "ANATOMY", 46, 53], ["T cells", "ANATOMY", 58, 65], ["CD4 T lymphocytes", "ANATOMY", 121, 138], ["TLR9", "GENE_OR_GENE_PRODUCT", 18, 22], ["leukocytes", "CELL", 34, 44], ["B cells", "CELL", 46, 53], ["T cells", "CELL", 58, 65], ["IL-6", "GENE_OR_GENE_PRODUCT", 98, 102], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-12", "GENE_OR_GENE_PRODUCT", 111, 116], ["CD4 T lymphocytes", "CELL", 121, 138], ["IL-12", "GENE_OR_GENE_PRODUCT", 214, 219], ["IL-10", "GENE_OR_GENE_PRODUCT", 224, 229], ["TLR9", "PROTEIN", 18, 22], ["leukocytes", "CELL_TYPE", 34, 44], ["B cells", "CELL_TYPE", 46, 53], ["T cells", "CELL_TYPE", 58, 65], ["IFN", "PROTEIN", 104, 107], ["CD4 T lymphocytes", "CELL_TYPE", 121, 138], ["leukocytes", "TEST", 34, 44], ["B cells", "TEST", 46, 53], ["T cells", "TEST", 58, 65], ["the secretion", "TEST", 81, 94], ["IL", "TEST", 98, 100], ["IFN", "TEST", 104, 107], ["IL", "TEST", 111, 113], ["CD4 T lymphocytes", "TEST", 121, 138], ["inflammatory response", "PROBLEM", 172, 193], ["enhanced IL", "TEST", 205, 216], ["IL", "TEST", 224, 226], ["lymphocytes", "ANATOMY", 127, 138], ["inflammatory", "OBSERVATION_MODIFIER", 172, 184]]], ["It also suppresses Th2 cytokine, airway eosinophilia, IgE levels, and bronchial hyperreactivity in in vitro and in vivo models [254] [255] [256] .", [["airway", "ANATOMY", 33, 39], ["bronchial", "ANATOMY", 70, 79], ["eosinophilia", "DISEASE", 40, 52], ["Th2", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgE", "GENE_OR_GENE_PRODUCT", 54, 57], ["Th2 cytokine", "PROTEIN", 19, 31], ["IgE", "PROTEIN", 54, 57], ["Th2 cytokine", "TEST", 19, 31], ["airway eosinophilia", "TEST", 33, 52], ["IgE levels", "TEST", 54, 64], ["bronchial hyperreactivity", "PROBLEM", 70, 95], ["Th2 cytokine", "OBSERVATION", 19, 31], ["airway", "ANATOMY", 33, 39], ["eosinophilia", "OBSERVATION", 40, 52], ["bronchial", "ANATOMY", 70, 79], ["hyperreactivity", "OBSERVATION", 80, 95]]], ["CpG-ODN has shown encouraging results in clinical trials against asthma and allergic rhinitis as well [257] .", [["CpG-ODN", "CHEMICAL", 0, 7], ["asthma", "DISEASE", 65, 71], ["allergic rhinitis", "DISEASE", 76, 93], ["CpG", "CHEMICAL", 0, 3], ["CpG-ODN", "SIMPLE_CHEMICAL", 0, 7], ["asthma", "PROBLEM", 65, 71], ["allergic rhinitis", "PROBLEM", 76, 93], ["allergic rhinitis", "OBSERVATION", 76, 93]]], ["Other TLR9 agonists like indoleamine 2, 3-dioxygenase, IMO-2055, MO-2125 and IMO-2134 are reported to have anti-inflammatory and anti-allergic responses [258, 259] .", [["indoleamine 2, 3-dioxygenase", "CHEMICAL", 25, 53], ["IMO-2055", "CHEMICAL", 55, 63], ["MO-2125", "CHEMICAL", 65, 72], ["IMO-2134", "CHEMICAL", 77, 85], ["indoleamine", "CHEMICAL", 25, 36], ["IMO-2055", "CHEMICAL", 55, 63], ["MO-2125", "CHEMICAL", 65, 72], ["IMO-2134", "CHEMICAL", 77, 85], ["TLR9", "GENE_OR_GENE_PRODUCT", 6, 10], ["indoleamine 2, 3-dioxygenase", "SIMPLE_CHEMICAL", 25, 53], ["IMO-2055", "SIMPLE_CHEMICAL", 55, 63], ["MO-2125", "SIMPLE_CHEMICAL", 65, 72], ["IMO-2134", "SIMPLE_CHEMICAL", 77, 85], ["TLR9", "PROTEIN", 6, 10], ["indoleamine", "TEST", 25, 36], ["anti-inflammatory", "OBSERVATION_MODIFIER", 107, 124]]], ["A TLR3 agonist, Rintatolimod is also being experimented for treatment of severe acute respiratory syndrome, influenza, hepatitis infections and cancer.", [["cancer", "ANATOMY", 144, 150], ["Rintatolimod", "CHEMICAL", 16, 28], ["acute respiratory syndrome", "DISEASE", 80, 106], ["influenza", "DISEASE", 108, 117], ["hepatitis infections", "DISEASE", 119, 139], ["cancer", "DISEASE", 144, 150], ["Rintatolimod", "CHEMICAL", 16, 28], ["TLR3", "GENE_OR_GENE_PRODUCT", 2, 6], ["Rintatolimod", "SIMPLE_CHEMICAL", 16, 28], ["cancer", "CANCER", 144, 150], ["TLR3", "PROTEIN", 2, 6], ["A TLR3 agonist", "TREATMENT", 0, 14], ["severe acute respiratory syndrome", "PROBLEM", 73, 106], ["influenza", "PROBLEM", 108, 117], ["hepatitis infections", "PROBLEM", 119, 139], ["cancer", "PROBLEM", 144, 150], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["respiratory syndrome", "OBSERVATION", 86, 106], ["influenza", "OBSERVATION", 108, 117], ["hepatitis infections", "OBSERVATION", 119, 139], ["cancer", "OBSERVATION", 144, 150]]], ["It is reported to modulate cellular RNase L enzyme levels in patients [260] .TLR antagonistsRecent advances related to the structure and role of TLRs in normal physiology as well as in diseased conditions have led to their exploitation for developing novel therapeutic strategies.", [["cellular", "ANATOMY", 27, 35], ["cellular", "CELL", 27, 35], ["RNase L enzyme", "GENE_OR_GENE_PRODUCT", 36, 50], ["patients", "ORGANISM", 61, 69], ["TLRs", "GENE_OR_GENE_PRODUCT", 145, 149], ["RNase L enzyme", "PROTEIN", 36, 50], ["TLRs", "PROTEIN", 145, 149], ["patients", "SPECIES", 61, 69], ["cellular RNase L enzyme levels", "TEST", 27, 57], [".TLR antagonists", "TREATMENT", 76, 92], ["novel therapeutic strategies", "TREATMENT", 251, 279]]], ["In this pursuit, TLR antagonists are being examined for treatment of various diseases mainly autoimmune disorders, although none of them have succeeded to be taken further than clinical trials.", [["autoimmune disorders", "DISEASE", 93, 113], ["TLR antagonists", "GENE_OR_GENE_PRODUCT", 17, 32], ["TLR", "PROTEIN", 17, 20], ["TLR antagonists", "TREATMENT", 17, 32], ["treatment", "TREATMENT", 56, 65], ["various diseases", "PROBLEM", 69, 85], ["autoimmune disorders", "PROBLEM", 93, 113]]], ["Antagonist treatment can reduce unwarranted inflammation by hindering the interaction between TLRs and pro-inflammatory ligands and their downstream signalling molecules.", [["inflammation", "DISEASE", 44, 56], ["TLRs", "GENE_OR_GENE_PRODUCT", 94, 98], ["TLRs", "PROTEIN", 94, 98], ["pro-inflammatory ligands", "PROTEIN", 103, 127], ["downstream signalling molecules", "PROTEIN", 138, 169], ["Antagonist treatment", "TREATMENT", 0, 20], ["unwarranted inflammation", "PROBLEM", 32, 56], ["TLRs and pro-inflammatory ligands", "TREATMENT", 94, 127], ["inflammation", "OBSERVATION", 44, 56]]], ["TLR2 and TLR4 antagonists are well studied and show great promise in preventing several diseases.", [["TLR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLR4", "GENE_OR_GENE_PRODUCT", 9, 13], ["TLR2", "PROTEIN", 0, 4], ["TLR4", "PROTEIN", 9, 13], ["TLR2 and TLR4 antagonists", "TREATMENT", 0, 25], ["several diseases", "PROBLEM", 80, 96], ["great", "OBSERVATION_MODIFIER", 52, 57], ["several", "OBSERVATION_MODIFIER", 80, 87], ["diseases", "OBSERVATION", 88, 96]]], ["Recently, a TLR4 antagonist, under acylated form of Rhodobacter sphaeroides LPS (RS-LPS) when inhaled, reduced the symptoms of asthma by inhibiting eosinophilia and lymphocytosis, also by reducing the levels of Th2 cytokines and lower airway hyperresponsiveness [261] .", [["airway", "ANATOMY", 235, 241], ["LPS", "CHEMICAL", 76, 79], ["RS-LPS", "CHEMICAL", 81, 87], ["asthma", "DISEASE", 127, 133], ["eosinophilia", "DISEASE", 148, 160], ["lymphocytosis", "DISEASE", 165, 178], ["TLR4", "GENE_OR_GENE_PRODUCT", 12, 16], ["Rhodobacter sphaeroides LPS", "GENE_OR_GENE_PRODUCT", 52, 79], ["RS-LPS", "GENE_OR_GENE_PRODUCT", 81, 87], ["TLR4", "PROTEIN", 12, 16], ["Th2 cytokines", "PROTEIN", 211, 224], ["Rhodobacter sphaeroides", "SPECIES", 52, 75], ["Rhodobacter sphaeroides", "SPECIES", 52, 75], ["a TLR4 antagonist", "TREATMENT", 10, 27], ["Rhodobacter sphaeroides LPS", "TREATMENT", 52, 79], ["the symptoms", "PROBLEM", 111, 123], ["asthma", "PROBLEM", 127, 133], ["inhibiting eosinophilia", "PROBLEM", 137, 160], ["lymphocytosis", "PROBLEM", 165, 178], ["Th2 cytokines", "PROBLEM", 211, 224], ["lower airway hyperresponsiveness", "PROBLEM", 229, 261], ["asthma", "OBSERVATION", 127, 133], ["eosinophilia", "OBSERVATION", 148, 160], ["lymphocytosis", "OBSERVATION", 165, 178], ["Th2 cytokines", "OBSERVATION", 211, 224], ["lower", "ANATOMY_MODIFIER", 229, 234], ["airway", "ANATOMY", 235, 241], ["hyperresponsiveness", "OBSERVATION", 242, 261]]], ["RS-LPS acts as a TLR4 antagonist by inhibiting the induction of IkBz (gene NFKBIZ, a member of the NF-kB family, playing a significant role in functioning of epithelial cells) in bronchial epithelial cells, consequently leading to inhibition of release of pro-inflammatory cytokines -IL6 and GMCSF in a co-culture based study of bronchial epithelial cells and monocytes stimulated with house dust mite mix (HDM) [262] .", [["epithelial cells", "ANATOMY", 158, 174], ["bronchial epithelial cells", "ANATOMY", 179, 205], ["bronchial epithelial cells", "ANATOMY", 329, 355], ["monocytes", "ANATOMY", 360, 369], ["LPS", "CHEMICAL", 3, 6], ["TLR4", "GENE_OR_GENE_PRODUCT", 17, 21], ["IkBz", "GENE_OR_GENE_PRODUCT", 64, 68], ["NFKBIZ", "GENE_OR_GENE_PRODUCT", 75, 81], ["NF-kB", "GENE_OR_GENE_PRODUCT", 99, 104], ["epithelial cells", "CELL", 158, 174], ["bronchial epithelial cells", "CELL", 179, 205], ["IL6", "GENE_OR_GENE_PRODUCT", 284, 287], ["GMCSF", "GENE_OR_GENE_PRODUCT", 292, 297], ["bronchial epithelial cells", "CELL", 329, 355], ["monocytes", "CELL", 360, 369], ["TLR4", "PROTEIN", 17, 21], ["IkBz", "PROTEIN", 64, 68], ["gene NFKBIZ", "DNA", 70, 81], ["NF-kB family", "PROTEIN", 99, 111], ["epithelial cells", "CELL_TYPE", 158, 174], ["bronchial epithelial cells", "CELL_TYPE", 179, 205], ["pro-inflammatory cytokines", "PROTEIN", 256, 282], ["IL6", "PROTEIN", 284, 287], ["GMCSF", "PROTEIN", 292, 297], ["bronchial epithelial cells", "CELL_TYPE", 329, 355], ["monocytes", "CELL_TYPE", 360, 369], ["a TLR4 antagonist", "TREATMENT", 15, 32], ["epithelial cells", "PROBLEM", 158, 174], ["bronchial epithelial cells", "PROBLEM", 179, 205], ["pro-inflammatory cytokines", "PROBLEM", 256, 282], ["IL6", "PROBLEM", 284, 287], ["GMCSF", "TREATMENT", 292, 297], ["a co-culture based study", "TEST", 301, 325], ["bronchial epithelial cells", "PROBLEM", 329, 355], ["epithelial cells", "ANATOMY", 158, 174], ["bronchial", "ANATOMY", 179, 188], ["epithelial cells", "OBSERVATION", 189, 205], ["pro-inflammatory cytokines", "OBSERVATION", 256, 282], ["bronchial epithelial", "ANATOMY", 329, 349]]], ["One of the few synthesized antibodies that target TLRs is NI-0101, which is specific to TLR4 and blocks TLR4 dimerization.", [["NI-0101", "CHEMICAL", 58, 65], ["TLRs", "GENE_OR_GENE_PRODUCT", 50, 54], ["NI-0101", "GENE_OR_GENE_PRODUCT", 58, 65], ["TLR4", "GENE_OR_GENE_PRODUCT", 88, 92], ["TLR4", "GENE_OR_GENE_PRODUCT", 104, 108], ["TLRs", "PROTEIN", 50, 54], ["TLR4", "PROTEIN", 88, 92], ["TLR4", "PROTEIN", 104, 108], ["NI", "TEST", 58, 60], ["TLR4 and blocks TLR4 dimerization", "TREATMENT", 88, 121]]], ["It has the potency to reduce cytokine secretion and averts flu and its symptoms in ex vivo and in vivo models.", [["cytokine", "PROTEIN", 29, 37], ["cytokine secretion", "PROBLEM", 29, 47], ["flu", "PROBLEM", 59, 62], ["its symptoms", "PROBLEM", 67, 79], ["cytokine secretion", "OBSERVATION", 29, 47]]], ["1A6, another anti-TLR4 monoclonal antibody is effective in reducing inflammatory disorders and has positive role in lung injury models [264] .", [["lung", "ANATOMY", 116, 120], ["lung injury", "DISEASE", 116, 127], ["1A6", "SIMPLE_CHEMICAL", 0, 3], ["anti-TLR4", "GENE_OR_GENE_PRODUCT", 13, 22], ["lung", "ORGAN", 116, 120], ["1A6", "PROTEIN", 0, 3], ["anti-TLR4 monoclonal antibody", "PROTEIN", 13, 42], ["another anti-TLR4 monoclonal antibody", "TREATMENT", 5, 42], ["reducing inflammatory disorders", "PROBLEM", 59, 90], ["lung injury models", "PROBLEM", 116, 134], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80], ["lung", "ANATOMY", 116, 120], ["injury", "OBSERVATION", 121, 127]]], ["Lipid A analogues specifically targets TLR4 signalling and has become potential therapeutic tool against airway diseases.", [["airway", "ANATOMY", 105, 111], ["airway diseases", "DISEASE", 105, 120], ["Lipid A analogues", "SIMPLE_CHEMICAL", 0, 17], ["TLR4", "GENE_OR_GENE_PRODUCT", 39, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["TLR4", "PROTEIN", 39, 43], ["Lipid A analogues", "TREATMENT", 0, 17], ["TLR4 signalling", "PROBLEM", 39, 54], ["airway diseases", "PROBLEM", 105, 120], ["airway", "ANATOMY", 105, 111], ["diseases", "OBSERVATION", 112, 120]]], ["Eritoran TM (E5564) is a TLR4 antagonist that affects TLR4/MD-2/LPS complex formation is the most advanced TLR agonist and is currently undergoing Phase III clinical trial for treatment of sepsis [265] .", [["Eritoran", "CHEMICAL", 0, 8], ["E5564", "CHEMICAL", 13, 18], ["LPS", "CHEMICAL", 64, 67], ["sepsis", "DISEASE", 189, 195], ["E5564", "CHEMICAL", 13, 18], ["E5564", "SIMPLE_CHEMICAL", 13, 18], ["TLR4", "GENE_OR_GENE_PRODUCT", 25, 29], ["TLR4", "GENE_OR_GENE_PRODUCT", 54, 58], ["MD-2", "GENE_OR_GENE_PRODUCT", 59, 63], ["LPS complex", "GENE_OR_GENE_PRODUCT", 64, 75], ["TLR", "GENE_OR_GENE_PRODUCT", 107, 110], ["TLR4", "PROTEIN", 25, 29], ["TLR4", "PROTEIN", 54, 58], ["TLR", "PROTEIN", 107, 110], ["a TLR4 antagonist", "TREATMENT", 23, 40], ["Phase III clinical trial", "TREATMENT", 147, 171], ["sepsis", "PROBLEM", 189, 195], ["sepsis", "OBSERVATION", 189, 195]]], ["A fully humanized IgG4 monoclonal TLR2 specific antibody, OPN-305 blocks TLR2-mediated pro-inflammatory cytokine production in pre-clinical phase I studies [266] .TLR antagonistsAntagonists of TLR7 are also in focus for their anti-asthmatic effects along with their bronchodilatory mechanism which leads to protection from airway obstruction during viral infections.", [["airway", "ANATOMY", 323, 329], ["OPN-305", "CHEMICAL", 58, 65], ["airway obstruction", "DISEASE", 323, 341], ["viral infections", "DISEASE", 349, 365], ["IgG4", "GENE_OR_GENE_PRODUCT", 18, 22], ["TLR2", "GENE_OR_GENE_PRODUCT", 34, 38], ["OPN-305", "SIMPLE_CHEMICAL", 58, 65], ["TLR2", "GENE_OR_GENE_PRODUCT", 73, 77], ["TLR7", "GENE_OR_GENE_PRODUCT", 193, 197], ["airway obstruction", "PATHOLOGICAL_FORMATION", 323, 341], ["IgG4 monoclonal TLR2 specific antibody", "PROTEIN", 18, 56], ["OPN", "PROTEIN", 58, 61], ["TLR2", "PROTEIN", 73, 77], ["pro-inflammatory cytokine", "PROTEIN", 87, 112], ["TLR7", "PROTEIN", 193, 197], ["A fully humanized IgG4 monoclonal TLR2 specific antibody", "TEST", 0, 56], ["OPN", "TEST", 58, 61], ["TLR2", "TEST", 73, 77], ["pro-inflammatory cytokine production", "PROBLEM", 87, 123], [".TLR antagonistsAntagonists", "TREATMENT", 162, 189], ["TLR7", "TREATMENT", 193, 197], ["their anti-asthmatic effects", "TREATMENT", 220, 248], ["their bronchodilatory mechanism", "TREATMENT", 260, 291], ["airway obstruction", "PROBLEM", 323, 341], ["viral infections", "PROBLEM", 349, 365], ["airway", "ANATOMY", 323, 329], ["obstruction", "OBSERVATION", 330, 341], ["viral infections", "OBSERVATION", 349, 365]]], ["One such TLR7 antagonist is R837 that plays a critical role in relaxing the airway passage through production of nitric oxide in a TLR7 dependent manner in in vitro as well as in vivo models [267] .", [["airway", "ANATOMY", 76, 82], ["R837", "CHEMICAL", 28, 32], ["nitric oxide", "CHEMICAL", 113, 125], ["nitric oxide", "CHEMICAL", 113, 125], ["TLR7", "GENE_OR_GENE_PRODUCT", 9, 13], ["R837", "SIMPLE_CHEMICAL", 28, 32], ["airway", "MULTI-TISSUE_STRUCTURE", 76, 82], ["nitric oxide", "SIMPLE_CHEMICAL", 113, 125], ["TLR7", "GENE_OR_GENE_PRODUCT", 131, 135], ["TLR7", "PROTEIN", 9, 13], ["TLR7", "PROTEIN", 131, 135], ["nitric oxide", "TREATMENT", 113, 125], ["a TLR7 dependent manner", "TREATMENT", 129, 152], ["airway", "ANATOMY", 76, 82], ["nitric oxide", "OBSERVATION", 113, 125]]], ["Recently, capsazepine and its analogues have been considered as TLR3 inhibitors and they have shown to repress the production of pro-inflammatory cytokines such as IL-8 and TNF-\u03b1 in asthmatic patients [268] .", [["capsazepine", "CHEMICAL", 10, 21], ["asthmatic", "DISEASE", 182, 191], ["capsazepine", "CHEMICAL", 10, 21], ["capsazepine", "SIMPLE_CHEMICAL", 10, 21], ["TLR3", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-8", "GENE_OR_GENE_PRODUCT", 164, 168], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 173, 178], ["patients", "ORGANISM", 192, 200], ["TLR3", "PROTEIN", 64, 68], ["pro-inflammatory cytokines", "PROTEIN", 129, 155], ["IL-8", "PROTEIN", 164, 168], ["TNF", "PROTEIN", 173, 176], ["patients", "SPECIES", 192, 200], ["capsazepine", "TREATMENT", 10, 21], ["its analogues", "TREATMENT", 26, 39], ["TLR3 inhibitors", "TREATMENT", 64, 79], ["pro-inflammatory cytokines", "TEST", 129, 155], ["IL", "TEST", 164, 166], ["TNF", "TEST", 173, 176]]], ["Apart from synthesized compounds, a natural product known as Resveratrol that is found in grapes and peanuts down regulates TLR3 and one of its adapter molecule (TRIF) and provides a defensive mechanism against asthma development [269] .", [["grapes", "ANATOMY", 90, 96], ["Resveratrol", "CHEMICAL", 61, 72], ["asthma", "DISEASE", 211, 217], ["Resveratrol", "CHEMICAL", 61, 72], ["Resveratrol", "SIMPLE_CHEMICAL", 61, 72], ["grapes", "ORGANISM_SUBDIVISION", 90, 96], ["peanuts", "ORGANISM_SUBDIVISION", 101, 108], ["TLR3", "GENE_OR_GENE_PRODUCT", 124, 128], ["TRIF", "GENE_OR_GENE_PRODUCT", 162, 166], ["TLR3", "PROTEIN", 124, 128], ["adapter molecule", "PROTEIN", 144, 160], ["TRIF", "PROTEIN", 162, 166], ["synthesized compounds", "PROBLEM", 11, 32], ["Resveratrol", "TREATMENT", 61, 72], ["TLR3", "TREATMENT", 124, 128], ["asthma development", "PROBLEM", 211, 229], ["synthesized compounds", "OBSERVATION", 11, 32]]], ["Though, antagonist therapy shows great potential, but their use can cause damage to the local immune defence and can result in development of other opportunistic disorders.TLR antagonistsDespite the substantial amount of research going on for development of novel TLRs agonist or antagonist in the treatment of airway as well as other diseases only limited success have been achieved.", [["airway", "ANATOMY", 311, 317], ["opportunistic disorders", "DISEASE", 148, 171], ["TLR antagonists", "GENE_OR_GENE_PRODUCT", 172, 187], ["TLRs", "GENE_OR_GENE_PRODUCT", 264, 268], ["airway", "MULTI-TISSUE_STRUCTURE", 311, 317], ["TLR", "PROTEIN", 172, 175], ["TLRs", "PROTEIN", 264, 268], ["antagonist therapy", "TREATMENT", 8, 26], ["damage", "PROBLEM", 74, 80], ["other opportunistic disorders", "PROBLEM", 142, 171], ["TLR antagonists", "TREATMENT", 172, 187], ["novel TLRs agonist", "TREATMENT", 258, 276], ["antagonist", "TREATMENT", 280, 290], ["other diseases", "PROBLEM", 329, 343], ["opportunistic", "OBSERVATION_MODIFIER", 148, 161], ["substantial", "OBSERVATION_MODIFIER", 199, 210], ["amount", "OBSERVATION_MODIFIER", 211, 217], ["airway", "ANATOMY", 311, 317]]], ["The failure of these drugs at clinical trials is most probably a result of inappropriate dosage, toxicity, lack of proper time and route of administration.", [["toxicity", "DISEASE", 97, 105], ["these drugs", "TREATMENT", 15, 26], ["inappropriate dosage", "PROBLEM", 75, 95], ["toxicity", "PROBLEM", 97, 105], ["failure", "OBSERVATION", 4, 11], ["most probably", "UNCERTAINTY", 49, 62]]], ["However, continuous effort and holistic approaches would open newer ways for utilizing these compounds as medicinal agents in the near future.ConclusionAn extended exposure of lung to environmental aggravations and likely pathogens perpetuates the innate immune system to acquire a critical role in maintenance of lung tissue homeostasis.", [["lung", "ANATOMY", 176, 180], ["lung tissue", "ANATOMY", 314, 325], ["lung", "ORGAN", 176, 180], ["lung tissue", "TISSUE", 314, 325], ["holistic approaches", "TREATMENT", 31, 50], ["these compounds", "TREATMENT", 87, 102], ["medicinal agents", "TREATMENT", 106, 122], ["lung to environmental aggravations", "PROBLEM", 176, 210], ["pathogens", "PROBLEM", 222, 231], ["lung tissue homeostasis", "PROBLEM", 314, 337], ["lung", "ANATOMY", 176, 180], ["likely", "UNCERTAINTY", 215, 221], ["pathogens", "OBSERVATION", 222, 231], ["lung", "ANATOMY", 314, 318], ["tissue homeostasis", "OBSERVATION", 319, 337]]], ["TLRs are principally involved in activation of innate immune system and an enormous amount of research has been carried out in recent years to explore the role of TLRs in host defence and tissue homeostasis.", [["immune system", "ANATOMY", 54, 67], ["tissue", "ANATOMY", 188, 194], ["TLRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["TLRs", "GENE_OR_GENE_PRODUCT", 163, 167], ["tissue", "TISSUE", 188, 194], ["TLRs", "PROTEIN", 0, 4], ["TLRs", "PROTEIN", 163, 167], ["innate immune system", "TREATMENT", 47, 67], ["enormous", "OBSERVATION_MODIFIER", 75, 83], ["amount", "OBSERVATION_MODIFIER", 84, 90]]], ["The acumens of this work have enabled us to predicate general principles associated with lung innate immunity.", [["lung", "ANATOMY", 89, 93], ["lung", "ORGAN", 89, 93], ["lung innate immunity", "TREATMENT", 89, 109], ["lung", "ANATOMY", 89, 93]]], ["These principles involve development of acute pulmonary diseases (for instance -bronchiolitis and ALI) customarily lead to progression of chronic inflammatory conditions such as fibroproliferative ARDS or may lead to exposition of relapsing or remitting conditions as found in asthma.", [["pulmonary", "ANATOMY", 46, 55], ["acute pulmonary diseases", "DISEASE", 40, 64], ["bronchiolitis", "DISEASE", 80, 93], ["ALI", "DISEASE", 98, 101], ["ARDS", "DISEASE", 197, 201], ["asthma", "DISEASE", 277, 283], ["pulmonary", "ORGAN", 46, 55], ["acute pulmonary diseases", "PROBLEM", 40, 64], ["bronchiolitis", "PROBLEM", 80, 93], ["ALI", "PROBLEM", 98, 101], ["chronic inflammatory conditions", "PROBLEM", 138, 169], ["fibroproliferative ARDS", "PROBLEM", 178, 201], ["relapsing or remitting conditions", "PROBLEM", 231, 264], ["asthma", "PROBLEM", 277, 283], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["pulmonary", "ANATOMY", 46, 55], ["diseases", "OBSERVATION", 56, 64], ["bronchiolitis", "OBSERVATION", 80, 93], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["inflammatory", "OBSERVATION", 146, 158], ["fibroproliferative", "OBSERVATION_MODIFIER", 178, 196], ["ARDS", "OBSERVATION", 197, 201], ["relapsing", "OBSERVATION_MODIFIER", 231, 240], ["asthma", "OBSERVATION", 277, 283]]], ["Secondly, infections (bacterial, fungal or viral) are the most prominent causes of prolonged inflammation in lung tissue, as represented by severe RSV infection preceding asthma development and progression of ARDS following severe influenza and pneumonia.", [["lung tissue", "ANATOMY", 109, 120], ["infections", "DISEASE", 10, 20], ["bacterial, fungal or viral)", "DISEASE", 22, 49], ["inflammation", "DISEASE", 93, 105], ["RSV infection", "DISEASE", 147, 160], ["asthma", "DISEASE", 171, 177], ["ARDS", "DISEASE", 209, 213], ["influenza", "DISEASE", 231, 240], ["pneumonia", "DISEASE", 245, 254], ["lung tissue", "TISSUE", 109, 120], ["RSV", "ORGANISM", 147, 150], ["RSV", "SPECIES", 147, 150], ["infections (bacterial, fungal or viral)", "PROBLEM", 10, 49], ["prolonged inflammation in lung tissue", "PROBLEM", 83, 120], ["severe RSV infection", "PROBLEM", 140, 160], ["asthma development", "PROBLEM", 171, 189], ["ARDS", "PROBLEM", 209, 213], ["severe influenza", "PROBLEM", 224, 240], ["pneumonia", "PROBLEM", 245, 254], ["infections", "OBSERVATION", 10, 20], ["bacterial", "OBSERVATION_MODIFIER", 22, 31], ["most prominent", "OBSERVATION_MODIFIER", 58, 72], ["prolonged", "OBSERVATION_MODIFIER", 83, 92], ["inflammation", "OBSERVATION", 93, 105], ["lung tissue", "ANATOMY", 109, 120], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["RSV", "OBSERVATION_MODIFIER", 147, 150], ["infection", "OBSERVATION", 151, 160], ["asthma", "OBSERVATION", 171, 177], ["progression", "OBSERVATION_MODIFIER", 194, 205], ["ARDS", "OBSERVATION", 209, 213], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["influenza", "OBSERVATION", 231, 240], ["pneumonia", "OBSERVATION", 245, 254]]], ["Furthermore, aberrations in innate immune system lead to the evolution of chronic obstructive lung diseases.", [["lung", "ANATOMY", 94, 98], ["chronic obstructive lung diseases", "DISEASE", 74, 107], ["lung", "ORGAN", 94, 98], ["aberrations in innate immune system", "PROBLEM", 13, 48], ["chronic obstructive lung diseases", "PROBLEM", 74, 107], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["obstructive", "OBSERVATION_MODIFIER", 82, 93], ["lung", "ANATOMY", 94, 98], ["diseases", "OBSERVATION", 99, 107]]], ["These disorders may be due to direct or indirect predilection of host to infection as in case of chronic P. aeruginosa infections leading to Cystic fibrosis, and S. pneumonia infections leading to subtle aggravations of COPD.", [["Cystic", "ANATOMY", 141, 147], ["infection", "DISEASE", 73, 82], ["P. aeruginosa infections", "DISEASE", 105, 129], ["Cystic fibrosis", "DISEASE", 141, 156], ["S. pneumonia infections", "DISEASE", 162, 185], ["COPD", "DISEASE", 220, 224], ["P. aeruginosa", "ORGANISM", 105, 118], ["P. aeruginosa", "SPECIES", 105, 118], ["S. pneumonia", "SPECIES", 162, 174], ["P. aeruginosa", "SPECIES", 105, 118], ["S. pneumonia", "SPECIES", 162, 174], ["These disorders", "PROBLEM", 0, 15], ["host to infection", "PROBLEM", 65, 82], ["chronic P. aeruginosa infections", "PROBLEM", 97, 129], ["Cystic fibrosis", "PROBLEM", 141, 156], ["S. pneumonia infections", "PROBLEM", 162, 185], ["COPD", "PROBLEM", 220, 224], ["may be due to", "UNCERTAINTY", 16, 29], ["infection", "OBSERVATION", 73, 82], ["chronic", "OBSERVATION_MODIFIER", 97, 104], ["Cystic", "OBSERVATION_MODIFIER", 141, 147], ["fibrosis", "OBSERVATION", 148, 156], ["pneumonia", "OBSERVATION", 165, 174], ["subtle", "OBSERVATION_MODIFIER", 197, 203], ["aggravations", "OBSERVATION_MODIFIER", 204, 216], ["COPD", "OBSERVATION", 220, 224]]], ["Irrevocably, tissue remodelling, and repair are imperative for pathogenesis of lung inflammation along with host defence, and TLR mediated mechanisms reconcile these processes.", [["tissue", "ANATOMY", 13, 19], ["lung", "ANATOMY", 79, 83], ["lung inflammation", "DISEASE", 79, 96], ["tissue", "TISSUE", 13, 19], ["lung", "ORGAN", 79, 83], ["TLR", "GENE_OR_GENE_PRODUCT", 126, 129], ["TLR", "PROTEIN", 126, 129], ["Irrevocably, tissue remodelling", "PROBLEM", 0, 31], ["repair", "TREATMENT", 37, 43], ["lung inflammation", "PROBLEM", 79, 96], ["host defence", "PROBLEM", 108, 120], ["tissue", "OBSERVATION_MODIFIER", 13, 19], ["remodelling", "OBSERVATION", 20, 31], ["repair", "OBSERVATION", 37, 43], ["lung", "ANATOMY", 79, 83], ["inflammation", "OBSERVATION", 84, 96], ["host defence", "OBSERVATION", 108, 120]]], ["Similarly, TLRs are also involved in lung cancer development and progression.", [["lung cancer", "ANATOMY", 37, 48], ["lung cancer", "DISEASE", 37, 48], ["TLRs", "GENE_OR_GENE_PRODUCT", 11, 15], ["lung cancer", "CANCER", 37, 48], ["TLRs", "PROTEIN", 11, 15], ["lung cancer", "PROBLEM", 37, 48], ["lung", "ANATOMY", 37, 41], ["cancer", "OBSERVATION", 42, 48], ["progression", "OBSERVATION_MODIFIER", 65, 76]]], ["Contemporary studies have demonstrated the tumor promoting as well as tumor suppressing roles of TLR signalling.", [["tumor", "ANATOMY", 43, 48], ["tumor", "ANATOMY", 70, 75], ["tumor", "DISEASE", 43, 48], ["tumor", "DISEASE", 70, 75], ["tumor", "CANCER", 43, 48], ["tumor", "CANCER", 70, 75], ["TLR", "GENE_OR_GENE_PRODUCT", 97, 100], ["TLR", "PROTEIN", 97, 100], ["Contemporary studies", "TEST", 0, 20], ["the tumor promoting", "PROBLEM", 39, 58], ["tumor", "OBSERVATION", 43, 48], ["tumor", "OBSERVATION", 70, 75], ["TLR", "OBSERVATION_MODIFIER", 97, 100]]], ["Activation of TLRs on cells of tumor microenvironment can promote immune evasion by alterations of Tregs, thereby promoting tumor cell proliferation.", [["cells", "ANATOMY", 22, 27], ["tumor", "ANATOMY", 31, 36], ["Tregs", "ANATOMY", 99, 104], ["tumor cell", "ANATOMY", 124, 134], ["tumor", "DISEASE", 31, 36], ["tumor", "DISEASE", 124, 129], ["TLRs", "GENE_OR_GENE_PRODUCT", 14, 18], ["cells", "CELL", 22, 27], ["tumor", "CANCER", 31, 36], ["Tregs", "CELL", 99, 104], ["tumor cell", "CELL", 124, 134], ["TLRs", "PROTEIN", 14, 18], ["Tregs", "CELL_TYPE", 99, 104], ["TLRs on cells of tumor microenvironment", "TREATMENT", 14, 53], ["immune evasion", "TREATMENT", 66, 80], ["Tregs", "TREATMENT", 99, 104], ["tumor cell proliferation", "PROBLEM", 124, 148], ["tumor cell proliferation", "OBSERVATION", 124, 148]]], ["On the other hand, they are also involved in activating immune system to generate anti-tumor immunity.", [["immune system", "ANATOMY", 56, 69], ["anti-tumor", "ANATOMY", 82, 92], ["anti-tumor", "CANCER", 82, 92]]], ["Moreover, it has been reported that TLRs mediate activation of immune cells present in tumor microenvironment, which may result in anti-tumor as well as pro-tumor effects, but the role of TLRs in tumorigenic effects have not yet been fully elucidated.ConclusionAlthough, TLR activation plays a critical role in progression of lung inflammatory diseases, there are still many questions that have to be answered.", [["immune cells", "ANATOMY", 63, 75], ["tumor", "ANATOMY", 87, 92], ["pro-tumor", "ANATOMY", 153, 162], ["lung", "ANATOMY", 326, 330], ["tumor", "DISEASE", 87, 92], ["lung inflammatory diseases", "DISEASE", 326, 352], ["TLRs", "GENE_OR_GENE_PRODUCT", 36, 40], ["immune cells", "CELL", 63, 75], ["tumor", "CANCER", 87, 92], ["anti-tumor", "CANCER", 131, 141], ["pro-tumor", "CANCER", 153, 162], ["TLRs", "GENE_OR_GENE_PRODUCT", 188, 192], ["TLR", "GENE_OR_GENE_PRODUCT", 271, 274], ["lung", "ORGAN", 326, 330], ["TLRs", "PROTEIN", 36, 40], ["immune cells", "CELL_TYPE", 63, 75], ["TLRs", "PROTEIN", 188, 192], ["TLR", "PROTEIN", 271, 274], ["immune cells", "PROBLEM", 63, 75], ["tumor microenvironment", "PROBLEM", 87, 109], ["pro-tumor effects", "PROBLEM", 153, 170], ["lung inflammatory diseases", "PROBLEM", 326, 352], ["immune cells", "OBSERVATION", 63, 75], ["tumor microenvironment", "OBSERVATION", 87, 109], ["progression", "OBSERVATION_MODIFIER", 311, 322], ["lung", "ANATOMY", 326, 330], ["inflammatory", "OBSERVATION", 331, 343]]], ["Besides this, using TLRs as therapeutic targets involve use of TLR agonists or antagonists.", [["TLRs", "GENE_OR_GENE_PRODUCT", 20, 24], ["TLR", "GENE_OR_GENE_PRODUCT", 63, 66], ["TLRs", "PROTEIN", 20, 24], ["TLR", "PROTEIN", 63, 66], ["TLRs", "TREATMENT", 20, 24], ["TLR agonists", "TREATMENT", 63, 75], ["antagonists", "TREATMENT", 79, 90]]], ["Few TLR agonists and antagonists have been used a therapeutic modality in case of airway diseases but success has not yet been achieved due to several reasons involving dosage toxicity and inappropriate time and route of administration.", [["airway", "ANATOMY", 82, 88], ["airway diseases", "DISEASE", 82, 97], ["toxicity", "DISEASE", 176, 184], ["TLR agonists", "GENE_OR_GENE_PRODUCT", 4, 16], ["airway", "MULTI-TISSUE_STRUCTURE", 82, 88], ["Few TLR agonists", "TREATMENT", 0, 16], ["antagonists", "TREATMENT", 21, 32], ["a therapeutic modality", "TREATMENT", 48, 70], ["airway diseases", "PROBLEM", 82, 97], ["dosage toxicity", "PROBLEM", 169, 184], ["airway", "ANATOMY", 82, 88], ["diseases", "OBSERVATION", 89, 97]]], ["Thus, more studies are needed to explore their potential as a therapeutic strategy.", [["a therapeutic strategy", "TREATMENT", 60, 82]]], ["Furthermore, a profound understanding of TLR associated mechanisms will help us elucidate the links between innate immune system and development of chronic inflammatory conditions in lung tissue.", [["immune system", "ANATOMY", 115, 128], ["lung tissue", "ANATOMY", 183, 194], ["TLR", "GENE_OR_GENE_PRODUCT", 41, 44], ["lung tissue", "TISSUE", 183, 194], ["TLR", "PROTEIN", 41, 44], ["TLR associated mechanisms", "TREATMENT", 41, 66], ["innate immune system", "TREATMENT", 108, 128], ["chronic inflammatory conditions in lung tissue", "PROBLEM", 148, 194], ["chronic", "OBSERVATION_MODIFIER", 148, 155], ["inflammatory", "OBSERVATION", 156, 168], ["lung", "ANATOMY", 183, 187], ["tissue", "OBSERVATION", 188, 194]]], ["This knowledge will benefit us to identify TLRs as novel therapeutic targets that could limit the burden of pulmonary diseases.Ethics approval and consent to participateNot applicable.Consent for publicationNot applicable.Availability of data and materialsNot applicable.Declaration of Competing InterestThe authors declare that they have no conflict of interest associated with this manuscript.", [["pulmonary", "ANATOMY", 108, 117], ["pulmonary diseases", "DISEASE", 108, 126], ["TLRs", "GENE_OR_GENE_PRODUCT", 43, 47], ["pulmonary", "ORGAN", 108, 117], ["TLRs", "PROTEIN", 43, 47], ["TLRs", "TREATMENT", 43, 47], ["pulmonary diseases", "PROBLEM", 108, 126], ["pulmonary", "ANATOMY", 108, 117], ["diseases", "OBSERVATION", 118, 126]]]], "PMC7306959": [["INTRODUCTIONCoronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an infectious disease.1 After its outbreak in Wuhan, China (December 2019), the rapid spread of the virus sparked alarm worldwide.", [["INTRODUCTIONCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 33, 41], ["acute respiratory syndrome coronavirus", "DISEASE", 60, 98], ["infectious disease", "DISEASE", 120, 138], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 53, 100], ["SARS-CoV-2", "ORGANISM", 102, 112], ["severe acute respiratory syndrome coronavirus", "SPECIES", 53, 98], ["SARS-CoV-2", "SPECIES", 102, 112], ["INTRODUCTIONCoronavirus disease", "PROBLEM", 0, 31], ["COVID", "TEST", 33, 38], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 53, 98], ["an infectious disease", "PROBLEM", 117, 138], ["the virus", "TREATMENT", 213, 222], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86], ["infectious", "OBSERVATION", 120, 130]]], ["As of May 4, 2020, over 3.3 million confirmed cases of COVID-19 have been reported, resulting in more than 238,730 deaths in 215 countries.2 As the virus spreads through close contact and by small droplets produced during cough, sneeze or talk,1,3 most of countries have responded with preventive measures through health advocacy campaigns, lockdowns and restricting public gatherings.", [["deaths", "DISEASE", 115, 121], ["cough", "DISEASE", 222, 227], ["COVID", "TEST", 55, 60], ["cough", "PROBLEM", 222, 227], ["small", "OBSERVATION_MODIFIER", 191, 196], ["droplets", "OBSERVATION", 197, 205]]], ["The hospitals are ramping up their capabilities to care for increasing numbers of infected patients.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["infected", "OBSERVATION", 82, 90]]], ["Meanwhile, scientists are exploring potential treatments, testing new therapies and vaccines to contain the virus.4INTRODUCTIONIn Pakistan the situation is no different with 20,186 confirmed cases of COVID-19 and 462 deaths till date.5 To control the spread of COVID-19, the government has implemented partial lockdowns with complete closure of non-essential services, shops, restaurants and air travel.", [["COVID", "DISEASE", 200, 205], ["deaths", "DISEASE", 217, 223], ["potential treatments", "TREATMENT", 36, 56], ["testing new therapies", "TREATMENT", 58, 79], ["vaccines", "TREATMENT", 84, 92], ["the virus", "PROBLEM", 104, 113], ["COVID", "TEST", 200, 205], ["no", "UNCERTAINTY", 156, 158], ["spread", "OBSERVATION_MODIFIER", 251, 257], ["air travel", "OBSERVATION", 392, 402]]], ["However, an across-the-board enforcement of such lockdowns remains beyond the capacity of the state and the numbers of people testing positive to COVID-19 continue to rise.INTRODUCTIONTo strengthen country and community emergency preparedness, the Government issued directives for closure of OPDs and elective surgical services in all the Tertiary Care Hospitals, District Headquarters Hospitals and Private Clinics.6 Specific hospitals have been designated for screening and management of cases.", [["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["such lockdowns", "PROBLEM", 44, 58], ["people testing", "TEST", 119, 133], ["COVID", "TEST", 146, 151], ["closure of OPDs", "TREATMENT", 281, 296], ["elective surgical services", "TREATMENT", 301, 327], ["screening", "TEST", 462, 471]]], ["Other measures included establishment of quarantine centers, testing facilities and public awareness regarding COVID-19.7 All the academic institutions were also given a three-week break.", [["COVID", "TEST", 111, 116]]], ["Recently, the Higher Education Commission (HEC), Pakistan issued guidelines suggesting delivery of online courses to minimize academic loss.8INTRODUCTIONThe health professionals have to juggle multiple roles including administrative, clinical and educational roles.9 During COVID-19 pandemic, the added online educational and clinical responsibilities may have had an impact.", [["online courses", "TREATMENT", 99, 113], ["academic loss", "PROBLEM", 126, 139], ["COVID", "TEST", 274, 279]]], ["Little previous history, evidence-base and lack of vaccine to contain this novel virus may have also incited panic.", [["panic", "DISEASE", 109, 114], ["vaccine", "TREATMENT", 51, 58], ["this novel virus", "PROBLEM", 70, 86], ["panic", "PROBLEM", 109, 114]]], ["Recognizing the huge potential ramifications, this study explores the impact of COVID-19 pandemic on health professionals personally and professionally, along with associated challenges.Questionnaire ::: METHODSAn open-ended qualitative questionnaire was developed, asking the participants regarding the personal and professional impact of COVID-19, and the associated challenges.", [["participants", "SPECIES", 277, 289], ["this study", "TEST", 46, 56], ["COVID", "TREATMENT", 340, 345]]], ["The sample size was not predetermined, and an iterative approach of simultaneous data collection and analysis was taken until data and time saturation were reached.Data Analysis ::: METHODSDescriptive statistics were calculated for the demographic data.", [["The sample size", "TEST", 0, 15], ["simultaneous data collection", "TEST", 68, 96], ["analysis", "TEST", 101, 109], ["time saturation", "TEST", 135, 150], ["the demographic data", "TEST", 232, 252], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["For qualitative data, each response was carefully read to develop in-vivo analytic codes.", [["qualitative data", "TEST", 4, 20]]], ["The selective codes were categorized, and themes were developed.10 Through reflective thinking and team discussions the themes were continuously refined to fit the data.Personal impact ::: RESULTSThe health professionals reported an impact on their mental, physical and social well-being.", [["selective", "OBSERVATION_MODIFIER", 4, 13]]], ["They felt anxious, frustrated and stressed out.", [["anxious", "PROBLEM", 10, 17], ["frustrated", "PROBLEM", 19, 29]]], ["A few reported having more time for self, family and work (Table-II).Professional impact ::: RESULTSHealth professionals experienced a temporary layoff initially with closure of academic institutions and private clinics, and disruption of hospital OPDs, elective procedures.", [["a temporary layoff", "TREATMENT", 133, 151], ["closure of academic institutions", "TREATMENT", 167, 199], ["elective procedures", "TREATMENT", 254, 273], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["However, their roles and responsibilities increased over the period of time.", [["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["Many participants offered remote access through telephone to their patients.", [["patients", "ORGANISM", 67, 75], ["participants", "SPECIES", 5, 17], ["patients", "SPECIES", 67, 75]]], ["They found it hard to work and also manage their household, families and children.", [["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81]]], ["They were not satisfied with the effectiveness of online teaching and mentioned their lack of training.", [["online teaching", "TREATMENT", 50, 65]]], ["In the hospital, the participants found it challenging to ensure their safety.", [["participants", "SPECIES", 21, 33]]], ["They reported unrealistic expectations to manage the patients without any safety provisions.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61]]], ["The standards observed in the hospital were far less than that needed for tackling COVID-19.", [["COVID-19", "CHEMICAL", 83, 91], ["tackling COVID", "TEST", 74, 88]]], ["Indifferent attitude of the public due to paranoia, misinformation and non-compliance was also challenging (Table-III).DISCUSSIONSince the last pandemic, our understanding of disease transmission and management has improved.", [["paranoia", "DISEASE", 42, 50], ["paranoia", "PROBLEM", 42, 50], ["management", "TREATMENT", 200, 210], ["paranoia", "OBSERVATION", 42, 50], ["improved", "OBSERVATION_MODIFIER", 215, 223]]], ["However, COVID-19 has shown the limits of our ability.", [["COVID-19", "CHEMICAL", 9, 17], ["COVID", "TEST", 9, 14]]], ["This study explored the impact of COVID-19 pandemic on the health professionals in Pakistan.", [["This study", "TEST", 0, 10], ["COVID", "TREATMENT", 34, 39]]], ["The study found an impact on the physical, mental and social well-being of health professionals as also reported from china.11 They felt considerable mental stress as they too have families, and so will also naturally be fearful that the virus might reach them.", [["The study", "TEST", 0, 9], ["considerable mental stress", "PROBLEM", 137, 163], ["the virus", "PROBLEM", 234, 243]]], ["Many clinicians experienced increased responsibilities related to COVID-19 in screening areas, testing labs, isolation wards and quarantine centers as also highlighted by Waris et al.7 They reported stepping directly into COVID-19\u2019s path to aid the affected people and help halt the spread.", [["people", "ORGANISM", 258, 264], ["people", "SPECIES", 258, 264], ["increased responsibilities", "PROBLEM", 28, 54], ["COVID", "TEST", 66, 71], ["testing labs", "TEST", 95, 107]]], ["The day-night work of health professionals have been recognized in other countries as well with many health professionals being infected and died.12DISCUSSIONAs private clinics were closed, some doctors adopted telemedicine to reach their patients.", [["patients", "ORGANISM", 239, 247], ["patients", "SPECIES", 239, 247]]], ["This may be because currently health professionals have more usage of technology and internet on day-to-day basis for research and entertainment purposes.13 It may also be related to their thirst for learning new methods to match with the evolving requirements of healthcare and education industry globally.", [["learning new methods", "TREATMENT", 200, 220]]], ["To avoid possible risk of infection, those in academia were also asked to work from home.", [["infection", "DISEASE", 26, 35], ["infection", "PROBLEM", 26, 35], ["possible risk of", "UNCERTAINTY", 9, 25], ["infection", "OBSERVATION", 26, 35]]], ["They adopted various online learning tools for teaching and learning, giving synchronous and asynchronous lectures, and also uploading resource materials.DISCUSSIONThe current study identified various challenges related to work-from-home and in the hospital.", [["The current study", "TEST", 164, 181]]], ["We recommend that work from home should not mean work 24/7 and they should create routines, have designated space and avoid extreme multitasking.15 Limitations such as inability to teach skills can be managed through procedural videos, synchronous demonstrations, 3D/virtual learning technologies and second-life for teaching technical skills.16 To improve satisfaction, it is important that the course designers offer authentic learning experiences with active participation for engagement and deeper learning.17 Faculty development in online modalities and lesson planning is recommended.DISCUSSIONThose working in the hospital reported their vulnerability to getting infected due to lack of personal protective equipment, standard operating procedures and infrastructure.", [["lesson planning", "TREATMENT", 559, 574], ["personal protective equipment", "TREATMENT", 694, 723], ["standard operating procedures", "TREATMENT", 725, 754]]], ["We recommend telephone triage to prevent patients who can be cared for at home from coming to hospital.18 Health professionals dealing with COVID-19 should have separately assigned rooms to wear/remove scrubs.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["scrubs", "TREATMENT", 202, 208]]], ["They should be given protective gears such as gowns, face-masks, glasses and face-shields.7 Once off duty, they should fully decontaminate themselves to prevent infection to themselves and their families.", [["infection", "DISEASE", 161, 170], ["protective gears", "TREATMENT", 21, 37], ["face-masks", "TREATMENT", 53, 63], ["glasses", "TREATMENT", 65, 72], ["infection", "PROBLEM", 161, 170], ["infection", "OBSERVATION", 161, 170]]], ["As misinformation can cause public panic and unrest, they should be asked to consider using government or hospital website/social media pages/mobile applications for COVID-19 related updates.18DISCUSSIONOur study participants mostly belonged to the medical colleges of Punjab and Khyber Pakhtunkhwa with fewer participants from Sindh province.", [["panic", "DISEASE", 35, 40], ["participants", "SPECIES", 213, 225], ["participants", "SPECIES", 310, 322], ["public panic", "PROBLEM", 28, 40]]], ["Due to the novelty of COVID-19, there is a lack of similar previously published studies, therefore comparison of all aspects of the results was difficult.Authors\u2019 Contribution ::: CONCLUSIONBAS and AS conceived the idea and designed the study.Authors\u2019 Contribution ::: CONCLUSIONAll the authors (BAS, AS, SA and HAS) were involved in data collection, analysis and data interpretation.", [["COVID", "TEST", 22, 27], ["the study", "TEST", 233, 242], ["analysis and data interpretation", "TEST", 351, 383]]]]}